01047000000000421000450099100020000070000020000270600020000470100020000609100090
00081300041000174210018000581510021000760350010000974800041001070300018001489300
00500166117000600171085000300177935001000180031000300190032000200193036000600195
04200020020120000020020306500090020512200030021404800140021704800140023104800240
02450490027002690490036002960490035003320490032003670490031003990430065004300430
06500495043006500560#1#0#i#1#20110406#Brazilian Journal of Infectious Diseases#B
raz J Infect Dis#Braz. j. infect. dis#1413-8670#Brazilian Society of Infectious 
Diseases#Braz J Infect Dis#BJID#other#nd#1413-8670#15#2#20112#1#0#20110400#21#^l
es^hSumario#^lpt^hSumário#^len^hTable of Contents#^len^cBJID020^tCase Report#^le
n^cBJID050^tLetter to the Editor#^len^cBJID160^tBrief Communication#^len^cBJID23
0^tOriginal Article#^len^cBJID240^tClinical Images#^les^tBraz J Infect Dis^vvol.
15^nno.2^cSalvador^mmar./abr.^a2011#^lpt^tBraz J Infect Dis^vvol.15^nno.2^cSalva
dor^mmar./abr.^a2011#^len^tBraz J Infect Dis^vvol.15^nno.2^cSalvador^mMar./Apr.^
a2011##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#o#1#1#article#1
#20110406#124758#v15n2a01.htm#198##
02958000000000613000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400100014403500100015401201020
01640100023002660100024002890100029003130100032003420100028003740700113004020700
16000515070010000675070011400775070008300889070011700972083107401089085000802163
08500300217108500340220108500160223508500340225111700060228507200030229111200090
2294111000902303114000902312113001002321002001302331#v15n2#V:\SciELO\serial\bjid
\v15n2\markup\v15n2a01.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#1#BJID23
0#nd#Braz J Infect Dis#15#2#20110400#^f97^l101#1413-8670#Survey of Mycoplasma pn
eumoniae in Iranian children with acute lower respiratory tract infections^len#^
rND^1A01^nNahal^sHadi#^rND^1A02^nSara^sKashef#^rND^1A03^nMohammad^sMoazzen#^rND^
1A04^nMichel Shamoon^sPour#^rND^1A05 A06^nNima^sRezaei#Shiraz University of Medi
cal Sciences^iA01^1Medical School^2Department of Bacteriologyand Virology^cShira
z^pIran#Shiraz University of Medical Sciences^iA02^1Namazi Hospital^2Division of
 Immunology and Allergy^3Department of Pediatrics Allergy Research Center^cShira
z^pIran#Shiraz University of Medical Sciences^iA03^1Namazi Hospital^2Department 
of Pediatrics^cShiraz^pIran#Shiraz University of Medical Sciences^iA04^1Medical 
School^2Department of Bacteriology and Virology^cShiraz^pIran#Tehran University 
of Medical Sciences^iA05^1Growth and Development Research Center#Tehran Universi
ty of Medical Sciences^iA06^1Children's Medical Center^2Pediatrics Center of Exc
ellence^cTehran^pIran#^len^aOBJECTIVES: Mycoplasma pneumoniae is an atypical pat
hogen, which is one of the major causes of lower respiratory tract infections (L
RTIs) worldwide. This study was performed to determine the role of M. pneumoniae
 in acute LRTIs in children, who were referred to main pediatric hospitals in Sh
iraz, Iran, with the diagnosis of LRTI. Polymerase chain reaction method on a th
roat-swab specimen was utilized to detect M. pneumoniae. RESULTS: One hundred pa
tients with acute LRTIs were investigated in this study. There were 10 positive 
PCR for M. pneumoniae (10%), including 6 of 62 hospitalized patients and 4 of 38
 outpatients. All patients with LRTIs due to M. pneumoniae had cough. Fever, flu
 like symptoms, dyspnea, pulmonary rales, wheezing, and conjunctivitis were othe
r common signs and symptoms. CONCLUSIONS: The percentage of cases with M. pneumo
niae infection in our population is similar to the reported in other parts of As
ia. Precise and early detection of pathogen and appropriate antibiotic therapy a
re the key points in management of patients with LRTIs.#^dnd^i1#^tm^len^katypica
l bacteria^i1#^tm^len^kMycoplasma pneumoniae^i1#^tm^len^kPCR^i1#^tm^len^krespira
tory infection^i1#other#40#20100308#3/8/2010#20100616#6/16/2010#v15n2a01.htm##
03042000000000613000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400100014403500100015401201160
01640100023002800100024003030100029003270100032003560100028003880700113004160700
16000529070010000689070011400789070008300903070011700986083113701103085000802240
08500300224808500410227808500160231908500340233511700060236907200030237511200090
2378111000902387114000902396113001002405002001302415#v15n2#V:\SciELO\serial\bjid
\v15n2\markup\v15n2a01.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#1#BJID23
0#nd#Braz J Infect Dis#15#2#20110400#^f97^l101#1413-8670#<b>Survey of <i>Mycopla
sma pneumoniae</i> in Iranian children with acute lower respiratory tract infect
ions</b>^len#^rND^1A01^nNahal^sHadi#^rND^1A02^nSara^sKashef#^rND^1A03^nMohammad^
sMoazzen#^rND^1A04^nMichel Shamoon^sPour#^rND^1A05 A06^nNima^sRezaei#Shiraz Univ
ersity of Medical Sciences^iA01^1Medical School^2Department of Bacteriologyand V
irology^cShiraz^pIran#Shiraz University of Medical Sciences^iA02^1Namazi Hospita
l^2Division of Immunology and Allergy^3Department of Pediatrics Allergy Research
 Center^cShiraz^pIran#Shiraz University of Medical Sciences^iA03^1Namazi Hospita
l^2Department of Pediatrics^cShiraz^pIran#Shiraz University of Medical Sciences^
iA04^1Medical School^2Department of Bacteriology and Virology^cShiraz^pIran#Tehr
an University of Medical Sciences^iA05^1Growth and Development Research Center#T
ehran University of Medical Sciences^iA06^1Children's Medical Center^2Pediatrics
 Center of Excellence^cTehran^pIran#^len^a<b>OBJECTIVES:</b> <i>Mycoplasma pneum
oniae</i> is an atypical pathogen, which is one of the major causes of lower res
piratory tract infections (LRTIs) worldwide. This study was performed to determi
ne the role of <i>M. pneumoniae</i> in acute LRTIs in children, who were referre
d to main pediatric hospitals in Shiraz, Iran, with the diagnosis of LRTI. Polym
erase chain reaction method on a throat-swab specimen was utilized to detect <i>
M. pneumoniae</i>. <b>RESULTS:</b> One hundred patients with acute LRTIs were in
vestigated in this study. There were 10 positive PCR for <i>M. pneumoniae</i> (1
0%), including 6 of 62 hospitalized patients and 4 of 38 outpatients. All patien
ts with LRTIs due to <i>M. pneumoniae</i> had cough. Fever, flu like symptoms, d
yspnea, pulmonary rales, wheezing, and conjunctivitis were other common signs an
d symptoms. <b>CONCLUSIONS:</b> The percentage of cases with <i>M. pneumoniae</i
> infection in our population is similar to the reported in other parts of Asia.
 Precise and early detection of pathogen and appropriate antibiotic therapy are 
the key points in management of patients with LRTIs.#^dnd^i1#^tm^len^katypical b
acteria^i1#^tm^len^k<i>Mycoplasma pneumoniae</i>^i1#^tm^len^kPCR^i1#^tm^len^kres
piratory infection^i1#other#40#20100308#3/8/2010#20100616#6/16/2010#v15n2a01.htm
##
03125000000000637000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000200117049000800119
15800030012703000210013003100030015103200020015406500090015601400100016503500100
01750120102001850100023002870100024003100100029003340100032003630100028003950700
11500423070016200538070010200700070011600802070009900918070011901017083108101136
08500080221708500300222508500340225508500160228908500340230511700060233907200030
2345112000902348111000902357114000902366113001002375002001302385008008902398#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#l#4#1#article#1#^mMar./Apr.
^a2011#oa#en#br1.1#1#4.0#ilus#tab#1#BJID230#nd#Braz. j. infect. dis#15#2#2011040
0#^f97^l101#1413-8670#Survey of Mycoplasma pneumoniae in Iranian children with a
cute lower respiratory tract infections^len#^rND^1A01^nNahal^sHadi#^rND^1A02^nSa
ra^sKashef#^rND^1A03^nMohammad^sMoazzen#^rND^1A04^nMichel Shamoon^sPour#^rND^1A0
5 A06^nNima^sRezaei#^iA01^1Shiraz University of Medical Sciences^2Medical School
^3Department of Bacteriologyand Virology^cShiraz^pIran#^iA02^1Shiraz University 
of Medical Sciences^2Namazi Hospital^3Division of Immunology and Allergy. Depart
ment of Pediatrics Allergy Research Center^cShiraz^pIran#^iA03^1Shiraz Universit
y of Medical Sciences^2Namazi Hospital^3Department of Pediatrics^cShiraz^pIran#^
iA04^1Shiraz University of Medical Sciences^2Medical School^3Department of Bacte
riology and Virology^cShiraz^pIran#^iA05^1Tehran University of Medical Sciences^
2Growth and Development Research Center^cTehran^pIran#^iA06^1Tehran University o
f Medical Sciences^2Children's Medical Center^3Pediatrics Center of Excellence^c
Tehran^pIran#^len^aOBJECTIVES: Mycoplasma pneumoniae is an atypical pathogen, wh
ich is one of the major causes of lower respiratory tract infections (LRTIs) wor
ldwide. This study was performed to determine the role of M. pneumoniae in acute
 LRTIs in children, who were referred to main pediatric hospitals in Shiraz, Ira
n, with the diagnosis of LRTI. Polymerase chain reaction method on a throat-swab
 specimen was utilized to detect M. pneumoniae. RESULTS: One hundred patients wi
th acute LRTIs were investigated in this study. There were 10 positive PCR for M
. pneumoniae (10 percent), including 6 of 62 hospitalized patients and 4 of 38 o
utpatients. All patients with LRTIs due to M. pneumoniae had cough. Fever, flu l
ike symptoms, dyspnea, pulmonary rales, wheezing, and conjunctivitis were other 
common signs and symptoms. CONCLUSIONS: The percentage of cases with M. pneumoni
ae infection in our population is similar to the reported in other parts of Asia
. Precise and early detection of pathogen and appropriate antibiotic therapy are
 the key points in management of patients with LRTIs.#^dnd^i1#^tm^len^katypical 
bacteria^i1#^tm^len^kMycoplasma pneumoniae^i1#^tm^len^kPCR^i1#^tm^len^krespirato
ry infection^i1#other#40#20100308#3/8/2010#20100616#6/16/2010#v15n2a01.htm#Inter
net^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000200
001##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#5#1#article#154#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLE</b><
/font></p>     ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#6#2#article#154#<p>&nbsp;</p>     ^cY
#v15n2a01.htm##
00445000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704021200074002001300286#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#7#3#article#154#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Survey of <i>Myco
plasma pneumoniae</i> in Iranian children with acute lower respiratory tract inf
ections</b></font></p>     ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#8#4#article#154#<p>&nbsp;</p>     ^cY
#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#9#5#article#154#<p>&nbsp;</p>     ^cY
#v15n2a01.htm##
00463000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704022900075002001300304#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#10#6#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Nahal Hadi<sup>I</sup>; Sara Kashe
f<sup>II</sup>; Mohammad Moazzen<sup>III</sup>; Michel Shamoon Pour<sup>IV</sup>
; Nima Rezaei<sup>V</sup></b></font></p>     ^cY#v15n2a01.htm##
00425000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704019100075002001300266#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#11#7#article#154#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Department of Bacteriolog
y and Virology, Medical School, Shiraz University of Medical Sciences, Shiraz, I
ran    ^cY#v15n2a01.htm##
00416000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704018200075002001300257#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#12#8#article#154#<br>   <sup>II</sup>
Allergy Research Center, Department of Pediatrics, Division of Immunology and Al
lergy, Namazi Hospital, Shiraz University of Medical Sciences,Shiraz, Iran    ^c
Y#v15n2a01.htm##
00357000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012300075002001300198#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#13#9#article#154#<br>   <sup>III</sup
>Department of Pediatrics, Namazi Hospital, Shiraz University of Medical Science
s, Shiraz, Iran    ^cY#v15n2a01.htm##
00371000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013600076002001300212#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#14#10#article#154#<br>   <sup>IV</sup
>Department of Bacteriology and Virology, Medical School, Shiraz University of M
edical Sciences, Shiraz, Iran    ^cY#v15n2a01.htm##
00477000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024200076002001300318#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#15#11#article#154#<br>   <sup>V</sup>
Growth and Development Research Center, Tehran University of Medical Sciences, T
ehran, Iran Pediatrics Center of Excellence, Children's Medical Center, Tehran U
niversity of Medical Sciences, Tehran, Iran</font></p>     ^cY#v15n2a01.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#16#12#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a><
/font></p>     ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#17#13#article#154#<p>&nbsp;</p>     ^
cY#v15n2a01.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#18#14#article#154#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v15n2a01.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#19#15#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
15n2a01.htm##
00762000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052700076002001300603#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#20#16#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>OBJECTIVES:</b> <i>Mycoplasma pne
umoniae</i> is an atypical pathogen, which is one of the major causes of lower r
espiratory tract infections (LRTIs) worldwide. This study was performed to deter
mine the role of <i>M. pneumoniae</i> in acute LRTIs in children, who were refer
red to main pediatric hospitals in Shiraz, Iran, with the diagnosis of LRTI. Pol
ymerase chain reaction method on a throat-swab specimen was utilized to detect <
i>M. pneumoniae</i>.    ^cY#v15n2a01.htm##
00642000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040700076002001300483#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#21#17#article#154#<br>   <b>RESULTS:<
/b> One hundred patients with acute LRTIs were investigated in this study. There
 were 10 positive PCR for <i>M. pneumoniae</i> (10%), including 6 of 62 hospital
ized patients and 4 of 38 outpatients. All patients with LRTIs due to <i>M. pneu
moniae</i> had cough. Fever, flu like symptoms, dyspnea, pulmonary rales, wheezi
ng, and conjunctivitis were other common signs and symptoms.    ^cY#v15n2a01.htm
##
00542000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030700076002001300383#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#22#18#article#154#<br>   <b>CONCLUSIO
NS:</b> The percentage of cases with <i>M. pneumoniae</i> infection in our popul
ation is similar to the reported in other parts of Asia. Precise and early detec
tion of pathogen and appropriate antibiotic therapy are the key points in manage
ment of patients with LRTIs.</font></p>     ^cY#v15n2a01.htm##
00433000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019800076002001300274#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#23#19#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> atypical bacteria; 
<i>Mycoplasma pneumoniae</i>; PCR; respiratory infection;</font></p> <hr size="1
" noshade>     ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#24#20#article#154#<p>&nbsp;</p>     ^
cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#25#21#article#154#<p>&nbsp;</p>     ^
cY#v15n2a01.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#26#22#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>INTRODUCTION</b></i></font></p
>     ^cY#v15n2a01.htm##
00967000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073200076002001300808#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#27#23#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Lower respiratory tract infections (
LRTIs) continue to be a common cause of morbidity and mortality, especially in t
he pediatric age group,<sup>1,2</sup> contributing to about 1.9 million children
s deaths yearly.<sup>3</sup> Determination of the putative pathogens is one of 
the main difficulties in LRTIs, as the diagnostic tests of respiratory samples a
re not sensitive enough to identify the causative microorganisms in most patient
s.<sup>4,5</sup> It is estimated that antigen screening, culture and serological
 methods can be helpful in only one third of the cases.<sup>6</sup> Therefore th
erapy is usually empiric in most cases.<sup>7,8</sup></font></p>     ^cY#v15n2a0
1.htm##
00926000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069100076002001300767#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#28#24#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Atypical pathogens, particularly <i>
Mycoplasma pneumoniae</i>, are major causes of acute LRTIs. Although <i>M. pneum
oniae</i> usually causes pneumonia and bronchitis, other clinical manifestations
 such as rhinitis, pharyngitis, sinusitis and otitis media can also be seen.<sup
>9,10</sup> There are some reports indicating significant role of <i>M. pneumoni
ae</i> as cause of LRTIs in children of all ages,<sup>11,12</sup> which undersco
res the importance of specific pathogen diagnosis, as the use of proper antibiot
ics, such as macrolides, can significantly reduce duration of the illnesses.<sup
>13,14</sup></font></p>     ^cY#v15n2a01.htm##
01490000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704125500076002001301331#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#29#25#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">SUnfortunately, as result of the dif
ficulty to detect <i>M. pneumoniae</i> due to insensitive culture and time-consu
ming and impractical in clinical practice, specific etiologic diagnoses have rem
ained unknown in the majority of cases.<sup>15</sup> Several methods were utiliz
ed for detection of this pathogen, including cold agglutination test,<sup>16</su
p> serological methods (<i>Mycoplasma</i> IgM antibody, complement fixation, ELI
SA)<sup>17,18</sup> and microparticle agglutination test.<sup>19</sup> However, 
there were a number of limitations with these methods, especially regarding sens
itivity and specificity. Therefore polymerase chain reaction (PCR) is suggested 
as of the most practical typing method for rapid and sensitive detection of <i>M
. pneumoniae</i> in throat swabs.<sup>20,21</sup> The PCR method could provide r
apid diagnosis of <i>M. pneumoniae</i> infection, especially in younger children
, and is a valuable method considering epidemiological, clinical, economic aspec
ts in addition to turnaround time of results.<sup>22-24</sup> The sensitivity an
d specificity of the PCR method has been estimated about 70% and 80%, respective
ly.<sup>24</sup></font></p>     ^cY#v15n2a01.htm##
00442000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020700076002001300283#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#30#26#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This study was performed to determin
e the role of <i>M. pneumoniae</i> in acute LRTIs in children, with use of PCR a
nalysis.</font></p>     ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#31#27#article#154#<p>&nbsp;</p>     ^
cY#v15n2a01.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011700076002001300193#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#32#28#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>PATIENTS AND METHODS</b></i></
font></p>     ^cY#v15n2a01.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009700076002001300173#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#33#29#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Setting</b></font></p>     ^cY#v1
5n2a01.htm##
00680000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044500076002001300521#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#34#30#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This prospective study was performed
 in 2006 on pediatric patients, who were referred to Namazee and Dastgheib Hospi
tals (Shiraz, Iran) because of acute lower respiratory tract infections. This st
udy was approved by Ethics Committee of the Hospital, Shiraz University of Medic
al Sciences. Written informed consent was taken from the parents of enrolled pat
ients.</font></p>     ^cY#v15n2a01.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#35#31#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Patients enrollment</b></font></p
>     ^cY#v15n2a01.htm##
01080000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084500076002001300921#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#36#32#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">One hundred children (64 boys and 36
 girls) were included in this study. Demographic data and patients' history were
 documented in the standardized questionnaire, designed for this study. All symp
toms and detected signs in the physical examination, including cough, flu-like s
ymptoms, dyspnea, pulmonary rales, wheezing, and conjunctivitis were also record
ed. Initial laboratory investigations, including complete cell blood count and c
hest X-ray, were done before throat-swab sampling. The patients with the followi
ng criteria were enrolled in this study: respiratory symptoms associated with ab
normal chest X-ray suggestive of pneumonia, respiratory distress, and presence o
f rales in lung examination. Fever was defined as body temperature higher than 3
7.8ºC.</font></p>     ^cY#v15n2a01.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#37#33#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Exclusion criteria</b></font></p>
     ^cY#v15n2a01.htm##
00700000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046500076002001300541#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#38#34#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Patients with chronic respiratory pr
oblems, such as asthma and cystic fibrosis, and other chronic diseases, such as 
malignant disease, tuberculosis and autoimmune diseases, were excluded from this
 study. Those who had history of blood transfusions or immunosuppressive therapy
 were also excluded. Enrolled patients were not receiving antibiotics during the
 72 hours before sampling.</font></p>     ^cY#v15n2a01.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#39#35#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>PCR method</b></font></p>     ^cY
#v15n2a01.htm##
01071000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083600076002001300912#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#40#36#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The polymerase chain reaction (PCR) 
method on a throat-swab specimen was utilized to detect <i>M. pneumoniae</i>. Al
though all the patients were prescribed a 10-day course of macrolides (erythromy
cin or azithromycin at the recommended dose), throat-swab specimens were taken a
t the first day prior to antibiotic therapy. The samples were transported in PPL
O broth to the microbiology laboratory and were incubated at 37ºC for a few hour
s after removing the swabs. The cultures were centrifuged at 1,000 g for 5 minut
es. The supernatant then was collected in a sterile 1 mL Eppendorf tube and cent
rifuged at 20,000 g for 20 minutes. After decanting the supernatant the pellet w
as suspended in 20 &#181;L of sterile Mili-Q water and boiled for 10 minutes.</f
ont></p>     ^cY#v15n2a01.htm##
00640000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040500076002001300481#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#41#37#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The latter was then used as DNA temp
late in PCR reactions which were performed by the <i>M. pneumoniae</i> PCR kit (
Genekam Biotechnology AG, Germany), based on the protocol. The negative and posi
tive controls provided in the kit were used in each assay. DNA fragments were vi
sualized on 1% agarose gel by electrophoresis.</font></p>     ^cY#v15n2a01.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011000076002001300186#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#42#38#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Statistical analysis</b></font></
p>     ^cY#v15n2a01.htm##
00595000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036000076002001300436#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#43#39#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Epi Info 6 program (version 6.2, Wor
ld Health Organization, Geneva, Switzerland) was used for statistical analyses. 
Association between categorical variables were assessed by Chi-square or Fisher'
s exact test. P-value of less than 0.05 was considered statistically significant
.</font></p>     ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#44#40#article#154#<p>&nbsp;</p>     ^
cY#v15n2a01.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#45#41#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>RESULTS</b></i></font></p>    
 ^cY#v15n2a01.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011700076002001300193#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#46#42#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Characteristics of patients</b></
font></p>     ^cY#v15n2a01.htm##
00508000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027300076002001300349#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#47#43#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">One hundred patients with acute LRTI
s (64 male and 36 female), including 62 hospitalized and 38 outpatients, were in
vestigated in this study. Patients' ages ranged from 6 months to 17 years.</font
></p>     ^cY#v15n2a01.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011100076002001300187#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#48#44#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Positive PCR patients</b></font><
/p>     ^cY#v15n2a01.htm##
00603000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036800076002001300444#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#49#45#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Among 100 investigated patients, PCR
 for <i>M. pneumoniae</i> turned out positive in 10 (10%) patients, being 5 boys
 (7,8%) and 5 girls (13,8%) &#91;p = 0.48&#93;. <i>M. pneumoniae</i> positivity 
rates among hospitalized patients (9.5%) and outpatients (10.5%) were similar (p
 = 0.57).</font></p>     ^cY#v15n2a01.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#50#46#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Seasonal variations</b></font></p
>     ^cY#v15n2a01.htm##
00543000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030800076002001300384#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#51#47#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Half of the identified <i>M. pneumon
iae</i> cases were referred during the autumn season, while only 3 cases occurre
d during the winter and 2 cases in the spring. No <i>M. pneumoniae</i> was detec
ted during the summer season.</font></p>     ^cY#v15n2a01.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#52#48#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Clinical manifestations</b></font
></p>     ^cY#v15n2a01.htm##
01318000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704108300076002001301159#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#53#49#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">All patients with acute LRTI due to 
<i>M. pneumoniae</i> complained of cough lasting for a mean of 9.5 days, compare
d to a mean duration of 7 days among PCR negative patients (p = 0.35). Although 
8 out of 10 patients with positive PCR had fever at the time of admission, and a
ll but one had low-grade fever. Half of the cases presented with productive coug
h, while the remaining half had dry cough, irrespective of being positive and ne
gative PCR for <i>M. pneumoniae</i>. Flu-like symptoms were present in 40% of th
e patients with <i>M. pneumoniae</i>, which was lower than the 63.3% seen in the
 negative patients. However, this difference was not significant (p = 0.18). In 
contrast, dyspnea was more common among PCR-positive patients for <i>M. pneumoni
ae</i> (50% vs. 36.7%, p = 0.49). Other characteristics of the patients are pres
ented in the <a href="/img/revistas/bjid/v15n2/a01tab01.jpg">Table 1</a>, which 
shows no significant difference on clinical manifestations between these two gro
ups.</font></p>     ^cY#v15n2a01.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011200076002001300188#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#54#50#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Para-clinical findings</b></font>
</p>     ^cY#v15n2a01.htm##
01095000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704086000076002001300936#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#55#51#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Complete blood cell count was simila
r in the two groups of positive and negative PCR for <i>M. pneumoniae</i>. Patie
nts with positive PCR for <i>M. pneumoniae</i> had a mean white blood cells (WBC
) count of 10,200/m<sup>3</sup> with 65% polymorphonuclear cells (PMN), whilst m
ean WBC in the PCR-negative cases was 10,000/m<sup>3</sup> with 54% PMN. Expert 
radiologist reports of chest X-ray were available for 70 patients; among PCR-pos
itive patients for <i>M. pneumoniae</i> there were 2 cases of lobar infiltration
s and 3 of interstitial infiltrations. Positive radiological findings among PCR-
positive patients for <i>M. pneumoniae</i> was 71.4% (5 of 7), lower than the 77
.8% (49 of 63) found among PCR-negative patients, but this difference was not si
gnificant (p = 0.66).</font></p>     ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#56#52#article#154#<p>&nbsp;</p>     ^
cY#v15n2a01.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#57#53#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>DISCUSSION</b></i></font></p> 
    ^cY#v15n2a01.htm##
00790000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055500076002001300631#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#58#54#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Respiratory infections with <i>M. pn
eumoniae</i> are common in most areas of the world, which cause atypical pneumon
ia and other respiratory tract diseases with outbreaks occurring every 4-7 year 
intervals. The annual rate of infection is estimated between 1.3% in endemic per
iods and 50% in epidemic periods. About 15-20% of community-acquired pneumonia w
as associated with <i>M. pneumoniae</i>, with an incidence of 2 cases per 1,000 
population annually.<sup>25,26</sup></font></p>     ^cY#v15n2a01.htm##
01424000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704118900076002001301265#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#59#55#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The role of <i>M. pneumoniae</i> in 
respiratory infections was investigated in different regions, but its prevalence
 varies greatly from study to study. Although geographical regions can alter the
 prevalence of <i>M. pneumoniae</i> in respiratory infections, type of study, ag
e of studied patients and the methods used for detecting <i>M. pneumoniae</i> ca
n be responsible for the discrepant results of previous studies. Our study revea
led that 10% of patients with LRTIs could be attributed to this atypical bacteri
a, which is similar to that one reported in other parts of Asia,<sup>27,28</sup>
 in spite of the fact that our study was conducted in a different location and a
t a different time. Ngeow <i>et al.</i> carried on a large surveillance study in
 Asia, which showed the prevalence of <i>M. pneumoniae</i> in about 12% among ch
ildren with community-acquired pneumonia.<sup>27</sup> In an earlier study from 
South-eastern Asia, Ouchi <i>et al.</i> studied 1,104 Japanese children with acu
te LRTIs and found <i>M. pneumoniae</i> in 13% of the patients,<sup>28</sup> als
o in agreement with our study.</font></p>     ^cY#v15n2a01.htm##
01550000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704131500076002001301391#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#60#56#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Low frequency of <i>M. pneumoniae</i
> was reported in only few studies, such as the study by Elkholy <i>et al.</i> i
nvolving 111 Egyptian children with positivity rate of only 4.5%<sup>29</sup> an
d the study by Meijer <i>et al.</i> on 557 Dutch patients with positivity rate o
f only 1.3%.<sup>30</sup> However, there are several studies reporting higher fr
equency of <i>M. pneumoniae</i>. In the study by Principi <i>et al.</i> on 613 I
talian children from 21 different centers, who were hospitalized because of comm
unity acquired LRTIs, this pathogen was found in 34% of the patients.<sup>31</su
p> In the study by Liu <i>et al.</i> on 256 Taiwanese patients with clinical sus
picion of atypical pneumonia, <i>M. pneumoniae</i> was positive in 32% of the ca
ses.<sup>24</sup> In another study by Maltezou <i>et al.</i> on 65 Greek childre
n, <i>M. pneumoniae</i> infection was confirmed in 27.5% of them.<sup>32</sup> A
s expected, the frequency of <i>M. pneumoniae</i> pneumonia should be much highe
r at the time of outbreaks. The study by Kim <i>et al.</i> in Seoul, Korea, on 2
34 hospitalized children with community-acquired LRTIs during two outbreaks reve
aled about 65% of patients with <i>M. pneumoniae</i> pneumonia.<sup>33</sup></fo
nt></p>     ^cY#v15n2a01.htm##
00990000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075500076002001300831#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#61#57#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">However, it should be emphasized tha
t some of these studies reflect the prevalence of <i>M. pneumoniae</i> in hospit
alized patients, while we also included outpatients, albeit with similar frequen
cy with hospitalized cases. Although the study by Sidal <i>et al.</i> in Istanbu
l, Turkey on 284 patients, seen at an outpatient clinic with respiratory symptom
s, showed positive antibody for <i>M. pneumoniae</i> in about 30% of cases.<sup>
34</sup> Another study by Butun <i>et al.</i> in Izmir, Turkey on 100 children, 
receiving care at the outpatient department with respiratory symptoms, revealed 
positive antibody for <i>M. pneumoniae</i> in only 8% of cases.<sup>35</sup></fo
nt></p>     ^cY#v15n2a01.htm##
00690000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045500076002001300531#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#62#58#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In our study, the <i>M. pneumoniae</
i> in autumn season was found higher compared to other seasons, which contrasts 
with the Turkish study indicating significantly higher frequency of this pathoge
n in winter season.<sup>34</sup> Meanwhile in the study by Foy <i>et al.</i> in 
Seattle during an 11-year period, no significant seasonal variation was document
ed.<sup>36</sup></font></p>     ^cY#v15n2a01.htm##
01670000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704143500076002001301511#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#63#59#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Atypical pneumonia could be distingu
ished from other types of pneumonias by its mild clinical course and its ability
 to cause different symptoms in different people. Cough and throat pain are comm
on symptoms, whilst fever is usually a symptom of hospitalized patients diagnose
d with pneumonia. However, we did not find any specific clinical characteristic 
that could accurately identify patients with <i>M. pneumoniae</i>, similarly to 
other studies.<sup>35,37</sup> In fact, none of the signs and symptoms was uniqu
e to <i>M. pneumoniae</i> infections enabling to predict atypical pathogens base
d on clinical characteristics. Such findings can emphasize the point that clinic
al and laboratory features alone cannot predict the etiology of community-acquir
ed pneumonia in children and therefore are not useful in therapeutic decision-ma
king.<sup>38,39</sup> It shows the importance of effective laboratory diagnosis 
tools to detect such pathogens. As clinical symptoms are nonspecific, persistent
 cough lasting more than a week, refractory to conventional antibiotic therapy s
hould prompt clinicians to suspect the diagnosis of LRTIs by atypical microorgan
isms.<sup>40</sup> However, initiation of effective antibiotic therapy is usuall
y delayed. Such delay may lead to some complications, while the patients are not
 appropriately treated.<sup>31</sup></font></p>     ^cY#v15n2a01.htm##
00816000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058100076002001300657#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#64#60#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Therefore, detection of microorganis
ms and appropriate treatments are the key points in the management of patients w
ith LRTIs. Although <i>M. pneumoniae</i> can be isolated from cultures, this is 
a difficult and time-consuming method which limits its clinical usefulness. Ther
efore, the PCR method for detecting <i>M. pneumoniae</i> in throat swabs could b
e considered as the most practical method for rapid diagnosis, particularly in y
ounger children and in early stage of disease.<sup>20,24</sup></font></p>     ^c
Y#v15n2a01.htm##
00633000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039800076002001300474#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#65#61#article#154#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>M. pneumoniae</i> is an atypical 
bacterium that could cause LRTIs worldwide, which requires adding a macrolide in
 the antibiotic regimen.<sup>40</sup> Prompt diagnosis by appropriate technique 
and starting appropriate antibiotic therapy could prevent the use of unnecessary
 antibiotics and further complications.</font></p>     ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#66#62#article#154#<p>&nbsp;</p>     ^
cY#v15n2a01.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#67#63#article#154#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p> 
    ^cY#v15n2a01.htm##
00409000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704016000078002001300238#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#68#64#article#154#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Mulholland K. Magni
tude of the problem of childhood pneumonia. Lancet 1999; 354:590-2.    ^cY#v15n2
a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#69#65#article#154#</font></p>     ^cY
#v15n2a01.htm##
00524000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027500078002001300353#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#70#66#article#154#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Vuori E, Peltola H,
 Kallio MJT <i>et al</i>. Etiology of pneumonia and other common childhood infec
tions requiring hospitalization and parenteral antimicrobial therapy. Clin Infec
t Dis 1998; 27:566-72.    ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#71#67#article#154#</font></p>     ^cY
#v15n2a01.htm##
00453000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020400078002001300282#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#72#68#article#154#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Klig JE, Shah NB. O
ffice pediatrics: current issues in lower respiratory infections in children. Cu
rr Opin Pediatr 2005; 17:111-8.    ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#73#69#article#154#</font></p>     ^cY
#v15n2a01.htm##
00419000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017000078002001300248#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#74#70#article#154#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Thomson RB. Laborat
ory diagnosis of respiratory infections. Curr Opin Infect Dis 1999; 12:115-9.   
 ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#75#71#article#154#</font></p>     ^cY
#v15n2a01.htm##
00560000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031100078002001300389#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#76#72#article#154#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Men&eacute;ndez R, 
C&oacute;rdoba J, de la Cuadra P <i>et al</i>. Value of the polymerase chain rea
ction assay in noninvasive respiratory samples for diagnosis of community-acquir
ed pneumonia. Am J Respir Crit Care Med 1999; 159:1868-73.    ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#77#73#article#154#</font></p>     ^cY
#v15n2a01.htm##
00434000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704018500078002001300263#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#78#74#article#154#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. George H, Mccracken
 JR. Diagnosis and management of pneumonia in children. Pediatr Infect Dis J 200
0; 19:924-8.    ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#79#75#article#154#</font></p>     ^cY
#v15n2a01.htm##
00552000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030300078002001300381#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#80#76#article#154#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Mandell LA, Wunderi
nk RG, Anzueto A <i>et al</i>. Infectious Diseases Society of America/American T
horacic Society consensus guidelines on the management of community-acquired pne
umonia in adults. Clin Infect Dis 2007; 44:S27-72.    ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#81#77#article#154#</font></p>     ^cY
#v15n2a01.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025400078002001300332#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#82#78#article#154#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Stolza D, Christ-Cr
aind M, Gencaya MM <i>et al</i>. Diagnostic value of signs, symptoms and laborat
ory values in lower respiratory tract infection. Swiss Med Wkly 2006; 136:434-40
.    ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#83#79#article#154#</font></p>     ^cY
#v15n2a01.htm##
00435000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704018600078002001300264#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#84#80#article#154#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Tan JS. Role of aty
pical pneumonia pathogens in respiratory tract infections. Can Respir J 1999; (S
uppl 6):15-9.    ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#85#81#article#154#</font></p>     ^cY
#v15n2a01.htm##
00540000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029000079002001300369#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#86#82#article#154#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Wadowsky RM, Cast
illa EA, Laus S <i>et al</i>. Evaluation of Chlamydia pneumoniae and <i>Mycoplas
ma pneumoniae</i> as etiologic agents of persistent cough in adolescents and adu
lts. J Clin Microbiol 2002; 40:637-40.    ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#87#83#article#154#</font></p>     ^cY
#v15n2a01.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028200079002001300361#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#88#84#article#154#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. File TM, Tan JS, 
Plouffe JF. The role of atypical pathogens: <i>Mycoplasma pneumoniae</i>, Chlamy
dia pneumoniae, and Legionella pneumophila in respiratory infection. Infect Dis 
Clin North Am 1998; 12:569-92.    ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#89#85#article#154#</font></p>     ^cY
#v15n2a01.htm##
00584000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704033400079002001300413#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#90#86#article#154#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Block S, Hedrick 
J, Hammerschlag MR <i>et al. Mycoplasma pneumoniae</i> and Chlamydia pneumoniae 
in pediatric community-acquired pneumonia: comparative efficacy and safety of cl
arithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 1995; 14:471-
7.    ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#91#87#article#154#</font></p>     ^cY
#v15n2a01.htm##
00477000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704022700079002001300306#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#92#88#article#154#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Taylor-Robinson D
, Bebear C. Antibiotic susceptibilities of mycoplasmas and treatment of mycoplas
mal infections. J Antimicrob Chemother 1997; 40:622-30.    ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#93#89#article#154#</font></p>     ^cY
#v15n2a01.htm##
00476000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704022600079002001300305#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#94#90#article#154#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Principi N, Espos
ito S. Comparative tolerability of erythromycin and newer macrolide antibacteria
ls in paediatric patients. Drug Safety 1999; 20:25-41.    ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#95#91#article#154#</font></p>     ^cY
#v15n2a01.htm##
00591000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704034100079002001300420#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#96#92#article#154#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Harris R, Marmion
 BP, Varkanis G <i>et al</i>. Laboratory diagnosis of <i>Mycoplasma pneumoniae</
i> infection. 2. Comparison of methods for the direct detection of specific anti
gen or nucleic acid sequences in respiratory exudates. Epidemiol Infect 1988; 10
1:685-94.    ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#97#93#article#154#</font></p>     ^cY
#v15n2a01.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704022100079002001300300#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#98#94#article#154#16#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Lind K, Bentzon M
W. Ten and a half years seroepidemiology of <i>Mycoplasma pneumoniae</i> infecti
on in Denmark. Epidemiol Infect 1991; 107:189-99.    ^cY#v15n2a01.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#99#95#article#154#</font></p>     ^cY
#v15n2a01.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704030300080002001300383#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#100#96#article#154#17#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Petitjean J, Vab
ret A, Gouarin S, Freymuth F. Evaluation of four commercial immunoglobulin G (Ig
G)- and IgM-specific enzyme immunoassays for diagnosis of <i>Mycoplasma pneumoni
ae</i> infections. J Clin Microbiol 2002; 40:165-71.    ^cY#v15n2a01.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#101#97#article#154#</font></p>     ^c
Y#v15n2a01.htm##
00568000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704031700080002001300397#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#102#98#article#154#18#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Uldum SA, S&#248
;nderg&#229;rd-Andersen J, Skov Jensen J, Lind K. Evaluation of a commercial enz
yme immunoassay for detection of <i>Mycoplasma pneumoniae</i> specific immunoglo
bulin G antibodies. Eur J Clin Microbiol Infect Dis 1990; 9:221-3.    ^cY#v15n2a
01.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#103#99#article#154#</font></p>     ^c
Y#v15n2a01.htm##
00566000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031400081002001300395#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#104#100#article#154#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Echevarr&iacute
;a JM, Le&oacute;n P, Balfag&oacute;n P <i>et al</i>. Diagnosis of <i>Mycoplasma
 pneumoniae</i> infection by microparticle agglutination and antibody-capture en
zymeimmunoassay. Eur J Clin Microbiol Infect Dis 1990; 9:217-20.    ^cY#v15n2a01
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#105#101#article#154#</font></p>     ^
cY#v15n2a01.htm##
00491000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023900081002001300320#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#106#102#article#154#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Bernet C, Garre
t M, de Barbeyrac B <i>et al</i>. Detection of <i>Mycoplasma pneumoniae</i> by u
sing the polymerase chain reaction. J Clin Microbiol 1989; 27:2492-6.    ^cY#v15
n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#107#103#article#154#</font></p>     ^
cY#v15n2a01.htm##
00571000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031900081002001300400#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#108#104#article#154#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Ieven M, Ursi D
, Van Bever H <i>et al</i>. Detection of <i>Mycoplasma pneumoniae</i> by two pol
ymerase chain reactions and role of <i>M. pneumoniae</i> in acute respiratory tr
act infections in pediatric patients. J Infect Dis 1996; 173:1445-52.    ^cY#v15
n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#109#105#article#154#</font></p>     ^
cY#v15n2a01.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024900081002001300330#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#110#106#article#154#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Abele-Horn M, B
usch U, Nitschko H <i>et al</i>. Molecular approaches to diagnosis of pulmonary 
diseases due to <i>Mycoplasma pneumoniae</i>. J Clin Microbiol 1998; 36:548-51. 
   ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#111#107#article#154#</font></p>     ^
cY#v15n2a01.htm##
00518000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026600081002001300347#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#112#108#article#154#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Skakni L, Sarde
t A, Just J <i>et al</i>. Detection of <i>Mycoplasma pneumoniae</i> in clinical 
samples from pediatric patients by polymerase chain reaction. J Clin Microbiol 1
992; 30:2638-43.    ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#113#109#article#154#</font></p>     ^
cY#v15n2a01.htm##
00509000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025700081002001300338#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#114#110#article#154#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Liu FC, Chen PY
, Huang F <i>et al</i>. Rapid diagnosis of <i>Mycoplasma pneumoniae</i> infectio
n in children by polymerase chain reaction. J Microbiol Immunol Infect 2007; 40:
507-12.    ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#115#111#article#154#</font></p>     ^
cY#v15n2a01.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024200081002001300323#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#116#112#article#154#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Foy HM, Cooney 
MK, McMahan R, Grayston JT. Viral and mycoplasmal pneumonia in a prepaid medical
 care group during an eight-year period. Am J Epidemiol 1973; 97:93-102.    ^cY#
v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#117#113#article#154#</font></p>     ^
cY#v15n2a01.htm##
00482000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023000081002001300311#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#118#114#article#154#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Foy HM. Infecti
ons caused by <i>Mycoplasma pneumoniae</i> and possible carrier state in differe
nt populations of patients. Clin Infect Dis 1993; 17:S37-46.    ^cY#v15n2a01.htm
##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#119#115#article#154#</font></p>     ^
cY#v15n2a01.htm##
00517000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026500081002001300346#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#120#116#article#154#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Ngeow YF, Suwan
jutha S, Chantarojanasriri T <i>et al</i>. An Asian study on the prevalence of a
typical respiratory pathogens in community-acquired pneumonia. Int J Infect Dis 
2005; 9:144-53.    ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#121#117#article#154#</font></p>     ^
cY#v15n2a01.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025100081002001300332#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#122#118#article#154#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Ouchi K, Komura
 H, Fujii M <i>et al</i>. Chlamydia pneumonia infection and <i>Mycoplasma pneumo
niae</i> infection in pediatric patients. Kansenshogaku Zasshi 1999; 73: 1177-82
.    ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#123#119#article#154#</font></p>     ^
cY#v15n2a01.htm##
00525000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027300081002001300354#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#124#120#article#154#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Elkholy A, Elka
raksy H, Fattouh A <i>et al</i>. Acute lower respiratory tract infection due to 
Chlamydia and Mycoplasma spp. in Egyptian children under 5 years of age. J Trop 
Pediatr 2009; 55:195-7.    ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#125#121#article#154#</font></p>     ^
cY#v15n2a01.htm##
00570000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031800081002001300399#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#126#122#article#154#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Meijer A, Dagne
lie CF, De Jong JC <i>et al</i>. Low prevalence of Chlamydia pneumoniae and <i>M
ycoplasma pneumoniae</i> among patients with symptoms of respiratory tract infec
tions in Dutch general practices. Eur J Epidemiol 2000; 16:1099-106.    ^cY#v15n
2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#127#123#article#154#</font></p>     ^
cY#v15n2a01.htm##
00548000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029600081002001300377#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#128#124#article#154#31#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Principi N, Esp
osito S, Blasi F, Allegra L, Mowgli Study Group. Role of Mycoplasma pneumonia an
d Chlamydia pneumonia in children with community-acquired lower respiratory trac
t infections. Clin Infect Dis 2001; 32:1281-9.    ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#129#125#article#154#</font></p>     ^
cY#v15n2a01.htm##
00572000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032000081002001300401#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#130#126#article#154#32#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Maltezou HC, La
-Scola B, Astra H <i>et al. Mycoplasma pneumoniae</i> and Legionella pneumophila
 in community-acquired lower respiratory tract infections among hospitalized chi
ldren: diagnosis by real time PCR. Scand J Infect Dis 2004; 36:639-42.    ^cY#v1
5n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#131#127#article#154#</font></p>     ^
cY#v15n2a01.htm##
00590000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033800081002001300419#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#132#128#article#154#33#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Kim NH, Lee JA,
 Eun BW <i>et al</i>. Comparison of polymerase chain reaction and the indirect p
article agglutination antibody test for the diagnosis of <i>Mycoplasma pneumonia
e</i> pneumonia in children during two outbreaks. Pediatr Infect Dis J 2007; 26:
897-903.    ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#133#129#article#154#</font></p>     ^
cY#v15n2a01.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#134#130#article#154#34#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Sidal M, Kilic 
A, Unuvar E <i>et al</i>. Frequency of Chlamydia pneumoniae and <i>Mycoplasma pn
eumoniae</i> infections in children. J Trop Pediatr 2007; 53:225-31.    ^cY#v15n
2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#135#131#article#154#</font></p>     ^
cY#v15n2a01.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024600081002001300327#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#136#132#article#154#35#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. B&uuml;t&uuml;n
 Y, K&ouml;se S, Babayi&#287;it A <i>et al</i>. Chlamydia and Mycoplasma serolog
y in respiratory tract infections of children. Tuberk Toraks 2006; 54:254-8.    
^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#137#133#article#154#</font></p>     ^
cY#v15n2a01.htm##
00469000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021700081002001300298#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#138#134#article#154#36#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Foy HM, Kenny G
E, Cooney MK <i>et al</i>. Longterm epidemiology of infections with <i>Mycoplasm
a pneumoniae</i>. J Infect Dis 1979; 139:681-7.    ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#139#135#article#154#</font></p>     ^
cY#v15n2a01.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023400081002001300315#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#140#136#article#154#37#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Esposito S, Bla
si F, Bellini F <i>et al. Mycoplasma pneumoniae</i> and Chlamydia pneumoniae inf
ections in children with pneumonia. Eur Respir J 2001; 17:241-5.    ^cY#v15n2a01
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#141#137#article#154#</font></p>     ^
cY#v15n2a01.htm##
00484000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023200081002001300313#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#142#138#article#154#38#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Wubbel L, Muniz
 L, Ahmed A <i>et al</i>. Etiology and treatment of community-acquired pneumonia
 in ambulatory children. Pediatr Infect Dis J 1999; 18:98-104.    ^cY#v15n2a01.h
tm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#143#139#article#154#</font></p>     ^
cY#v15n2a01.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023300081002001300314#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#144#140#article#154#39#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. Korppi M, Heisk
anen-Kosma T, Jaloner E <i>et al</i>. Aetiology of community-acquired pneumonia 
in children treated in hospital. Eur J Pediatr 1993; 152:24-30.    ^cY#v15n2a01.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#145#141#article#154#</font></p>     ^
cY#v15n2a01.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022700081002001300308#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#146#142#article#154#40#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">40. Esposito S. Imp
ortance of acute <i>Mycoplasma pneumoniae</i> and Clamydia pneumoniae infections
 in children with wheezing. Eur Respir J 2000; 16:1142-6.    ^cY#v15n2a01.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#147#143#article#154#</font></p>     ^
cY#v15n2a01.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#148#144#article#154#<p>&nbsp;</p>    
 ^cY#v15n2a01.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#149#145#article#154#<p>&nbsp;</p>    
 ^cY#v15n2a01.htm##
00433000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019600078002001300274#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#150#146#article#154#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><b><a name="ad"></a><a href="#add"
><img src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence 
to:</b></b>    ^cY#v15n2a01.htm##
00262000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002500078002001300103#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#151#147#article#154#<br>   Nahal Hadi
    ^cY#v15n2a01.htm##
00411000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704017400078002001300252#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#152#148#article#154#<br>   Academic U
nit of Infection &amp;   Immunity, School of Medicine &amp; Biomedical Sciences,
 Medical School, University  of Sheffield, Beech Hill Road, Sheffield    ^cY#v15
n2a01.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#153#149#article#154#<br>    F Floor, 
S10 2RX, UK    ^cY#v15n2a01.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#154#150#article#154#<br>   Phone: +44
 755 602 0485    ^cY#v15n2a01.htm##
00318000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008100078002001300159#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#155#151#article#154#<br> <a href="mai
lto:hadina@sums.ac.ir">hadina@sums.ac.ir</a></font></p>     ^cY#v15n2a01.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009300078002001300171#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#156#152#article#154#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted on: 3/8/2010    ^cY#v15n
2a01.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003700078002001300115#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#157#153#article#154#<br>   Approved o
n: 6/16/2010    ^cY#v15n2a01.htm##
00299000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006200078002001300140#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a01.htm#S#p#158#154#article#154#<br>   We declare
 no conflict of interest.</font></p>     ^cY#v15n2a01.htm##
00485000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770120052000970300
00700149065000900156064000500165031000400170014000600174865000900180002001300189
035001000202801000700212#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S
#c#159#1#article#40#1#^rND^sMulholland^nK#Magnitude of the problem of childhood 
pneumonia^len#Lancet#19990000#1999#354#590-2#20110400#v15n2a01.htm#0099-5355#Lan
cet##
00650000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100017000920100
01800109810000600127012012700133030001600260065000900276064000500285031000300290
014000700293865000900300002001300309035001000322801001600332#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#160#2#article#40#2#^rND^sVuori^nE#^rND^sP
eltola^nH#^rND^sKallio^nMJT#et al#Etiology of pneumonia and other common childho
od infections requiring hospitalization and parenteral antimicrobial therapy^len
#Clin Infect Dis#19980000#1998#27#566-72#20110400#v15n2a01.htm#1058-4838#Clin In
fect Dis##
00558000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100015000920120
08200107030001800189065000900207064000500216031000300221014000600224865000900230
002001300239035001000252801001800262#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a01.htm#S#c#161#3#article#40#3#^rND^sKlig^nJE#^rND^sShah^nNB#Office pediatric
s: current issues in lower respiratory infections in children^len#Curr Opin Pedi
atr#20050000#2005#17#111-8#20110400#v15n2a01.htm#1040-8703#Curr Opin Pediatr##
00468000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120051000950300
02100146710000200167065000900169064000500178031000300183014000600186865000900192
002001300201#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#c#162#4#art
icle#40#4#^rND^sThomson^nRB#Laboratory diagnosis of respiratory infections^len#C
urr Opin Infect Dis#2#19990000#1999#12#115-9#20110400#v15n2a01.htm##
00682000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100017000950100
02200112810000600134012013000140030002600270065000900296064000500305031000400310
014000800314865000900322002001300331035001000344801002600354#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#163#5#article#40#5#^rND^sMenéndez^nR#^rND
^sCórdoba^nJ#^rND^sde la Cuadra^nP#et al#Value of the polymerase chain reaction 
assay in noninvasive respiratory samples for diagnosis of community-acquired pne
umonia^len#Am J Respir Crit Care Med#19990000#1999#159#1868-73#20110400#v15n2a01
.htm#1073-449X#Am J Respir Crit Care Med##
00542000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100020000930120
05400113030002100167065000900188064000500197031000300202014000600205865000900211
002001300220035001000233801002100243#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a01.htm#S#c#164#6#article#40#6#^rND^sGeorge^nH#^rND^sMccracken^nJR#Diagnosis 
and management of pneumonia in children^len#Pediatr Infect Dis J#20000000#2000#1
9#924-8#20110400#v15n2a01.htm#0891-3668#Pediatr Infect Dis J##
00677000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100020000950100
01700115810000600132012015000138030001600288065000900304064000500313031000300318
014000600321865000900327002001300336035001000349801001600359#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#165#7#article#40#7#^rND^sMandell^nLA#^rND
^sWunderink^nRG#^rND^sAnzueto^nA#et al#Infectious Diseases Society of America/Am
erican Thoracic Society consensus guidelines on the management of community-acqu
ired pneumonia in adults^len#Clin Infect Dis#20070000#2007#44#27-72#20110400#v15
n2a01.htm#1058-4838#Clin Infect Dis##
00593000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100023000930100
01800116810000600134012009900140030001500239710000200254065000900256064000500265
031000400270014000700274865000900281002001300290#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a01.htm#S#c#166#8#article#40#8#^rND^sStolza^nD#^rND^sChrist-Crain
d^nM#^rND^sGencaya^nMM#et al#Diagnostic value of signs, symptoms and laboratory 
values in lower respiratory tract infection^len#Swiss Med Wkly#2#20060000#2006#1
36#434-40#20110400#v15n2a01.htm##
00511000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770120073000910300
01300164065000900177064000500186032000400191014000500195865000900200002001300209
035001000222801001300232#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S
#c#167#9#article#40#9#^rND^sTan^nJS#Role of atypical pneumonia pathogens in resp
iratory tract infections^len#Can Respir J#19990000#1999#^s6#15-9#20110400#v15n2a
01.htm#1198-2241#Can Respir J##
00660000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980100
01400117810000600131012013100137030001700268065000900285064000500294031000300299
014000700302865000900309002001300318035001000331801001700341#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#168#10#article#40#10#^rND^sWadowsky^nRM#^
rND^sCastilla^nEA#^rND^sLaus^nS#et al#Evaluation of Chlamydia pneumoniae and Myc
oplasma pneumoniae as etiologic agents of persistent cough in adolescents and ad
ults^len#J Clin Microbiol#20020000#2002#40#637-40#20110400#v15n2a01.htm#0095-113
7#J Clin Microbiol##
00655000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100014000940100
01800108012013300126030002500259065000900284064000500293031000300298014000700301
865000900308002001300317035001000330801002500340#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a01.htm#S#c#169#11#article#40#11#^rND^sFile^nTM#^rND^sTan^nJS#^rN
D^sPlouffe^nJF#The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia 
pneumoniae, and Legionella pneumophila in respiratory infection^len#Infect Dis C
lin North Am#19980000#1998#12#569-92#20110400#v15n2a01.htm#0891-5520#Infect Dis 
Clin North Am##
00715000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
02300111810000600134012017600140030002100316065000900337064000500346031000300351
014000600354865000900360002001300369035001000382801002100392#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#170#12#article#40#12#^rND^sBlock^nS#^rND^
sHedrick^nJ#^rND^sHammerschlag^nMR#et al#Mycoplasma pneumoniae and Chlamydia pne
umoniae in pediatric community-acquired pneumonia: comparative efficacy and safe
ty of clarithromycin vs. erythromycin ethylsuccinate^len#Pediatr Infect Dis J#19
950000#1995#14#471-7#20110400#v15n2a01.htm#0891-3668#Pediatr Infect Dis J##
00587000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100025000790100016001040120
08700120030002300207065000900230064000500239031000300244014000700247865000900254
002001300263035001000276801002300286#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a01.htm#S#c#171#13#article#40#13#^rND^sTaylor-Robinson^nD#^rND^sBebear^nC#Ant
ibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections^
len#J Antimicrob Chemother#19970000#1997#40#622-30#20110400#v15n2a01.htm#0305-74
53#J Antimicrob Chemother##
00575000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970120
10300115030001200218065000900230064000500239031000300244014000600247865000900253
002001300262035001000275801001200285#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a01.htm#S#c#172#14#article#40#14#^rND^sPrincipi^nN#^rND^sEsposito^nS#Comparat
ive tolerability of erythromycin and newer macrolide antibacterials in paediatri
c patients^len#Drug Safety#19990000#1999#20#25-41#20110400#v15n2a01.htm#0114-591
6#DRUG SAFETY##
00711000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01800113810000600131012018100137030001700318065000900335064000500344031000400349
014000700353865000900360002001300369035001000382801001700392#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#173#15#article#40#15#^rND^sHarris^nR#^rND
^sMarmion^nBP#^rND^sVarkanis^nG#et al#Laboratory diagnosis of Mycoplasma pneumon
iae infection: 2. Comparison of methods for the direct detection of specific ant
igen or nucleic acid sequences in respiratory exudates^len#Epidemiol Infect#1988
0000#1988#101#685-94#20110400#v15n2a01.htm#0950-2688#Epidemiol Infect##
00568000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100018000930120
08800111030001700199065000900216064000500225031000400230014000700234865000900241
002001300250035001000263801001700273#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a01.htm#S#c#174#16#article#40#16#^rND^sLind^nK#^rND^sBentzon^nMW#Ten and a ha
lf years seroepidemiology of Mycoplasma pneumoniae infection in Denmark^len#Epid
emiol Infect#19910000#1991#107#189-99#20110400#v15n2a01.htm#0950-2688#Epidemiol 
Infect##
00686000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01700114010001800131012014500149030001700294065000900311064000500320031000300325
014000700328865000900335002001300344035001000357801001700367#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#175#17#article#40#17#^rND^sPetitjean^nJ#^
rND^sVabret^nA#^rND^sGouarin^nS#^rND^sFreymuth^nF#Evaluation of four commercial 
immunoglobulin G (IgG)- and IgM-specific enzyme immunoassays for diagnosis of My
coplasma pneumoniae infections^len#J Clin Microbiol#20020000#2002#40#165-71#2011
0400#v15n2a01.htm#0095-1137#J Clin Microbiol##
00705000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100029000950100
02100124010001400145012012600159030003200285065000900317064000500326031000200331
014000600333865000900339002001300348035001000361801003200371#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#176#18#article#40#18#^rND^sUldum^nSA#^rND
^sSøndergård-Andersen^nJ#^rND^sSkov Jensen^nJ#^rND^sLind^nK#Evaluation of a comm
ercial enzyme immunoassay for detection of Mycoplasma pneumoniae specific immuno
globulin G antibodies^len#Eur J Clin Microbiol Infect Dis#19900000#1990#9#221-3#
20110400#v15n2a01.htm#0722-2211#Eur J Clin Microbiol Infect Dis##
00678000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100014001000100
01800114810000600132012011900138030003200257065000900289064000500298031000200303
014000700305865000900312002001300321035001000334801003200344#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#177#19#article#40#19#^rND^sEchevarría^nJM
#^rND^sLeón^nP#^rND^sBalfagón^nP#et al#Diagnosis of Mycoplasma pneumoniae infect
ion by microparticle agglutination and antibody-capture enzymeimmunoassay^len#Eu
r J Clin Microbiol Infect Dis#19900000#1990#9#217-20#20110400#v15n2a01.htm#0722-
2211#Eur J Clin Microbiol Infect Dis##
00609000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
02200111810000600133012007800139030001700217065000900234064000500243031000300248
014000700251865000900258002001300267035001000280801001700290#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#178#20#article#40#20#^rND^sBernet^nC#^rND
^sGarret^nM#^rND^sde Barbeyrac^nB#et al#Detection of Mycoplasma pneumoniae by us
ing the polymerase chain reaction^len#J Clin Microbiol#19890000#1989#27#2492-6#2
0110400#v15n2a01.htm#0095-1137#J Clin Microbiol##
00678000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100014000940100
01900108810000600127012015900133030001300292065000900305064000500314031000400319
014000800323865000900331002001300340035001000353801001300363#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#179#21#article#40#21#^rND^sIeven^nM#^rND^
sUrsi^nD#^rND^sVan Bever^nH#et al#Detection of Mycoplasma pneumoniae by two poly
merase chain reactions and role of M. pneumoniae in acute respiratory tract infe
ctions in pediatric patients^len#J Infect Dis#19960000#1996#173#1445-52#20110400
#v15n2a01.htm#0022-1899#J Infect Dis##
00619000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100015000990100
01800114810000600132012008900138030001700227065000900244064000500253031000300258
014000700261865000900268002001300277035001000290801001700300#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#180#22#article#40#22#^rND^sAbele-Horn^nM#
^rND^sBusch^nU#^rND^sNitschko^nH#et al#Molecular approaches to diagnosis of pulm
onary diseases due to Mycoplasma pneumoniae^len#J Clin Microbiol#19980000#1998#3
6#548-51#20110400#v15n2a01.htm#0095-1137#J Clin Microbiol##
00636000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01400111810000600125012011200131030001700243065000900260064000500269031000300274
014000800277865000900285002001300294035001000307801001700317#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#181#23#article#40#23#^rND^sSkakni^nL#^rND
^sSardet^nA#^rND^sJust^nJ#et al#Detection of Mycoplasma pneumoniae in clinical s
amples from pediatric patients by polymerase chain reaction^len#J Clin Microbiol
#19920000#1992#30#2638-43#20110400#v15n2a01.htm#0095-1137#J Clin Microbiol##
00590000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100015000930100
01500108810000600123012009600129030002700225710000200252065000900254064000500263
031000300268014000700271865000900278002001300287#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a01.htm#S#c#182#24#article#40#24#^rND^sLiu^nFC#^rND^sChen^nPY#^rN
D^sHuang^nF#et al#Rapid diagnosis of Mycoplasma pneumoniae infection in children
 by polymerase chain reaction^len#J Microbiol Immunol Infect#2#20070000#2007#40#
507-12#20110400#v15n2a01.htm##
00630000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100017000930100
01700110010001900127012009600146030001500242065000900257064000500266031000300271
014000700274865000900281002001300290035001000303801001500313#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#183#25#article#40#25#^rND^sFoy^nHM#^rND^s
Cooney^nMK#^rND^sMcMahan^nR#^rND^sGrayston^nJT#Viral and mycoplasmal pneumonia i
n a prepaid medical care group during an eight-year period^len#Am J Epidemiol#19
730000#1973#97#93-102#20110400#v15n2a01.htm#0002-9262#Am J Epidemiol##
00557000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790120111000930300
01600204065000900220064000500229031000300234014000600237865000900243002001300252
035001000265801001600275#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S
#c#184#26#article#40#26#^rND^sFoy^nHM#Infections caused by Mycoplasma pneumoniae
 and possible carrier state in different populations of patients^len#Clin Infect
 Dis#19930000#1993#17#37-46#20110400#v15n2a01.htm#1058-4838#Clin Infect Dis##
00642000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100020000950100
02700115810000600142012010300148030001700251065000900268064000500277031000200282
014000700284865000900291002001300300035001000313801001700323#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#185#27#article#40#27#^rND^sNgeow^nYF#^rND
^sSuwanjutha^nS#^rND^sChantarojanasriri^nT#et al#An Asian study on the prevalenc
e of atypical respiratory pathogens in community-acquired pneumonia^len#Int J In
fect Dis#20050000#2005#9#144-53#20110400#v15n2a01.htm#1201-9712#Int J Infect Dis
##
00624000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01500110810000600125012009200131030002100223065000900244064000500253031000300258
014000800261865000900269002001300278035001000291801002100301#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#186#28#article#40#28#^rND^sOuchi^nK#^rND^
sKomura^nH#^rND^sFujii^nM#et al#Chlamydia pneumonia infection and Mycoplasma pne
umoniae infection in pediatric patients^len#Kansenshogaku Zasshi#19990000#1999#7
3#1177-82#20110400#v15n2a01.htm#0387-5911#Kansenshogaku Zasshi##
00648000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
01700115810000600132012012300138030001500261065000900276064000500285031000300290
014000600293865000900299002001300308035001000321801001500331#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#187#29#article#40#29#^rND^sElkholy^nA#^rN
D^sElkaraksy^nH#^rND^sFattouh^nA#et al#Acute lower respiratory tract infection d
ue to Chlamydia and Mycoplasma spp. in Egyptian children under 5 years of age^le
n#J Trop Pediatr#20090000#2009#55#195-7#20110400#v15n2a01.htm#0142-6338#J Trop P
ediatr##
00687000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950100
01800114810000600132012015700138030001600295065000900311064000500320031000300325
014000900328865000900337002001300346035001000359801001600369#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#188#30#article#40#30#^rND^sMeijer^nA#^rND
^sDagnelie^nCF#^rND^sDe Jong^nJC#et al#Low prevalence of Chlamydia pneumoniae an
d Mycoplasma pneumoniae among patients with symptoms of respiratory tract infect
ions in Dutch general practices^len#Eur J Epidemiol#20000000#2000#16#1099-106#20
110400#v15n2a01.htm#0392-2990#Eur J Epidemiol##
00696000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01500115010001700130011001900147012012800166030001600294065000900310064000500319
031000300324014000700327865000900334002001300343035001000356801001600366#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S#c#189#31#article#40#31#^rND^sPr
incipi^nN#^rND^sEsposito^nS#^rND^sBlasi^nF#^rND^sAllegra^nL#Mowgli Study Group#R
ole of Mycoplasma pneumonia and Chlamydia pneumonia in children with community-a
cquired lower respiratory tract infections^len#Clin Infect Dis#20010000#2001#32#
1281-9#20110400#v15n2a01.htm#1058-4838#Clin Infect Dis##
00699000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01500116810000600131012016600137030001900303065000900322064000500331031000300336
014000700339865000900346002001300355035001000368801001900378#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#190#32#article#40#32#^rND^sMaltezou^nHC#^
rND^sLa-Scola^nB#^rND^sAstra^nH#et al#Mycoplasma pneumoniae and Legionella pneum
ophila in community-acquired lower respiratory tract infections among hospitaliz
ed children: diagnosis by real time PCR^len#Scand J Infect Dis#20040000#2004#36#
639-42#20110400#v15n2a01.htm#0036-5548#Scand J Infect Dis##
00712000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100014000930100
01400107810000600121012018400127030002100311065000900332064000500341031000300346
014000800349865000900357002001300366035001000379801002100389#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#191#33#article#40#33#^rND^sKim^nNH#^rND^s
Lee^nJA#^rND^sEun^nBW#et al#Comparison of polymerase chain reaction and the indi
rect particle agglutination antibody test for the diagnosis of Mycoplasma pneumo
niae pneumonia in children during two outbreaks^len#Pediatr Infect Dis J#2007000
0#2007#26#897-903#20110400#v15n2a01.htm#0891-3668#Pediatr Infect Dis J##
00606000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940100
01600109810000600125012008700131030001500218065000900233064000500242031000300247
014000700250865000900257002001300266035001000279801001500289#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#192#34#article#40#34#^rND^sSidal^nM#^rND^
sKilic^nA#^rND^sUnuvar^nE#et al#Frequency of Chlamydia pneumoniae and Mycoplasma
 pneumoniae infections in children^len#J Trop Pediatr#20070000#2007#53#225-31#20
110400#v15n2a01.htm#0142-6338#J Trop Pediatr##
00571000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100014000940100
02400108810000600132012008200138030001400220710000200234065000900236064000500245
031000300250014000600253865000900259002001300268#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a01.htm#S#c#193#35#article#40#35#^rND^sBütün^nY#^rND^sKöse^nS#^rN
D^sBabayi&#287;it^nA#et al#Chlamydia and Mycoplasma serology in respiratory trac
t infections of children^len#Tuberk Toraks#2#20060000#2006#54#254-8#20110400#v15
n2a01.htm##
00583000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100016000930100
01700109810000600126012006700132030001300199065000900212064000500221031000400226
014000600230865000900236002001300245035001000258801001300268#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#194#36#article#40#36#^rND^sFoy^nHM#^rND^s
Kenny^nGE#^rND^sCooney^nMK#et al#Longterm epidemiology of infections with Mycopl
asma pneumoniae^len#J Infect Dis#19790000#1979#139#681-7#20110400#v15n2a01.htm#0
022-1899#J Infect Dis##
00607000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
01700112810000600129012008900135030001300224065000900237064000500246031000300251
014000600254865000900260002001300269035001000282801001300292#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#195#37#article#40#37#^rND^sEsposito^nS#^r
ND^sBlasi^nF#^rND^sBellini^nF#et al#Mycoplasma pneumoniae and Chlamydia pneumoni
ae infections in children with pneumonia^len#Eur Respir J#20010000#2001#17#241-5
#20110400#v15n2a01.htm#0903-1936#Eur Respir J##
00613000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01500110810000600125012008200131030002100213065000900234064000500243031000300248
014000700251865000900258002001300267035001000280801002100290#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#196#38#article#40#38#^rND^sWubbel^nL#^rND
^sMuniz^nL#^rND^sAhmed^nA#et al#Etiology and treatment of community-acquired pne
umonia in ambulatory children^len#Pediatr Infect Dis J#19990000#1999#18#98-104#2
0110400#v15n2a01.htm#0891-3668#Pediatr Infect Dis J##
00607000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100025000950100
01700120810000600137012007800143030001400221065000900235064000500244031000400249
014000600253865000900259002001300268035001000281801001400291#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a01.htm#S#c#197#39#article#40#39#^rND^sKorppi^nM#^rND
^sHeiskanen-Kosma^nT#^rND^sJaloner^nE#et al#Aetiology of community-acquired pneu
monia in children treated in hospital^len#Eur J Pediatr#19930000#1993#152#24-30#
20110400#v15n2a01.htm#0340-6199#Eur J Pediatr##
00552000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120107000970300
01300204065000900217064000500226031000300231014000700234865000900241002001300250
035001000263801001300273#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a01.htm#S
#c#198#40#article#40#40#^rND^sEsposito^nS#Importance of acute Mycoplasma pneumon
iae and Clamydia pneumoniae infections in children with wheezing^len#Eur Respir 
J#20000000#2000#16#1142-6#20110400#v15n2a01.htm#0903-1936#Eur Respir J##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#o#1#1#article#1
#20110406#124802#v15n2a02.htm#140##
03286000000000673000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400110014403500100015501200830
01650100026002480100024002740100030002980100020003280100018003480100021003660100
02400387010002100411010002500432010002400457070007100481070009300552070010200645
08315860074708500080233308500180234108500410235908500290240005800670242906000130
24960580035025090600008025441170006025520720003025581120009025611110010025701140
00902580113001002589002001302599#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a
02.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#2#BJID230#nd#Braz J Infect D
is#15#2#20110400#^f102^l108#1413-8670#Mask-wearing and respiratory infection in 
healthcare workers in Beijing, China^len#^rND^1A01 A02^nPeng^sYang#^rND^1A03^nHo
lly^sSeale#^rND^1A03^nC Raina^sMacIntyre#^rND^nHaiyan^sZhang#^rND^nZhen^sZhang#^
rND^1A02^nYi^sZhang#^rND^1A02^nXiaoli^sWang#^rND^1A02^nXinyu^sLi#^rND^1A02^nXing
huo^sPang#^rND^1A02^nQuanyi^sWang#Beijing Center for Disease Prevention and Cont
rol^iA01^cBeijing^pChina#Capital Medical University^iA02^1School of Public Healt
h and Family Medicine^cBeijing^pChina#University of New South Wales^iA03^1School
 of Public Health and Community Medicine^cSydney^pAustralia#^len^aOBJECTIVES: Th
e aim of the study was to determine rates of mask-wearing, of respiratory infect
ion and the factors associated with mask-wearing and of respiratory infection in
 healthcare workers (HCWs) in Beijing during the winter of 2007/2008. METHODS: W
e conducted a survey of 400 HCWs working in eight hospitals in Beijing by face t
o face interview using a standardized questionnaire. RESULTS: We found that 280/
400 (70.0%) of HCWs were compliant with mask-wearing while in contact with patie
nts. Respiratory infection occurred in 238/400 (59.5%) subjects from November, 2
007 through February, 2008. Respiratory infection was higher among females (odds
 ratio [OR], 2.00 [95% confidence interval {CI}, 1.16-3.49]) and staff working i
n larger hospitals (OR, 1.72 [95% CI, 1.092.72]), but was lower among subjects w
ith seasonal influenza vaccination (OR, 0.46 [95% CI, 0.280.76]), wearing medica
l masks (reference: cotton-yarn; OR, 0.60 [95% CI, 0.39-0.91]) or with good mask
-wearing adherence (OR, 0.60 [95% CI, 0.37-0.98]). The risk of respiratory infec
tion of HCWs working in low risk areas was similar to that of HCWs in high risk 
area. CONCLUSION: Our data suggest that female HCWs and staffs working in larger
 hospitals are the focus of prevention and control of respiratory infection in B
eijing hospitals. Mask-wearing and seasonal influenza vaccination are protective
 for respiratory infection in HCWs; the protective efficacy of medical masks is 
better than that of cotton yarn ones; respiratory infection of HCWs working in l
ow risk areas should also be given attention.#^dnd^i1#^tm^len^kmasks^i1#^tm^len^
krespiratory tract infections^i1#^tm^len^khealth personnel^i1#National High Tech
nology Research and Development Program of China#2008AA02Z416#Beijing Natural Sc
ience Foundation#7082047#other#17#20100812#8/12/2010#20100928#9/28/2010#v15n2a02
.htm##
03459000000000673000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400110014403500100015501200900
01650100026002550100024002810100030003050100020003350100018003550100021003730100
02400394010002100418010002500439010002400464070007100488070009300559070010200652
08316140075408500080236808500180237608500410239408500290243505800670246406000820
25310580035026130600077026481170006027250720003027311120009027341110010027431140
00902753113001002762002001302772#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a
02.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#2#BJID230#nd#Braz J Infect D
is#15#2#20110400#^f102^l108#1413-8670#<b>Mask-wearing and respiratory infection 
in healthcare workers in Beijing, China</b>^len#^rND^1A01 A02^nPeng^sYang#^rND^1
A03^nHolly^sSeale#^rND^1A03^nC Raina^sMacIntyre#^rND^nHaiyan^sZhang#^rND^nZhen^s
Zhang#^rND^1A02^nYi^sZhang#^rND^1A02^nXiaoli^sWang#^rND^1A02^nXinyu^sLi#^rND^1A0
2^nXinghuo^sPang#^rND^1A02^nQuanyi^sWang#Beijing Center for Disease Prevention a
nd Control^iA01^cBeijing^pChina#Capital Medical University^iA02^1School of Publi
c Health and Family Medicine^cBeijing^pChina#University of New South Wales^iA03^
1School of Public Health and Community Medicine^cSydney^pAustralia#^len^a<b>OBJE
CTIVES:</b> The aim of the study was to determine rates of mask-wearing, of resp
iratory infection and the factors associated with mask-wearing and of respirator
y infection in healthcare workers (HCWs) in Beijing during the winter of 2007/20
08. <b>METHODS:</b> We conducted a survey of 400 HCWs working in eight hospitals
 in Beijing by face to face interview using a standardized questionnaire. <b>RES
ULTS:</b> We found that 280/400 (70.0%) of HCWs were compliant with mask-wearing
 while in contact with patients. Respiratory infection occurred in 238/400 (59.5
%) subjects from November, 2007 through February, 2008. Respiratory infection wa
s higher among females (odds ratio [OR], 2.00 [95% confidence interval {CI}, 1.1
6-3.49]) and staff working in larger hospitals (OR, 1.72 [95% CI, 1.092.72]), bu
t was lower among subjects with seasonal influenza vaccination (OR, 0.46 [95% CI
, 0.280.76]), wearing medical masks (reference: cotton-yarn; OR, 0.60 [95% CI, 0
.39-0.91]) or with good mask-wearing adherence (OR, 0.60 [95% CI, 0.37-0.98]). T
he risk of respiratory infection of HCWs working in low risk areas was similar t
o that of HCWs in high risk area. <b>CONCLUSION:</b> Our data suggest that femal
e HCWs and staffs working in larger hospitals are the focus of prevention and co
ntrol of respiratory infection in Beijing hospitals. Mask-wearing and seasonal i
nfluenza vaccination are protective for respiratory infection in HCWs; the prote
ctive efficacy of medical masks is better than that of cotton yarn ones; respira
tory infection of HCWs working in low risk areas should also be given attention.
#^dnd^i1#^tm^len^kmasks^i1#^tm^len^krespiratory tract infections^i1#^tm^len^khea
lth personnel^i1#National High Technology Research and Development Program of Ch
ina#<span lang=EN-US style='font-size:10.0pt;font-family:Verdana'>2008AA02Z416</
span>#Beijing Natural Science Foundation#<span lang=EN-US style='font-size:10.0p
t;font-family:Verdana'>7082047</span>#other#17#20100812#8/12/2010#20100928#9/28/
2010#v15n2a02.htm##
03475000000000697000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000200117049000800119
15800030012703000210013003100030015103200020015406500090015601400110016503500100
01760120083001860100026002690100024002950100030003190100020003490100018003690100
02100387010002400408010002100432010002500453010002400478070007300502070009500575
07001040067008316350077408500080240908500180241708500410243508500290247605800670
25050600013025720580035025850600008026201170006026280720003026341120009026371110
01002646114000902656113001002665002001302675008008902688#v15n2#V:\SciELO\serial\
bjid\v15n2\markup\v15n2a02.htm#S#l#4#1#article#1#^mMar./Apr.^a2011#oa#en#br1.1#1
#4.0#ilus#tab#2#BJID230#nd#Braz. j. infect. dis#15#2#20110400#^f102^l108#1413-86
70#Mask-wearing and respiratory infection in healthcare workers in Beijing, Chin
a^len#^rND^1A01 A02^nPeng^sYang#^rND^1A03^nHolly^sSeale#^rND^1A03^nC Raina^sMacI
ntyre#^rND^nHaiyan^sZhang#^rND^nZhen^sZhang#^rND^1A02^nYi^sZhang#^rND^1A02^nXiao
li^sWang#^rND^1A02^nXinyu^sLi#^rND^1A02^nXinghuo^sPang#^rND^1A02^nQuanyi^sWang#^
iA01^1Beijing Center for Disease Prevention and Control^cBeijing^pChina#^iA02^1C
apital Medical University^2School of Public Health and Family Medicine^cBeijing^
pChina#^iA03^1University of New South Wales^2School of Public Health and Communi
ty Medicine^cSydney^pAustralia#^len^aOBJECTIVES: The aim of the study was to det
ermine rates of mask-wearing, of respiratory infection and the factors associate
d with mask-wearing and of respiratory infection in healthcare workers (HCWs) in
 Beijing during the winter of 2007/2008. METHODS: We conducted a survey of 400 H
CWs working in eight hospitals in Beijing by face to face interview using a stan
dardized questionnaire. RESULTS: We found that 280/400 (70.0 percent) of HCWs we
re compliant with mask-wearing while in contact with patients. Respiratory infec
tion occurred in 238/400 (59.5 percent) subjects from November, 2007 through Feb
ruary, 2008. Respiratory infection was higher among females (odds ratio [OR], 2.
00 [95 percent confidence interval {CI}, 1.16-3.49]) and staff working in larger
 hospitals (OR, 1.72 [95 percent CI, 1.092.72]), but was lower among subjects wi
th seasonal influenza vaccination (OR, 0.46 [95 percent CI, 0.280.76]), wearing 
medical masks (reference: cotton-yarn; OR, 0.60 [95 percent CI, 0.39-0.91]) or w
ith good mask-wearing adherence (OR, 0.60 [95 percent CI, 0.37-0.98]). The risk 
of respiratory infection of HCWs working in low risk areas was similar to that o
f HCWs in high risk area. CONCLUSION: Our data suggest that female HCWs and staf
fs working in larger hospitals are the focus of prevention and control of respir
atory infection in Beijing hospitals. Mask-wearing and seasonal influenza vaccin
ation are protective for respiratory infection in HCWs; the protective efficacy 
of medical masks is better than that of cotton yarn ones; respiratory infection 
of HCWs working in low risk areas should also be given attention.#^dnd^i1#^tm^le
n^kmasks^i1#^tm^len^krespiratory tract infections^i1#^tm^len^khealth personnel^i
1#National High Technology Research and Development Program of China#2008AA02Z41
6#Beijing Natural Science Foundation#7082047#other#17#20100812#8/12/2010#2010092
8#9/28/2010#v15n2a02.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_ar
ttext&pid=S1413-86702011000200002##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#5#1#article#119#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLE</b><
/font></p>     ^cY#v15n2a02.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#6#2#article#119#<p>&nbsp;</p>     ^cY
#v15n2a02.htm##
00419000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704018600074002001300260#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#7#3#article#119#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Mask-wearing and 
respiratory infection in healthcare workers in Beijing, China</b></font></p>    
 ^cY#v15n2a02.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#8#4#article#119#<p>&nbsp;</p>     ^cY
#v15n2a02.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#9#5#article#119#<p>&nbsp;</p>     ^cY
#v15n2a02.htm##
00585000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704035100075002001300426#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#10#6#article#119#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Peng Yang<sup>I</sup>; Holly Seale
<sup>II</sup>; C Raina MacIntyre<sup>III</sup>; Haiyan Zhang<sup>IV</sup>; Zhen 
Zhang<sup>V</sup>; Yi Zhang<sup>VI</sup>; Xiaoli Wang<sup>VI</sup>; Xinyu Li<sup
>VII</sup>; Xinghuo Pang<sup>VIII</sup>; Quanyi Wang<sup>VIII</sup></b></font></
p>     ^cY#v15n2a02.htm##
00491000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704025700075002001300332#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#11#7#article#119#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>MD; Lecturer, Beijing Cen
ter for Disease Prevention and Control (CDC), Beijing, China; Capital Medical Un
iversity School of Public Health and Family Medicine, Beijing, China     ^cY#v15
n2a02.htm##
00373000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704013900075002001300214#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#12#8#article#119#<br>   <sup>II</sup>
MD; Lecturer, School of Public Health and Community Medicine, University of New 
South Wales, Sydney, Australia     ^cY#v15n2a02.htm##
00371000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704013700075002001300212#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#13#9#article#119#<br>   <sup>III</sup
>Professor, School of Public Health and Community Medicine, University of New So
uth Wales, Sydney, Australia     ^cY#v15n2a02.htm##
00317000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008200076002001300158#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#14#10#article#119#<br>   <sup>IV</sup
>MD; Lecturer, Dong Cheng District CDC, Beijing, China     ^cY#v15n2a02.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007800076002001300154#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#15#11#article#119#<br>   <sup>V</sup>
MD; Lecturer, Xi Cheng District CDC, Beijing, China    ^cY#v15n2a02.htm##
00403000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016800076002001300244#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#16#12#article#119#<br>   <sup>VI</sup
>MD; Associate Lecturer, Beijing CDC, Beijing, China; Capital Medical University
 School of Public Health and Family Medicine, Beijing, China     ^cY#v15n2a02.ht
m##
00394000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015900076002001300235#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#17#13#article#119#<br>   <sup>VII</su
p>MD; Lecturer, Beijing CDC, Beijing, China; Capital Medical University School o
f Public Health and Family Medicine, Beijing, China     ^cY#v15n2a02.htm##
00405000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017000076002001300246#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#18#14#article#119#<br> <sup>VIII</sup
>MD; Professor, Beijing CDC, Beijing, China; Capital Medical University School o
f Public Health and Family Medicine, Beijing, China</font></p>     ^cY#v15n2a02.
htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#19#15#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a><
/font></p>     ^cY#v15n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#20#16#article#119#<p>&nbsp;</p>     ^
cY#v15n2a02.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#21#17#article#119#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v15n2a02.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#22#18#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
15n2a02.htm##
00556000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032100076002001300397#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#23#19#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>OBJECTIVES:</b> The aim of the st
udy was to determine rates of mask-wearing, of respiratory infection and the fac
tors associated with mask-wearing and of respiratory infection in healthcare wor
kers (HCWs) in Beijing during the winter of 2007/2008.    ^cY#v15n2a02.htm##
00399000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016400076002001300240#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#24#20#article#119#<br>   <b>METHODS:<
/b> We conducted a survey of 400 HCWs working in eight hospitals in Beijing by f
ace to face interview using a standardized questionnaire.    ^cY#v15n2a02.htm##
01055000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082000076002001300896#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#25#21#article#119#<br> <b>RESULTS:</b
> We found that 280/400 (70.0%) of HCWs were compliant with mask-wearing while i
n contact with patients. Respiratory infection occurred in 238/400 (59.5%) subje
cts from November, 2007 through February, 2008. Respiratory infection was higher
 among females (odds ratio &#91;OR&#93;, 2.00 &#91;95% confidence interval {CI},
 1.16-3.49&#93;) and staff working in larger hospitals (OR, 1.72 &#91;95% CI, 1.
092.72&#93;), but was lower among subjects with seasonal influenza vaccination (
OR, 0.46 &#91;95% CI, 0.280.76&#93;), wearing medical masks (reference: cotton-y
arn; OR, 0.60 &#91;95% CI, 0.39-0.91&#93;) or with good mask-wearing adherence (
OR, 0.60 &#91;95% CI, 0.37-0.98&#93;). The risk of respiratory infection of HCWs
 working in low risk areas was similar to that of HCWs in high risk area.    ^cY
#v15n2a02.htm##
00706000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047100076002001300547#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#26#22#article#119#<br> <b>CONCLUSION:
</b> Our data suggest that female HCWs and staffs working in larger hospitals ar
e the focus of prevention and control of respiratory infection in Beijing hospit
als. Mask-wearing and seasonal influenza vaccination are protective for respirat
ory infection in HCWs; the protective efficacy of medical masks is better than t
hat of cotton yarn ones; respiratory infection of HCWs working in low risk areas
 should also be given attention.</font></p>     ^cY#v15n2a02.htm##
00411000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017600076002001300252#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#27#23#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> masks; respiratory 
tract infections; health personnel.</font></p> <hr size="1" noshade>     ^cY#v15
n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#28#24#article#119#<p>&nbsp;</p>     ^
cY#v15n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#29#25#article#119#<p>&nbsp;</p>     ^
cY#v15n2a02.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#30#26#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>INTRODUCTION</b></i></font></p
>     ^cY#v15n2a02.htm##
01227000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704099200076002001301068#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#31#27#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Influenza pandemic has been a global
 public   health issue in recent years,<sup>1</sup> and in 2009, a pandemic   of
 a novel H1N1 influenza virus of swine   origin occurred.<sup>2,3</sup> During t
he initial stages of an   influenza pandemic, supplies of vaccines and   antivir
al medications are likely to be delayed or   inadequate to treat a very large nu
mber of affected   individuals. Therefore, non-pharmacological   interventions w
ill be important, including the   use of respirators and/or medical masks, which
   is able to confer respiratory protection.<sup>4-6</sup> If hospitals   are to
 continue to function adequately   during a pandemic, reliable access to effecti
ve   protection strategies for healthcare workers   (HCWs) will be imperative. R
educing transmission   to HCWs may not only help support the   healthcare workfo
rce, but may also prevent influenza transmission to patients.<sup>7</sup></font>
</p>     ^cY#v15n2a02.htm##
01105000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087000076002001300946#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#32#28#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">It is commonly acknowledged that adh
erence   with an intervention can change with perception   of risk during a pand
emic or an outbreak   of unknown origin. Since the epidemic of   SARS in Beijing
 in 2003, awareness and commitment   to infection control increased, including  
 the use of masks among HCWs. However,   we are not aware of the exact rate of a
nd adherence   to mask-wearing after the SARS outbreak   in 2003. Furthermore, w
e commonly assume   that frontline HCWs are at increased risk   of respiratory i
nfection, but to the best of our   knowledge there is no data examining this in 
  our setting. Therefore, the purpose of our study   was to determine the level 
of mask-wearing   and respiratory infection in healthcare workers during an infl
uenza season in Beijing, China.</font></p>     ^cY#v15n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#33#29#article#119#<p>&nbsp;</p>     ^
cY#v15n2a02.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#34#30#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b><i>METHODS</i></b></font></p>    
 ^cY#v15n2a02.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011600076002001300192#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#35#31#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Subjects and survey design</b></f
ont></p>     ^cY#v15n2a02.htm##
01733000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704149800076002001301574#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#36#32#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Between April 20, 2008 and May 15, 2
008,   we undertook a survey to examine the level   of mask-wearing and respirat
ory infection in   HCWs from eight hospitals, in Beijing, China. If we assumed t
hat the proportion of HCWs with good mask-wearing adherence (wearing the mask fo
r <u>&gt;</u> 70% of patient-contact time) was equal to 50%, a 5% precision, wit
h a 95% confidence interval according to the formula stated by Daniel,<sup>8</su
p> the required sample size for this survey would be 384 HCWs. Eventually, 400 H
CWs were enrolled. These 400 HCWs came from a range of different departments and
 wards representing high and low risk settings for respiratory infection (respir
atory, emergency, infectious disease and surgical departments) of eight hospital
s in Beijing, using a two-stage random sampling technique. For this study, we cl
assified the first three wards/departments as being high-risk settings for respi
ratory pathogen transmission and the surgical department as being low risk. In t
he first stage, eight hospitals were randomly selected from 23 level 2 or 3 hosp
itals in Beijing. In China, hospitals are categorized into three levels (Level 1
, 2 and 3) according to the magnitude (Level 3 &gt; Level 2 &gt; Level 1).<sup>9
</sup> In the second stage, for each selected hospital, 50 subjects were randoml
y enrolled in this survey from respiratory, emergency, infectious disease and su
rgical departments.</font></p>     ^cY#v15n2a02.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010500076002001300181#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#37#33#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Data collection</b></font></p>   
  ^cY#v15n2a02.htm##
00878000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064300076002001300719#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#38#34#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Using a standardized questionnaire, 
we developed a survey that assessed: demographic characteristics; professional d
esignation and clinical duties; attitude and adherence to mask-wearing, mask typ
es used; hand washing frequency, seasonal influenza vaccination; and respiratory
 infection (clinical respiratory illness &#91;CRI&#93;, defined as having at lea
st two of the following symptoms simultaneously: fever, cough, sore throat, nasa
l congestion or rhinorrhea)<sup>10</sup> during the 2007/2008 (from November, 20
07 through February, 2008) influenza season.</font></p>     ^cY#v15n2a02.htm##
00630000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039500076002001300471#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#39#35#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Attitude to mask-wearing was assesse
d by asking the following question: Do you think it is necessary to wear masks w
hen in contact with patients? Attitude was categorized as active (necessary to w
ear masks when in contact with patients) and not active (not necessary to wear m
asks when in contact with patients).</font></p>     ^cY#v15n2a02.htm##
00651000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041600076002001300492#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#40#36#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Mask-wearing adherence was measured 
by the following question: for what percentage of patient-contact time did you w
ear a mask or respirator? According to expert opinion, adherence was categorized
 as good (wearing the mask for <u>&gt;</u> 70% of patient-contact time) and poor
 (wearing the mask for &lt; 70% of patient-contact time).</font></p>     ^cY#v15
n2a02.htm##
00639000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040400076002001300480#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#41#37#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Hand washing frequency was assessed 
by asking the following question: Do you think it is necessary to wash hands aft
er contact with each patient? Frequency was categorized as frequent (necessary t
o wash hands after contact with each patient) and not frequent (not necessary to
 wash hands after contact with each patient).</font></p>     ^cY#v15n2a02.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011000076002001300186#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#42#38#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Statistical analysis</b></font></
p>     ^cY#v15n2a02.htm##
01057000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082200076002001300898#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#43#39#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Questionnaire data were entered in d
uplicate using EpiData Software, and data were analyzed using SPSS 11.5 statisti
cal package (SPSS Inc., Chicago, Illinois, USA). Univariate and multivariate log
istic regression analyses were conducted to determine predictors of mask-wearing
 adherence and respiratory infection in HCWs. Predictive factors were first anal
yzed by univariate analysis, and then factors with p-values &lt; 0.5 or those th
at were thought to be clinically significant by professional view were included 
in the multivariable model; backward logistic regression was conducted by removi
ng variables with p &gt; 0.1. For all statistical analyses two-tailed tests were
 used, and statistical significance was defined as p &lt; 0.05.</font></p>     ^
cY#v15n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#44#40#article#119#<p>&nbsp;</p>     ^
cY#v15n2a02.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#45#41#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>RESULTS</b></i></font></p>    
 ^cY#v15n2a02.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#46#42#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Subject characteristics</b></font
></p>     ^cY#v15n2a02.htm##
00822000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058700076002001300663#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#47#43#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">All 400 subjects selected for this s
urvey participated in and completed the study. The median age was 35 years and a
bout 81% (324/400) were female. About 47.8 % (191/400) were doctors, and 52.2% (
209/400) were nurses; 52.7% (211/400) were classified as being in a junior role,
 and 80% (320/400) were working in high-risk settings. About 28.5% (114/400) rep
orted having taken seasonal influenza vaccination. Detailed demographic characte
ristics of the subjects are reported in <a href="#tab1">Table 1</a>.</font></p> 
    ^cY#v15n2a02.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#48#44#article#119#<p><a name="tab1"><
/a></p>     ^cY#v15n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#49#45#article#119#<p>&nbsp;</p>     ^
cY#v15n2a02.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#50#46#article#119#<p align="center"><
img src="/img/revistas/bjid/v15n2/a02tab01.jpg"></p>     ^cY#v15n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#51#47#article#119#<p>&nbsp;</p>     ^
cY#v15n2a02.htm##
00400000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016500076002001300241#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#52#48#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Mask use and respiratory infectio
n in subjects in seasonal influenza season</b></font></p>     ^cY#v15n2a02.htm##
01005000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077000076002001300846#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#53#49#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">All subjects (100%) reported mask us
e. The majority (70%, 280/400) of participants self reported good adherence with
 masks. About 84.0% (336/400) reported adverse effects of mask-wearing, and 43.0
% (172/400) reported more than two adverse effects (<a href="#tab2">Table 2</a>)
. The most commonly reported adverse effect was breathing difficulties (56.5%, 2
26/400). The washable, reusable cotton-yarn mask was the most common type of mas
k used as reported by participants (59.8%, 239/400), followed by medical masks (
40.2%, 161/400). Close to 60% of participants reported having had clinical respi
ratory illness (59.5%, 238/400) during the influenza season. (<a href="#tab2">Ta
ble 2</a>).</font></p>     ^cY#v15n2a02.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#54#50#article#119#<p><a name="tab2"><
/a></p>     ^cY#v15n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#55#51#article#119#<p>&nbsp;</p>     ^
cY#v15n2a02.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#56#52#article#119#<p align="center"><
img src="/img/revistas/bjid/v15n2/a02tab02.jpg"></p>     ^cY#v15n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#57#53#article#119#<p>&nbsp;</p>     ^
cY#v15n2a02.htm##
00370000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013500076002001300211#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#58#54#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Predictors associated with mask u
se adherence</b></font></p>     ^cY#v15n2a02.htm##
01089000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085400076002001300930#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#59#55#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Multivariate analysis showed that go
od mask-wearing adherence was higher among females (odds ratio &#91;OR&#93;, 3.3
4 &#91;95% confidence interval {CI}, 1.77-6.33; p &lt; 0.001), level 3 hospital 
(reference: level 2; OR, 2.61 &#91;95% CI, 1.52-4.49&#93;; p= 0.001), high risk 
department (reference: low risk; OR, 2.05 &#91;95% CI, 1.06-3.97&#93;; p = 0.033
), intermediate level (reference: senior level; OR, 2.55 &#91;95% CI, 1.10-5.91&
#93;; p = 0.029) and junior level (reference: senior level; OR, 2.77 &#91;95% CI
, 1.23-6.24&#93;; p = 0.014), active attitude to mask-wearing (OR, 12.25 &#91;95
% CI, 6.13-24.50&#93;; p &lt; 0.001) and frequent hand-washing (OR, 2.06 &#91;95
% CI, 1.20-3.54&#93;; p = 0.009) (<a href="/img/revistas/bjid/v15n2/a02tab03.jpg
">Table 3</a>).</font></p>     ^cY#v15n2a02.htm##
00373000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013800076002001300214#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#60#56#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Predictors associated with respir
atory infection</b></font></p>     ^cY#v15n2a02.htm##
01304000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704106900076002001301145#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#61#57#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Multivariate analysis showed that fe
males (OR, 2.0 &#91;95% CI, 1.16-3.49&#93;; p = 0.013) and staff working in leve
l 3 hospitals (reference: level 2; OR, 1.72 &#91;95% CI, 1.09-2.72&#93;; p = 0.0
2) were at increased risk of respiratory infection. But subjects with seasonal i
nfluenza vaccination (OR, 0.46 &#91;95% CI, 0.28-0.76&#93;; p = 0.002), wearing 
medical masks (reference: cotton-yarn; OR, 0.60 &#91;95% CI, 0.39-0.91&#93;; p =
 0.018) or with good mask-wearing adherence (reference: poor; OR, 0.60 &#91;95% 
CI, 0.37-0.98&#93;; p = 0.041) were at lower risk. The risk of respiratory infec
tion of HCWs working in low risk areas was similar to that of HCWs in high risk 
areas (<a href="/img/revistas/bjid/v15n2/a02tab04.jpg">Table 4</a>). Although fr
equent hand-washing was a protective predictor for respiratory infection (OR, 0.
65 &#91;95% CI, 0.43-0.97&#93;; p = 0.034) in univariate analysis, this action w
as not associated with respiratory infection in multivariate analysis.</font></p
>     ^cY#v15n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#62#58#article#119#<p>&nbsp;</p>     ^
cY#v15n2a02.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#63#59#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>DISCUSSION</b></i></font></p> 
    ^cY#v15n2a02.htm##
01147000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704091200076002001300988#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#64#60#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In our study, we found high self-rep
orted mask adherence, despite the majority of HCWs having reported adverse effec
ts of mask-wearing. This high level of mask-wearing adherence may be attributed 
to enhanced management of nosocomial infection control and improved consciousnes
s among HCWs following the SARS outbreak in Beijing in 2003, especially after th
e occurrence of SARS infection in HCWs.<sup>11</sup> We found that the majority 
of our participants used re-usable cotton-yarn masks, followed by medical masks.
 N95 masks were not reported as being used routinely. It may be hypothesized tha
t the cost of N95 masks may be a potential barrier for their use in these wards,
 and departments prefer to re-usable cotton-yarn masks which could be considered
 as more economically viable in the setting of limited funding/resources.</font>
</p>     ^cY#v15n2a02.htm##
00841000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060600076002001300682#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#65#61#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In this study, female and junior/int
ermediate HCWs had better adherence to mask-wearing than their counterparts, whi
ch may be due to better consciousness of self-protection of females and junior/i
ntermediate HCWs who are much more prone to comply with the hospital infection c
ontrol policies. HCWs of level 3 hospitals had higher level of adherence to mask
-wearing, compared to their counterparts in level 2 facilities. This may be due 
to the stricter and more complete regulations of infection control in larger hos
pitals.</font></p>     ^cY#v15n2a02.htm##
00849000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061400076002001300690#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#66#62#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">HCWs from high risk departments were
 found to have higher levels of adherence with mask-wearing, compared to their c
ounterparts from low risk areas. This may be due to increased awareness of risk 
in these departments. We found that it did not matter if the staff member was wo
rking in a high or low risk department, anyone who had a "positive attitude" to 
mask-wearing also had good adherence with mask-wearing. In our study, participan
ts who reported frequent hand-washing were also found to have good adherence wit
h mask-wearing.</font></p>     ^cY#v15n2a02.htm##
00742000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050700076002001300583#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#67#63#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In this study close to 60% of partic
ipants self-reported having a respiratory infection during the influenza season.
 Surprisingly, there was no significant difference between rates reported among 
participants of high risk areas and those from low risk areas. This finding sugg
ested that healthcare workers working in low risk areas had the same risk of res
piratory infection as those in high risk areas in Beijing hospitals.</font></p> 
    ^cY#v15n2a02.htm##
00753000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051800076002001300594#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#68#64#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We are unsure why females had a high
er reported rate of infection - a possible explanation could be that female heal
thcare workers have closer patient contact than their male counterparts. The lev
el 3 hospital represented the higher risk of respiratory infection compared to l
evel 2 facilities suggesting that level 3 hospitals, which have larger populatio
n of sick patients, are a priority for measures to protect health care workers.<
/font></p>     ^cY#v15n2a02.htm##
00636000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040100076002001300477#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#69#65#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The coverage of seasonal influenza v
accination is always of concern, especially in HCWs.<sup>12-14</sup> In this sur
vey, we found that 28.5% (114/400) of participants were vaccinated, and seasonal
 influenza vaccination showed a protective effect, underscoring the importance o
f seasonal influenza vaccination for HCWs.</font></p>     ^cY#v15n2a02.htm##
01641000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704140600076002001301482#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#70#66#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This study showed that HCWs with goo
d adherence to mask-wearing were at lower risk of respiratory infection, which i
ndicates the protective effect of masks, also found in previous studies.<sup>4-6
,15</sup> The protective efficacy of masks/respirators is provided through a com
bined effect of transmission blocking potential, the fit and related air leakage
 of the mask/respirator, and the consistency in the use of masks/respirators. Th
eir efficacy is graded on the level of protection the material offers, assuming 
a perfect fit and optimal compliance.<sup>16</sup> Medical masks are designed to
 protect the environment from respiratory droplets produced by the wearer. Resea
rch studies on the filtration and fit of medical masks show wide variation in pe
netration of aerosol particles (4% to 90%) and a higher amount of face seal leak
age when compared to respirators.<sup>17</sup> The fit of cloth masks/cottonyarn
 masks, which are widely used in Asia, is likely to be even looser than medical 
masks and hence, cloth masks are likely to have a lower level of protection, sug
gested by the higher efficacy of medical masks found in this study. In addition,
 reuse of cloth masks may lead to contamination, which adds to the risk of respi
ratory infection. But there are no clinical data associated with cloth masks cur
rently.</font></p>     ^cY#v15n2a02.htm##
00788000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055300076002001300629#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#71#67#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">There are a number of limitations in
 this study. Firstly, information regarding vaccine uptake, frequency of masks/r
espirators use, frequency of hand washing and cases of respiratory infection wer
e all based on self-report. This study is therefore subject to problems of recal
l bias, and final results may be overestimated. Another limitation is that we ca
nnot comment on whether HCWs who reported a respiratory infection were infected 
in or out of the hospital setting.</font></p>     ^cY#v15n2a02.htm##
00512000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027700076002001300353#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#72#68#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Despite these limitations, we provid
e the first quantitative estimate of mask-wearing and respiratory infection amon
g HCWs in Beijing during the influenza season after the SARS outbreak in 2003.</
font></p>     ^cY#v15n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#73#69#article#119#<p>&nbsp;</p>     ^
cY#v15n2a02.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011200076002001300188#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#74#70#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>ACKNOWLEDGMENTS</b></i></font>
</p>     ^cY#v15n2a02.htm##
00507000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027200076002001300348#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#75#71#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This study was supported by grants f
rom the National High Technology Research and Development Program of China (863 
Program) (2008AA02Z416) and Beijing Natural Science Foundation (7082047).</font>
</p>     ^cY#v15n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#76#72#article#119#<p>&nbsp;</p>     ^
cY#v15n2a02.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#77#73#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p> 
    ^cY#v15n2a02.htm##
00657000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704040800078002001300486#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#78#74#article#119#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. World Health Organi
zation. WHO strategic action plan for pandemic influenza 2006-2007. 2006 &#91;ci
ted 2010 Mar 6&#93;; Available from: <a href="http://www.who.int/csr/resources/p
ublications/influenza/WHO_CDS_EPR_GIP_2006_2c.pdf" target="_blank">http://www.wh
o.int/csr/resources/publications/influenza/WHO_CDS_EPR_GIP_2006_2c.pdf</a>.    ^
cY#v15n2a02.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#79#75#article#119#</font></p>     ^cY
#v15n2a02.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023700078002001300315#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#80#76#article#119#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Centers for Disease
 Control and Prevention (CDC). Swine influenza A (H1N1) infection in two childre
n Southern California. MMWR Morb Mortal Wkly Rep 2009; 58:400-2.    ^cY#v15n2a02
.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#81#77#article#119#</font></p>     ^cY
#v15n2a02.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026600078002001300344#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#82#78#article#119#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Centers for Disease
 Control and Prevention (CDC). Update: infections with a swine-origin influenza 
A (H1N1) virus - United States and other countries. MMWR Morb Mortal Wkly Rep 20
09; 58:431-3.    ^cY#v15n2a02.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#83#79#article#119#</font></p>     ^cY
#v15n2a02.htm##
00483000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023400078002001300312#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#84#80#article#119#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. MacIntyre CR, Cauch
emez S, Dwyer DE <i>et al.</i> Face mask use and control of respiratory virus tr
ansmission in house-holds. Emerg Infect Dis. 2009; 15:233-41.    ^cY#v15n2a02.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#85#81#article#119#</font></p>     ^cY
#v15n2a02.htm##
00483000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023400078002001300312#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#86#82#article#119#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Wu J, Xu F, Zhou W 
<i>et al.</i> Risk factors for SARS among persons without known contact with SAR
S patients, Beijing, China. Emerg Infect Dis. 2004; 10:210-6.    ^cY#v15n2a02.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#87#83#article#119#</font></p>     ^cY
#v15n2a02.htm##
00531000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028200078002001300360#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#88#84#article#119#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Seto WH, Tsang D, Y
ung RW <i>et al.</i> Effectiveness of precautions against droplets and contact i
n prevention of nosocomial transmission of severe acute respiratory syndrome (SA
RS). Lancet 2003; 36:1519-20.    ^cY#v15n2a02.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#89#85#article#119#</font></p>     ^cY
#v15n2a02.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024100078002001300319#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#90#86#article#119#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Loeb M, Dafoe N, Ma
hony J <i>et al.</i> Surgical Mask vs N95 Respirator for Preventing Influenza Am
ong Health Care Workers: A Randomized Trial. JAMA 2009; 302:1865-71.    ^cY#v15n
2a02.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#91#87#article#119#</font></p>     ^cY
#v15n2a02.htm##
00450000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020100078002001300279#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#92#88#article#119#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Daniel WW. Biostati
stics: A Foundation for Analysis in the Health Sciences. 7th edition. New York: 
John Wiley &amp; Sons, 1999.    ^cY#v15n2a02.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#93#89#article#119#</font></p>     ^cY
#v15n2a02.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022200078002001300300#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#94#90#article#119#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Yang P, Duan W, Lv 
M <i>et al.</i> Review of an influenza surveillance system, Beijing, Peoples Rep
ublic of China. Emerg Infect Dis 2009; 15:1603-8.    ^cY#v15n2a02.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#95#91#article#119#</font></p>     ^cY
#v15n2a02.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025800079002001300337#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#96#92#article#119#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Carrat F, Sahler 
C, Rogez S <i>et al.</i> Influenza burden of illness: estimates from a national 
prospective survey of household contacts in France. Arch Intern Med 2002; 162:18
42-48.    ^cY#v15n2a02.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#97#93#article#119#</font></p>     ^cY
#v15n2a02.htm##
00428000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704017800079002001300257#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#98#94#article#119#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Li L, Cheng S, Gu
 J. SARS infection among health care workers in Beijing, China. JAMA 2003; 290:2
662-3.    ^cY#v15n2a02.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#99#95#article#119#</font></p>     ^cY
#v15n2a02.htm##
00461000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704021000080002001300290#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#100#96#article#119#12#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Talbot TR. Do de
clination statements increase health care worker seasonal influenza vaccination 
rates? Clin Infect Dis. 2009; 49:773-9.    ^cY#v15n2a02.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#101#97#article#119#</font></p>     ^c
Y#v15n2a02.htm##
00472000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704022100080002001300301#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#102#98#article#119#13#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Gavazzi G. Seaso
nal influenza vaccination for healthcare workers: from a simple concept to a res
istant issue? Aging Clin Exp Res. 2009; 21:216-21.    ^cY#v15n2a02.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#103#99#article#119#</font></p>     ^c
Y#v15n2a02.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027100081002001300352#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#104#100#article#119#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Zimmerman RK, N
owalk MP, Lin CJ <i>et al.</i> Factorial design for improving seasonal influenza
 vaccination among employees of a large health system. Infect Control Hosp Epide
miol. 2009; 30:691-7.    ^cY#v15n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#105#101#article#119#</font></p>     ^
cY#v15n2a02.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020200081002001300283#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#106#102#article#119#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Lau JT, Tsui H,
 Lau M, Yang X. SARS transmission, risk factors, and prevention in Hong Kong. Em
erg Infect Dis. 2004; 10:587-92.    ^cY#v15n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#107#103#article#119#</font></p>     ^
cY#v15n2a02.htm##
00495000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024300081002001300324#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#108#104#article#119#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. van der Sande M
, Teunis P, Sabel R. Professional and homemade face masks reduce exposure to res
piratory infections among the general population. PLoS ONE 2008; 3:e2618.    ^cY
#v15n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#109#105#article#119#</font></p>     ^
cY#v15n2a02.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027100081002001300352#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#110#106#article#119#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Ba&#322;azy A, 
Toivola M, Adhikari A <i>et al.</i> Do N95 respirators provide 95% protection le
vel against airborne viruses, and how adequate are surgical masks? Am J Infect C
ontrol 2006; 34:51-7.    ^cY#v15n2a02.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#111#107#article#119#</font></p>     ^
cY#v15n2a02.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#112#108#article#119#<p>&nbsp;</p>    
 ^cY#v15n2a02.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#113#109#article#119#<p>&nbsp;</p>    
 ^cY#v15n2a02.htm##
00426000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018900078002001300267#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#114#110#article#119#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:
</b>    ^cY#v15n2a02.htm##
00261000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002400078002001300102#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#115#111#article#119#<br> Quanyi Wang 
   ^cY#v15n2a02.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005000078002001300128#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#116#112#article#119#<br> MD, MPH No.1
6 He Pingli Middle Street    ^cY#v15n2a02.htm##
00293000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005600078002001300134#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#117#113#article#119#<br>   Dongcheng 
District,Beijing, 100013, China    ^cY#v15n2a02.htm##
00297000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006000078002001300138#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#118#114#article#119#<br> Phone: (86) 
10 6440 7108 Fax: (86) 10 6440 7113    ^cY#v15n2a02.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007700078002001300155#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#119#115#article#119#<br> <a href="mai
lto:bjcdcxm@126.com">bjcdcxm@126.com</a></font></p>     ^cY#v15n2a02.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009400078002001300172#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#120#116#article#119#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted on: 8/12/2010    ^cY#v15
n2a02.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#121#117#article#119#<br> Approved on:
 9/28/2010    ^cY#v15n2a02.htm##
00458000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704022100078002001300299#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#122#118#article#119#<br> Financial Su
pport: This study was supported by grants from the National High Technology Rese
arch and Development Program of China (863 Program) (2008AA02Z416) and Beijing N
atural Science Foundation (7082047).    ^cY#v15n2a02.htm##
00297000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006000078002001300138#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a02.htm#S#p#123#119#article#119#<br> We declare n
o conflict of interest.</font></p>     ^cY#v15n2a02.htm##
00548000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170026000770180063001030650
00900166064000500175110000900180109001100189037008400200865000900284002001300293
#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#c#124#1#article#17#1#Wo
rld Health Organization#WHO strategic action plan for pandemic influenza 2006-20
07^len#20060000#2006#20100306#2010 Mar 6#http://www.who.int/csr/resources/public
ations/influenza/WHO_CDS_EPR_GIP_2006_2c.pdf#20110400#v15n2a02.htm##
00568000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750110043000770120075001200300
02600195065000900221064000500230031000300235014000600238865000900244002001300253
035001000266801002600276#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S
#c#125#2#article#17#2#Centers for Disease Control and Prevention#Swine influenza
 A (H1N1) infection in two children Southern California^len#MMWR Morb Mortal Wkl
y Rep#20090000#2009#58#400-2#20110400#v15n2a02.htm#0149-2195#MMWR Morb Mortal Wk
ly Rep##
00597000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750110043000770120104001200300
02600224065000900250064000500259031000300264014000600267865000900273002001300282
035001000295801002600305#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S
#c#126#3#article#17#3#Centers for Disease Control and Prevention#Update: infecti
ons with a swine-origin influenza A (H1N1) virus - United States and other count
ries^len#MMWR Morb Mortal Wkly Rep#20090000#2009#58#431-3#20110400#v15n2a02.htm#
0149-2195#MMWR Morb Mortal Wkly Rep##
00609000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100019000970100
01600116810000600132012007900138030001700217065000900234064000500243031000300248
014000700251865000900258002001300267035001000280801001700290#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a02.htm#S#c#127#4#article#17#4#^rND^sMacIntyre^nCR#^r
ND^sCauchemez^nS#^rND^sDwyer^nDE#et al#Face mask use and control of respiratory 
virus transmission in house-holds^len#Emerg Infect Dis#20090000#2009#15#233-41#2
0110400#v15n2a02.htm#1080-6040#Emerg Infect Dis##
00609000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100012000770100012000890100
01400101810000600115012009700121030001700218065000900235064000500244031000300249
014000600252865000900258002001300267035001000280801001700290#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a02.htm#S#c#128#5#article#17#5#^rND^sWu^nJ#^rND^sXu^n
F#^rND^sZhou^nW#et al#Risk factors for SARS among persons without known contact 
with SARS patients, Beijing, China^len#Emerg Infect Dis#20040000#2004#10#210-6#2
0110400#v15n2a02.htm#1080-6040#Emerg Infect Dis##
00648000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100015000920100
01500107810000600122012014700128030000700275065000900282064000500291031000300296
014000800299865000900307002001300316035001000329801000700339#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a02.htm#S#c#129#6#article#17#6#^rND^sSeto^nWH#^rND^sT
sang^nD#^rND^sYung^nRW#et al#Effectiveness of precautions against droplets and c
ontact in prevention of nosocomial transmission of severe acute respiratory synd
rome (SARS)^len#Lancet#20030000#2003#36#1519-20#20110400#v15n2a02.htm#0099-5355#
Lancet##
00605000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100015000910100
01600106810000600122012010700128030000500235065000900240064000500249031000400254
014000800258865000900266002001300275035001000288801000500298#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a02.htm#S#c#130#7#article#17#7#^rND^sLoeb^nM#^rND^sDa
foe^nN#^rND^sMahony^nJ#et al#Surgical Mask vs N95 Respirator for Preventing Infl
uenza Among Health Care Workers: A Randomized Trial^len#JAMA#20090000#2009#302#1
865-71#20110400#v15n2a02.htm#0098-7484#JAMA##
00469000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160017000770180068000940630
00200162066000900164062001800173065000900191064000500200865000900205002001300214
#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#c#131#8#article#17#8#^r
ND^sDaniel^nWW#Biostatistics: A Foundation for Analysis in the Health Sciences^l
en#7#New York#John Wiley & Sons#19990000#1999#20110400#v15n2a02.htm##
00598000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100014000910100
01200105810000600117012008300123030001700206065000900223064000500232031000300237
014000700240865000900247002001300256035001000269801001700279#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a02.htm#S#c#132#9#article#17#9#^rND^sYang^nP#^rND^sDu
an^nW#^rND^sLv^nM#et al#Review of an influenza surveillance system, Beijing, Peo
ples Republic of China^len#Emerg Infect Dis#20090000#2009#15#1603-8#20110400#v15
n2a02.htm#1080-6040#Emerg Infect Dis##
00634000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01500111810000600126012011000132030001600242065000900258064000500267031000400272
014000800276865000900284002001300293035001000306801001600316#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a02.htm#S#c#133#10#article#17#10#^rND^sCarrat^nF#^rND
^sSahler^nC#^rND^sRogez^nS#et al#Influenza burden of illness: estimates from a n
ational prospective survey of household contacts in France^len#Arch Intern Med#2
0020000#2002#162#1842-48#20110400#v15n2a02.htm#0003-9926#Arch Intern Med##
00538000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100012000790100015000910100
01200106012006300118030000500181065000900186064000500195031000400200014000700204
865000900211002001300220035001000233801000500243#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a02.htm#S#c#134#11#article#17#11#^rND^sLi^nL#^rND^sCheng^nS#^rND^
sGu^nJ#SARS infection among health care workers in Beijing, China^len#JAMA#20030
000#2003#290#2662-3#20110400#v15n2a02.htm#0098-7484#JAMA##
00545000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120096000960300
01600192065000900208064000500217031000300222014000600225865000900231002001300240
035001000253801001600263#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S
#c#135#12#article#17#12#^rND^sTalbot^nTR#Do declination statements increase heal
th care worker seasonal influenza vaccination rates?^len#Clin Infect Dis#2009000
0#2009#49#773-9#20110400#v15n2a02.htm#1058-4838#Clin Infect Dis##
00520000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120103000960300
01900199710000200218065000900220064000500229031000300234014000700237865000900244
002001300253#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a02.htm#S#c#136#13#ar
ticle#17#13#^rND^sGavazzi^nG#Seasonal influenza vaccination for healthcare worke
rs: from a simple concept to a resistant issue?^len#Aging Clin Exp Res#2#2009000
0#2009#21#216-21#20110400#v15n2a02.htm##
00660000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100017000990100
01400116810000600130012010700136030003000243065000900273064000500282031000300287
014000600290865000900296002001300305035001000318801003000328#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a02.htm#S#c#137#14#article#17#14#^rND^sZimmerman^nRK#
^rND^sNowalk^nMP#^rND^sLin^nCJ#et al#Factorial design for improving seasonal inf
luenza vaccination among employees of a large health system^len#Infect Control H
osp Epidemiol#20090000#2009#30#691-7#20110400#v15n2a02.htm#0899-823X#Infect Cont
rol Hosp Epidemiol##
00591000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100014000930100
01300107010001400120012006500134030001700199065000900216064000500225031000300230
014000700233865000900240002001300249035001000262801001700272#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a02.htm#S#c#138#15#article#17#15#^rND^sLau^nJT#^rND^s
Tsui^nH#^rND^sLau^nM#^rND^sYang^nX#SARS transmission, risk factors, and preventi
on in Hong Kong^len#Emerg Infect Dis#20040000#2004#10#587-92#20110400#v15n2a02.h
tm#1080-6040#Emerg Infect Dis##
00577000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100016001020100
01500118012011200133030000900245710000200254065000900256064000500265031000200270
020000500272865000900277002001300286#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a02.htm#S#c#139#16#article#17#16#^rND^svan der Sande^nM#^rND^sTeunis^nP#^rND^
sSabel^nR#Professional and homemade face masks reduce exposure to respiratory in
fections among the general population^len#PLoS ONE#2#20080000#2008#3#2618#201104
00#v15n2a02.htm##
00652000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100017001000100
01800117810000600135012011500141030002000256065000900276064000500285031000300290
014000500293865000900298002001300307035001000320801002000330#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a02.htm#S#c#140#17#article#17#17#^rND^sBa&#322;azy^nA
#^rND^sToivola^nM#^rND^sAdhikari^nA#et al#Do N95 respirators provide 95% protect
ion level against airborne viruses, and how adequate are surgical masks?^len#Am 
J Infect Control#20060000#2006#34#51-7#20110400#v15n2a02.htm#0196-6553#Am J Infe
ct Control##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#o#1#1#article#1
#20110406#124806#v15n2a03.htm#169##
02633000000000565000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400110014403500100015501200640
01650100045002290100033002740100036003070100038003430100038003810700055004190700
10000474083131000574085000801884085002201892085002601914085003001940085003701970
11700060200707200030201311200090201611100090202511400090203411300110204300200130
2054#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#h#2#1#article#1#oa#
en#br1.1#1#4.0#ILUS#TAB#3#BJID230#nd#Braz J Infect Dis#15#2#20110400#^f109^l115#
1413-8670#Surgical-site infection risk in oncologic digestive surgery^len#^rND^1
A01^nPaulo de Tarso Oliveira e^sCastro#^rND^1A01^nAndré Lopes^sCarvalho#^rND^1A0
1^nStela Verzinhasse^sPeres#^rND^1A01^nMilene Mitsuyuki^sFoschini#^rND^1A02^nAfo
nso Dinis Costa^sPassos#Hospital de Câncer de Barretos^iA01^cSão Paulo^pBrazil#U
SP^iA02^1Faculdade de Medicina de Ribeirão Preto^2Department of Social Medicine^
cSão Paulo^pBrazil#^len^aSurgical-site infection (SSI) is the most prevalent typ
e of hospital infection in surgical patients and is associated with an increase 
in hospital stay, costs and morbidity/lethality. The knowledge of the main risk 
factors for this type of infection is important for the establishment of prevent
ion measures regarding modifiable risks factors. The objective of the preset stu
dy was to assess the occurrence of SSI and study the risk factors in oncologic s
urgeries of the digestive system at Hospital de Câncer in Barretos, São Paulo, B
razil. Individuals undergoing oncologic surgeries of the digestive system in the
 period of 08/01/2007 to 08/10/2008 were prospectively followed for 30 days afte
r surgery. Possible risk factors related to the patient and to the surgical proc
edure were also studied. A total of 210 surgeries were analyzed, with a global S
SI incidence of 23.8%. The following variables were independently associated wit
h SSI: time and type of surgery, radiotherapy before surgery and surgeon's years
 of experience. The risk factors found in this study have been described by othe
r authors and are not amenable to intervention for SSI prevention. Further studi
es are recommended with the objective of investigating interventions that could 
reduce the risk for SSI in this type of surgery.#^dnd^i1#^tm^len^kinfection^i1#^
tm^len^ksurgical site^i1#^tm^len^koncologic surgery^i1#^tm^len^kdigestive system
 surgery^i1#other#27#20100308#3/8/2010#20101019#10/19/2010#v15n2a03.htm##
02647000000000565000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400110014403500100015501200710
01650100045002360100033002810100036003140100038003500100038003880700055004260700
10000481083131700581085000801898085002201906085002601928085003001954085003701984
11700060202107200030202711200090203011100090203911400090204811300110205700200130
2068#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#f#3#1#article#1#oa#
en#br1.1#1#4.0#ILUS#TAB#3#BJID230#nd#Braz J Infect Dis#15#2#20110400#^f109^l115#
1413-8670#<b>Surgical-site infection risk in oncologic digestive surgery</b>^len
#^rND^1A01^nPaulo de Tarso Oliveira e^sCastro#^rND^1A01^nAndré Lopes^sCarvalho#^
rND^1A01^nStela Verzinhasse^sPeres#^rND^1A01^nMilene Mitsuyuki^sFoschini#^rND^1A
02^nAfonso Dinis Costa^sPassos#Hospital de Câncer de Barretos^iA01^cSão Paulo^pB
razil#USP^iA02^1Faculdade de Medicina de Ribeirão Preto^2Department of Social Me
dicine^cSão Paulo^pBrazil#^len^aSurgical-site infection (SSI) is the most preval
ent type of hospital infection in surgical patients and is associated with an in
crease in hospital stay, costs and morbidity/lethality. The knowledge of the mai
n risk factors for this type of infection is important for the establishment of 
prevention measures regarding modifiable risks factors. The objective of the pre
set study was to assess the occurrence of SSI and study the risk factors in onco
logic surgeries of the digestive system at <i>Hospital de Câncer</i> in Barretos
, São Paulo, Brazil. Individuals undergoing oncologic surgeries of the digestive
 system in the period of 08/01/2007 to 08/10/2008 were prospectively followed fo
r 30 days after surgery. Possible risk factors related to the patient and to the
 surgical procedure were also studied. A total of 210 surgeries were analyzed, w
ith a global SSI incidence of 23.8%. The following variables were independently 
associated with SSI: time and type of surgery, radiotherapy before surgery and s
urgeon's years of experience. The risk factors found in this study have been des
cribed by other authors and are not amenable to intervention for SSI prevention.
 Further studies are recommended with the objective of investigating interventio
ns that could reduce the risk for SSI in this type of surgery.#^dnd^i1#^tm^len^k
infection^i1#^tm^len^ksurgical site^i1#^tm^len^koncologic surgery^i1#^tm^len^kdi
gestive system surgery^i1#other#27#20100308#3/8/2010#20101019#10/19/2010#v15n2a0
3.htm##
02778000000000589000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000200117049000800119
15800030012703000210013003100030015103200020015406500090015601400110016503500100
01760120064001860100045002500100033002950100036003280100038003640100038004020700
05700440070010200497083131700599085000801916085002201924085002601946085003001972
08500370200211700060203907200030204511200090204811100090205711400090206611300110
2075002001302086008008902099#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.h
tm#S#l#4#1#article#1#^mMar./Apr.^a2011#oa#en#br1.1#1#4.0#ilus#tab#3#BJID230#nd#B
raz. j. infect. dis#15#2#20110400#^f109^l115#1413-8670#Surgical-site infection r
isk in oncologic digestive surgery^len#^rND^1A01^nPaulo de Tarso Oliveira e^sCas
tro#^rND^1A01^nAndré Lopes^sCarvalho#^rND^1A01^nStela Verzinhasse^sPeres#^rND^1A
01^nMilene Mitsuyuki^sFoschini#^rND^1A02^nAfonso Dinis Costa^sPassos#^iA01^1Hosp
ital de Câncer de Barretos^cSão Paulo^pBrazil#^iA02^1USP^2Faculdade de Medicina 
de Ribeirão Preto^3Department of Social Medicine^cSão Paulo^pBrazil#^len^aSurgic
al-site infection (SSI) is the most prevalent type of hospital infection in surg
ical patients and is associated with an increase in hospital stay, costs and mor
bidity/lethality. The knowledge of the main risk factors for this type of infect
ion is important for the establishment of prevention measures regarding modifiab
le risks factors. The objective of the preset study was to assess the occurrence
 of SSI and study the risk factors in oncologic surgeries of the digestive syste
m at Hospital de Câncer in Barretos, São Paulo, Brazil. Individuals undergoing o
ncologic surgeries of the digestive system in the period of 08/01/2007 to 08/10/
2008 were prospectively followed for 30 days after surgery. Possible risk factor
s related to the patient and to the surgical procedure were also studied. A tota
l of 210 surgeries were analyzed, with a global SSI incidence of 23.8 percent. T
he following variables were independently associated with SSI: time and type of 
surgery, radiotherapy before surgery and surgeon's years of experience. The risk
 factors found in this study have been described by other authors and are not am
enable to intervention for SSI prevention. Further studies are recommended with 
the objective of investigating interventions that could reduce the risk for SSI 
in this type of surgery.#^dnd^i1#^tm^len^kinfection^i1#^tm^len^ksurgical site^i1
#^tm^len^koncologic surgery^i1#^tm^len^kdigestive system surgery^i1#other#27#201
00308#3/8/2010#20101019#10/19/2010#v15n2a03.htm#Internet^ihttp://www.scielo.br/s
cielo.php?script=sci_arttext&pid=S1413-86702011000200003##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#5#1#article#138#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLE</b><
/font></p>     ^cY#v15n2a03.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#6#2#article#138#<p>&nbsp;</p>     ^cY
#v15n2a03.htm##
00400000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704016700074002001300241#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#7#3#article#138#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Surgical-site inf
ection risk in oncologic digestive surgery</b></font></p>     ^cY#v15n2a03.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#8#4#article#138#<p>&nbsp;</p>     ^cY
#v15n2a03.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#9#5#article#138#<p>&nbsp;</p>     ^cY
#v15n2a03.htm##
00528000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704029400075002001300369#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#10#6#article#138#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Paulo de Tarso Oliveira e Castro<s
up>I</sup>; Andr&eacute; Lopes Carvalho<sup>II</sup>; Stela Verzinhasse Peres<su
p>III</sup>; Milene Mitsuyuki Foschini<sup>IV</sup>; Afonso Dinis Costa Passos<s
up>V</sup></b></font></p>     ^cY#v15n2a03.htm##
00395000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704016100075002001300236#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#11#7#article#138#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Infectologist , Hospital 
de C&acirc;ncer de Barretos, S&atilde;o Paulo, Brazil    ^cY#v15n2a03.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704009900075002001300174#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#12#8#article#138#<br> <sup>II</sup>Pr
of. Dr., Hospital de C&acirc;ncer de Barretos, S&atilde;o Paulo, Brazil    ^cY#v
15n2a03.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704010700075002001300182#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#13#9#article#138#<br>   <sup>III</sup
>Epidemiologist, Hospital de C&acirc;ncer de Barretos, S&atilde;o Paulo, Brazil 
   ^cY#v15n2a03.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#14#10#article#138#<br>   <sup>IV</sup
>Biostatistician, Hospital de C&acirc;ncer de Barretos, S&atilde;o Paulo, Brazil
    ^cY#v15n2a03.htm##
00395000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016000076002001300236#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#15#11#article#138#<br>   <sup>V</sup>
Prof. Dr., Department of Social Medicine of Faculdade de Medicina de Ribeir&atil
de;o Preto, USP, S&atilde;o Paulo, Brazil</font></p>     ^cY#v15n2a03.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#16#12#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a><
/font></p>     ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#17#13#article#138#<p>&nbsp;</p>     ^
cY#v15n2a03.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#18#14#article#138#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v15n2a03.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#19#15#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
15n2a03.htm##
01641000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704140600076002001301482#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#20#16#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Surgical-site infection (SSI) is the
 most prevalent type of hospital infection in surgical patients and is associate
d with an increase in hospital stay, costs and morbidity/lethality. The knowledg
e of the main risk factors for this type of infection is important for the estab
lishment of prevention measures regarding modifiable risks factors. The objectiv
e of the preset study was to assess the occurrence of SSI and study the risk fac
tors in oncologic surgeries of the digestive system at <i>Hospital de C&acirc;nc
er</i> in Barretos, S&atilde;o Paulo, Brazil. Individuals undergoing oncologic s
urgeries of the digestive system in the period of 08/01/2007 to 08/10/2008 were 
prospectively followed for 30 days after surgery. Possible risk factors related 
to the patient and to the surgical procedure were also studied. A total of 210 s
urgeries were analyzed, with a global SSI incidence of 23.8%. The following vari
ables were independently associated with SSI: time and type of surgery, radiothe
rapy before surgery and surgeon's years of experience. The risk factors found in
 this study have been described by other authors and are not amenable to interve
ntion for SSI prevention. Further studies are recommended with the objective of 
investigating interventions that could reduce the risk for SSI in this type of s
urgery.</font></p>     ^cY#v15n2a03.htm##
00427000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019200076002001300268#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#21#17#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> infection; surgical
 site; oncologic surgery; digestive system surgery.</font></p> <hr size="1" nosh
ade>     ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#22#18#article#138#<p>&nbsp;</p>     ^
cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#23#19#article#138#<p>&nbsp;</p>     ^
cY#v15n2a03.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#24#20#article#138#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>INTRODUCTION</b></i></font></p
>     ^cY#v15n2a03.htm##
00720000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048500076002001300561#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#25#21#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Midway through the twentieth century
, it was believed that pain, anesthetic incidents,   surgical wound infection an
d postoperative   sepsis, which were important obstacles to   the success of sur
gical treatment, had been   overcome. In a way, such predictions came to   pass;
 however, these complications are still   around and persist as causes of postop
erative morbidity and lethality.<sup>1-3</sup></font></p>     ^cY#v15n2a03.htm##
00760000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052500076002001300601#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#26#22#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">It is estimated that 500,000 cases o
f surgical-   site infection (SSI) occur annually in the   United States of Amer
ica (USA) and, among   the ranking of hospital infections, SSI is   among the mo
st frequent ones, contributing   with 14% to 16% of the cases.<sup>1,3</sup> How
ever,   among surgical patients, SSI is the hospital infection   with the highes
t incidence, representing   38% of all infections in this population.<sup>1,4</s
up>   </font></p>     ^cY#v15n2a03.htm##
01232000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704099700076002001301073#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#27#23#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">SSI has a great impact on mortality,
 as 30%   to 40% of the deaths in the postoperative period   are caused by this 
infection.<sup>5</sup> When patients   with SSI die, the SSI itself is the cause
 of   death, most cases (93%) with severe infections   involving organs and spac
es.<sup>1</sup> Another important   consequence, with considerable impact   for 
the healthcare system and society, is the   impact on healthcare costs.<sup>1,5-
7</sup> In the USA, it   is estimated that the annual excess costs due   to SSI 
is &gt; 1.6 billion dollars.<sup>6</sup> Among the factors   that contribute the
 most to the cost increase   is the length of hospital stay, with a described   
mean increase of 5.7 to 13.7 days.<sup>5,7-10</sup>   The need to prescribe anti
biotics and perform   reoperations as well as laboratory and radiologic   assess
ments also has a considerable impact on healthcare expenditures.<sup>3,8</sup></
font></p>     ^cY#v15n2a03.htm##
00755000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052000076002001300596#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#28#24#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">SSI is a multifactorial condition an
d the risk   factors involved in its onset are common for   most surgeries (age,
 obesity, surgical time, etc);   however, other factors are peculiar to certain 
  procedures. Thus, it is important to identify   these factors to evaluate the 
procedures that   carry the highest risk and, if possible, define   adequate ind
ices that can predict the risk of SSI in different types of surgery.<sup>11</sup
></font></p>     ^cY#v15n2a03.htm##
00699000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046400076002001300540#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#29#25#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Hospital de C&acirc;ncer</i> in t
he town of Barretos, S&atilde;o Paulo State, Brazil, is specialized in oncology 
and performs around 6,000 surgeries annually, with approximately 11% being neopl
asias of the digestive tract. In spite of the relevance of SSI, this is the firs
t study of systematic collection of information on its distribution and characte
ristics in this hospital.</font></p>     ^cY#v15n2a03.htm##
00441000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020600076002001300282#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#30#26#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The study was approved by the Ethics
 Committee in Research of <i>Hospital de C&acirc;ncer de Barretos</i>, process #
 95/07.</font></p>     ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#31#27#article#138#<p>&nbsp;</p>     ^
cY#v15n2a03.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#32#28#article#138#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>METHODS</b></i></font></p>    
 ^cY#v15n2a03.htm##
00670000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043500076002001300511#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#33#29#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Individuals aged 18 years and older,
 undergoing curative or palliative surgery for primary malignant neoplasias of t
he digestive system from August 1, 2007 to July 31, 2008, were enrolled in the s
tudy. Those who had not completed 30 days of postoperative follow-up were exclud
ed, except cases of death due to SSI before completion of the 30-day period.</fo
nt></p>     ^cY#v15n2a03.htm##
01357000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704112200076002001301198#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#34#30#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Information on the following variabl
es were collected for each study participant: name, hospital registration number
, age, sex, level of schooling, cancer type, neoplasia staging, diabetes mellitu
s, nutritional status and obesity, history of alcohol consumption, smoking statu
s, surgery performed, date of surgery, surgical outcome (curative or palliative)
, surgical condition (elective or emergency), time of surgery, radiotherapy on t
he topography of the operative field prior to surgery, chemotherapy prior to sur
gery, hyperglycemia in the perioperative period, polytransfusion of blood deriva
tives in the perioperative period, antibiotic prophylaxis (antibiotic agent used
, dose, moment of start, intraoperative repeat dosing and duration of use), leng
th of preoperative hospitalization, surgical team, surgeon's years of experience
, ASA classification, type of anesthesia, potential for surgery contamination, S
SI data (date of diagnosis, depth, microbial etiology, evolution). The CDC crite
ria<sup>11</sup> were used to diagnose SSI.</font></p>     ^cY#v15n2a03.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018800076002001300264#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#35#31#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The information were stored in a dat
abase and analyzed using the software SPSS for Windows, release 17.0.</font></p>
     ^cY#v15n2a03.htm##
00909000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067400076002001300750#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#36#32#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">First, the sample was characterized 
by absolute and relative frequencies, central tendency measures (mean and median
) and dispersion (range and standard deviation). For quantitative variables, adh
erence to the normal curve was verified by the Kolmogorov-Smirnov test. As the v
ariables did not have a normal distribution, the non-parametric Mann-Whitney tes
t was applied to compare the groups with and without SSI. Association between in
dependent qualitative variables and SSI was initially assessed through univariat
e analysis using the Chi-square test or Fisher's exact test when indicated.</fon
t></p>     ^cY#v15n2a03.htm##
00683000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044800076002001300524#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#37#33#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Subsequently, multiple logistic regr
ession models were used to verify the independent association between the studie
d variables and SSI. A p-value <u>&lt;</u> 0.25 was the cut-off used to determin
e which variables would enter the multivariate model. Statistical significance w
as set at </font>&#945;<font size="2" face="Verdana, Arial, Helvetica, sans-seri
f"> = 5%.</font></p>     ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#38#34#article#138#<p>&nbsp;</p>     ^
cY#v15n2a03.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#39#35#article#138#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>RESULTS</b></i></font></p>    
 ^cY#v15n2a03.htm##
00614000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037900076002001300455#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#40#36#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Of the 224 potential participants, 1
4 patients were excluded: seven did not complete the 30-day follow-up, five did 
not have cancer, and two for reoperation due to non-infectious surgical complica
tions before the end of the 30-day period. Therefore, the final sample consisted
 of 210 individuals.</font></p>     ^cY#v15n2a03.htm##
00929000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069400076002001300770#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#41#37#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Among participants, 59.5% (125/210) 
were male and 50% were less than 60 years old. As for the nutritional status, 7%
 (14/210) were malnourished, 48% (97/210) were overweight/obese, and 45% (91/210
) had normal weight. Up to 14.6% (30/205) had diabetes mellitus, 23% (48/160) we
re smokers, and 15.6% (32/205) reported history of alcohol consumption. The ASA 
score was defined in 204 participants and, of these, 30.9% were classified as AS
A 1, 56% as ASA 2 and 12.7% as ASA 3/4. Neoplasia staging was assessed in 192 in
dividuals, with 89 (46.4%) being classified as stages I/II and the remaining as 
stages III//IV.</font></p>     ^cY#v15n2a03.htm##
00975000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074000076002001300816#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#42#38#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Regarding the type of surgery (<a hr
ef="#tab1">Table 1</a>), 12.9% (27/210) were derivations/jejunum, 23.8% (50/210)
 were of the upper digestive system and 63.3% (133/210) of the lower digestive t
ract. SSI was diagnosed in 50 surgeries (23.8%) and most were classified as supe
rficial (46%). Deep infections and infections of organs and spaces represented, 
respectively, 20% and 34% of the total. There was a predominance of contaminated
/infected surgeries (66.7%), ICU stay <u>&gt;</u> 3 days (60%), absence of previ
ous surgery (58.4%), and combination of spinal and general anesthesia (59.6%). T
he mean time between surgery and SSI diagnosis was 11.9 days.</font></p>     ^cY
#v15n2a03.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#43#39#article#138#<p><a name="tab1"><
/a></p>     ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#44#40#article#138#<p>&nbsp;</p>     ^
cY#v15n2a03.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#45#41#article#138#<p align="center"><
img src="/img/revistas/bjid/v15n2/a03tab01.jpg"></p>     ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#46#42#article#138#<p>&nbsp;</p>     ^
cY#v15n2a03.htm##
00731000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049600076002001300572#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#47#43#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Surgical antibiotic prophylaxis was 
prescribed in 99.5% of the surgeries and its use was adequate in 74.5% of them. 
The most common inadequacy was the use of a lower than recommended dose (10.1%).
 On the other hand, there was a high rate of appropriateness regarding the antib
iotic agent selected, moment of prophylaxis initiation, intraoperative repeat do
ses and prophylaxis period (<a href="#tab2">Table 2</a>).</font></p>     ^cY#v15
n2a03.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#48#44#article#138#<p><a name="tab2"><
/a></p>     ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#49#45#article#138#<p>&nbsp;</p>     ^
cY#v15n2a03.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#50#46#article#138#<p align="center"><
img src="/img/revistas/bjid/v15n2/a03tab02.jpg"></p>     ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#51#47#article#138#<p>&nbsp;</p>     ^
cY#v15n2a03.htm##
01074000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083900076002001300915#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#52#48#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As for the etiology of SSI, it was n
ot possible to identify the agent in 15 patients, as material for laboratory ana
lysis was not collected before the start of antibiotics or the surgical procedur
e for treating the infection. Therefore, 70% of the SSI were microbiologically c
onfirmed (35/50). Gram-negative bacteria were most frequently isolated, totaling
 31 cases with <i>Escherichia coli</i> being the most prevalent. Bacteria consid
ered multi-resistant to antimicrobial agents were isolated from only seven cases
, mainly oxacillin-resistant <i>Staphylococcus aureus</i>. Anaerobic microorgani
sms were not isolated as the Microbiology Laboratory of of <i>Hospital de C&acir
c;ncer de Barretos</i> does not have the methodology to isolate these pathogens.
</font></p>     ^cY#v15n2a03.htm##
00472000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023700076002001300313#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#53#49#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Among SSI patients, three died, two 
due to the underlying neoplasia and one attributed to SSI itself, thus resulting
 in a SSI lethality rate of 2% (1/50).</font></p>     ^cY#v15n2a03.htm##
01377000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704114200076002001301218#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#54#50#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Statistical analysis of the quantita
tive variables (<a href="/img/revistas/bjid/v15n2/a03tab03.jpg">Table 3</a>) sho
wed that only time of surgery was significantly higher among SSI patients, when 
compared to those without SSI (p = 0.007). The logistic regression analysis is s
ummarized in <a href="/img/revistas/bjid/v15n2/a03tab04.jpg">Table 4</a>, showin
g the following variables that presented a significant independent association w
ith SSI: contaminated/infected surgery, lower digestive surgery, adjuvant treatm
ent (chemotherapy and/or radiotherapy before surgery), and surgeon's less years 
  of experience. The analysis of the surgeon's years of   experience did not sho
w a correlation with the time   of surgery (p = 0.45). At the multivariate analy
sis adjusted   for the presence of diabetes mellitus (<a href="/img/revistas/bji
d/v15n2/a03tab05.jpg">Table 5</a>)   the variables that had an independent signi
ficant association   with SSI were: surgeon's experience &lt; 10 years,   chemot
herapy and/or radiotherapy before surgery and surgery duration.</font></p>     ^
cY#v15n2a03.htm##
00410000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017500076002001300251#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#55#51#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Type of surgery (contaminated or inf
ected) was at the threshold of statistical significance.</font></p>     ^cY#v15n
2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#56#52#article#138#<p>&nbsp;</p>     ^
cY#v15n2a03.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#57#53#article#138#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>DISCUSSION</b></i></font></p> 
    ^cY#v15n2a03.htm##
00681000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044600076002001300522#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#58#54#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The observed incidence of SSI in the
 present study was 23.8%. As the incidence from previous reports in the pertinen
t literature has a great deal of variability, the SSI incidence observed at our 
hospital would sometimes be considered higher and sometimes lower. However, it m
ust be emphasized that few studies included only oncologic surgeries.<sup>9,12-1
9</sup></font></p>     ^cY#v15n2a03.htm##
01459000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704122400076002001301300#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#59#55#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Smith <i>et al</i>.<sup>19</sup> rep
orted an incidence of SSI of 25.6%; however, they assessed only incision infecti
ons (superficial and deep) in patients undergoing colorectal resections, either 
oncologic or not. Konishi <i>et al</i>.<sup>13</sup> also studied only incision 
infections (superficial and deep) in colon and rectal surgeries, having found in
cidences of 9.4% and 18.0%, respectively (p = 0.003). Velasco <i>et al</i>.<sup>
18</sup> found an incidence of SSI of 22.4% in oncologic abdominal surgeries, wh
ereas Oliveira <i>et al</i>.<sup>14</sup> reported an incidence of 22.1% in gast
ric surgeries, either oncologic or not. Imai <i>et al</i>.<sup>12</sup> studied 
1,116 oncologic open gastric surgeries and found an incidence of 13.8%, with tim
e of surgery being verified as the only risk factor. Another study by Vilar-Comp
te <i>et al</i>.<sup>16</sup> investigated the SSI incidence in oncologic surger
ies of seven specialties. Overall, the SSI rate was 9.3%, being as high as 14.1%
 in digestive system surgeries. The main associated risk factors were diabetes m
ellitus, obesity and presence of a drain for more than five days.</font></p>    
 ^cY#v15n2a03.htm##
01280000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704104500076002001301121#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#60#56#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The findings of the present study co
nfirmed the knowledge that surgeries with higher microbial load in the operative
 field is associated with higher risk of SSI,<sup>1,8,20</sup> considering that 
surgeries of the lower digestive system (contaminated) had an incidence of 32.3%
, whereas those of the upper digestive system had 12%. In lower digestive system
 surgeries, the incidence found in Barretos was higher than that observed by Smi
th <i>et al</i>.<sup>19</sup> and Konish <i>et al</i>.,<sup>13</sup> although it
 must be recalled that these authors did not account for organ and space infecti
ons when they studied oncologic and non-oncologic surgeries. The latter study fo
und that the incidence of SSI was almost two-fold higher in rectal surgeries (18
%) than in colon surgeries (9.4%), which emphasizes the importance of performing
 a detailed analysis by procedure, as the risk can vary even in situations with 
similar microbial load in the operative field.</font></p>     ^cY#v15n2a03.htm##
00665000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043000076002001300506#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#61#57#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In upper digestive system surgeries,
 the incidence of SSI in the present investigation (12%) was lower than the one 
reported by Oliveira <i>et al</i>.,<sup>14</sup> Velasco <i>et al</i>.<sup>18</s
up> and Imai <i>et al</i>.,<sup>12</sup> albeit higher than that reported by the
 National Nosocomial Infection Surveillance System (NNIS).<sup>15</sup></font></
p>     ^cY#v15n2a03.htm##
00757000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052200076002001300598#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#62#58#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The comparison of SSI incidence betw
een hospitals from different locations and countries must always be carefull, as
 there are specific characteristics for each place and patient population that m
ake it difficult to reach valid conclusions. The ideal situation would be for ea
ch hospital to critically analyze its own data, preferably focusing such analysi
s on the historical series and particularizing it for the several types of surge
ry.</font></p>     ^cY#v15n2a03.htm##
00626000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039100076002001300467#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#63#59#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In the present study, the variables 
that had a statistical association with SSI (type of surgery, surgeon's experien
ce, duration of surgery and chemo/radiotherapy before the surgery) are risk fact
ors that have been previously reported by other authors in different investigati
ons.<sup>12,14,17,18,21-23</sup></font></p>     ^cY#v15n2a03.htm##
00927000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069200076002001300768#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#64#60#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Of the neoplasms assessed in the pre
sent study, chemotherapy/radiotherapy before the surgical procedure is only indi
cated for lower rectal tumors. This might be a confounding variable, as surgerie
s with resection of the rectum already have an increased risk of infection due t
o the high microbial load present in the operative field, in addition to the low
 anastomosis, close to the anal border, thus considered of high risk for dehisce
nce and SSI.<sup>13</sup> However, the association was maintained even at the mu
ltivariate analysis, showing this is an independent risk factor in the present i
nvestigation.</font></p>     ^cY#v15n2a03.htm##
01043000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080800076002001300884#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#65#61#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The use of neoadjuvant chemotherapy/
radiotherapy for rectal neoplasia is associated with better treatment results; h
owever, it increases the risk of SSI and other complications.<sup>13,18,24</sup>
 This is mainly determined by radiotherapy, as the surgery is carried out after 
the conclusion of the adjuvant therapy and, obviously, outside the period of neu
tropenia and mucositis that can be induced by chemotherapy. On the other hand, r
adiotherapy causes several local tissue damages, which are very often irreversib
le, such as vascular lesions that lead to ischemia and compromise the venous ret
urn and lymphatic drainage, decreasing oxygen supply to the irradiated tissues a
nd, consequently, local defenses.<sup>13,24</sup></font></p>     ^cY#v15n2a03.ht
m##
00822000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058700076002001300663#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#66#62#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The present study is also in accorda
nce with the literature regarding the risk of SSI determined by the duration of 
the surgery.<sup>9,12-14,23</sup> Longer interventions increase the risk of SSI 
as they cause higher tissue exposure, as well as surgeries that present higher t
echnical complexity or take longer due to accidents and complications (hypotensi
on, hemorrhage, etc). All these conditions provide better opportunity for microb
ial invasion of tissues and the subsequent development of infection.</font></p> 
    ^cY#v15n2a03.htm##
00699000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046400076002001300540#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#67#63#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A good surgical technique is recogni
zed to be one of the main SSI prevention measures.<sup>1,22</sup> Adequate homeo
stasis, with maintenance of tissue perfusion, careful handling/dissection of tis
sues, devitalized tissue removal and careful use of the electrocautery are consi
dered critical points, among others. Both the technique and the surgeon's skills
 are difficult to assess.</font></p>     ^cY#v15n2a03.htm##
01837000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704160200076002001301678#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#68#64#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Generally, the technique/skill is in
ferred by the surgery duration and the incidence of complications such as SSI an
d reoperation, to mention a few. It is known that the learning curve for the per
formance of surgical procedures can be long and demand a great deal of training,
 and little is known about the necessary time for a surgeon to reach the apex fo
r performing a certain type of intervention. Nevertheless, most studies do not a
ssess the impact of the the surgeon's years of experience on the incidence of SS
I. A study by Wurtz <i>et al</i>.<sup>25</sup> assessed this variable and found 
a significant difference in the SSI incidence between less experienced and more 
experienced surgeons (p &lt; 0.05), after adjusting for possible confounders. Mu
ilwijk <i>et al</i>.<sup>26</sup> evaluated the risk of SSI based on the surgica
l volume, comparing hospitals and surgeons. The surgeries that were part of this
 study were radical mastectomy, colon resection, appendectomy, total abdominal h
ysterectomy, Cesarean section, partial femoral arthroplasty, femoral arthroplast
y review and knee arthroplasty. No difference was observed in the SSI incidence 
among the different hospitals; however, the surgeons who performed the least num
ber of procedures also had the longest time of surgery and had a tendency toward
s higher incidence of SSI. The authors concluded that surgeons should be made aw
are of the increased risk of SSI when performing procedures that were not freque
nt in their clinical practice.<sup>26</sup></font></p>     ^cY#v15n2a03.htm##
01578000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704134300076002001301419#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#69#65#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The ASA score evaluates the basal co
ndition of individuals and their comorbidities and, therefore, it is also a good
 predictor for SSI. This association has been demonstrated by several authors. H
owever, it has not been observed in the town of Barretos, where the incidence of
 SSI in individuals that had ASA &gt; II was 7.7% (2/26), <i>versus</i> 27% (48/
178) in individuals with ASA <u>&lt;</u> II. When analyzing the association betw
een ASA score and time of surgery, it was observed that 26.4% of the individuals
 (47/178) with ASA <u>&lt;</u> II, the surgery duration was &gt; 235 minutes (75
th percentile), whereas the same duration occurred in only 11.5% (3/26) of the i
ndividuals with ASA &gt; II. It is also noteworthy that 21.5% (38/177) of indivi
duals with ASA <u>&lt;</u> II were submitted to palliative surgery, whereas 34.6
% (9/26) of the individuals with ASA III or IV were submitted to this type of su
rgery. Possibly, individuals with more comorbidities had the highest risk of sur
gical complications and thus, were submitted to less aggressive and more conserv
ative surgeries, of shorter durations. The small sample size, with only 26 parti
cipants classified as ASA &gt; II, might also have influenced the findings of th
e present investigation.</font></p>     ^cY#v15n2a03.htm##
00611000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037600076002001300452#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#70#66#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Some questions were not addressed in
 the Barretos study. Among them, the moment of hair removal, as it is a routine 
procedure in the hospital to perform with an electric shaver in the operation ro
om, immediately before degermation and aseptic techniques are carried out in the
 operative field.</font></p>     ^cY#v15n2a03.htm##
01264000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704102900076002001301105#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#71#67#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This investigation has several limit
ations. One is the lack of assessment in colon and rectum resections (lower dige
stive system) and whether the colostomy or ileostomy had an impact on the incide
nce of SSI. Similarly, we did not assess the role of the persistence of cavity d
rainage and mainly, the type of drainage used. Additionally, it was assessed in 
the current study the quality of intestinal preparation in surgeries that needed
 such preoperative procedure and the occurrence of accidents/complications (hypo
tension, hypothermia, etc) during the procedure. Although it is a routine at <i>
Hospital de C&acirc;ncer de Barretos</i> to perform a preoperative bath, adheren
ce to the procedure and its possible interference with the onset of SSI was not 
studied. Other variables, equally not studied, included the impact of SSI on the
 hospitalization time, the need for reoperations and re-hospitalizations and the
 increase in healthcare costs.</font></p>     ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#72#68#article#138#<p>&nbsp;</p>     ^
cY#v15n2a03.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#73#69#article#138#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>CONCLUSION</b></i></font></p> 
    ^cY#v15n2a03.htm##
00737000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050200076002001300578#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#74#70#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The following risk factors for SSI w
ere identified in oncologic surgeries of the digestive system: type of surgery, 
potential for contamination of the surgical wound, time of surgery, neoadjuvant 
radiotherapy applied to the operative field, and surgeon's years of experience. 
Such factors describe a group of individuals at a higher risk for the developmen
t of SSI, for whom new prevention protocols must be considered.</font></p>     ^
cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#75#71#article#138#<p>&nbsp;</p>     ^
cY#v15n2a03.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#76#72#article#138#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>ACKNOWLEDGEMENTS</b></i></font
></p>     ^cY#v15n2a03.htm##
00615000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038000076002001300456#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#77#73#article#138#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We would like to thank Ms. Allini Ma
fra da Costa and Mr. Thiago Buosi Silva for their essential collaboration in typ
ing, tabulating and analyzing data; and Dr. Vinicius de Lima Vazques, Dr. Armand
o Geraldo F. Melani and Dr. Jos&eacute; Humberto Tavares G. Fregnani, for their 
valuable suggestions.</font></p>     ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#78#74#article#138#<p>&nbsp;</p>     ^
cY#v15n2a03.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#79#75#article#138#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p> 
    ^cY#v15n2a03.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030800078002001300386#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#80#76#article#138#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Mangram AJ, Horan T
C, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site i
nfection, 1999. Hospital Infection Control Practices Advisory Committee. Infect 
Control Hosp Epidemiol. 1999; 20(4):250-78; quiz 79-80.    ^cY#v15n2a03.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#81#77#article#138#</font></p>     ^cY
#v15n2a03.htm##
00487000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023800078002001300316#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#82#78#article#138#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Haynes AB, Weiser T
G, Berry WR <i>et al</i>. A surgical safety checklist to reduce morbidity and mo
rtality in a global population. N Engl J Med. 2009; 360(5):491-9.    ^cY#v15n2a0
3.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#83#79#article#138#</font></p>     ^cY
#v15n2a03.htm##
00525000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027600078002001300354#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#84#80#article#138#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Bratzler DW, Hunt D
R. The surgical infection prevention and surgical care improvement projects: nat
ional initiatives to improve outcomes for patients having surgery. Clin Infect D
is. 2006; 43(3):322-30.    ^cY#v15n2a03.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#85#81#article#138#</font></p>     ^cY
#v15n2a03.htm##
00522000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027300078002001300351#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#86#82#article#138#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Martone WJ, Nichols
 RL. Recognition, prevention, surveillance, and management of surgical site infe
ctions: introduction to the problem and symposium overview. Clin Infect Dis. 200
1; 33 Suppl 2:S67-8.    ^cY#v15n2a03.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#87#83#article#138#</font></p>     ^cY
#v15n2a03.htm##
00564000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031500078002001300393#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#88#84#article#138#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Kirkland KB, Briggs
 JP, Trivette SL, Wilkinson WE, Sexton DJ. The impact of surgical-site infection
s in the 1990s: attributable mortality, excess length of hospitalization, and ex
tra costs. Infect Control Hosp Epidemiol. 1999; 20(11):725-30.    ^cY#v15n2a03.h
tm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#89#85#article#138#</font></p>     ^cY
#v15n2a03.htm##
00521000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027200078002001300350#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#90#86#article#138#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. de Lissovoy G, Frae
man K, Hutchins V, Murphy D, Song D, Vaughn BB. Surgical site infection: inciden
ce and impact on hospital utilization and treatment costs. Am J Infect Control. 
2009; 37(5):387-97.    ^cY#v15n2a03.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#91#87#article#138#</font></p>     ^cY
#v15n2a03.htm##
00453000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020400078002001300282#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#92#88#article#138#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Gaynes RP. Surveill
ance of surgical-site infections: the world coming together? Infect Control Hosp
 Epidemiol. 2000; 21(5):309-10.    ^cY#v15n2a03.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#93#89#article#138#</font></p>     ^cY
#v15n2a03.htm##
00419000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017000078002001300248#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#94#90#article#138#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Fry DE, Fry RV. Sur
gical site infection: the host factor. AORN J. 2007; 86(5):801-10; quiz 11-4.   
 ^cY#v15n2a03.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#95#91#article#138#</font></p>     ^cY
#v15n2a03.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028300078002001300361#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#96#92#article#138#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. de Oliveira AC, Cio
sak SI. Infec&ccedil;&atilde;o de s&iacute;tio cir&uacute;rgico em hospital univ
ersit&aacute;rio: vigil&acirc;ncia p&oacute;s-alta e fatores de risco. Rev Esc E
nferm USP. 2007; 41(2):258-63.    ^cY#v15n2a03.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#97#93#article#138#</font></p>     ^cY
#v15n2a03.htm##
00615000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704036500079002001300444#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#98#94#article#138#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Alves A, Panis Y,
 Mantion G, Slim K, Kwiatkowski F, Vicaut E. The AFC score: validation of a 4-it
em predicting score of postoperative mortality after colorectal resection for ca
ncer or diverticulitis: results of a prospective multicenter study in 1049 patie
nts. Ann Surg. 2007; 246(1):91-6.    ^cY#v15n2a03.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#99#95#article#138#</font></p>     ^cY
#v15n2a03.htm##
00553000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704030200080002001300382#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#100#96#article#138#11#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Ercole FF, Starl
ing CE, Chianca TC, Carneiro M. Applicability of the national nosocomial infecti
ons surveillance system risk index for the prediction of surgical site infection
s: a review. Braz J Infect Dis. 2007; 11(1):134-41.    ^cY#v15n2a03.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#101#97#article#138#</font></p>     ^c
Y#v15n2a03.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704030600080002001300386#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#102#98#article#138#12#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Horan TC, Gaynes
 RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical sit
e infections, 1992; a modification of CDC definitions of surgical wound infectio
ns. Infect Control Hosp Epidemiol. 1992; 13(10):606-08.    ^cY#v15n2a03.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#103#99#article#138#</font></p>     ^c
Y#v15n2a03.htm##
00528000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027600081002001300357#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#104#100#article#138#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Imai E, Ueda M,
 Kanao K, Miyaki K, Kubota T, Kitajima M. Surgical site infection surveillance a
fter open gastrectomy and risk factors for surgical site infection. J Infect Che
mother. 2005; 11(3):141-5.    ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#105#101#article#138#</font></p>     ^
cY#v15n2a03.htm##
00518000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026600081002001300347#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#106#102#article#138#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Konishi T, Wata
nabe T, Kishimoto J, Nagawa H. Elective colon and rectal surgery differ in risk 
factors for wound infection: results of prospective surveillance. Ann Surg. 2006
; 244(5):758-63.    ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#107#103#article#138#</font></p>     ^
cY#v15n2a03.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027400081002001300355#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#108#104#article#138#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. de Oliveira AC,
 Ciosak SI, Ferraz EM, Grinbaum RS. Surgical site infection in patients submitte
d to digestive surgery: risk prediction and the NNIS risk index. Am J Infect Con
trol. 2006; 34(4):201-7.    ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#109#105#article#138#</font></p>     ^
cY#v15n2a03.htm##
00581000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032900081002001300410#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#110#106#article#138#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Gaynes RP, Culv
er DH, Horan TC, Edwards JR, Richards C, Tolson JS. Surgical site infection (SSI
) rates in the United States, 1992-1998: the National Nosocomial Infections Surv
eillance System basic SSI risk index. Clin Infect Dis. 2001; 33 Suppl 2:S69-77. 
   ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#111#107#article#138#</font></p>     ^
cY#v15n2a03.htm##
00524000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027200081002001300353#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#112#108#article#138#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Vilar-Compte D,
 Mohar A, Sandoval S, Rosa M, Gordillo P, Volkow P. Surgical site infections at 
the National Cancer Institute in Mexico: A case-control study. Am J Infect Contr
ol. 2000; 28(1):14-20.    ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#113#109#article#138#</font></p>     ^
cY#v15n2a03.htm##
00540000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028800081002001300369#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#114#110#article#138#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Velasco E, Sant
os LC, de Souza Martins CA, de Castro Dias LM, da S.e C. Gon&ccedil;alves VM. Ri
sk index for prediction of surgical site infection after oncology operations. Am
 J Infect Control. 1998; 26(3):217-23.    ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#115#111#article#138#</font></p>     ^
cY#v15n2a03.htm##
00547000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029500081002001300376#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#116#112#article#138#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Velasco E, Thul
er LCS, de Souza Martins CA, de Castro Dias LM, da S.e C. Gon&ccedil;alves VM. R
isk factors for infections complications after abdominal surgery for malignant d
isease. Am J Infect Control. 1996; 24(1):1-6.    ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#117#113#article#138#</font></p>     ^
cY#v15n2a03.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022100081002001300302#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#118#114#article#138#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Smith RL, Bohl 
JK, McElearney ST <i>et al</i>. Wound infection after elective colorectal resect
ion. Ann Surg. 2004; 239(5):599-605; discussion -7.    ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#119#115#article#138#</font></p>     ^
cY#v15n2a03.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020500081002001300286#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#120#116#article#138#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Platell C, Hall
 JC. The prevention of wound infection in patients undergoing colorectal surgery
. J Hosp Infect. 2001; 49(4):233-8.    ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#121#117#article#138#</font></p>     ^
cY#v15n2a03.htm##
00546000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029400081002001300375#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#122#118#article#138#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Delgado-Rodrigu
ez M, Gomez-Ortega A, Sillero-Arenas M, Llorca J. Epidemiology of surgical-site 
infections diagnosed after hospital discharge: a prospective cohort study. Infec
t Control Hosp Epidemiol. 2001; 22(1):24-30.    ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#123#119#article#138#</font></p>     ^
cY#v15n2a03.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020500081002001300286#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#124#120#article#138#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Dominioni L, Im
peratori A, Rotolo N, Rovera F. Risk factors for surgical infections. Surg Infec
t (Larchmt). 2006; 7 Suppl 2:S9-12.    ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#125#121#article#138#</font></p>     ^
cY#v15n2a03.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029700081002001300378#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#126#122#article#138#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Imai E, Ueda M,
 Kanao K <i>et al</i>. Surgical site infection risk factors identified by multiv
ariate analysis for patient undergoing laparoscopic, open colon, and gastric sur
gery. Am J Infect Control. 2008; 36(10):727-31.    ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#127#123#article#138#</font></p>     ^
cY#v15n2a03.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027100081002001300352#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#128#124#article#138#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Turina M, Mulha
ll AM, Mahid SS, Yashar C, Galandiuk S. Frequency and surgical management of chr
onic complications related to pelvic radiation. Arch Surg. 2008; 143(1):46-52; d
iscussion</font></p>     ^cY#v15n2a03.htm##
00475000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022300081002001300304#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#129#125#article#138#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Wurtz R, Wittro
ck B, Lavin MA, Zawacki A. Do new surgeons have higher surgical site infection r
ates? . Infect Control Hosp Epidemiol. 2001; 22:000-.    ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#130#126#article#138#</font></p>     ^
cY#v15n2a03.htm##
00587000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033500081002001300416#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#131#127#article#138#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Muilwijk J, Hof
 S, Wille JC. Associations Between Surgical Site Infection Risk and Hospital Ope
ration Volume and Surgeon Operation Volume Among Hospitals in the Dutch Nosocomi
al Infection Surveillance Network. Infect Control Hosp Epidemiol. 2007; 28(5):55
7-63.    ^cY#v15n2a03.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#132#128#article#138#</font></p>     ^
cY#v15n2a03.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#133#129#article#138#<p>&nbsp;</p>    
 ^cY#v15n2a03.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#134#130#article#138#<p>&nbsp;</p>    
 ^cY#v15n2a03.htm##
00426000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018900078002001300267#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#135#131#article#138#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:
</b>    ^cY#v15n2a03.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004500078002001300123#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#136#132#article#138#<br> Paulo de Tar
so Oliveira e Castro    ^cY#v15n2a03.htm##
00285000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004800078002001300126#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#137#133#article#138#<br> Rua Antenor 
Duarte Villela, Nº 1331    ^cY#v15n2a03.htm##
00281000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004400078002001300122#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#138#134#article#138#<br> 14784-400, B
arretos, SP, Brazil    ^cY#v15n2a03.htm##
00324000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008700078002001300165#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#139#135#article#138#<br> <a href="mai
lto:pitarso@terra.com.br">pitarso@terra.com.br</a></font></p>     ^cY#v15n2a03.h
tm##
00330000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009300078002001300171#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#140#136#article#138#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted on: 3/8/2010    ^cY#v15n
2a03.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#141#137#article#138#<br>   Approved o
n: 10/19/2010    ^cY#v15n2a03.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006100078002001300139#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a03.htm#S#p#142#138#article#138#<br>   We declare
 no conflict of interest</font></p>     ^cY#v15n2a03.htm##
00749000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950100
01800111010001700129010001700146012011900163030003000282065000900312064000500321
03100030032603200020032901400070033106100110033886500090034900200130035803500100
0371801003000381#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#143#1
#article#27#1#^rND^sMangram^nAJ#^rND^sHoran^nTC#^rND^sPearson^nML#^rND^sSilver^n
LC#^rND^sJarvis^nWR#Guideline for prevention of surgical site infection, 1999: H
ospital Infection Control Practices Advisory Committee^len#Infect Control Hosp E
pidemiol#19990000#1999#20#4#250-78#quiz 79-80#20110400#v15n2a03.htm#0899-823X#In
fect Control Hosp Epidemiol##
00620000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
01600111810000600127012008900133030001300222065000900235064000500244031000400249
032000200253014000600255865000900261002001300270035001000283801001300293#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#144#2#article#27#2#^rND^sHayn
es^nAB#^rND^sWeiser^nTG#^rND^sBerry^nWR#et al#A surgical safety checklist to red
uce morbidity and mortality in a global population^len#N Engl J Med#20090000#200
9#360#5#491-9#20110400#v15n2a03.htm#0028-4793#N Engl J Med##
00638000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100015000960120
14700111030001600258065000900274064000500283031000300288032000200291014000700293
865000900300002001300309035001000322801001600332#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a03.htm#S#c#145#3#article#27#3#^rND^sBratzler^nDW#^rND^sHunt^nDR#
The surgical infection prevention and surgical care improvement projects: nation
al initiatives to improve outcomes for patients having surgery^len#Clin Infect D
is#20060000#2006#43#3#322-30#20110400#v15n2a03.htm#1058-4838#Clin Infect Dis##
00631000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100018000950120
13800113030001600251065000900267064000500276031000300281032000400284014000500288
865000900293002001300302035001000315801001600325#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a03.htm#S#c#146#4#article#27#4#^rND^sMartone^nWJ#^rND^sNichols^nR
L#Recognition, prevention, surveillance, and management of surgical site infecti
ons: introduction to the problem and symposium overview^len#Clin Infect Dis#2001
0000#2001#33#^s2#67-8#20110400#v15n2a03.htm#1058-4838#Clin Infect Dis##
00745000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100017000960100
01900113010002000132010001700152012013100169030003000300065000900330064000500339
03100030034403200030034701400070035086500090035700200130036603500100037980100300
0389#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#147#5#article#27#
5#^rND^sKirkland^nKB#^rND^sBriggs^nJP#^rND^sTrivette^nSL#^rND^sWilkinson^nWE#^rN
D^sSexton^nDJ#The impact of surgical-site infections in the 1990s: attributable 
mortality, excess length of hospitalization, and extra costs^len#Infect Control 
Hosp Epidemiol#19990000#1999#20#11#725-30#20110400#v15n2a03.htm#0899-823X#Infect
 Control Hosp Epidemiol##
00710000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100021000770100017000980100
01800115010001600133010001400149010001700163012009400180030002000274065000900294
06400050030303100030030803200020031101400070031386500090032000200130032903500100
0342801002000352#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#148#6
#article#27#6#^rND^sde Lissovoy^nG#^rND^sFraeman^nK#^rND^sHutchins^nV#^rND^sMurp
hy^nD#^rND^sSong^nD#^rND^sVaughn^nBB#Surgical site infection: incidence and impa
ct on hospital utilization and treatment costs^len#Am J Infect Control#20090000#
2009#37#5#387-97#20110400#v15n2a03.htm#0196-6553#Am J Infect Control##
00563000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770120073000940300
03000167065000900197064000500206031000300211032000200214014000700216865000900223
002001300232035001000245801003000255#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a03.htm#S#c#149#7#article#27#7#^rND^sGaynes^nRP#Surveillance of surgical-site
 infections: the world coming together?^len#Infect Control Hosp Epidemiol#200000
00#2000#21#5#309-10#20110400#v15n2a03.htm#0899-823X#Infect Control Hosp Epidemio
l##
00534000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100014000910120
04500105030000700150065000900157064000500166031000300171032000200174014000700176
061001000183865000900193002001300202035001000215801000700225#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a03.htm#S#c#150#8#article#27#8#^rND^sFry^nDE#^rND^sFr
y^nRV#Surgical site infection: the host factor^len#AORN J#20070000#2007#86#5#801
-10#quiz 11-4#20110400#v15n2a03.htm#0001-2092#AORN J##
00600000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100022000770100017000990120
09800116030001900214065000900233064000500242031000300247032000200250014000700252
865000900259002001300268035001000281801001900291#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a03.htm#S#c#151#9#article#27#9#^rND^sde Oliveira^nAC#^rND^sCiosak
^nSI#Infecção de sítio cirúrgico em hospital universitário: vigilância pós-alta 
e fatores de risco^lpt#Rev Esc Enferm USP#20070000#2007#41#2#258-63#20110400#v15
n2a03.htm#0080-6234#Rev Esc Enferm USP##
00793000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940100
01700109010001400126010002100140010001600161012020300177030000900380065000900389
06400050039803100040040303200020040701400050040986500090041400200130042303500100
0436801000900446#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#152#1
0#article#27#10#^rND^sAlves^nA#^rND^sPanis^nY#^rND^sMantion^nG#^rND^sSlim^nK#^rN
D^sKwiatkowski^nF#^rND^sVicaut^nE#The AFC score: validation of a 4-item predicti
ng score of postoperative mortality after colorectal resection for cancer or div
erticulitis: results of a prospective multicenter study in 1049 patients^len#Ann
 Surg#20070000#2007#246#1#91-6#20110400#v15n2a03.htm#0003-4932#Ann Surg##
00726000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
01800115010001800133012014400151030001800295065000900313064000500322031000300327
032000200330014000700332865000900339002001300348035001000361801004100371#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#153#11#article#27#11#^rND^sEr
cole^nFF#^rND^sStarling^nCE#^rND^sChianca^nTC#^rND^sCarneiro^nM#Applicability of
 the national nosocomial infections surveillance system risk index for the predi
ction of surgical site infections: a review^len#Braz J Infect Dis#20070000#2007#
11#1#134-41#20110400#v15n2a03.htm#1413-8670#Brazilian Journal of Infectious Dise
ases##
00737000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01800112010001700130010001600147012012900163030003000292065000900322064000500331
03100030033603200030033901400070034286500090034900200130035803500100037180100300
0381#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#154#12#article#27
#12#^rND^sHoran^nTC#^rND^sGaynes^nRP#^rND^sMartone^nWJ#^rND^sJarvis^nWR#^rND^sEm
ori^nTG#CDC definitions of nosocomial surgical site infections, 1992; a modifica
tion of CDC definitions of surgical wound infections^len#Infect Control Hosp Epi
demiol#19920000#1992#13#10#606-08#20110400#v15n2a03.htm#0899-823X#Infect Control
 Hosp Epidemiol##
00675000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100014000930100
01500107010001600122010001600138010001800154012010900172030001900281710000200300
06500090030206400050031103100030031603200020031901400060032186500090032700200130
0336#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#155#13#article#27
#13#^rND^sImai^nE#^rND^sUeda^nM#^rND^sKanao^nK#^rND^sMiyaki^nK#^rND^sKubota^nT#^
rND^sKitajima^nM#Surgical site infection surveillance after open gastrectomy and
 risk factors for surgical site infection^len#J Infect Chemother#2#20050000#2005
#11#3#141-5#20110400#v15n2a03.htm##
00658000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01900114010001600133012011800149030000900267065000900276064000500285031000400290
032000200294014000700296865000900303002001300312035001000325801000900335#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#156#14#article#27#14#^rND^sKo
nishi^nT#^rND^sWatanabe^nT#^rND^sKishimoto^nJ#^rND^sNagawa^nH#Elective colon and
 rectal surgery differ in risk factors for wound infection: results of prospecti
ve surveillance^len#Ann Surg#20060000#2006#244#5#758-63#20110400#v15n2a03.htm#00
03-4932#Ann Surg##
00677000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100017001010100
01700118010001900135012011200154030002000266065000900286064000500295031000300300
032000200303014000600305865000900311002001300320035001000333801002000343#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#157#15#article#27#15#^rND^sde
 Oliveira^nAC#^rND^sCiosak^nSI#^rND^sFerraz^nEM#^rND^sGrinbaum^nRS#Surgical site
 infection in patients submitted to digestive surgery: risk prediction and the N
NIS risk index^len#Am J Infect Control#20060000#2006#34#4#201-7#20110400#v15n2a0
3.htm#0196-6553#Am J Infect Control##
00760000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01600113010001800129010001800147010001700165012014900182030001600331065000900347
06400050035603100030036103200040036401400060036886500090037400200130038303500100
0396801001600406#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#158#1
6#article#27#16#^rND^sGaynes^nRP#^rND^sCulver^nDH#^rND^sHoran^nTC#^rND^sEdwards^
nJR#^rND^sRichards^nC#^rND^sTolson^nJS#Surgical site infection (SSI) rates in th
e United States, 1992-1998: the National Nosocomial Infections Surveillance Syst
em basic SSI risk index^len#Clin Infect Dis#20010000#2001#33#^s2#69-77#20110400#
v15n2a03.htm#1058-4838#Clin Infect Dis##
00711000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100015001010100
01800116010001400134010001800148010001600166012009400182030002000276065000900296
06400050030503100030031003200020031301400060031586500090032100200130033003500100
0343801002000353#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#159#1
7#article#27#17#^rND^sVilar-Compte^nD#^rND^sMohar^nA#^rND^sSandoval^nS#^rND^sRos
a^nM#^rND^sGordillo^nP#^rND^sVolkow^nP#Surgical site infections at the National 
Cancer Institute in Mexico: A case-control study^len#Am J Infect Control#2000000
0#2000#28#1#14-20#20110400#v15n2a03.htm#0196-6553#Am J Infect Control##
00702000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
02700113010002500140010003000165012008300195030002000278065000900298064000500307
03100030031203200020031501400070031786500090032400200130033303500100034680100200
0356#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#160#18#article#27
#18#^rND^sVelasco^nE#^rND^sSantos^nLC#^rND^sde Souza Martins^nCA#^rND^sde Castro
 Dias^nLM#^rND^sda S.e C. Gonçalves^nVM#Risk index for prediction of surgical si
te infection after oncology operations^len#Am J Infect Control#19980000#1998#26#
3#217-23#20110400#v15n2a03.htm#0196-6553#Am J Infect Control##
00709000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
02700114010002500141010003000166012009200196030002000288065000900308064000500317
03100030032203200020032501400040032786500090033100200130034003500100035380100200
0363#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#161#19#article#27
#19#^rND^sVelasco^nE#^rND^sThuler^nLCS#^rND^sde Souza Martins^nCA#^rND^sde Castr
o Dias^nLM#^rND^sda S.e C. Gonçalves^nVM#Risk factors for infections complicatio
ns after abdominal surgery for malignant disease^len#Am J Infect Control#1996000
0#1996#24#1#1-6#20110400#v15n2a03.htm#0196-6553#Am J Infect Control##
00611000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
02100110810000600131012005600137030000900193065000900202064000500211031000400216
03200020022001400080022206100140023086500090024400200130025303500100026680100090
0276#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#162#20#article#27
#20#^rND^sSmith^nRL#^rND^sBohl^nJK#^rND^sMcElearney^nST#et al#Wound infection af
ter elective colorectal resection^len#Ann Surg#20040000#2004#239#5#599-605#discu
ssion -7#20110400#v15n2a03.htm#0003-4932#Ann Surg##
00566000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960120
08000111030001400191065000900205064000500214031000300219032000200222014000600224
865000900230002001300239035001000252801001400262#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a03.htm#S#c#163#21#article#27#21#^rND^sPlatell^nC#^rND^sHall^nJC#
The prevention of wound infection in patients undergoing colorectal surgery^len#
J Hosp Infect#20010000#2001#49#4#233-8#20110400#v15n2a03.htm#0195-6701#J Hosp In
fect##
00707000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100027000790100022001060100
02400128010001600152012010800168030003000276065000900306064000500315031000300320
032000200323014000600325865000900331002001300340035001000353801003000363#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#164#22#article#27#22#^rND^sDe
lgado-Rodriguez^nM#^rND^sGomez-Ortega^nA#^rND^sSillero-Arenas^nM#^rND^sLlorca^nJ
#Epidemiology of surgical-site infections diagnosed after hospital discharge: a 
prospective cohort study^len#Infect Control Hosp Epidemiol#20010000#2001#22#1#24
-30#20110400#v15n2a03.htm#0899-823X#Infect Control Hosp Epidemiol##
00564000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100020000980100
01600118010001600134012004100150030002200191710000200213065000900215064000500224
031000200229032000400231014000500235865000900240002001300249#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a03.htm#S#c#165#23#article#27#23#^rND^sDominioni^nL#^
rND^sImperatori^nA#^rND^sRotolo^nN#^rND^sRovera^nF#Risk factors for surgical inf
ections^len#Surg Infect (Larchmt)#2#20060000#2006#7#^s2#9-12#20110400#v15n2a03.h
tm##
00687000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100014000930100
01500107810000600122012014600128030002000274065000900294064000500303031000300308
032000300311014000700314865000900321002001300330035001000343801002000353#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#166#24#article#27#24#^rND^sIm
ai^nE#^rND^sUeda^nM#^rND^sKanao^nK#et al#Surgical site infection risk factors id
entified by multivariate analysis for patient undergoing laparoscopic, open colo
n, and gastric surgery^len#Am J Infect Control#20080000#2008#36#10#727-31#201104
00#v15n2a03.htm#0196-6553#Am J Infect Control##
00682000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01600113010001600129010001900145012009100164030001000255065000900265064000500274
03100040027903200020028301400060028506100110029186500090030200200130031103500100
0324801001000334#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a03.htm#S#c#167#2
5#article#27#25#^rND^sTurina^nM#^rND^sMulhall^nAM#^rND^sMahid^nSS#^rND^sYashar^n
C#^rND^sGalandiuk^nS#Frequency and surgical management of chronic complications 
related to pelvic radiation^len#Arch Surg#20080000#2008#143#1#46-52#discussion#2
0110400#v15n2a03.htm#0004-0010#Arch Surg##
00623000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940100
01600112010001700128012006300145030003000208065000900238064000500247031000300252
061000400255865000900259002001300268035001000281801003000291#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a03.htm#S#c#168#26#article#27#26#^rND^sWurtz^nR#^rND^
sWittrock^nB#^rND^sLavin^nMA#^rND^sZawacki^nA#Do new surgeons have higher surgic
al site infection rates?^len#Infect Control Hosp Epidemiol#20010000#2001#22#000#
20110400#v15n2a03.htm#0899-823X#Infect Control Hosp Epidemiol##
00730000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100013000970100
01600110012018400126030003000310065000900340064000500349031000300354032000200357
014000700359865000900366002001300375035001000388801003000398#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a03.htm#S#c#169#27#article#27#27#^rND^sMuilwijk^nJ#^r
ND^sHof^nS#^rND^sWille^nJC#Associations Between Surgical Site Infection Risk and
 Hospital Operation Volume and Surgeon Operation Volume Among Hospitals in the D
utch Nosocomial Infection Surveillance Network^len#Infect Control Hosp Epidemiol
#20070000#2007#28#5#557-63#20110400#v15n2a03.htm#0899-823X#Infect Control Hosp E
pidemiol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#o#1#1#article#1
#20110406#124809#v15n2a04.htm#153##
01970000000000529000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000200095049000800097158000300105030001800108
03100030012603200020012906500090013101400110014003500100015101201110016101000460
02720100043003180100037003610100035003980100033004330700050004660830740005160850
00801256085003001264085005701294085002701351117000601378072000301384112000901387
111001101396114000901407113001101416002001301427#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a04.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#4#BJID230#nd#Bra
z J Infect Dis#15#2#20110400#^f116^l118#1413-8670#Incidence of Trypanosoma cruzi
 transmission through breastfeeding during acute experimental Chagas disease^len
#^rND^1A01^nLuciamare Perinetti Alves^sMartins#^rND^1A01^nRoberto Esteves Pires^
sCastanho#^rND^1A01^nAdriano Barbosa^sNogueira#^rND^1A01^nOtavio Turolo da^sSilv
a#^rND^1A01^nAlex Silva de^sGusmão#Faculdade de Medicina de Marília^iA01^sSP^pBr
azil#^len^aOBJECTIVE: To verify the incidence of T. cruzi transmission through b
reastfeeding during acute experimental Chagas' disease. METHODS: Fifteen female 
Swiss mice were mated and, after pregnancy confirmation, placed in individual ca
ges. A few hours after birth, the females were inoculated with 0.1 mL of blood c
ontaining approximately 3 x 10(5) trypomastigote forms of Y strain of T. cruzi a
nd continued breastfeeding for 25 days. RESULTS: In 142 offspring examined no in
fection through breast-feeding was observed. CONCLUSIONS: The low number of tryp
omastigote forms ingested by the newborn mice combined with biological and bioch
emical characteristics of blood trypomastigotes may explain the lack of transmis
sion in this experiment.#^dnd^i1#^tm^len^kTrypanosoma cruzi^i1#^tm^len^kfoods fo
r pregnant and breastfeeding mothers^i1#^tm^len^kChagas disease^i1#other#30#2010
0630#06/30/2010#20101002#10/02/2010#v15n2a04.htm##
02042000000000529000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000200095049000800097158000300105030001800108
03100030012603200020012906500090013101400110014003500100015101201250016101000460
02860100043003320100037003750100035004120100033004470700050004800830791005300850
00801321085003701329085005701366085002701423117000601450072000301456112000901459
111001101468114000901479113001101488002001301499#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a04.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#4#BJID230#nd#Bra
z J Infect Dis#15#2#20110400#^f116^l118#1413-8670#<b>Incidence of <i>Trypanosoma
 cruzi</i> transmission through breastfeeding during acute experimental Chagas d
isease</b>^len#^rND^1A01^nLuciamare Perinetti Alves^sMartins#^rND^1A01^nRoberto 
Esteves Pires^sCastanho#^rND^1A01^nAdriano Barbosa^sNogueira#^rND^1A01^nOtavio T
urolo da^sSilva#^rND^1A01^nAlex Silva de^sGusmão#Faculdade de Medicina de Maríli
a^iA01^sSP^pBrazil#^len^a<b>OBJECTIVE:</b> To verify the incidence of <i>T. cruz
i</i> transmission through breastfeeding during acute experimental Chagas' disea
se. <b>METHODS:</b> Fifteen female Swiss mice were mated and, after pregnancy co
nfirmation, placed in individual cages. A few hours after birth, the females wer
e inoculated with 0.1 mL of blood containing approximately 3 x 10<sup>5</sup> tr
ypomastigote forms of Y strain of <i>T. cruzi</i> and continued breastfeeding fo
r 25 days. <b>RESULTS:</b> In 142 offspring examined no infection through breast
-feeding was observed. <b>CONCLUSIONS:</b> The low number of trypomastigote form
s ingested by the newborn mice combined with biological and biochemical characte
ristics of blood trypomastigotes may explain the lack of transmission in this ex
periment.#^dnd^i1#^tm^len^k<i>Trypanosoma cruzi</i>^i1#^tm^len^kfoods for pregna
nt and breastfeeding mothers^i1#^tm^len^kChagas disease^i1#other#30#20100630#06/
30/2010#20101002#10/02/2010#v15n2a04.htm##
02106000000000553000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108121000200113049000800115158000300123
03000210012603100030014703200020015006500090015201400110016103500100017201201110
01820100046002930100043003390100037003820100035004190100033004540700052004870830
74000539085000801279085003001287085005701317085002701374117000601401072000301407
112000901410111001101419114000901430113001101439002001301450008008901463#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#l#4#1#article#1#^mMar./Apr.^a20
11#oa#en#br1.1#1#4.0#ilus#4#BJID230#nd#Braz. j. infect. dis#15#2#20110400#^f116^
l118#1413-8670#Incidence of Trypanosoma cruzi transmission through breastfeeding
 during acute experimental Chagas disease^len#^rND^1A01^nLuciamare Perinetti Alv
es^sMartins#^rND^1A01^nRoberto Esteves Pires^sCastanho#^rND^1A01^nAdriano Barbos
a^sNogueira#^rND^1A01^nOtavio Turolo da^sSilva#^rND^1A01^nAlex Silva de^sGusmão#
^iA01^1Faculdade de Medicina de Marília^sSP^pBrazil#^len^aOBJECTIVE: To verify t
he incidence of T. cruzi transmission through breastfeeding during acute experim
ental Chagas' disease. METHODS: Fifteen female Swiss mice were mated and, after 
pregnancy confirmation, placed in individual cages. A few hours after birth, the
 females were inoculated with 0.1 mL of blood containing approximately 3 x 10(5)
 trypomastigote forms of Y strain of T. cruzi and continued breastfeeding for 25
 days. RESULTS: In 142 offspring examined no infection through breast-feeding wa
s observed. CONCLUSIONS: The low number of trypomastigote forms ingested by the 
newborn mice combined with biological and biochemical characteristics of blood t
rypomastigotes may explain the lack of transmission in this experiment.#^dnd^i1#
^tm^len^kTrypanosoma cruzi^i1#^tm^len^kfoods for pregnant and breastfeeding moth
ers^i1#^tm^len^kChagas disease^i1#other#30#20100630#06/30/2010#20101002#10/02/20
10#v15n2a04.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid
=S1413-86702011000200004##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#5#1#article#119#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLE</b><
/font></p>     ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#6#2#article#119#<p>&nbsp;</p>     ^cY
#v15n2a04.htm##
00454000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704022100074002001300295#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#7#3#article#119#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Incidence of <i>T
rypanosoma cruzi</i> transmission through breastfeeding during acute experimenta
l Chagas disease</b></font></p>     ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#8#4#article#119#<p>&nbsp;</p>     ^cY
#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#9#5#article#119#<p>&nbsp;</p>     ^cY
#v15n2a04.htm##
00531000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704029700075002001300372#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#10#6#article#119#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Luciamare Perinetti Alves Martins<
sup>I</sup>; Roberto Esteves Pires Castanho<sup>I</sup>; Adriano Barbosa Nogueir
a<sup>II</sup>; Otavio Turolo da Silva<sup>II</sup>; Alex Silva de Gusm&atilde;o
<sup>II</sup></b></font></p>     ^cY#v15n2a04.htm##
00384000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015000075002001300225#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#11#7#article#119#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>PhD; Professor, Faculdade
 de Medicina de Mar&iacute;lia, SP, Brazil    ^cY#v15n2a04.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704010600075002001300181#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#12#8#article#119#<br> <sup>II</sup>Me
dical Student, Faculdade de Medicina de Mar&iacute;lia, SP, Brazil</font></p>   
  ^cY#v15n2a04.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011800075002001300193#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#13#9#article#119#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a></
font></p>     ^cY#v15n2a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#14#10#article#119#<p>&nbsp;</p>     ^
cY#v15n2a04.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#15#11#article#119#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v15n2a04.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#16#12#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
15n2a04.htm##
00444000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020900076002001300285#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#17#13#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>OBJECTIVE:</b> To verify the inci
dence of <i>T. cruzi</i> transmission through breastfeeding during acute experim
ental Chagas' disease.    ^cY#v15n2a04.htm##
00574000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033900076002001300415#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#18#14#article#119#<br> <b>METHODS:</b
> Fifteen female Swiss mice were mated and, after pregnancy confirmation, placed
 in individual cages. A few hours after birth, the females were inoculated with 
0.1 mL of blood containing approximately 3 x 10<sup>5</sup> trypomastigote forms
 of Y strain of <i>T. cruzi</i> and continued breastfeeding for 25 days.    ^cY#
v15n2a04.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#19#15#article#119#<br> <b>RESULTS:</b
> In 142 offspring examined no infection through breast-feeding was observed.   
 ^cY#v15n2a04.htm##
00488000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025300076002001300329#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#20#16#article#119#<br>   <b>CONCLUSIO
NS:</b> The low number of trypomastigote forms ingested by the newborn mice comb
ined with biological and biochemical characteristics of blood trypomastigotes ma
y explain the lack of transmission in this experiment.</font></p>     ^cY#v15n2a
04.htm##
00444000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020900076002001300285#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#21#17#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> <i>Trypanosoma cruz
i</i>; foods for pregnant and breastfeeding mothers; Chagas disease.</font></p> 
<hr size="1" noshade>     ^cY#v15n2a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#22#18#article#119#<p>&nbsp;</p>     ^
cY#v15n2a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#23#19#article#119#<p>&nbsp;</p>     ^
cY#v15n2a04.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#24#20#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>INTRODUCTION</b></i></font></p
>     ^cY#v15n2a04.htm##
00593000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035800076002001300434#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#25#21#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In Central and South America, approx
imately 13 million individuals are infected by <i>Trypanosoma cruzi</i>, and eac
h year 200,000 new cases are reported.<sup>1</sup> According to the Ministry of 
Health, there are around three million infected patients in Brazil.<sup>2</sup><
/font></p>     ^cY#v15n2a04.htm##
00564000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032900076002001300405#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#26#22#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Chagas disease, caused by the protoz
oan <i>T. cruzi</i>, has the vector transmission as the primary mechanism for sp
reading the disease, whereby humans are infected by contact with vector contamin
ated feces containing the metacyclics.<sup>3</sup></font></p>     ^cY#v15n2a04.h
tm##
00663000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042800076002001300504#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#27#23#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">After control of vector transmission
 and blood transfusion, the oral route became the most important and frequent me
ans of transmission of Chagas disease to humans.<sup>4</sup> Besides this route,
 other less common ones, like laboratory accidents, handling of infected animals
, organ transplants, and breast milk, have been reported.<sup>3</sup></font></p>
     ^cY#v15n2a04.htm##
00711000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047600076002001300552#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#28#24#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Since Brumpt,<sup>5</sup> there have
 been numerous studies and facts recording the oral infection with <i>T. cruzi</
i>.<sup>6-10</sup> It was observed that metacyclic trypomastigotes are more effe
ctive in producing oral infections than trypomastigotes obtained from culture or
 feces of <i>R. prolixus</i>, as they are partially resistant to the action of t
he canine gastric juice.<sup>11</sup></font></p>     ^cY#v15n2a04.htm##
00755000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052000076002001300596#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#29#25#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Although blood, metacyclic, and cult
ure trypomastigotes are morphologically identical,<sup>12</sup> different glycop
roteins are used for cell invasion. According to Yoshida,<sup>13</sup> metacycli
c trypomastigote uses surface glycoproteins such as gp82 and gp35/50, while the 
forms from tissue culture make use of gp85. Despite the molecular similarity, th
e glycoproteins have adhesive properties and different receptors on target cells
.</font></p>     ^cY#v15n2a04.htm##
00855000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062000076002001300696#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#30#26#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Considering the above mentioned stud
ies and reports by Mazza <i>et al.</i><sup>14</sup> and Medina-Lopes<sup>15</sup
> who described the presence of <i>T. cruzi</i> in human colostrum of patients w
ith acute form of the disease and, later, the report by Medina-Lopes<sup>16</sup
> on a case of <i>T. cruzi</i> detected in a breast-feeding mother in the chroni
c phase of disease, it was decided to undertake this research to assess the inci
dence of <i>T. cruzi</i> transmission through breastfeeding during acute experim
ental Chagas disease.</font></p>     ^cY#v15n2a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#31#27#article#119#<p>&nbsp;</p>     ^
cY#v15n2a04.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011700076002001300193#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#32#28#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>MATERIAL AND METHODS</b></i></
font></p>     ^cY#v15n2a04.htm##
00526000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029100076002001300367#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#33#29#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Strain of <i>Trypanosoma cruzi</i>: 
the Y strain<sup>17</sup> was used which is maintained by successive samplings i
n Swiss mice in the Parasitology laboratory, Faculty of Medicine of Mar&iacute;l
ia (FAMEMA).</font></p>     ^cY#v15n2a04.htm##
01057000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082200076002001300898#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#34#30#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Experimental infection: 15 healthy "
Swiss" female mice, about three months old, were mated with healthy "Swiss" male
 mice. After pregnancy confirmation, they were placed in individual cages and fe
d with chow and water <i>ad libitum</i>. A few hours after birth, the females we
re inoculated with 0.1 mL of blood containing approximately 3 x 10<sup>5</sup> f
orms of Y strain trypomastigotes obtained from a mouse previously infected. Brea
stfeeding of pups were continued for 25 days. Infection in lactating females was
 assessed ten days after inoculation by searching for trypomastigotes in a drop 
of blood taken from the tail according to the method proposed by Brener,<sup>19<
/sup> with correction for inter microscopic field.<sup>20</sup></font></p>     ^
cY#v15n2a04.htm##
00535000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030000076002001300376#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#35#31#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This research was approved by the FA
MEMA Research Ethics Committee under nº 306/09. Care for the maintenance, treatm
ent and euthanasia of the mice followed the standards set by COBEA according to 
Sogayar.<sup>18</sup></font></p>     ^cY#v15n2a04.htm##
00610000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037500076002001300451#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#36#32#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Examination of the offspring: 142 of
fspring were nursed by their infected mothers and after 25 days were investigate
d for the presence of trypomastigotes by collecting a sample of blood from the t
ail for a fresh exam, observing at least 100 microscopic fields with magnificati
on of 400 times.</font></p>     ^cY#v15n2a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#37#33#article#119#<p>&nbsp;</p>     ^
cY#v15n2a04.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#38#34#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>RESULTS</b></i></font></p>    
 ^cY#v15n2a04.htm##
00484000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024900076002001300325#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#39#35#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">All 15 females had confirmed infecti
on on the tenth day, having on average 23,060 trypomastigotes/5 &#181;L blood wi
th a standard deviation of 15,275 trypomastigotes.</font></p>     ^cY#v15n2a04.h
tm##
00409000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017400076002001300250#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#40#36#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">On blood examination of the 140 offs
pring trypomastigotes were not observed in any of them.</font></p>     ^cY#v15n2
a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#41#37#article#119#<p>&nbsp;</p>     ^
cY#v15n2a04.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#42#38#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>DISCUSSION</b></i></font></p> 
    ^cY#v15n2a04.htm##
00698000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046300076002001300539#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#43#39#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Although in this research no offspri
ng was infected through breastfeeding, Michie and Gilmour<sup>21</sup> argue tha
t, in theory, infection with <i>T. cruzi</i> through colostrum and breast milk c
ould occur, since the multiplication of the parasite is intracellular, and it ca
n be found in the mammary gland, as described in other body glands, during the a
cute phase of infection.</font></p>     ^cY#v15n2a04.htm##
00646000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041100076002001300487#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#44#40#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Also according to these authors, it 
is possible that the parasite reaches the mammary secretions through inter-cellu
lar spaces of the mammary gland, indicating that it loses the cell cytoplasm fro
m acini during lactation. If it occurs at the site of parasite multiplication, i
t may shed in the acini and from there to the ducts.</font></p>     ^cY#v15n2a04
.htm##
00930000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069500076002001300771#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#45#41#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The results of this research reinfor
ce those found by Campos <i>et al.</i><sup>22</sup> who also failed to infect la
ctating pups born to females in the acute phase of infection. Experiments conduc
ted in our laboratory allowed us to observe that oral infections were establishe
d only when metacyclic forms were used.<sup>23</sup> In a previous study blood t
rypomastigotes and epimastigotes obtained from cultures in LIT medium failed to 
produce infection.<sup>24</sup> Diaz-Ungria, 1968<sup>11</sup> also noticed that
 the most infectious material in oral experiments were those obtained from feces
 of triatomines.</font></p>     ^cY#v15n2a04.htm##
00937000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070200076002001300778#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#46#42#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">According to Hoft,<sup>25</sup> meta
cyclic trypomastigotes express specific surface molecules that are not present i
n the bloodstream forms, which are necessary for adhesion and penetration of the
 parasite in the mucin layer with the ensuing oral infection. In a study by Aray
a<sup>12</sup> and Neira,<sup>26</sup> the metacyclic trypomastigotes using gp82
 present in its membrane were shown to promote adherence to gastric mucin. Thus,
 host-parasite interaction is mediated by gp82 in cells that trigger signals tha
t induce calcium release, an event essential for the internalization of <i>T. cr
uzi</i>.<sup>4,13</sup></font></p>     ^cY#v15n2a04.htm##
00956000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072100076002001300797#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#47#43#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Even having used the Y strain, which
 expresses gp82 in metacyclic forms and therefore has highly infective features,
 the differences in biological characteristics of blood trypomastigotes may have
 influenced the success of this research, because according to Yoshida,<sup>13</
sup> blood forms cross the extra cellular matrix using gp85/TS superfamily molec
ules that bind to fibronectin and laminin, thus triggering the action of enzymes
 to the process of cellular internalization. In addition to the glycoproteins, t
he use of cruzipain may also contribute to the variation in infectivity among th
e strains of <i>T. cruzi</i>.<sup>27</sup></font></p>     ^cY#v15n2a04.htm##
01179000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704094400076002001301020#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#48#44#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Despite the confirmation of infectio
n in lactating females, non-transmission of Chagas disease to their offspring ma
y also be due to the low number of trypomastigotes ingested during breastfeeding
. Owing to the difficulty of carrying out milking in females counting of parasit
ic forms in colostrum and milk was not made, but based on reports of Medina-Lope
s and Macedo<sup>15</sup> one could assume that the number of parasitic forms in
 milk is lower than in peripheral blood. Ara&uacute;jo <i>et al.</i><sup>28</sup
> and Lima <i>et al.</i>,<sup>29</sup> using blood trypomastigotes were able to 
orally infect laboratory animals infusing through a gastric tube 103 parasites p
er gram of body weight and 5 x 10<sup>4</sup> trypomastigotes respectively, corr
oborating reports of Dias,<sup>11</sup> where the success of oral infection is d
ependent on the inoculum.</font></p>     ^cY#v15n2a04.htm##
00666000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043100076002001300507#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#49#45#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">To Dias,<sup>11</sup> oral infection
s take longer for trypomastigotes to reach the bloodstream, so we believed that 
the period of 25 days was sufficient for examining the blood of offspring, since
 Castanho <i>et al.</i><sup>23</sup> found positivity around the second week and
 Camandaroba <i>et al.</i><sup>30</sup> from the 10<sup>th</sup> day on.</font><
/p>     ^cY#v15n2a04.htm##
00674000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043900076002001300515#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#50#46#article#119#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Thus, it is possible that the low nu
mber of trypomastigotes ingested by the offspring together with biological and b
iochemical characteristics of blood trypomastigotes may explain the lack of tran
smission in this experiment. Further studies are needed to understand the invasi
ve capacity of blood trypomastigotes of <i>T. cruzi</i> in non-phagocytic cells.
</font></p>     ^cY#v15n2a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#51#47#article#119#<p>&nbsp;</p>     ^
cY#v15n2a04.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#52#48#article#119#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p> 
    ^cY#v15n2a04.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023600078002001300314#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#53#49#article#119#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. WHO (World Health O
rganization). 17th Programme Report (Progress 2003-2004): Making Health Research
 Work for Poor People. Tropical Disease Research, Geneva, 2005.    ^cY#v15n2a04.
htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#54#50#article#119#</font></p>     ^cY
#v15n2a04.htm##
00510000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026100078002001300339#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#55#51#article#119#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. SVS/MS - Minist&eac
ute;rio da Sa&uacute;de. Secretaria de Vigil&acirc;ncia em Sa&uacute;de. Guia de
 Vigil&acirc;ncia Epidemiol&oacute;gica. Doen&ccedil;a de Chagas. Bras&iacute;li
a, 2005.    ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#56#52#article#119#</font></p>     ^cY
#v15n2a04.htm##
00658000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704040900078002001300487#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#57#53#article#119#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Gontijo ED, Santos 
SE. Mecanismos principais e at&iacute;picos de transmiss&atilde;o da doen&ccedil
;a de Chagas, 2009. Dispon&iacute;vel em: &lt;<a href="http://www.fiocruz.br/cha
gas/cgi/cgilua.exe/sys/start.htm?sid=173" target="_blank">http://www.fiocruz.br/
chagas/cgi/cgilua.exe/sys/start.htm?sid=173</a>&gt;. Accessed on 05/04/2010.    
^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#58#54#article#119#</font></p>     ^cY
#v15n2a04.htm##
00458000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020900078002001300287#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#59#55#article#119#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Yoshida N. Molecula
r mechanism of <i>Trypanosoma cruzi</i> infection by oral route. Mem. Inst. Oswa
ldo Cruz 2009;104 (suppl I):101-107.    ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#60#56#article#119#</font></p>     ^cY
#v15n2a04.htm##
00590000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704034100078002001300419#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#61#57#article#119#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Brumpt E. Immunit&e
acute; partielle dans les infections &agrave; <i>Trypanosoma cruzi</i>, transmis
sion de ce trypanosome par Cimex rotundus. Role regulateur d&ecirc;s hotes inter
mediaires. Passage &agrave; travers la peau. Bull. Soc. Path. Exotique, 1913; 6:
172-176.    ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#62#58#article#119#</font></p>     ^cY
#v15n2a04.htm##
00537000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028800078002001300366#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#63#59#article#119#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Nery-Guimaraes F, S
ilva NN, C, lausell DT <i>et al.</i> Surto epid&ecirc;mico de doen&ccedil;a de C
hagas com prov&aacute;vel contamina&ccedil;&atilde;o oral. Rev. Inst. Med. Trop.
 S&atilde;o Paulo 1968; 10:265-276.    ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#64#60#article#119#</font></p>     ^cY
#v15n2a04.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023000078002001300308#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#65#61#article#119#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Lainson R, Shaw JJ,
 Naif RD. Chagas' disease in the Amazon Basin: speculation on transmission per o
s. Rev. Inst. Med. Trop. S&atilde;o Paulo 1980; 22:62-67.    ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#66#62#article#119#</font></p>     ^cY
#v15n2a04.htm##
00482000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023300078002001300311#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#67#63#article#119#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Coura JR. Mecanismo
 de transmiss&atilde;o da infec&ccedil;&atilde;o chag&aacute;sica ao homem por v
ia oral. Rev. Soc. Bras. Med. Trop. 1997; 30 (supl 1):45-47.    ^cY#v15n2a04.htm
##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#68#64#article#119#</font></p>     ^cY
#v15n2a04.htm##
00500000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025100078002001300329#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#69#65#article#119#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Shikanai-Yassuda MA
; Marcondes BC, Guedes LA <i>et al.</i> Possible oral transmission of acute Chag
as'disease in Brazil. Rev. Inst. Med. Trop. S&atilde;o Paulo 1991; 33:355-361.  
  ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#70#66#article#119#</font></p>     ^cY
#v15n2a04.htm##
00416000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704016600079002001300245#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#71#67#article#119#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Ianni BM, Mady C.
 Como era gostoso o meu caldo de cana... Arq. Bras. Card.2005; 85:379-380.    ^c
Y#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#72#68#article#119#</font></p>     ^cY
#v15n2a04.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027600079002001300355#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#73#69#article#119#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Dias JCP. Notas s
obre o <i>Trypanosoma cruzi</i> e suas caracter&iacute;sticas bio-ecol&oacute;gi
cas, como agente de enfermidades transmitidas por alimentos.Rev. Soc. Bras. Med.
 Trop. 2006; 39:370-375.    ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#74#70#article#119#</font></p>     ^cY
#v15n2a04.htm##
00678000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704042800079002001300507#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#75#71#article#119#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Araya MIR. Expres
s&atilde;o da glicoprote&iacute;na de superf&iacute;cie de 82 KDa (GP82) de trip
omastigotas metac&iacute;clicos de <i>Trypanosoma cruzi</i> em c&eacute;lulas de
 mam&iacute;feros e em formas epimastigotas do parasita. 130f. Tese (doutorado) 
- Escola Paulista de Medicina, Universidade Federal de S&atilde;o Paulo, S&atild
e;o Paulo, 1998.    ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#76#72#article#119#</font></p>     ^cY
#v15n2a04.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704019300079002001300272#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#77#73#article#119#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Yoshida N. Molecu
lar basis of mammalian cell invasion by <i>Trypanosoma cruzi</i>. An. Ac. Bras. 
Cien.2006; 78:87-110.    ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#78#74#article#119#</font></p>     ^cY
#v15n2a04.htm##
00477000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704022700079002001300306#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#79#75#article#119#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Mazza S, Montana 
A, Benitez C, Janzi E. Transmission del Schizotripanum cruzi al nino por leche d
e madre com enfermedad de Chagas. MEPRA 1936; 28:41-49.    ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#80#76#article#119#</font></p>     ^cY
#v15n2a04.htm##
00431000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704018100079002001300260#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#81#77#article#119#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Medina-Lopes MD, 
Macedo V. Trypanossoma cruzi no colostro humano. Rev. Soc. Bras. Med. Trop. 1983
; 16:170.    ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#82#78#article#119#</font></p>     ^cY
#v15n2a04.htm##
00502000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025200079002001300331#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#83#79#article#119#16#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Medina-Lopes MD. 
Transmiss&atilde;o do Trypanossoma cruzi em um caso, durante aleitamento, em &aa
cute;rea n&atilde;o end&ecirc;mica. Rev. Soc. Bras. Med. Trop. 1988; 21:151-153.
    ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#84#80#article#119#</font></p>     ^cY
#v15n2a04.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023600079002001300315#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#85#81#article#119#17#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Silva LHP, Nussen
zweig, V. Sobre uma cepa de <i>Trypanosoma cruzi</i> altamente virulenta para o 
camundongo branco. Folia Cl&iacute;n. et Biol. 1953; 20:191-208.    ^cY#v15n2a04
.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#86#82#article#119#</font></p>     ^cY
#v15n2a04.htm##
00525000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027500079002001300354#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#87#83#article#119#18#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Sogayar R. &Eacut
e;tica na experimenta&ccedil;&atilde;o animal: Consci&ecirc;ncia &amp; A&ccedil;
&atilde;o. Botucatu: Funda&ccedil;&atilde;o de Estudos e Pesquisas Agr&iacute;co
las e Florestais, 2006.    ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#88#84#article#119#</font></p>     ^cY
#v15n2a04.htm##
00491000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024100079002001300320#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#89#85#article#119#19#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Brener Z. Therape
utic activity and criterion of cure on mice experimentally infected with <i>Tryp
anosoma cruzi</i>. Rev Inst Med Trop S&atilde;o Paulo1962; 4:389-396.    ^cY#v15
n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#90#86#article#119#</font></p>     ^cY
#v15n2a04.htm##
00728000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704047800079002001300557#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#91#87#article#119#20#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Martins LPA. Veri
fica&ccedil;&atilde;o da susceptibilidade de tr&ecirc;s esp&eacute;cies de Triat
ominae (Hem&iacute;ptera, Reduviidae) a infec&ccedil;&atilde;o por duas cepas de
 <i>Trypanosoma cruzi</i> (Kinetoplastidae, Trypanosomatidae) utilizando xenodia
gn&oacute;stico artificial. 105f. Disserta&ccedil;&atilde;o (Mestrado) - Faculda
de de Ci&ecirc;ncias Farmac&ecirc;uticas, UNESP, Araraquara, 1999.    ^cY#v15n2a
04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#92#88#article#119#</font></p>     ^cY
#v15n2a04.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020700079002001300286#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#93#89#article#119#21#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Michie CA, Gilmou
r J. Doen&ccedil;a de Chagas e transmiss&atilde;o pela amamenta&ccedil;&atilde;o
.Arch. Dis. Child 2001; 84:381-382.    ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#94#90#article#119#</font></p>     ^cY
#v15n2a04.htm##
00525000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027500079002001300354#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#95#91#article#119#22#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Campos R, Pinto P
LS, Moreira AAB <i>et al.</i> Estudo experimental sobre a transmiss&atilde;o da 
doen&ccedil;a de Chagas por meio do leite. Rev. Hosp. Cl&iacute;n. Fac. Med. S. 
Paulo 1988; 43:146-147.    ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#96#92#article#119#</font></p>     ^cY
#v15n2a04.htm##
00617000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704036700079002001300446#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#97#93#article#119#23#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Castanho REP, Mar
tins LPA, Godoy CAP <i>et al.</i> Infec&ccedil;&atilde;o experimental de camundo
ngos atrav&eacute;s da ingest&atilde;o de caldo de cana contaminado por <i>Trypa
nosoma cruzi</i>. In: Program and abstracts: XXXVIII Congresso da Soc. Bras. Med
. Trop. Foz do Igua&ccedil;u, 2002.    ^cY#v15n2a04.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#98#94#article#119#</font></p>     ^cY
#v15n2a04.htm##
00698000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704044800079002001300527#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#99#95#article#119#24#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Martins LPA, Dal 
Bello PP, Samaan Filho S <i>et al.</i> Tentativa de infec&ccedil;&atilde;o oral 
em camundongos atrav&eacute;s de caldo de cana contaminado por formas de cultura
 de <i>Trypanosoma cruzi</i>. In: Program and abstracts: XXII Reuni&atilde;o de 
pesquisa aplicada em doen&ccedil;a de Chagas, X Reuni&atilde;o de pesquisa aplic
ada em leishmanioses. Uberaba, 2006.    ^cY#v15n2a04.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#100#96#article#119#</font></p>     ^c
Y#v15n2a04.htm##
00462000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704021100080002001300291#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#101#97#article#119#25#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Hoft DF. Differe
ntial mucosal infectivity of different life stages of <i>Trypanosoma cruzi</i>. 
Am. J. Trop. Med. Hyg. 1996; 55:360-364.    ^cY#v15n2a04.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#102#98#article#119#</font></p>     ^c
Y#v15n2a04.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704029800080002001300378#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#103#99#article#119#26#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Neira I, Silva F
A, Cortez M, Yoshida N. Involvement of <i>Trypanosoma cruzi</i> metacyclic trypo
mastigote surface molecule gp82 in adhesion to gastric mucin and invasion of epi
thelial cells. Infect. Immun. 2003; 71:557-561.    ^cY#v15n2a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#104#100#article#119#</font></p>     ^
cY#v15n2a04.htm##
00518000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026600081002001300347#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#105#101#article#119#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Aparicio IM, Sc
harfstein J, Lima APCA. A new cruzipain-mediated pathway of human cell invasion 
by <i>Trypanosoma cruzi</i> requires trypomastigotes membranes. Infect Immun 200
4; 72:5892-5902.    ^cY#v15n2a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#106#102#article#119#</font></p>     ^
cY#v15n2a04.htm##
00507000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025500081002001300336#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#107#103#article#119#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Araujo RGM, Ner
y ACS, Bueno LM <i>et al.</i> Infec&ccedil;&atilde;o experimental do <i>Trypanos
oma cruzi</i> utilizando a via oral. Rev Soc Bras Med Trop 1998; 31 (supl III):5
0-51.    ^cY#v15n2a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#108#104#article#119#</font></p>     ^
cY#v15n2a04.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028900081002001300370#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#109#105#article#119#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Lima CMP, Caman
daroba ELP, Andrade SG. Influencia da cepa do <i>Trypanosoma cruzi</i> na infec&
ccedil;&atilde;o experimental de camundongos pela via digestiva. Rev. Soc. Bras.
 Med. Trop. 2000; 33 (supl II):110-111.    ^cY#v15n2a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#110#106#article#119#</font></p>     ^
cY#v15n2a04.htm##
00551000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029900081002001300380#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#111#107#article#119#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Camandaroba ELP
, Lima CMP, Andrade SG. Oral transmisssion of Chagas disease: importance of <i>T
rypanosoma cruzi</i> biodeme in the intragastric experimental infection. Rev. In
st. Med. Trop. S&atilde;o Paulo, 2002; 44:97-103.    ^cY#v15n2a04.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#112#108#article#119#</font></p>     ^
cY#v15n2a04.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#113#109#article#119#<p>&nbsp;</p>    
 ^cY#v15n2a04.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#114#110#article#119#<p>&nbsp;</p>    
 ^cY#v15n2a04.htm##
00425000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018800078002001300266#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#115#111#article#119#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a><b>Correspondence to:<
/b>    ^cY#v15n2a04.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004600078002001300124#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#116#112#article#119#<br> Luciamare Pe
rinetti Alves Martins    ^cY#v15n2a04.htm##
00290000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005300078002001300131#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#117#113#article#119#<br> Rua Dona Mar
ia Feres, 165 Bairro Fragata    ^cY#v15n2a04.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003900078002001300117#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#118#114#article#119#<br> Mar&iacute;l
ia, SP, Brazil    ^cY#v15n2a04.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006800078002001300146#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#119#115#article#119#<br> Phone: 55 14
 3402-1744 - ext. 1303 Fax: 55 14 3413 4781    ^cY#v15n2a04.htm##
00320000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008300078002001300161#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#120#116#article#119#<br> <a href="mai
lto:luciapam@famema.br">luciapam@famema.br</a></font></p>     ^cY#v15n2a04.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009500078002001300173#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#121#117#article#119#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted on: 06/30/2010    ^cY#v1
5n2a04.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#122#118#article#119#<br>   Approved o
n: 10/02/2010    ^cY#v15n2a04.htm##
00299000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006200078002001300140#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a04.htm#S#p#123#119#article#119#<br>   We declare
 no conflict of interest.</font></p>     ^cY#v15n2a04.htm##
00494000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170026000770180092001030620
02600195066000700221065000900228064000500237865000900242002001300251#v15n2#V:\Sc
iELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#c#124#1#article#30#1#World Health O
rganization#17th Programme Report (Progress 2003-2004): Making Health Research W
ork for Poor People^len#Tropical Disease Research#Geneva#20050000#2005#20110400#
v15n2a04.htm##
00451000000000217000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170055000770180056001320660
00900188065000900197064000500206865000900211002001300220#v15n2#V:\SciELO\serial\
bjid\v15n2\markup\v15n2a04.htm#S#c#125#2#article#30#2#Ministério da Saúde^dSecre
taria de Vigilância em Saúde#Guia de Vigilância Epidemiológica: Doença de Chagas
^lpt#Brasília#20050000#2005#20110400#v15n2a04.htm##
00560000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160018000770160017000950180
07200112065000900184064000500193037006600198110000900264109001100273865000900284
002001300293#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#c#126#3#art
icle#30#3#^rND^sGontijo^nED#^rND^sSantos^nSE#Mecanismos principais e atípicos de
 transmissão da doença de Chagas^lpt#20090000#2009#http://www.fiocruz.br/chagas/
cgi/cgilua.exe/sys/start.htm?sid=173#20100405#05/04/2010#20110400#v15n2a04.htm##
00551000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770120069000940300
02400163065000900187064000500196031000400201032000400205014000800209865000900217
002001300226035001000239801002400249#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a04.htm#S#c#127#4#article#30#4#^rND^sYoshida^nN#Molecular mechanism of Trypan
osoma cruzi infection by oral route^len#Mem. Inst. Oswaldo Cruz#20090000#2009#10
4#^sI#101-107#20110400#v15n2a04.htm#0074-0276#Mem. Inst. Oswaldo Cruz##
00604000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770120183000930300
02600276710000200302065000900304064000500313031000200318014000800320865000900328
002001300337#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#c#128#5#art
icle#30#5#^rND^sBrumpt^nE#Immunité partielle dans les infections à Trypanosoma c
ruzi, transmission de ce trypanosome par Cimex rotundus: Role regulateur dês hot
es intermediaires. Passage à travers la peau^lfr#Bull. Soc. Path. Exotique#2#191
30000#1913#6#172-176#20110400#v15n2a04.htm##
00586000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100024000770100016001010100
02100117810000600138012007100144030003200215710000200247065000900249064000500258
031000300263014000800266865000900274002001300283#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a04.htm#S#c#129#6#article#30#6#^rND^sNery-Guimaraes^nF#^rND^sSilv
a^nNN#^rND^sC, lausell^nDT#et al#Surto epidêmico de doença de Chagas com prováve
l contaminação oral^lpt#Rev. Inst. Med. Trop. São Paulo#2#19680000#1968#10#265-2
76#20110400#v15n2a04.htm##
00557000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100015000940100
01500109012007600124030003200200710000200232065000900234064000500243031000300248
014000600251865000900257002001300266#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a04.htm#S#c#130#7#article#30#7#^rND^sLainson^nR#^rND^sShaw^nJJ#^rND^sNaif^nRD
#Chagas' disease in the Amazon Basin: speculation on transmission per os^len#Rev
. Inst. Med. Trop. São Paulo#2#19800000#1980#22#62-67#20110400#v15n2a04.htm##
00555000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770120073000930300
02600166065000900192064000500201031000300206032000400209014000600213865000900219
002001300228035001000241801002600251#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a04.htm#S#c#131#8#article#30#8#^rND^sCoura^nJR#Mecanismo de transmissão da in
fecção chagásica ao homem por via oral^lpt#Rev. Soc. Bras. Med. Trop#19970000#19
97#30#^s1#45-47#20110400#v15n2a04.htm#0037-8682#Rev. Soc. bras. Med. trop##
00583000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100027000770100020001040100
01700124810000600141012006500147030003200212710000200244065000900246064000500255
031000300260014000800263865000900271002001300280#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a04.htm#S#c#132#9#article#30#9#^rND^sShikanai-Yassuda^nMA#^rND^sM
arcondes^nBC#^rND^sGuedes^nLA#et al#Possible oral transmission of acute Chagas'd
isease in Brazil^len#Rev. Inst. Med. Trop. São Paulo#2#19910000#1991#33#355-361#
20110400#v15n2a04.htm##
00484000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100014000950120
04400109030001600153710000200169065000900171064000500180031000300185014000800188
865000900196002001300205#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S
#c#133#10#article#30#10#^rND^sIanni^nBM#^rND^sMady^nC#Como era gostoso o meu cal
do de cana...^lpt#Arq. Bras. Card#2#20050000#2005#85#379-380#20110400#v15n2a04.h
tm##
00600000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120130000950300
02600225065000900251064000500260031000300265014000800268865000900276002001300285
035001000298801002600308#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S
#c#134#11#article#30#11#^rND^sDias^nJCP#Notas sobre o Trypanosoma cruzi e suas c
aracterísticas bio-ecológicas, como agente de enfermidades transmitidas por alim
entos^lpt#Rev. Soc. Bras. Med. Trop#20060000#2006#39#370-375#20110400#v15n2a04.h
tm#0037-8682#Rev. Soc. bras. Med. trop##
00650000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160017000790180177000960200
00400273051001000277050006300287046001000350045000900360044000500369865000900374
002001300383#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#c#135#12#ar
ticle#30#12#^rND^sAraya^nMIR#Expressão da glicoproteína de superfície de 82 KDa 
(GP82) de tripomastigotas metacíclicos de Trypanosoma cruzi em células de mamífe
ros e em formas epimastigotas do parasita^lpt#130#doutorado#Universidade Federal
 de São Paulo^dEscola Paulista de Medicina#São Paulo#19980000#1998#20110400#v15n
2a04.htm##
00485000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120068000960300
01900164710000200183065000900185064000500194031000300199014000700202865000900209
002001300218#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#c#136#13#ar
ticle#30#13#^rND^sYoshida^nN#Molecular basis of mammalian cell invasion by Trypa
nosoma cruzi^len#An. Ac. Bras. Cien#2#20060000#2006#78#87-110#20110400#v15n2a04.
htm##
00566000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160015000790160017000940160
01700111016001500128018009400143062000600237065000900243064000500252031000300257
014000600260865000900266002001300275#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a04.htm#S#c#137#14#article#30#14#^rND^sMazza^nS#^rND^sMontana^nA#^rND^sBenite
z^nC#^rND^sJanzi^nE#Transmission del Schizotripanum cruzi al nino por leche de m
adre com enfermedad de Chagas^les#MEPRA#19360000#1936#28#41-49#20110400#v15n2a04
.htm##
00543000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100016001020120
04200118030002600160065000900186064000500195031000300200020000400203865000900207
002001300216035001000229801002600239#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a04.htm#S#c#138#15#article#30#15#^rND^sMedina-Lopes^nMD#^rND^sMacedo^nV#Trypa
nossoma cruzi no colostro humano^lpt#Rev. Soc. Bras. Med. Trop#19830000#1983#16#
170#20110400#v15n2a04.htm#0037-8682#Rev. Soc. bras. Med. trop##
00569000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790120092001020300
02600194065000900220064000500229031000300234014000800237865000900245002001300254
035001000267801002600277#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S
#c#139#16#article#30#16#^rND^sMedina-Lopes^nMD#Transmissão do Trypanossoma cruzi
 em um caso, durante aleitamento, em área não endêmica^lpt#Rev. Soc. Bras. Med. 
Trop#19880000#1988#21#151-153#20110400#v15n2a04.htm#0037-8682#Rev. Soc. bras. Me
d. trop##
00537000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100021000960120
08500117030002000202710000200222065000900224064000500233031000300238014000800241
865000900249002001300258#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S
#c#140#17#article#30#17#^rND^sSilva^nLHP#^rND^sNussenzweig^nV#Sobre uma cepa de 
Trypanosoma cruzi altamente virulenta para o camundongo branco^lpt#Folia Clín. e
t Biol#2#19530000#1953#20#191-208#20110400#v15n2a04.htm##
00481000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160017000790180055000960660
00900151062005500160065000900215064000500224865000900229002001300238#v15n2#V:\Sc
iELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#c#141#18#article#30#18#^rND^sSogaya
r^nR#Ética na experimentação animal: Consciência & Ação^lpt#Botucatu#Fundação de
 Estudos e Pesquisas Agrícolas e Florestais#20060000#2006#20110400#v15n2a04.htm#
#
00575000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120102000950300
02800197065000900225064000500234031000200239014000800241865000900249002001300258
035001000271801002800281#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S
#c#142#19#article#30#19#^rND^sBrener^nZ#Therapeutic activity and criterion of cu
re on mice experimentally infected with Trypanosoma cruzi^len#Rev Inst Med Trop 
São Paulo#19620000#1962#4#389-396#20110400#v15n2a04.htm#0036-4665#Rev Inst Med T
rop São Paulo##
00668000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160019000790180213000980200
00400311051000900315050004300324046001100367045000900378044000500387865000900392
002001300401#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#c#143#20#ar
ticle#30#20#^rND^sMartins^nLPA#Verificação da susceptibilidade de três espécies 
de Triatominae (Hemíptera, Reduviidae) a infecção por duas cepas de Trypanosoma 
cruzi (Kinetoplastidae, Trypanosomatidae) utilizando xenodiagnóstico artificial^
lpt#105#Mestrado#UNESP^dFaculdade de Ciências Farmacêuticas#Araraquara#19990000#
1999#20110400#v15n2a04.htm##
00534000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960120
05200113030001700165065000900182064000500191031000300196014000800199865000900207
002001300216035001000229801001700239#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a04.htm#S#c#144#21#article#30#21#^rND^sMichie^nCA#^rND^sGilmour^nJ#Doença de 
Chagas e transmissão pela amamentação^lpt#Arch. Dis. Child#20010000#2001#84#381-
382#20110400#v15n2a04.htm#0003-9888#Arch. dis. child##
00650000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01900112810000600131012008200137030003600219065000900255064000500264031000300269
014000800272865000900280002001300289035001000302801003600312#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a04.htm#S#c#145#22#article#30#22#^rND^sCampos^nR#^rND
^sPinto^nPLS#^rND^sMoreira^nAAB#et al#Estudo experimental sobre a transmissão da
 doença de Chagas por meio do leite^lpt#Rev. Hosp. Clín. Fac. Med. S. Paulo#1988
0000#1988#43#146-147#20110400#v15n2a04.htm#0041-8781#Rev. Hosp. Clín. Fac. Med. 
S. Paulo##
00665000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100019000990100
01700118810000600135012011200141018002600253053004900279056001700328055001200345
054000800357865000900365002001300374#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a04.htm#S#c#146#23#article#30#23#^rND^sCastanho^nREP#^rND^sMartins^nLPA#^rND^
sGodoy^nCAP#et al#Infecção experimental de camundongos através da ingestão de ca
ldo de cana contaminado por Trypanosoma cruzi^lpt#Program and abstracts^len#Cong
resso da Soc. Bras. Med. Trop^nXXXVIII^i1^i1#Foz do Iguaçu^i1#20020000^i1#2002^i
1#20110400#v15n2a04.htm##
00757000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100020000980100
02200118810000600140012012600146018002600272053006100298053005500359056001100414
055001200425054000800437865000900445002001300454#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a04.htm#S#c#147#24#article#30#24#^rND^sMartins^nLPA#^rND^sDal Bel
lo^nPP#^rND^sSamaan Filho^nS#et al#Tentativa de infecção oral em camundongos atr
avés de caldo de cana contaminado por formas de cultura de Trypanosoma cruzi^lpt
#Program and abstracts^len#Reunião de pesquisa aplicada em doença de Chagas^nXXI
I^i1^i1#Reunião de pesquisa aplicada em leishmanioses^nX^i1^i1#Uberaba^i1#200600
00^i1#2006^i1#20110400#v15n2a04.htm##
00544000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790120083000940300
02200177065000900199064000500208031000300213014000800216865000900224002001300233
035001000246801002200256#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S
#c#148#25#article#30#25#^rND^sHoft^nDF#Differential mucosal infectivity of diffe
rent life stages of Trypanosoma cruzi^len#Am. J. Trop. Med. Hyg#19960000#1996#55
#360-364#20110400#v15n2a04.htm#0002-9637#Am. j. trop. med. hyg##
00677000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01600110010001700126012014700143030001400290065000900304064000500313031000300318
014000800321865000900329002001300338035001000351801001400361#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a04.htm#S#c#149#26#article#30#26#^rND^sNeira^nI#^rND^
sSilva^nFA#^rND^sCortez^nM#^rND^sYoshida^nN#Involvement of Trypanosoma cruzi met
acyclic trypomastigote surface molecule gp82 in adhesion to gastric mucin and in
vasion of epithelial cells^len#Infect. Immun#20030000#2003#71#557-561#20110400#v
15n2a04.htm#0019-9567#Infect. Immun##
00627000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100021000980100
01700119012011600136030001300252065000900265064000500274031000300279014001000282
865000900292002001300301035001000314801001300324#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a04.htm#S#c#150#27#article#30#27#^rND^sAparicio^nIM#^rND^sScharfs
tein^nJ#^rND^sLima^nAPCA#A new cruzipain-mediated pathway of human cell invasion
 by Trypanosoma cruzi requires trypomastigotes membranes^len#Infect Immun#200400
00#2004#72#5892-5902#20110400#v15n2a04.htm#0019-9567#Infect Immun##
00623000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01600113810000600129012006900135030002200204065000900226064000500235031000300240
032000600243014000600249865000900255002001300264035001000277801002200287#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a04.htm#S#c#151#28#article#30#28#^rND^sAr
aujo^nRGM#^rND^sNery^nACS#^rND^sBueno^nLM#et al#Infecção experimental do Trypano
soma cruzi utilizando a via oral^lpt#Rev Soc Bras Med Trop#19980000#1998#31#^sII
I#50-51#20110400#v15n2a04.htm#0037-8682#Rev Soc Bras Med Trop##
00655000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100023000950100
01800118012010300136030002600239065000900265064000500274031000300279032000500282
014000800287865000900295002001300304035001000317801002600327#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a04.htm#S#c#152#29#article#30#29#^rND^sLima^nCMP#^rND
^sCamandaroba^nELP#^rND^sAndrade^nSG#Influencia da cepa do Trypanosoma cruzi na 
infecção experimental de camundongos pela via digestiva^lpt#Rev. Soc. Bras. Med.
 Trop#20000000#2000#33#^sII#110-111#20110400#v15n2a04.htm#0037-8682#Rev. Soc. br
as. Med. trop##
00619000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100016001020100
01800118012012500136030003200261710000200293065000900295064000500304031000300309
014000700312865000900319002001300328#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a04.htm#S#c#153#30#article#30#30#^rND^sCamandaroba^nELP#^rND^sLima^nCMP#^rND^
sAndrade^nSG#Oral transmisssion of Chagas disease: importance of Trypanosoma cru
zi biodeme in the intragastric experimental infection^len#Rev. Inst. Med. Trop. 
São Paulo#2#20020000#2002#44#97-103#20110400#v15n2a04.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#o#1#1#article#1
#20110406#124814#v15n2a05.htm#226##
02972000000000589000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400110014403500100015501201610
01650100038003260100043003640100030004070700035004370700058004720700123005300831
53500653085000802188085002202196085003402218085002202252085002302274058000702297
05800050230406000140230911700060232307200030232911200090233211100090234111400090
2350113001002359002001302369#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.h
tm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#5#BJID230#nd#Braz J Infect Dis#1
5#2#20110400#^f119^l125#1413-8670#Validation and utilization of PCR for differen
tial diagnosis and prevalence determination of Entamoeba histolytica/Entamoeba d
ispar in Salvador City, Brazil^len#^rND^1A01^nFred Luciano Neves^sSantos#^rND^1A
02 A03^nMarilda de Souza^sGonçalves#^rND^1A02^nNeci Matos^sSoares#FIOCRUZ^iA01^1
CPqGM^sBahia^pBrazil#Universidade Federal da Bahia^iA02^1Faculdade de Farmácia#F
undação Oswaldo Cruz^iA03^1Centro de Pesquisa Gonçalo Moniz^2Laboratory of Patho
logy and Molecular Biology^sBahia^pBrazil#^len^aAmoebiasis is an infection cause
d by Entamoeba histolytica and is a potential health risk in countries in which 
health barriers are inappropriate. Since the discovery of Entamoeba dispar, the 
prevalence of amoebiasis has been modified. OBJECTIVE: This study has standardiz
ed the PCR technique applied for the diagnosis of different species of the E. hi
stolytica/E. dispar complex and has evaluated the prevalence of infection among 
patients attending private and public clinical laboratories in Salvador City, Ba
hia State, Brazil. RESULTS: Analysis of 52,704 stool samples by microscopic exam
ination demonstrated that 1,788 (3.4%) were positive for the E. histolytica/E. d
ispar complex and infection occurred more often in samples originated from publi
c clinical laboratories (5.0%) than those that came from private laboratories (3
.2%). PCR performed in approximately 15% (262) E. histolytica/E. dispar complex 
positive samples, randomly chosen, amplified 227 samples (86.6%), all of them po
sitive for E. dispar. The non-amplified 35 samples (13.4%) were also negative fo
r E. histolytica-specific galactose adhesin. Moreover, to exclude a probable inf
ection caused by E. hartmanni, morphometric analysis demonstrated that non-ampli
fied samples had cyst sizes comparable to E. histolytica/E. dispar (>10 µm). CON
CLUSION: The absence of amplification of these samples indicates the presence of
 PCR inhibitors in the stool samples or the presence of DNA from Entamoeba speci
es other than E. dispar, E. histolytica or E. hartmanni.#^dnd^i1#^tm^len^kamebia
sis^i1#^tm^len^kEntamoeba histolytica^i1#^tm^len^kdiagnosis^i1#^tm^len^kprevalen
ce^i1#FAPESB#CNPq#620219/2008-4#other#39#20100703#7/3/2010#20100819#8/19/2010#v1
5n2a05.htm##
03170000000000589000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400110014403500100015501201750
01650100038003400100043003780100030004210700035004510700058004860700123005440831
64300667085000802310085002202318085004102340085002202381085002302403058000702426
05800050243306000830243811700060252107200030252711200090253011100090253911400090
2548113001002557002001302567#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.h
tm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#5#BJID230#nd#Braz J Infect Dis#1
5#2#20110400#^f119^l125#1413-8670#<b>Validation and utilization of PCR for diffe
rential diagnosis and prevalence determination of <i>Entamoeba histolytica/Entam
oeba dispar</i> in Salvador City, Brazil</b>^len#^rND^1A01^nFred Luciano Neves^s
Santos#^rND^1A02 A03^nMarilda de Souza^sGonçalves#^rND^1A02^nNeci Matos^sSoares#
FIOCRUZ^iA01^1CPqGM^sBahia^pBrazil#Universidade Federal da Bahia^iA02^1Faculdade
 de Farmácia#Fundação Oswaldo Cruz^iA03^1Centro de Pesquisa Gonçalo Moniz^2Labor
atory of Pathology and Molecular Biology^sBahia^pBrazil#^len^aAmoebiasis is an i
nfection caused by <i>Entamoeba histolytica</i> and is a potential health risk i
n countries in which health barriers are inappropriate. Since the discovery of <
i>Entamoeba dispar</i>, the prevalence of amoebiasis has been modified. <b>OBJEC
TIVE:</b> This study has standardized the PCR technique applied for the diagnosi
s of different species of the <i>E. histolytica/E. dispar</i> complex and has ev
aluated the prevalence of infection among patients attending private and public 
clinical laboratories in Salvador City, Bahia State, Brazil. <b>RESULTS:</b> Ana
lysis of 52,704 stool samples by microscopic examination demonstrated that 1,788
 (3.4%) were positive for the <i>E. histolytica/E. dispar</i> complex and infect
ion occurred more often in samples originated from public clinical laboratories 
(5.0%) than those that came from private laboratories (3.2%). PCR performed in a
pproximately 15% (262) <i>E. histolytica/E. dispar</i> complex positive samples,
 randomly chosen, amplified 227 samples (86.6%), all of them positive for <i>E. 
dispar</i>. The non-amplified 35 samples (13.4%) were also negative for <i>E. hi
stolytica</i>-specific galactose adhesin. Moreover, to exclude a probable infect
ion caused by <i>E. hartmanni</i>, morphometric analysis demonstrated that non-a
mplified samples had cyst sizes comparable to <i>E. histolytica/E. dispar</i> (&
gt;10 µm). <b>CONCLUSION:</b> The absence of amplification of these samples indi
cates the presence of PCR inhibitors in the stool samples or the presence of DNA
 from <i>Entamoeba</i> species other than <i>E. dispar, E. histolytica</i> or <i
>E. hartmanni.</i>#^dnd^i1#^tm^len^kamebiasis^i1#^tm^len^k<i>Entamoeba histolyti
ca</i>^i1#^tm^len^kdiagnosis^i1#^tm^len^kprevalence^i1#FAPESB#CNPq#<span lang=EN
-US style='font-size:10.0pt;font-family:Verdana'>620219/2008-4</span>#other#39#2
0100703#7/3/2010#20100819#8/19/2010#v15n2a05.htm##
03154000000000613000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000200117049000800119
15800030012703000210013003100030015103200020015406500090015601400110016503500100
01760120161001860100038003470100043003850100030004280700037004580700060004950700
12500555083157700680085000802257085002202265085003402287085002202321085002302343
05800070236605800050237306000140237811700060239207200030239811200090240111100090
2410114000902419113001002428002001302438008008902451#v15n2#V:\SciELO\serial\bjid
\v15n2\markup\v15n2a05.htm#S#l#4#1#article#1#^mMar./Apr.^a2011#oa#en#br1.1#1#4.0
#ilus#tab#5#BJID230#nd#Braz. j. infect. dis#15#2#20110400#^f119^l125#1413-8670#V
alidation and utilization of PCR for differential diagnosis and prevalence deter
mination of Entamoeba histolytica/Entamoeba dispar in Salvador City, Brazil^len#
^rND^1A01^nFred Luciano Neves^sSantos#^rND^1A02 A03^nMarilda de Souza^sGonçalves
#^rND^1A02^nNeci Matos^sSoares#^iA01^1FIOCRUZ^2CPqGM^sBahia^pBrazil#^iA02^1Unive
rsidade Federal da Bahia^2Faculdade de Farmácia#^iA03^1Fundação Oswaldo Cruz^2Ce
ntro de Pesquisa Gonçalo Moniz^3Laboratory of Pathology and Molecular Biology^sB
ahia^pBrazil#^len^aAmoebiasis is an infection caused by Entamoeba histolytica an
d is a potential health risk in countries in which health barriers are inappropr
iate. Since the discovery of Entamoeba dispar, the prevalence of amoebiasis has 
been modified. OBJECTIVE: This study has standardized the PCR technique applied 
for the diagnosis of different species of the E. histolytica/E. dispar complex a
nd has evaluated the prevalence of infection among patients attending private an
d public clinical laboratories in Salvador City, Bahia State, Brazil. RESULTS: A
nalysis of 52,704 stool samples by microscopic examination demonstrated that 1,7
88 (3.4 percent) were positive for the E. histolytica/E. dispar complex and infe
ction occurred more often in samples originated from public clinical laboratorie
s (5.0 percent) than those that came from private laboratories (3.2 percent). PC
R performed in approximately 15 percent (262) E. histolytica/E. dispar complex p
ositive samples, randomly chosen, amplified 227 samples (86.6 percent), all of t
hem positive for E. dispar. The non-amplified 35 samples (13.4 percent) were als
o negative for E. histolytica-specific galactose adhesin. Moreover, to exclude a
 probable infection caused by E. hartmanni, morphometric analysis demonstrated t
hat non-amplified samples had cyst sizes comparable to E. histolytica/E. dispar 
(>10 µm). CONCLUSION: The absence of amplification of these samples indicates th
e presence of PCR inhibitors in the stool samples or the presence of DNA from En
tamoeba species other than E. dispar, E. histolytica or E. hartmanni.#^dnd^i1#^t
m^len^kamebiasis^i1#^tm^len^kEntamoeba histolytica^i1#^tm^len^kdiagnosis^i1#^tm^
len^kprevalence^i1#FAPESB#CNPq#620219/2008-4#other#39#20100703#7/3/2010#20100819
#8/19/2010#v15n2a05.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_art
text&pid=S1413-86702011000200005##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#5#1#article#183#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLE</b><
/font></p>     ^cY#v15n2a05.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#6#2#article#183#<p>&nbsp;</p>     ^cY
#v15n2a05.htm##
00505000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704027200074002001300346#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#7#3#article#183#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Validation and ut
ilization of PCR for differential diagnosis and prevalence determination of <i>E
ntamoeba histolytica/Entamoeba dispar</i> in Salvador City, Brazil </b></font></
p>     ^cY#v15n2a05.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#8#4#article#183#<p>&nbsp;</p>     ^cY
#v15n2a05.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#9#5#article#183#<p>&nbsp;</p>     ^cY
#v15n2a05.htm##
00442000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704020800075002001300283#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#10#6#article#183#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Fred Luciano Neves Santos<sup>I</s
up>; Marilda de Souza Gon&ccedil;alves<sup>II</sup>; Neci Matos Soares<sup>III</
sup></b></font></p>     ^cY#v15n2a05.htm##
00413000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704017900075002001300254#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#11#7#article#183#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>MSc, PhD Student, Health 
and Investigative Medicine Biotechnology (CPqGM-FIOCRUZ), Bahia, Brazil    ^cY#v
15n2a05.htm##
00508000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704027400075002001300349#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#12#8#article#183#<br> <sup>II</sup>Ph
D; Professor, Clinical Hematology, Faculdade de Farm&aacute;cia, Universidade Fe
deral da Bahia; Researcher, Laboratory of Pathology and Molecular Biology, Centr
o de Pesquisa Gon&ccedil;alo Moniz, Funda&ccedil;&atilde;o Oswaldo Cruz, Bahia, 
Brazil    ^cY#v15n2a05.htm##
00385000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015100075002001300226#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#13#9#article#183#<br> <sup>III</sup>P
hD; Professor, Clinical Parasitology,Faculdade de Farm&aacute;cia, Universidade 
Federal da Bahia, Bahia, Brazil</font></p>     ^cY#v15n2a05.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#14#10#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a><
/font></p>     ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#15#11#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#16#12#article#183#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v15n2a05.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#17#13#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
15n2a05.htm##
00555000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032000076002001300396#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#18#14#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Amoebiasis is an infection caused by
 <i>Entamoeba histolytica</i> and is a potential health risk in countries in whi
ch health barriers are inappropriate. Since the discovery of <i>Entamoeba dispar
</i>, the prevalence of amoebiasis has been modified.    ^cY#v15n2a05.htm##
00556000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032100076002001300397#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#19#15#article#183#<br> <b>OBJECTIVE:<
/b> This study has standardized the PCR technique applied for the diagnosis of d
ifferent species of the <i>E. histolytica/E. dispar</i> complex and has evaluate
d the prevalence of infection among patients attending private and public clinic
al laboratories in Salvador City, Bahia State, Brazil.    ^cY#v15n2a05.htm##
01084000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084900076002001300925#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#20#16#article#183#<br>   <b>RESULTS:<
/b> Analysis of 52,704 stool samples by microscopic examination demonstrated tha
t 1,788 (3.4%) were positive for the <i>E. histolytica/E. dispar</i> complex and
 infection occurred more often in samples originated from public clinical labora
tories (5.0%) than those that came from private laboratories (3.2%). PCR perform
ed in approximately 15% (262) <i>E. histolytica/E. dispar</i> complex positive s
amples, randomly chosen, amplified 227 samples (86.6%), all of them positive for
 <i>E. dispar</i>. The non-amplified 35 samples (13.4%) were also negative for <
i>E. histolytica</i>-specific galactose adhesin. Moreover, to exclude a probable
 infection caused by <i>E. hartmanni</i>, morphometric analysis demonstrated tha
t non-amplified samples had cyst sizes comparable to <i>E. histolytica/E. dispar
</i> (&gt;10 &#181;m).    ^cY#v15n2a05.htm##
00509000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027400076002001300350#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#21#17#article#183#<br>   <b>CONCLUSIO
N:</b> The absence of amplification of these samples indicates the presence of P
CR inhibitors in the stool samples or the presence of DNA from <i>Entamoeba</i> 
species other than <i>E. dispar, E. histolytica</i> or <i>E. hartmanni.</i></fon
t></p>     ^cY#v15n2a05.htm##
00420000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018500076002001300261#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#22#18#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> amebiasis; <i>Entam
oeba histolytica</i>; diagnosis; prevalence.</font></p> <hr size="1" noshade>   
  ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#23#19#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#24#20#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#25#21#article#183#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>INTRODUCTION</b></i></font></p
>     ^cY#v15n2a05.htm##
01014000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077900076002001300855#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#26#22#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Parasitic infections are endemic and
 represent   a major public health problem in developing   countries.<sup>1-6</s
up> In particular, <i>Entamoeba histolytica</i>,   the etiologic agent of amoebi
c colitis   and liver abscess, causes human infections on   a global scale, resu
lting in significant human   suffering and death. Approximately 50 million   peo
ple have this invasive disease annually, resulting   in 100,000 deaths per year 
and making   this the second most common cause of parasitic   death in humans.<s
up>7</sup> The high prevalence of   infection is due to fecal contamination of f
ood   and water supply; thus, the disease is predominantly seen in developing co
untries.<sup>8</sup></font></p>     ^cY#v15n2a05.htm##
01684000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704144900076002001301525#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#27#23#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>E. histolytica</i> cysts measure 
10-15 &mu;m in   diameter, possess a rigid cyst wall and can   contain up to fou
r nuclei. They are morphologically   indistinguishable from cysts of the   comme
nsal <i>Entamoeba dispar</i> and share characteristics   with cysts of <i>Entamo
eba hartmanni</i>,   which are smaller than 10 &mu;m in diameter. Optical   micr
oscopy is a desirable tool for the diagnosis   of amoebiasis:<sup>9</sup> it is 
simple and cheap   to execute and does not require sophisticated   technology. H
owever, microscopy is unable to   differentiate between species belonging to the
   <i>E. histolytica/E. dispar</i> complex. Moreover, intermittent   releasing o
f cysts decreases the sensitivity   of this method. Therefore, the positivity   
rate is enhanced by the use of concentration   procedures, one of which is forma
lin-ether sedimentation.<sup>10</sup> Concentrated and purified cysts   of <i>E.
 histolytica/E. dispar</i> can improve diagnostic   sensitivity to differentiate
 <i>E. histolytica</i> from   <i>E. dispar</i> by polymerase chain reaction (PCR
),   especially in feces that contain low numbers of   cysts. The coproantigen E
LISA technique has   been suggested for use in routine diagnostic   procedures a
nd epidemiological studies. However,   PCR is used for final confirmatory identi
fication of intestinal amoebiasis.<sup>11-14</sup></font></p>     ^cY#v15n2a05.h
tm##
00789000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055400076002001300630#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#28#24#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The prevalence of the <i>E. histolyt
ica/E. dispar</i> complex differs among the five regions of Brazil with 2.5-11% 
in the South and Southeast, 19% in the North and the Amazon region and approxima
tely 10% in the Northeast and Midwest.<sup>4,15</sup> This variation in prevalen
ce is associated with regional differences in sanitation and socio-economic cond
itions, mainly related to housing, sewage facilities, water quality, and other a
s yet unknown factors.<sup>16</sup></font></p>     ^cY#v15n2a05.htm##
00768000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053300076002001300609#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#29#25#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Given the medical importance of diff
erentiating species that belong to the <i>E. histolytica/E. dispar</i> complex a
nd the fact that the prevalence of each species is unknown in Salvador City, the
 purpose of this study was to perform a survey to determine the prevalence of <i
>E. histolytica</i> and <i>E. dispar</i> using a nested and multiplex PCR techni
que with genomic DNA extracted from stool specimens of individuals residents in 
Salvador City.</font></p>     ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#30#26#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#31#27#article#183#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>MATERIALS AND METHODS</b></i><
/font></p>     ^cY#v15n2a05.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#32#28#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Sample details</b></font></p>    
 ^cY#v15n2a05.htm##
01151000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704091600076002001300992#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#33#29#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A total of 52,704 stool samples were
 collected from patients attending Datalab and NKB-Bahia groups (private clinica
l laboratories, n = 47,080) and the Clinical Laboratory of Pharmacy Faculty and 
University Hospital, <i>Universidade Federal da Bahia</i> (public clinical labor
atories, n = 5,624), from February to August 2006. A single fresh stool specimen
 was collected from each patient, and diagnosis of the <i>E. histolytica/E. disp
ar</i> complex was performed by the spontaneous sedimentation technique.<sup>17<
/sup> Daily, around 8-15 samples were positive for <i>E. histolytica/E. dispar</
i> complex. From these, 262 samples were randomly selected for cysts concentrati
on and extraction of genomic DNA. Approximately 800 mg of each positive sample w
as preserved without fixative and stored at -20º C for immunologic diagnosis.</f
ont></p>     ^cY#v15n2a05.htm##
00888000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065300076002001300729#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#34#30#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This study was carried out in Salvad
or City (Bahia State, Northeast Brazil), which has a population of 2,892,625 inh
abitants,<sup>18</sup> and was approved by Committee of Ethics in Research of th
e Gon&ccedil;alo Moniz Institute number 100/2006. Informed consent for participa
tion was obtained from patients (or legal guardians in the case of minors) durin
g collection of clinical specimens. A form for personal (age, sex) and epidemiol
ogic data (e.g., race, signs and symptoms, drugs) was completed for all patients
 positive for <i>E. histolytica/E. dispar</i> complex.</font></p>     ^cY#v15n2a
05.htm##
00712000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047700076002001300553#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#35#31#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The sample was estimated for differe
nt scenarios based on the following parameters: error </font>&#945;<font size="2
" face="Verdana, Arial, Helvetica, sans-serif"> = 0.05 and power of test (1-</fo
nt>&#946;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">) = 0.90, m
inimum detectable odds ratio (OR) = 2.0 and frequency of exposure 3.2%, accordin
g to Santos <i>et al.</i><sup>19</sup></font></p>     ^cY#v15n2a05.htm##
00369000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013400076002001300210#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#36#32#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Cyst concentration and morphometr
ic analysis</b></font></p>     ^cY#v15n2a05.htm##
00918000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068300076002001300759#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#37#33#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">To concentrate the cysts of these pa
rasites, 25 <i>E. histolytica/E. dispar </i>-positive samples were used to test 
the efficiency of spontaneous sedimentation, formalin-ether and flotation by zin
c sulfate or sucrose.<sup>20</sup> The cysts were concentrated from 5 g of fresh
 stools as described by Troll <i>et al.</i><sup>21</sup> Approximately 25 &#181;
L of the concentrated sample and 50 &#181;L of iodine were mixed, spotted on gla
ss slides and covered by a coverslip (24 x 24 mm). The slides were analyzed by 4
0 x magnification, and the average of cysts was quantified in 20 microscopic fie
lds.</font></p>     ^cY#v15n2a05.htm##
00471000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023600076002001300312#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#38#34#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Morphometric analysis of cysts was p
erformed using reticule calibration in a millimeter scale (mm). Each 0.01 mm cor
responded to 10 &#181;m in cyst size.</font></p>     ^cY#v15n2a05.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#39#35#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Extraction of genomic DNA</b></fo
nt></p>     ^cY#v15n2a05.htm##
01457000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704122200076002001301298#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#40#36#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Cysts purified from 5 g of fresh sto
ols by the formalinether technique were used for DNA extraction. A 50 &#181;L pe
llet was washed four times with distilled water at 2,000 x <i>g</i> for 30s in a
n Eppendorf microfuge. The pellet was resuspended in a small volume (50 - 100 &#
181;L) of a solution containing 100 mM Tris, pH 8.0, and 2.5 mM EDTA. The tubes 
were immersed in a mixture of dry ice and ethanol for 4 min and incubated at 50º
C for 3 min. This process was repeated six times to rupture the cysts. The sampl
es were then sonicated three times by being immersed in picked ice in an ultraso
nic cleaner (model 250, Branson Sonifier, USA) for 30s at an amplitude of 35 wit
hout pulses. Then, 200 &#181;L of buffer containing 100 mM Tris (pH 8.0), 1% sod
ium dodecyl sulfate, 25 mM EDTA and 200 &#181;g of proteinase K (Boehringer, Man
nheim, Germany) was added to each tube, mixed, incubated at 50ºC for 24h, boiled
 for 10 min and centrifuged at 12,000 x g for 5 min. The DNA in the supernatant 
was precipitated with 360 &#181;L ice-cold isopropanol, resuspended with 20 &#18
1;L of 10 mM Tris and 1 mM EDTA and frozen for analysis by PCR.</font></p>     ^
cY#v15n2a05.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010300076002001300179#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#41#37#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Multiplex PCR</b></font></p>     
^cY#v15n2a05.htm##
01160000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704092500076002001301001#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#42#38#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Nested and multiplex PCR was carried
 out according to the protocol described by Evangelopoulos <i>et al.</i>,<sup>12
</sup> with some modifications. A set of oligonucleotide primers based on small 
subunit rDNA (SSU-rDNA) sequences of <i>E. histolytica</i> and <i>E. dispar</i> 
were prepared. The outer primer set, E1 (5'-TGC TGT GAT TAA AAC GCT-3') and E2 (
5'-TTA ACT ATT TCA ATC TCG G-3'), which specifies a 1,076-bp fragment, is common
 to and specifically designed for both species. The inner primer pair for pathog
enic sequences, Eh-L (5'-ACA TTT TGA AGA CTT TAT GTA AGT A-3') and Eh-R (5'-CAG 
ATC TAG AAA CAA TGC TTC TCT-3'), brackets a 427-bp region, whereas the inner pri
mer pair Ed-L (5'-GTT AGT TAT CTA ATT TCG ATT AGA A-3') and Ed-R (5'-ACA CCA CTT
 ACT ATA CCT ACC-3') is specific for <i>E. dispar</i>, resulting in a 195-bp fra
gment.</font></p>     ^cY#v15n2a05.htm##
01790000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704155500076002001301631#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#43#39#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Amplification was performed in a tot
al volume of 50 &#181;L containing 0.5 &#181;M of each primer, 5 &#181;L 10X PCR
 buffer (200 mM Tris-HCl, pH 8.4, 500 mM KCl), 0.2 mM of each dNTP, 1.5 mM MgCl<
sub>2</sub>, 0.75U Taq DNA polymerase (Gibco BRL, Rockville, MD) and 3 &#181;L o
f DNA sample. An initial DNA amplification was performed using the E1, E2 primer
 set in a GenAmp PCR system 2400 (AB Applied Biosystems) thermal cycler. The fir
st cycle of 5 min at 94ºC was followed by 45 cycles of denaturation for 1 min at
 94ºC. Primers were annealed for 1.5 min at 47º C and elongated for 2.5 min at 7
2ºC. As positive controls, 5 &#181;L of DNA from cultured <i>E. histolytica</i> 
strain HM-1:IMSS, grew in TYI-S-33 medium axenically, and 5 &#181;L of DNA from 
cultured <i>E. dispar</i> strain MCR, grew in Pavlova medium polyxenically (kind
ly provided by Dr. Maria Aparecida Gomes, Amoebiasis Laboratory, <i>Universidade
 Federal de Minas Gerais</i>, Brazil) were used. For subsequent amplifications, 
5 &#181;L of DNA from the first reaction and primer sets Eh-L, Eh-R and Ed-L, Ed
-R were used under the conditions described above, except that the annealing tem
perature was 58ºC. The analysis of PCR products was performed using gel electrop
horesis. DNA fragments were separated on a 1.5% (w/v) agarose gel (Invitrogen Li
fe Technologies, USA) containing 0.5 &#181;g ethidium bromide/mL. Gels were phot
ographed under ultraviolet illumination (Sigma Chem. Co., USA, model T1201).</fo
nt></p>     ^cY#v15n2a05.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011100076002001300187#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#44#40#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Immunoenzymatic assay</b></font><
/p>     ^cY#v15n2a05.htm##
00668000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043300076002001300509#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#45#41#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The presence of <i>E. histolytica</i
>-specific galactose adhesin was determined in 35 stool samples, without preserv
atives, that were negative by PCR and 60 randomly selected stool samples that we
re positive for <i>E. dispar.</i> The ELISA test was performed according to the 
manufacturer's instructions (TechLab <i>E. histolytica</i> II ELISA, USA).</font
></p>     ^cY#v15n2a05.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011000076002001300186#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#46#42#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Statistical analysis</b></font></
p>     ^cY#v15n2a05.htm##
00571000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033600076002001300412#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#47#43#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The statistics tests used in this st
udy were performed using the SPSS program 15.0 for Windows. The Wilcoxon test wa
s used to evaluate the statistical significance between analyzed variables; a tw
o-tail p-value less than 0.05 was considered significant.</font></p>     ^cY#v15
n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#48#44#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#49#45#article#183#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>RESULTS</b></i></font></p>    
 ^cY#v15n2a05.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#50#46#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Cyst concentration</b></font></p>
     ^cY#v15n2a05.htm##
01286000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704105100076002001301127#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#51#47#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The effects of spontaneous sedimenta
tion, formalin-ether and flotation by sulfate zinc or sucrose on the concentrati
on of cysts of the <i>E. histolytica/E. dispar</i> complex were evaluated. The f
ormalin-ether technique yielded more cysts than any other method analyzed with a
 mean of 5.88 cysts under 40 x magnification, varying from 0.1 to 8 cysts (<a hr
ef="/img/revistas/bjid/v15n2/a05tab01.jpg">Table 1</a>). The mean number of <i>E
. histolytica/E. dispar</i> complex cysts by formalin-ether was 3.42 (p = 0.02),
 8.17 (p &lt; 0.001) and 9.19 (p &lt; 0.001) times more than that of the spontan
eous sedimentation, zinc sulfate and sucrose flotation procedures, respectively.
 Likewise, the formalin-ether technique concentrated 7.73 (p = 0.008), 3.25 (p =
 0.021) and 4.5 (p = 0.01) times more cysts of <i>Entamoeba coli</i> than the ab
ove mentioned techniques. Statistically significant differences between other co
ncentration methods were not observed (p &gt; 0.05).</font></p>     ^cY#v15n2a05
.htm##
00374000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013900076002001300215#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#52#48#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Amplification of DNA extracted fr
om stool samples</b></font></p>     ^cY#v15n2a05.htm##
01054000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081900076002001300895#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#53#49#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The standardization of nested and mu
ltiplex PCR was performed using DNA from cultured trophozoites of <i>E. histolyt
ica</i> strain HM-1 and <i>E. dispar</i> strain MCR. The detection limit was det
ermined by the addition of 100 &#181;L of stools free of parasites to either dif
ferent concentrations of <i>E. histolytica</i> DNA (12 ng/mL, 6 ng/mL, 3 ng/mL, 
1.5 ng/mL and 0.75 ng/mL; data not shown) or different concentrations of <i>E. d
ispar</i> DNA (18 ng/mL, 9 ng/mL, 4.5 ng/mL, 2.25 ng/mL and 1.12 ng/mL; <a href=
"#fig1">Figure 1</a>). Multiplex PCR was capable of detecting the specific targe
t sequence when a minimum of 1.5 ng/mL of DNA template was used for <i>E. histol
ytica</i> and when 2.25 ng/mL was used for <i>E. dispar.</i></font></p>     ^cY#
v15n2a05.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#54#50#article#183#<p><a name="fig1"><
/a></p>     ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#55#51#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#56#52#article#183#<p align="center"><
img src="/img/revistas/bjid/v15n2/a05fig01.jpg"></p>     ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#57#53#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00868000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063300076002001300709#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#58#54#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A positive stool sample for the <i>E
. histolytica/E. dispar</i> complex was fractionated into six aliquots and store
d at -20ºC. At monthly intervals, one aliquot was thawed, and its DNA was used t
o observe the inter-testing reproducibility of the PCR (<a href="#fig2">Figure 2
</a>). Compatible profile bands are shown with the species of <i>amoeba</i> test
ed. Similar results were obtained when the samples were amplified twice in the s
ame reaction to demonstrate the reproducibility of intra-testing of PCR, as show
n in <a href="#fig3">Figure 3</a>.</font></p>     ^cY#v15n2a05.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#59#55#article#183#<p><a name="fig2"><
/a></p>     ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#60#56#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#61#57#article#183#<p align="center"><
img src="/img/revistas/bjid/v15n2/a05fig02.jpg"></p>     ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#62#58#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#63#59#article#183#<p><a name="fig3"><
/a></p>     ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#64#60#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#65#61#article#183#<p align="center"><
img src="/img/revistas/bjid/v15n2/a05fig03.jpg"></p>     ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#66#62#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#67#63#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Analyses of stool samples</b></fo
nt></p>     ^cY#v15n2a05.htm##
00813000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057800076002001300654#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#68#64#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Analyses of 52,704 stool samples by 
microscopic examination demonstrated that 3.4% (1,788) of the samples were posit
ive for the presence of four-nucleus amoebae. Of these stool samples, 47,080 wer
e from private clinical laboratories, and 5,624 were from public clinical labora
tories. According to the source of samples, the prevalence of the <i>E. histolyt
ica/E. dispar</i> complex was 3.2% (1,507) and 5% (281) in the private and publi
c laboratories, respectively (<a href="#tab2">Table 2</a>).</font></p>     ^cY#v
15n2a05.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#69#65#article#183#<p><a name="tab2"><
/a></p>     ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#70#66#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#71#67#article#183#<p align="center"><
img src="/img/revistas/bjid/v15n2/a05tab02.jpg"></p>     ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#72#68#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
01044000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080900076002001300885#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#73#69#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Extraction of DNA from 262 samples p
ositive for the <i>E. histolytica/E. dispar</i> complex followed by PCR showed t
hat 227 samples (86.6%) were positive for <i>E. dispar</i>, as demonstrated by a
mplification of the species-specific fragment (195 bp). No amplification was obs
erved for pathogenic <i>E. histolytica.</i> To evaluate the efficiency of detect
ing <i>E. histolytica</i> fragments, we spiked negative samples with DNA templat
e from <i>E. histolytica</i> strain HM-1:IMSS. Thereafter, the <i>E. histolytica
</i> DNA fragment (495 bp) was amplified from all samples. This demonstrates tha
t nested and multiplex PCR can be used for both <i>E. histolytica</i> and <i>E. 
dispar</i> species (<a href="#fig4">Figure 4</a>).</font></p>     ^cY#v15n2a05.h
tm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#74#70#article#183#<p><a name="fig4"><
/a></p>     ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#75#71#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#76#72#article#183#<p align="center"><
img src="/img/revistas/bjid/v15n2/a05fig04.jpg"></p>     ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#77#73#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
01262000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704102700076002001301103#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#78#74#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The mean number of cysts found in am
plified samples was 116 cysts per gram of stool, while the mean number of cysts 
in the 35 non-amplified samples was 173 cysts. After successive dilution (1:20 t
o 1:160), these 35 samples remained negative. Even after having carried out the 
spike technique the samples did not amplify. In order to resolve this problem, n
on-amplified samples and 60 randomly chosen samples positive for <i>E. dispar</i
> by PCR were submitted to an <i>E. histolytica</i>-specific galactose adhesin i
mmunoenzymatic assay. This technique demonstrated that all 35 non-amplified samp
les were negative for <i>E. histolytica</i>-specific galactose adhesin, suggesti
ng a high PCR specificity in <i>E. histolytica</i> diagnosis. Furthermore, to di
stinguish a probable infection caused by <i>E. hartmanni,</i> morphometric analy
sis demonstrated that non-amplified samples had cyst sizes comparable to <i>E. d
ispar</i> (&gt; 10 &#181;m).</font></p>     ^cY#v15n2a05.htm##
00370000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013500076002001300211#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#79#75#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Characteristics of <i>E. dispar</
i> infection</b></font></p>     ^cY#v15n2a05.htm##
00766000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053100076002001300607#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#80#76#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The mean age of the 262 <i>E. histol
ytica/E. dispar</i> complex-positive individuals submitted to amplification reac
tions was 35.7 years (with a range of 2 to 79 years), and the median was 35 (25 
and 75% quartiles were 22.5 and 50, respectively). Sixty-four percent were male,
 and 65.5% were of African descent (p &lt; 0.005), with a monthly income of less
 than 5 minimum wages (p &lt; 0.005) and an educational level at the 2 grade (p 
&lt; 0.005).</font></p>     ^cY#v15n2a05.htm##
00946000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071100076002001300787#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#81#77#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The study population was asymptomati
c or presented non-specific symptoms that could be attributed to amoebiasis. The
 primary reason for seeking medical attention was routine medical check-up, as r
eported by 67.2% of participants. Among the cases, 21.3% reported having gastroi
ntestinal disturbances, flatulence and diarrhea, 11.5% reported using metronidaz
ole, and no confirmation of <i>E. histolytica</i> infection. We identified 31 in
dividuals with liquid stool samples (12% samples) and none with mucus or blood i
n their stools. A total of 45 individuals (17%) had loose stool samples, and 186
 (71%) had formed stool samples.</font></p>     ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#82#78#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00357000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012200076002001300198#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#83#79#article#183#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>DISCUSSION AND CONCLUSION</b><
/i></font></p>     ^cY#v15n2a05.htm##
01193000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704095800076002001301034#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#84#80#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In this report, we described a PCR-b
ased technique for selective identification of <i>E. histolytica</i> and <i>E. d
ispar</i> in stool samples. The technique consists of an initial amplification o
f a 1,076-bp fragment of the SSU-rDNA sequence of both species, followed by an a
dditional amplification for the two species differentiation. This multiplex PCR 
permits specific identification in a single reaction mixture and is therefore mo
re cost-effective and less laborious than other PCR-based methods.<sup>12</sup> 
Some studies have shown methods used to isolate DNA from in vitro amoeba culture
s.<sup>5,27,28</sup> However, the cultivation of amoebae before concentrating cy
sts is more expensive and time-consuming.<sup>29</sup> Here, we isolated DNA for
 PCR amplification of amoeba DNA directly from the stools, reducing time and the
 possibility of false negative results.</font></p>     ^cY#v15n2a05.htm##
00930000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069500076002001300771#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#85#81#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">However, PCR presents some disadvant
ages. It can be difficult to purify DNA from stool samples due to hardness of th
e cyst wall and the presence of inhibiting substances, which can inhibit the Taq
 polymerase.<sup>13,30-32</sup> According to Campos-G&oacute;rgora <i>et al.</i>
,<sup>33</sup> the major component of the <i>Entamoeba</i> cyst wall is chitin, 
a homopolymer of beta-(1,4)-linked N-acetyl-D-glucosamine that confers great rig
idity and resistance. Therefore, the utilization of both chemistry and physical 
conditions was sufficient to yield a great quantity of genetic material to proce
ed with the PCR.</font></p>     ^cY#v15n2a05.htm##
01362000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704112700076002001301203#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#86#82#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Until now, there had not been an ide
al method for extracting <i>Entamoeba</i> DNA from feces because various substan
ces could act as inhibitors.<sup>34,35</sup> In fact, inhibition occurred in 13.
3% of samples. It is likely that non-specific substances inhibited amplification
, since the number of cysts found in these samples did not influence the reactio
n and the presence of non-specific substances in feces, indirectly evaluated by 
spike, showed that added DNA did not suffer similarly in amplification of succes
sive dilutions. Specific column chromatography could minimize the influence of e
nzymatic inhibitors present in feces. According to Verweij <i>et al.</i>,<sup>13
</sup> it is fast and simple to use. The authors observed that only 1.7% of 657 
samples could not be amplified by PCR. We observed an inhibition in 13.3% of our
 samples, and the utilization of the columns might have lowered this figure. How
ever, specific column chromatography use increases the cost of PCR, making this 
technique impracticable in laboratory diagnosis.</font></p>     ^cY#v15n2a05.htm
##
01210000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704097500076002001301051#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#87#83#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In 1997, it was formally accepted th
at the species once called <i>E. histolytica</i> comprises two distinct species:
 the potentially invasive <i>E. histolytica</i> and the non-invasive, commensal 
<i>E. dispar</i>.<sup>7</sup> The cysts and trophozoites of these species cannot
 be distinguished microscopically. As no inexpensive or practical diagnostic pro
cedures are currently available for the identification of <i>E. histolytica</i> 
at health centers in countries with limited resources, we are left with the comm
on practice of identifying the <i>E. histolytica/E. dispar</i> complex as "<i>E.
 histolytica.</i>" The likely consequence of this is over-diagnosis and over-tre
atment, which could be the cause of anti-amoebic drug resistance.<sup>22</sup> T
herefore, a method capable of differentiating both species is essential for appr
opriate treatment and follow-up of infected individuals.</font></p>     ^cY#v15n
2a05.htm##
00843000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060800076002001300684#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#88#84#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As a result, there has been a lot of
 progress in the search for molecular methods to distinguish <i>E. histolytica/E
. dispar</i> complex species in the last few decades. Coproantigen searching, fo
r example, has innumerable advantages relative to other methodologies. However, 
antigens can denature during the preservation process, yielding false negative r
esults. Another alternative to differentiating the species is PCR. This techniqu
e has been used frequently in epidemiological investigations worldwide.<sup>5,23
-26</sup></font></p>     ^cY#v15n2a05.htm##
01415000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704118000076002001301256#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#89#85#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In this report, the prevalence of <i
>E. histolytica/E. dispar</i> based on fecal examination by optical microscopy w
as 3.4%. This finding corroborates the results in the literature that state that
 the prevalence of infection varies a great deal throughout Brazil, reaching 19%
 in the Amazon and varying from 2 to 29.5% in other regions.<sup>4,15,16,36</sup
> In the present study, the analysis of 262 samples with <i>E. histolytica/E. di
spar</i> using specific set of primers showed that 227 (86.6%) were positive for
 <i>E. dispar</i>. No amplification was observed in 35 samples (13.4%) that were
 negative for <i>E. histolytica</i>-specific galactose adhesin. Moreover, to exc
lude a probable infection caused by <i>E. hartmanni</i>, morphometric analysis d
emonstrated that non-amplified samples had cyst sizes comparable to <i>E. histol
ytica/E. dispar</i> (&gt; 10 &#181;m). The absence of amplification of these sam
ples indicates the presence of PCR inhibitors in the stool samples or the presen
ce of DNA from Entamoeba species other than <i>E. dis-par, E. histolytica</i> or
 <i>E. hartmanni.</i></font></p>     ^cY#v15n2a05.htm##
00892000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065700076002001300733#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#90#86#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In fact, Oliveira-Costa <i>et al</i>
.<sup>37</sup> in Belo Horizonte City, Southeast Brazil, and Dourado <i>et al.</
i><sup>38</sup> in Pernambuco State, Northeast Brazil, described only the presen
ce of <i>E. dispar</i> in their studies. Santos <i>et al</i>.<sup>5</sup> found 
a prevalence of 21% for four-nucleus amoebae in two slums in Rio de Janeiro Stat
e, Southeast Brazil, but only two samples were positive for <i>E. histolytica</i
>. It appears that <i>E. histolytica</i> is more common in North and extreme Nor
theast Brazil and is rare in other regions.<sup>4,39</sup></font></p>     ^cY#v1
5n2a05.htm##
01513000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704127800076002001301354#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#91#87#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Our described protocol provides a me
thod to sensitively and selectively detect and diferentiate <i>E. histolytica</i
> and <i>E. dispar</i> DNA directly from stool specimens without the need for pr
ior cultivation. Apart from often unsuccessful and time-consuming cultivation at
tempts, possible misdiagnoses by one strain displacing the other in mixed infect
ions can be avoided. We believe that difficulties in the differential diagnosis 
of the <i>E. histolytica/E. dispar</i> complex need to be overcome for the adequ
ate treatment of <i>E. histolytica</i>. PCR is expensive, and the majority of la
boratories do not have adequate infrastructure for its use. The utilization of t
his method in Brazil is in its initial phase and restricted to research centers 
located in big cities. However, once the method is established and standardized,
 its cost will decrease. The main limitations to this technique are the difficul
ty in obtaining conserved DNA from cysts, and the presence of unspecific inhibit
ors. More inquiries about simpler, faster and cheaper methodologies should be en
couraged and, after approval, should be established in laboratories that compose
 the public and private health network.</font></p>     ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#92#88#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#93#89#article#183#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>ACKNOWLEDGEMENTS</b></i></font
></p>     ^cY#v15n2a05.htm##
00983000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074800076002001300824#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#94#90#article#183#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We thank Dr Moacir Paranhos Silva (G
on&ccedil;alo Moniz Public Health Central Laboratory - LACEN-BA). We also thank 
Dr Mitermayer Galv&atilde;o dos Reis (Pathology and Molecular Biology Laboratory
 - Gon&ccedil;alo Moniz Institute, Ministry of Health of Brazil). We are indebte
d to Dr M&aacute;rcia Cristina Aquino Teixeira (Pharmacy School - <i>Universidad
e Federal da Bahia</i>) for her kind support and repeated reviews and opinions, 
who had always been available when requested. We especially acknowledge Dr Maria
 Aparecida Gomes (Amoebiasis Laboratory, <i>Universidade Federal de Minas Gerais
</i>). The work was supported by FAPESB and CNPq grant 620219/2008-4.</font></p>
     ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#95#91#article#183#<p>&nbsp;</p>     ^
cY#v15n2a05.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#96#92#article#183#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p> 
    ^cY#v15n2a05.htm##
00466000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021700078002001300295#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#97#93#article#183#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Caballero-Salcedo A
, Viveros-Rogel M, Salvatierra B <i>et al</i>. Seroepidemiology of amebiasis in 
Mexico. Am J Trop Med Hyg 1994; 50(4):412-9.    ^cY#v15n2a05.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#98#94#article#183#</font></p>     ^cY
#v15n2a05.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020500078002001300283#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#99#95#article#183#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Kreidl P, Imnadze P
, Baidoshvili L, Greco D. Investigation of an outbreak of amoebiasis in Georgia.
 Euro Surveil 1999; 4(10):103-6.    ^cY#v15n2a05.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#100#96#article#183#</font></p>     ^c
Y#v15n2a05.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704030400079002001300383#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#101#97#article#183#3#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Gatti S, Swierczyn
ski G, Robinson F <i>et al</i>. Amebic infections due to the <i>Entamoeba histol
ytica-Entamoeba dispar</i> complex: a study of the incidence in a remote rural a
rea of Ecuador. Am J Trop Med Hyg 2002; 67(1):123-7.    ^cY#v15n2a05.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#102#98#article#183#</font></p>     ^c
Y#v15n2a05.htm##
00614000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704036400079002001300443#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#103#99#article#183#4#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Benetton ML, Gon&c
cedil;alves AV, Meneghini ME <i>et al</i>. Risk factors for infection by the <i>
Entamoeba histolytica/E. dispar</i> complex: an epidemiological study conducted 
in outpatient clinics in the city of Manaus, Amazon region, Brazil. Trans R Soc 
Trop Med Hyg 2005; 99(7):532-40.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#104#100#article#183#</font></p>     ^
cY#v15n2a05.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704027200080002001300352#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#105#101#article#183#5#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Santos HL, Peralt
a RH, de Macedo HW, <i>et al</i>. Comparison of multiplex-PCR and antigen detect
ion for differential diagnosis of <i>Entamoeba histolytica</i>. Braz J Infect Di
s 2007; 11(3):365-70.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#106#102#article#183#</font></p>     ^
cY#v15n2a05.htm##
00569000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704031800080002001300398#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#107#103#article#183#6#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Mora L, Garc&iacu
te;a A, De Donato M, Urdaneta H. Epidemiologic and molecular study of <i>Entamoe
ba histolytica</i> and <i>Entamoeba dispar</i> strains in patients with diarrhea
 in Cumana, Sucre state, Venezuela. Invest Clin 2008; 49(2):225-37.    ^cY#v15n2
a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#108#104#article#183#</font></p>     ^
cY#v15n2a05.htm##
00500000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704024900080002001300329#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#109#105#article#183#7#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. World Health Orga
nization. Amoebiasis. Report on the WHO/Pan American Health Organization/UNESCO 
Expert Consultation, Mexico City. Geneva-WHO. W Epidemiol Rec 1997; 72:97-100.  
  ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#110#106#article#183#</font></p>     ^
cY#v15n2a05.htm##
00456000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704020500080002001300285#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#111#107#article#183#8#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Ashbolt NJ. Micro
bial contamination of drinking water and disease outcomes in developing regions.
 Toxicology 2004; 198(1-3):229-38.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#112#108#article#183#</font></p>     ^
cY#v15n2a05.htm##
00521000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704027000080002001300350#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#113#109#article#183#9#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Ch&aacute;vez B, 
Mart&iacute;nez-Palomo A, De La Torre M. Ultramicroscopic structure of the cyst 
wall of <i>Entamoeba invadens, E. histolytica and E. coli.</i> Arch Invest Med 1
978; Suppl 1:113-6.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#114#110#article#183#</font></p>     ^
cY#v15n2a05.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018900081002001300270#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#115#111#article#183#10#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Ritchie LS. An 
ether sedimentation technique for routine stool examinations. Bull U S Army Med 
Dep 1948; 8(4):326.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#116#112#article#183#</font></p>     ^
cY#v15n2a05.htm##
00545000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029300081002001300374#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#117#113#article#183#11#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Acuna-Soto R, S
amuelson J, De Girolami P <i>et al</i>. Application of the polymerase chain reac
tion to the epidemiology of pathogenic and nonpathogenic <i>Entamoeba histolytic
a</i>. Am J Trop Med Hyg 1993; 48(1):58-70.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#118#114#article#183#</font></p>     ^
cY#v15n2a05.htm##
00577000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032500081002001300406#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#119#115#article#183#12#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Evangelopoulos 
A, Spanakos G, Patsoula E <i>et al</i>. A nested, multiplex, PCR assay for the s
imultaneous detection and differentiation of <i>Entamoeba histolytica</i> and <i
>Entamoeba dispar</i> in faeces. Ann Trop Med Parasitol 2000; 94(3):233-40.    ^
cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#120#116#article#183#</font></p>     ^
cY#v15n2a05.htm##
00588000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033600081002001300417#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#121#117#article#183#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Verweij JJ, Blo
tkamp J, Brienen EA <i>et al</i>. Differentiation of <i>Entamoeba histolytica</i
> and <i>Entamoeba dispar</i> cysts using polymerase chain reaction on DNA isola
ted from faeces with spin columns. Eur J Clin Microbiol Infect Dis 2000; 19(5):3
58-61.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#122#118#article#183#</font></p>     ^
cY#v15n2a05.htm##
00517000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026500081002001300346#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#123#119#article#183#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Zaman S, Khoo J
, Ng SW <i>et al</i>. Direct amplification of <i>Entamoeba histolytica</i> DNA f
rom amoebic liver abscess pus using polymerase chain reaction. Parasitol Res 200
0; 86(9):724-8.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#124#120#article#183#</font></p>     ^
cY#v15n2a05.htm##
00521000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026900081002001300350#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#125#121#article#183#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Silva EF, Gomes
 MA. Ameb&iacute;ase: <i>Entamoeba histolytica/Entamoeba dispar</i>. In: Neves D
P, Melo AL, Genaro O <i>et al</i>. eds Parasitologia Humana. S&atilde;o Paulo: A
theneu Press, 2001.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#126#122#article#183#</font></p>     ^
cY#v15n2a05.htm##
00573000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032100081002001300402#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#127#123#article#183#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Ara&uacute;jo R
, Bichara CNC, Chaves LCL <i>et al</i>. Doen&ccedil;as infecciosas e parasit&aac
ute;rias - enfoque Amaz&ocirc;nico. In: Le&atilde;o RNQ. eds. CEJUP. Universidad
e Federal do Par&aacute;, Instituto Evandro Chagas. Bel&eacute;m, 1997.    ^cY#v
15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#128#124#article#183#</font></p>     ^
cY#v15n2a05.htm##
00483000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023100081002001300312#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#129#125#article#183#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Hoffman WA, Pon
s JA, Janer JL. The sedimentation concentration method in schistosomiasis manson
i. <i>Puerto Rico J Publ Health Trop Med</i> 1934; 9:283-298.    ^cY#v15n2a05.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#130#126#article#183#</font></p>     ^
cY#v15n2a05.htm##
00639000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704038700081002001300468#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#131#127#article#183#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Brazilian Insti
tute of Geography and Statistics. Contagem da Popula&ccedil;&atilde;o, 2007. <a 
href="http://www.ibge.gov.br/home/estatistica/populacao/contagem2007/contagem_fi
nal/tabela1_1_16.pdf" target="_blank">http://www.ibge.gov.br/home/estatistica/po
pulacao/contagem2007/contagem_final/tabela1_1_16.pdf</a>.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#132#128#article#183#</font></p>     ^
cY#v15n2a05.htm##
00571000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031900081002001300400#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#133#129#article#183#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Santos FLN, Hil
tner AN, Ara&uacute;jo FG <i>et al</i>. Preval&ecirc;ncia e perfil epidemiol&oac
ute;gico das enteroparasitoses em Salvador (BA). In: 40º Congresso Brasileiro de
 Patologia Cl&iacute;nica e Medicina Laboratorial, Curitiba-PR, 2006.    ^cY#v15
n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#134#130#article#183#</font></p>     ^
cY#v15n2a05.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023400081002001300315#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#135#131#article#183#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Rey L. Parasito
logia: parasitos e doen&ccedil;as parasit&aacute;rias do homem nos tr&oacute;pic
os ocidentais. Rio de Janeiro, BR: Guanabara-Koogan Press, 2008.    ^cY#v15n2a05
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#136#132#article#183#</font></p>     ^
cY#v15n2a05.htm##
00567000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031500081002001300396#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#137#133#article#183#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Troll H, Marti 
H, Weiss N. Simple differential detection of <i>Entamoeba histolytica</i> and <i
>Entamoeba dispar</i> in fresh stool specimens by sodium acetate-acetic acid-for
malin concentration and PCR. J Clin Microbiol 1997; 35(7):1701-5.    ^cY#v15n2a0
5.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#138#134#article#183#</font></p>     ^
cY#v15n2a05.htm##
00552000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030000081002001300381#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#139#135#article#183#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Leiva B, Lebbad
 M, Winiecka-Krusnell J <i>et al</i>. Overdiagnosis of <i>Entamoeba histolytica<
/i> and <i>Entamoeba dispar</i> in Nicaragua: a microscopic, triage parasite pan
el and PCR study. Arch Med Res 2006; 37(4):529-34.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#140#136#article#183#</font></p>     ^
cY#v15n2a05.htm##
00507000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025500081002001300336#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#141#137#article#183#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Valle PR, Souza
 MB, Pires EM <i>et al</i>. Arbitrarily primed PCR fingerprint of RNA and DNA in
 <i>Entamoeba histolytica</i>. Rev Inst Med Trop S&atilde;o Paulo 2000; 42(5):24
9-53.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#142#138#article#183#</font></p>     ^
cY#v15n2a05.htm##
00478000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022600081002001300307#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#143#139#article#183#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Evangelopoulos 
A, Legakis N, Vakalis N. Microscopy, PCR and ELISA applied to the epidemiology o
f amoebiasis in Greece. Parasitol Int 2001; 50(3):185-9.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#144#140#article#183#</font></p>     ^
cY#v15n2a05.htm##
00480000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022800081002001300309#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#145#141#article#183#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Roy S, Kabir M,
 Mondal D <i>et al</i>. Real-time-PCR assay for diagnosis of <i>Entamoeba histol
ytica</i> infection. J Clin Microbiol 2005; 43(5):2168-72.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#146#142#article#183#</font></p>     ^
cY#v15n2a05.htm##
00539000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028700081002001300368#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#147#143#article#183#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Vianna EN, Cost
a JO, Santos CK <i>et al</i>. An alternative method for DNA extraction and PCR i
dentification of <i>Entamoeba histolytica</i> and <i>E. dispar</i> in fecal samp
les. Parasitology 2009; 136(7):765-9.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#148#144#article#183#</font></p>     ^
cY#v15n2a05.htm##
00487000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023500081002001300316#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#149#145#article#183#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Zindrou S, Oroz
co E, Linder E <i>et al</i>. Specific detection of <i>Entamoeba histolytica</i> 
DNA by hemolysin gene targeted PCR. Acta Trop 2001; 78(2):117-25.    ^cY#v15n2a0
5.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#150#146#article#183#</font></p>     ^
cY#v15n2a05.htm##
00543000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029100081002001300372#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#151#147#article#183#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Calderaro A, Go
rrini C, Bommezzadri S <i>et al. Entamoeba histolytica</i> and <i>Entamoeba disp
ar</i>: comparison of two PCR assays for diagnosis in a non-endemic setting. Tra
ns R Soc Trop Med Hyg 2006; 100(5):450-7.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#152#148#article#183#</font></p>     ^
cY#v15n2a05.htm##
00427000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017500081002001300256#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#153#149#article#183#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Tanyuksel M, Pe
tri WA Jr. Laboratory diagnosis of amoebiasis. Clin Microbiol Rev 2003; 16(4):71
3-29.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#154#150#article#183#</font></p>     ^
cY#v15n2a05.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021500081002001300296#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#155#151#article#183#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Deuter R, Piets
ch S, Hertel S, M&uuml;ller O. A method for preparation of fecal DNA suitable fo
r PCR. Nucleic Acids Res 1995; 23(18):3800-1.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#156#152#article#183#</font></p>     ^
cY#v15n2a05.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030500081002001300386#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#157#153#article#183#31#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Lantz PG, Tjern
eld F, Hahn-H&auml;gerdal B, Radstr&ouml;m P. Use of aqueous two-phase systems i
n sample preparation for polymerase chain reaction-based detection of microorgan
isms. J Chromatogr B Biomed Appl 1996; 680(1-2):165-70.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#158#154#article#183#</font></p>     ^
cY#v15n2a05.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022700081002001300308#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#159#155#article#183#32#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Vandenberg N, v
an Oorschot RA. Extraction of human nuclear DNA from feces samples using the QIA
amp DNA Stool Mini Kit. J Forensic Sci 2002; 47(5):993-5.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#160#156#article#183#</font></p>     ^
cY#v15n2a05.htm##
00468000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021600081002001300297#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#161#157#article#183#33#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Campos-G&oacute
;ngora E, Ebert F, Willhoeft U <i>et al</i>. Characterization of chitin synthase
s from Entamoeba. Protist 2004; 155(3):323-30.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#162#158#article#183#</font></p>     ^
cY#v15n2a05.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024600081002001300327#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#163#159#article#183#34#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Monteiro L, Bon
nemaison D, Vekris A <i>et al</i>. Complex polysaccharides as PCR inhibitors in 
feces: <i>Helicobacter pylori</i> model. J Clin Microbiol 1997; 35(4):995-8.    
^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#164#160#article#183#</font></p>     ^
cY#v15n2a05.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018900081002001300270#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#165#161#article#183#35#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Wilson IG. Inhi
bition and facilitation of nucleic acid amplification. Appl Environ Microbiol 19
97; 63(10):3741-51.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#166#162#article#183#</font></p>     ^
cY#v15n2a05.htm##
00522000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027000081002001300351#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#167#163#article#183#36#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Cunha AS, Silva
 EF, Ferrari TCA <i>et al</i>. Ameb&iacute;ase em t&oacute;picos e gastroenterol
ogia. In: Castro L.P., Rocha P.R.S., Cunha A.S. eds. Amebiases. Rio de Janeiro: 
Medicis Press, 1991.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#168#164#article#183#</font></p>     ^
cY#v15n2a05.htm##
00643000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704039100081002001300472#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#169#165#article#183#37#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Oliveira-Costa 
J, Resende JA, Gomes MA. Preval&ecirc;ncia de <i>Entamoeba histolytica</i> e <i>
Entamoeba dispar</i> em amostras fecais de um laborat&oacute;rio privado na gran
de Belo Horizonte. In: Semana de Inicia&ccedil;&atilde;o Cient&iacute;fica da Un
iversidade Federal de Minas Gerais, Belo Horizonte, MG, 2006.    ^cY#v15n2a05.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#170#166#article#183#</font></p>     ^
cY#v15n2a05.htm##
00497000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024500081002001300326#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#171#167#article#183#38#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Dourado A, Maci
el A, Aca Ida S. Occurrence of <i>Entamoeba histolytica/Entamoeba dispar</i> in 
ambulatory patients of Recife, PE. Rev Soc Bras Med Trop 2006; 39(4):388-9.    ^
cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#172#168#article#183#</font></p>     ^
cY#v15n2a05.htm##
00556000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030400081002001300385#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#173#169#article#183#39#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. Braga LL, Gomes
 ML, Silva MW <i>et al. Entamoeba histolytica</i> and <i>Entamoeba dispar</i> in
fections as detected by monoclonal antibody in an urban slum in Fortaleza, North
east Brazil. Rev Soc Bras Med Trop 2001; 34(5):467-71.    ^cY#v15n2a05.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#174#170#article#183#</font></p>     ^
cY#v15n2a05.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#175#171#article#183#<p>&nbsp;</p>    
 ^cY#v15n2a05.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#176#172#article#183#<p>&nbsp;</p>    
 ^cY#v15n2a05.htm##
00426000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018900078002001300267#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#177#173#article#183#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:
</b>    ^cY#v15n2a05.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#178#174#article#183#<br> Fred Luciano
 Neves Santos    ^cY#v15n2a05.htm##
00326000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008900078002001300167#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#179#175#article#183#<br> Departamento
 de An&aacute;lises Cl&iacute;nicas e Toxicol&oacute;gicas, UFBA    ^cY#v15n2a05
.htm##
00291000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005400078002001300132#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#180#176#article#183#<br> Rua Bar&atil
de;o de Geremoabo S/N. Ondina    ^cY#v15n2a05.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004600078002001300124#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#181#177#article#183#<br> 40170115, Sa
lvador, Bahia, Brazil    ^cY#v15n2a05.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#182#178#article#183#<br> Phone: 55 71
 3283 6950    ^cY#v15n2a05.htm##
00326000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008900078002001300167#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#183#179#article#183#<br> <a href="mai
lto:flucianon@hotmail.com">flucianon@hotmail.com</a></font></p>     ^cY#v15n2a05
.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009300078002001300171#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#184#180#article#183#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted on: 7/3/2010    ^cY#v15n
2a05.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003700078002001300115#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#185#181#article#183#<br>   Approved o
n: 8/19/2010    ^cY#v15n2a05.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011300078002001300191#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#186#182#article#183#<br>   Financial 
Support: This study received financial support from FAPESB and CNPq grant 620219
/2008-4.    ^cY#v15n2a05.htm##
00299000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006200078002001300140#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a05.htm#S#p#187#183#article#183#<br>   We declare
 no conflict of interest.</font></p>     ^cY#v15n2a05.htm##
00605000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100027000770100023001040100
02100127810000600148012004400154030001800198065000900216064000500225031000300230
032000200233014000600235865000900241002001300250035001000263801001800273#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#188#1#article#39#1#^rND^sCaba
llero-Salcedo^nA#^rND^sViveros-Rogel^nM#^rND^sSalvatierra^nB#et al#Seroepidemiol
ogy of amebiasis in Mexico^len#Am J Trop Med Hyg#19940000#1994#50#4#412-9#201104
00#v15n2a05.htm#0002-9637#Am J Trop Med Hyg##
00568000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930100
02100110010001500131012005800146030001300204710000200217065000900219064000500228
031000200233032000300235014000600238865000900244002001300253#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a05.htm#S#c#189#2#article#39#2#^rND^sKreidl^nP#^rND^s
Imnadze^nP#^rND^sBaidoshvili^nL#^rND^sGreco^nD#Investigation of an outbreak of a
moebiasis in Georgia^len#Euro Surveil#2#19990000#1999#4#10#103-6#20110400#v15n2a
05.htm##
00685000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100022000920100
01800114810000600132012014000138030001800278065000900296064000500305031000300310
032000200313014000600315865000900321002001300330035001000343801001800353#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#190#3#article#39#3#^rND^sGatt
i^nS#^rND^sSwierczynski^nG#^rND^sRobinson^nF#et al#Amebic infections due to the 
Entamoeba histolytica-Entamoeba dispar complex: a study of the incidence in a re
mote rural area of Ecuador^len#Am J Trop Med Hyg#20020000#2002#67#1#123-7#201104
00#v15n2a05.htm#0002-9637#Am J Trop Med Hyg##
00745000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100020000960100
02000116810000600136012018100142030002500323065000900348064000500357031000300362
032000200365014000700367865000900374002001300383035001000396801002500406#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#191#4#article#39#4#^rND^sBene
tton^nML#^rND^sGonçalves^nAV#^rND^sMeneghini^nME#et al#Risk factors for infectio
n by the Entamoeba histolytica/E. dispar complex: an epidemiological study condu
cted in outpatient clinics in the city of Manaus, Amazon region, Brazil^len#Tran
s R Soc Trop Med Hyg#20050000#2005#99#7#532-40#20110400#v15n2a05.htm#0035-9203#T
rans R Soc Trop Med Hyg##
00675000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
02000112810000600132012010600138030001800244065000900262064000500271031000300276
032000200279014000700281865000900288002001300297035001000310801004100320#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#192#5#article#39#5#^rND^sSant
os^nHL#^rND^sPeralta^nRH#^rND^sde Macedo^nHW#et al#Comparison of multiplex-PCR a
nd antigen detection for differential diagnosis of Entamoeba histolytica^len#Bra
z J Infect Dis#20070000#2007#11#3#365-70#20110400#v15n2a05.htm#1413-8670#Brazili
an Journal of Infectious Diseases##
00692000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100016000910100
01900107010001800126012015200144030001200296065000900308064000500317031000300322
032000200325014000700327865000900334002001300343035001000356801001200366#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#193#6#article#39#6#^rND^sMora
^nL#^rND^sGarcía^nA#^rND^sDe Donato^nM#^rND^sUrdaneta^nH#Epidemiologic and molec
ular study of Entamoeba histolytica and Entamoeba dispar strains in patients wit
h diarrhea in Cumana, Sucre state, Venezuela^len#Invest Clin#20080000#2008#49#2#
225-37#20110400#v15n2a05.htm#0535-5133#Invest Clin##
00540000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750110026000770120119001030300
01600222710000200238065000900240064000500249031000300254014000700257865000900264
002001300273#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#194#7#art
icle#39#7#World Health Organization#Amoebiasis: Report on the WHO/Pan American H
ealth Organization/UNESCO Expert Consultation, Mexico City. Geneva-WHO^len#W Epi
demiol Rec#2#19970000#1997#72#97-100#20110400#v15n2a05.htm##
00545000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120089000950300
01100184065000900195064000500204031000400209032000400213014000700217865000900224
002001300233035001000246801001100256#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a05.htm#S#c#195#8#article#39#8#^rND^sAshbolt^nNJ#Microbial contamination of d
rinking water and disease outcomes in developing regions^len#Toxicology#20040000
#2004#198#1-3#229-38#20110400#v15n2a05.htm#0300-483X#Toxicology##
00579000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100025000930100
02100118012009800139030001600237710000200253065000900255064000500264032000400269
014000600273865000900279002001300288#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a05.htm#S#c#196#9#article#39#9#^rND^sChávez^nB#^rND^sMartínez-Palomo^nA#^rND^
sDe La Torre^nM#Ultramicroscopic structure of the cyst wall of Entamoeba invaden
s, E. histolytica and E. coli^len#Arch Invest Med#2#19780000#1978#^s1#113-6#2011
0400#v15n2a05.htm##
00499000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120068000970300
02200165710000200187065000900189064000500198031000200203032000200205020000400207
865000900211002001300220#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S
#c#197#10#article#39#10#^rND^sRitchie^nLS#An ether sedimentation technique for r
outine stool examinations^len#Bull U S Army Med Dep#2#19480000#1948#8#4#326#2011
0400#v15n2a05.htm##
00675000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100019000990100
02100118810000600139012012300145030001800268065000900286064000500295031000300300
032000200303014000600305865000900311002001300320035001000333801001800343#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#198#11#article#39#11#^rND^sAc
una-Soto^nR#^rND^sSamuelson^nJ#^rND^sDe Girolami^nP#et al#Application of the pol
ymerase chain reaction to the epidemiology of pathogenic and nonpathogenic Entam
oeba histolytica^len#Am J Trop Med Hyg#19930000#1993#48#1#58-70#20110400#v15n2a0
5.htm#0002-9637#Am J Trop Med Hyg##
00705000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100024000790100018001030100
01800121810000600139012014200145030002300287065000900310064000500319031000300324
032000200327014000700329865000900336002001300345035001000358801002300368#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#199#12#article#39#12#^rND^sEv
angelopoulos^nA#^rND^sSpanakos^nG#^rND^sPatsoula^nE#et al#A nested, multiplex, P
CR assay for the simultaneous detection and differentiation of Entamoeba histoly
tica and Entamoeba dispar in faeces^len#Ann Trop Med Parasitol#20000000#2000#94#
3#233-40#20110400#v15n2a05.htm#0003-4983#Ann Trop Med Parasitol##
00725000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01800115810000600133012015000139030003200289065000900321064000500330031000300335
032000200338014000700340865000900347002001300356035001000369801003200379#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#200#13#article#39#13#^rND^sVe
rweij^nJJ#^rND^sBlotkamp^nJ#^rND^sBrienen^nEA#et al#Differentiation of Entamoeba
 histolytica and Entamoeba dispar cysts using polymerase chain reaction on DNA i
solated from faeces with spin columns^len#Eur J Clin Microbiol Infect Dis#200000
00#2000#19#5#358-61#20110400#v15n2a05.htm#0722-2211#Eur J Clin Microbiol Infect 
Dis##
00643000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100014000940100
01300108810000600121012011700127030001400244065000900258064000500267031000300272
032000200275014000600277865000900283002001300292035001000305801001400315#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#201#14#article#39#14#^rND^sZa
man^nS#^rND^sKhoo^nJ#^rND^sNg^nSW#et al#Direct amplification of Entamoeba histol
ytica DNA from amoebic liver abscess pus using polymerase chain reaction^len#Par
asitol Res#20000000#2000#86#9#724-8#20110400#v15n2a05.htm#0044-3255#Parasitol Re
s##
00604000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950120
05300111016001600164016001500180016001600195810000600211018002500217066001000242
062001400252065000900266064000500275865000900280002001300289#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a05.htm#S#c#202#15#article#39#15#^rND^sSilva^nEF#^rND
^sGomes^nMA#Amebíase: Entamoeba histolytica/Entamoeba dispar^len#^rED^sNeves^nDP
#^rED^sMelo^nAL#^rED^sGenaro^nO#et al#Parasitologia Humana^lpt#São Paulo#Atheneu
 Press#20010000#2001#20110400#v15n2a05.htm##
00616000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950100
01800114810000600132012005800138016001600196062000600212062002900218062002500247
066000600272065000900278064000500287865000900292002001300301#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a05.htm#S#c#203#16#article#39#16#^rED^sAraújo^nR#^rED
^sBichara^nCNC#^rED^sChaves^nLCL#et al#Doenças infecciosas e parasitárias: enfoq
ue Amazônico^lpt#^rED^sLeão^nRNQ#CEJUP#Universidade Federal do Pará#Instituto Ev
andro Chagas#Belém#19970000#1997#20110400#v15n2a05.htm##
00559000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
01600112012007000128030003500198710000200233065000900235064000500244031000200249
014000800251865000900259002001300268#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a05.htm#S#c#204#17#article#39#17#^rND^sHoffman^nWA#^rND^sPons^nJA#^rND^sJaner
^nJL#The sedimentation concentration method in schistosomiasis mansoni^len#Puert
o Rico J Publ Health Trop Med#2#19340000#1934#9#283-298#20110400#v15n2a05.htm##
00470000000000193000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170048000790180032001270370
09500159865000900254002001300263#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a
05.htm#S#c#205#18#article#39#18#Brazilian Institute of Geography and Statistics#
Contagem da População, 2007^lpt#http://www.ibge.gov.br/home/estatistica/populaca
o/contagem2007/contagem_final/tabela1_1_16.pdf#20110400#v15n2a05.htm##
00620000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01700115810000600132012007900138053007600217056001900293055001200312054000800324
865000900332002001300341#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S
#c#206#19#article#39#19#^rND^sSantos^nFLN#^rND^sHiltner^nAN#^rND^sAraújo^nFG#et 
al#Prevalência e perfil epidemiológico das enteroparasitoses em Salvador (BA)^lp
t#Congresso Brasileiro de Patologia Clínica e Medicina Laboratorial^n40^i1^i1#Cu
ritiba^i1^ePR^i1#20060000^i1#2006^i1#20110400#v15n2a05.htm##
00496000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160013000790180085000920660
01500177067000300192062002300195065000900218064000500227865000900232002001300241
#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#207#20#article#39#20#
^rND^sRey^nL#Parasitologia: parasitos e doenças parasitárias do homem nos trópic
os ocidentais^lpt#Rio de Janeiro#BR#Guanabara-Koogan Press#20080000#2008#2011040
0#v15n2a05.htm##
00684000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940100
01500109012016600124030001700290065000900307064000500316031000300321032000200324
014000700326865000900333002001300342035001000355801001700365#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a05.htm#S#c#208#21#article#39#21#^rND^sTroll^nH#^rND^
sMarti^nH#^rND^sWeiss^nN#Simple differential detection of Entamoeba histolytica 
and Entamoeba dispar in fresh stool specimens by sodium acetate-acetic acid-form
alin concentration and PCR^len#J Clin Microbiol#19970000#1997#35#7#1701-5#201104
00#v15n2a05.htm#0095-1137#J Clin Microbiol##
00670000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
02700110810000600137012012900143030001300272065000900285064000500294031000300299
032000200302014000700304865000900311002001300320035001000333801001300343#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#209#22#article#39#22#^rND^sLe
iva^nB#^rND^sLebbad^nM#^rND^sWiniecka-Krusnell^nJ#et al#Overdiagnosis of Entamoe
ba histolytica and Entamoeba dispar in Nicaragua: a microscopic, triage parasite
 panel and PCR study^len#Arch Med Res#20060000#2006#37#4#529-34#20110400#v15n2a0
5.htm#0188-0128#Arch Med Res##
00640000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01600111810000600127012007900133030002800212065000900240064000500249031000300254
032000200257014000700259865000900266002001300275035001000288801002800298#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#210#23#article#39#23#^rND^sVa
lle^nPR#^rND^sSouza^nMB#^rND^sPires^nEM#et al#Arbitrarily primed PCR fingerprint
 of RNA and DNA in Entamoeba histolytica^len#Rev Inst Med Trop São Paulo#2000000
0#2000#42#5#249-53#20110400#v15n2a05.htm#0036-4665#Rev Inst Med Trop São Paulo##
00572000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100024000790100017001030100
01700120012008200137030001400219710000200233065000900235064000500244031000300249
032000200252014000600254865000900260002001300269#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a05.htm#S#c#211#24#article#39#24#^rND^sEvangelopoulos^nA#^rND^sLe
gakis^nN#^rND^sVakalis^nN#Microscopy, PCR and ELISA applied to the epidemiology 
of amoebiasis in Greece^len#Parasitol Int#2#20010000#2001#50#3#185-9#20110400#v1
5n2a05.htm##
00609000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100015000920100
01600107810000600123012007300129030001700202065000900219064000500228031000300233
032000200236014000800238865000900246002001300255035001000268801001700278#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#212#25#article#39#25#^rND^sRo
y^nS#^rND^sKabir^nM#^rND^sMondal^nD#et al#Real-time-PCR assay for diagnosis of E
ntamoeba histolytica infection^len#J Clin Microbiol#20050000#2005#43#5#2168-72#2
0110400#v15n2a05.htm#0095-1137#J Clin Microbiol##
00657000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01700112810000600129012012400135030001300259065000900272064000500281031000400286
032000200290014000600292865000900298002001300307035001000320801001300330#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#213#26#article#39#26#^rND^sVi
anna^nEN#^rND^sCosta^nJO#^rND^sSantos^nCK#et al#An alternative method for DNA ex
traction and PCR identification of Entamoeba histolytica and E. dispar in fecal 
samples^len#Parasitology#20090000#2009#136#7#765-9#20110400#v15n2a05.htm#0031-18
20#Parasitology##
00609000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01600112810000600128012008300134030001000217065000900227064000500236031000300241
032000200244014000700246865000900253002001300262035001000275801001000285#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#214#27#article#39#27#^rND^sZi
ndrou^nS#^rND^sOrozco^nE#^rND^sLinder^nE#et al#Specific detection of Entamoeba h
istolytica DNA by hemolysin gene targeted PCR^len#Acta Trop#20010000#2001#78#2#1
17-25#20110400#v15n2a05.htm#0001-706X#Acta Trop##
00680000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
02100115810000600136012011600142030002500258065000900283064000500292031000400297
032000200301014000600303865000900309002001300318035001000331801002500341#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#215#28#article#39#28#^rND^sCa
lderaro^nA#^rND^sGorrini^nC#^rND^sBommezzadri^nS#et al#Entamoeba histolytica and
 Entamoeba dispar: comparison of two PCR assays for diagnosis in a non-endemic s
etting^len#Trans R Soc Trop Med Hyg#20060000#2006#100#5#450-7#20110400#v15n2a05.
htm#0035-9203#Trans R Soc Trop Med Hyg##
00542000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980120
03900117030001900156065000900175064000500184031000300189032000200192014000700194
865000900201002001300210035001000223801001900233#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a05.htm#S#c#216#29#article#39#29#^rND^sTanyuksel^nM#^rND^sPetri^n
WA Jr#Laboratory diagnosis of amoebiasis^len#Clin Microbiol Rev#20030000#2003#16
#4#713-29#20110400#v15n2a05.htm#0893-8512#Clin Microbiol Rev##
00612000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01600112010001600128012005900144030001800203065000900221064000500230031000300235
032000300238014000700241865000900248002001300257035001000270801001800280#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#217#30#article#39#30#^rND^sDe
uter^nR#^rND^sPietsch^nS#^rND^sHertel^nS#^rND^sMüller^nO#A method for preparatio
n of fecal DNA suitable for PCR^len#Nucleic Acids Res#19950000#1995#23#18#3800-1
#20110400#v15n2a05.htm#0305-1048#Nucleic Acids Res##
00706000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
02300113010001800136012012300154030002700277065000900304064000500313031000400318
032000400322014000700326865000900333002001300342035001000355801002700365#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#218#31#article#39#31#^rND^sLa
ntz^nPG#^rND^sTjerneld^nF#^rND^sHahn-Hägerdal^nB#^rND^sRadström^nP#Use of aqueou
s two-phase systems in sample preparation for polymerase chain reaction-based de
tection of microorganisms^len#J Chromatogr B Biomed Appl#19960000#1996#680#1-2#1
65-70#20110400#v15n2a05.htm#0378-4347#J Chromatogr B Biomed Appl##
00590000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100023000990120
09100122030001500213065000900228064000500237031000300242032000200245014000600247
865000900253002001300262035001000275801001500285#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a05.htm#S#c#219#32#article#39#32#^rND^sVandenberg^nN#^rND^svan Oo
rschot^nRA#Extraction of human nuclear DNA from feces samples using the QIAamp D
NA Stool Mini Kit^len#J Forensic Sci#20020000#2002#47#5#993-5#20110400#v15n2a05.
htm#0022-1198#J Forensic Sci##
00588000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100024000790100015001030100
01900118810000600137012005600143030000800199065000900207064000500216031000400221
032000200225014000700227865000900234002001300243035001000256801000800266#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#220#33#article#39#33#^rND^sCa
mpos-Góngora^nE#^rND^sEbert^nF#^rND^sWillhoeft^nU#et al#Characterization of chit
in synthases from Entamoeba^len#Protist#20040000#2004#155#3#323-30#20110400#v15n
2a05.htm#1434-4610#PROTIST##
00627000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100021000970100
01600118810000600134012008200140030001700222065000900239064000500248031000300253
032000200256014000600258865000900264002001300273035001000286801001700296#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#221#34#article#39#34#^rND^sMo
nteiro^nL#^rND^sBonnemaison^nD#^rND^sVekris^nA#et al#Complex polysaccharides as 
PCR inhibitors in feces: Helicobacter pylori model^len#J Clin Microbiol#19970000
#1997#35#4#995-8#20110400#v15n2a05.htm#0095-1137#J Clin Microbiol##
00542000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120062000960300
02300158065000900181064000500190031000300195032000300198014000800201865000900209
002001300218035001000231801002300241#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a05.htm#S#c#222#35#article#39#35#^rND^sWilson^nIG#Inhibition and facilitation
 of nucleic acid amplification^len#Appl Environ Microbiol#19970000#1997#63#10#37
41-51#20110400#v15n2a05.htm#0099-2240#Appl Environ Microbiol##
00627000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01900111810000600130012004400136016001800180016001900198016001700217018001400234
066001500248062001400263065000900277064000500286865000900291002001300300#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#223#36#article#39#36#^rND^sCu
nha^nAS#^rND^sSilva^nEF#^rND^sFerrari^nTCA#et al#Amebíase em tópicos e gastroent
erologia^lpt#^rED^sCastro^nL.P#^rED^sRocha^nP.R.S#^rED^sCunha^nA.S#Amebiases^lpt
#Rio de Janeiro#Medicis Press#19910000#1991#20110400#v15n2a05.htm##
00662000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100024000790100018001030100
01600121012013000137053007400267056002500341055001200366054000800378865000900386
002001300395#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#224#37#ar
ticle#39#37#^rND^sOliveira-Costa^nJ#^rND^sResende^nJA#^rND^sGomes^nMA#Prevalênci
a de Entamoeba histolytica e Entamoeba dispar em amostras fecais de um laboratór
io privado na grande Belo Horizonte^lpt#Semana de Iniciação Científica da Univer
sidade Federal de Minas Gerais^i1#Belo Horizonte^i1^eMG^i1#20060000^i1#2006^i1#2
0110400#v15n2a05.htm##
00626000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01700112012009400129030002200223065000900245064000500254031000300259032000200262
014000600264865000900270002001300279035001000292801002200302#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a05.htm#S#c#225#38#article#39#38#^rND^sDourado^nA#^rN
D^sMaciel^nA#^rND^sAca Ida^nS#Occurrence of Entamoeba histolytica/Entamoeba disp
ar in ambulatory patients of Recife, PE^len#Rev Soc Bras Med Trop#20060000#2006#
39#4#388-9#20110400#v15n2a05.htm#0037-8682#Rev Soc Bras Med Trop##
00690000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01600111810000600127012014100133030002200274065000900296064000500305031000300310
032000200313014000700315865000900322002001300331035001000344801002200354#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a05.htm#S#c#226#39#article#39#39#^rND^sBr
aga^nLL#^rND^sGomes^nML#^rND^sSilva^nMW#et al#Entamoeba histolytica and Entamoeb
a dispar infections as detected by monoclonal antibody in an urban slum in Forta
leza, Northeast Brazil^len#Rev Soc Bras Med Trop#20010000#2001#34#5#467-71#20110
400#v15n2a05.htm#0037-8682#Rev Soc Bras Med Trop##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#o#1#1#article#1
#20110406#124817#v15n2a06.htm#134##
02941000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400110014403500100015501201770
01650100035003420100037003770100025004140100042004390100035004810700148005160700
06400664070003400728070003300762083132400795085000802119085002502127085003602152
08500230218808500280221111700060223907200030224511200090224811100100225711400090
2267113001102276058000502287058000502292058000502297002001302302#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#
TAB#6#BJID230#nd#Braz J Infect Dis#15#2#20110400#^f126^l131#1413-8670#Chlamydia 
trachomatis and human papillomavirus coinfection: association with p16INK4a and 
Ki67 expression in biopsies of patients with pre-neoplastic and neoplastic lesio
ns^len#^rND^1A01 A02^nLuciane Noal^sCalil#^rND^1A03^nCristine Nascente^sIgansi#^
rND^1A02^nLuise^sMeurer#^rND^1A04^nMaria Isabel Albano^sEdelweiss#^rND^1A04^nMar
y Clarisse^sBozzetti#Universidade Federal do Rio Grande do Sul^iA01^1Post-gradua
te Program in Medical Sciences Faculty of Pharmacy Post-graduate Program in Epid
emiology#Hospital de Clínicas de Porto Alegre^iA02^cPorto Alegre^pBrazil#Brazili
an Ministry of Health^iA03#UFRGS^iA04^cPorto Alegre^pBrazil#^len^aThe objective 
of this study was to identify the frequency of coinfection by human papillomavir
us (HPV) and Chlamydia trachomatis (CT) in cervical lesions and relate it with i
mmunohistochemical expression of p16INK4a and Ki67, both oncogenicity markers. A
 cross-sectional study with 86 women from primary care units in southern Brazil 
was conducted. Cervical swabs were collected for HPV-DNA and CT-DNA detection, t
hrough the polymerase chain reaction technique (PCR). The immunohistochemical an
alysis was performed on biopsy cervical tissue material to identify the expressi
on of p16INK4a and Ki67 cell cycle markers. About 83 % were positive for HPV-DNA
 and 19% had coinfection with CT-DNA. Among coinfected women, 56% expressed p16I
NK4a. There was a statistically significant association between the histological
 grade of the lesion and Ki67 expression. All high-grade lesions, 50% of low-gra
de lesions and 31% of negative biopsies expressed Ki67 (p = 0.004). A total of 3
7% of coinfected women expressed both markers. In conclusion, although more than
 half of the coinfected patients have expressed p16INK4a and more than one third
 have expressed both markers, these results suggest no association between those
 variables. However, other studies involving larger samples are necessary to cor
roborate such findings.#^dnd^i1#^tm^len^kepidemiology^i1#^tm^len^khuman papillom
avirus 16^i1#^tm^len^kbiomarkers^i1#^tm^len^kpharmacological^i1#other#20#2010081
0#8/10/2010#20101210#12/10/2010#FIPE#HCPA#CNPq#v15n2a06.htm##
02976000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400110014403500100015501202050
01650100035003700100037004050100025004420100042004670100035005090700148005440700
06400692070003400756070003300790083133100823085000802154085002502162085003602187
08500230222308500280224611700060227407200030228011200090228311100100229211400090
2302113001102311058000502322058000502327058000502332002001302337#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#
TAB#6#BJID230#nd#Braz J Infect Dis#15#2#20110400#^f126^l131#1413-8670#<b><i>Chla
mydia trachomatis</i></b><b> and human papillomavirus coinfection</b>: <b>associ
ation with p16INK4a and Ki67 expression in biopsies of patients with pre-neoplas
tic and neoplastic lesions</b>^len#^rND^1A01 A02^nLuciane Noal^sCalil#^rND^1A03^
nCristine Nascente^sIgansi#^rND^1A02^nLuise^sMeurer#^rND^1A04^nMaria Isabel Alba
no^sEdelweiss#^rND^1A04^nMary Clarisse^sBozzetti#Universidade Federal do Rio Gra
nde do Sul^iA01^1Post-graduate Program in Medical Sciences Faculty of Pharmacy P
ost-graduate Program in Epidemiology#Hospital de Clínicas de Porto Alegre^iA02^c
Porto Alegre^pBrazil#Brazilian Ministry of Health^iA03#UFRGS^iA04^cPorto Alegre^
pBrazil#^len^aThe objective of this study was to identify the frequency of coinf
ection by human papillomavirus (HPV) and <i>Chlamydia trachomatis</i> (CT) in ce
rvical lesions and relate it with immunohistochemical expression of p16INK4a and
 Ki67, both oncogenicity markers. A cross-sectional study with 86 women from pri
mary care units in southern Brazil was conducted. Cervical swabs were collected 
for HPV-DNA and CT-DNA detection, through the polymerase chain reaction techniqu
e (PCR). The immunohistochemical analysis was performed on biopsy cervical tissu
e material to identify the expression of p16INK4a and Ki67 cell cycle markers. A
bout 83 % were positive for HPV-DNA and 19% had coinfection with CT-DNA. Among c
oinfected women, 56% expressed p16INK4a. There was a statistically significant a
ssociation between the histological grade of the lesion and Ki67 expression. All
 high-grade lesions, 50% of low-grade lesions and 31% of negative biopsies expre
ssed Ki67 (p = 0.004). A total of 37% of coinfected women expressed both markers
. In conclusion, although more than half of the coinfected patients have express
ed p16INK4a and more than one third have expressed both markers, these results s
uggest no association between those variables. However, other studies involving 
larger samples are necessary to corroborate such findings.#^dnd^i1#^tm^len^kepid
emiology^i1#^tm^len^khuman papillomavirus 16^i1#^tm^len^kbiomarkers^i1#^tm^len^k
pharmacological^i1#other#20#20100810#8/10/2010#20101210#12/10/2010#FIPE#HCPA#CNP
q#v15n2a06.htm##
03125000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000200117049000800119
15800030012703000210013003100030015103200020015406500090015601400110016503500100
01760120177001860100035003630100037003980100025004350100042004600100035005020700
15000537070006600687070003600753070003500789083136600824085000802190085002502198
08500360222308500230225908500280228211700060231007200030231611200090231911100100
23281140009023381130011023470580005023580580005023630580005023680020013023730080
08902386#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#l#4#1#article#1
#^mMar./Apr.^a2011#oa#en#br1.1#1#4.0#ilus#tab#6#BJID230#nd#Braz. j. infect. dis#
15#2#20110400#^f126^l131#1413-8670#Chlamydia trachomatis and human papillomaviru
s coinfection: association with p16INK4a and Ki67 expression in biopsies of pati
ents with pre-neoplastic and neoplastic lesions^len#^rND^1A01 A02^nLuciane Noal^
sCalil#^rND^1A03^nCristine Nascente^sIgansi#^rND^1A02^nLuise^sMeurer#^rND^1A04^n
Maria Isabel Albano^sEdelweiss#^rND^1A04^nMary Clarisse^sBozzetti#^iA01^1Univers
idade Federal do Rio Grande do Sul^2Post-graduate Program in Medical Sciences Fa
culty of Pharmacy Post-graduate Program in Epidemiology#^iA02^1Hospital de Clíni
cas de Porto Alegre^cPorto Alegre^pBrazil#^iA03^1Brazilian Ministry of Health#^i
A04^1UFRGS^cPorto Alegre^pBrazil#^len^aThe objective of this study was to identi
fy the frequency of coinfection by human papillomavirus (HPV) and Chlamydia trac
homatis (CT) in cervical lesions and relate it with immunohistochemical expressi
on of p16INK4a and Ki67, both oncogenicity markers. A cross-sectional study with
 86 women from primary care units in southern Brazil was conducted. Cervical swa
bs were collected for HPV-DNA and CT-DNA detection, through the polymerase chain
 reaction technique (PCR). The immunohistochemical analysis was performed on bio
psy cervical tissue material to identify the expression of p16INK4a and Ki67 cel
l cycle markers. About 83  percent were positive for HPV-DNA and 19 percent had 
coinfection with CT-DNA. Among coinfected women, 56 percent expressed p16INK4a. 
There was a statistically significant association between the histological grade
 of the lesion and Ki67 expression. All high-grade lesions, 50 percent of low-gr
ade lesions and 31 percent of negative biopsies expressed Ki67 (p = 0.004). A to
tal of 37 percent of coinfected women expressed both markers. In conclusion, alt
hough more than half of the coinfected patients have expressed p16INK4a and more
 than one third have expressed both markers, these results suggest no associatio
n between those variables. However, other studies involving larger samples are n
ecessary to corroborate such findings.#^dnd^i1#^tm^len^kepidemiology^i1#^tm^len^
khuman papillomavirus 16^i1#^tm^len^kbiomarkers^i1#^tm^len^kpharmacological^i1#o
ther#20#20100810#8/10/2010#20101210#12/10/2010#FIPE#HCPA#CNPq#v15n2a06.htm#Inter
net^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000200
006##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#5#1#article#110#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLE</b><
/font></p>     ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#6#2#article#110#<p>&nbsp;</p>     ^cY
#v15n2a06.htm##
00520000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704028700074002001300361#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#7#3#article#110#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b><i>Chlamydia trac
homatis</i> and human papillomavirus coinfection: association with p16INK4a and 
Ki67 expression in biopsies of patients with pre-neoplastic and neoplastic lesio
ns</b></font></p>     ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#8#4#article#110#<p>&nbsp;</p>     ^cY
#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#9#5#article#110#<p>&nbsp;</p>     ^cY
#v15n2a06.htm##
00501000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704026700075002001300342#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#10#6#article#110#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Luciane Noal Calil<sup>I</sup>; Cr
istine Nascente Igansi<sup>II</sup>; Luise Meurer<sup>III</sup>; Maria Isabel Al
bano Edelweiss<sup>IV</sup>; Mary Clarisse Bozzetti<sup>V</sup></b></font></p>  
   ^cY#v15n2a06.htm##
00561000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704032700075002001300402#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#11#7#article#110#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>PhD; Professor, Post-grad
uate Program in Medical Sciences, Faculty of Pharmacy, Post-graduate Program in 
Epidemiology at Universidade Federal do Rio Grande do Sul - UFRGS; Hospital de C
l&iacute;nicas de Porto Alegre - HCPA, Porto Alegre, Brazil    ^cY#v15n2a06.htm#
#
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704007900075002001300154#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#12#8#article#110#<br> <sup>II</sup>MS
c, PhD; Brazilian Ministry of Health Epidemiologist    ^cY#v15n2a06.htm##
00306000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704007200075002001300147#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#13#9#article#110#<br>   <sup>III</sup
>MD; Pathologist, HCPA, Porto Alegre, Brazil    ^cY#v15n2a06.htm##
00321000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008600076002001300162#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#14#10#article#110#<br>   <sup>IV</sup
>MD, PhD; Associated Professor, UFRGS, Porto Alegre, Brazil    ^cY#v15n2a06.htm#
#
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#15#11#article#110#<br>   <sup>V</sup>
MD, MSc, PhD; Associated Professor, UFRGS, Porto Alegre, Brazil</font></p>     ^
cY#v15n2a06.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#16#12#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a><
/font></p>     ^cY#v15n2a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#17#13#article#110#<p>&nbsp;</p>     ^
cY#v15n2a06.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#18#14#article#110#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v15n2a06.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#19#15#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
15n2a06.htm##
01642000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704140700076002001301483#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#20#16#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The objective of this study was to i
dentify the frequency of coinfection by human papillomavirus (HPV) and <i>Chlamy
dia trachomatis</i> (CT) in cervical lesions and relate it with immunohistochemi
cal expression of p16INK4a and Ki67, both oncogenicity markers. A cross-sectiona
l study with 86 women from primary care units in southern Brazil was conducted. 
Cervical swabs were collected for HPV-DNA and CT-DNA detection, through the poly
merase chain reaction technique (PCR). The immunohistochemical analysis was perf
ormed on biopsy cervical tissue material to identify the expression of p16INK4a 
and Ki67 cell cycle markers. About 83 % were positive for HPV-DNA and 19% had co
infection with CT-DNA. Among coinfected women, 56% expressed p16INK4a. There was
 a statistically significant association between the histological grade of the l
esion and Ki67 expression. All high-grade lesions, 50% of low-grade lesions and 
31% of negative biopsies expressed Ki67 (p = 0.004). A total of 37% of coinfecte
d women expressed both markers. In conclusion, although more than half of the co
infected patients have expressed p16INK4a and more than one third have expressed
 both markers, these results suggest no association between those variables. How
ever, other studies involving larger samples are necessary to corroborate such f
indings.</font></p>     ^cY#v15n2a06.htm##
00424000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018900076002001300265#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#21#17#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> epidemiology; human
 papillomavirus 16; biomarkers; pharmacological.</font></p> <hr size="1" noshade
>     ^cY#v15n2a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#22#18#article#110#<p>&nbsp;</p>     ^
cY#v15n2a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#23#19#article#110#<p>&nbsp;</p>     ^
cY#v15n2a06.htm##
00615000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038000076002001300456#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#24#20#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Each year, approximately 493,000 new
 cases of cervical cancer are diagnosed worldwide and approximately 273,000 wome
n die from the disease, making it the second most frequent cancer in women and t
he second leading cause of cancer-related death worldwide among women 15 to 44 y
ears old.<sup>1</sup></font></p>     ^cY#v15n2a06.htm##
00745000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051000076002001300586#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#25#21#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Chlamydia trachomatis</i> (CT) is
 the most common bacterial sexually transmitted infection (STI) worldwide.<sup>2
</sup> Bacterial coinfection by CT in women with a history of HPV infection has 
been studied as a potential factor that contributes to the development of malign
acies and cervical cancer. Some authors<sup>3</sup> have suggested that previous
 CT infection is associated with a high risk of developing the disease.</font></
p>     ^cY#v15n2a06.htm##
00884000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064900076002001300725#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#26#22#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The p16INK4a is a cyclin-dependent k
inase inhibitor (CDK) that reduces the cell cycle's speed by controlling the exp
ression of E2F transcription factor. High-grade infection by HPV is involved in 
the carcinogenesis and, HPV integration in the human genome results in overexpre
ssion of E6 and E7 viral oncoproteins.<sup>4</sup> E7 HPV protein interacts with
 retinoblastoma protein (pRb) and neutralizes the function of these proteins, re
sulting in the release of E2F transcription factor of the pRb-E2F complex. E2F a
ccumulation induces p16INK4a activity.<sup>5</sup></font></p>     ^cY#v15n2a06.h
tm##
01386000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704115100076002001301227#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#27#23#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Results of a study<sup>6</sup> showe
d that none of the negative cervical tissues were positive for p16INK4a, while t
here was a constant and significant increase in the positivity of this marker, a
ccording to histological grade, where cervical intraepithelial neoplasia (CIN) 1
 had 31% positivity, 90% in CIN 2 and 100% in CIN 3 and carcinomas (p &lt; 0.000
1). Thus, p16INK4a overexpression has consistently shown high sensitivity (84%) 
and specificity (98%) to detect the high-risk HPV with a high positive predictiv
e value (97%). Ki67 monoclonal antibody reacts with a non-histone nuclear protei
n that is expressed in the nucleus of proliferating cells through the cell cycle
, except in G0 and in early G1 phase. Some authors<sup>7</sup> have shown a rela
tionship between Ki67, lesion severity or growth rate, and its utility in the st
udy of vulvar and vaginal lesions caused by HPV. Therefore, the determination of
 Ki67 seems to be a relevant additional and complementary examination in the det
ection and distinction of different lesion grades of the uterine cervix.</font><
/p>     ^cY#v15n2a06.htm##
00758000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052300076002001300599#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#28#24#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">It is known that high-risk HPV, thro
ugh oncoproteins, can deplete the action of suppressor genes like the p53 and pR
b, causing overexpression of CDK inhibitors. However, in coinfected patients (HP
V/CT), this effect has not yet been studied. The purpose of this study was to ve
rify p16INK4a and Ki67 immunohistochemical expression in women with positive HPV
-DNA and/or CT-DNA who attended the primary health care services in southern Bra
zil.</font></p>     ^cY#v15n2a06.htm##
01479000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704124400076002001301320#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#29#25#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This was a cross-sectional study tha
t enrolled 86 women from primary care services, selected from participants of a 
cohort study<sup>8</sup> started in February 2003. This sample included women wh
o were tested for HPV-DNA/CT-DNA and performed uterine cervix biopsy for histopa
thological analysis. HPV-DNA and CT-DNA detection in uterine cervical samples we
re performed through the PCR technique. DNA extraction from material collected w
ith cervical-vaginal swabs was carried out using the proteinase K protocol.<sup>
9</sup> The technique was directed to the L1 gene and the primers used were My09
 and My11. PCR conditions were described by Bauer <i>et al.</i> (1993) and Coutl
&eacute;e <i>et al.</i> (2002). For the PCR reaction internal control, </font>&#
946;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">-globin primers 
were used and tested in all samples.<sup>10,11</sup> For CT-DNA, the technique w
as standardized by Becker D<sup>9</sup> using the CTP1 and CTP2 primers that amp
lify a 201pb segment of the ORF number 4 of the cryptic <i>Chlamydia trachomatis
</i> plasmid. This segment is situated 2940pb from the single BamHI restriction 
site:</font></p>     ^cY#v15n2a06.htm##
00355000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012000076002001300196#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#30#26#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">CTP1 5'... TAGTAACTGCCACTTCATCA... 3
'</font></p>     ^cY#v15n2a06.htm##
00355000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012000076002001300196#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#31#27#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">CTP2 5'... TTCCCCTTGTAATTCGTTGC... 3
'</font></p>     ^cY#v15n2a06.htm##
01722000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704148700076002001301563#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#32#28#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In order to control the reactions, a
long with each DNA PCR of clinical samples, a positive control was tested, which
 consisted of a 450bp fragment corresponding to Caski and Siha cells, a 201bp fr
agment corresponds to cells infected by CT; and a negative control with the omis
sion of any DNA. In all tested samples for HPV PCR and CT PCR, multiplex PCR wer
e performed using specific primers for each microorganism and primers complement
ing the human </font>&#946;<font size="2" face="Verdana, Arial, Helvetica, sans-
serif">-globin gene (gH20 and PC04). </font>&#946;<font size="2" face="Verdana, 
Arial, Helvetica, sans-serif">-globin primers were used to verify the viability 
of tested DNA. All positive samples in the HPV-DNA screening were tested for hig
h risk (HR) HPV types (HPV16, 18, 31), using specific primers. The amplification
 conditions and the primers used are based on the methodology described by Cuzic
k <i>et al.</i><sup>12</sup> and are HPV-16 (5'...GC GAT CCT GTC TGC TTT TAT ACT
 AA...3' &#91;sense&#93;; 5'...AAG GCC AAC TAA ATG TCA C...3' &#91;antisense&#93
;) and the temperature was 54ºC; HPV-18 (5'...TGC AGC ACG AAT GGC ACT GGC CTG...
3' &#91;sense&#93;; 5'...CAC GGC GAC CCT ACA AGC TAC CTG...3' &#91;antisense&#93
;), temperature was 70ºC. For HPV-31 (31A 5'...TACCTGTGTTTCTGTTAAC...3' &#91;sen
se&#93;; S5'...AGAAAGACCTCGGAAATTG...' &#91;antisense&#93;)and the temperature w
as 52ºC.</font></p>     ^cY#v15n2a06.htm##
00817000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058200076002001300658#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#33#29#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The paraffin blocks of biopsy materi
al have been stained by the hematoxylin-eosin technique for histological classif
ication, as follows: LSIL, HSIL, where LSIL category included the results with C
IN1, and HSIL the findings with CIN 2 and 3 diagnoses. Absence of malignant alte
rations was reported when no abnormalities were observed. Later, the cases were 
reviewed by trained pathologists (MIE and LM) from Hospital de Cl&iacute;nicas d
e <i>Porto Alegre</i> (HCPA), in Porto Alegre, southern Brazil.</font></p>     ^
cY#v15n2a06.htm##
00716000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048100076002001300557#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#34#30#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The paraffin blocks were cut, depara
ffinized in xylene and then rehydrated. Antigen retrieval was made in citrate bu
ffer pH 6.0 and, later taken to microwave for 20 minutes. The sections were plac
ed at room temperature and washed three times with phosphate buffer. After the e
ndogenous peroxidase blockage, the sections were rehydrated and the slides were 
submitted to immunohistochemistry process.</font></p>     ^cY#v15n2a06.htm##
01075000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084000076002001300916#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#35#31#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The antibodies used were p16INK4a, "
Neomarkers, CA, USA", clone 16P07 at a dilution of 1:75 and antiKi67, "DAKO, Glo
strup, Denmark", clone MIB-1, at a dilution of 1:30. The p16INK4a pattern expres
sion for squamous intraepithelial lesions (SIL) was graduated as suggested in Bu
lten J. <i>et al.:</i><sup>13</sup> negative (-) if none of the cells were color
ed; positive (+, weak) if the percentage of expressing cells ranged between 1-25
%; (++, moderate) if the percentage ranged between 26-75%; and (+++, strong) if 
over 75% of the cells were colored, both in the cytoplasm and nucleus. The cells
' expression pattern was divided into focal if the expression was concentrated i
n some areas, and diffuse if the expression was distributed throughout the slide
.</font></p>     ^cY#v15n2a06.htm##
00584000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034900076002001300425#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#36#32#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ki67 was considered positive if the 
cell's nucleus was brown-colored. In all samples, 100 to 200 cells were counted 
and the results were expressed in percentage. All samples were evaluated by two 
pathologists (MIE e LM) and, when necessary, they reached a consensus.</font></p
>     ^cY#v15n2a06.htm##
00964000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072900076002001300805#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#37#33#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The study outcomes were genital infe
ction by HPV and/or <i>Chlamydia trachomatis</i> and histopathological diagnosis
 of uterine cervical lesions. The relation of p16INK4a and Ki67 expression in ce
rvical lesions of women infected by HPV and <i>Chlamydia trachomatis</i> p16INK4
a and Ki67 expressions to such outcomes were assessed. The independent variables
 studied included demographic characteristics, sexual behavior, reproductive dat
a and previous morbidities. Data was stored in a database by double-entry, where
 20% of the questionnaires were selected at random and compared to the original.
 Possible errors and discrepancies were corrected.</font></p>     ^cY#v15n2a06.h
tm##
00779000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054400076002001300620#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#38#34#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Chi-square test or Fisher's exact te
st when indicated were used to compare categorical variables. Continuous variabl
es were analyzed using the student's t test and ANOVA. The findings with p-value
 <u>&lt;</u> 0.05 were considered statistically significant. Sensitivity, specif
icity and the positive and negative predictive values for both markers, using th
e histological results as gold-standard, were calculated with the correspondent 
95% confidence intervals.</font></p>     ^cY#v15n2a06.htm##
00686000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045100076002001300527#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#39#35#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A total of 86 patients were analyzed
, among which 83% (71/86) were positive for HPV-DNA and 19% (16/86) for CT-DNA. 
All women with positive CT-DNA were also positive for HPV-DNA (p = 0.06). About 
40% (34/86) were positive for HR-HPV, among which 37% (6/34) were positive for C
T-DNA. The most frequent HR-HPV was HPV-16 (50%), followed by HPV-31 (38%) and H
PV-18 (12%).</font></p>     ^cY#v15n2a06.htm##
00540000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030500076002001300381#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#40#36#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#tab1">Table 1</a> describe
s the characteristics of women who presented coinfection (HPV-DNA and CT-DNA). T
here was noted a statistically significant association between coinfection and e
ducation level (p = 0.04).</font></p>     ^cY#v15n2a06.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#41#37#article#110#<p><a name="tab1"><
/a></p>     ^cY#v15n2a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#42#38#article#110#<p>&nbsp;</p>     ^
cY#v15n2a06.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#43#39#article#110#<p align="center"><
img src="/img/revistas/bjid/v15n2/a06tab01.jpg"></p>     ^cY#v15n2a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#44#40#article#110#<p>&nbsp;</p>     ^
cY#v15n2a06.htm##
00424000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018900076002001300265#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#45#41#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">No statistically significant associa
tion was observed between lesion histology and coinfection (p = 0.75).</font></p
>     ^cY#v15n2a06.htm##
00829000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059400076002001300670#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#46#42#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In the immunohistochemical analysis,
 56% of the coinfected patients expressed p16INK4a, (p = 0.38), which ranged fro
m moderate to strong in approximately 37% and the expression pattern was diffuse
 in 50%. In HPV-DNA positive biopsies, 78% expressed p16INK4a, ranging from mode
rate to strong in 54% and with a diffuse pattern in 56%. Regarding histology, 83
% of the high-grade lesions expressed p16INK4a. Among low-grade lesions and nega
tive biopsies, 72% and 60% expressed this protein, respectively (p = 0.43).</fon
t></p>     ^cY#v15n2a06.htm##
00447000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021200076002001300288#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#47#43#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">About 50% (8/16) of coinfected women
 expressed Ki67 antibody. In HPV infected women, this antibody was present in 38
% (p = 0.73).</font></p>     ^cY#v15n2a06.htm##
00545000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031000076002001300386#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#48#44#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">There was a statistically significan
t association between the grade of lesion histology and Ki67 expression, which w
as expressed in 100% of high-grade lesions, 50% of low-grade lesions and 31% of 
negative biopsies  (p = 0.004).</font></p>     ^cY#v15n2a06.htm##
00438000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020300076002001300279#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#49#45#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Approximately 37% (p = 0.31) of coin
fected women and 29% (p = 0.16) of those without coinfection expressed both mark
ers.</font></p>     ^cY#v15n2a06.htm##
00689000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045400076002001300530#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#50#46#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In relation to lesion histology amon
g coinfected patients, the sensitivity of p16INK4a was 25% (95%CI: 0.7-49.3%), t
he specificity, 72.9% (95%CI: 61.7- 84%), PPV, 17.4% (95%CI: 0-35%) and NPV of 8
1% (95%CI: 70.5-91.40%). Regarding Ki67, the sensitivity was 50% (95%CI: 23-78.0
%), specificity, 66% (95%CI: 54-79%), PPV de 25% (95CI%: 8.4-42%), and NPV 85% (
95%CI: 75-96%).</font></p>     ^cY#v15n2a06.htm##
00478000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024300076002001300319#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#51#47#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="/img/revistas/bjid/v15n2/a0
6tab02.jpg">Table 2</a> describes the distribution of the number of cells (%) th
at expressed both p16INK4a and Ki67 markers.</font></p>     ^cY#v15n2a06.htm##
00686000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045100076002001300527#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#52#48#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Studies have shown that the HPV is a
n important factor for the development of cervical precursor lesions and cancer;
 however, cofactors such as age, use of oral contraceptives, other hormones, par
ity, smoking and previous exposure to other sexually transmitted agents, such as
 <i>Clamydia trachomatis</i> and herpes simplex virus 2, have been mentioned.<su
p>1,14</sup></font></p>     ^cY#v15n2a06.htm##
00889000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065400076002001300730#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#53#49#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">CT is necessarily an intracellular a
gent that infects epithelial cells of the genital tract and the ocular tissue. I
t is one of the most common infection worldwide with 89 million new cases/year.<
sup>15</sup> Asymptomatic infection is common, but nonetheless it is considered 
as a cause of morbidity in sexually active women, causing severe sequelae such a
s pelvic inflammatory disease, ectopic pregnancy and tubal infertility. It is al
so associated with hypertrophy and induction of metaplasia, suggesting that it m
ay have a role in cervical cancerogenesis.<sup>15</sup></font></p>     ^cY#v15n2
a06.htm##
00889000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065400076002001300730#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#54#50#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In addition, there are evidences tha
t HPV-infected women present a higher risk to contract another infection, like C
T infection.<sup>3</sup> In the present study, the frequency of HPV infection wa
s of 83% and CT infection 19%. These rates are higher than previous reports,<sup
>16</sup> possibly because this was a high risk sample, provided that every wome
n had undergone cervical biopsy. A previous report<sup>16</sup> found an 8% prev
alence of CT infection and significantly associated with high risk HPV (OR = 2.5
, p &lt; 0.005), especially in women over 41 years old.</font></p>     ^cY#v15n2
a06.htm##
00803000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056800076002001300644#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#55#51#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Education was significantly associat
ed with coinfection in the present study. It maybe suggested that education may 
interfere in the level of knowledge about risk factors, exposure and information
 about means of prevention. A higher risk of infection was also observed in the 
HPV-infected patients.<sup>15</sup> In relation to the viral types tested, the p
resent study shows that HPV-16 was the most frequent high-risk viral type, which
 is in agreement with other authors.<sup>15</sup></font></p>     ^cY#v15n2a06.ht
m##
00779000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054400076002001300620#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#56#52#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A study<sup>17</sup> that enrolled 5
,328 women, aged between 15-44 years, in eight countries presented a CT infectio
n prevalence of 0.2% (95%CI: 0.0-0.7%) in Spain and 5.6% (95%CI 3.4-7.8%) in Nig
eria, being higher in the age range between 15-24 years (4.5, 95%CI: 3.4-8.0%) t
han the age range of 25-44 years (2.6, 95%CI: 2.1-3.1). The same investigators<s
up>17</sup> believe that such prevalence data are low and do not express the rea
lity for high-risk women.</font></p>     ^cY#v15n2a06.htm##
01264000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704102900076002001301105#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#57#53#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">De Paula <i>et al.</i><sup>18</sup> 
investigated the presence of CT-DNA and HPV-DNA in 250 cervical-vaginal samples 
of normal patients or patients with cytological alterations. Among them, 70% wer
e negative, 40% were HPV-DNA positive and 5.2% had a positive diagnosis of CT in
fection. Among samples with abnormal cytology, HPV-DNA was detected in 73.3% and
 CT-DNA, in 9.33%. The higher coinfection rate, 15.4%, was found in samples diag
nosed as atypical squamous cells/glandular cells of undetermined significance. A
n association between HPV infection and cytological alterations was verified; ho
wever, for CT infection or coinfection, such association was not observed. Takin
g that into account and relating it to the results found in the present study, i
t can be suggested that the association was not verified due to the low number o
f CT cases. However, it can be noticed that only 4/16 (25%) of the cases had coi
nfection and normal histology.</font></p>     ^cY#v15n2a06.htm##
00706000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047100076002001300547#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#58#54#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In a study<sup>19</sup> with 114 cas
es, where 72 were incident and 42 were prevalent at the study entrance, HPV-16 s
eropositivity was associated with cervical cancer (OR = 6.33, 95% CI: 3.45-11.62
). In general, the CT infection was not associated with the cervical cancer; how
ever, there was an association when incidental cases were evaluated (OR = 2.94, 
95% CI: 1.16-8.47).<sup>19</sup></font></p>     ^cY#v15n2a06.htm##
01071000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083600076002001300912#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#59#55#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The p16INK4a expression has been men
tioned<sup>5,6</sup> as a promising marker for HR-HPV-induced lesions. However, 
studies did not evaluate if its expression is increased in HPV and CT coinfectio
n. In HPV positive patients, 78.2% expressed the protein, where the intensity wa
s moderate to strong in 54.5% of the cases and the pattern was diffuse in 56.4%,
 as expected. The p16INK4a appeared as overexpressed by the interaction of high-
risk HPV E7 oncoprotein and the pRb, resulting in the release of the E2F transcr
iption factor. This interaction is analogous to the CDK-mediated phosphorylation
, resulting in the p16INK4a inhibitor accumulation. However, among patients with
 coinfection in the present study, the p16INK4a expression occurred in 56.3%.</f
ont></p>     ^cY#v15n2a06.htm##
00976000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074100076002001300817#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#60#56#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Ki67 is a proliferation antigen that
 has been related to carcinogenesis in different tumor types. High-risk HPV infe
ctions and cell cycle alterations with higher Ki67 expression have been mentione
d.<sup>9,10</sup> CT infection has been suggested as a risk factor for HPV and, 
consequently for carcinogenesis.<sup>3,14</sup> The objective of the present stu
dy was to verify if coinfection increases proliferation, through Ki67 determinat
ion in relation to HPV infection, provided that studies verifying this associati
on were not found in literature. In this study, Ki67 was expressed in 50% of the
 coinfected cases and in 34% of the positive cases of HPV-DNA.</font></p>     ^c
Y#v15n2a06.htm##
01165000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093000076002001301006#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#61#57#article#110#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Through this immunohistochemical ana
lysis, we had intended to investigate if some of these markers or the combinatio
n of both could suggest a larger association in the patients with coinfection. N
o significant difference was found in the p16INK4a and Ki67 expression in patien
ts with coinfection, in relation to HPV-DNA positivity alone. Just like the resu
lts observed by Feh&eacute;r and Szalm&aacute;z,<sup>20</sup> our findings sugge
st that the presence of CT infection does not seem to be associated with cervica
l carcinogenesis. Thus, although more than a half of the coinfected patients exp
ressed p16INK4a and more than one third expressed both markers studied, the resu
lts suggest no association between these variables. However, other studies invol
ving larger samples are necessary to corroborate such findings in a more conclus
ive manner.</font></p>     ^cY#v15n2a06.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#62#58#article#110#<p>&nbsp;</p>     ^
cY#v15n2a06.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#63#59#article#110#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p> 
    ^cY#v15n2a06.htm##
00461000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021200078002001300290#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#64#60#article#110#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Velicer C, Zhu X, V
uocolo S <i>et al.</i> Prevalence and incidence of HPV genital infection in wome
n. Sex Transm Dis 2009; 36(11):696-703.    ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#65#61#article#110#</font></p>     ^cY
#v15n2a06.htm##
00596000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704034700078002001300425#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#66#62#article#110#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Bilardi FJ, Fairley
 CK, Hopkins CA <i>et al.</i> Experiences and Outcomes of partner notification a
mong men and women recently diagnosed with <i>Chlamydia</i> and their views on i
nnovative resources aimed at improving notification rates. Sex Transm Dis 2010; 
37(4):253-258.    ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#67#63#article#110#</font></p>     ^cY
#v15n2a06.htm##
00517000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026800078002001300346#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#68#64#article#110#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Wallin KL, Wiklund 
F, Luostarinen T <i>et al.</i> A population-based prospective study of <i>Chlamy
dia trachomatis</i> infection and cervical cancer carcinoma. Int J Cancer 2002; 
101(4):371-374.    ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#69#65#article#110#</font></p>     ^cY
#v15n2a06.htm##
00489000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024000078002001300318#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#70#66#article#110#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Doeberitz VK. New m
arkers for cervical dysplasia to visualise the genomic chaos created by oncogeni
c human papillomavirus infections. Eur J Cancer 2002; 38:2229-2242.    ^cY#v15n2
a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#71#67#article#110#</font></p>     ^cY
#v15n2a06.htm##
00527000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027800078002001300356#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#72#68#article#110#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Queiroz C, Silva TC
, Alves VAF <i>et al.</i> p16INK4a and Ki67 expression as a potential prognostic
 marker in ceical pre-neoplastic and neoplastic lesions. Pathology Research and 
Practice 2006; 202:77-83.    ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#73#69#article#110#</font></p>     ^cY
#v15n2a06.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026400078002001300342#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#74#70#article#110#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Benevolo M, Mottole
se M, Marandino F <i>et al.</i> Immunohistochemical expression of p16INK4a is pr
edictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol 2006; 19(
3):384-391.    ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#75#71#article#110#</font></p>     ^cY
#v15n2a06.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029500078002001300373#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#76#72#article#110#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Sarian LO, Derchain
 SF, Yoshida A <i>et al.</i> Expression of cycloxygenase-2 (COX-2) and Ki67 as r
elated to disease severity and HPV detection in squamous lesions of the cervix. 
Gynecologic Oncology 2006; 102(3):537-541.    ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#77#73#article#110#</font></p>     ^cY
#v15n2a06.htm##
00519000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027000078002001300348#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#78#74#article#110#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Rosa MI, Fachel JM,
 Rosa DD <i>et al.</i> Persistence and clearance of human papillomavirus infecti
on: a prospective cohort study. Am J Obstet Gynecol. 2008 Dec;199(6):617. e1-7. 
Epub 2008 Sep 16.    ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#79#75#article#110#</font></p>     ^cY
#v15n2a06.htm##
00649000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704040000078002001300478#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#80#76#article#110#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Becker D. Detec&cce
dil;&atilde;o de <i>Chlamydia trachomatis</i> em amostras cervicais por Rea&cced
il;&atilde;o em cadeia da Polimerase (Disserta&ccedil;&atilde;o de Mestrado). Po
rto Alegre: Universidade Federal do Rio Grande do Sul, Programa de P&oacute;s-Gr
adua&ccedil;&atilde;o em Biologia Celular e Molecular. 2005. P. 90.    ^cY#v15n2
a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#81#77#article#110#</font></p>     ^cY
#v15n2a06.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025300079002001300332#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#82#78#article#110#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Bauer HM, Hildesh
eim A, Schiffman MH <i>et al.</i> Determinants of genital human papillomavirus i
nfection in low-risk women in Portland, Oregon. Sex Transm Dis 1993; 20(5):274-8
.    ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#83#79#article#110#</font></p>     ^cY
#v15n2a06.htm##
00514000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026400079002001300343#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#84#80#article#110#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Coutlee F, Gravit
t P, Kornegay J <i>et al.</i> Use of PGMY primers in L1 consensus PCR improves d
etection of human papillomavirus DNA in genital samples. J Clin Microbiol 2002; 
40(3):902-7.    ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#85#81#article#110#</font></p>     ^cY
#v15n2a06.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026600079002001300345#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#86#82#article#110#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Cuzick J, Terry G
, Ho L <i>et al.</i> Type-specific human papillomavirus DNA in abnormal smears a
s a predictor of high-grade cervical intraepithelial neoplasia.Br J Cancer 1994;
 69(1):167-71.    ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#87#83#article#110#</font></p>     ^cY
#v15n2a06.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028200079002001300361#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#88#84#article#110#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Bulten J, van der
 Avoort IA, Melchers WJ <i>et al.</i> p14ARF and p16INK4a, two products of the s
ame gene, are differently expressed in cervical intraepithelial neoplasia. Gynec
ol Oncol 2006; 101(3):487-494.    ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#89#85#article#110#</font></p>     ^cY
#v15n2a06.htm##
00451000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020100079002001300280#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#90#86#article#110#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Bosh FX, de San J
ose S. The epidemiology of human papilomavirus infection and cervical cancer. Di
s Markers 2007; 23(4):213-17.    ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#91#87#article#110#</font></p>     ^cY
#v15n2a06.htm##
00538000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028800079002001300367#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#92#88#article#110#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. De Lucca G.D, Mar
in H, Schelover E <i>et al.</i> Infeccion por <i>Chlamydia trachomatis</i> y Pap
ilomavirus en mujeres con alteraciones citohistologicas de cuello uterino. Medic
ina (Buenos Aires) 2006; 66:303-306.    ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#93#89#article#110#</font></p>     ^cY
#v15n2a06.htm##
00552000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704030200079002001300381#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#94#90#article#110#16#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Denks K, Spaeth E
L, J&eacute;rs K <i>et al.</i> Coinfection of <i>Chlamydia trachomatis, Uresplas
ma urealyticum</i> and human papillomavirus among patients attending STD clinics
 in Estonia. Scand J Infect Dis 2007; 39(8):714-8.    ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#95#91#article#110#</font></p>     ^cY
#v15n2a06.htm##
00567000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704031700079002001300396#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#96#92#article#110#17#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Franceschi S, Smi
th JS, Van den Brule A <i>et al.</i> Cervical infection with <i>Chlamydia tracho
matis</i> and <i>Neisseria gonorrhoeae</i> in women from ten areas in four conti
nents. A cross-sectional study. Sex Transm Dis 2007; 34(8):563-9.    ^cY#v15n2a0
6.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#97#93#article#110#</font></p>     ^cY
#v15n2a06.htm##
00555000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704030500079002001300384#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#98#94#article#110#18#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. De Paula FD, Fern
andes AP, Carmo BB <i>et al.</i> Molecular detection of <i>Chlamydia trachomatis
</i> and HPV infections in cervical samples with normal and abmormal cytopatholo
gical findings. Diagn Cytopathol 2007; 35(4):198-202.    ^cY#v15n2a06.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#99#95#article#110#</font></p>     ^cY
#v15n2a06.htm##
00528000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704027700080002001300357#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#100#96#article#110#19#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Naucler P, Chen 
NC, Persson K <i>et al.</i> Seroprevalence of Human Papillomaviruses and <i>Chla
mydia trachomatis</i> and cervical cancer risk: nested case-control study. J Gen
 Virol 2007; 88(3):814-22.    ^cY#v15n2a06.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#101#97#article#110#</font></p>     ^c
Y#v15n2a06.htm##
00545000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704029400080002001300374#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#102#98#article#110#20#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Feh&eacute;r E, 
Szalm&aacute;s A. Prevalence of <i>Chlamydia trachomatis</i> and oncogenic human
 papillomavirus types in cytologic atypia of the uterine cervix. Acta Microbiol 
Immunol Hung 2006; 53(4):479-87</font></p>     ^cY#v15n2a06.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002200077002001300099#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#103#99#article#110#<p>&nbsp;</p>     
^cY#v15n2a06.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#104#100#article#110#<p>&nbsp;</p>    
 ^cY#v15n2a06.htm##
00426000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018900078002001300267#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#105#101#article#110#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:
</b>    ^cY#v15n2a06.htm##
00268000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003100078002001300109#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#106#102#article#110#<br> Luciane Noal
 Calil    ^cY#v15n2a06.htm##
00307000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007000078002001300148#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#107#103#article#110#<br> Avenida Ipir
anga, 2752, 3º Andar, Laborat&oacute;rio 304D    ^cY#v15n2a06.htm##
00289000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005200078002001300130#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#108#104#article#110#<br> 90610-000, R
io Branco, Porto Alegre, RS    ^cY#v15n2a06.htm##
00293000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005600078002001300134#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#109#105#article#110#<br> Fax: +55 51 
33085437 Phone: +55 51 33085276    ^cY#v15n2a06.htm##
00326000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008900078002001300167#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#110#106#article#110#<br> <a href="mai
lto:luciane1011@gmail.com">luciane1011@gmail.com</a></font></p>     ^cY#v15n2a06
.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009300078002001300171#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#111#107#article#110#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted on 8/10/2010    ^cY#v15n
2a06.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#112#108#article#110#<br>   Approved o
n: 12/10/2010    ^cY#v15n2a06.htm##
00290000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005300078002001300131#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#113#109#article#110#<br>   Financial 
Support: FIPE/ HCPA and CNPq    ^cY#v15n2a06.htm##
00299000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006200078002001300140#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a06.htm#S#p#114#110#article#110#<br>   We declare
 no conflict of interest.</font></p>     ^cY#v15n2a06.htm##
00597000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100013000940100
01700107810000600124012006300130030001500193065000900208064000500217031000300222
032000300225014000800228865000900236002001300245035001000258801001500268#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#115#1#article#20#1#^rND^sVeli
cer^nC#^rND^sZhu^nX#^rND^sVuocolo^nS#et al#Prevalence and incidence of HPV genit
al infection in women^len#Sex Transm Dis#20090000#2009#36#11#696-703#20110400#v1
5n2a06.htm#0148-5717#Sex Transm Dis##
00725000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100018000950100
01800113810000600131012018500137030001500322065000900337064000500346031000300351
032000200354014000800356865000900364002001300373035001000386801001500396#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#116#2#article#20#2#^rND^sBila
rdi^nFJ#^rND^sFairley^nCK#^rND^sHopkins^nCA#et al#Experiences and Outcomes of pa
rtner notification among men and women recently diagnosed with Chlamydia and the
ir views on innovative resources aimed at improving notification rates^len#Sex T
ransm Dis#20100000#2010#37#4#253-258#20110400#v15n2a06.htm#0148-5717#Sex Transm 
Dis##
00644000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
02100111810000600132012010600138030001300244065000900257064000500266031000400271
032000200275014000800277865000900285002001300294035001000307801001300317#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#117#3#article#20#3#^rND^sWall
in^nKL#^rND^sWiklund^nF#^rND^sLuostarinen^nT#et al#A population-based prospectiv
e study of Chlamydia trachomatis infection and cervical cancer carcinoma^len#Int
 J Cancer#20020000#2002#101#4#371-374#20110400#v15n2a06.htm#0020-7136#Int J Canc
er##
00571000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770120123000970300
01300220065000900233064000500242031000300247014001000250865000900260002001300269
035001000282801001300292#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S
#c#118#4#article#20#4#^rND^sDoeberitz^nVK#New markers for cervical dysplasia to 
visualise the genomic chaos created by oncogenic human papillomavirus infections
^len#Eur J Cancer#20020000#2002#38#2229-2242#20110400#v15n2a06.htm#0014-2964#Eur
 J Cancer##
00617000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
01700110810000600127012011400133030003200247710000200279065000900281064000500290
031000400295014000600299865000900305002001300314#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a06.htm#S#c#119#5#article#20#5#^rND^sQueiroz^nC#^rND^sSilva^nTC#^
rND^sAlves^nVAF#et al#p16INK4a and Ki67 expression as a potential prognostic mar
ker in ceical pre-neoplastic and neoplastic lesions^len#Pathology Research and P
ractice#2#20060000#2006#202#77-83#20110400#v15n2a06.htm##
00645000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100019000950100
01900114810000600133012011100139030001100250065000900261064000500270031000300275
032000200278014000800280865000900288002001300297035001000310801001100320#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#120#6#article#20#6#^rND^sBene
volo^nM#^rND^sMottolese^nM#^rND^sMarandino^nF#et al#Immunohistochemical expressi
on of p16INK4a is predictive of HR-HPV infection in cervical low-grade lesions^l
en#Mod Pathol#20060000#2006#19#3#384-391#20110400#v15n2a06.htm#0893-3952#Mod Pat
hol##
00686000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100019000940100
01700113810000600130012013400136030002100270065000900291064000500300031000400305
032000200309014000800311865000900319002001300328035001000341801002100351#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#121#7#article#20#7#^rND^sSari
an^nLO#^rND^sDerchain^nSF#^rND^sYoshida^nA#et al#Expression of cycloxygenase-2 (
COX-2) and Ki67 as related to disease severity and HPV detection in squamous les
ions of the cervix^len#Gynecologic Oncology#20060000#2006#102#3#537-541#20110400
#v15n2a06.htm#0090-8258#Gynecologic Oncology##
00655000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100017000920100
01500109810000600124012009200130030002000222031000400242032000200246020000400248
01400040025206500090025606400120026586500090027700200130028603500100029980100200
0309#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#122#8#article#20#
8#^rND^sRosa^nMI#^rND^sFachel^nJM#^rND^sRosa^nDD#et al#Persistence and clearance
 of human papillomavirus infection: a prospective cohort study^len#Am J Obstet G
ynecol#199#6#617#1-7#20080916#2008 Sep 16#20110400#v15n2a06.htm#0002-9378#Am J O
bstet Gynecol##
00604000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160016000770180095000930510
00900188046001300197050010100210045000900311044000500320020000300325865000900328
002001300337#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#123#9#art
icle#20#9#^rND^sBecker^nD#Detecção de Chlamydia trachomatis em amostras cervicai
s por Reação em cadeia da Polimerase^lpt#Mestrado#Porto Alegre#Universidade Fede
ral do Rio Grande do Sul^dPrograma de Pós-Graduação em Biologia Celular e Molecu
lar#20050000#2005#90#20110400#v15n2a06.htm##
00639000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100020000950100
02000115810000600135012009700141030001500238065000900253064000500262031000300267
032000200270014000600272865000900278002001300287035001000300801001500310#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#124#10#article#20#10#^rND^sBa
uer^nHM#^rND^sHildesheim^nA#^rND^sSchiffman^nMH#et al#Determinants of genital hu
man papillomavirus infection in low-risk women in Portland, Oregon^len#Sex Trans
m Dis#19930000#1993#20#5#274-8#20110400#v15n2a06.htm#0148-5717#Sex Transm Dis##
00652000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01800113810000600131012011000137030001700247065000900264064000500273031000300278
032000200281014000600283865000900289002001300298035001000311801001700321#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#125#11#article#20#11#^rND^sCo
utlee^nF#^rND^sGravitt^nP#^rND^sKornegay^nJ#et al#Use of PGMY primers in L1 cons
ensus PCR improves detection of human papillomavirus DNA in genital samples^len#
J Clin Microbiol#20020000#2002#40#3#902-7#20110400#v15n2a06.htm#0095-1137#J Clin
 Microbiol##
00650000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01200110810000600122012012600128030001200254065000900266064000500275031000300280
032000200283014000700285865000900292002001300301035001000314801001200324#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#126#12#article#20#12#^rND^sCu
zick^nJ#^rND^sTerry^nG#^rND^sHo^nL#et al#Type-specific human papillomavirus DNA 
in abnormal smears as a predictor of high-grade cervical intraepithelial neoplas
ia^len#Br J Cancer#19940000#1994#69#1#167-71#20110400#v15n2a06.htm#0007-0920#Br 
J Cancer##
00667000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100025000950100
01900120810000600139012012000145030001400265065000900279064000500288031000400293
032000200297014000800299865000900307002001300316035001000329801001400339#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#127#13#article#20#13#^rND^sBu
lten^nJ#^rND^svan der Avoort^nIA#^rND^sMelchers^nWJ#et al#p14ARF and p16INK4a, t
wo products of the same gene, are differently expressed in cervical intraepithel
ial neoplasia^len#Gynecol Oncol#20060000#2006#101#3#487-494#20110400#v15n2a06.ht
m#0090-8258#Gynecol Oncol##
00561000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100021000940120
07400115030001200189065000900201064000500210031000300215032000200218014000700220
865000900227002001300236035001000249801001200259#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a06.htm#S#c#128#14#article#20#14#^rND^sBosh^nFX#^rND^sde San Jose
^nS#The epidemiology of human papilomavirus infection and cervical cancer^len#Di
s Markers#20070000#2007#23#4#213-17#20110400#v15n2a06.htm#0278-0240#Dis Markers#
#
00660000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100015000990100
01900114810000600133012011900139030000900258066001300267065000900280064000500289
031000300294014000800297865000900305002001300314035001000327801000900337#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#129#15#article#20#15#^rND^sDe
 Lucca^nG.D#^rND^sMarin^nH#^rND^sSchelover^nE#et al#Infeccion por Chlamydia trac
homatis y Papilomavirus en mujeres con alteraciones citohistologicas de cuello u
terino^les#Medicina#Buenos Aires#20060000#2006#66#303-306#20110400#v15n2a06.htm#
0025-7680#MEDICINA##
00678000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01400111810000600125012013800131030001900269065000900288064000500297031000300302
032000200305014000600307865000900313002001300322035001000335801001900345#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#130#16#article#20#16#^rND^sDe
nks^nK#^rND^sSpaeth^nEL#^rND^sJérs^nK#et al#Coinfection of Chlamydia trachomatis
, Uresplasma urealyticum and human papillomavirus among patients attending STD c
linics in Estonia^len#Scand J Infect Dis#20070000#2007#39#8#714-8#20110400#v15n2
a06.htm#0036-5548#Scand J Infect Dis##
00689000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100016000990100
02300115810000600138012014400144030001500288065000900303064000500312031000300317
032000200320014000600322865000900328002001300337035001000350801001500360#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#131#17#article#20#17#^rND^sFr
anceschi^nS#^rND^sSmith^nJS#^rND^sVan den Brule^nA#et al#Cervical infection with
 Chlamydia trachomatis and Neisseria gonorrhoeae in women from ten areas in four
 continents: A cross-sectional study^len#Sex Transm Dis#20070000#2007#34#8#563-9
#20110400#v15n2a06.htm#0148-5717#Sex Transm Dis##
00686000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100020000980100
01600118810000600134012013900140030001700279065000900296064000500305031000300310
032000200313014000800315865000900323002001300332035001000345801001700355#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#132#18#article#20#18#^rND^sDe
 Paula^nFD#^rND^sFernandes^nAP#^rND^sCarmo^nBB#et al#Molecular detection of Chla
mydia trachomatis and HPV infections in cervical samples with normal and abmorma
l cytopathological findings^len#Diagn Cytopathol#20070000#2007#35#4#198-202#2011
0400#v15n2a06.htm#8755-1039#Diagn Cytopathol##
00653000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
01700111810000600128012012300134030001200257065000900269064000500278031000300283
032000200286014000700288865000900295002001300304035001000317801001200327#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a06.htm#S#c#133#19#article#20#19#^rND^sNa
ucler^nP#^rND^sChen^nNC#^rND^sPersson^nK#et al#Seroprevalence of Human Papilloma
viruses and Chlamydia trachomatis and cervical cancer risk: nested case-control 
study^len#J Gen Virol#20070000#2007#88#3#814-22#20110400#v15n2a06.htm#0022-1317#
J Gen Virol##
00638000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940120
12300111030002800234065000900262064000500271031000300276032000200279014000700281
865000900288002001300297035001000310801002800320#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a06.htm#S#c#134#20#article#20#20#^rND^sFehér^nE#^rND^sSzalmás^nA#
Prevalence of Chlamydia trachomatis and oncogenic human papillomavirus types in 
cytologic atypia of the uterine cervix^len#Acta Microbiol Immunol Hung#20060000#
2006#53#4#479-87#20110400#v15n2a06.htm#1217-8950#Acta Microbiol Immunol Hung##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#o#1#1#article#1
#20110406#124822#v15n2a07.htm#187##
04058000000000757000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400110014403500100015501201910
01650100026003560100027003820100029004090100037004380100031004750100037005060100
02800543010002600571070009900597070015000696070005300846070013400899083179301033
08500080282608500450283408500250287908500280290408500200293205800490295205800250
30010600009030260580100030350600015031350600011031500580017031610600014031780600
01403192060001403206058001803220117000603238072000303244112000903247111001103256
114000903267113001103276002001303287#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a07.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#7#BJID230#nd#Braz J Infe
ct Dis#15#2#20110400#^f132^l137#1413-8670#Enterotoxins, colonization factors, se
rotypes and antimicrobial resistance of enterotoxigenic Escherichia coli (ETEC) 
strains isolated from hospitalized children with diarrhea in Bolivia^len#^rND^1A
01^nClaudia^sRodas#^rND^1A02^nRosalía^sMamani#^rND^1A01 A03^nJorge^sBlanco#^rND^
1A01 A03^nJesus Eulogio^sBlanco#^rND^1A01 A03^nGudrun^sWiklund#^rND^1A01 A03^nAn
n-Mari^sSvennerholm#^rND^1A01 A03^nÅsa^sSjöling#^rND^1A04^nVolga^sIniguez#Univer
sity of Gothenburg^iA01^1Institute of Biomedicine^2Department of Microbiology an
d Immunology#Universidad de Santiago de Compostela^iA02^1Departamento de Microbi
ología y Parasitología^2Laboratorio de Referencia de Escherichia coli^cLugo^pSpa
in#WHO^iA03^1Collaborating Centre for Reasearch on ETEC#Universidad Mayor de San
 Andrés^iA04^1Facultad de Ciencias Puras y Naturales^2Intituto de Biología Molec
ular y Biotecnología^pBolivia#^len^aEnterotoxigenic Escherichia coli (ETEC) is r
ecognized as the main cause of bacterial diarrhoea among children in Asia, Afric
a and Latin America but less investigated in Bolivia. OBJECTIVE: To determine th
e relation between enterotoxins, CFs and serotypes as well as the antimicrobial 
resistance patterns in a set of ETEC isolates collected from hospitalized childr
en with acute diarrhea. In the present study we characterized 43 ETEC strains is
olated from 2002 to 2006 from hospitalized children (0-5 years) with acute diarr
hea in Bolivia. The strains were analyzed for heat-labile (LT) and heat-stable (
ST) enterotoxins and colonization factor (CF) profiles, as well as for serogroup
s and antimicrobial resistance using phenotypic (ELISA, dot blot, slide agglutin
ation and disc diffusion) and genotypic (Multiplex PCR) methods. Among the ETEC 
isolates tested, 30 were positive for LT, 3 for STh and 10 for LT/STh. Sixty-fiv
e percent (28/43) of the strains expressed one or more CF. The most common CFs w
ere CS17 (n = 8) and CFA/I (n = 8). The phenotypical and genotypical results for
 toxins and CFs were congruent except for CS21 that was amplified in 10 of the s
trains by multiplex PCR, but CS21 pili was only detected phenotypically in four 
of these strains. The ETEC strains had diverse O and H antigens and the most com
mon types were O8:H9 LT CS17 (n = 6; 14%) and O78:HNM LT-ST CFA/I (n = 4; 9%). T
he analysis of antibiotic resistance showed that 67% (n = 29/43) of the strains 
were resistant to one or several of the antimicrobial agents tested. Presence of
 CFs was associated with antibiotic resistance. CONCLUSION: The most common toxi
n profile was LT 70%, LT/STh 23% and STh 7%. High antimicrobial resistance to am
picillin among serogroups O6, O8 and O78 were the most common.#^dnd^i1#^tm^len^k
enterotoxigenic Escherichia coli^i1#^tm^len^kenterotoxins^i1#^tm^len^kdrug resis
tance^i1#^tm^len^kBolivia^i1#Swedish Agency for Research Economic Cooperation#Sw
edish Research Council#6X-09084#Ministerio de Ciencia e Innovación^dInstituto de
 Salud Carlos III, Fondo de Investigación Sanitaria#RD06/0008-1018#PS09/01273#Xu
nta de Galicia#07MRU036261PR#09TAL007261PR#2007/000044-0#Swedish Institute#other
#37#20100811#08/11/2010#20100927#09/27/2010#v15n2a07.htm##
04471000000000757000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400110014403500100015501202050
01650100026003700100027003960100029004230100037004520100031004890100037005200100
02800557010002600585070009900611070015000710070005300860070013400913083181401047
08500080286108500520286908500250292108500280294608500200297405800490299405800250
30430600067030680580114031350600074032490600069033230580024033920600072034160600
07303488060007203561058001803633117000603651072000303657112000903660111001103669
114000903680113001103689002001303700#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a07.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#7#BJID230#nd#Braz J Infe
ct Dis#15#2#20110400#^f132^l137#1413-8670#<b>Enterotoxins, colonization factors,
 serotypes and antimicrobial resistance of enterotoxigenic <i>Escherichia coli</
i> (ETEC) strains isolated from hospitalized children with diarrhea in Bolivia</
b>^len#^rND^1A01^nClaudia^sRodas#^rND^1A02^nRosalía^sMamani#^rND^1A01 A03^nJorge
^sBlanco#^rND^1A01 A03^nJesus Eulogio^sBlanco#^rND^1A01 A03^nGudrun^sWiklund#^rN
D^1A01 A03^nAnn-Mari^sSvennerholm#^rND^1A01 A03^nÅsa^sSjöling#^rND^1A04^nVolga^s
Iniguez#University of Gothenburg^iA01^1Institute of Biomedicine^2Department of M
icrobiology and Immunology#Universidad de Santiago de Compostela^iA02^1Departame
nto de Microbiología y Parasitología^2Laboratorio de Referencia de Escherichia c
oli^cLugo^pSpain#WHO^iA03^1Collaborating Centre for Reasearch on ETEC#Universida
d Mayor de San Andrés^iA04^1Facultad de Ciencias Puras y Naturales^2Intituto de 
Biología Molecular y Biotecnología^pBolivia#^len^aEnterotoxigenic <i>Escherichia
 coli</i> (ETEC) is recognized as the main cause of bacterial diarrhoea among ch
ildren in Asia, Africa and Latin America but less investigated in Bolivia. <b>OB
JECTIVE:</b> To determine the relation between enterotoxins, CFs and serotypes a
s well as the antimicrobial resistance patterns in a set of ETEC isolates collec
ted from hospitalized children with acute diarrhea. In the present study we char
acterized 43 ETEC strains isolated from 2002 to 2006 from hospitalized children 
(0-5 years) with acute diarrhea in Bolivia. The strains were analyzed for heat-l
abile (LT) and heat-stable (ST) enterotoxins and colonization factor (CF) profil
es, as well as for serogroups and antimicrobial resistance using phenotypic (ELI
SA, dot blot, slide agglutination and disc diffusion) and genotypic (Multiplex P
CR) methods. Among the ETEC isolates tested, 30 were positive for LT, 3 for STh 
and 10 for LT/STh. Sixty-five percent (28/43) of the strains expressed one or mo
re CF. The most common CFs were CS17 (n = 8) and CFA/I (n = 8). The phenotypical
 and genotypical results for toxins and CFs were congruent except for CS21 that 
was amplified in 10 of the strains by multiplex PCR, but CS21 pili was only dete
cted phenotypically in four of these strains. The ETEC strains had diverse O and
 H antigens and the most common types were O8:H9 LT CS17 (n = 6; 14%) and O78:HN
M LT-ST CFA/I (n = 4; 9%). The analysis of antibiotic resistance showed that 67%
 (n = 29/43) of the strains were resistant to one or several of the antimicrobia
l agents tested. Presence of CFs was associated with antibiotic resistance. <b>C
ONCLUSION:</b> The most common toxin profile was LT 70%, LT/STh 23% and STh 7%. 
High antimicrobial resistance to ampicillin among serogroups O6, O8 and O78 were
 the most common.#^dnd^i1#^tm^len^kenterotoxigenic <i>Escherichia coli</i>^i1#^t
m^len^kenterotoxins^i1#^tm^len^kdrug resistance^i1#^tm^len^kBolivia^i1#Swedish A
gency for Research Economic Cooperation#Swedish Research Council#<span style='fo
nt-size:10.0pt;font-family:Verdana'>6X-09084</span>#<i>Ministerio de Ciencia e I
nnovación</i>^d<i>Instituto de Salud Carlos III, Fondo de Investigación Sanitari
a</i>#<span style='font-size:10.0pt;font-family: Verdana'>RD06/0008-1018</span>#
<span style='font-size:10.0pt;font-family:Verdana'>PS09/01273</span>#<i>Xunta de
 Galicia</i>#<span style='font-size:10.0pt;font-family:Verdana'>07MRU036261PR</s
pan>#<span style='font-size: 10.0pt;font-family:Verdana'>09TAL007261PR</span>#<s
pan style='font-size:10.0pt;font-family:Verdana'>2007/000044-0</span>#Swedish In
stitute#other#37#20100811#08/11/2010#20100927#09/27/2010#v15n2a07.htm##
04242000000000781000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000200117049000800119
15800030012703000210013003100030015103200020015406500090015601400110016503500100
01760120191001860100026003770100027004030100029004300100037004590100031004960100
03700527010002800564010002600592070010100618070015200719070005500871070013600926
08318350106208500080289708500450290508500250295008500280297508500200300305800490
30230580025030720600009030970580100031060600015032060600011032210580017032320600
01403249060001403263060001403277058001803291117000603309072000303315112000903318
111001103327114000903338113001103347002001303358008008903371#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a07.htm#S#l#4#1#article#1#^mMar./Apr.^a2011#oa#en#br1
.1#1#4.0#ilus#tab#7#BJID230#nd#Braz. j. infect. dis#15#2#20110400#^f132^l137#141
3-8670#Enterotoxins, colonization factors, serotypes and antimicrobial resistanc
e of enterotoxigenic Escherichia coli (ETEC) strains isolated from hospitalized 
children with diarrhea in Bolivia^len#^rND^1A01^nClaudia^sRodas#^rND^1A02^nRosal
ía^sMamani#^rND^1A01 A03^nJorge^sBlanco#^rND^1A01 A03^nJesus Eulogio^sBlanco#^rN
D^1A01 A03^nGudrun^sWiklund#^rND^1A01 A03^nAnn-Mari^sSvennerholm#^rND^1A01 A03^n
Åsa^sSjöling#^rND^1A04^nVolga^sIniguez#^iA01^1University of Gothenburg^2Institut
e of Biomedicine^3Department of Microbiology and Immunology#^iA02^1Universidad d
e Santiago de Compostela^2Departamento de Microbiología y Parasitología^3Laborat
orio de Referencia de Escherichia coli^cLugo^pSpain#^iA03^1WHO^2Collaborating Ce
ntre for Reasearch on ETEC#^iA04^1Universidad Mayor de San Andrés^2Facultad de C
iencias Puras y Naturales^3Intituto de Biología Molecular y Biotecnología^pBoliv
ia#^len^aEnterotoxigenic Escherichia coli (ETEC) is recognized as the main cause
 of bacterial diarrhoea among children in Asia, Africa and Latin America but les
s investigated in Bolivia. OBJECTIVE: To determine the relation between enteroto
xins, CFs and serotypes as well as the antimicrobial resistance patterns in a se
t of ETEC isolates collected from hospitalized children with acute diarrhea. In 
the present study we characterized 43 ETEC strains isolated from 2002 to 2006 fr
om hospitalized children (0-5 years) with acute diarrhea in Bolivia. The strains
 were analyzed for heat-labile (LT) and heat-stable (ST) enterotoxins and coloni
zation factor (CF) profiles, as well as for serogroups and antimicrobial resista
nce using phenotypic (ELISA, dot blot, slide agglutination and disc diffusion) a
nd genotypic (Multiplex PCR) methods. Among the ETEC isolates tested, 30 were po
sitive for LT, 3 for STh and 10 for LT/STh. Sixty-five percent (28/43) of the st
rains expressed one or more CF. The most common CFs were CS17 (n = 8) and CFA/I 
(n = 8). The phenotypical and genotypical results for toxins and CFs were congru
ent except for CS21 that was amplified in 10 of the strains by multiplex PCR, bu
t CS21 pili was only detected phenotypically in four of these strains. The ETEC 
strains had diverse O and H antigens and the most common types were O8:H9 LT CS1
7 (n = 6; 14 percent) and O78:HNM LT-ST CFA/I (n = 4; 9 percent). The analysis o
f antibiotic resistance showed that 67 percent (n = 29/43) of the strains were r
esistant to one or several of the antimicrobial agents tested. Presence of CFs w
as associated with antibiotic resistance. CONCLUSION: The most common toxin prof
ile was LT 70 percent, LT/STh 23 percent and STh 7 percent. High antimicrobial r
esistance to ampicillin among serogroups O6, O8 and O78 were the most common.#^d
nd^i1#^tm^len^kenterotoxigenic Escherichia coli^i1#^tm^len^kenterotoxins^i1#^tm^
len^kdrug resistance^i1#^tm^len^kBolivia^i1#Swedish Agency for Research Economic
 Cooperation#Swedish Research Council#6X-09084#Ministerio de Ciencia e Innovació
n^dInstituto de Salud Carlos III, Fondo de Investigación Sanitaria#RD06/0008-101
8#PS09/01273#Xunta de Galicia#07MRU036261PR#09TAL007261PR#2007/000044-0#Swedish 
Institute#other#37#20100811#08/11/2010#20100927#09/27/2010#v15n2a07.htm#Internet
^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000200007
##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#5#1#article#146#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLE</b><
/font></p>     ^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#6#2#article#146#<p>&nbsp;</p>     ^cY
#v15n2a07.htm##
00534000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704030100074002001300375#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#7#3#article#146#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Enterotoxins, col
onization factors, serotypes and antimicrobial resistance of enterotoxigenic <i>
Escherichia coli</i> (ETEC) strains isolated from hospitalized children with dia
rrhea in Bolivia</b></font></p>     ^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#8#4#article#146#<p>&nbsp;</p>     ^cY
#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#9#5#article#146#<p>&nbsp;</p>     ^cY
#v15n2a07.htm##
00575000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704034100075002001300416#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#10#6#article#146#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Claudia Rodas<sup>I</sup>; Rosal&i
acute;a Mamani<sup>II</sup>; Jorge Blanco<sup>III</sup>; Jesus Eulogio Blanco<su
p>III</sup>; Gudrun Wiklund<sup>IV</sup>; Ann-Mari Svennerholm<sup>V</sup>; &#19
7;sa Sj&ouml;ling<sup>V</sup>; Volga Iniguez<sup>VI</sup></b></font></p>     ^cY
#v15n2a07.htm##
00449000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704021500075002001300290#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#11#7#article#146#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>MSc, Microbiology; PhD st
udent, Department of Microbiology and Immunology, Institute of Biomedicine, Univ
ersity of Gothenburg, Swede    ^cY#v15n2a07.htm##
00455000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704022100075002001300296#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#12#8#article#146#<br> <sup>II</sup>Ms
C, Bioscience; PhD student, Laboratorio de Referencia de <i>Escherichia coli</i>
, Departamento de Microbiolog&iacute;a y Parasitolog&iacute;a, Universidad de Sa
ntiago de Compostela, Lugo, Spain    ^cY#v15n2a07.htm##
00425000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704019100075002001300266#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#13#9#article#146#<br>   <sup>III</sup
>Dr., PhD, WHO Collaborating Centre for Reasearch on ETEC and Department of Micr
obiology and Immunology, Institute of Biomedicine, University of Gothenburg, Swe
den    ^cY#v15n2a07.htm##
00419000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018400076002001300260#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#14#10#article#146#<br>   <sup>IV</sup
>MSc, WHO Collaborating Centre for Reasearch on ETEC and Departmentof Microbiolo
gy and Immunology, Institute of Biomedicine, University of Gothenburg, Sweden   
 ^cY#v15n2a07.htm##
00428000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019300076002001300269#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#15#11#article#146#<br>   <sup>V</sup>
MD, Professor, WHO Collaborating Centre for Reasearch on ETEC and Department of 
Microbiologyand Immunology, Institute of Biomedicine, University of Gothenburg, 
Sweden    ^cY#v15n2a07.htm##
00434000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019900076002001300275#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#16#12#article#146#<br>   <sup>VI</sup
>Dr., PhD, Intituto de Biolog&iacute;a Molecular y Biotecnolog&iacute;a, Faculta
d de Ciencias Puras y Naturales, Universidad Mayor de San Andr&eacute;s, Bolivia
</font></p>     ^cY#v15n2a07.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#17#13#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a><
/font></p>     ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#18#14#article#146#<p>&nbsp;</p>     ^
cY#v15n2a07.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#19#15#article#146#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v15n2a07.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#20#16#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
15n2a07.htm##
00490000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025500076002001300331#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#21#17#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Enterotoxigenic <i>Escherichia coli<
/i> (ETEC) is recognized as the main cause of bacterial diarrhoea among children
 in Asia, Africa and Latin America but less investigated in Bolivia.    ^cY#v15n
2a07.htm##
01688000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704145300076002001301529#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#22#18#article#146#<br> <b>OBJECTIVE:<
/b> To determine the relation between enterotoxins, CFs and serotypes as well as
 the antimicrobial resistance patterns in a set of ETEC isolates collected from 
hospitalized children with acute diarrhea. In the present study we characterized
 43 ETEC strains isolated from 2002 to 2006 from hospitalized children (0-5 year
s) with acute diarrhea in Bolivia. The strains were analyzed for heat-labile (LT
) and heat-stable (ST) enterotoxins and colonization factor (CF) profiles, as we
ll as for serogroups and antimicrobial resistance using phenotypic (ELISA, dot b
lot, slide agglutination and disc diffusion) and genotypic (Multiplex PCR) metho
ds. Among the ETEC isolates tested, 30 were positive for LT, 3 for STh and 10 fo
r LT/STh. Sixty-five percent (28/43) of the strains expressed one or more CF. Th
e most common CFs were CS17 (n = 8) and CFA/I (n = 8). The phenotypical and geno
typical results for toxins and CFs were congruent except for CS21 that was ampli
fied in 10 of the strains by multiplex PCR, but CS21 pili was only detected phen
otypically in four of these strains. The ETEC strains had diverse O and H antige
ns and the most common types were O8:H9 LT CS17 (n = 6; 14%) and O78:HNM LT-ST C
FA/I (n = 4; 9%). The analysis of antibiotic resistance showed that 67% (n = 29/
43) of the strains were resistant to one or several of the antimicrobial agents 
tested. Presence of CFs was associated with antibiotic resistance.    ^cY#v15n2a
07.htm##
00441000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020600076002001300282#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#23#19#article#146#<br> <b>CONCLUSION:
</b> The most common toxin profile was LT 70%, LT/STh 23% and STh 7%. High antim
icrobial resistance to ampicillin among serogroups O6, O8 and O78 were the most 
common.</font></p>     ^cY#v15n2a07.htm##
00437000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020200076002001300278#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#24#20#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> enterotoxigenic <i>
Escherichia coli</i>; enterotoxins; drug resistance; Bolivia.</font></p> <hr siz
e="1" noshade>     ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#25#21#article#146#<p>&nbsp;</p>     ^
cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#26#22#article#146#<p>&nbsp;</p>     ^
cY#v15n2a07.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#27#23#article#146#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>INTRODUCTION</b></i></font></p
>     ^cY#v15n2a07.htm##
01642000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704140700076002001301483#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#28#24#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Acute diarrheal diseases are an impo
rtant   health problem among children under five   in developing countries and a
nnually cause   between 1.4 to 2.5 million deaths.<sup>1,2</sup> Diarrheal   dis
eases cause high rates of pediatric   morbidity and mortality in Bolivia, leadin
g   annually to more than 500,000 cases and between   13,000 and 15,000 deaths r
espectively.<sup>3</sup>   Enterotoxigenic <i>Escherichia coli</i> (ETEC) is an 
  important cause of diarrhea among children   in developing countries and among
 travelers   to ETEC-endemic areas.<sup>4</sup> Clinical human   ETEC isolates p
roduce one or more of three   enterotoxins; the heat stable toxins (STp and   ST
h) and heat labile toxin (LT) and may produce   one or more of several colonizat
ion factors   (CFs).<sup>5</sup> The CFs mediate adherence to the   small intest
inal mucosa, and to date, more   than 22 different CFs have been described in   
human ETEC strains (<i>e.g</i> CFA/I, CS1-CS8,   CS12-CS15, and CS17-CS22).<sup>
5-8</sup> In developing   countries, the incidence of ETEC-associated   diarrhea
 decreases during the first five years   of life<sup>9</sup> whereas children an
d adults from industrialized   areas who travel to these countries   are suscept
ible to this type of diarrhea, indicating that natural immunity develops.<sup>4,
10</sup></font></p>     ^cY#v15n2a07.htm##
01764000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704152900076002001301605#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#29#25#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The LT enterotoxin and the CF antige
ns   are immunogenic and hence the main candidates   for vaccines that are being
 developed   against ETEC diarrhea.10,11 Since ETEC strains   have diverse toxin
, CF and serogroup profiles   it is important to characterize clinical ETEC   is
olates from different parts of the world with   respect to virulence profiles to
 evaluate the impact   that different vaccine compositions could have on ETEC di
arrhea. Moreover, antibiotic resistance among ETEC strains is increasing, perhap
s due to indiscriminate use of antibiotics. Although rehydration therapy is the 
most important part of therapy for acute diarrhea, antimicrobials are important 
adjuvants for therapy and their use results in a marked decrease in overall stoo
l volume and decreased length of illness. Most cases of bacterial gastroenteriti
s are self-limiting and in otherwise healthy patients, administration of antibio
tics is not necessary. However in infants, elderly people, granulocytopenic or i
mmunodepressed patients with enteritis, and for patients with extra-intestinal i
nfections, particularly when bacteremia is suspected, antibiotic therapy is fund
amental for disease control.<sup>12</sup> The knowledge of antimicrobial resista
nce patterns locally in different countries is important when prescribing antibi
otics for diarrheagenic bacteria, and can serve as a guide for implementing publ
ic health interventions against diarrheal disease.</font></p>     ^cY#v15n2a07.h
tm##
00533000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029800076002001300374#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#30#26#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In this study, we determined the rel
ation between enterotoxins, CFs and serotypes, as well as the antimicrobial resi
stance patterns in a set of ETEC isolates collected from hospitalized children w
ith acute diarrhea.</font></p>     ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#31#27#article#146#<p>&nbsp;</p>     ^
cY#v15n2a07.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011700076002001300193#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#32#28#article#146#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>MATERIAL AND METHODS</b></i></
font></p>     ^cY#v15n2a07.htm##
00378000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014300076002001300219#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#33#29#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Bacterial strains and determinati
on of toxins and CFs</b></font></p>     ^cY#v15n2a07.htm##
01342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704110700076002001301183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#34#30#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">ETEC strains were isolated from acut
e watery non-bloody stool samples obtained from hospitalized children with diarr
hea under five years of age in La Paz, Bolivia, between 2002-2006. ETEC strains 
were grown on MacConkey agar plates, incubated at 37ºC for 18 hours and five lac
tose positive colonies were tested for the presence of ETEC toxins and CFs by GM
1 ELISA, toxin multiplex PCR and dot blot.<sup>13</sup> Confirmed ETEC strains w
ere stored at -70ºC in Luria broth (Difco) containing 25% glycerol and subsequen
tly shipped to Sweden on deep agar stabs. All strains were re-analyzed twice by 
toxin GM1-ELISA, dot blot and Multiplex PCR in Sweden.<sup>13,14</sup> For the d
ot blot the MAbs used were CFA/I, CS1 to CS6, CS8, CS12, CS14, CS17, CS19 and CS
21. From the original set of ETEC strains (n = 79), we analyzed 43 ETEC strains 
that survived the transport, had identical toxin and CF profiles when tested bot
h in Bolivia, Spain and Sweden and that were not mixed infections for serotype a
nd antimicrobial resistance.</font></p>     ^cY#v15n2a07.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#35#31#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Serotyping</b></font></p>     ^cY
#v15n2a07.htm##
01037000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080200076002001300878#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#36#32#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">O- and H-antigens were determined ac
cording to the method described by Guin&eacute;e <i>et al.</i><sup>15</sup> and 
employing all available O (O1-O185) and H (H1-H56) antisera in the <i>E. coli</i
> Reference laboratory (LREC) at the <i>Universidad of Santiago de Compostela</i
>, Lugo, Spain. All antisera were obtained and absorbed with the corresponding c
ross-reacting antigens to remove nonspecific agglutinins. The O antisera were pr
oduced in the LREC and the H antisera were obtained from the Stat-ens Serum Inst
itute (Copenhagen, Denmark). Isolates that did not react with any of the O and H
 antisera used were classified as non-typeable (ONT and HNT), and those that wer
e non-motile were denoted HNM.<sup>16</sup></font></p>     ^cY#v15n2a07.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#37#33#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Antimicrobial resistance</b></fon
t></p>     ^cY#v15n2a07.htm##
01157000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704092200076002001300998#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#38#34#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Colonies from McConkey agar cultures
 were homogenized in 0.85% saline, and the turbidity was adjusted to that of a 0
.5 McFarland standard. The inoculum suspension was spread on a Mueller-Hinton ag
ar plate surface with a swab, and incubated in room temperature for 15 min befor
e antimicrobial disks were applied. The antimicrobials tested were ampicillin, n
alidixic acid, chloramphenicol, ampicillin-sulbactam, tetracycline, ciprofloxaci
n, trimethoprim-sulfamethoxazole, gentamicin, and cefoxitin. The bacterial cultu
res were incubated for 20 hours at 37ºC, and the zone of inhibition was determin
ed. The National Committee for Clinical Laboratory Standards<sup>17</sup> breakp
oints were used to differentiate between susceptible and resistant isolates. <i>
E. coli</i> ATCC 25922 was used as a reference strain for quality control purpos
es.</font></p>     ^cY#v15n2a07.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#39#35#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Statistics</b></font></p>     ^cY
#v15n2a07.htm##
00505000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027000076002001300346#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#40#36#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The two-tailed Fishers' exact test w
as used for statistical analysis using the GraphPad InStat Software and a 2 x 2 
contingency table. A p-value less than 0.05 was considered significant.</font></
p>     ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#41#37#article#146#<p>&nbsp;</p>     ^
cY#v15n2a07.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#42#38#article#146#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>RESULTS</b></i></font></p>    
 ^cY#v15n2a07.htm##
00949000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071400076002001300790#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#43#39#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">ETEC strains were obtained from a pr
ospective study in children under five years of age seeking care in three differ
ent hospitals in La Paz, Bolivia during 2002-2006. The children all suffered fro
m non-bloody, acute diarrhea. In total, 853 clinical samples were analyzed and E
TEC was isolated from 79 patients. Forty-tree individual ETEC strains isolated f
rom watery non-bloody diarrhea samples with only one microbial pathogen isolated
 and with confirmed enterotoxin and CF expression in La Paz, Santiago de Compost
ela and Gothenburg were selected for further studies (<a href="/img/revistas/bji
d/v15n2/a07tab01.jpg">Table 1</a>).</font></p>     ^cY#v15n2a07.htm##
00610000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037500076002001300451#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#44#40#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The most common toxin profile among 
the selected strains was LT in 30 strains (70%), followed by LT/STh in 10 strain
s (23%) and STh in three strains (7%). The presence of STp was not recorded in B
olivia and when analyzed for STp in Sweden and in Spain none of the strains harb
ored this toxin.</font></p>     ^cY#v15n2a07.htm##
01137000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704090200076002001300978#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#45#41#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The CFs in the selected strains were
 analyzed both by multiplex PCR<sup>14</sup> and dot blot.<sup>13</sup> Overall,
 65% (28/43) of the ETEC strains expressed one or more of the 19 CFs analyzed in
 multiplex PCR and results were corroborated by the phenotypic analyses and all 
cases except for CS21. The CFs found in the strains were CFA/I (n = 8) and CS17 
(n = 8), CS1 + CS3 (n = 3), CS2 + CS3 (n = 3), and CS12 (n = 3), and CS7 (n = 2)
, and CS6 (n = 1). CS21 was often found in association with other CFs, especiall
y with CFA/I and the CFA/II group (CS1, CS2 and CS3). CS21 was detected by multi
plex PCR in 10 strains but was only detected by phenotypic dot blot test in four
 of the strains. The pattern of phenotypically silent CS21 has previously been r
eported in Bolivian and Bangladeshi strains by us.<sup>14</sup></font></p>     ^
cY#v15n2a07.htm##
01585000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704135000076002001301426#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#46#42#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">When analyzing the serogroups of the
 ETEC strains, we found that they belonged to a diverse set of O groups (<a href
="/img/revistas/bjid/v15n2/a07tab01.jpg">Table 1</a>). Of these serogroups, O6, 
O8, O78, O114, O120, O148, O153 and O159 have frequently been associated with ET
EC in previous studies<sup>18-20</sup> and these 8 O-groups were detected in 26 
of the 43 ETEC strains. A small number of additional strains were of O serogroup
s that have infrequently been detected in ETEC strains, namely, O1, O41 and O21.
<sup>19</sup> The remaining serogroups O34 and O174 have to our knowledge not pr
eviously been described for any category of diarrheagenic <i>E. coli</i>. The st
rains that had O groups commonly found in ETEC were statistically more often CF 
positive than strains that either possessed an O serogroup not commonly found in
 ETEC or were non-typeable (p &lt; 0.0070). An H flagellar antigen was detected 
in 31 strains. The most common H-antigen was H9 (n = 9); eight of these strains 
were O8 serogroup and six of these strains were O8:H9 LT/CS17 which is a common 
ETEC phenotype and probably constituted a clone that circulated in Bolivia from 
2002 to 2005. Other common H-antigens were H16 (n = 4), all of which were O6: H1
6, H40 (n = 5) and H45 (n = 2).</font></p>     ^cY#v15n2a07.htm##
00894000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065900076002001300735#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#47#43#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The results of the antimicrobial sus
ceptibility of the ETEC strains are shown in <a href="/img/revistas/bjid/v15n2/a
07tab01.jpg">Table 1</a>. Several of the strains were resistant to many antimicr
obial drugs. The highest resistance rate was found for ampicillin (53.5%; n = 23
), followed by ampicillin-sulbactam (46.5%; n = 20), trimethoprim-sulfamethoxazo
le (32.5%; n = 14), tetracycline (28 %; n = 12) and chloramphenicol (14%; n = 6)
. Most strains were not resistant to nalidixic acid, gentamicin, and cefoxitin a
nd all the tested strains were susceptible to ciprofloxacin.</font></p>     ^cY#
v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#48#44#article#146#<p>&nbsp;</p>     ^
cY#v15n2a07.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#49#45#article#146#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>DISCUSSION</b></i></font></p> 
    ^cY#v15n2a07.htm##
01638000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704140300076002001301479#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#50#46#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In our analysis of the 43 ETEC strai
ns from Bolivia we found an unusually high prevalence of LT-only strains. LT, ST
 and LT/ST strains worldwide often occur at comparable frequencies,<sup>19</sup>
 but LT strains have previously been reported to be more common in South America
n surveys of ETEC prevalence than in surveys in Asia and Africa<sup>21,22</sup> 
and recently an increase in LT strains also in Bangladesh was reported.<sup>23</
sup> The observed percentage of CF positive and negative strains is in agreement
 with other findings with approximately 2/3 of the strains expressing known CFs.
 The most common CFs were CFA/I and CS17 and while CFA/I always is one of the mo
st commonly detected CF in surveys worldwide the high prevalence of both CS17 an
d LT-only strains in this collection seemed to be due to an unusually high frequ
ency of LT/CS17 strains. CS21 was commonly detected by PCR but less commonly by 
dot blot as reported earlier.<sup>14</sup> These results may be due to the obser
ved variability in the coding region for CS21.<sup>8,24</sup> The high prevalenc
e of PCR positive CS21 strains among the Bolivian strains is in agreement with t
hat observed in other countries in Asia and South America where CS21 frequencies
 between 19% to 36.5% have been reported in ETEC strain collections.<sup>25-27</
sup></font></p>     ^cY#v15n2a07.htm##
01040000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080500076002001300881#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#51#47#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">There was a large variation of serot
ypes among the 43 ETEC strains. Unlike the genes for toxins and CFs, which are u
sually plasmid encoded, the O and H biosynthetic genes are chromosomal.<sup>28</
sup> This suggests a high degree of clonal diversity of disease-associated ETEC 
in this geographic area over a relatively short period of time. Notably, several
 of the serotypes detected were not those typically associated with ETEC. Since 
there is only evidence of protection against homologous O groups and no evidence
 that ETEC O- and H-antigens are protective against heterologous serotypes,<sup>
28-30</sup> there would seem to be little to gain from incorporation of specific
 O- or H-antigens into a vaccine against ETEC.</font></p>     ^cY#v15n2a07.htm##
00750000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051500076002001300591#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#52#48#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We found a relation between serotype
, toxin and CF profile. Thus, O8:H9 strains commonly expressed LT and CS17 (6 st
rains) while the O78:HNM strain expressed LT, STh and CFA/I and carried the gene
 for CS21 (4 strains). We also detected three O6:H16 strains that expressed LT, 
STh and CS1 + CS3 + CS21 which has previously been reported to be the most frequ
ently detected and widely distributed ETEC phenotype worldwide.<sup>19</sup></fo
nt></p>     ^cY#v15n2a07.htm##
00736000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050100076002001300577#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#53#49#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">ETEC strains that have identical tox
in and CF profiles have been proposed to be genetically closely related.<sup>31,
32</sup> The results from this and other studies on ETEC serotypes support that 
strains with certain toxin and CF profiles often have certain O- and H-antigens 
indicating that there might be a genetic relationship between strains with simil
ar phenotypes regardless of where they are found in the world.</font></p>     ^c
Y#v15n2a07.htm##
01064000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082900076002001300905#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#54#50#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We found a high level of antibiotics
 resistance in the Bolivian ETEC strains (<a href="/img/revistas/bjid/v15n2/a07t
ab01.jpg">Table 1</a>). It is reasonable that this multiresistance of ETEC might
 emerge to classical antibiotics such as ampicillin, tetracycline, and trimethop
rim-sulfamethoxazole<sup>33</sup> since they have been widely used in Bolivia du
ring the past few years. For instance the Integrated Management of Childhood Ill
ness (AIEPI) manual recommends the use of trimethoprim-sulfamethoxazole as the f
irst line antibiotic for the treatment of bloody diarrhea<sup>34</sup> and tetra
cycline is prescribed for the treatment of different infectious diseases. Theref
ore, these antibiotics are widely used in medical settings in Bolivia.</font></p
>     ^cY#v15n2a07.htm##
01485000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704125000076002001301326#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#55#51#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Initially, doxycycline was recommend
ed for the treatment of travelers' diarrhea but recently the fluoroquinolones ha
ve become the drug of choice. However, these drugs are not recommended for child
ren and it should be taken into consideration that in spite of the minimal use o
f quinolones in Bolivia, we detected nalidixic acid-resistant ETEC strains. The 
quinolone resistance in <i>E. coli</i> has mainly been associated with mutations
 in the <i>gyrA</i> and <i>parC</i> genes. Strains resistant to nalidixic acid a
re likely to have at least one mutation of the <i>gyrA</i> gene. If quinolones a
re used as a first drug of choice for diarrhea in countries where the use of ant
ibiotics is not regulated, a rapid emergence of quinolone resistance will likely
 occur. Therefore it is important to continue the surveillance of enteric bacter
ial pathogens for quinolone resistance.<sup>35</sup> Rifaximin is a non-absorbab
le antimicrobial agent which has been shown to be effective for treatment of sev
ere episodes of bacterial diarrhea in children in developed countries,<sup>36</s
up> and according to our results, resistance to ciprofloxacin is still uncommon 
in Bolivia.</font></p>     ^cY#v15n2a07.htm##
00679000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044400076002001300520#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#56#52#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Based on our results, we recommend a
 better control of prescribed antibiotics in Bolivia. Since most mild diarrhea c
ases are indeed successfully managed with oral rehydration therapy, our results 
further support that antimicrobial treatment should not be considered for treatm
ent of ETEC diarrhea unless for more severe or persistent diarrhea cases.<sup>4<
/sup></font></p>     ^cY#v15n2a07.htm##
01159000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704092400076002001301000#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#57#53#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Finally, we found that there was a s
tatistically significant correlation (<a href="#tab2">Table 2</a>) between expre
ssion of CFs and presence of antimicrobial resistance, since 82% (23/28) of the 
CF positive strains harbored antimicrobial resistance, in contrast to the CF neg
ative strains which only were resistant in 47% (7/15) of the cases. This finding
 may suggest that resistance genes might be located on ETEC virulence plasmids. 
Presence of CFs has previously been found to correlate to disease<sup>37</sup> a
nd we found in this study that a high proportion of the ETEC strains that all we
re collected from hospitalized children expressed known CFs. Since these strains
 may also be more likely to also carry antibiotic resistance genes, our results 
further implicate that vaccination is a better solution than antimicrobial treat
ment.</font></p>     ^cY#v15n2a07.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#58#54#article#146#<p><a name="tab2"><
/a></p>     ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#59#55#article#146#<p>&nbsp;</p>     ^
cY#v15n2a07.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#60#56#article#146#<p align="center"><
img src="/img/revistas/bjid/v15n2/a07tab02.jpg"></p>     ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#61#57#article#146#<p>&nbsp;</p>     ^
cY#v15n2a07.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011200076002001300188#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#62#58#article#146#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>ACKNOWLEDGMENTS</b></i></font>
</p>     ^cY#v15n2a07.htm##
00847000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061200076002001300688#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#63#59#article#146#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This work is part of the UMSA-IBMB "
Diarrheal Disease Project" supported by the Swedish Agency for Research Economic
 Cooperation (SIDA). Support was also obtained from the Swedish Research Council
, grant no. 6X-09084, <i>Ministerio de Ciencia e Innovaci&oacute;n (Instituto de
 Salud Carlos III, Fondo de Investigaci&oacute;n Sanitaria</i>, REIPI- RD06/0008
-1018 and PS09/01273) and <i>Xunta de Galicia</i> (07MRU036261PR, 09TAL007261PR,
 2007/000044-0). Claudia Rodas acknowledges the financial support from the Swedi
sh Institute.</font></p>     ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#64#60#article#146#<p>&nbsp;</p>     ^
cY#v15n2a07.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#65#61#article#146#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p> 
    ^cY#v15n2a07.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023600078002001300314#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#66#62#article#146#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Kosek M, Bern C, Gu
errant RL. The magnitude of the global burden of diarrhoeal disease from studies
 published 1992-2000. Bull World Health Organ 2003; 81:197-204.    ^cY#v15n2a07.
htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#67#63#article#146#</font></p>     ^cY
#v15n2a07.htm##
00447000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019800078002001300276#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#68#64#article#146#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Parashar UD, Bresee
 JS, Glass RI. The global burden of diarrhoeal disease in children. Bull World H
ealth Organ 2004; 81:236.    ^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#69#65#article#146#</font></p>     ^cY
#v15n2a07.htm##
00408000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015900078002001300237#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#70#66#article#146#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. SNIS. Sistema Nacio
nal de Informaci&oacute;n en Salud 2009. Bol Minis Salud Pub 2009.    ^cY#v15n2a
07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#71#67#article#146#</font></p>     ^cY
#v15n2a07.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029500078002001300373#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#72#68#article#146#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Qadri F, Svennerhol
m AM, Faruque AS, Sack RB. Enterotoxigenic <i>Escherichia coli</i> in developing
 countries: epidemiology, microbiology, clinical features, treatment, and preven
tion. Clin Microbiol Rev 2005; 18:465-483.    ^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#73#69#article#146#</font></p>     ^cY
#v15n2a07.htm##
00462000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021300078002001300291#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#74#70#article#146#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Gaastra W, Svennerh
olm AM. Colonization factors of human enterotoxigenic <i>Escherichia coli</i> (E
TEC). Trends Microbiol 1996; 4:444- 452.    ^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#75#71#article#146#</font></p>     ^cY
#v15n2a07.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027400078002001300352#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#76#72#article#146#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Grewal H, Valvatine
 H, Bhan MK, van Dijk L, Gaastra W, Sommerfelt H. A new putative fimbrial coloni
zation factor, CS19, of human enterotoxigenic <i>Escherichia coli</i>. Infect Im
mun 1997; 65:507-513.    ^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#77#73#article#146#</font></p>     ^cY
#v15n2a07.htm##
00578000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704032900078002001300407#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#78#74#article#146#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Pichel MG, Binsztei
n N, Qadri F, Gir&oacute;n JA. Type IV longus pilus of enterotoxigenic <i>Escher
ichia coli</i>: occurrence and association with toxin types and colonization fac
tors among strains isolated in Argentina. J Clin Microbiol 2002; 40:694-697.    
^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#79#75#article#146#</font></p>     ^cY
#v15n2a07.htm##
00551000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030200078002001300380#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#80#76#article#146#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Gomez-Duarte OG, Ch
attopadhyay S, Weissman SJ, Giron JA, Kaper JB, Sokurenko EV. Genetic diversity 
of the gene cluster encoding longus, a type IV pilus of enterotoxigenic <i>Esche
richia coli</i>. J Bacteriol 2007; 189:9145-9149.    ^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#81#77#article#146#</font></p>     ^cY
#v15n2a07.htm##
00540000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029100078002001300369#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#82#78#article#146#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. L&oacute;pez-Vidal 
Y, Calva JJ, Trujillo A <i>et al.</i> Enterotoxins and adhesins of enterotoxigen
ic <i>Escherichia coli</i>: are they risk factors for acute diarrhea in the comm
unity? J Infect Dis 1990; 162:442-447.    ^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#83#79#article#146#</font></p>     ^cY
#v15n2a07.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026500079002001300344#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#84#80#article#146#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Walker RI, Steele
 D, Aguado T. Analysis of strategies to successfully vaccinate infants in develo
ping countries against enterotoxigenic <i>E. coli</i> (ETEC) disease. Vac 2007; 
25:2545-2566.    ^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#85#81#article#146#</font></p>     ^cY
#v15n2a07.htm##
00445000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704019500079002001300274#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#86#82#article#146#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Svennerholm AM, T
obias J. Vaccines against enterotoxigenic <i>Escherichia coli</i>. Expert Rev Va
ccines 2008; 7:795-804.    ^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#87#83#article#146#</font></p>     ^cY
#v15n2a07.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025800079002001300337#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#88#84#article#146#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Pratts G, Mirelis
 B, Llovet T. Antibiotic resistance trends in enteropathogenic bacteria isolated
 in 1985-1987 and 1995-1998 in Barcelona. Antimicrob Agents Chemother 2000; 44:1
140-5.    ^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#89#85#article#146#</font></p>     ^cY
#v15n2a07.htm##
00579000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704032900079002001300408#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#90#86#article#146#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Sj&ouml;ling &#19
7;, Wiklund G, Savarino SJ, Cohen DI, Svennerholm AM. Comparative analyzes of ph
enotypic and genotypic methods for detection of enterotoxigenic <i>Escherichia c
oli</i> toxins and colonization factors. J Clin Microbiol 2007; 45:3295-3301.   
 ^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#91#87#article#146#</font></p>     ^cY
#v15n2a07.htm##
00565000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704031500079002001300394#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#92#88#article#146#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Rodas C, Iniguez 
V, Qadri F, Wiklund G, Svennerholm AM, Sj&ouml;ling &#197;. Development of multi
plex PCR assays for detection of enterotoxigenic <i>Escherichia coli</i> coloniz
ation factors and toxins. J Clinl Microbiol 2009; 47:1218-1220.    ^cY#v15n2a07.
htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#93#89#article#146#</font></p>     ^cY
#v15n2a07.htm##
00605000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704035500079002001300434#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#94#90#article#146#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Guine&eacute; PAM
, Jansen H, Wadstrom T, Sellwood R. <i>Escherichia coli</i> associated with neon
atal diarrhoea in piglets and calves. In: de Leeuw PW, Guinee PAM (eds) Laborato
ry diagnosis in neonatal calf and animal science, 13. The Netherlands, Martinus 
Nijhoff. 1981; 126-162.    ^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#95#91#article#146#</font></p>     ^cY
#v15n2a07.htm##
00517000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026700079002001300346#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#96#92#article#146#16#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Blanco J, Gonz&aa
cute;lez EA, Blanco M <i>et al.</i> Enterotoxigenic <i>Escherichia coli</i> asso
ciated with infant diarrhoea in Galicia, north-western Spain. J Med Microbiol 19
91; 35:162-167.    ^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#97#93#article#146#</font></p>     ^cY
#v15n2a07.htm##
00517000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026700079002001300346#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#98#94#article#146#17#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. National Committe
e for Clinical Laboratory Standards. Performance Standards for Antimicrobial Dis
k Susceptibility Tests-Eighth Edition: Approved Standard M2-A8. NCCLS, Villanova
, PA, USA 2002.    ^cY#v15n2a07.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#99#95#article#146#</font></p>     ^cY
#v15n2a07.htm##
00520000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704026900080002001300349#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#100#96#article#146#18#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Blanco J, Blanco
 M, Gonz&aacute;lez EA <i>et al.</i> Serotypes and colonization factors of enter
otoxigenic <i>Escherichia coli</i> isolated in various countries. Eur J Epidemio
l 1993; 9:489-496.    ^cY#v15n2a07.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#101#97#article#146#</font></p>     ^c
Y#v15n2a07.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704027200080002001300352#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#102#98#article#146#19#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Wolf MK. Occurre
nce, distribution, and associations of O and H serogroups, colonization factor a
ntigens, and toxins of enterotoxigenic <i>Escherichia coli</i>. Clin Microbiol R
ev. 1997; 10:569-584.    ^cY#v15n2a07.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#103#99#article#146#</font></p>     ^c
Y#v15n2a07.htm##
00551000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029900081002001300380#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#104#100#article#146#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Ansaruzzaman M,
 Bhuiyan NA, Begum YA <i>et al.</i> Characterization of enterotoxigenic <i>Esche
richia coli</i> from diarrhoeal patients in Bangladesh using phenotyping and gen
etic profiling. J Med Microbiol 2007; 56:217-222.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#105#101#article#146#</font></p>     ^
cY#v15n2a07.htm##
00546000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029400081002001300375#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#106#102#article#146#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Vicente AC, Tei
xeira LF, Iniguez-Rojas L <i>et al.</i> Outbreaks of cholera-like diarrhoea caus
ed by enterotoxigenic <i>Escherichia coli</i> in the Brazilian Amazon Rainforest
 Trans R Soc Trop Med Hyg 2005; 99: 669-674.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#107#103#article#146#</font></p>     ^
cY#v15n2a07.htm##
00540000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028800081002001300369#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#108#104#article#146#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Rivas M, Binszt
ein N, Basanta G <i>et al.</i> Antibody responses against <i>Escherichia coli</i
> heat-labile toxin and colonization factor antigens I and II in Argentinean chi
ldren. J Inf Dis 1995; 171: 1045-1049.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#109#105#article#146#</font></p>     ^
cY#v15n2a07.htm##
00553000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030100081002001300382#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#110#106#article#146#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Harris AM, Chow
dhury F, Begum YA <i>et al.</i> Shifting prevalence of major diarrheal pathogens
 in patients seeking hospital care during floods in 1998, 2004, and 2007 in Dhak
a, Bangladesh. Am J Trop Med Hyg 2008; 79: 708-714.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#111#107#article#146#</font></p>     ^
cY#v15n2a07.htm##
00585000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033300081002001300414#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#112#108#article#146#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Steinsland H, V
alentiner-Branth P, Grewal HM, Gaastra W, M&#248;lbak KK, Sommerfelt H. Developm
ent and evaluation of genotypic assays for the detection and characterization of
 enterotoxigenic <i>Escherichia coli</i>. Diag Microbiol Infec Dis 2003; 45:97-1
05.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#113#109#article#146#</font></p>     ^
cY#v15n2a07.htm##
00595000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034300081002001300424#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#114#110#article#146#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Gir&oacute;n JA
, Viboud GI, Sperandio V <i>et al.</i> Prevalence and association of the longus 
pilus structural gene (lngA) with colonization factor antigens, enterotoxin type
s, and serotypes of enterotoxigenic <i>Escherichia coli</i>. Infect Immun 1995; 
63:4195-4198.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#115#111#article#146#</font></p>     ^
cY#v15n2a07.htm##
00551000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029900081002001300380#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#116#112#article#146#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Guti&eacute;rre
z-C&aacute;zarez Z, Qadri F, Albert MJ, Gir&oacute;n JA. Identification of enter
otoxigenic <i>Escherichia coli</i> harboring longus type IV pilus gene by DNA am
plification. J Clin Microbiol 2000; 38:1767-1771.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#117#113#article#146#</font></p>     ^
cY#v15n2a07.htm##
00519000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026700081002001300348#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#118#114#article#146#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Nishimura LS, G
ir&oacute;n JA, Nunes SL, Guth BE. Prevalence of enterotoxigenic <i>Escherichia 
coli</i> strains harboring the longus pilus gene in Brazil. J Clin Microbiol. 20
02; 40:2606-2608.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#119#115#article#146#</font></p>     ^
cY#v15n2a07.htm##
00447000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019500081002001300276#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#120#116#article#146#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Orskov F, Orsko
v I. <i>Escherichia coli</i> serotyping and disease in man and animals. Can J Mi
crobiol 1992; 38:699-704.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#121#117#article#146#</font></p>     ^
cY#v15n2a07.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026300081002001300344#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#122#118#article#146#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. &#197;hr&eacute
;n CM, Svennerholm AM. Synergistic protective effect of antibodies against <i>Es
cherichia coli</i> enterotoxin and colonization factor antigens. Infect Immun 19
82; 38:74-79.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#123#119#article#146#</font></p>     ^
cY#v15n2a07.htm##
00537000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028500081002001300366#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#124#120#article#146#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Reis MH, Matos 
DP, de Castro AF, Toledo MR, Trabulsi LR. Relationship among enterotoxigenic phe
notypes, serotypes, and sources of strains in enterotoxigenic <i>Escherichia col
i</i>. Infect Immun 1980; 28:24-27.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#125#121#article#146#</font></p>     ^
cY#v15n2a07.htm##
00511000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025900081002001300340#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#126#122#article#146#31#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Sommerfelt H, S
teinsland H, Grewal H <i>et al.</i> Colonization factors of enterotoxigenic <i>E
scherichia coli</i> isolated from children in North India. J Infec Dis 1996; 174
:768-776.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#127#123#article#146#</font></p>     ^
cY#v15n2a07.htm##
00593000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034100081002001300422#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#128#124#article#146#32#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Pacheco A, Guth
 BE, Soares KC, Nishimura L, de Almeida DF, Ferreira LC. Random amplification of
 polymorphic DNA reveals serotype-specific clonal clusters among enterotoxigenic
 <i>Escherichia coli</i> strains isolated from humans. J Clin Microbiol 1997; 35
:1521-1525.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#129#125#article#146#</font></p>     ^
cY#v15n2a07.htm##
00559000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030700081002001300388#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#130#126#article#146#33#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Black RE, Levin
e MM, Clements ML, Cisneros L, Daya V. Treatment of experimentally induced enter
otoxigenic <i>Escherichia coli</i> diarrhea with trimethoprim, trimethoprim-sulf
amethoxazole, or placebo. Rev Infect Dis 1982; 4:540-545.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#131#127#article#146#</font></p>     ^
cY#v15n2a07.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019100081002001300272#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#132#128#article#146#34#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Benguigui Y. At
enci&oacute;n Integrada a las Enfermedades Prevalentes de la Infancia. Bol Notic
ias IRA 2007; 33:2-5.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#133#129#article#146#</font></p>     ^
cY#v15n2a07.htm##
00546000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029400081002001300375#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#134#130#article#146#35#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Vila J, Vargas 
M, Ruiz J. Quinolone resistance in Enterotoxigenic <i>Escherichia coli</i> causi
ng diarrhea in travelers to India in comparison with other geographical areas. A
ntimicrob Agents Chemother 2000; 44:1731-33.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#135#131#article#146#</font></p>     ^
cY#v15n2a07.htm##
00509000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025700081002001300338#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#136#132#article#146#36#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Frisari L, Vigg
iano V, Pelagalli M. An open, controlled study of two non-absorbable antibiotics
 for the oral treatment of paediatric infectious diarrhoea. Curr Med Res1997; 14
:39-45.    ^cY#v15n2a07.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#137#133#article#146#</font></p>     ^
cY#v15n2a07.htm##
00566000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031400081002001300395#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#138#134#article#146#37#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Qadri F, Das SK
, Faruque AS <i>et al.</i> Prevalence of toxin types and colonization factors in
 enterotoxigenic <i>Escherichia coli</i> isolated during a 2-year period from di
arrheal patients in Bangladesh. J Clin Microbiol 2000; 38:27-31.    ^cY#v15n2a07
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#139#135#article#146#</font></p>     ^
cY#v15n2a07.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#140#136#article#146#<p>&nbsp;</p>    
 ^cY#v15n2a07.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#141#137#article#146#<p>&nbsp;</p>    
 ^cY#v15n2a07.htm##
00426000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018900078002001300267#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#142#138#article#146#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:
</b>    ^cY#v15n2a07.htm##
00263000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002600078002001300104#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#143#139#article#146#<br> Claudia Roda
s    ^cY#v15n2a07.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010600078002001300184#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#144#140#article#146#<br> Department o
f Microbiology and Immunology, Institute of Biomedicine, University of Gothenbur
g    ^cY#v15n2a07.htm##
00284000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004700078002001300125#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#145#141#article#146#<br> Box 435, 405
 30 Gothenburg, Sweden    ^cY#v15n2a07.htm##
00290000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005300078002001300131#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#146#142#article#146#<br> Phone: +46-3
1-7866233 Fax: +46-317866205    ^cY#v15n2a07.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010300078002001300181#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#147#143#article#146#<br> <a href="mai
lto:claudia.rodas@microbio.gu.se">claudia.rodas@microbio.gu.se</a></font></p>   
  ^cY#v15n2a07.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009500078002001300173#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#148#144#article#146#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted on: 08/11/2010    ^cY#v1
5n2a07.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#149#145#article#146#<br>   Approved o
n: 09/27/2010    ^cY#v15n2a07.htm##
00299000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006200078002001300140#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a07.htm#S#p#150#146#article#146#<br>   We declare
 no conflict of interest.</font></p>     ^cY#v15n2a07.htm##
00614000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100014000920100
01900106012009400125030002400219065000900243064000500252031000300257014000800260
865000900268002001300277035001000290801002400300#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a07.htm#S#c#151#1#article#37#1#^rND^sKosek^nM#^rND^sBern^nC#^rND^
sGuerrant^nRL#The magnitude of the global burden of diarrhoeal disease from stud
ies published 1992-2000^len#Bull World Health Organ#20030000#2003#81#197-204#201
10400#v15n2a07.htm#0042-9686#Bull World Health Organ##
00576000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100017000960100
01600113012005600129030002400185065000900209064000500218031000300223020000400226
865000900230002001300239035001000252801002400262#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a07.htm#S#c#152#2#article#37#2#^rND^sParashar^nUD#^rND^sBresee^nJ
S#^rND^sGlass^nRI#The global burden of diarrhoeal disease in children^len#Bull W
orld Health Organ#20040000#2004#81#236#20110400#v15n2a07.htm#0042-9686#Bull Worl
d Health Organ##
00420000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750110005000770120050000820300
02000132710000200152065000900154064000500163865000900168002001300177#v15n2#V:\Sc
iELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#c#153#3#article#37#3#SNIS#Sistema N
acional de Información en Salud 2009^les#Bol Minis Salud Pub#2#20090000#2009#201
10400#v15n2a07.htm##
00679000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100022000920100
01800114010001500132012013500147030001900282065000900301064000500310031000300315
014000800318865000900326002001300335035001000348801001900358#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a07.htm#S#c#154#4#article#37#4#^rND^sQadri^nF#^rND^sS
vennerholm^nAM#^rND^sFaruque^nAS#^rND^sSack^nRB#Enterotoxigenic Escherichia coli
 in developing countries: epidemiology, microbiology, clinical features, treatme
nt, and prevention^len#Clin Microbiol Rev#20050000#2005#18#465-483#20110400#v15n
2a07.htm#0893-8512#Clin Microbiol Rev##
00559000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100022000940120
07400116030001700190065000900207064000500216031000200221014000900223865000900232
002001300241035001000254801001700264#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a07.htm#S#c#155#5#article#37#5#^rND^sGaastra^nW#^rND^sSvennerholm^nAM#Coloniz
ation factors of human enterotoxigenic Escherichia coli (ETEC)^len#Trends Microb
iol#19960000#1996#4#444- 452#20110400#v15n2a07.htm#0966-842X#Trends microbiol##
00688000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100019000930100
01500112010001800127010001700145010002000162012009700182030001300279065000900292
06400050030103100030030601400080030986500090031700200130032603500100033980100130
0349#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#c#156#6#article#37#
6#^rND^sGrewal^nH#^rND^sValvatine^nH#^rND^sBhan^nMK#^rND^svan Dijk^nL#^rND^sGaas
tra^nW#^rND^sSommerfelt^nH#A new putative fimbrial colonization factor, CS19, of
 human enterotoxigenic Escherichia coli^len#Infect Immun#19970000#1997#65#507-51
3#20110400#v15n2a07.htm#0019-9567#Infect Immun##
00704000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100019000940100
01500113010001600128012016700144030001700311065000900328064000500337031000300342
014000800345865000900353002001300362035001000375801001700385#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a07.htm#S#c#157#7#article#37#7#^rND^sPichel^nMG#^rND^
sBinsztein^nN#^rND^sQadri^nF#^rND^sGirón^nJA#Type IV longus pilus of enterotoxig
enic Escherichia coli: occurrence and association with toxin types and colonizat
ion factors among strains isolated in Argentina^len#J Clin Microbiol#20020000#20
02#40#694-697#20110400#v15n2a07.htm#0095-1137#J Clin Microbiol##
00715000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100023000770100023001000100
01900123010001600142010001600158010002000174012011100194030001200305065000900317
06400050032603100040033101400100033586500090034500200130035403500100036780100120
0377#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#c#158#8#article#37#
8#^rND^sGomez-Duarte^nOG#^rND^sChattopadhyay^nS#^rND^sWeissman^nSJ#^rND^sGiron^n
JA#^rND^sKaper^nJB#^rND^sSokurenko^nEV#Genetic diversity of the gene cluster enc
oding longus, a type IV pilus of enterotoxigenic Escherichia coli^len#J Bacterio
l#20070000#2007#189#9145-9149#20110400#v15n2a07.htm#0021-9193#J Bacteriol##
00650000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100021000770100016000980100
01800114810000600132012012600138030001300264065000900277064000500286031000400291
014000800295865000900303002001300312035001000325801001300335#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a07.htm#S#c#159#9#article#37#9#^rND^sLópez-Vidal^nY#^
rND^sCalva^nJJ#^rND^sTrujillo^nA#et al#Enterotoxins and adhesins of enterotoxige
nic Escherichia coli: are they risk factors for acute diarrhea in the community?
^len#J Infect Dis#19900000#1990#162#442-447#20110400#v15n2a07.htm#0022-1899#J In
fect Dis##
00593000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01600112012013200128030000400260710000200264065000900266064000500275031000300280
014001000283865000900293002001300302#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a07.htm#S#c#160#10#article#37#10#^rND^sWalker^nRI#^rND^sSteele^nD#^rND^sAguad
o^nT#Analysis of strategies to successfully vaccinate infants in developing coun
tries against enterotoxigenic E. coli (ETEC) disease^len#Vac#2#20070000#2007#25#
2545-2566#20110400#v15n2a07.htm##
00505000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100016001010120
05400117030002000171710000200191065000900193064000500202031000200207014000800209
865000900217002001300226#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S
#c#161#11#article#37#11#^rND^sSvennerholm^nAM#^rND^sTobias^nJ#Vaccines against e
nterotoxigenic Escherichia coli^len#Expert Rev Vaccines#2#20080000#2008#7#795-80
4#20110400#v15n2a07.htm##
00641000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01600112012011100128030002800239065000900267064000500276031000300281014000700284
865000900291002001300300035001000313801002800323#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a07.htm#S#c#162#12#article#37#12#^rND^sPratts^nG#^rND^sMirelis^nB
#^rND^sLlovet^nT#Antibiotic resistance trends in enteropathogenic bacteria isola
ted in 1985-1987 and 1995-1998 in Barcelona^len#Antimicrob Agents Chemother#2000
0000#2000#44#1140-5#20110400#v15n2a07.htm#0066-4804#Antimicrob Agents Chemother#
#
00720000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01900113010001600132010002200148012014300170030001700313065000900330064000500339
031000300344014001000347865000900357002001300366035001000379801001700389#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#c#163#13#article#37#13#^rND^sSj
öling^nÅ#^rND^sWiklund^nG#^rND^sSavarino^nSJ#^rND^sCohen^nDI#^rND^sSvennerholm^n
AM#Comparative analyzes of phenotypic and genotypic methods for detection of ent
erotoxigenic Escherichia coli toxins and colonization factors^len#J Clin Microbi
ol#20070000#2007#45#3295-3301#20110400#v15n2a07.htm#0095-1137#J Clin Microbiol##
00687000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01500111010001700126010002200143010001700165012012200182030001800304710000200322
065000900324064000500333031000300338014001000341865000900351002001300360#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#c#164#14#article#37#14#^rND^sRo
das^nC#^rND^sIniguez^nV#^rND^sQadri^nF#^rND^sWiklund^nG#^rND^sSvennerholm^nAM#^r
ND^sSjöling^nÅ#Development of multiplex PCR assays for detection of enterotoxige
nic Escherichia coli colonization factors and toxins^len#J Clinl Microbiol#2#200
90000#2009#47#1218-1220#20110400#v15n2a07.htm##
00720000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01800113010001800131012007800149016001900227016001800246018006500264061001600329
062001700345065000900362064000500371014000800376865000900384002001300393#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#c#165#15#article#37#15#^rND^sGu
ineé^nPAM#^rND^sJansen^nH#^rND^sWadstrom^nT#^rND^sSellwood^nR#Escherichia coli a
ssociated with neonatal diarrhoea in piglets and calves^len#^rED^sde Leeuw^nPW#^
rED^sGuinee^nPAM#Laboratory diagnosis in neonatal calf and animal science, 13^le
n#The Netherlands#Martinus Nijhoff#19810000#1981#126-162#20110400#v15n2a07.htm##
00629000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950100
01600114810000600130012010200136030001600238065000900254064000500263031000300268
014000800271865000900279002001300288035001000301801001600311#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a07.htm#S#c#166#16#article#37#16#^rND^sBlanco^nJ#^rND
^sGonzález^nEA#^rND^sBlanco^nM#et al#Enterotoxigenic Escherichia coli associated
 with infant diarrhoea in Galicia, north-western Spain^len#J Med Microbiol#19910
000#1991#35#162-167#20110400#v15n2a07.htm#0022-2615#J Med Microbiol##
00557000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170053000790180110001320620
00600242061001000248066000500258067000400263065000900267064000500276865000900281
002001300290#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#c#167#17#ar
ticle#37#17#National Committee for Clinical Laboratory Standards#Performance Sta
ndards for Antimicrobial Disk Susceptibility Tests-Eighth Edition: Approved Stan
dard M2-A8^len#NCCLS#Villanova#^ePA#USA#20020000#2002#20110400#v15n2a07.htm##
00631000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01900111810000600130012010500136030001600241065000900257064000500266031000200271
014000800273865000900281002001300290035001000303801001600313#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a07.htm#S#c#168#18#article#37#18#^rND^sBlanco^nJ#^rND
^sBlanco^nM#^rND^sGonzález^nEA#et al#Serotypes and colonization factors of enter
otoxigenic Escherichia coli isolated in various countries^len#Eur J Epidemiol#19
930000#1993#9#489-496#20110400#v15n2a07.htm#0392-2990#Eur J Epidemiol##
00602000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790120147000940300
01900241065000900260064000500269031000300274014000800277865000900285002001300294
035001000307801001900317#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S
#c#169#19#article#37#19#^rND^sWolf^nMK#Occurrence, distribution, and association
s of O and H serogroups, colonization factor antigens, and toxins of enterotoxig
enic Escherichia coli^len#Clin Microbiol Rev#19970000#1997#10#569-584#20110400#v
15n2a07.htm#0893-8512#Clin Microbiol Rev##
00668000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100018001010100
01600119810000600135012013600141030001600277065000900293064000500302031000300307
014000800310865000900318002001300327035001000340801001600350#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a07.htm#S#c#170#20#article#37#20#^rND^sAnsaruzzaman^n
M#^rND^sBhuiyan^nNA#^rND^sBegum^nYA#et al#Characterization of enterotoxigenic Es
cherichia coli from diarrhoeal patients in Bangladesh using phenotyping and gene
tic profiling^len#J Med Microbiol#20070000#2007#56#217-222#20110400#v15n2a07.htm
#0022-2615#J Med Microbiol##
00672000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
02300116810000600139012011800145030002500263065000900288064000500297031000300302
014000800305865000900313002001300322035001000335801002500345#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a07.htm#S#c#171#21#article#37#21#^rND^sVicente^nAC#^r
ND^sTeixeira^nLF#^rND^sIniguez-Rojas^nL#et al#Outbreaks of cholera-like diarrhoe
a caused by enterotoxigenic Escherichia coli in the Brazilian Amazon Rainforest^
len#Trans R Soc Trop Med Hyg#20050000#2005#99#669-674#20110400#v15n2a07.htm#0035
-9203#Trans R Soc Trop Med Hyg##
00620000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100019000940100
01700113810000600130012013200136030001000268710000200278065000900280064000500289
031000400294014001000298865000900308002001300317#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a07.htm#S#c#172#22#article#37#22#^rND^sRivas^nM#^rND^sBinsztein^n
N#^rND^sBasanta^nG#et al#Antibody responses against Escherichia coli heat-labile
 toxin and colonization factor antigens I and II in Argentinean children^len#J I
nf Dis#2#19950000#1995#171#1045-1049#20110400#v15n2a07.htm##
00678000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
01600115810000600131012014600137030001800283065000900301064000500310031000300315
014000800318865000900326002001300335035001000348801001800358#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a07.htm#S#c#173#23#article#37#23#^rND^sHarris^nAM#^rN
D^sChowdhury^nF#^rND^sBegum^nYA#et al#Shifting prevalence of major diarrheal pat
hogens in patients seeking hospital care during floods in 1998, 2004, and 2007 i
n Dhaka, Bangladesh^len#Am J Trop Med Hyg#20080000#2008#79#708-714#20110400#v15n
2a07.htm#0002-9637#Am J Trop Med Hyg##
00710000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100027000990100
01700126010001700143010001700160010002000177012012600197030002500323710000200348
065000900350064000500359031000300364014000700367865000900374002001300383#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#c#174#24#article#37#24#^rND^sSt
einsland^nH#^rND^sValentiner-Branth^nP#^rND^sGrewal^nHM#^rND^sGaastra^nW#^rND^sM
ølbak^nKK#^rND^sSommerfelt^nH#Development and evaluation of genotypic assays for
 the detection and characterization of enterotoxigenic Escherichia coli^len#Diag
 Microbiol Infec Dis#2#20030000#2003#45#97-105#20110400#v15n2a07.htm##
00702000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01900112810000600131012017800137030001300315065000900328064000500337031000300342
014001000345865000900355002001300364035001000377801001300387#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a07.htm#S#c#175#25#article#37#25#^rND^sGirón^nJA#^rND
^sViboud^nGI#^rND^sSperandio^nV#et al#Prevalence and association of the longus p
ilus structural gene (lngA) with colonization factor antigens, enterotoxin types
, and serotypes of enterotoxigenic Escherichia coli^len#Infect Immun#19950000#19
95#63#4195-4198#20110400#v15n2a07.htm#0019-9567#Infect Immun##
00661000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100027000790100015001060100
01700121010001600138012011200154030001700266065000900283064000500292031000300297
014001000300865000900310002001300319035001000332801001700342#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a07.htm#S#c#176#26#article#37#26#^rND^sGutiérrez-Cáza
rez^nZ#^rND^sQadri^nF#^rND^sAlbert^nMJ#^rND^sGirón^nJA#Identification of enterot
oxigenic Escherichia coli harboring longus type IV pilus gene by DNA amplificati
on^len#J Clin Microbiol#20000000#2000#38#1767-1771#20110400#v15n2a07.htm#0095-11
37#J Clin Microbiol##
00642000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100016000990100
01600115010001500131012010100146030001700247065000900264064000500273031000300278
014001000281865000900291002001300300035001000313801001700323#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a07.htm#S#c#177#27#article#37#27#^rND^sNishimura^nLS#
^rND^sGirón^nJA#^rND^sNunes^nSL#^rND^sGuth^nBE#Prevalence of enterotoxigenic Esc
herichia coli strains harboring the longus pilus gene in Brazil^len#J Clin Micro
biol#20020000#2002#40#2606-2608#20110400#v15n2a07.htm#0095-1137#J Clin Microbiol
##
00541000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950120
06300111030001600174065000900190064000500199031000300204014000800207865000900215
002001300224035001000237801001600247#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a07.htm#S#c#178#28#article#37#28#^rND^sOrskov^nF#^rND^sOrskov^nI#Escherichia 
coli serotyping and disease in man and animals^len#Can J Microbiol#19920000#1992
#38#699-704#20110400#v15n2a07.htm#0008-4166#Can J Microbiol##
00594000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100022000950120
11800117030001300235065000900248064000500257031000300262014000600265865000900271
002001300280035001000293801001300303#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a07.htm#S#c#179#29#article#37#29#^rND^sÅhrén^nCM#^rND^sSvennerholm^nAM#Synerg
istic protective effect of antibodies against Escherichia coli enterotoxin and c
olonization factor antigens^len#Infect Immun#19820000#1982#38#74-79#20110400#v15
n2a07.htm#0019-9567#Infect Immun##
00682000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
02000110010001700130010001900147012012100166030001300287065000900300064000500309
031000300314014000600317865000900323002001300332035001000345801001300355#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#c#180#30#article#37#30#^rND^sRe
is^nMH#^rND^sMatos^nDP#^rND^sde Castro^nAF#^rND^sToledo^nMR#^rND^sTrabulsi^nLR#R
elationship among enterotoxigenic phenotypes, serotypes, and sources of strains 
in enterotoxigenic Escherichia coli^len#Infect Immun#19800000#1980#28#24-27#2011
0400#v15n2a07.htm#0019-9567#Infect Immun##
00592000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100020000990100
01600119810000600135012009900141030001200240710000200252065000900254064000500263
031000400268014000800272865000900280002001300289#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a07.htm#S#c#181#31#article#37#31#^rND^sSommerfelt^nH#^rND^sSteins
land^nH#^rND^sGrewal^nH#et al#Colonization factors of enterotoxigenic Escherichi
a coli isolated from children in North India^len#J Infec Dis#2#19960000#1996#174
#768-776#20110400#v15n2a07.htm##
00760000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
01700111010001900128010002100147010001900168012015400187030001700341065000900358
06400050036703100030037201400100037586500090038500200130039403500100040780100170
0417#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#c#182#32#article#37
#32#^rND^sPacheco^nA#^rND^sGuth^nBE#^rND^sSoares^nKC#^rND^sNishimura^nL#^rND^sde
 Almeida^nDF#^rND^sFerreira^nLC#Random amplification of polymorphic DNA reveals 
serotype-specific clonal clusters among enterotoxigenic Escherichia coli strains
 isolated from humans^len#J Clin Microbiol#19970000#1997#35#1521-1525#20110400#v
15n2a07.htm#0095-1137#J Clin Microbiol##
00706000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01900112010001800131010001400149012014300163030001500306065000900321064000500330
031000200335014000800337865000900345002001300354035001000367801001500377#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#c#183#33#article#37#33#^rND^sBl
ack^nRE#^rND^sLevine^nMM#^rND^sClements^nML#^rND^sCisneros^nL#^rND^sDaya^nV#Trea
tment of experimentally induced enterotoxigenic Escherichia coli diarrhea with t
rimethoprim, trimethoprim-sulfamethoxazole, or placebo^len#Rev Infect Dis#198200
00#1982#4#540-545#20110400#v15n2a07.htm#0162-0886#Rev Infect Dis##
00483000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790120069000980300
01700167710000200184065000900186064000500195031000300200014000400203865000900207
002001300216#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a07.htm#S#c#184#34#ar
ticle#37#34#^rND^sBenguigui^nY#Atención Integrada a las Enfermedades Prevalentes
 de la Infancia^les#Bol Noticias IRA#2#20070000#2007#33#2-5#20110400#v15n2a07.ht
m##
00670000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100016000930100
01400109012014400123030002800267065000900295064000500304031000300309014000800312
865000900320002001300329035001000342801002800352#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a07.htm#S#c#185#35#article#37#35#^rND^sVila^nJ#^rND^sVargas^nM#^r
ND^sRuiz^nJ#Quinolone resistance in Enterotoxigenic Escherichia coli causing dia
rrhea in travelers to India in comparison with other geographical areas^len#Anti
microb Agents Chemother#20000000#2000#44#1731-33#20110400#v15n2a07.htm#0066-4804
#Antimicrob Agents Chemother##
00626000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01900114012012200133030001300255065000900268064000500277031000300282014000600285
865000900291002001300300035001000313801001300323#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a07.htm#S#c#186#36#article#37#36#^rND^sFrisari^nL#^rND^sViggiano^
nV#^rND^sPelagalli^nM#An open, controlled study of two non-absorbable antibiotic
s for the oral treatment of paediatric infectious diarrhoea^len#Curr Med Res#199
70000#1997#14#39-45#20110400#v15n2a07.htm#0590-4021#Curr Med Res##
00684000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100014000940100
01800108810000600126012016100132030001700293065000900310064000500319031000300324
014000600327865000900333002001300342035001000355801001700365#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a07.htm#S#c#187#37#article#37#37#^rND^sQadri^nF#^rND^
sDas^nSK#^rND^sFaruque^nAS#et al#Prevalence of toxin types and colonization fact
ors in enterotoxigenic Escherichia coli isolated during a 2-year period from dia
rrheal patients in Bangladesh^len#J Clin Microbiol#20000000#2000#38#27-31#201104
00#v15n2a07.htm#0095-1137#J Clin Microbiol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#o#1#1#article#1
#20110406#124826#v15n2a08.htm#181##
03272000000000613000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400110014403500100015501201640
01650100029003290100033003580100026003910100029004170100033004460100033004790100
02700512010003400539010003600573070008000609070007500689070005400764083166200818
08500080248008500300248808500380251808500400255611700060259607200030260211200090
2605111001102614114000902625113001102634002001302645#v15n2#V:\SciELO\serial\bjid
\v15n2\markup\v15n2a08.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#8#BJID23
0#nd#Braz J Infect Dis#15#2#20110400#^f138^l143#1413-8670#Nosocomial and communi
ty infections due to class A extended-spectrum &#946;-lactamase (ESBLA)-producin
g Escherichia coli and Klebsiella spp. in southern Brazil^len#^rND^1A01^nClaudia
^sWollheim#^rND^1A01^nIvani Maria F^sGuerra#^rND^1A01^nVania D^sConte#^rND^1A01^
nSheila P^sHoffman#^rND^1A01^nFernando J^sSchreiner#^rND^1A02^nAna Paula L^sDela
mare#^rND^1A03^nAfonso L^sBarth#^rND^1A02^nSérgio^sEcheverrigaray#^rND^1A02^nSér
gio Olavo P da^sCosta#Universidade de Caxias do Sul^iA01^1Medical Microbiology L
aboratory^sRS^pBrazil#Universidade de Caxias do Sul^iA02^1Instituto de Biotecnol
ogia^sRS^pBrazil#Hospital de Clínicas de Porto Alegre^iA03^sRS^pBrazil#^len^aOBJ
ECTIVES: To determine the prevalence of class A extended spectrum &#946;-lactama
ses (ESBL)-producing Escherichia coli and Klebsiella spp., and to investigate cl
onality among ESBL-producing isolates of nosocomial and community infections. ME
THODS: The study involved 354 nosocomial infections samples and 992 community in
fections samples, obtained between 2003 and 2006 at Caxias do Sul, RS. The detec
tion of ESBL was performed by the disk-diffusion test. Presence of blaCTX-M, bla
SHV and blaTEM &#946;-lactamase genes was evaluated by PCR, and genomic typing w
as determined by pulsed-field gel electrophoresis analysis. RESULTS: Higher freq
uency of ESBL-producing isolates were detected among nosocomial samples of E. co
li (6.7%) and Klebsiella (43.7%), than those obtained from community infections 
(0.4% and 2.6%). blaTEM and blaCTX were the most prevalent ESBL gene families in
 both E. coli and Klebsiella isolates. Different pulsotypes were obtained among 
ESBL-producing E. coli and 11 clones for Klebsiella spp., which occurred over th
e years and in different hospital wards. Among ESBL-producing K. pneumoniae, 74.
3% transferred ESBL genes by conjugation and exhibited concomitant decreased ami
noglycosides susceptibility. CONCLUSION: ESBL-producing E. coli, and especially 
K. pneumoniae are essentially a nosocomial problem, and their dissemination to t
he community is relatively limited. The great genetic variability observed among
 ESBL-producing bacteria indicates polyclonal spread and high transference of ES
BL genes between bacteria in the hospital environment. This information is of pa
ramount importance for nosocomial infection control.#^dnd^i1#^tm^len^k&#946;-lac
tamases^i1#^tm^len^kpolymerase chain reaction^i1#^tm^len^kbacterial typing techn
iques^i1#other#30#20100612#06/12/2010#20100929#09/29/2010#v15n2a08.htm##
03502000000000613000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400110014403500100015501201990
01650100029003640100033003930100026004260100029004520100033004810100033005140100
02700547010003400574010003600608070008000644070007500724070005400799083185700853
08500080271008500300271808500380274808500400278611700060282607200030283211200090
2835111001102844114000902855113001102864002001302875#v15n2#V:\SciELO\serial\bjid
\v15n2\markup\v15n2a08.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#8#BJID23
0#nd#Braz J Infect Dis#15#2#20110400#^f138^l143#1413-8670#<b>Nosocomial and comm
unity infections due to class A extended-spectrum </b><b>&#946;</b><b>-lactamase
 (ESBLA)-producing <i>Escherichia coli</i> and <i>Klebsiella</i> spp. in souther
n Brazil</b>^len#^rND^1A01^nClaudia^sWollheim#^rND^1A01^nIvani Maria F^sGuerra#^
rND^1A01^nVania D^sConte#^rND^1A01^nSheila P^sHoffman#^rND^1A01^nFernando J^sSch
reiner#^rND^1A02^nAna Paula L^sDelamare#^rND^1A03^nAfonso L^sBarth#^rND^1A02^nSé
rgio^sEcheverrigaray#^rND^1A02^nSérgio Olavo P da^sCosta#Universidade de Caxias 
do Sul^iA01^1Medical Microbiology Laboratory^sRS^pBrazil#Universidade de Caxias 
do Sul^iA02^1Instituto de Biotecnologia^sRS^pBrazil#Hospital de Clínicas de Port
o Alegre^iA03^sRS^pBrazil#^len^a<b>OBJECTIVES:</b> To determine the prevalence o
f class A extended spectrum &#946;-lactamases (ESBL)-producing <i>Escherichia co
li</i> and <i>Klebsiella</i> spp., and to investigate clonality among ESBL-produ
cing isolates of nosocomial and community infections. <b>METHODS:</b> The study 
involved 354 nosocomial infections samples and 992 community infections samples,
 obtained between 2003 and 2006 at Caxias do Sul, RS. The detection of ESBL was 
performed by the disk-diffusion test. Presence of <i>bla</i><sub>CTX-M</sub>, <i
>bla</i><sub>SHV</sub> and <i>bla</i><sub>TEM</sub> &#946;-lactamase genes was e
valuated by PCR, and genomic typing was determined by pulsed-field gel electroph
oresis analysis. <b>RESULTS:</b> Higher frequency of ESBL-producing isolates wer
e detected among nosocomial samples of <i>E. coli</i> (6.7%) and <i>Klebsiella</
i> (43.7%), than those obtained from community infections (0.4% and 2.6%). <i>bl
a</i><sub>TEM</sub> and <i>bla</i><sub>CTX</sub> were the most prevalent ESBL ge
ne families in both <i>E. coli</i> and <i>Klebsiella</i> isolates. Different pul
sotypes were obtained among ESBL-producing <i>E. coli</i> and 11 clones for <i>K
lebsiella</i> spp., which occurred over the years and in different hospital ward
s. Among ESBL-producing <i>K. pneumoniae</i>, 74.3% transferred ESBL genes by co
njugation and exhibited concomitant decreased aminoglycosides susceptibility. <b
>CONCLUSION:</b> ESBL-producing <i>E. coli</i>, and especially <i>K. pneumoniae<
/i> are essentially a nosocomial problem, and their dissemination to the communi
ty is relatively limited. The great genetic variability observed among ESBL-prod
ucing bacteria indicates polyclonal spread and high transference of ESBL genes b
etween bacteria in the hospital environment. This information is of paramount im
portance for nosocomial infection control.#^dnd^i1#^tm^len^k&#946;-lactamases^i1
#^tm^len^kpolymerase chain reaction^i1#^tm^len^kbacterial typing techniques^i1#o
ther#30#20100612#06/12/2010#20100929#09/29/2010#v15n2a08.htm##
03447000000000637000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000200117049000800119
15800030012703000210013003100030015103200020015406500090015601400110016503500100
01760120164001860100029003500100033003790100026004120100029004380100033004670100
03300500010002700533010003400560010003600594070008200630070007700712070005600789
08316970084508500080254208500300255008500380258008500400261811700060265807200030
2664112000902667111001102676114000902687113001102696002001302707008008902720#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#l#4#1#article#1#^mMar./Apr.
^a2011#oa#en#br1.1#1#4.0#ilus#tab#8#BJID230#nd#Braz. j. infect. dis#15#2#2011040
0#^f138^l143#1413-8670#Nosocomial and community infections due to class A extend
ed-spectrum &#946;-lactamase (ESBLA)-producing Escherichia coli and Klebsiella s
pp. in southern Brazil^len#^rND^1A01^nClaudia^sWollheim#^rND^1A01^nIvani Maria F
^sGuerra#^rND^1A01^nVania D^sConte#^rND^1A01^nSheila P^sHoffman#^rND^1A01^nFerna
ndo J^sSchreiner#^rND^1A02^nAna Paula L^sDelamare#^rND^1A03^nAfonso L^sBarth#^rN
D^1A02^nSérgio^sEcheverrigaray#^rND^1A02^nSérgio Olavo P da^sCosta#^iA01^1Univer
sidade de Caxias do Sul^2Medical Microbiology Laboratory^sRS^pBrazil#^iA02^1Univ
ersidade de Caxias do Sul^2Instituto de Biotecnologia^sRS^pBrazil#^iA03^1Hospita
l de Clínicas de Porto Alegre^sRS^pBrazil#^len^aOBJECTIVES: To determine the pre
valence of class A extended spectrum &#946;-lactamases (ESBL)-producing Escheric
hia coli and Klebsiella spp., and to investigate clonality among ESBL-producing 
isolates of nosocomial and community infections. METHODS: The study involved 354
 nosocomial infections samples and 992 community infections samples, obtained be
tween 2003 and 2006 at Caxias do Sul, RS. The detection of ESBL was performed by
 the disk-diffusion test. Presence of blaCTX-M, blaSHV and blaTEM &#946;-lactama
se genes was evaluated by PCR, and genomic typing was determined by pulsed-field
 gel electrophoresis analysis. RESULTS: Higher frequency of ESBL-producing isola
tes were detected among nosocomial samples of E. coli (6.7 percent) and Klebsiel
la (43.7 percent), than those obtained from community infections (0.4 percent an
d 2.6 percent). blaTEM and blaCTX were the most prevalent ESBL gene families in 
both E. coli and Klebsiella isolates. Different pulsotypes were obtained among E
SBL-producing E. coli and 11 clones for Klebsiella spp., which occurred over the
 years and in different hospital wards. Among ESBL-producing K. pneumoniae, 74.3
 percent transferred ESBL genes by conjugation and exhibited concomitant decreas
ed aminoglycosides susceptibility. CONCLUSION: ESBL-producing E. coli, and espec
ially K. pneumoniae are essentially a nosocomial problem, and their disseminatio
n to the community is relatively limited. The great genetic variability observed
 among ESBL-producing bacteria indicates polyclonal spread and high transference
 of ESBL genes between bacteria in the hospital environment. This information is
 of paramount importance for nosocomial infection control.#^dnd^i1#^tm^len^k&#94
6;-lactamases^i1#^tm^len^kpolymerase chain reaction^i1#^tm^len^kbacterial typing
 techniques^i1#other#30#20100612#06/12/2010#20100929#09/29/2010#v15n2a08.htm#Int
ernet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-867020110002
00008##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#5#1#article#147#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLE</b><
/font></p>     ^cY#v15n2a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#6#2#article#147#<p>&nbsp;</p>     ^cY
#v15n2a08.htm##
00617000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704038400074002001300458#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#7#3#article#147#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Nosocomial and co
mmunity infections due to class A extended-spectrum </b></font><font size="4"><b
>&#946;</b></font><font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b
>-lactamase (ESBLA)-producing <i>Escherichia coli</i> and <i>Klebsiella</i> spp.
 in southern Brazil</b></font></p>     ^cY#v15n2a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#8#4#article#147#<p>&nbsp;</p>     ^cY
#v15n2a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#9#5#article#147#<p>&nbsp;</p>     ^cY
#v15n2a08.htm##
00633000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704039900075002001300474#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#10#6#article#147#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Claudia Wollheim<sup>I</sup>; Ivan
i Maria F Guerra<sup>II</sup>; Vania D Conte<sup>III</sup>; Sheila P Hoffman<sup
>III</sup>; Fernando J Schreiner<sup>I</sup>; Ana Paula L Delamare<sup>IV</sup>;
 Afonso L Barth<sup>V</sup>; S&eacute;rgio Echeverrigaray<sup>VI</sup>; S&eacute
;rgio Olavo P da Costa<sup>VI</sup></b></font></p>     ^cY#v15n2a08.htm##
00396000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704016200075002001300237#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#11#7#article#147#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>PhD, Medical Microbiology
 Laboratory, Universidade de Caxias do Sul, RS, Brazil    ^cY#v15n2a08.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704010400075002001300179#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#12#8#article#147#<br> <sup>II</sup>MS
; Medical Microbiology Laboratory, Universidade de Caxias do Sul, RS, Brazil    
^cY#v15n2a08.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011500075002001300190#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#13#9#article#147#<br>   <sup>III</sup
>Pharmacist; Medical Microbiology Laboratory, Universidade de Caxias do Sul, RS,
 Brazil    ^cY#v15n2a08.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#14#10#article#147#<br>   <sup>IV</sup
>PhD,Instituto de Biotecnologia, Universidade de Caxias do Sul, RS, Brazil    ^c
Y#v15n2a08.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008700076002001300163#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#15#11#article#147#<br>   <sup>V</sup>
PhD, Hospital de Cl&iacute;nicas de Porto Alegre, RS, Brazil    ^cY#v15n2a08.htm
##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011400076002001300190#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#16#12#article#147#<br>   <sup>VI</sup
>PhD, Instituto de Biotecnologia, Universidade de Caxias do Sul, RS, Brazil</fon
t></p>     ^cY#v15n2a08.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#17#13#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a><
/font></p>     ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#18#14#article#147#<p>&nbsp;</p>     ^
cY#v15n2a08.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#19#15#article#147#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v15n2a08.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#20#16#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
15n2a08.htm##
00634000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039900076002001300475#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#21#17#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>OBJECTIVES:</b> To determine the 
prevalence of class A extended spectrum </font>&#946;<font size="2" face="Verdan
a, Arial, Helvetica, sans-serif">-lactamases (ESBL)-producing <i>Escherichia col
i</i> and <i>Klebsiella</i> spp., and to investigate clonality among ESBL-produc
ing isolates of nosocomial and community infections.    ^cY#v15n2a08.htm##
00757000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052200076002001300598#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#22#18#article#147#<br> <b>METHODS:</b
> The study involved 354 nosocomial infections samples and 992 community infecti
ons samples, obtained between 2003 and 2006 at Caxias do Sul, RS. The detection 
of ESBL was performed by the disk-diffusion test. Presence of <i>bla</i><sub>CTX
-M</sub>, <i>bla</i><sub>SHV</sub> and <i>bla</i><sub>TEM</sub> </font>&#946;<fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">-lactamase genes was ev
aluated by PCR, and genomic typing was determined by pulsed-field gel electropho
resis analysis.    ^cY#v15n2a08.htm##
00950000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071500076002001300791#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#23#19#article#147#<br>   <b>RESULTS:<
/b> Higher frequency of ESBL-producing isolates were detected among nosocomial s
amples of <i>E. coli</i> (6.7%) and <i>Klebsiella</i> (43.7%), than those obtain
ed from community infections (0.4% and 2.6%). <i>bla</i><sub>TEM</sub> and <i>bl
a</i><sub>CTX</sub> were the most prevalent ESBL gene families in both <i>E. col
i</i> and <i>Klebsiella</i> isolates. Different pulsotypes were obtained among E
SBL-producing <i>E. coli</i> and 11 clones for <i>Klebsiella</i> spp., which occ
urred over the years and in different hospital wards. Among ESBL-producing <i>K.
 pneumoniae</i>, 74.3% transferred ESBL genes by conjugation and exhibited conco
mitant decreased aminoglycosides susceptibility.    ^cY#v15n2a08.htm##
00706000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047100076002001300547#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#24#20#article#147#<br>   <b>CONCLUSIO
N:</b> ESBL-producing <i>E. coli</i>, and especially <i>K. pneumoniae</i> are es
sentially a nosocomial problem, and their dissemination to the community is rela
tively limited. The great genetic variability observed among ESBL-producing bact
eria indicates polyclonal spread and high transference of ESBL genes between bac
teria in the hospital environment. This information is of paramount importance f
or nosocomial infection control.</font></p>     ^cY#v15n2a08.htm##
00498000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026300076002001300339#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#25#21#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> </font>&#946;<font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">-lactamases; polymerase ch
ain reaction; bacterial typing techniques.</font></p> <hr size="1" noshade>     
^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#26#22#article#147#<p>&nbsp;</p>     ^
cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#27#23#article#147#<p>&nbsp;</p>     ^
cY#v15n2a08.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#28#24#article#147#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>INTRODUCTION</b></i></font></p
>     ^cY#v15n2a08.htm##
00665000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043000076002001300506#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#29#25#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Extended-spectrum b-lactamase-produc
ing clinical isolates among members of the Enterobacteriaceae family, especially
 Klebsiella pneumoniae and Escherichia coli, represent one of the most important
 world problems of b-lactam antimicrobial resistance, commonly used in the treat
ment of many bacterial nosocomial and community infections.<sup>1</sup></font></
p>     ^cY#v15n2a08.htm##
00835000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060000076002001300676#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#30#26#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Traditionally ESBLs appeared just af
ter the introduction of third-generation cephalosporins, and evolved from parent
 enzymes due to point mutation in the bla<sub>TEM-1/2</sub> and bla<sub>SHV-1</s
ub> genes around the b-lactamase active site.<sup>2</sup> The majority of ESBLs 
belong to the functional class 2be/molecular class A, particularly TEM and SHV t
ypes, and the CTX-M family b-lactamases encoded by genes captured by mobile elem
ents from the chromosomes of the environmental bacteria Kluyvera spp.<sup>1</sup
></font></p>     ^cY#v15n2a08.htm##
01222000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704098700076002001301063#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#31#27#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">At present, the definition of ESBL a
s 2be/ molecular class A, clavulanic acid inhibited enzymes that cause resistanc
e to penicillins, to all cephalosporin generations, and to the monobactam aztreo
nam, but not to cephamycins or carbapenems, is narrow and excludes other clinica
lly important acquired b-lactamase with wider spectrum.<sup>1</sup> In the effor
t to prevent the spread of acquired b-lactamase, a new classification had been p
roposed including b-lactamase with activity against extended-spectrum cephalospo
rins and/or carbapenems, making the classification more accessible to clinicians
, infection control professionals, hospital managers, and politicians. Three gro
ups of ESBL were projected: (1) ESBL<sub>A</sub> (classical class A ESBLs); (2) 
ESBL<sub>M</sub> (plasmid-mediated AmpC and OXA-ESBLs classedw as miscellaneous 
ESBLs); and (3) ESBL<sub>CARBA</sub> (carbapenemases).<sup>1,3</sup></font></p> 
    ^cY#v15n2a08.htm##
01628000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704139300076002001301469#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#32#28#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The correct identification of ESBL-p
roducing bacteria has important clinical-epidemiological and laboratory implicat
ions. First, patients may experience a delay in appropriate treatment if ESBL-pr
oducing bacteria are not correctly detected by routine antimicrobial susceptibil
ity tests.<sup>4</sup> Second, while carbapenemics are the most effective therap
y for ESBL bacterial infections, their routine use can select resistant strains,
 as the emergence of imipenem-resistant <i>Acinetobacter baumanii, Pseudomonas a
eruginosa</i> and <i>K. pneumoniae</i>.<sup>5,6</sup> Third, ESBL genes are loca
ted on large plasmids that can harbor genes for resistance to other non-b-lactam
s antibiotics, and therefore, ESBL-producing bacteria often exhibit multidrug-re
sistant phenotypes, reducing the drug arsenal even further.<sup>1</sup> Fourth, 
genes encoding ESBLs are typically located in conjugative plasmids or integron-l
ike structures and can be effectively transferred to other strains and species.<
sup>7,8</sup> Finally, ESBL-producing organisms, especially <i>K. pneumoniae</i>
, but also <i>E. coli</i>, have been responsible for serious nosocomial infectio
n outbreaks that lead to prolonged hospital stay, increased morbidity and mortal
ity, and consequently increase healthcare associated costs.<sup>9-11</sup></font
></p>     ^cY#v15n2a08.htm##
00869000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063400076002001300710#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#33#29#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Since the first description of ESBL 
in 1983, in Germany, ESBL-producing clinical isolates have spread rapidly throug
hout Europe and the United States and are now disseminated worldwide.<sup>12,13<
/sup> However, the world prevalence of ESBL producers varies greatly, even among
 health institutions in the same country.<sup>14</sup> Although it is a major th
reat for patients in the hospital, currently ESBL are becoming an emerging probl
em for patients in long-term care facilities, and also in the community in some 
areas of the world.<sup>15-17</sup></font></p>     ^cY#v15n2a08.htm##
00870000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063500076002001300711#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#34#30#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The aims of this study were to deter
mine the prevalence of ESBL among <i>E. coli</i> and <i>Klebsiella</i> spp. in C
axias do Sul, in the southern region of Brazil, to identify the prevalence of </
font>&#946;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">-lactamas
e genes (<i>bla</i><sub>TEM</sub>, <i>bla</i><sub>SHV</sub> and <i>bla</i><sub>C
TX-M</sub>), and to investigate clonality among clinical isolates of ESBL-produc
ing <i>E. coli</i> and <i>Klebsiella</i> spp. of nosocomial and community infect
ions during a period of three years.</font></p>     ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#35#31#article#147#<p>&nbsp;</p>     ^
cY#v15n2a08.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011700076002001300193#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#36#32#article#147#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>MATERIAL AND METHODS</b></i></
font></p>     ^cY#v15n2a08.htm##
00359000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012400076002001300200#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#37#33#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Patient population and definition
s</b></font></p>     ^cY#v15n2a08.htm##
01491000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704125600076002001301332#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#38#34#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The study was carried between April 
2003 and May 2006 at a private clinical analyses laboratory, and at the General 
Hospital of Caxias do Sul (HG), located in Rio Grande do Sul State Brazil. The H
G is a 257-bed public university teaching hospital and acts as a referral hospit
al for a wider area of Northeast RS, covering a population of about one million 
inhabitants. Personal data (age, sex), type of specimens, and the hospital ward 
at the HG where the patient had been assigned were obtained. Nosocomial infectio
n was defined as infection which occurred more than 48 hours after hospital admi
ssion; infection which occurred less than 48 hours after hospital admission, if 
that patient had been hospitalized within the prior 30 days; or infection which 
occurred in a patient transferred from another hospital or from a nursing home.<
sup>18</sup> Patients with community infection were those presenting it at a com
munity clinical analyses laboratory and those who had a positive culture at the 
time of or within 48 hours of hospitalization; in both cases, patients had no pr
evious contacts with hospitals or long-term care facility in the previous two we
eks.<sup>19</sup></font></p>     ^cY#v15n2a08.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#39#35#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Bacterial isolates</b></font></p>
     ^cY#v15n2a08.htm##
00792000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055700076002001300633#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#40#36#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Clinical specimens obtained from pat
ients with nosocomial infection yielded 354 isolates (209 <i>E. coli</i>, 142 <i
>K. pneumoniae</i> and 3 <i>K. oxytoca</i>), and a total of 992 isolates (953 <i
>E. coli</i>, 38 <i>K. pneumoniae</i> and 1 <i>K. oxytoca</i>) were obtained fro
m patients with community infection. Isolates were identified using the conventi
onal biochemical tests and stored at -70ºC in skim milk. Only one isolate from e
ach patient was included in the study.</font></p>     ^cY#v15n2a08.htm##
00366000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013100076002001300207#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#41#37#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Screening and confirmation tests 
of ESBLs</b></font></p>     ^cY#v15n2a08.htm##
00972000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073700076002001300813#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#42#38#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">ESBL-producing isolates identificati
on was made by the disk-diffusion screening test with aztreonam, cefotaxime, cef
tazidime, ceftriaxone, and cefpodoxime, followed by a confirmatory test with cef
tazidime and cefotaxime, combined with clavulanic acid as recommended by the Cli
nical and Laboratory Standards Institute (CLSI).<sup>20</sup> An additional conf
irmatory test was performed with cefepime and cefpodoxime discs containing clavu
lanic acid. All the tests were conducted with Oxoid antibiotic discs. The standa
rd strains <i>E. coli</i> ATCC 25922 and <i>K. pneumoniae</i> ATCC 700603 were u
sed as negative and positive controls of ESBLs production.</font></p>     ^cY#v1
5n2a08.htm##
00463000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022800076002001300304#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#43#39#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>PCR amplification for detection o
f </b></font><b>&#946;</b><font size="2" face="Verdana, Arial, Helvetica, sans-s
erif"><b>-lactamase genes</b></font></p>     ^cY#v15n2a08.htm##
00747000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051200076002001300588#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#44#40#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The bacterial isolates with confirme
d ESBL phenotype were submitted to PCR assay to identify <i>bla</i><sub>CTX-M</s
ub>, <i>bla</i><sub>SHV</sub> and <i>bla</i> TEM </font>&#946;<font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">-lactamase genes, using the primers an
d method described by Paterson <i>et al</i>.<sup>14</sup> The <i>K. pneumoniae</
i> ATCC 700603 strain was used as a positive control for the blaSHV gene.</font>
</p>     ^cY#v15n2a08.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#45#41#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Molecular typing</b></font></p>  
   ^cY#v15n2a08.htm##
00982000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074700076002001300823#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#46#42#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Genomic typing of ESBL producing iso
lates was performed by the pulsed-field gel electrophoresis (PFGE) technique bas
ed on PulseNet PFGE protocol.<sup>21</sup> Briefly, genomic DNA was prepared in 
agarose plugs, cut with restriction endonuclease SpeI (Invitrogen), and restrict
ion fragments separated using a CHEF-DRIII system (Bio-Rad). Photographs of ethi
dium bromide-stained gels were examined visually and the macrorestriction patter
ns were interpreted according to the criteria proposed by Tenover <i>et al.</i><
sup>22</sup> A 48.5 Kb bacteriophage </font>&#955;<font size="2" face="Verdana, 
Arial, Helvetica, sans-serif"> ladder was used as a DNA size marker.</font></p> 
    ^cY#v15n2a08.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011000076002001300186#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#47#43#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Gene transfer assays</b></font></
p>     ^cY#v15n2a08.htm##
01527000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704129200076002001301368#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#48#44#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Conjugation assays were carried out 
by a broth mating procedure in Lurian-Bertani (LB) broth with 35 ESBL-producing 
<i>K. pneumoniae</i> isolates susceptible to streptomycin and ceftriaxone. DH5</
font>&#945;<font size="2" face="Verdana, Arial, Helvetica, sans-serif"> <i>E. co
li</i> (streptomycin resistant, lactose fermentation negative, and plasmid free)
 was used as the recipient.<sup>23</sup> Overnight cultures of donor and recipie
nt strains grown in LB broth were added to 8 mL of fresh LB broth at a donor-rec
ipient ratio of 1:1 (300 &#181;L of cultures each), and incubated for 4 hours at
 37ºC. The mixed culture was plated onto MacConkey agar containing 30 &#181;g/mL
 of ceftriaxone and 300 &#181;g/mL of streptomycin. Six colonies growing on the 
selections plates and again on subculture on selective MacConkey agar were subje
cted to confirmatory tests of ESBLs and to antimicrobial susceptibility by disk 
diffusion assays according to CLSI recommendation with amikacin, gentamicin, tob
ramicin, ciprofloxacin, gatifloxacin, nitrofurantoin, trimethoprim/sulfamethoxaz
ole and chloramphenicol. Resistance was considered nontransferable when the isol
ates failed to transfer in more than two experiments.</font></p>     ^cY#v15n2a0
8.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#49#45#article#147#<p>&nbsp;</p>     ^
cY#v15n2a08.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#50#46#article#147#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>RESULTS</b></i></font></p>    
 ^cY#v15n2a08.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011700076002001300193#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#51#47#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Prevalence of ESBL isolates</b></
font></p>     ^cY#v15n2a08.htm##
01078000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084300076002001300919#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#52#48#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A total of 1,346 non-replicated isol
ates (354 from nosocomial and 992 from community infection patients) were analyz
ed. Overall, 21.8% (77/354) and 0.5% (5/992) of the isolates were confirmed as E
SBL producers by the clavulanic acid inhibition disk diffusion assay. Fourteen (
6.7%) of 209 patients with <i>E. coli</i> infection had ESBL-producing strain, c
ompared with 4 (0.4%) of 953 patients with community-acquired <i>E. coli</i> inf
ection. ESBL-producing <i>K. pneumoniae</i> were isolated from 62 (43.7%) of 142
 patients with nosocomial infection, and from one (2.6%) of 38 isolates with com
munity-acquired infection. Among the four <i>K. oxytoca</i> isolates, one obtain
ed from a nosocomial patient exhibited ESBL phenotype (<a href="#tab1">Table 1</
a>).</font></p>     ^cY#v15n2a08.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#53#49#article#147#<p><a name="tab1"><
/a></p>     ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#54#50#article#147#<p>&nbsp;</p>     ^
cY#v15n2a08.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#55#51#article#147#<p align="center"><
img src="/img/revistas/bjid/v15n2/a08tab01.jpg"></p>     ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#56#52#article#147#<p>&nbsp;</p>     ^
cY#v15n2a08.htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013300076002001300209#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#57#53#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b> Patient population and source of
 specimens</b></font></p>     ^cY#v15n2a08.htm##
01181000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704094600076002001301022#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#58#54#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Of the 1,346 patients studied, the m
ean age and gender of patients with nosocomial infection were different among th
ose with community infections (51.4 ± 28.0 years and 54.8% female versus 39.1 ± 
22.4 years and 89.3% female). In both patient populations, the most frequent sou
rce of infection was urinary. The high frequency of urinary infections (97.7%) a
mong community patients explains the difference on gender proportion. The mean a
ge of the patients with nosocomial infection due to ESBL-producing <i>E. coli</i
> and <i>Klebsiella</i> spp. differed significantly (40.7 ± 31.7 years, range: 8
.3 months to 88 years versus 4.8 ± 2.9 years, range: 4 days to 92 years), respec
tively. Most patients (65.1%) with nosocomial infection due to ESBL-producing <i
>Klebsiella</i> spp. were male, while no gender difference was observed among co
mmunity infection patients.</font></p>     ^cY#v15n2a08.htm##
01069000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083400076002001300910#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#59#55#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The ESBL-producing bacteria obtained
 from patients with nosocomial infections were isolated from the urinary tract (
5.8% <i>E. coli</i> and 49% <i>Klebsiella</i> spp.), respiratory tract (14.3% <i
>E. coli</i> and 41.9% <i>Klebsiella</i> spp.), blood/catheter (12.5% <i>E. coli
</i> and 48.4% <i>Klebsiella</i> spp.), peritoneal liquid (25% <i>Klebsiella</i>
 spp.), and skin/soft tissue (25% <i>Klebsiella</i> spp.). Most ESBL-producers w
ere detected on patients hospitalized in Intensive-Care Units, including the Neo
natal, Pediatric and Adult ICUs (15.9% <i>E. coli</i> and 51.7% <i>Klebsiella</i
> spp.), in Clinical-Surgical Units (4.3% <i>E. coli</i> and 45.5% <i>Klebsiella
</i> spp.), and Urgency and Emergency wards (31.6% <i>Klebsiella</i> spp.).</fon
t></p>     ^cY#v15n2a08.htm##
00457000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022200076002001300298#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#60#56#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Prevalence of </b></font><b>&#946
;</b><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>-lactamase g
enes and genotyping</b></font></p>     ^cY#v15n2a08.htm##
00556000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032100076002001300397#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#61#57#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As shown in <a href="/img/revistas/b
jid/v15n2/a08fig01.jpg">Figure 1</a>, 61.1% of ESBL-producing <i>E. coli</i> wer
e isolated during 2005 to 2006, whereas 67.2% of ESBL <i>Klebsiella</i> spp. iso
lates were collected between 2003 to 2004.</font></p>     ^cY#v15n2a08.htm##
01309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704107400076002001301150#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#62#58#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The PCR assay allowed detection of <
i>bla</i><sub>TEM</sub> gene family in 66.7% of the isolates of ESBL-producing <
i>E. coli</i>, followed by <i>bla</i><sub>CTX-M</sub> gene (50%) and the <i>bla<
/i><sub>SHV</sub> gene (11.1%) (<a href="/img/revistas/bjid/v15n2/a08fig01.jpg">
Figure 1A</a>). Several <i>E. coli</i> isolates exhibited </font>&#946;<font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif">-lactamase gene combinations 
(<i>bla</i><sub>CTX-M</sub> and <i>bla</i><sub>SHV</sub>, <i>bla</i><sub>CTX-M</
sub> and <i>bla</i><sub>TEM</sub>), and no amplification products were observed 
in one ESBL isolate. Among <i>Klebsiella</i> spp. with ESBL-phenotype, <i>bla</i
><sub>TEM</sub> gene was the most prevalent (95.3%), followed by the <i>bla</i><
sub>CTX-M</sub> (82.8%), and the blaSHV gene (42.2%) (<a href="/img/revistas/bji
d/v15n2/a08fig01.jpg">Figure 1B</a>). Combination of two and three ESBL genes wa
s detected in 59.4% and 31.3% of ESBL-producing <i>Klebsiella</i> isolates.</fon
t></p>     ^cY#v15n2a08.htm##
00644000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040900076002001300485#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#63#59#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The clonal relatedness was studied b
y PFGE. Eighteen different pulsotypes were obtained among 18 ESBL-producing <i>E
. coli</i> isolates, and 23 pulsotypes among 63 ESBL-producing <i>K. pneumoniae<
/i> (<a href="/img/revistas/bjid/v15n2/a08fig01.jpg">Figure 1</a>). One isolate 
was consistently untypeable by the applied method.</font></p>     ^cY#v15n2a08.h
tm##
00830000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059500076002001300671#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#64#60#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Genotyping revealed that 82.3% of <i
>K. pneumoniae</i> isolated were non-unique and could be separated into 11 clone
s. The most prevalent (Clone 5) with 13 isolates, emerged in 2003 with four isol
ates in two hospital wards   (Clinical-Surgical floor 5 and Adult ICU floor 3), 
and   was detected again in 2004, with 9 isolates recovered   from the same hosp
ital wards. The occurrence of different   clones over the years and hospital war
ds are shown in <a href="/img/revistas/bjid/v15n2/a08tab02.jpg">Table 2</a>.</fo
nt></p>     ^cY#v15n2a08.htm##
00671000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043600076002001300512#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#65#61#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Among the 35 ESBL-producing <i>K. pn
eumoniae</i> isolates selected   for conjugation experiments, 74.3% (26 isolates
) transferred   ESBL genes by conjugation. All donor strains harbored   the <i>b
la</i><sub>CTX-M</sub> gene. The transconjugants obtained exhibited decreased   
susceptibilities to the aminoglycosides, amikacin, gentamicin and tobramicin.</f
ont></p>     ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#66#62#article#147#<p>&nbsp;</p>     ^
cY#v15n2a08.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#67#63#article#147#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>DISCUSSION</b></i></font></p> 
    ^cY#v15n2a08.htm##
01193000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704095800076002001301034#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#68#64#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Although, in our study, <i>E. coli</
i> was more frequently isolated than <i>K. pneumoniae</i>, ESBL production was m
ore prevalent in <i>K. pneumoniae</i>, with a high prevalence (43.7%) in the hos
pital environment, and especially in pediatric patients from the neonatal ICU. T
he high frequency of ESBL-producing bacteria in ICUs is expected due the great s
elective pressure resulting from the large use of antibiotics on ICU patients. H
igh prevalence of ESBL among isolated <i>K. pneumoniae</i> had been detected in 
numerous studies as reviewed by Paterson and Bonomo.<sup>1</sup> However, the pr
evalence of ESBL-positive <i>K. pneumoniae</i> and <i>E. coli</i> varies greatly
 among different geographical areas, with one of the highest reported rate (<i>K
. pneumoniae</i> 30% to 60%, <i>E. coli</i> 4.5% to 12%) in Latin American count
ries, including Brazil.<sup>24,25</sup></font></p>     ^cY#v15n2a08.htm##
00712000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047700076002001300553#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#69#65#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">As previously reported in Juiz de Fo
ra, Brazil,<sup>26</sup> low prevalence of ESBL phenotype was detected in commun
ity isolates, independently of the bacteria species, 2.6% for <i>K. pneumoniae</
i> and 0.4% for <i>E. coli</i>. Moreover, two of the five community-acquired cas
es reported healthcare contact (undergoing chemotherapy on day hospital) and may
 be health-care associated infections.</font></p>     ^cY#v15n2a08.htm##
01844000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704160900076002001301685#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#70#66#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Although the clinical impact of ESBL
s is related to a combination of factors that rely more heavily on functional ra
ther than structural characteristics, in terms of epidemiology or long-term effe
cts of antibiotic use, identification of specific </font>&#946;<font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">-lactamases and/or their genes can pl
ay an important role. Among ESLB gene families, <i>bla</i><sub>TEM</sub> was the
 most prevalent in both <i>E. coli</i> and <i>K. pneumoniae</i> ESBL-producing i
solates obtained from nosocomial and community infections. A very high prevalenc
e of <i>bla</i><sub>CTX-M</sub> (82.8%) was also detected among <i>K. pneumoniae
</i> isolates, and <i>bla</i><sub>SHV</sub> was present in 42.2% and 11.1% of <i
>K. pneumoniae</i> and <i>E. coli</i> ESBL-producing isolates, respectively. <i>
bla</i><sub>TEM</sub> family genes are frequent among enterobacteria,<sup>1</sup
> but not all TEM enzymes can be considered ESBL, and sequencing is therefore ne
cessary for allele identification.<sup>13</sup> Extra-intestinal infections caus
ed by <i>E. coli</i> harbouring plasmid-encoded <i>bla</i><sub>CTX-M</sub> have 
been increasingly reported worldwide, from both developed and developing countri
es in the last decades.<sup>1,15,27-30</sup> Moreover, while most of the SHV </f
ont>&#946;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">-lactamase
s are ESBLs, it is known that the chromosomic <i>bla</i><sub>SHV-1</sub> is high
ly prevalent in <i>K. pneumoniae</i>.<sup>14</sup></font></p>     ^cY#v15n2a08.h
tm##
01206000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704097100076002001301047#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#71#67#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Genotyping using PFGE analysis of ES
BL-producing <i>K. pneumoniae</i> revealed 23 different pulsotypes, consisting o
f 11 clones and 12 single patterns. Of the 11 clones, clone 5 was predominant an
d a persistent endemic clone in different wards and throughout the years. While 
multiclonal dissemination of ESBL-producing <i>K. pneumoniae</i> was found, no c
lonal dissemination of ESBL-producing <i>E. coli</i> was observed. Clonal dissem
ination suggests cross-transmission, which implies adopting precautionary measur
es of contact, including wearing aprons and gloves for contact with the colonize
d or infected patient, together with an efficient hygienization and antisepsis. 
Alternatively, the great genomic variability suggests strong selective pressure 
on bacterial populations, indicating the necessity of proper management of antib
iotic therapy, particularly within healthcare units.</font></p>     ^cY#v15n2a08
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#72#68#article#147#<p>&nbsp;</p>     ^
cY#v15n2a08.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#73#69#article#147#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>CONCLUSION</b></i></font></p> 
    ^cY#v15n2a08.htm##
00728000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049300076002001300569#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#74#70#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">To sum up, the data obtained in this
 study showed that ESBL-producing isolates of <i>E. coli</i> and especially of <
i>Klebsiella</i> spp. are essentially a nosocomial problem, and their disseminat
ion to the community are not very significant. However, public health profession
als must remain alert to the advancing issues associated with ESBLs to assist po
tential healthcare-associated and community outbreaks.</font></p>     ^cY#v15n2a
08.htm##
00759000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052400076002001300600#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#75#71#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Genes <i>bla</i><sub>TEM</sub>, <i>b
la</i><sub>CTX-M</sub>, and <i>bla</i><sub>SHV</sub> were detected in high frequ
ency among ESBL-positive <i>K. pneumoniae</i> and <i>E. coli</i> isolates, occur
ring alone or in combination. The high prevalence of ESBL genes that are frequen
tly found in conjugative plasmids and/or integrons may be considered a risk fact
or as they can be efficiently transferred within and between enterobacterial spe
cies.</font></p>     ^cY#v15n2a08.htm##
00985000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075000076002001300826#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#76#72#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Moreover, it was observed a great ge
nomic variability in the ESBL-producing isolates of <i>E. coli</i> and <i>Klebsi
ella</i> spp., indicating a strong selective pressure of antimicrobials. However
, it was also found that the polyclonal spread of strains might contribute to th
e proliferation of ESBL <i>K. pneumoniae</i> in the hospital and that endemic ES
BL clone persisted throughout the years in the hospital. Finally, we have shown 
that molecular typing ESBL-producing <i>K. pneumoniae</i> was clinically relevan
t, given that patient-to-patient transmission of organisms harboring ESBLs, whic
h were fundamental for infection control interventions, clearly occurs.</font></
p>     ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#77#73#article#147#<p>&nbsp;</p>     ^
cY#v15n2a08.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#78#74#article#147#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p> 
    ^cY#v15n2a08.htm##
00505000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025600078002001300334#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#79#75#article#147#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Paterson DL, Bonomo
 RA. Extended-spectrum </font>&#946;<font size="2" face="Verdana, Arial, Helveti
ca, sans-serif">-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657-
86.    ^cY#v15n2a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#80#76#article#147#</font></p>     ^cY
#v15n2a08.htm##
00570000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704032100078002001300399#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#81#77#article#147#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Bush K, Jacoby GA, 
Medeiros AA. A functional classification scheme for </font>&#946;<font size="2" 
face="Verdana, Arial, Helvetica, sans-serif">-lactamases and its correlation wit
h molecular structure. Antimicrob Agents Chemothey 1995; 39:1211-33.    ^cY#v15n
2a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#82#78#article#147#</font></p>     ^cY
#v15n2a08.htm##
00561000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031200078002001300390#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#83#79#article#147#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Giske CG, Sundsfjor
d AS, Kahlmeter G <i>et al.</i> Redefining extended-spectrum </font>&#946;<font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">-lactamase: balancing scie
nce and clinical need. J Antimicrob Chemother 2009; 63:1-4.    ^cY#v15n2a08.htm#
#
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#84#80#article#147#</font></p>     ^cY
#v15n2a08.htm##
00618000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704036900078002001300447#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#85#81#article#147#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Jacoby GA, Walsh KE
, Walker VJ. Identification of extended-spectrum, AmpC, and carbapenem-hydrolyzi
ng </font>&#946;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">-lac
tamases in <i>Escherichia coli</i> and <i>Klebsiella</i> pneumoniae by disk test
s. J Clin Microbiol 2006; 44:1971-6.    ^cY#v15n2a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#86#82#article#147#</font></p>     ^cY
#v15n2a08.htm##
00562000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031300078002001300391#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#87#83#article#147#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Mena A, Plasencia V
, Garc&iacute;a L <i>et al.</i> Characterization of a large outbreak by CTX-M-1-
producing <i>Klebsiella</i> pneumoniae and mechanisms leading to in vivo carbape
nem resistance development. J Clin Microbiob2006; 44:2831-7.    ^cY#v15n2a08.htm
##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#88#84#article#147#</font></p>     ^cY
#v15n2a08.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019400078002001300272#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#89#85#article#147#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Rahal JJ. The role 
of carbapenems in initial therapy for serious Gram-negative infectious. Critical
 Care 2008; (12):2-7.    ^cY#v15n2a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#90#86#article#147#</font></p>     ^cY
#v15n2a08.htm##
00581000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704033200078002001300410#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#91#87#article#147#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Poirel L, Decousser
 JW, Nordmann, P. Insertion sequence ISEcp1B is involved in expression and mobil
ization of the blaCTX-M </font>&#946;<font size="2" face="Verdana, Arial, Helvet
ica, sans-serif">-lactamase gene. Antimicrob Agents Chemother 2003; 47:2938-45. 
   ^cY#v15n2a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#92#88#article#147#</font></p>     ^cY
#v15n2a08.htm##
00636000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704038700078002001300465#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#93#89#article#147#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Machado E, Cant&oac
ute;n R, Baquero F <i>et al.</i> Integron content of extended-spectrum-</font>&#
946;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">-lactamase-produ
cing <i>Escherichia coli</i> strains over 12 years in a single hospital in Madri
d, Spain. Antimicrob Agents Chemother 2005; 49:1823-9.    ^cY#v15n2a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#94#90#article#147#</font></p>     ^cY
#v15n2a08.htm##
00421000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017200078002001300250#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#95#91#article#147#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Slama TG. Gram-nega
tive antibiotic resistance: there is a price to pay. Critical Care 2008; 12:S4. 
   ^cY#v15n2a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#96#92#article#147#</font></p>     ^cY
#v15n2a08.htm##
00323000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008800076002001300164#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#97#93#article#147#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">10. ?</font></p>     ^cY#v15n2a08.ht
m##
00637000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704038700079002001300466#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#98#94#article#147#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Paterson DL, Ko W
-C, Gottberg A Von <i>et al.</i> International prospective study of <i>Klebsiell
a</i> pneumoniae bacteremia: implications of extended-spectrum </font>&#946;<fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif">-lactamase production in
 nosocomial infections. Ann Intern Med 2004; 140:26-32.    ^cY#v15n2a08.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#99#95#article#147#</font></p>     ^cY
#v15n2a08.htm##
00655000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704040400080002001300484#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#100#96#article#147#11#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Garcia DO, Doi Y
, Szabo D <i>et al.</i> Multiclonal outbreak of <i>Klebsiella</i> pneumoniae pro
ducing extended-spectrum </font>&#946;<font size="2" face="Verdana, Arial, Helve
tica, sans-serif">-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal in
tensive care unit in Brazil. Antimicrob Agents Chemother 2008; 52:1790-3.    ^cY
#v15n2a08.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#101#97#article#147#</font></p>     ^c
Y#v15n2a08.htm##
00547000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704029600080002001300376#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#102#98#article#147#12#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Knothe H, Shah P
, Kramery V <i>et al.</i> Transferable resistance to cefotaxime, cefoxitin, cefa
mandole and cefuroxime in clinical isolates of <i>Klebsiella</i> pneumoniae and 
Serratia marcescens. Infection 1983;11:315-7.    ^cY#v15n2a08.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#103#99#article#147#</font></p>     ^c
Y#v15n2a08.htm##
00594000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034200081002001300423#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#104#100#article#147#13#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Bradford, PA. E
xtended-spectrum </font>&#946;<font size="2" face="Verdana, Arial, Helvetica, sa
ns-serif">-lactamases in the 21<sup>st</sup> century: characterization, epidemio
logy, and detection of this important resistance threat. Clin Microbiol Rev 2001
; 14:933-51.    ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#105#101#article#147#</font></p>     ^
cY#v15n2a08.htm##
00741000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704048900081002001300570#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#106#102#article#147#14#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Paterson DL, Hu
jer KM, Hujer AM <i>et al.</i> Extended-spectrum </font>&#946;<font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">-lactamases in <i>Klebsiella</i> pneum
oniae bloodstream isolates from seven countries: dominance and widespread preval
ence of SHV- and CTX-M-type </font>&#946;<font size="2" face="Verdana, Arial, He
lvetica, sans-serif">-lactamases. Antimicrob Agents Chemother 2003; 47:3554-60. 
   ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#107#103#article#147#</font></p>     ^
cY#v15n2a08.htm##
00577000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032500081002001300406#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#108#104#article#147#15#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Rodriguez-Ba&nt
ilde;o J, Navarro MD, Romero L <i>et al.</i> Epidemiology and clinical features 
of infections caused by extended-spectrum beta-lactamase-producing <i>Escherichi
a coli</i> in non-hospitalized patients. J Clin Microbiol 2004; 42:1089-94.    ^
cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#109#105#article#147#</font></p>     ^
cY#v15n2a08.htm##
00578000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032600081002001300407#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#110#106#article#147#16#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Oteo J, Navarro
 C, Cercenado E <i>et al.</i> Spread of <i>Escherichia coli</i> strains with hig
h-level cefotaxime and ceftazidime resistance between the community, long-term c
are facilities and hospital institutions. J Clin Microbiol 2006; 44:2359-66.    
^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#111#107#article#147#</font></p>     ^
cY#v15n2a08.htm##
00735000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704048300081002001300564#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#112#108#article#147#17#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Mendon&ccedil;a
 N, Leit&atilde;o J, Manageiro V <i>et al.</i> Antimicrobial Resistance Surveill
ance Program in Portugal; Cani&ccedil;a, M. Spread of extended-spectrum </font>&
#946;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">-lactamase CTX-
M-producing <i>Escherichia coli</i> clinical isolates in community and nosocomia
l environments in Portugal. Antimicrob Agents Chemother 2007; 51:1946-55.    ^cY
#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#113#109#article#147#</font></p>     ^
cY#v15n2a08.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020800081002001300289#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#114#110#article#147#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Garner JS, Jarv
is WR, Emori TG <i>et al.</i> CDC definitions isolated for nosocomial infections
. Am J Infect Control 1988; 16:128-40.    ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#115#111#article#147#</font></p>     ^
cY#v15n2a08.htm##
00580000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032800081002001300409#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#116#112#article#147#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Rodriguez-Ba&nt
ilde;o, J, Navarro, MD, Romero, L <i>et al.</i> Epidemiology and clinical featur
es of infections caused by extended-spectrum beta-lactamase-producing <i>Escheri
chia coli</i> in non-hospitalized patients. J Clin Microbiol 2004; 42:1089-94.  
  ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#117#113#article#147#</font></p>     ^
cY#v15n2a08.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028000081002001300361#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#118#114#article#147#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Clinical and La
boratory Standards Institute. (CLSI). Performance standards for antimicrobial di
sk susceptibility testing. Approved standard M2-A10. Clinical Laboratory Standar
ds Institute, Wayne, PA, 2007.    ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#119#115#article#147#</font></p>     ^
cY#v15n2a08.htm##
00786000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704053400081002001300615#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#120#116#article#147#21#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Centers for Dis
ease Control and Prevention. One-Day (24-28 h) Standardized Laboratory Protocol 
for Molecular Subtyping of <i>Escherichia coli</i> O157:H7, non-typhoidal Salmon
ella serotypes, and Shigella sonnei by Pulsed Field Gel Electrophoresis. In: Pul
seNet PFGE Manual <a href="http://www.cdc.gov/PulseNet/protocols/ecoli_salmonell
a_shigella_protocols.pdf" target="_blank">http://www.cdc.gov/PulseNet/protocols/
ecoli_salmonella_shigella_protocols.pdf</a>.    ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#121#117#article#147#</font></p>     ^
cY#v15n2a08.htm##
00540000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028800081002001300369#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#122#118#article#147#22#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Tenover F, Arbe
it R, Goering R <i>et al.</i> Interpreting chromosomal DNA restriction patterns 
produced by pulsed-field gel electrophoresis: criteria for bacterial strain typi
ng. J Clin Microbiol 1995; 33:2233-39.    ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#123#119#article#147#</font></p>     ^
cY#v15n2a08.htm##
00674000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704042200081002001300503#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#124#120#article#147#23#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Coque TM, Liver
 A, P&eacute;rez-Dias JC <i>et al.</i> Genes encoding TEM-4, SHV-2, and CTX-M-10
 extended-spectrum </font>&#946;<font size="2" face="Verdana, Arial, Helvetica, 
sans-serif">-lactamase are carried by multiple <i>Klebsiella</i> pneumoniae clon
es in a single hospital (Madrid, 1989 to 2000). Antimicrob Agents Chemother 2002
; 46:500-10.    ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#125#121#article#147#</font></p>     ^
cY#v15n2a08.htm##
00665000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704041300081002001300494#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#126#122#article#147#24#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Winokur PL, Can
ton R, Casellas JM <i>et al.</i> Variations in the prevalence of strains express
ing an extended-spectrum </font>&#946;<font size="2" face="Verdana, Arial, Helve
tica, sans-serif">-lactamases phenotype and characterization of isolates from Eu
rope, the Americas, and the Western Pacific region. Clin Infec Dis 2001; 32:94-1
03.    ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#127#123#article#147#</font></p>     ^
cY#v15n2a08.htm##
00559000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030700081002001300388#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#128#124#article#147#25#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Sader, HS, Gale
s, AC, Pfaller, MA <i>et al.</i> Pathogens frequency and resistance patterns in 
Brazilian hospitals: summary of results from three years of SENTRY antimicrobial
 surveillance program. Braz J Infect Dis 2001; 59:200-14.    ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#129#125#article#147#</font></p>     ^
cY#v15n2a08.htm##
00582000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033000081002001300411#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#130#126#article#147#26#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Minarini LA, Ga
les AC, Palazzo IC <i>et al.</i> Prevalence of community-occurring extended spec
trum </font>&#946;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">-l
actamase-producing Enterobacteriaceae in Brazil. Curr Microbiol 2007; 54:335-41.
    ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#131#127#article#147#</font></p>     ^
cY#v15n2a08.htm##
00524000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027200081002001300353#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#132#128#article#147#27#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Nicolas-Chanoin
e, MH, Blanco, J, Leflon-Guibout, V <i>et al.</i> Intercontinental emergence of 
<i>Escherichia coli</i> clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chem
other 2008; 61:273-81.    ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#133#129#article#147#</font></p>     ^
cY#v15n2a08.htm##
00648000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704039600081002001300477#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#134#130#article#147#28#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Romero, L, L&oa
cute;pez, L, Rodrigues-Ba&ntilde;o, L <i>et al.</i> Long-term study of the frequ
ency of <i>Escherichia coli</i> and <i>Klebsiella</i> pneumoniae isolates produc
ing extended-spectrum </font>&#946;<font size="2" face="Verdana, Arial, Helvetic
a, sans-serif">-lactamases. Clin Microbiol Infect 2005; 11:625-31.    ^cY#v15n2a
08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#135#131#article#147#</font></p>     ^
cY#v15n2a08.htm##
00484000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023200081002001300313#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#136#132#article#147#29#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Canton R, Coque
 TM. The CTX-M </font>&#946;<font size="2" face="Verdana, Arial, Helvetica, sans
-serif">-lactamase pandemic. Curr Opin Microbiol 2006; 466-75.    ^cY#v15n2a08.h
tm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#137#133#article#147#</font></p>     ^
cY#v15n2a08.htm##
00636000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704038400081002001300465#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#138#134#article#147#30#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Lewis JS, Herre
ra M, Wickers B <i>et al.</i> First report of the emergence of CTX-M-type extend
ed-spectrum </font>&#946;<font size="2" face="Verdana, Arial, Helvetica, sans-se
rif">-lactamases (ES-BLs) as the predominant ESBL isolated in a U.S. health care
 system. Antimicrob Agents Chemother 2007; 51:4015-21.    ^cY#v15n2a08.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#139#135#article#147#</font></p>     ^
cY#v15n2a08.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#140#136#article#147#<p>&nbsp;</p>    
 ^cY#v15n2a08.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#141#137#article#147#<p>&nbsp;</p>    
 ^cY#v15n2a08.htm##
00426000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018900078002001300267#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#142#138#article#147#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:
</b>    ^cY#v15n2a08.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#143#139#article#147#<br> Cl&aacute;ud
ia Wollheim    ^cY#v15n2a08.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009900078002001300177#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#144#140#article#147#<br> Laborat&oacu
te;rio de Microbiologia M&eacute;dica Humana Universidade de Caxias do Sul    ^c
Y#v15n2a08.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007300078002001300151#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#145#141#article#147#<br> Rua Francisc
o Get&uacute;lio Vargas, 1130, Petr&oacute;polis    ^cY#v15n2a08.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#146#142#article#147#<br> Caxias do Su
l, RS, Brazil    ^cY#v15n2a08.htm##
00297000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006000078002001300138#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#147#143#article#147#<br> Phone: + 55 
54 3218-2548 Fax: + 55 54 3218-2041    ^cY#v15n2a08.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007700078002001300155#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#148#144#article#147#<br> <a href="mai
lto:cwollhei@ucs.br">cwollhei@ucs.br</a></font></p>     ^cY#v15n2a08.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009500078002001300173#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#149#145#article#147#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted on: 06/12/2010    ^cY#v1
5n2a08.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#150#146#article#147#<br>   Approved o
n: 09/29/2010    ^cY#v15n2a08.htm##
00299000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006200078002001300140#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a08.htm#S#p#151#147#article#147#<br>   We declare
 no conflict of interest.</font></p>     ^cY#v15n2a08.htm##
00544000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100017000960120
05900113030001900172065000900191064000500200031000300205014000700208865000900215
002001300224035001000237801001900247#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a08.htm#S#c#152#1#article#30#1#^rND^sPaterson^nDL#^rND^sBonomo^nRA#Extended-s
pectrum &#946;-lactamases: a clinical update^len#Clin Microbiol Rev#20050000#200
5#18#657-86#20110400#v15n2a08.htm#0893-8512#Clin Microbiol Rev##
00588000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100017000910100
01900108012010600127030002800233710000200261065000900263064000500272031000300277
014000800280865000900288002001300297#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a08.htm#S#c#153#2#article#30#2#^rND^sBush^nK#^rND^sJacoby^nGA#^rND^sMedeiros^
nAA#A functional classification scheme for &#946;-lactamases and its correlation
 with molecular structure^len#Antimicrob Agents Chemothey#2#19950000#1995#39#121
1-33#20110400#v15n2a08.htm##
00627000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100021000930100
01900114810000600133012008700139030002300226065000900249064000500258031000300263
014000400266865000900270002001300279035001000292801002300302#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#154#3#article#30#3#^rND^sGiske^nCG#^rND^s
Sundsfjord^nAS#^rND^sKahlmeter^nG#et al#Redefining extended-spectrum &#946;-lact
amase: balancing science and clinical need^len#J Antimicrob Chemother#20090000#2
009#63#1-4#20110400#v15n2a08.htm#0305-7453#J Antimicrob Chemother##
00659000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
01700110012015200127030001700279065000900296064000500305031000300310014000700313
865000900320002001300329035001000342801001700352#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a08.htm#S#c#155#4#article#30#4#^rND^sJacoby^nGA#^rND^sWalsh^nKE#^
rND^sWalker^nVJ#Identification of extended-spectrum, AmpC, and carbapenem-hydrol
yzing &#946;-lactamases in Escherichia coli and Klebsiella pneumoniae by disk te
sts^len#J Clin Microbiol#20060000#2006#44#1971-6#20110400#v15n2a08.htm#0095-1137
#J Clin Microbiol##
00639000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100019000910100
01600110810000600126012015200132030001700284710000200301065000900303064000500312
031000300317014000700320865000900327002001300336#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a08.htm#S#c#156#5#article#30#5#^rND^sMena^nA#^rND^sPlasencia^nV#^
rND^sGarcía^nL#et al#Characterization of a large outbreak by CTX-M-1-producing K
lebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance dev
elopment^len#J Clin Microbiob#2#20060000#2006#44#2831-7#20110400#v15n2a08.htm##
00524000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770120084000930300
01400177065000900191064000500200032000300205014000400208865000900212002001300221
035001000234801001400244#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S
#c#157#6#article#30#6#^rND^sRahal^nJJ#The role of carbapenems in initial therapy
 for serious Gram-negative infectious^len#Critical Care#20080000#2008#12#2-7#201
10400#v15n2a08.htm#0270-7462#CRITICAL CARE##
00646000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100020000930100
01800113012011200131030002800243065000900271064000500280031000300285014000800288
865000900296002001300305035001000318801002800328#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a08.htm#S#c#158#7#article#30#7#^rND^sPoirel^nL#^rND^sDecousser^nJ
W#^rND^sNordmann^nP#Insertion sequence ISEcp1B is involved in expression and mob
ilization of the blaCTX-M &#946;-lactamase gene^len#Antimicrob Agents Chemother#
20030000#2003#47#2938-45#20110400#v15n2a08.htm#0066-4804#Antimicrob Agents Chemo
ther##
00693000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
01700110810000600127012014600133030002800279065000900307064000500316031000300321
014000700324865000900331002001300340035001000353801002800363#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#159#8#article#30#8#^rND^sMachado^nE#^rND^
sCantón^nR#^rND^sBaquero^nF#et al#Integron content of extended-spectrum-&#946;-l
actamase-producing Escherichia coli strains over 12 years in a single hospital i
n Madrid, Spain^len#Antimicrob Agents Chemother#20050000#2005#49#1823-9#20110400
#v15n2a08.htm#0066-4804#Antimicrob Agents Chemother##
00503000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770120065000930300
01400158065000900172064000500181031000300186020000200189865000900191002001300200
035001000213801001400223#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S
#c#160#9#article#30#9#^rND^sSlama^nTG#Gram-negative antibiotic resistance: there
 is a price to pay^len#Critical Care#20080000#2008#12#4#20110400#v15n2a08.htm#02
70-7462#CRITICAL CARE##
00688000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100014000980100
02200112810000600134012016000140030001500300065000900315064000500324031000400329
014000600333865000900339002001300348035001000361801001500371#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#161#10#article#30#11#^rND^sPaterson^nDL#^
rND^sKo^nW-C#^rND^sGottberg^nA Von#et al#International prospective study of Kleb
siella pneumoniae bacteremia: implications of extended-spectrum &#946;-lactamase
 production in nosocomial infections^len#Ann Intern Med#20040000#2004#140#26-32#
20110400#v15n2a08.htm#0003-4819#Ann Intern Med##
00718000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100013000960100
01500109810000600124012017400130030002800304065000900332064000500341031000300346
014000700349865000900356002001300365035001000378801002800388#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#162#11#article#30#12#^rND^sGarcia^nDO#^rN
D^sDoi^nY#^rND^sSzabo^nD#et al#Multiclonal outbreak of Klebsiella pneumoniae pro
ducing extended-spectrum &#946;-lactamase CTX-M-2 and novel variant CTX-M-59 in 
a neonatal intensive care unit in Brazil^len#Antimicrob Agents Chemother#2008000
0#2008#52#1790-3#20110400#v15n2a08.htm#0066-4804#Antimicrob Agents Chemother##
00660000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100014000950100
01700109810000600126012015100132030001000283065000900293064000500302031000300307
014000600310865000900316002001300325035001000338801001000348#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#163#12#article#30#13#^rND^sKnothe^nH#^rND
^sShah^nP#^rND^sKramery^nV#et al#Transferable resistance to cefotaxime, cefoxiti
n, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and 
Serratia marcescens^len#Infection#19830000#1983#11#315-7#20110400#v15n2a08.htm#0
173-2129#Infection##
00601000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790120143000980300
01900241065000900260064000500269031000300274014000700277865000900284002001300293
035001000306801001900316#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S
#c#164#13#article#30#14#^rND^sBradford^nPA#Extended-spectrum &#946;-lactamases i
n the 21st century: characterization, epidemiology, and detection of this import
ant resistance threat^len#Clin Microbiol Rev#20010000#2001#14#933-51#20110400#v1
5n2a08.htm#0893-8512#Clin Microbiol Rev##
00736000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01600114810000600130012018500136030002800321065000900349064000500358031000300363
014000800366865000900374002001300383035001000396801002800406#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#165#14#article#30#15#^rND^sPaterson^nDL#^
rND^sHujer^nKM#^rND^sHujer^nAM#et al#Extended-spectrum &#946;-lactamases in Kleb
siella pneumoniae bloodstream isolates from seven countries: dominance and wides
pread prevalence of SHV- and CTX-M-type &#946;-lactamases^len#Antimicrob Agents 
Chemother#20030000#2003#47#3554-60#20110400#v15n2a08.htm#0066-4804#Antimicrob Ag
ents Chemother##
00688000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100024000790100018001030100
01600121810000600137012015200143030001700295065000900312064000500321031000300326
014000800329865000900337002001300346035001000359801001700369#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#166#15#article#30#16#^rND^sRodriguez-Baño
^nJ#^rND^sNavarro^nMD#^rND^sRomero^nL#et al#Epidemiology and clinical features o
f infections caused by extended-spectrum beta-lactamase-producing Escherichia co
li in non-hospitalized patients^len#J Clin Microbiol#20040000#2004#42#1089-94#20
110400#v15n2a08.htm#0095-1137#J Clin Microbiol##
00696000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100017000930100
01900110810000600129012016800135030001700303065000900320064000500329031000300334
014000800337865000900345002001300354035001000367801001700377#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#167#16#article#30#17#^rND^sOteo^nJ#^rND^s
Navarro^nC#^rND^sCercenado^nE#et al#Spread of Escherichia coli strains with high
-level cefotaxime and ceftazidime resistance between the community, long-term ca
re facilities and hospital institutions^len#J Clin Microbiol#20060000#2006#44#23
59-66#20110400#v15n2a08.htm#0095-1137#J Clin Microbiol##
00706000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01900113810000600132012015300138030002800291065000900319064000500328031000300333
014000800336865000900344002001300353035001000366801002800376#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#168#17#article#30#18#^rND^sMendonça^nN#^r
ND^sLeitão^nJ#^rND^sManageiro^nV#et al#Spread of extended-spectrum &#946;-lactam
ase CTX-M-producing Escherichia coli clinical isolates in community and nosocomi
al environments in Portugal^len#Antimicrob Agents Chemother#20070000#2007#51#194
6-55#20110400#v15n2a08.htm#0066-4804#Antimicrob Agents Chemother##
00588000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01600113810000600129012005500135030002000190065000900210064000500219031000300224
014000700227865000900234002001300243035001000256801002000266#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#169#18#article#30#19#^rND^sGarner^nJS#^rN
D^sJarvis^nWR#^rND^sEmori^nTG#et al#CDC definitions isolated for nosocomial infe
ctions^len#Am J Infect Control#19880000#1988#16#128-40#20110400#v15n2a08.htm#019
6-6553#Am J Infect Control##
00688000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100024000790100018001030100
01600121810000600137012015200143030001700295065000900312064000500321031000300326
014000800329865000900337002001300346035001000359801001700369#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#170#19#article#30#20#^rND^sRodriguez-Baño
^nJ#^rND^sNavarro^nMD#^rND^sRomero^nL#et al#Epidemiology and clinical features o
f infections caused by extended-spectrum beta-lactamase-producing Escherichia co
li in non-hospitalized patients^len#J Clin Microbiol#20040000#2004#42#1089-94#20
110400#v15n2a08.htm#0095-1137#J Clin Microbiol##
00537000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170044000790180098001230620
04000221066001000261065000900271064000500280865000900285002001300294#v15n2#V:\Sc
iELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#c#171#20#article#30#21#Clinical and
 Laboratory Standards Institute#Performance standards for antimicrobial disk sus
ceptibility testing: Approved standard M2-A10^len#Clinical Laboratory Standards 
Institute#Wayne^ePA#20070000#2007#20110400#v15n2a08.htm##
00677000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760110043000790120200001220170
00900322061000500331018001100336037007800347865000900425002001300434#v15n2#V:\Sc
iELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#c#172#21#article#30#22#Centers for 
Disease Control and Prevention#One-Day (24-28 h) Standardized Laboratory Protoco
l for Molecular Subtyping of Escherichia coli O157:H7, non-typhoidal Salmonella 
serotypes, and Shigella sonnei by Pulsed Field Gel Electrophoresis^len#PulseNet#
PFGE#Manual^lpt#http://www.cdc.gov/PulseNet/protocols/ecoli_salmonella_shigella_
protocols.pdf#20110400#v15n2a08.htm##
00665000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01700112810000600129012013700135030001700272065000900289064000500298031000300303
014000800306865000900314002001300323035001000336801001700346#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#173#22#article#30#23#^rND^sTenover^nF#^rN
D^sArbeit^nR#^rND^sGoering^nR#et al#Interpreting chromosomal DNA restriction pat
terns produced by pulsed-field gel electrophoresis: criteria for bacterial strai
n typing^len#J Clin Microbiol#19950000#1995#33#2233-39#20110400#v15n2a08.htm#009
5-1137#J Clin Microbiol##
00729000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
02100110810000600131012017800137030002800315065000900343064000500352031000300357
014000700360865000900367002001300376035001000389801002800399#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#174#23#article#30#24#^rND^sCoque^nTM#^rND
^sLiver^nA#^rND^sPérez-Dias^nJC#et al#Genes encoding TEM-4, SHV-2, and CTX-M-10 
extended-spectrum &#946;-lactamase are carried by multiple Klebsiella pneumoniae
 clones in a single hospital (Madrid, 1989 to 2000)^len#Antimicrob Agents Chemot
her#20020000#2002#46#500-10#20110400#v15n2a08.htm#0066-4804#Antimicrob Agents Ch
emother##
00686000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01900113810000600132012019500138030001500333710000200348065000900350064000500359
031000300364014000700367865000900374002001300383#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a08.htm#S#c#175#24#article#30#25#^rND^sWinokur^nPL#^rND^sCanton^n
R#^rND^sCasellas^nJM#et al#Variations in the prevalence of strains expressing an
 extended-spectrum &#946;-lactamases phenotype and characterization of isolates 
from Europe, the Americas, and the Western Pacific region^len#Clin Infec Dis#2#2
0010000#2001#32#94-103#20110400#v15n2a08.htm##
00644000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01800111810000600129012015300135030001800288710000200306065000900308064000500317
031000300322014000700325865000900332002001300341#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a08.htm#S#c#176#25#article#30#26#^rND^sSader^nHS#^rND^sGales^nAC#
^rND^sPfaller^nMA#et al#Pathogens frequency and resistance patterns in Brazilian
 hospitals: summary of results from three years of SENTRY antimicrobial surveill
ance program^len#Braz J Infect Dis#2#20010000#2001#59#200-14#20110400#v15n2a08.h
tm##
00638000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01800114810000600132012011200138030001500250065000900265064000500274031000300279
014000700282865000900289002001300298035001000311801001500321#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#177#26#article#30#27#^rND^sMinarini^nLA#^
rND^sGales^nAC#^rND^sPalazzo^nIC#et al#Prevalence of community-occurring extende
d spectrum &#946;-lactamase-producing Enterobacteriaceae in Brazil^len#Curr Micr
obiol#20070000#2007#54#335-41#20110400#v15n2a08.htm#0343-8651#Curr Microbiol##
00645000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100027000790100016001060100
02400122810000600146012008900152030002300241065000900264064000500273031000300278
014000700281865000900288002001300297035001000310801002300320#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#178#27#article#30#28#^rND^sNicolas-Chanoi
ne^nMH#^rND^sBlanco^nJ#^rND^sLeflon-Guibout^nV#et al#Intercontinental emergence 
of Escherichia coli clone O25:H4-ST131 producing CTX-M-15^len#J Antimicrob Chemo
ther#20080000#2008#61#273-81#20110400#v15n2a08.htm#0305-7453#J Antimicrob Chemot
her##
00638000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
02400110810000600134012013800140030002200278710000200300065000900302064000500311
031000300316014000700319865000900326002001300335#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a08.htm#S#c#179#28#article#30#29#^rND^sRomero^nL#^rND^sLópez^nL#^
rND^sRodrigues-Baño^nL#et al#Long-term study of the frequency of Escherichia col
i and Klebsiella pneumoniae isolates producing extended-spectrum &#946;-lactamas
es^len#Clin Microbiol Infect#2#20050000#2005#11#625-31#20110400#v15n2a08.htm##
00470000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950120
04000111030002000151710000200171065000900173064000500182014000700187865000900194
002001300203#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a08.htm#S#c#180#29#ar
ticle#30#30#^rND^sCanton^nR#^rND^sCoque^nTM#The CTX-M &#946;-lactamase pandemic^
len#Curr Opin Microbiol#2#20060000#2006#466-75#20110400#v15n2a08.htm##
00705000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01700112810000600129012015500135030002800290065000900318064000500327031000300332
014000800335865000900343002001300352035001000365801002800375#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a08.htm#S#c#181#30#article#30#31#^rND^sLewis^nJS#^rND
^sHerrera^nM#^rND^sWickers^nB#et al#First report of the emergence of CTX-M-type 
extended-spectrum &#946;-lactamases (ES-BLs) as the predominant ESBL isolated in
 a U.S. health care system^len#Antimicrob Agents Chemother#20070000#2007#51#4015
-21#20110400#v15n2a08.htm#0066-4804#Antimicrob Agents Chemother##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#o#1#1#article#1
#20110406#124829#v15n2a09.htm#127##
02655000000000589000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400110014403500100015501201410
01650100028003060100029003340100042003630100036004050700032004410831334004730850
00801807085002901815085002101844085002201865085003801887085002501925085004001950
11700060199007200030199611200090199911100110200811400090201911300110202805800070
2039058000602046002001302052#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.h
tm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#9#BJID230#nd#Braz J Infect Dis#1
5#2#20110400#^f144^l150#1413-8670#Identification of putative new Escherichia col
i flagellar antigens from human origin using serology, PCR-RFlP and DNA sequenci
ng methods^len#^rND^nMonique Ribeiro^sTiba#^rND^1A01^nClaúdia de^sMoura#^rND^1A0
1^nMarcelo Falsarella^sCarazzolle#^rND^1A01^nDomingos da Silva^sLeite#UNICAMP^iA
01^cSão Paulo^pBrazil#^len^aEscherichia coli has been isolated frequently, showi
ng flagellar antigens that are not recognized by any of the 53 antisera, provide
d by the most important reference center of E. coli, The International Escherich
ia and Klebsiella Center (WHO) of the Statens Serum Institute, Copenhagen, Denma
rk. The objective of this study was to characterize flagellar antigens of E. col
i that express non-typeable H antigens. The methods used were serology, PCR-RFLP
 and DNA sequencing. This characterization was performed by gene amplification o
f the fliC (flagellin protein) by polymerase chain reaction in all 53 standards 
E.coli strains for the H antigens and 20 E. coli strains for which the H antigen
 was untypeable. The amplicons were digested by restriction enzymes, and differe
nt restriction enzyme profiles were observed. Anti-sera were produced in rabbits
, for the non-typeable strains, and agglutination tests were carried out. In con
clusion,the results showed that although non-typeable and typable H antigens str
ains had similar flagellar antigens, the two types of strains were distinct in t
erms of nucleotide sequence, and did not phenotypically react with the standard 
antiserum, as expected. Thirteen strains had been characterized as likely putati
ve new H antigen using PCR-RFLP techniques, DNA sequencing and/or serology.#^dnd
^i1#^tm^len^kEscherichia coli^i1#^tm^len^kantigens^i1#^tm^len^kbacterial^i1#^tm^
len^kpolymerase chain reaction^i1#^tm^len^kpolymorphism^i1#^tm^len^krestriction 
fragment length^i1#other#12#20100815#08/15/2010#20101021#10/21/2010#FAPESP#CAPES
#v15n2a09.htm##
02725000000000589000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000200099049000800101158000300109
03000180011203100030013003200020013306500090013501400110014403500100015501201550
01650100028003200100029003480100042003770100036004190700032004550831383004870850
00801870085003601878085002101914085002201935085003801957085002501995085004002020
11700060206007200030206611200090206911100110207811400090208911300110209805800070
2109058000602116002001302122#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.h
tm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#9#BJID230#nd#Braz J Infect Dis#1
5#2#20110400#^f144^l150#1413-8670#<b>Identification of putative new <i>Escherich
ia coli</i> flagellar antigens from human origin using serology, PCR-RFlP and DN
A sequencing methods</b>^len#^rND^nMonique Ribeiro^sTiba#^rND^1A01^nClaúdia de^s
Moura#^rND^1A01^nMarcelo Falsarella^sCarazzolle#^rND^1A01^nDomingos da Silva^sLe
ite#UNICAMP^iA01^cSão Paulo^pBrazil#^len^a<i>Escherichia coli</i> has been isola
ted frequently, showing flagellar antigens that are not recognized by any of the
 53 antisera, provided by the most important reference center of <i>E. coli</i>,
 The International <i>Escherichia</i> and <i>Klebsiella</i> Center (WHO) of the 
Statens Serum Institute, Copenhagen, Denmark. The objective of this study was to
 characterize flagellar antigens of <i>E. coli</i> that express non-typeable H a
ntigens. The methods used were serology, PCR-RFLP and DNA sequencing. This chara
cterization was performed by gene amplification of the fliC (flagellin protein) 
by polymerase chain reaction in all 53 standards <i>E.coli</i> strains for the H
 antigens and 20 <i>E. coli</i> strains for which the H antigen was untypeable. 
The amplicons were digested by restriction enzymes, and different restriction en
zyme profiles were observed. Anti-sera were produced in rabbits, for the non-typ
eable strains, and agglutination tests were carried out. In conclusion,the resul
ts showed that although non-typeable and typable H antigens strains had similar 
flagellar antigens, the two types of strains were distinct in terms of nucleotid
e sequence, and did not phenotypically react with the standard antiserum, as exp
ected. Thirteen strains had been characterized as likely putative new H antigen 
using PCR-RFLP techniques, DNA sequencing and/or serology.#^dnd^i1#^tm^len^k<i>E
scherichia coli</i>^i1#^tm^len^kantigens^i1#^tm^len^kbacterial^i1#^tm^len^kpolym
erase chain reaction^i1#^tm^len^kpolymorphism^i1#^tm^len^krestriction fragment l
ength^i1#other#12#20100815#08/15/2010#20101021#10/21/2010#FAPESP#CAPES#v15n2a09.
htm##
02791000000000613000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000200117049000800119
15800030012703000210013003100030015103200020015406500090015601400110016503500100
01760120141001860100028003270100029003550100042003840100036004260700034004620831
33400496085000801830085002901838085002101867085002201888085003801910085002501948
08500400197311700060201307200030201911200090202211100110203111400090204211300110
2051058000702062058000602069002001302075008008902088#v15n2#V:\SciELO\serial\bjid
\v15n2\markup\v15n2a09.htm#S#l#4#1#article#1#^mMar./Apr.^a2011#oa#en#br1.1#1#4.0
#ilus#tab#9#BJID230#nd#Braz. j. infect. dis#15#2#20110400#^f144^l150#1413-8670#I
dentification of putative new Escherichia coli flagellar antigens from human ori
gin using serology, PCR-RFlP and DNA sequencing methods^len#^rND^nMonique Ribeir
o^sTiba#^rND^1A01^nClaúdia de^sMoura#^rND^1A01^nMarcelo Falsarella^sCarazzolle#^
rND^1A01^nDomingos da Silva^sLeite#^iA01^1UNICAMP^cSão Paulo^pBrazil#^len^aEsche
richia coli has been isolated frequently, showing flagellar antigens that are no
t recognized by any of the 53 antisera, provided by the most important reference
 center of E. coli, The International Escherichia and Klebsiella Center (WHO) of
 the Statens Serum Institute, Copenhagen, Denmark. The objective of this study w
as to characterize flagellar antigens of E. coli that express non-typeable H ant
igens. The methods used were serology, PCR-RFLP and DNA sequencing. This charact
erization was performed by gene amplification of the fliC (flagellin protein) by
 polymerase chain reaction in all 53 standards E.coli strains for the H antigens
 and 20 E. coli strains for which the H antigen was untypeable. The amplicons we
re digested by restriction enzymes, and different restriction enzyme profiles we
re observed. Anti-sera were produced in rabbits, for the non-typeable strains, a
nd agglutination tests were carried out. In conclusion,the results showed that a
lthough non-typeable and typable H antigens strains had similar flagellar antige
ns, the two types of strains were distinct in terms of nucleotide sequence, and 
did not phenotypically react with the standard antiserum, as expected. Thirteen 
strains had been characterized as likely putative new H antigen using PCR-RFLP t
echniques, DNA sequencing and/or serology.#^dnd^i1#^tm^len^kEscherichia coli^i1#
^tm^len^kantigens^i1#^tm^len^kbacterial^i1#^tm^len^kpolymerase chain reaction^i1
#^tm^len^kpolymorphism^i1#^tm^len^krestriction fragment length^i1#other#12#20100
815#08/15/2010#20101021#10/21/2010#FAPESP#CAPES#v15n2a09.htm#Internet^ihttp://ww
w.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000200009##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012000074002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#5#1#article#111#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ORIGINAL ARTICLE</b><
/font></p>     ^cY#v15n2a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#6#2#article#111#<p>&nbsp;</p>     ^cY
#v15n2a09.htm##
00484000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704025100074002001300325#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#7#3#article#111#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Identification of
 putative new <i>Escherichia coli</i> flagellar antigens from human origin using
 serology, PCR-RFlP and DNA sequencing methods</b></font></p>     ^cY#v15n2a09.h
tm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#8#4#article#111#<p>&nbsp;</p>     ^cY
#v15n2a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#9#5#article#111#<p>&nbsp;</p>     ^cY
#v15n2a09.htm##
00477000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704024300075002001300318#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#10#6#article#111#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Monique Ribeiro Tiba<sup>I</sup>; 
Cla&uacute;dia de Moura<sup>II</sup>; Marcelo Falsarella Carazzolle<sup>III</sup
>; Domingos da Silva Leite<sup>IV</sup></b></font></p>     ^cY#v15n2a09.htm##
00412000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704017800075002001300253#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#11#7#article#111#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>MSc; Dr.; Post-doctorate,
 Universidade Estadual de Campinas - UNICAMP, S&atilde;o Paulo, Brazil    ^cY#v1
5n2a09.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704007900075002001300154#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#12#8#article#111#<br> <sup>II</sup>MS
c; PhD Candidate, UNICAMP, S&atilde;o Paulo, Brazil    ^cY#v15n2a09.htm##
00317000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704008300075002001300158#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#13#9#article#111#<br>   <sup>III</sup
>MSc, Dr.; Physicist, UNICAMP, S&atilde;o Paulo, Brazil    ^cY#v15n2a09.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009400076002001300170#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#14#10#article#111#<br>   <sup>IV</sup
>MSc, Dr.; Professor, UNICAMP, S&atilde;o Paulo, Brazil</font></p>     ^cY#v15n2
a09.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#15#11#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a><
/font></p>     ^cY#v15n2a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#16#12#article#111#<p>&nbsp;</p>     ^
cY#v15n2a09.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#17#13#article#111#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v15n2a09.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#18#14#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
15n2a09.htm##
01694000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704145900076002001301535#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#19#15#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Escherichia coli</i> has been iso
lated frequently, showing flagellar antigens that are not recognized by any of t
he 53 antisera, provided by the most important reference center of <i>E. coli</i
>, The International <i>Escherichia</i> and <i>Klebsiella</i> Center (WHO) of th
e Statens Serum Institute, Copenhagen, Denmark. The objective of this study was 
to characterize flagellar antigens of <i>E. coli</i> that express non-typeable H
 antigens. The methods used were serology, PCR-RFLP and DNA sequencing. This cha
racterization was performed by gene amplification of the fliC (flagellin protein
) by polymerase chain reaction in all 53 standards <i>E.coli</i> strains for the
 H antigens and 20 <i>E. coli</i> strains for which the H antigen was untypeable
. The amplicons were digested by restriction enzymes, and different restriction 
enzyme profiles were observed. Anti-sera were produced in rabbits, for the non-t
ypeable strains, and agglutination tests were carried out. In conclusion,the res
ults showed that although non-typeable and typable H antigens strains had simila
r flagellar antigens, the two types of strains were distinct in terms of nucleot
ide sequence, and did not phenotypically react with the standard antiserum, as e
xpected. Thirteen strains had been characterized as likely putative new H antige
n using PCR-RFLP techniques, DNA sequencing and/or serology.</font></p>     ^cY#
v15n2a09.htm##
00472000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023700076002001300313#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#20#16#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> <i>Escherichia coli
</i>; antigens; bacterial; polymerase chain reaction; polymorphism; restriction 
fragment length.</font></p> <hr size="1" noshade>     ^cY#v15n2a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#21#17#article#111#<p>&nbsp;</p>     ^
cY#v15n2a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#22#18#article#111#<p>&nbsp;</p>     ^
cY#v15n2a09.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#23#19#article#111#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>INTRODUCTION</b></i></font></p
>     ^cY#v15n2a09.htm##
01053000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081800076002001300894#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#24#20#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>Escherichia coli</i> is the predo
minant facultative   member of the normal human intestinal   flora. This species
 also includes different   pathovars which are associated with intestinal   and 
extraintestinal diseases in humans   and animals. Some <i>E. coli</i> variants h
ave been   identified as pathogens that encode an array   of pathogenic factors 
harmful for the respective   host.<sup>1,2</sup> The O polysaccharide and flagel
lin   are the two major antigens of Gram-negative   bacteria, also known respect
ively as the O and   H antigens. Since the early 1940's, agglutination   of thes
e two antigens has served as the   foundation of <i>E. coli</i> serotyping with 
187 "O" and 53 "H" being characterized to date.<sup>3</sup></font></p>     ^cY#v
15n2a09.htm##
01074000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083900076002001300915#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#25#21#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Serology has been used to track stra
ins   in epidemiological studies and has allowed   the characterization of patho
genic <i>E. coli</i> serotypes.   Two main groups of such frequent   serotypes w
ere defined: serotypes from diarrhoeal   disease and serotypes from extraintesti
nal   disease.<sup>4</sup> However, several difficulties   have been observed, w
hen the H serotyping   of <i>E. coli</i> is applied as routine laboratory   stan
dard: (I) the expression of H-antigens   can be dependent on various environment
al   signals and identification of the complete set   of serotypes is a time-con
suming process and   requires the use of 53 specific antisera; and   (II) there 
is a great deal of cross-reactions among <i>E. coli</i> strains.<sup>1,2,5</sup>
</font></p>     ^cY#v15n2a09.htm##
01119000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704088400076002001300960#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#26#22#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The flagellum (the organelle respons
ible for   motility) consists of repeated subunits of the   protein flagellin (f
liC). The flagellin proteins are   conserved in their terminal domains, whereas,
   the central domain is variable and carries   serotype-specific epitopes.<sup>
6</sup> Flagellin genes are   suitable for PCR amplification, and variability   
between the PCR products can subsequently be   assessed by restriction analysis 
(PCR-RFLP) or   DNA sequencing.<sup>1,3,7</sup> Molecular biology techniques   o
ffer the potential for rapid and reproducible analysis of bacterial diversity.<s
up>8</sup> However, serotyping has been the mainstay in the characterization and
 diagnostic of <i>E. coli</i>, and this technique remains essential for taxonomi
c and epidemiological purposes.<sup>2,9</sup></font></p>     ^cY#v15n2a09.htm##
00992000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075700076002001300833#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#27#23#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The aim of this study was to charact
erize the H antigens of motile, serologically non-typeable H antigens strains, f
rom various clinical origins (cases of gastroenteritis, bloody diarrhoea, HUS, u
rinary tract infection). Rabbit antisera were produced against non-typeable stra
ins. A PCR-restriction fragment length polymorphism (PCR-RFLP) test that detects
 and characterizes fli<i>C</i> was used to build a database of restriction patte
rns (P-types) and to recognize H-types.<sup>1,2</sup> One non-typeable strain th
at the H antigen was not recognized by PCR-RFLP was selected and the fli<i>C</i>
 gene was sequenced to compare with those already described in the literature.</
font></p>     ^cY#v15n2a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#28#24#article#111#<p>&nbsp;</p>     ^
cY#v15n2a09.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#29#25#article#111#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>MATERIALS AND METHODS</b></i><
/font></p>     ^cY#v15n2a09.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#30#26#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Bacterial strains</b></font></p> 
    ^cY#v15n2a09.htm##
01209000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704097400076002001301050#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#31#27#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The reference strains belonging to v
arious O- and H-antigen groups representing the flagella antigens H1 to H56 were
 included in this study,<sup>10</sup> and they were obtained from the <i>E. coli
</i> Reference Laboratory, Santiago de Compostela, Spain (<a href="#tab1">Table1
</a>). Moreover, a total of 20 serologically non-typeable H antigens strains fro
m various clinical origins were used in this study (<a href="/img/revistas/bjid/
v15n2/a09tab02.jpg">Table 2</a>). The clinical <i>E. coli</i> strains were donat
ed by Dr. Helmut Tsch&auml;pe (Robert Koch Institute, National Reference Centre 
of <i>Salmonella</i> and other enterics, Wernigerode, Germany) and by Dr. Jorge 
Blanco (<i>E. coli</i> Reference Laboratory, Santiago de Compostela, Spain). All
 <i>E. coli</i> isolates were stored at room temperature in nutrient broth (NB) 
0.75% agar and preserved in glycerol cultures at -80ºC.</font></p>     ^cY#v15n2
a09.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#32#28#article#111#<p><a name="tab1"><
/a></p>     ^cY#v15n2a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#33#29#article#111#<p>&nbsp;</p>     ^
cY#v15n2a09.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#34#30#article#111#<p align="center"><
img src="/img/revistas/bjid/v15n2/a09tab01.jpg"></p>     ^cY#v15n2a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#35#31#article#111#<p>&nbsp;</p>     ^
cY#v15n2a09.htm##
00373000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013800076002001300214#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#36#32#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Sera, serum absorption, and H-ant
igen serotyping</b></font></p>     ^cY#v15n2a09.htm##
00839000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060400076002001300680#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#37#33#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">To determine the O- and H-antigens, 
we used antisera against reference <i>E. coli</i> H-antigens that were obtained 
from the <i>E. coli</i> Reference Laboratory, Santiago de Compostela, Spain. The
 application of the <i>E. coli</i> reference collection and the reference sera p
roduced according to recommendation of the International <i>Escherichia</i> and 
<i>Klebsiella</i> Centre (WHO) was used. Reference <i>E. coli</i> and clinical <
i>E. coli</i> strains were serotyped at the <i>Universidade Estadual de Campinas
.</i></font></p>     ^cY#v15n2a09.htm##
00714000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047900076002001300555#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#38#34#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Hyperimmune rabbit antisera against 
non-typeable strains were produced by the Bacterial Antigens Laboratory in <i>Un
iversidade Estadual de Campinas.</i> Using the clinical <i>E. coli</i> strains a
nd the standard protocol for deriving rabbit antisera.<sup>11</sup> The producti
on and absorption of antisera and tube H-antigen agglutination were carried out 
as described previously by Ewing (1986).</font></p>     ^cY#v15n2a09.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010500076002001300181#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#39#35#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>DNA preparation</b></font></p>   
  ^cY#v15n2a09.htm##
00569000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033400076002001300410#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#40#36#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A single colony was grown in 3.0 mL 
of Luria-Bertani medium, overnight at 37ºC. Genomic DNA was purified by using th
e "Wizard Genomic DNA Purification System Kit" (Promega/EUA). The purified DNA w
as suspended in 100 &#181;L of water and stored at 4ºC.</font></p>     ^cY#v15n2
a09.htm##
00354000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011900076002001300195#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#41#37#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Primers and PCR amplification</b>
</font></p>     ^cY#v15n2a09.htm##
01269000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704103400076002001301110#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#42#38#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The primers used in this study are l
isted in <a href="#tab3">Table 3</a>. Each PCR was carried out using a 30 &#181;
L reaction mixture containing 2 mM MgCl<sub>2</sub>, each deoxynucleoside tripho
sphate at a concentration of 0.2 mM, each primer at a concentration of 10 pmol a
nd 1.5 U of Taq DNA polymerase (Fermentas). PCR conditions included denaturation
 for 60s at 94ºC, annealing for 60s at 60ºC and extension for 120s at 72ºC for 3
0 cycles, in a Thermal Cycler (Gene Amp PCR System 9700/Perkin Elmer Corporation
, Norwal CT/USA). The amplified DNA product was visualized by standard submarine
 gel electrophoresis using 10 mL of the final reaction mixture on a 1.5% agarose
 gel in TAE buffer (1.6 M Tris-EDTA, 0.025 M acetic acid). Amplified DNA fragmen
ts of specific sizes were located by UV fluorescence, after staining with ethidi
um bromide. The 1-kpb DNA ladder (Fermentas) was used as a standard for determin
ing molecular size of PCR products.</font></p>     ^cY#v15n2a09.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#43#39#article#111#<p><a name="tab3"><
/a></p>     ^cY#v15n2a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#44#40#article#111#<p>&nbsp;</p>     ^
cY#v15n2a09.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#45#41#article#111#<p align="center"><
img src="/img/revistas/bjid/v15n2/a09tab03.jpg"></p>     ^cY#v15n2a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#46#42#article#111#<p>&nbsp;</p>     ^
cY#v15n2a09.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011000076002001300186#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#47#43#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Restriction patterns</b></font></
p>     ^cY#v15n2a09.htm##
01384000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704114900076002001301225#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#48#44#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The PCR-RFLP protocol developed by F
ields <i>et al.,<sup>7</sup> </i> and Machado <i>et al.,</i><sup>1</sup> was car
ried out. The amplified fli<i>C</i> gene was cleaved with <i>HhaI</i> restrictio
n endonuclease (Invitrogen), when fliC(M) primers were used, and <i>RsaI</i> res
triction endonuclease (Invitrogen), when fliC(F) primers were used. Fifteen micr
oliters of each PCR product was digested with restriction endonuclease, accordin
g to the manufacture's instructions. Restriction fragments were separated by ele
ctrophoresis on a 2% agarose gel Metaphor (FMC Bioproducts/USA) for 5h at 4.8 V/
cm.<sup>1</sup> A 100-bp DNA ladder (Fermentas) was used as external and interna
l fragment size standard. The restriction fragments were stained with ethidium b
romide and documented by Image Master VDS (Amersham Pharmacia Biotech/ USA. Gel 
Compar II (Applied Maths/ Belgium) was used to identify RFLP patterns and to est
ablish a database for fli<i>C</i> fingerprinting. Fragments were considered iden
tical if their sizes did not differ by more than 3.5% (allowed error).</font></p
>     ^cY#v15n2a09.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012100076002001300197#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#49#45#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>DNA manipulation and sequencing</
b></font></p>     ^cY#v15n2a09.htm##
01489000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704125400076002001301330#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#50#46#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The fli<i>C</i> gene was first PCR a
mplified, and the PCR product was inserted into pGEM T-easy kit (Promega/USA). A
nalysis of cloned fragments and transformation in DH5</font>&#945;<font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"> strain were performed using stand
ard methods.<sup>12</sup> fli<i>C</i> PCR products were purified with the enzyme
 <i>Exo</i>SAP-IT, according to the instructions of the manufacturer (GE Health 
Care/USA). Subsequently, 5.0 &#181;L of purified PCR product were mixed with 4.0
 &#181;L ET Terminator<sup>TM</sup> mix (GE Health Care/USA), 1.0 &#181;L sequen
cing primers T7 (forward) and M13 (reverse). The thermal program consisted of 30
 cycles of 20s at 95ºC, 15s at 50ºC and 1 min at 60ºC. The purification of the s
equencing products was obtained by mixing 1 &#181;L of ammonium acetate (7.5M) a
nd 27.5 &#181;L absolute ethanol, followed by incubation in the dark for 30 min,
 and subsequent centrifugation at 3,700 rpm for 75 min at 4ºC. Separation of the
 DNA fragments was obtained in a Megabace 1,000 system (GE Health Care/USA). Vol
tage and time of injection were 3kV and 120s. Running was performed at 9kV for 1
00 min at 44ºC.</font></p>     ^cY#v15n2a09.htm##
00929000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069400076002001300770#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#51#47#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">DNA sequence was assembled and edite
d by using the programs Phred, Phrap, and Consed. BLAST was used for searching d
atabases, including the Gen-Bank. Sequence alignment and comparison were carried
 out using ClustalW. After analysis, an internal primer pair was constructed: <i
>fliC</i> 1C: AACTAACGGTACTAACTCTGACA and <i>fliC</i>1Crev: CCACTACCGTCTCAGCTTT 
to obtain a complete <i>fliC</i> sequence, because the entire gene was large and
 when the DNA sequencer (Megabace 1000 system) was used approximately just 600 p
b were obtained.The DNA sequence has been deposited in GenBank under the accessi
on nº GQ423574.</font></p>     ^cY#v15n2a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#52#48#article#111#<p>&nbsp;</p>     ^
cY#v15n2a09.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#53#49#article#111#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>RESULTS</b></i></font></p>    
 ^cY#v15n2a09.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#54#50#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Serotyping</b></font></p>     ^cY
#v15n2a09.htm##
00621000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038600076002001300462#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#55#51#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Determination of the O- and H-antige
ns was performed according to Ewing, 1986, by agglutination with specific hyperi
mmune rabbit antisera. All H-antigen reference collection and from various clini
cal origin strains were serotyped with respect to their H-antigens using the cla
ssical agglutination tests.</font></p>     ^cY#v15n2a09.htm##
00547000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031200076002001300388#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#56#52#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">All clinical strains were titrated w
ith all existing 53 antisera initially in 1:100 dilutions and the results of agg
lutination tests were negative, meaning that the clinical strains used in this w
ork, had non-typeable H-antigens.</font></p>     ^cY#v15n2a09.htm##
00885000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065000076002001300726#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#57#53#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">To analyze the flagellar serology of
 the non-typeable strains, hyperimmune rabbit antisera against the H-antigen wer
e produced. Antibody cross-absorption assays were carried out, and the H-antigen
 agglutination tests were performed in tubes. Moreover, the results of serotypin
g (<a href="#tab4">Table 4</a>) showed that these antisera produced against non-
typeable strains shared a specific partial H-antigen factor absent in the refere
nce strains. All non-typeable <i>E. coli</i> clinical strains were negative to s
erotyping using reference antisera (53 H-antisera).</font></p>     ^cY#v15n2a09.
htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#58#54#article#111#<p><a name="tab4"><
/a></p>     ^cY#v15n2a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#59#55#article#111#<p>&nbsp;</p>     ^
cY#v15n2a09.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#60#56#article#111#<p align="center"><
img src="/img/revistas/bjid/v15n2/a09tab04.jpg"></p>     ^cY#v15n2a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#61#57#article#111#<p>&nbsp;</p>     ^
cY#v15n2a09.htm##
00386000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015100076002001300227#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#62#58#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>fli<i>C-</i>RFLP analysis of <i>E
. coli</i> reference strains</b></font></p>     ^cY#v15n2a09.htm##
00934000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069900076002001300775#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#63#59#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">To correlate the H-antigen pattern w
ith fli<i>C</i> polymorphisms, PCR-amplified fli<i>C</i> fragments were subjecte
d to RFLP analysis. This analysis was performed three times or more for each str
ain studied. Patterns were designated by a letter P, followed by a number (<a hr
ef="#tab1">Table 1</a>). All <i>E. coli</i> reference strains tested gave rise t
o a PCR product (varying in size from 0.8 to 2.7 kbp) with the exception of fliC
(F) H17, H25, and H53. The fli<i>C</i> was not amplified either in the H53 antig
en when fliC(M) was used, even under different PCR condition, indicating inadequ
ate primer homology.</font></p>     ^cY#v15n2a09.htm##
01286000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704105100076002001301127#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#64#60#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>HhaI</i>-fli<i>C</i> gene restric
tion fragments were observed in 52 <i>E. coli</i> reference strains. A total of 
44 different patterns were observed after <i>HhaI</i> restriction (<a href="/img
/revistas/bjid/v15n2/a09tab05.jpg">Table 5</a>) and a total of 40 different patt
erns were observed after <i>RsaI</i> restriction (<a href="/img/revistas/bjid/v1
5n2/a09tab05.jpg">Table 5</a>). When <i>RsaI</i>- fliC(F) was used, a common pat
tern was observed for the fli<i>C</i> from the H1, H28, H31 strains (P1), the H2
, H30 and H35 strains (P2), the H7, H19 and H27 strains (P7), the H9 and H14 str
ains (P8), the H11 and H47 strains (P10). When <i>HhaI</i>-fliC(M) was used, the
 H3 and H8 strains (P3), the H6, H10, H19 and H27 strains (P6), the H11 and H47 
strains (P9), the H23 and H43 strains (P18), the H28 and H42 strains (P22) had a
 common pattern. The fli<i>C</i> genes for H11, H19, H27, H28 and H47 antigens w
ere indistinguishable with both restriction enzymes.</font></p>     ^cY#v15n2a09
.htm##
00370000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013500076002001300211#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#65#61#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Detection of non-typeable antigen
 by PCR-RFLP</b></font></p>     ^cY#v15n2a09.htm##
01713000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704147800076002001301554#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#66#62#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Since many pathogenic <i>E. coli</i>
 strains were motile but, non-typeable by serotyping, the determination of <i>fl
iC</i> polymorphism might be a quick altenative for H-antigen typing. The flagel
lin gene was amplified in all strains studied (<a href="/img/revistas/bjid/v15n2
/a09tab06.jpg">Table 6</a>). We detected single bands ranging from 1.1 to 2.6 kb
p when fliC(M) was used and single bands from 1.3 to 2.7 kbp when fliC(F) was us
ed. When <i>RsaI</i>-flic(F) was used, in eleven non-typeable strains there were
 no patterns comparable to those from <i>E. coli</i> reference strains. Three st
rains sharing the P2 pattern, and four strains sharing the P8, P10, P11, and P13
 patterns respectively (<a href="/img/revistas/bjid/v15n2/a09tab05.jpg">Table 5<
/a>). When <i>HhaI</i>-fliC(M) was used there were no patterns comparable to tho
se from reference strains in thirteen non-typeable strains. Two strains shared t
he P2 pattern, two other strains shared the P10 pattern and three strains sharin
g the P9, P13 and P41 patterns respectively (<a href="/img/revistas/bjid/v15n2/a
09tab06.jpg">Table 6</a>). Two strains had the same pattern (P2) when both techn
iques were used. This strain was identified as being similar to the H2 antigen. 
Most of these non-typeable strains revealed unknown RFLP patterns among the H an
tigens H1 to H56 (<a href="/img/revistas/bjid/v15n2/a09tab06.jpg">Table 6</a>).<
/font></p>     ^cY#v15n2a09.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#67#63#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Nucleotide sequence analysis</b><
/font></p>     ^cY#v15n2a09.htm##
00788000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055300076002001300629#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#68#64#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The full gene sequence was obtained 
for one strain and T7 and M13 primers based on the pGEMT-easy vector were used. 
An internal pair of primers based on within sequenced <i>E. coli</i> fli<i>C</i>
 gene was also constructed. The non-typeable strain, showed two expected conserv
ed regions in the N-terminal and C-terminal portions, whereas the central region
 was quite variable. The complete nucleotide sequence of fli<i>C</i> gene has 1,
541bp (accession number GQ423574).</font></p>     ^cY#v15n2a09.htm##
00741000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050600076002001300582#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#69#65#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">DNA alignment was based on the amino
 acid alignment stored in the database of the National Center for Biotecnology I
nformation (NCBI). Our sequence for the type strain VTH-15 is 99% identical to t
hose of H21 antigen. Synonymous and nonsynonymous substitution were observed thr
oug the program BLASTx. The deduced amino acid sequences of this fli<i>C</i> gen
e differ in up to one amino acid from those of the H21 type strain.</font></p>  
   ^cY#v15n2a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#70#66#article#111#<p>&nbsp;</p>     ^
cY#v15n2a09.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#71#67#article#111#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>DISCUSSION</b></i></font></p> 
    ^cY#v15n2a09.htm##
00811000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057600076002001300652#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#72#68#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i>E. coli</i> of specific serotype 
can be associated with certain clinical syndromes, even though the serological a
ntigens do not correlate with virulence. It has been shown that antigenic typing
 of <i>E. coli</i> is extremely useful in epidemiological studies.<sup>4</sup> C
urrently, some isolates are generally not very motile and non-typeable and sever
al difficulties have been observed, when the H serotyping of <i>E. coli</i> was 
applied as a routine laboratory standard.<sup>1,2,5</sup></font></p>     ^cY#v15
n2a09.htm##
01307000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704107200076002001301148#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#73#69#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">To confirm putative new H-antigens, 
hyperimmune rabbit antisera were produced and endpoint agglutination tests with 
all known H-group reference strains were used to confirm specificity. Six antise
ra obtained against non-typeable H antigen crossreacted with the reference H-ant
igen, but the fliC(F) and fliC(M) patterns results were distinct. Although there
 are several minor relationships among the recognized H-antigens, the absorbed H
 antiserum is required for their exact identification. An important relationship
 exists between <i>E. coli</i> H-antigens H11 and H21.<sup>11</sup> We demonstra
ted that the antiserum obtained from VTH-15 strain had the final antiserum dilut
ion of 1:6,400, while nucleotide sequencing demonstrated similarity of 99% to H2
1 type strain. Results by tests in absorbed antiserum were negative to H11 and H
21 antigens. Defining and establishing new H-antigen types will remain a task of
 the International <i>Escherichia</i> and <i>Klebsiella</i> Centre (WHO).</font>
</p>     ^cY#v15n2a09.htm##
00717000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048200076002001300558#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#74#70#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Using the fli<i>C</i> PCR-RFLP metho
d several authors showed that non-motile <i>E. coli</i> strains possess fli<i>C<
/i>- RFLP patterns that did not correspond to known H <i>E. coli</i> antigens.<s
up>7,8</sup> However, non-typeable strains have fli<i>C</i> RFLP patterns that d
id not correspond to the pattern identified for the H1 to H56 antigens and might
 therefore represent novel H-antigen types.</font></p>     ^cY#v15n2a09.htm##
00693000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045800076002001300534#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#75#71#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In the present study, we have shown 
that the fli<i>C</i> gene could be amplified in all non-typeable <i>E. coli</i> 
strains, and a considerable polymorphism of the <i>HhaI</i> and <i>RsaI</i> rest
rictions products of the amplified fli<i>C</i> gene could be detected (<a href="
/img/revistas/bjid/v15n2/a09tab06.jpg">Table 6</a>) and used for a flagellar ide
ntification system.</font></p>     ^cY#v15n2a09.htm##
00810000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057500076002001300651#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#76#72#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The diversity of amplification produ
cts was examined with the use of <i>HhaI</i> and <i>RsaI</i>, which demonstrated
 to be a feasible and rapid method for identification and subtyping of H-antigen
s. For each of the fli<i>C</i> products obtained from non-typeable strains, a re
striction pattern (P-type) was generated. A total of 12 kinds of P-types were de
termined, when <i>RsaI</i> (PCR-RFLP <i>RsaI</i>) was used and a total of 13 kin
ds of P-types were detected with the use of <i>HhaI</i>.</font></p>     ^cY#v15n
2a09.htm##
00880000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064500076002001300721#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#77#73#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Nucleotide sequencing of the non-typ
eable <i>E. coli</i> (VTH-15) from human clinical isolates is deposited in GenBa
nk as GQ423574. Flagellin genes are identified on the basis of the homology with
 known flagellin genes. Complete nucleotide sequencing of <i>fliC</i> gene from 
non-typeable strain demonstrated similarity of 99% to those previously published
 for the H21 type strain. Although most of the H-antigens of <i>E. coli</i> have
 been already described at the molecular level<sup>3</sup> a few remained to be 
analyzed, especially the non-typeable strains.</font></p>     ^cY#v15n2a09.htm##
00712000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047700076002001300553#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#78#74#article#111#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In conclusion, fli<i>C</i> diversity
 has been showed by using the PCR-RFLP technique in non-typeable strains. These 
putative new H groups in <i>E. coli</i> strains isolated from humans will be use
d in the epidemiological and occurrence studies. However, defining and establish
ing new H antigens type will remain a task of the International <i>Escherichia</
i> and <i>Klebsiella</i> Centre (WHO).</font></p>     ^cY#v15n2a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#79#75#article#111#<p>&nbsp;</p>     ^
cY#v15n2a09.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#80#76#article#111#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p> 
    ^cY#v15n2a09.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024900078002001300327#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#81#77#article#111#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Machado J, Grimont 
F, Grimont PAD. Identification of <i>Escherichia coli</i> flagellar types by res
triction of the amplified <i>fliC</i> gene. Res Microbiol 2000; 151:535-546.    
^cY#v15n2a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#82#78#article#111#</font></p>     ^cY
#v15n2a09.htm##
00539000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029000078002001300368#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#83#79#article#111#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Prager R, Strutz U,
 Fruth A, Tsch&auml;pe H. Subtyping of pathogenic <i>Escherichia coli</i> strain
s using flagellar (H) - antigens: serotyping versus <i>fliC</i> polymorphisms. I
nt J Med Microbiol 2003; 292:477-486.    ^cY#v15n2a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#84#80#article#111#</font></p>     ^cY
#v15n2a09.htm##
00477000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022800078002001300306#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#85#81#article#111#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Wang L, Rothemund D
, Curd H, Reeves PR. Species-wide variation in the <i>Escherichia coli</i> flage
llin (H-antigen) gene. J Bacteriol 2003; 185:2936-2943.    ^cY#v15n2a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#86#82#article#111#</font></p>     ^cY
#v15n2a09.htm##
00445000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019600078002001300274#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#87#83#article#111#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. &#216;rskov I, &#21
6;rskov F. <i>Escherichia coli</i> serotyping and in man and animals. Can J Micr
obiol 1992; 38:699-704.    ^cY#v15n2a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#88#84#article#111#</font></p>     ^cY
#v15n2a09.htm##
00451000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020200078002001300280#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#89#85#article#111#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Ratiner YA. Tempera
ture-dependent flagellar antigen phase variation in <i>Escherichia</i> coli. Res
 Microbiol 1999; 150:457-463.    ^cY#v15n2a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#90#86#article#111#</font></p>     ^cY
#v15n2a09.htm##
00556000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030700078002001300385#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#91#87#article#111#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Schoenhals G, Whitf
ield C. Comparative analysis of flagellin sequences from <i>Escherichia coli</i>
 strains possessing serologically distinct flagellar filaments with a shared com
plex surface pattern. J Bacteriol 1993; 175:5395-5402.    ^cY#v15n2a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#92#88#article#111#</font></p>     ^cY
#v15n2a09.htm##
00637000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704038800078002001300466#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#93#89#article#111#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Fields PI, Blom K, 
Hughes HJ, Helsel LO, Feng P, Swaminathan B. Molecular characterization of the g
ene encoding H antigen in <i>Escherichia coli</i> and development of a PCR-Restr
iction fragment length polymorphism test for identification of <i>E. coli</i> O1
57:H7 and O157:NM. J Clin Microbiol 1997; 35:1066-1070.    ^cY#v15n2a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#94#90#article#111#</font></p>     ^cY
#v15n2a09.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030800078002001300386#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#95#91#article#111#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Amhaz JMK, Andrade 
A, Bando SY, Tanaka TL, Moreira-Filha CA, Martinez MB. Molecular typing and phyl
ogenetic analysis of enteroinvasive <i>Escherichia coli</i> using the <i>fliC</i
> gene sequence. FEMS Microbiol Lett 2004; 235:259-264.    ^cY#v15n2a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#96#92#article#111#</font></p>     ^cY
#v15n2a09.htm##
00590000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704034100078002001300419#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#97#93#article#111#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Scheutz F, Cheasty 
T,Woodward D, Smith HR. Designation of O174 and O175 to temporary O groups OX3 a
nd OX7, and six new <i>E. coli</i> O groups that include Verocytotoxin-producing
 <i>E. coli</i> (VTEC): O176, O177, O178, O179, O180 and O181. AP-MIS 2004; 112:
569-584.    ^cY#v15n2a09.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#98#94#article#111#</font></p>     ^cY
#v15n2a09.htm##
00484000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023400079002001300313#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#99#95#article#111#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. &#216;rskov F, &#
216;rskov I, Jann B, Jann K. Serology, chemistry, and genetics of O and K antige
ns of <i>Escherichia</i> coli. Bacteriol Rev 1977; 41:667-710.    ^cY#v15n2a09.h
tm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#100#96#article#111#</font></p>     ^c
Y#v15n2a09.htm##
00444000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704019300080002001300273#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#101#97#article#111#11#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Ewing WH, Edward
s, PR. The genus <i>Escherichia</i>. Identification of Enterobacteriaceae, Burge
ss, Minneapolis, 1983.    ^cY#v15n2a09.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#102#98#article#111#</font></p>     ^c
Y#v15n2a09.htm##
00422000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704017100080002001300251#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#103#99#article#111#12#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Sambrook J, Frit
sch EF, Maniatis T. Molecular cloning: A laboratory manual. New York CSHL, 1989.
    ^cY#v15n2a09.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#104#100#article#111#</font></p>     ^
cY#v15n2a09.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#105#101#article#111#<p>&nbsp;</p>    
 ^cY#v15n2a09.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#106#102#article#111#<p>&nbsp;</p>    
 ^cY#v15n2a09.htm##
00426000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018900078002001300267#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#107#103#article#111#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:
</b>    ^cY#v15n2a09.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003300078002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#108#104#article#111#<br> Monique Ribe
iro Tiba    ^cY#v15n2a09.htm##
00294000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005700078002001300135#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#109#105#article#111#<br> Rua Visconde
 de Taunay, 147/41, Vila Itapura    ^cY#v15n2a09.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003300078002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#110#106#article#111#<br> Campinas, SP
, Brazil    ^cY#v15n2a09.htm##
00316000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007900078002001300157#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#111#107#article#111#<br> <a href="mai
lto:mrtiba@gmail.com">mrtiba@gmail.com</a></font></p>     ^cY#v15n2a09.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009500078002001300173#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#112#108#article#111#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted on: 08/15/2010    ^cY#v1
5n2a09.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#113#109#article#111#<br>   Approved o
n: 10/21/2010    ^cY#v15n2a09.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004600078002001300124#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#114#110#article#111#<br>   Financial 
Support: FAPESP CAPES    ^cY#v15n2a09.htm##
00299000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006200078002001300140#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a09.htm#S#p#115#111#article#111#<br>   We declare
 no conflict of interest.</font></p>     ^cY#v15n2a09.htm##
00603000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
01900111012009700130030001400227065000900241064000500250031000400255014000800259
865000900267002001300276035001000289801001400299#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a09.htm#S#c#116#1#article#12#1#^rND^sMachado^nJ#^rND^sGrimont^nF#
^rND^sGrimont^nPAD#Identification of Escherichia coli flagellar types by restric
tion of the amplified fliC gene^len#Res Microbiol#20000000#2000#151#535-546#2011
0400#v15n2a09.htm#0923-2508#Res Microbiol##
00663000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01500109010001700124012012200141030002000263065000900283064000500292031000400297
014000800301865000900309002001300318035001000331801002000341#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a09.htm#S#c#117#2#article#12#2#^rND^sPrager^nR#^rND^s
Strutz^nU#^rND^sFruth^nA#^rND^sTschäpe^nH#Subtyping of pathogenic Escherichia co
li strains using flagellar (H) - antigens: serotyping versus fliC polymorphisms^
len#Int J Med Microbiol#20030000#2003#292#477-486#20110400#v15n2a09.htm#0934-884
0#Int J Med Microbiol##
00605000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100019000910100
01400110010001700124012007800141030001200219065000900231064000500240031000400245
014001000249865000900259002001300268035001000281801001200291#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a09.htm#S#c#118#3#article#12#3#^rND^sWang^nL#^rND^sRo
themund^nD#^rND^sCurd^nH#^rND^sReeves^nPR#Species-wide variation in the Escheric
hia coli flagellin (H-antigen) gene^len#J Bacteriol#20030000#2003#185#2936-2943#
20110400#v15n2a09.htm#0021-9193#J Bacteriol##
00531000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930120
05500109030001600164065000900180064000500189031000300194014000800197865000900205
002001300214035001000227801001600237#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a09.htm#S#c#119#4#article#12#4#^rND^sØrskov^nI#^rND^sØrskov^nF#Escherichia co
li serotyping and in man and animals^len#Can J Microbiol#19920000#1992#38#699-70
4#20110400#v15n2a09.htm#0008-4166#Can J Microbiol##
00527000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120080000950300
01400175065000900189064000500198031000400203014000800207865000900215002001300224
035001000237801001400247#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S
#c#120#5#article#12#5#^rND^sRatiner^nYA#Temperature-dependent flagellar antigen 
phase variation in Escherichia coli^len#Res Microbiol#19990000#1999#150#457-463#
20110400#v15n2a09.htm#0923-2508#Res Microbiol##
00648000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100019000970120
17000116030001200286065000900298064000500307031000400312014001000316865000900326
002001300335035001000348801001200358#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a09.htm#S#c#121#6#article#12#6#^rND^sSchoenhals^nG#^rND^sWhitfield^nC#Compara
tive analysis of flagellin sequences from Escherichia coli strains possessing se
rologically distinct flagellar filaments with a shared complex surface pattern^l
en#J Bacteriol#19930000#1993#175#5395-5402#20110400#v15n2a09.htm#0021-9193#J Bac
teriol##
00799000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100014000940100
01700108010001700125010001400142010002100156012020300177030001700380065000900397
06400050040603100030041101400100041486500090042400200130043303500100044680100170
0456#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#c#122#7#article#12#
7#^rND^sFields^nPI#^rND^sBlom^nK#^rND^sHughes^nHJ#^rND^sHelsel^nLO#^rND^sFeng^nP
#^rND^sSwaminathan^nB#Molecular characterization of the gene encoding H antigen 
in Escherichia coli and development of a PCR-Restriction fragment length polymor
phism test for identification of E. coli O157:H7 and O157:NM^len#J Clin Microbio
l#19970000#1997#35#1066-1070#20110400#v15n2a09.htm#0095-1137#J Clin Microbiol##
00722000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
01600111010001700127010002400144010001900168012011100187030002000298065000900318
06400050032703100040033201400080033686500090034400200130035303500100036680100200
0376#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#c#123#8#article#12#
8#^rND^sAmhaz^nJMK#^rND^sAndrade^nA#^rND^sBando^nSY#^rND^sTanaka^nTL#^rND^sMorei
ra-Filha^nCA#^rND^sMartinez^nMB#Molecular typing and phylogenetic analysis of en
teroinvasive Escherichia coli using the fliC gene sequence^len#FEMS Microbiol Le
tt#20040000#2004#235#259-264#20110400#v15n2a09.htm#0378-1097#FEMS Microbiol Lett
##
00680000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
01800111010001600129012018800145030000700333710000200340065000900342064000500351
031000400356014000800360865000900368002001300377#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a09.htm#S#c#124#9#article#12#9#^rND^sScheutz^nF#^rND^sCheasty^nT#
^rND^sWoodward^nD#^rND^sSmith^nHR#Designation of O174 and O175 to temporary O gr
oups OX3 and OX7, and six new E. coli O groups that include Verocytotoxin-produc
ing E. coli (VTEC): O176, O177, O178, O179, O180 and O181^len#AP-MIS#2#20040000#
2004#112#569-584#20110400#v15n2a09.htm##
00604000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01400111010001400125012007800139030001400217065000900231064000500240031000300245
014000800248865000900256002001300265035001000278801001400288#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a09.htm#S#c#125#10#article#12#10#^rND^sØrskov^nF#^rND
^sØrskov^nI#^rND^sJann^nB#^rND^sJann^nK#Serology, chemistry, and genetics of O a
nd K antigens of Escherichia coli^len#Bacteriol Rev#19770000#1977#41#667-710#201
10400#v15n2a09.htm#0005-3678#Bacteriol Rev##
00475000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790160018000950180
06400113061000800177066001200185065000900197064000500206865000900211002001300220
#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#c#126#11#article#12#11#
^rND^sEwing^nWH#^rND^sEdwards^nPR#The genus Escherichia: Identification of Enter
obacteriaceae^len#Burgess#Minneapolis#19830000#1983#20110400#v15n2a09.htm##
00480000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160018000790160018000970160
01800115018004300133066000900176062000500185065000900190064000500199865000900204
002001300213#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a09.htm#S#c#127#12#ar
ticle#12#12#^rND^sSambrook^nJ#^rND^sFritsch^nEF#^rND^sManiatis^nT#Molecular clon
ing: A laboratory manual^len#New York#CSHL#19890000#1989#20110400#v15n2a09.htm##
00274000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00300101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#o#1#1#article#1
#20110406#124845#v15n2a16.htm#97##
02647000000000637000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400110014503500100015601201150
01660100031002810100035003120100029003470100033003760100023004090100031004320100
02900463070012800492070006200620070006800682070004700750070007300797083095400870
08500080182408500230183208500370185508500210189208500290191305800050194211700060
1947072000301953112000901956111001101965114000901976113001101985002001301996#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#h#2#1#article#1#oa#en#br1.1
#1#4.0#ILUS#TAB#16#BJID020#nd#Braz J Infect Dis#15#2#20110400#^f174^l177#1413-86
70#Genital schistosomiasis mansoni concomitant to genital tumor in areas of low 
endemicity: challenging diagnosis^len#^rND^1A01^nMarta G^sCavalcanti#^rND^1A02^n
Margareth MI^sGonçalves#^rND^1A03^nMagali M^sBarreto#^rND^1A04^nAline Helen da^s
Silva#^rND^1A04^nKalil^sMadi#^rND^1A02^nJosé Mauro^sPeralta#^rND^1A05^nRicardo P
^sIgreja#Universidade Federal do Rio de Janeiro^iA01^1Hospital Clementino Fraga 
Filho^2Infectious and Parasitic Diseases Service^pBrazil#UFRJ^iA02^1Instituto de
 Microbiologia Professor Paulo de Góes#FIOCRUZ^iA03^1Instituto Oswaldo Cruz^2Dep
artment of Biology^pBrazil#UFRJ^iA04^1HUCFF^2Pathological Anatomy Service#UFRJ^i
A05^1School of Medicine^2Department of Preventive Medicine^pBrazil#^len^aGenital
 infection by Schistosoma mansoni is usually misdiagnosed in individuals who res
ide in, or travel to endemic areas. We describe two cases of genital tumor assoc
iated with S. mansoni infection manifested by methrorragy. Surgical specimens re
vealed leiomyomas in both cases associated with S. mansoni. In one of them, gran
ulomas were found in the ovary and in the other they were found in the uterine t
ube. Although none presented intestinal/hepatic disease, fecal egg excretion was
 detected in one. Both had elevated pretreatment antibody reactivity to S. manso
ni antigen, but follow-up showed different outcomes. Schistosomiasis should be c
onsidered as a diagnosis in individuals with methrorragy residing in or having t
raveled to endemic areas. Since diagnosis follows genital amputation, and cure c
ontrol is troublesome, improvement of diagnostic tools and follow-up markers are
 important priorities to decrease schistosomiasis morbidity.#^dnd^i1#^tm^len^kS.
 mansoni^i1#^tm^len^kfemale genital infection^i1#^tm^len^kserology^i1#^tm^len^kl
ow endemic area^i1#CNPq#other#12#20090210#02/10/2009#20090522#05/22/2009#v15n2a1
6.htm##
02696000000000637000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400110014503500100015601201290
01660100031002950100035003260100029003610100033003900100023004230100031004460100
02900477070012800506070006200634070006800696070004700764070007300811083098200884
08500080186608500300187408500370190408500210194108500290196205800050199111700060
1996072000302002112000902005111001102014114000902025113001102034002001302045#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#f#3#1#article#1#oa#en#br1.1
#1#4.0#ILUS#TAB#16#BJID020#nd#Braz J Infect Dis#15#2#20110400#^f174^l177#1413-86
70#<b>Genital schistosomiasis mansoni concomitant to genital tumor in areas of l
ow endemicity</b>: <b>challenging diagnosis</b>^len#^rND^1A01^nMarta G^sCavalcan
ti#^rND^1A02^nMargareth MI^sGonçalves#^rND^1A03^nMagali M^sBarreto#^rND^1A04^nAl
ine Helen da^sSilva#^rND^1A04^nKalil^sMadi#^rND^1A02^nJosé Mauro^sPeralta#^rND^1
A05^nRicardo P^sIgreja#Universidade Federal do Rio de Janeiro^iA01^1Hospital Cle
mentino Fraga Filho^2Infectious and Parasitic Diseases Service^pBrazil#UFRJ^iA02
^1Instituto de Microbiologia Professor Paulo de Góes#FIOCRUZ^iA03^1Instituto Osw
aldo Cruz^2Department of Biology^pBrazil#UFRJ^iA04^1HUCFF^2Pathological Anatomy 
Service#UFRJ^iA05^1School of Medicine^2Department of Preventive Medicine^pBrazil
#^len^aGenital infection by <i>Schistosoma mansoni</i> is usually misdiagnosed i
n individuals who reside in, or travel to endemic areas. We describe two cases o
f genital tumor associated with <i>S. mansoni</i> infection manifested by methro
rragy. Surgical specimens revealed leiomyomas in both cases associated with <i>S
. mansoni</i>. In one of them, granulomas were found in the ovary and in the oth
er they were found in the uterine tube. Although none presented intestinal/hepat
ic disease, fecal egg excretion was detected in one. Both had elevated pretreatm
ent antibody reactivity to <i>S. mansoni</i> antigen, but follow-up showed diffe
rent outcomes. Schistosomiasis should be considered as a diagnosis in individual
s with methrorragy residing in or having traveled to endemic areas. Since diagno
sis follows genital amputation, and cure control is troublesome, improvement of 
diagnostic tools and follow-up markers are important priorities to decrease schi
stosomiasis morbidity.#^dnd^i1#^tm^len^k<i>S. mansoni</i>^i1#^tm^len^kfemale gen
ital infection^i1#^tm^len^kserology^i1#^tm^len^klow endemic area^i1#CNPq#other#1
2#20090210#02/10/2009#20090522#05/22/2009#v15n2a16.htm##
02807000000000661000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000210013103100030015203200020015506500090015701400110016603500100
01770120115001870100031003020100035003330100029003680100033003970100023004300100
03100453010002900484070013000513070007200643070007000715070005700785070007500842
08309540091708500080187108500230187908500370190208500210193908500290196005800050
19891170006019940720003020001120009020031110011020121140009020231130011020320020
01302043008008902056#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#l#4
#1#article#1#^mMar./Apr.^a2011#oa#en#br1.1#1#4.0#ilus#tab#16#BJID020#nd#Braz. j.
 infect. dis#15#2#20110400#^f174^l177#1413-8670#Genital schistosomiasis mansoni 
concomitant to genital tumor in areas of low endemicity: challenging diagnosis^l
en#^rND^1A01^nMarta G^sCavalcanti#^rND^1A02^nMargareth MI^sGonçalves#^rND^1A03^n
Magali M^sBarreto#^rND^1A04^nAline Helen da^sSilva#^rND^1A04^nKalil^sMadi#^rND^1
A02^nJosé Mauro^sPeralta#^rND^1A05^nRicardo P^sIgreja#^iA01^1Universidade Federa
l do Rio de Janeiro^2Hospital Clementino Fraga Filho^3Infectious and Parasitic D
iseases Service^pBrazil#^iA02^1UFRJ^2Instituto de Microbiologia Professor Paulo 
de Góes^pBrazil#^iA03^1FIOCRUZ^2Instituto Oswaldo Cruz^3Department of Biology^pB
razil#^iA04^1UFRJ^2HUCFF^3Pathological Anatomy Service^pBrazil#^iA05^1UFRJ^2Scho
ol of Medicine^3Department of Preventive Medicine^pBrazil#^len^aGenital infectio
n by Schistosoma mansoni is usually misdiagnosed in individuals who reside in, o
r travel to endemic areas. We describe two cases of genital tumor associated wit
h S. mansoni infection manifested by methrorragy. Surgical specimens revealed le
iomyomas in both cases associated with S. mansoni. In one of them, granulomas we
re found in the ovary and in the other they were found in the uterine tube. Alth
ough none presented intestinal/hepatic disease, fecal egg excretion was detected
 in one. Both had elevated pretreatment antibody reactivity to S. mansoni antige
n, but follow-up showed different outcomes. Schistosomiasis should be considered
 as a diagnosis in individuals with methrorragy residing in or having traveled t
o endemic areas. Since diagnosis follows genital amputation, and cure control is
 troublesome, improvement of diagnostic tools and follow-up markers are importan
t priorities to decrease schistosomiasis morbidity.#^dnd^i1#^tm^len^kS. mansoni^
i1#^tm^len^kfemale genital infection^i1#^tm^len^kserology^i1#^tm^len^klow endemi
c area^i1#CNPq#other#12#20090210#02/10/2009#20090522#05/22/2009#v15n2a16.htm#Int
ernet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-867020110002
00016##
00347000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704011500073002001300188#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#5#1#article#81#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>CASE REPORT</b></font>
</p>     ^cY#v15n2a16.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#6#2#article#81#<p>&nbsp;</p>     ^cY#
v15n2a16.htm##
00450000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704021800073002001300291#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#7#3#article#81#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Genital schistosom
iasis mansoni concomitant to genital tumor in areas of low endemicity: challengi
ng diagnosis</b></font></p>     ^cY#v15n2a16.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#8#4#article#81#<p>&nbsp;</p>     ^cY#
v15n2a16.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#9#5#article#81#<p>&nbsp;</p>     ^cY#
v15n2a16.htm##
00559000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704032600074002001300400#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#10#6#article#81#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Marta G Cavalcanti<sup>I</sup>; Mar
gareth MI Gon&ccedil;alves<sup>II</sup>; Magali M Barreto<sup>III</sup>; Aline H
elen da Silva<sup>IV</sup>; Kalil Madi<sup>IV</sup>; Jos&eacute; Mauro Peralta<s
up>II</sup>; Ricardo P Igreja<sup>V</sup></b></font></p>     ^cY#v15n2a16.htm##
00451000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704021800074002001300292#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#11#7#article#81#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Infectious and Parasitic D
iseases Service, Hospital Clementino Fraga Filho, Universidade Federal do Rio de
 Janeiro - HUCFF/UFRJ, Brazil    ^cY#v15n2a16.htm##
00324000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704009100074002001300165#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#12#8#article#81#<br>   <sup>II</sup>I
nstituto de Microbiologia Professor Paulo de G&oacute;es, UFRJ    ^cY#v15n2a16.h
tm##
00324000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704009100074002001300165#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#13#9#article#81#<br>   <sup>III</sup>
Department of Biology, Instituto Oswaldo Cruz, FIOCRUZ, Brazil    ^cY#v15n2a16.h
tm##
00302000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006800075002001300143#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#14#10#article#81#<br>   <sup>IV</sup>
Pathological Anatomy Service, HUCFF/UFRJ    ^cY#v15n2a16.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010600075002001300181#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#15#11#article#81#<br>   <sup>V</sup>D
epartment of Preventive Medicine, School of Medicine, UFRJ, Brazil</font></p>   
  ^cY#v15n2a16.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011800075002001300193#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#16#12#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a></
font></p>     ^cY#v15n2a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#17#13#article#81#<p>&nbsp;</p>     ^c
Y#v15n2a16.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004400075002001300119#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#18#14#article#81#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v15n2a16.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009800075002001300173#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#19#15#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v1
5n2a16.htm##
01292000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704105800075002001301133#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#20#16#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Genital infection by <i>Schistosoma m
ansoni</i> is usually misdiagnosed in individuals who reside in, or travel to en
demic areas. We describe two cases of genital tumor associated with <i>S. manson
i</i> infection manifested by methrorragy. Surgical specimens revealed leiomyoma
s in both cases associated with <i>S. mansoni</i>. In one of them, granulomas we
re found in the ovary and in the other they were found in the uterine tube. Alth
ough none presented intestinal/hepatic disease, fecal egg excretion was detected
 in one. Both had elevated pretreatment antibody reactivity to <i>S. mansoni</i>
 antigen, but follow-up showed different outcomes. Schistosomiasis should be con
sidered as a diagnosis in individuals with methrorragy residing in or having tra
veled to endemic areas. Since diagnosis follows genital amputation, and cure con
trol is troublesome, improvement of diagnostic tools and follow-up markers are i
mportant priorities to decrease schistosomiasis morbidity.</font></p>     ^cY#v1
5n2a16.htm##
00428000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704019400075002001300269#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#21#17#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> <i>S. mansoni</i>; f
emale genital infection; serology; low endemic area.</font></p> <hr size="1" nos
hade>     ^cY#v15n2a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#22#18#article#81#<p>&nbsp;</p>     ^c
Y#v15n2a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#23#19#article#81#<p>&nbsp;</p>     ^c
Y#v15n2a16.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010900075002001300184#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#24#20#article#81#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>INTRODUCTION</b></i></font></p>
     ^cY#v15n2a16.htm##
01353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704111900075002001301194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#25#21#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Schistosomiasis is a chronic parasiti
c infection endemic in several countries in the tropics, which contributes to in
creased morbidity, and even mortality. Concern has grown, since schistosomiasis 
may progress to chronicity in the absence of any signs and symptoms of disease i
n individuals who are repeatedly or occasionally exposed to contaminated water, 
for example, travelers.<sup>1,2</sup> Chronic infection is commonly characterize
d by intestinal and/ or hepatic involvement. However, reports of ectopic present
ations even in individuals who are not residents of endemic areas and who travel
 or migrate from transmission areas of schistosomiasis are becoming more common.
<sup>3,4</sup> Ectopic presentations affect individuals with any parasitic load 
even after years of primary exposure. Among the ectopic presentations is genital
 schistosomiasis. Although <i>Schistosoma hematobium</i> is very often detected 
in the genital tract, other species may also be involved in genital infection, s
uch as <i>S. mansoni</i>.<sup>5-7</sup></font></p>     ^cY#v15n2a16.htm##
00912000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704067800075002001300753#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#26#22#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Genital infection by <i>S. mansoni</i
> is a less-recognized complication of schistosomiasis even in areas of high end
emicity. Prevalence of male and female genital schistosomiasis (FGS) is still un
known in South America.<sup>8</sup> In FGS, clinical manifestations are often ab
sent or resemble those of myomatosis and other genital affections, being frequen
tly misdiagnosed.<sup>6,8</sup> Usually, FGS is a postsurgical diagnosis. Also, 
no clinical or laboratory assays are shown to be reliable diagnostic or prognost
ic markers of infection or disease, and treatment efficacy is rarely assessed.</
font></p>     ^cY#v15n2a16.htm##
00969000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704073500075002001300810#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#27#23#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">We report two FGS cases in individual
s residing in Rio de Janeiro, Brazil, who presented methorragy and abdominal pai
n without a previous history of schistosomiasis. Postsurgical histopathology rev
ealed eggs and granulomas in genital organs but only in one case eggs of <i>S. m
ansoni</i> in stool samples were found. Serum reactivity to <i>S. mansoni</i> ad
ult worm antigen was detected before treatment with antiparasitic drugs in both 
patients. However, post-treatment serum antibody reactivity was distinct in each
 individual. The role of serological tests as a clinical marker of infection and
/or disease has yet to be determined in these patients.</font></p>     ^cY#v15n2
a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#28#24#article#81#<p>&nbsp;</p>     ^c
Y#v15n2a16.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010900075002001300184#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#29#25#article#81#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>CASE REPORTS</b></i></font></p>
     ^cY#v15n2a16.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009600075002001300171#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#30#26#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Case 1</b></font></p>     ^cY#v15n
2a16.htm##
01350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704111600075002001301191#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#31#27#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Female, 42-years-old, born and raised
 in Paracambi (Rio de Janeiro, Brazil), during summer vacations used to go to Ju
iz de Fora (Minas Gerais, Brazil). Mother of two, had no history of abortions. S
he presented early symptoms of methrorragy, and abdominal pain four years before
 surgical intervention in 2004. Histopathological analysis showed few granulomat
ous reactions and calcified eggs of <i>S. mansoni</i> in the left ovary (<a href
="#fig1ab">Figures 1A</a> and <a href="#fig1ab">B</a>). Examination of the uteru
s also demonstrated presence of adenomyosis and leiomyomas. Abdominal ultrasound
 did not show signs of hepatosplenic or portal disturbances. No eggs were detect
ed in the stool samples. Pretreatment serum levels of IgG1 and IgE anti-<i>S. ma
nsoni</i> adult worm determined by in-house ELISA<sup>9</sup> were elevated, as 
shown in <a href="/img/revistas/bjid/v15n2/a16tab01.jpg">Table 1</a>. Praziquant
el at a dose of 40 mg/kg was prescribed, and two years thereafter the levels of 
antibody isotypes were undetectable.</font></p>     ^cY#v15n2a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#32#28#article#81#<p>&nbsp;</p>     ^c
Y#v15n2a16.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007500075002001300150#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#33#29#article#81#<p align="center"><i
mg src="/img/revistas/bjid/v15n2/a16fig01.jpg">    ^cY#v15n2a16.htm##
00321000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704008700075002001300162#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#34#30#article#81#<br>   <a name="fig1
ab"></a><img src="/img/revistas/bjid/v15n2/a16fig01ab.jpg">    ^cY#v15n2a16.htm#
#
00326000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009200075002001300167#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#35#31#article#81#<br>   <a name="fig1
cd"></a><img src="/img/revistas/bjid/v15n2/a16fig01cd.jpg"></p>     ^cY#v15n2a16
.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#36#32#article#81#<p>&nbsp;</p>     ^c
Y#v15n2a16.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009600075002001300171#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#37#33#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Case 2</b></font></p>     ^cY#v15n
2a16.htm##
01289000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704105500075002001301130#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#38#34#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Female, 40-years-old, born in Minas G
erais, living in Rio de Janeiro (Brazil) for the past 24 years, presented with i
ntense methrorragy and pelvic pain for two years before admission in January, 20
06 at the HUCFF, <i>Universidade Federal do Rio de Janeiro.</i> The patient repo
rted urinary incontinency in the past four years and an ovarian cyst three years
 earlier. Mother of three, she had an abortion in 1988. An USG showed uterine in
tramural nodules in the posterior and anterior wall, respectively, and cysts wer
e also detected in the right ovary and on the left annex. The patient had a hist
ory of hypertension, type II diabetes, and dyslipidemia since January, 2006. In 
June, 2006, subtotal hysterectomy and excision of both right and left ovaries we
re performed, and histopathological analysis showed <i>Schistosoma mansoni</i> e
ggs, several granulomas at the left uterine tube, and uterine leiomyoma (<a href
="#fig1cd">Figures 1C</a> and <a href="#fig1cd">D</a>).</font></p>     ^cY#v15n2
a16.htm##
01346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704111200075002001301187#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#39#35#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">In September, the patient was admitte
d to the Infectious Diseases Clinic. Clinical history and examination revealed n
o signs and symptoms of enteric or hepatosplenic disease. No portal hypertension
 was detected by ultrasound, which revealed slight hepatic steatosis compatible 
with the diagnosis of obesity (grade III). Coproscopy detected 696 eggs /g of fe
ces and IgG, IgG1, IgG4, and IgG E serum levels were increased in two different 
samples before therapy (<a href="/img/revistas/bjid/v15n2/a16tab01.jpg">Table 1<
/a>). At the time, only oxamniquine was available and administered at a dose of 
15 mg/kg, but a strong gastrointestinal reaction ensued. Despite subsequent post
-treatment stool samples being negative, IgG1 and IgG4 levels were particularly 
elevated for 6, 16, and 20 months after treatment, as shown in <a href="/img/rev
istas/bjid/v15n2/a16tab01.jpg">Table 1</a>. Rectal biopsy was performed and demo
nstrated the presence of viable eggs of <i>S .mansoni.</i> Praziquantel (40 mg/k
g of body weight) was indicated.</font></p>     ^cY#v15n2a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#40#36#article#81#<p>&nbsp;</p>     ^c
Y#v15n2a16.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010700075002001300182#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#41#37#article#81#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>DISCUSSION</b></i></font></p>  
   ^cY#v15n2a16.htm##
00937000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704070300075002001300778#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#42#38#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Schistosomiasis is a chronic infectio
n which is one of the leading causes of high morbidity in tropical areas. It aff
ects not only residents of endemic areas, but also immigrants and travelers who 
are no longer exposed to <i>S. mansoni</i> infection.<sup>2,10</sup> Usually inf
ected individuals present as asymptomatic. However, intestinal and/or hepatosple
nic disease are current abnormalities in individuals from areas with high or eve
n low endemicity.<sup>11</sup> Like other <i>Schistosoma</i> species, <i>S. mans
oni</i> may also induce pathology in other sites such as the lower and upper gen
ital tract.<sup>8</sup></font></p>     ^cY#v15n2a16.htm##
01820000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704158600075002001301661#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#43#39#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Upper genital infection by <i>Schisto
soma</i> spp. in women is frequently disguised as tumors or other genital diseas
es. Differential diagnosis is challenging in women presenting methrorragy as the
 main clinical finding.<sup>8,12</sup> The present report describes two cases of
 female genital infection in patients residing in different geographical areas o
f Rio de Janeiro State, Brazil. The two patients showed clinical findings which 
could not be distinguished from benign or malignant genital diseases. In one of 
the cases, presurgical USG showed cysts in the right ovary and left annex, besid
es uterine mural nodules. In both cases, surgical specimen demonstrated the pres
ence of cysts in ovaries and also in the annex in one patient. Both presented ut
erine leiomyoma. In <i>S. haematobium</i> infection, lower genital infection may
 present with characteristic lesions but upper infection lacks particular clinic
al presentation.<sup>6</sup> Regarding <i>S. mansoni</i> infection, the manifest
ations of lower and upper genital tract infection remain elusive. Other concomit
ant conditions may also respond for the signs and symptoms of genital disease, w
hich might overlap with <i>S. mansoni</i> infection manifestations. Association 
with other tumors and malignancies has been described in female genital infectio
n by <i>S. haematobium</i>.<sup>7,12</sup> However, its role in tumorigenesis is
 still speculative, and no evidence points to the involvement of <i>S. mansoni</
i> in either of the cases.</font></p>     ^cY#v15n2a16.htm##
01516000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704128200075002001301357#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#44#40#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">In schistosomal upper-genital infecti
on, diagnosis is usually based on histopathological examination of surgical spec
imens.<sup>6,7</sup> However, detection of eggs in atypical sites does not rule 
out infection in traditional ones. Nonetheless, detection of ova excretion and s
erology are used less frequently as diagnostic tools in those cases. Long-term f
ollow-up for cure control is rarely assessed. We found that despite the absence 
of clinical history of schistosomiasis, one of the patients presented eggs in th
e stools. Possible treatment failure also resulted in maintained egg excretion a
s seen in the rectal biopsy, and persistent reactivity in serological tests. In 
contrast, the first patient who presented only calcified eggs in the genital tis
sue, and no ova excretion had negative reactivity to schistosoma antigens post-t
reatment. This data suggest that detection of egg excretion and serology are imp
ortant diagnostic tools to determine concomitant infection in other sites. Furth
er studies are warranted to evaluate the role of combined parasitological and im
munological tests as markers for treatment response in individuals with differen
t presentations of schistosomal infection.</font></p>     ^cY#v15n2a16.htm##
00731000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704049700075002001300572#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#45#41#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">In conclusion, female genital infecti
on by <i>S. mansoni</i> is a silent chronic infection that may occur even in ind
ividuals who no longer live in endemic areas. Concomitant infection of other sit
es must also be investigated through detection of ova excretion and serum reacti
vity to <i>S. mansoni</i>. Further, cure control might be determined by the comb
ination of both parasitological and immunological assays.</font></p>     ^cY#v15
n2a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#46#42#article#81#<p>&nbsp;</p>     ^c
Y#v15n2a16.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011200075002001300187#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#47#43#article#81#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>ACKNOWLEDGMENTS</b></i></font><
/p>     ^cY#v15n2a16.htm##
00572000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704033800075002001300413#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#48#44#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">We thank Dr Helena Ribeiro LaGrega, D
ra Vera Lucia Chagas (HUCFF/UFRJ, Rio de Janeiro, Brazil) and Dr Carlos Santos P
ereira, <i>Laborat&oacute;rio LUPA</i> (Rio de Janeiro, Brazil) for their invalu
able cooperation, and CNPq (Brazil) for financial support.</font></p>     ^cY#v1
5n2a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#49#45#article#81#<p>&nbsp;</p>     ^c
Y#v15n2a16.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010700075002001300182#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#50#46#article#81#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p>  
   ^cY#v15n2a16.htm##
00518000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704027000077002001300347#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#51#47#article#81#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Boers KE, Sastrowijo
to PH, Elsakker van EP, and Hermans MP. Schistosomiasis of the uterus in a patie
nt with dysmenorrheal and menorrhagia. Eur. J. Obstet. Gynecol. Reprod Biol., 20
03; 108:106-108.    ^cY#v15n2a16.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#52#48#article#81#</font></p>     ^cY#
v15n2a16.htm##
00590000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704034200077002001300419#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#53#49#article#81#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Raglio A, Russo V, S
wierczynski G, Sonzogni A, Goglio A, Garcia LS. Acute Schistosomiasis mansoni in
fection with progression to chronic lesion in Italian travelers returning from C
ameroon, West Africa: diagnostic and prevention problem. J Travel Med., 2002; 9:
101-102.    ^cY#v15n2a16.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#54#50#article#81#</font></p>     ^cY#
v15n2a16.htm##
00459000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704021100077002001300288#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#55#51#article#81#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. P&eacute;rignon A, P
elicot M, Consigny PH. Genital Schistosomiasis in a traveler coming back from Ma
li. J. Travel Med., 2007; 14:197-199.    ^cY#v15n2a16.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#56#52#article#81#</font></p>     ^cY#
v15n2a16.htm##
00435000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704018700077002001300264#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#57#53#article#81#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Sheorey H, Charles P
GP, Pyman J. Ectopic Schistosomiasis in a returned traveler. J Travel Med., 2004
; 11:251-252.    ^cY#v15n2a16.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#58#54#article#81#</font></p>     ^cY#
v15n2a16.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704026700077002001300344#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#59#55#article#81#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Hoffmann H, Bauerfei
nd I. High tissue egg burden mechanically impairing the tubal motility in genita
l schistosomiasis of the female. Acta. Obstect. Gynecol. Scand., 2003; 82:970-97
1</font></p>     ^cY#v15n2a16.htm##
00462000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704021400077002001300291#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#60#56#article#81#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Ponggensee G, Feldme
ier H , Krantz I. Schistosomiasis of the female genital tract: public health asp
ects. Parasitol Today. 1999; 15:378-381.    ^cY#v15n2a16.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#61#57#article#81#</font></p>     ^cY#
v15n2a16.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704030100077002001300378#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#62#58#article#81#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Swai B, Ponggensee G
, Mtweve S, Krantz I. Female genital schistosomiasis as an evidence of a neglect
ed cause for reproductive ill-health: a retrospective histopathological study fr
om Tanzania. BMC Infect. Dis., 2006; 6:134-141.    ^cY#v15n2a16.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#63#59#article#81#</font></p>     ^cY#
v15n2a16.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704029300077002001300370#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#64#60#article#81#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Oliveira FAS, Soares
 VL, Dacal RC <i>et al</i>. Absence of cervical schistosomiasis among women from
 two areas of north-eastern Brazil with endemic <i>Schistosoma mansoni</i>. Ann.
 Trop. Med. Parasitol. 2006; 100:49-54.    ^cY#v15n2a16.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#65#61#article#81#</font></p>     ^cY#
v15n2a16.htm##
00558000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704031000077002001300387#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#66#62#article#81#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Gon&ccedil;alves MM,
 Barreto MG, Peralta RH <i>et al</i>. Immunoassays as an auxiliary tool for the 
serodiagnosis of <i>Schistosoma mansoni</i> infection in individuals with low in
tensity of egg elimination. Acta Trop., 2006; 100:24-30.    ^cY#v15n2a16.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#67#63#article#81#</font></p>     ^cY#
v15n2a16.htm##
00517000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704026800078002001300346#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#68#64#article#81#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Posey DL, Blackbur
n BG, Weinberg M <i>et al</i>. High prevalence and presumptive treatment of schi
stosomiasis and strongyloidiasis among African refugees. Clin Infect Dis., 2007;
 45: 1310-1315.    ^cY#v15n2a16.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#69#65#article#81#</font></p>     ^cY#
v15n2a16.htm##
00604000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704035500078002001300433#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#70#66#article#81#11#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Igreja RP, Matos J
A, Gon&ccedil;alves MM, Barreto MM, Peralta JM. <i>Schistosoma mansoni</i>-relat
ed morbidity in a low prevalence area in Brazil: a comparison between egg-excret
ors and <i>S. mansoni</i> antibody positive individuals. Ann Trop Med Parasitol.
 2007; 101(7):575-584.    ^cY#v15n2a16.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#71#67#article#81#</font></p>     ^cY#
v15n2a16.htm##
00484000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704023500078002001300313#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#72#68#article#81#12#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Helling-Giese G, K
jetland EF, Gundersen SG <i>et al</i>. Schistosomiasis in women: manifestations 
in the upper reproductive tract. Acta Trop., 1996; 62:225-238.    ^cY#v15n2a16.h
tm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#73#69#article#81#</font></p>     ^cY#
v15n2a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#74#70#article#81#<p>&nbsp;</p>     ^c
Y#v15n2a16.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#75#71#article#81#<p>&nbsp;</p>     ^c
Y#v15n2a16.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704018900075002001300264#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#76#72#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img 
src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:</b
>    ^cY#v15n2a16.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003300075002001300108#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#77#73#article#81#<br>   Marta G Caval
canti    ^cY#v15n2a16.htm##
00407000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704017300075002001300248#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#78#74#article#81#<br>   Servi&ccedil;
o de Doen&ccedil;as Infecciosas e Parasit&aacute;rias Hospital Universit&aacute;
rio Clementino Fraga Filho Universidade Federal do Rio de Janeiro    ^cY#v15n2a1
6.htm##
00351000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011700075002001300192#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#79#75#article#81#<br>   Rua Prof. Rod
olfo Rocco 255 - 5º andar Cidade Universit&aacute;ria, Campus do Fund&atilde;o 2
1 941-913    ^cY#v15n2a16.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003700075002001300112#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#80#76#article#81#<br>   Rio de Janeir
o, Brazil    ^cY#v15n2a16.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007500075002001300150#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#81#77#article#81#<br>   Phone: 55-21-
2562-2526, 55-21-9156-8630 Fax: 55-21 2551 7023    ^cY#v15n2a16.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010100075002001300176#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#82#78#article#81#<br>   <a href="mail
to:cavalcanti@openlink.com.br">cavalcanti@openlink.com.br</a></font></p>     ^cY
#v15n2a16.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009500075002001300170#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#83#79#article#81#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Submitted on: 02/10/2009    ^cY#v15n2
a16.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003800075002001300113#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#84#80#article#81#<br>   Approved on: 
05/22/2009    ^cY#v15n2a16.htm##
00296000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006200075002001300137#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a16.htm#S#p#85#81#article#81#<br>   We declare no
 conflict of interest.</font></p>     ^cY#v15n2a16.htm##
00615000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100016000760100023000920100
02300115010001800138012008200156030003700238710000200275065000900277064000500286
031000400291014000800295865000900303002001300312#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a16.htm#S#c#86#1#article#12#1#^rND^sBoers^nKE#^rND^sSastrowijoto^
nPH#^rND^sElsakker van^nEP#^rND^sHermans^nMP#Schistosomiasis of the uterus in a 
patient with dysmenorrheal and menorrhagia^len#Eur. J. Obstet. Gynecol. Reprod B
iol#2#20030000#2003#108#106-108#20110400#v15n2a16.htm##
00760000000000325000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100016000760100015000920100
02200107010001800129010001600147010001700163012017200180030001300352065000900365
06400050037403100020037901400080038186500090038900200130039803500100041180100130
0421#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#c#87#2#article#12#2
#^rND^sRaglio^nA#^rND^sRusso^nV#^rND^sSwierczynski^nG#^rND^sSonzogni^nA#^rND^sGo
glio^nA#^rND^sGarcia^nLS#Acute Schistosomiasis mansoni infection with progressio
n to chronic lesion in Italian travelers returning from Cameroon, West Africa: d
iagnostic and prevention problem^len#J Travel Med#20020000#2002#9#101-102#201104
00#v15n2a16.htm#1195-1982#J Travel Med##
00535000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100018000760100017000940100
01900111012006400130030001400194710000200208065000900210064000500219031000300224
014000800227865000900235002001300244#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a16.htm#S#c#88#3#article#12#3#^rND^sPérignon^nA#^rND^sPelicot^nM#^rND^sConsig
ny^nPH#Genital Schistosomiasis in a traveler coming back from Mali^len#J. Travel
 Med#2#20070000#2007#14#197-199#20110400#v15n2a16.htm##
00551000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100017000760100019000930100
01500112012005100127030001300178065000900191064000500200031000300205014000800208
865000900216002001300225035001000238801001300248#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a16.htm#S#c#89#4#article#12#4#^rND^sSheorey^nH#^rND^sCharles^nPGP
#^rND^sPyman^nJ#Ectopic Schistosomiasis in a returned traveler^len#J Travel Med#
20040000#2004#11#251-252#20110400#v15n2a16.htm#1195-1982#J Travel Med##
00569000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100018000760100020000940120
11000114030003000224710000200254065000900256064000500265031000300270014000800273
865000900281002001300290#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S
#c#90#5#article#12#5#^rND^sHoffmann^nH#^rND^sBauerfeind^nI#High tissue egg burde
n mechanically impairing the tubal motility in genital schistosomiasis of the fe
male^len#Acta. Obstect. Gynecol. Scand#2#20030000#2003#82#970-971#20110400#v15n2
a16.htm##
00581000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100020000760100019000960100
01600115012007100131030001600202065000900218064000500227031000300232014000800235
865000900243002001300252035001000265801001600275#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a16.htm#S#c#91#6#article#12#6#^rND^sPonggensee^nG#^rND^sFeldmeier
^nH#^rND^sKrantz^nI#Schistosomiasis of the female genital tract: public health a
spects^len#Parasitol Today#19990000#1999#15#378-381#20110400#v15n2a16.htm#0169-4
758#Parasitol Today##
00650000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100014000760100020000900100
01600110010001600126012015400142030001600296710000200312065000900314064000500323
031000200328014000800330865000900338002001300347#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a16.htm#S#c#92#7#article#12#7#^rND^sSwai^nB#^rND^sPonggensee^nG#^
rND^sMtweve^nS#^rND^sKrantz^nI#Female genital schistosomiasis as an evidence of 
a neglected cause for reproductive ill-health: a retrospective histopathological
 study from Tanzania^len#BMC Infect. Dis#2#20060000#2006#6#134-141#20110400#v15n
2a16.htm##
00669000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100020000760100017000960100
01600113810000600129012012400135030002600259065000900285064000500294031000400299
014000600303865000900309002001300318035001000331801002600341#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a16.htm#S#c#93#8#article#12#8#^rND^sOliveira^nFAS#^rN
D^sSoares^nVL#^rND^sDacal^nRC#et al#Absence of cervical schistosomiasis among wo
men from two areas of north-eastern Brazil with endemic Schistosoma mansoni^len#
Ann. Trop. Med. Parasitol#20060000#2006#100#49-54#20110400#v15n2a16.htm#0003-498
3#Ann. trop. med. parasitol##
00662000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100020000760100018000960100
01800114810000600132012014600138030001000284065000900294064000500303031000400308
014000600312865000900318002001300327035001000340801001000350#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a16.htm#S#c#94#9#article#12#9#^rND^sGonçalves^nMM#^rN
D^sBarreto^nMG#^rND^sPeralta^nRH#et al#Immunoassays as an auxiliary tool for the
 serodiagnosis of Schistosoma mansoni infection in individuals with low intensit
y of egg elimination^len#Acta Trop#20060000#2006#100#24-30#20110400#v15n2a16.htm
#0001-706X#Acta Trop##
00640000000000301000450000400060000070200480000670500020005470600020005670000030
00587010003000617090008000647080003000721180003000750100016000780100020000940100
01800114810000600132012010900138030001600247065000900263064000500272031000300277
014001000280865000900290002001300299035001000312801001600322#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a16.htm#S#c#95#10#article#12#10#^rND^sPosey^nDL#^rND^
sBlackburn^nBG#^rND^sWeinberg^nM#et al#High prevalence and presumptive treatment
 of schistosomiasis and strongyloidiasis among African refugees^len#Clin Infect 
Dis#20070000#2007#45#1310-1315#20110400#v15n2a16.htm#1058-4838#Clin Infect Dis##
00757000000000325000450000400060000070200480000670500020005470600020005670000030
00587010003000617090008000647080003000721180003000750100017000780100016000950100
02000111010001800131010001800149012015800167030002300325065000900348064000500357
03100040036203200020036601400080036886500090037600200130038503500100039880100230
0408#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a16.htm#S#c#96#11#article#12#
11#^rND^sIgreja^nRP#^rND^sMatos^nJA#^rND^sGonçalves^nMM#^rND^sBarreto^nMM#^rND^s
Peralta^nJM#Schistosoma mansoni-related morbidity in a low prevalence area in Br
azil: a comparison between egg-excretors and S. mansoni antibody positive indivi
duals^len#Ann Trop Med Parasitol#20070000#2007#101#7#575-584#20110400#v15n2a16.h
tm#0003-4983#Ann Trop Med Parasitol##
00602000000000301000450000400060000070200480000670500020005470600020005670000030
00587010003000617090008000647080003000721180003000750100023000780100019001010100
02000120810000600140012007700146030001000223065000900233064000500242031000300247
014000800250865000900258002001300267035001000280801001000290#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a16.htm#S#c#97#12#article#12#12#^rND^sHelling-Giese^n
G#^rND^sKjetland^nEF#^rND^sGundersen^nSG#et al#Schistosomiasis in women: manifes
tations in the upper reproductive tract^len#Acta Trop#19960000#1996#62#225-238#2
0110400#v15n2a16.htm#0001-706X#Acta Trop##
00274000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00300101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#o#1#1#article#1
#20110406#124848#v15n2a17.htm#88##
01917000000000553000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030001800109
03100030012703200020013006500090013201400110014103500100015201201690016201000400
03310100035003710100032004060100030004380700044004680700053005120830581005650850
00801146085003801154085003701192085003501229085002401264058001501288117000601303
072000301309112000901312111001001321114000901331113001001340002001301350#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#h#2#1#article#1#oa#en#br1.1#1#4
.0#ILUS#17#BJID020#nd#Braz J Infect Dis#15#2#20110400#^f178^l180#1413-8670#Fatal
 meningococcal meningitis in a HIV-infected patient caused by serogroup C Neisse
ria meningitidis belonging to the non-hypervirulent clonal complex ST-60 (cc60)^
len#^rND^1A01^nClaudia Ferreira de^sAndrade#^rND^1A02^nDenise Cotrim da^sCunha#^
rND^1A02^nVeronica^sCavalcanti#^rND^1A01^nIvano de^sFilippis#FIOCRUZ^iA01^1INCQS
^cRio de Janeiro^pBrazil#Hospital Lourenço Jorge^iA02^cRio de Janeiro^pBrazil#^l
en^aMeningococcal strains belonging to clonal complex cc60 are not associated wi
th hypervirulent lineages and were never reported as causing disease in Latin Am
erican countries. This is the first report of a fatal meningitis case caused by 
a cc60 clonal complex meningococcus in Brazil. Despite the immune-compromised st
ate of the patient, the fatal outcome here described shows the potential pathoge
nic behavior of strains belonging to this clonal complex and how compromised hos
ts can be susceptible to meningococcal infections even if the strain is not part
icularly invasive.#^dnd^i1#^tm^len^kmeningitis, meningococcal^i1#^tm^len^kmening
ococcal infections^i1#^tm^len^kNeisseria meningitidis^i1#^tm^len^kserogroup C^i1
#FIOCRUZ^dINCQS#other#12#20100218#2/18/2010#20100617#6/17/2010#v15n2a17.htm##
01938000000000553000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030001800109
03100030012703200020013006500090013201400110014103500100015201201830016201000400
03450100035003850100032004200100030004520700044004820700053005260830581005790850
00801160085003801168085003701206085004201243085002401285058001501309117000601324
072000301330112000901333111001001342114000901352113001001361002001301371#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#f#3#1#article#1#oa#en#br1.1#1#4
.0#ILUS#17#BJID020#nd#Braz J Infect Dis#15#2#20110400#^f178^l180#1413-8670#<b>Fa
tal meningococcal meningitis in a HIV-infected patient caused by serogroup C <i>
Neisseria meningitidis</i> belonging to the non-hypervirulent clonal complex ST-
60 (cc60)</b>^len#^rND^1A01^nClaudia Ferreira de^sAndrade#^rND^1A02^nDenise Cotr
im da^sCunha#^rND^1A02^nVeronica^sCavalcanti#^rND^1A01^nIvano de^sFilippis#FIOCR
UZ^iA01^1INCQS^cRio de Janeiro^pBrazil#Hospital Lourenço Jorge^iA02^cRio de Jane
iro^pBrazil#^len^aMeningococcal strains belonging to clonal complex cc60 are not
 associated with hypervirulent lineages and were never reported as causing disea
se in Latin American countries. This is the first report of a fatal meningitis c
ase caused by a cc60 clonal complex meningococcus in Brazil. Despite the immune-
compromised state of the patient, the fatal outcome here described shows the pot
ential pathogenic behavior of strains belonging to this clonal complex and how c
ompromised hosts can be susceptible to meningococcal infections even if the stra
in is not particularly invasive.#^dnd^i1#^tm^len^kmeningitis, meningococcal^i1#^
tm^len^kmeningococcal infections^i1#^tm^len^k<i>Neisseria meningitidis</i>^i1#^t
m^len^kserogroup C^i1#FIOCRUZ^dINCQS#other#12#20100218#2/18/2010#20100617#6/17/2
010#v15n2a17.htm##
02055000000000577000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108121000300113049000800116158000300124
03000210012703100030014803200020015106500090015301400110016203500100017301201690
01830100040003520100035003920100032004270100030004590700046004890700055005350830
58100590085000801171085003801179085003701217085003501254085002401289058001501313
11700060132807200030133411200090133711100100134611400090135611300100136500200130
1375008008901388#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#l#4#1#a
rticle#1#^mMar./Apr.^a2011#oa#en#br1.1#1#4.0#ilus#17#BJID020#nd#Braz. j. infect.
 dis#15#2#20110400#^f178^l180#1413-8670#Fatal meningococcal meningitis in a HIV-
infected patient caused by serogroup C Neisseria meningitidis belonging to the n
on-hypervirulent clonal complex ST-60 (cc60)^len#^rND^1A01^nClaudia Ferreira de^
sAndrade#^rND^1A02^nDenise Cotrim da^sCunha#^rND^1A02^nVeronica^sCavalcanti#^rND
^1A01^nIvano de^sFilippis#^iA01^1FIOCRUZ^2INCQS^cRio de Janeiro^pBrazil#^iA02^1H
ospital Lourenço Jorge^cRio de Janeiro^pBrazil#^len^aMeningococcal strains belon
ging to clonal complex cc60 are not associated with hypervirulent lineages and w
ere never reported as causing disease in Latin American countries. This is the f
irst report of a fatal meningitis case caused by a cc60 clonal complex meningoco
ccus in Brazil. Despite the immune-compromised state of the patient, the fatal o
utcome here described shows the potential pathogenic behavior of strains belongi
ng to this clonal complex and how compromised hosts can be susceptible to mening
ococcal infections even if the strain is not particularly invasive.#^dnd^i1#^tm^
len^kmeningitis, meningococcal^i1#^tm^len^kmeningococcal infections^i1#^tm^len^k
Neisseria meningitidis^i1#^tm^len^kserogroup C^i1#FIOCRUZ^dINCQS#other#12#201002
18#2/18/2010#20100617#6/17/2010#v15n2a17.htm#Internet^ihttp://www.scielo.br/scie
lo.php?script=sci_arttext&pid=S1413-86702011000200017##
00347000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704011500073002001300188#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#5#1#article#72#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>CASE REPORT</b></font>
</p>     ^cY#v15n2a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#6#2#article#72#<p>&nbsp;</p>     ^cY#
v15n2a17.htm##
00511000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704027900073002001300352#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#7#3#article#72#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Fatal meningococca
l meningitis in a HIV-infected patient caused by serogroup C <i>Neisseria mening
itidis</i> belonging to the non-hypervirulent clonal complex ST-60 (cc60)</b></f
ont></p>     ^cY#v15n2a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#8#4#article#72#<p>&nbsp;</p>     ^cY#
v15n2a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#9#5#article#72#<p>&nbsp;</p>     ^cY#
v15n2a17.htm##
00466000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704023300074002001300307#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#10#6#article#72#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Claudia Ferreira de Andrade<sup>I</
sup>; Denise Cotrim da Cunha<sup>II</sup>; Veronica Cavalcanti<sup>III</sup>; Iv
ano de Filippis<sup>IV</sup></b></font></p>     ^cY#v15n2a17.htm##
00387000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704015400074002001300228#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#11#7#article#72#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Biologist; Laboratory Tech
nician, INCQS/FIOCRUZ, Rio de Janeiro, Brazil    ^cY#v15n2a17.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704009500074002001300169#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#12#8#article#72#<br> <sup>II</sup>MD;
 Physician, Hospital Louren&ccedil;o Jorge, Rio de Janeiro, Brazil    ^cY#v15n2a
17.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704012500074002001300199#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#13#9#article#72#<br>   <sup>III</sup>
Biologist; Clinical Pathology Technician, Hospital Louren&ccedil;o Jorge, Rio de
 Janeiro, Brazil    ^cY#v15n2a17.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011400075002001300189#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#14#10#article#72#<br>   <sup>IV</sup>
Post-doctorate; Senior Technologist, INCQS/FIOCRUZ, Rio de Janeiro, Brazil</font
></p>     ^cY#v15n2a17.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011800075002001300193#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#15#11#article#72#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a></
font></p>     ^cY#v15n2a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#16#12#article#72#<p>&nbsp;</p>     ^c
Y#v15n2a17.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004400075002001300119#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#17#13#article#72#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v15n2a17.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009800075002001300173#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#18#14#article#72#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v1
5n2a17.htm##
00891000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704065700075002001300732#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#19#15#article#72#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Meningococcal strains belonging to cl
onal complex cc60 are not associated with hypervirulent lineages and were never 
reported as causing disease in Latin American countries. This is the first repor
t of a fatal meningitis case caused by a cc60 clonal complex meningococcus in Br
azil. Despite the immune-compromised state of the patient, the fatal outcome her
e described shows the potential pathogenic behavior of strains belonging to this
 clonal complex and how compromised hosts can be susceptible to meningococcal in
fections even if the strain is not particularly invasive.</font></p>     ^cY#v15
n2a17.htm##
00452000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704021800075002001300293#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#20#16#article#72#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> meningitis, meningoc
occal; meningococcal infections; <i>Neisseria meningitidis</i>; serogroup C.</fo
nt></p> <hr size="1" noshade>     ^cY#v15n2a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#21#17#article#72#<p>&nbsp;</p>     ^c
Y#v15n2a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#22#18#article#72#<p>&nbsp;</p>     ^c
Y#v15n2a17.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010900075002001300184#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#23#19#article#72#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>INTRODUCTION</b></i></font></p>
     ^cY#v15n2a17.htm##
01475000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704124100075002001301316#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#24#20#article#72#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Meningococcal disease (MD) is a life-
threatening illness that may affect susceptible patients and is presented in two
 clinical forms: meningitis and septicemia. Both forms lead to high fatality rat
es ranging from 5% in developed countries to 20% in developing countries. When n
ot fatal, the disease may leave severe sequelae. The etiological agent of MD is 
the bacterium <i>Neisseria meningitidis</i> (meningococcus), a Gram-negative dip
lococcus harboring a polysaccharide capsule (PSC) which is the main responsible 
for the severity of the disease when it is released into the bloodstream during 
the infection process. The capsular polysaccharide of the meningococcus has diff
erent biochemical features which are used for typing the microorganism into 13 d
ifferent serogroups according to their reactivity against specific antisera. Des
pite the great number of different serogroups, only 5 (A, B, C, W135 and Y) acco
unt for more than 90% of the strains producing disease worldwide. Serogrouping h
as been widely used in epidemiological studies to track epidemic strains and the
 PSC has been the main target of several effective vaccines against meningococci
.</font></p>     ^cY#v15n2a17.htm##
01104000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704087000075002001300945#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#25#21#article#72#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A number of proteins exposed on the m
eningococcal outer membrane have been used for typing strains giving an addition
al typing system dividing strains into serotypes and serosubtypes. Specific and 
consistent groups of serotypes and serosubtypes have been associated with diseas
es caused by certain serogroups. Also, a widely used molecular typing method cal
led multilocus sequence typing (MLST) that indexes variation in multiple houseke
eping genes, has been successfully applied to track hypervirulent strains during
 outbreaks. Under this molecular approach, a huge database of sequence types (ST
) and serosubtypes has been developed and is hosted at the Oxford University, UK
, <a href="http://neisseria.org/nm/typing/" target="_blank">http://neisseria.org
/nm/typing/</a>.<sup>1,2</sup></font></p>     ^cY#v15n2a17.htm##
01017000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704078300075002001300858#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#26#22#article#72#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The so-called clonal complexes (cc) i
dentified by MLST studies, are the main unit for epidemiological analysis of men
ingococci. A sub-group of cc, the so-called hyperinvasive or hypervirulent linea
ges, has been responsible for most reported meningococcal disease globally durin
g the latter half of the twentieth century.<sup>3</sup> Hypervirulent cc are cle
arly disease-associated, but a great number of lineages has been only found in c
arriers such as the clonal complex 60 (cc60). Strains belonging to this cc have 
been isolated in Europe, USA and Canada from nasopharynx of healthy carriers and
 from sporadic invasive disease. To our knowledge, cc60 was never reported in La
tin American countries.</font></p>     ^cY#v15n2a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#27#23#article#72#<p>&nbsp;</p>     ^c
Y#v15n2a17.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010800075002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#28#24#article#72#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>CASE REPORT</b></i></font></p> 
    ^cY#v15n2a17.htm##
01223000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704098900075002001301064#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#29#25#article#72#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">We report the case of a 33 year old f
emale patient previously diagnosed with HIV and currently on antiviral therapy (
AZT/3TC/lopinavir + ritonavir). She was admitted to a public hospital in Rio de 
Janeiro, Brazil, because of loss of consciousness with suspected bacterial menin
gitis, toxoplasmosis or cryptococcosis of the CNS. A xanthochromic turbid CSF wa
s collected on the 2<sup>nd</sup> day of admission and cultivated in chocolate a
gar with negative growth after 48h of incubation in a 5% CO<sub>2</sub> atmosphe
re. Hemoculture, latex seroagglutination and Ziehl-Neelsen stain (AFB) also turn
ed out negative. CSF white blood cell count was 25 cells with 80% monocytes and 
20% PMN. Antibiotic therapy was initiated with ceftriaxone, sulfadiazine and pyr
imethamine on the 3<sup>rd</sup> day of admission. On the 4<sup>th</sup> day the
 patient died after tracheal intubation and use of vasoactive amines.</font></p>
     ^cY#v15n2a17.htm##
02503000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704226900075002001302344#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#30#26#article#72#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">A CSF aliquot collected on the 2<sup>
nd</sup> day was sent to our laboratory for investigation of bacterial meningiti
s pathogens <i>Neisseria meningitidis</i> (Nm), <i>Haemophilus influenzae</i> (H
i) and <i>Streptococcus pneumoniae</i> (Sp) by molecular methods. The CSF sample
 was firstly inoculated into Brain Heart Infusion chocolate agar (Difco) enriche
d with 10% defibrinated rabbit blood at 37ºC, but no growth was observed after 4
8h in 5% CO<sub>2</sub> atmosphere. The CSF sample was then used for DNA extract
ion and purification with DNeasy Blood &amp; Tissue kit (Qiagen) and submitted t
o a multiplex-PCR approach using specific primers for detection of the three bac
terial agents previously described. The targeted genomic regions were the outer 
membrane protein <i>nsp</i>A gene for Nm, the capsular gene <i>bex</i>A for Hi a
nd the pneumolysin gene <i>ply</i> for Sp. The primers used for the specific PCR
 amplification were previously described for <i>nsp</i>A,<sup>4</sup> <i>bex</i>
A<sup>5</sup> and <i>ply</i>.<sup>6</sup> Agarose gel electrophoresis of PCR pro
ducts, showed a unique 481bp band confirming the presence of meningococcal genom
ic DNA in the CSF sample received. CSF DNA sample was also analyzed aiming at ge
notype determination of the outer membrane protein genes <i>porA, porB, fetA</i>
 and for MLST housekeeping genes analysis for sequence type (ST) and clonal comp
lex (cc) characterization. Serogroup prediction was also performed with the DNA 
samples, using the SIAD-PCR previously described<sup>7</sup> since latex aggluti
nation test for serogroup determination was negative for serogroups A, B, C and 
W135/Y. For PCR amplification and DNA sequencing of the above mentioned genes, w
e followed the protocol described in the Nesisseria.org database at <a href="htt
p://neisseria.org/nm/typing/" target="_blank">http://neisseria.org/nm/typing/</a
>. Sequencing results showed the following genotype: C:NT:P1.22,14-6,36-2: ST-73
27 (cc60). After many attempts and protocol changes, we were not able to amplify
 <i>porB</i> and <i>fetA</i> genes. This was probably due to degradation of the 
genomic DNA extracted from the CSF sample received from the hospital.</font></p>
     ^cY#v15n2a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#31#27#article#72#<p>&nbsp;</p>     ^c
Y#v15n2a17.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010700075002001300182#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#32#28#article#72#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>DISCUSSION</b></i></font></p>  
   ^cY#v15n2a17.htm##
02494000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704226000075002001302335#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#33#29#article#72#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Serogroups B and C meningococci, acco
unt for more than 90% of meningococcal cases in Brazil. Recent studies showed th
at the most frequent genotypes in Brazil are B:4,7:P1.19,15(P1.7,1):ST-33 (cc32)
 and C:2b:P1.3(P1.2):ST-103 (cc103), but other hyperinvasive cc also have been f
ound among Brazilian isolates.<sup>8-12</sup> These cc, also called hypervirulen
t, are part of a group of nine hyperinvasive lineages associated with most endem
ic and epidemic meningococcal disease of the latter half of the twentieth centur
y. The distribution of such lineages varies within geographical regions. In Braz
il, non-hypervirulent cc causing invasive disease is not frequent. According to 
the Neisseria.org database, 31.4% of the isolates characterized by MLST in Brazi
l (n = 271), belong to non-hypervirulent cc; however, none of the isolates was a
ssociated with cc60. Worldwide, the occurrence of cc60 strains is 1.9% according
 to the Neisseria. org database. To date, the total number of isolates reported 
by the database is 13,621 with only 260 strains belonging to cc60. The associati
on of a specific serogroup, serotype or subtype to cc60 as it is observed with h
ypervirulent cc is not clear. The strain isolated from the patient here describe
d belongs to serogroup C, serotype not determined and subtype P1.22,14-6. Among 
the 260 cc60 strains reported worldwide, only 7 (2.7%) were serogroup C and only
 one isolate (0.4%) belonged to families 22 and 14 of PorA VR1 and VR2, respecti
vely. Also, 57% of the cc60 isolates reported in the Neisseria. org database wer
e recovered from carriers, while 36.5% from disease and other 6.5% from unknown 
source. The genetic heterogeneity found among cc60 strains has been more commonl
y observed within carrier isolates, while hypervirulent associated strains frequ
ently show a clear link to specific serogroups and serosubtypes. It is noteworth
y that although the meningococcal strain was isolated from an HIV positive patie
nt, the organism showed a high virulence demonstrated by the short period of tim
e elapsed from the onset of symptoms to the patient death. This aggressive patte
rn is often observed with hypervirulent associated lineages.</font></p>     ^cY#
v15n2a17.htm##
00733000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704049900075002001300574#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#34#30#article#72#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The first report of a meningococcus s
train belonging to cc60 in Brazil, causing fatal meningitis even in an immune-co
mpromised HIV patient, may be seen as a concerning issue. The fatal outcome of c
ase here described shows the potential pathogenic behavior of strains belonging 
to cc60 clonal complex and how compromised hosts can be susceptible to meningoco
ccal infections even if they are not particularly invasive.</font></p>     ^cY#v
15n2a17.htm##
00477000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704024300075002001300318#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#35#31#article#72#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Improvement of the public health surv
eillance system would be advisable to monitor the spread of this clone within Br
azil and adjacent Latin American countries.</font></p>     ^cY#v15n2a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#36#32#article#72#<p>&nbsp;</p>     ^c
Y#v15n2a17.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011200075002001300187#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#37#33#article#72#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>ACKNOWLEDGMENTS</b></i></font><
/p>     ^cY#v15n2a17.htm##
00988000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704075400075002001300829#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#38#34#article#72#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">This study made use of the <i>Neisser
ia</i> multilocus sequence typing web site (<a href="http://pubmlst.org/neisseri
a/" target="_blank">http://pubmlst.org/neisseria/</a>) developed by Man-Suen Cha
n and Keith Jolley and sited at the University of Oxford (curator, Keith Jolley)
 and the <i>N. meningitidis</i> PorA typing web site (<a href="http://neisseria.
org/nm/typing/" target="_blank">http://neisseria.org/nm/typing/</a>), developed 
by Keith Jolley (curators, Janet Suker and Ian Feavers, respectively). The autho
rs thank the "Plataforma Genomica - Sequenciamento de DNA/PDTIS-FIOCRUZ' for the
 sequencing reactions. This work was funded by INCQS/FIOCRUZ (MS), Brazil.</font
></p>     ^cY#v15n2a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#39#35#article#72#<p>&nbsp;</p>     ^c
Y#v15n2a17.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010700075002001300182#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#40#36#article#72#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p>  
   ^cY#v15n2a17.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704029600077002001300373#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#41#37#article#72#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Maiden MC, Bygraves 
JA, Feil E <i>et al</i>. Multilocus sequence typing: a portable approach to the 
identification of clones within populations of pathogenic microorganisms. Proc N
atl Acad Sci U S A. 1998; 17;95(6):3140-5.    ^cY#v15n2a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#42#38#article#72#</font></p>     ^cY#
v15n2a17.htm##
00512000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704026400077002001300341#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#43#39#article#72#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Urwin R, Russell JE,
 Thompson EA <i>et al</i>. Distribution of surface protein variants among hyperi
nvasive meningococci: implications for vaccine design. Infect Immun. 2004; 72(10
):5955-62.    ^cY#v15n2a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#44#40#article#72#</font></p>     ^cY#
v15n2a17.htm##
00431000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704018300077002001300260#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#45#41#article#72#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Caugant DA. Populati
on genetics and molecular epidemiology of Neisseria meningitidis. Apmis 1998; 10
6:505-25.    ^cY#v15n2a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#46#42#article#72#</font></p>     ^cY#
v15n2a17.htm##
00550000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704030200077002001300379#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#47#43#article#72#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. de Filippis I, do Na
scimento CR, Clementino MB <i>et al</i>. Rapid detection of Neisseria meningitid
is in cerebrospinal fluid by one-step polymerase chain reaction of the nspA gene
. Diagn Microbiol Infect Dis. 2005; 51(2):85-90.    ^cY#v15n2a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#48#44#article#72#</font></p>     ^cY#
v15n2a17.htm##
00455000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704020700077002001300284#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#49#45#article#72#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Falla TJ, Crook DW, 
Brophy LN <i>et al</i>. PCR for capsular typing of Haemophilus influenzae. J Cli
n Microbiol. 1994; 32(10):2382-6.    ^cY#v15n2a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#50#46#article#72#</font></p>     ^cY#
v15n2a17.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704023700077002001300314#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#51#47#article#72#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Toikka P, Nikkari S,
 Ruuskanen O <i>et al</i>. Pneumolysin PCR-based diagnosis of invasive pneumococ
cal infection in children. J Clin Microbiol. 1999; 37(3):633-7.    ^cY#v15n2a17.
htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#52#48#article#72#</font></p>     ^cY#
v15n2a17.htm##
00555000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704030700077002001300384#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#53#49#article#72#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Pollard AJ, Probe G,
 Trombley C <i>et al</i>. Evaluation of a diagnostic polymerase chain reaction a
ssay for Neisseria meningitidis in North America and field experience during an 
outbreak. Arch Pathol Lab Med. 2002; 126(10):1209-15.    ^cY#v15n2a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#54#50#article#72#</font></p>     ^cY#
v15n2a17.htm##
00576000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704032800077002001300405#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#55#51#article#72#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Baethgen LF, Weidlic
h L, Moraes C <i>et al</i>. Epidemiology of meningococcal disease in southern Br
azil from 1995 to 2003, and molecular characterization of Neisseria meningitidis
 using multilocus sequence typing. Trop Med Int Health. 2008; 13(1):31-40.    ^c
Y#v15n2a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#56#52#article#72#</font></p>     ^cY#
v15n2a17.htm##
00540000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704029200077002001300369#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#57#53#article#72#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. de Filippis I, de An
drade CF, Silva L <i>et al</i>. PorA variable antigenic regions VR1, VR2, and VR
3 of Neisseria meningitidis serogroups B and C isolated in Brazil from 1999 to 2
004. Infect Immun. 2007; 75(7):3683-5.    ^cY#v15n2a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#58#54#article#72#</font></p>     ^cY#
v15n2a17.htm##
00701000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704045200078002001300530#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#59#55#article#72#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">10. de Filippis I, Vic
ente AC. Multilocus sequence typing and repetitive element-based polymerase chai
n reaction analysis of Neisseria meningitides isolates in Brazil reveal the emer
gence of 11 new sequence types genetically related to the ST-32 and ST-41/44 com
plexes and high prevalence of strains related to hypervirulent lineages. Diagn M
icrobiol Infect Dis. 2005; 53(3):161-7.    ^cY#v15n2a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#60#56#article#72#</font></p>     ^cY#
v15n2a17.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704030000078002001300378#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#61#57#article#72#11#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">11. de Lemos AP, Yara 
TY, Gorla MC <i>et al</i>. Clonal distribution of invasive Neisseria meningitidi
s serogroup C strains circulating from 1976 to 2005 in greater S&atilde;o Paulo,
 Brazil. J Clin Microbiol. 2007; 45(4):1266-73.    ^cY#v15n2a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#62#58#article#72#</font></p>     ^cY#
v15n2a17.htm##
00536000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704028700078002001300365#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#63#59#article#72#12#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Lemos AP, Brand&at
ilde;o AP, Gorla MC <i>et al</i>. Phenotypic characterization of Neisseria menin
gitidis strains isolated from invasive disease in Brazil from 1990 to 2001. J Me
d Microbiol. 2006; 55(Pt 6):751-7.    ^cY#v15n2a17.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#64#60#article#72#</font></p>     ^cY#
v15n2a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#65#61#article#72#<p>&nbsp;</p>     ^c
Y#v15n2a17.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#66#62#article#72#<p>&nbsp;</p>     ^c
Y#v15n2a17.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704018900075002001300264#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#67#63#article#72#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img 
src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:</b
>    ^cY#v15n2a17.htm##
00264000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003000075002001300105#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#68#64#article#72#<br> Ivano de Filipp
is    ^cY#v15n2a17.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010800075002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#69#65#article#72#<br> Instituto Nacio
nal de Controle de Qualidade em Sa&uacute;de Funda&ccedil;&atilde;o Oswaldo Cruz
    ^cY#v15n2a17.htm##
00263000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002900075002001300104#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#70#66#article#72#<br> Av. Brasil, 436
5    ^cY#v15n2a17.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004500075002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#71#67#article#72#<br> Rio de Janeiro,
 Brazil 21045-900    ^cY#v15n2a17.htm##
00292000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704005800075002001300133#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#72#68#article#72#<br> Phone: +55-21-3
865-5236 Fax: +55-21-2290-0915    ^cY#v15n2a17.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011300075002001300188#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#73#69#article#72#<br> <a href="mailto
:ivano.defilippis@incqs.fiocruz.br">ivano.defilippis@incqs.fiocruz.br</a></font>
</p>     ^cY#v15n2a17.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009400075002001300169#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#74#70#article#72#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Submitted on: 2/18/2010    ^cY#v15n2a
17.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003700075002001300112#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#75#71#article#72#<br>   Approved on: 
6/17/2010    ^cY#v15n2a17.htm##
00296000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006200075002001300137#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a17.htm#S#p#76#72#article#72#<br>   We declare no
 conflict of interest.</font></p>     ^cY#v15n2a17.htm##
00701000000000325000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100017000760100019000930100
01400112810000600126012013200132030002500264065000900289064000500298061000300303
03100030030603200020030901400070031186500090031800200130032703500100034080100250
0350#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#c#77#1#article#12#1
#^rND^sMaiden^nMC#^rND^sBygraves^nJA#^rND^sFeil^nE#et al#Multilocus sequence typ
ing: a portable approach to the identification of clones within populations of p
athogenic microorganisms^len#Proc Natl Acad Sci U S A#19980000#1998#17#95#6#3140
-5#20110400#v15n2a17.htm#0027-8424#Proc Natl Acad Sci U S A##
00645000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100015000760100018000910100
01900109810000600128012011100134030001300245065000900258064000500267031000300272
032000300275014000800278865000900286002001300295035001000308801001300318#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#c#78#2#article#12#2#^rND^sUrwin
^nR#^rND^sRussell^nJE#^rND^sThompson^nEA#et al#Distribution of surface protein v
ariants among hyperinvasive meningococci: implications for vaccine design^len#In
fect Immun#20040000#2004#72#10#5955-62#20110400#v15n2a17.htm#0019-9567#Infect Im
mun##
00506000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100018000760120077000940300
00600171065000900177064000500186031000400191014000700195865000900202002001300211
035001000224801000600234#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S
#c#79#3#article#12#3#^rND^sCaugant^nDA#Population genetics and molecular epidemi
ology of Neisseria meningitidis^len#Apmis#19980000#1998#106#505-25#20110400#v15n
2a17.htm#0903-4641#APMIS##
00697000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100021000760100024000970100
02100121810000600142012012400148030002700272065000900299064000500308031000300313
032000200316014000600318865000900324002001300333035001000346801002700356#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#c#80#4#article#12#4#^rND^sde Fi
lippis^nI#^rND^sdo Nascimento^nCR#^rND^sClementino^nMB#et al#Rapid detection of 
Neisseria meningitidis in cerebrospinal fluid by one-step polymerase chain react
ion of the nspA gene^len#Diagn Microbiol Infect Dis#20050000#2005#51#2#85-90#201
10400#v15n2a17.htm#0732-8893#Diagn Microbiol Infect Dis##
00592000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100016000760100016000920100
01700108810000600125012005400131030001700185065000900202064000500211031000300216
032000300219014000700222865000900229002001300238035001000251801001700261#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#c#81#5#article#12#5#^rND^sFalla
^nTJ#^rND^sCrook^nDW#^rND^sBrophy^nLN#et al#PCR for capsular typing of Haemophil
us influenzae^len#J Clin Microbiol#19940000#1994#32#10#2382-6#20110400#v15n2a17.
htm#0095-1137#J Clin Microbiol##
00622000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100016000760100017000920100
01900109810000600128012008300134030001700217065000900234064000500243031000300248
032000200251014000600253865000900259002001300268035001000281801001700291#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#c#82#6#article#12#6#^rND^sToikk
a^nP#^rND^sNikkari^nS#^rND^sRuuskanen^nO#et al#Pneumolysin PCR-based diagnosis o
f invasive pneumococcal infection in children^len#J Clin Microbiol#19990000#1999
#37#3#633-7#20110400#v15n2a17.htm#0095-1137#J Clin Microbiol##
00695000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100018000760100015000940100
01800109810000600127012014700133030002000280065000900300064000500309031000400314
032000300318014000800321865000900329002001300338035001000351801002000361#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#c#83#7#article#12#7#^rND^sPolla
rd^nAJ#^rND^sProbe^nG#^rND^sTrombley^nC#et al#Evaluation of a diagnostic polymer
ase chain reaction assay for Neisseria meningitidis in North America and field e
xperience during an outbreak^len#Arch Pathol Lab Med#20020000#2002#126#10#1209-1
5#20110400#v15n2a17.htm#0003-9985#Arch Pathol Lab Med##
00716000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100019000760100018000950100
01600113810000600129012017000135030002000305065000900325064000500334031000300339
032000200342014000600344865000900350002001300359035001000372801002000382#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#c#84#8#article#12#8#^rND^sBaeth
gen^nLF#^rND^sWeidlich^nL#^rND^sMoraes^nC#et al#Epidemiology of meningococcal di
sease in southern Brazil from 1995 to 2003, and molecular characterization of Ne
isseria meningitidis using multilocus sequence typing^len#Trop Med Int Health#20
080000#2008#13#1#31-40#20110400#v15n2a17.htm#1360-2276#Trop Med Int Health##
00673000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100021000760100021000970100
01500118810000600133012013600139030001300275065000900288064000500297031000300302
032000200305014000700307865000900314002001300323035001000336801001300346#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#c#85#9#article#12#9#^rND^sde Fi
lippis^nI#^rND^sde Andrade^nCF#^rND^sSilva^nL#et al#PorA variable antigenic regi
ons VR1, VR2, and VR3 of Neisseria meningitidis serogroups B and C isolated in B
razil from 1999 to 2004^len#Infect Immun#20070000#2007#75#7#3683-5#20110400#v15n
2a17.htm#0019-9567#Infect Immun##
00825000000000289000450000400060000070200480000670500020005470600020005670000030
00587010003000617090008000647080003000721180003000750100021000780100018000990120
30700117030002700424065000900451064000500460031000300465032000200468014000600470
865000900476002001300485035001000498801002700508#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a17.htm#S#c#86#10#article#12#10#^rND^sde Filippis^nI#^rND^sVicent
e^nAC#Multilocus sequence typing and repetitive element-based polymerase chain r
eaction analysis of Neisseria meningitides isolates in Brazil reveal the emergen
ce of 11 new sequence types genetically related to the ST-32 and ST-41/44 comple
xes and high prevalence of strains related to hypervirulent lineages^len#Diagn M
icrobiol Infect Dis#20050000#2005#53#3#161-7#20110400#v15n2a17.htm#0732-8893#Dia
gn Microbiol Infect Dis##
00679000000000313000450000400060000070200480000670500020005470600020005670000030
00587010003000617090008000647080003000721180003000750100019000780100015000970100
01600112810000600128012013800134030001700272065000900289064000500298031000300303
032000200306014000800308865000900316002001300325035001000338801001700348#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#c#87#11#article#12#11#^rND^sde 
Lemos^nAP#^rND^sYara^nTY#^rND^sGorla^nMC#et al#Clonal distribution of invasive N
eisseria meningitidis serogroup C strains circulating from 1976 to 2005 in great
er São Paulo, Brazil^len#J Clin Microbiol#20070000#2007#45#4#1266-73#20110400#v1
5n2a17.htm#0095-1137#J Clin Microbiol##
00662000000000313000450000400060000070200480000670500020005470600020005670000030
00587010003000617090008000647080003000721180003000750100016000780100018000940100
01600112810000600128012012500134030001600259065000900275064000500284031000300289
061000200292014000600294865000900300002001300309035001000322801001600332#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a17.htm#S#c#88#12#article#12#12#^rND^sLem
os^nAP#^rND^sBrandão^nAP#^rND^sGorla^nMC#et al#Phenotypic characterization of Ne
isseria meningitidis strains isolated from invasive disease in Brazil from 1990 
to 2001^len#J Med Microbiol#20060000#2006#55#6#751-7#20110400#v15n2a17.htm#0022-
2615#J Med Microbiol##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a18.htm#S#o#1#1#text#1#20
110406#124850#v15n2a18.htm#53##
00859000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030001800106
03100030012403200020012706500090012901400110013803500100014912300020015901200640
01610100034002250100043002590100048003020700078003501170006004280720002004340020
01300436#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a18.htm#S#h#2#1#text#1#oa
#en#br1.1#1#4.0#ILUS#18#BJID240#nd#Braz J Infect Dis#15#2#20110400#^f181^l183#14
13-8670#1#Cryosurgery as adjuvant therapy in cutaneous sporotrichosis^len#^rND^1
A01^nCassio Porto^sFerreira#^rND^1A01^nMaria Clara Gutierrez^sGalhardo#^rND^1A01
^nAntônio Carlos Francescone do^sValle#FIOCRUZ^iA01^1IPEC^2Laboratory of Clinica
l Research in Infectious Dermatology#other#4#v15n2a18.htm##
00866000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030001800106
03100030012403200020012706500090012901400110013803500100014912300020015901200710
01610100034002320100043002660100048003090700078003571170006004350720002004410020
01300443#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a18.htm#S#f#3#1#text#1#oa
#en#br1.1#1#4.0#ILUS#18#BJID240#nd#Braz J Infect Dis#15#2#20110400#^f181^l183#14
13-8670#1#<b>Cryosurgery as adjuvant therapy in cutaneous sporotrichosis</b>^len
#^rND^1A01^nCassio Porto^sFerreira#^rND^1A01^nMaria Clara Gutierrez^sGalhardo#^r
ND^1A01^nAntônio Carlos Francescone do^sValle#FIOCRUZ^iA01^1IPEC^2Laboratory of 
Clinical Research in Infectious Dermatology#other#4#v15n2a18.htm##
00995000000000433000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101038000500105121000300110049000800113158000300121
03000210012403100030014503200020014806500090015001400110015903500100017012300020
01800120064001820100034002460100043002800100048003230700080003711170006004510720
00200457002001300459008008900472#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a
18.htm#S#l#4#1#text#1#^mMar./Apr.^a2011#oa#en#br1.1#1#4.0#ilus#18#BJID240#nd#Bra
z. j. infect. dis#15#2#20110400#^f181^l183#1413-8670#1#Cryosurgery as adjuvant t
herapy in cutaneous sporotrichosis^len#^rND^1A01^nCassio Porto^sFerreira#^rND^1A
01^nMaria Clara Gutierrez^sGalhardo#^rND^1A01^nAntônio Carlos Francescone do^sVa
lle#^iA01^1FIOCRUZ^2IPEC^3Laboratory of Clinical Research in Infectious Dermatol
ogy#other#4#v15n2a18.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_ar
ttext&pid=S1413-86702011000200018##
00348000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704011900070002001300189#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#5#1#text#45#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>CLINICAL IMAGES</b></font
></p>     ^cY#v15n2a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#6#2#text#45#<p>&nbsp;</p>     ^cY#v15
n2a18.htm##
00396000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704016700070002001300237#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#7#3#text#45#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Cryosurgery as adjuva
nt therapy in cutaneous sporotrichosis</b></font></p>     ^cY#v15n2a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#8#4#text#45#<p>&nbsp;</p>     ^cY#v15
n2a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#9#5#text#45#<p>&nbsp;</p>     ^cY#v15
n2a18.htm##
00455000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704022500071002001300296#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#10#6#text#45#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Cassio Porto Ferreira<sup>I</sup>; Mar
ia Clara Gutierrez Galhardo<sup>II</sup>; Ant&ocirc;nio Carlos Francescone do Va
lle<sup>III</sup></b></font></p>     ^cY#v15n2a18.htm##
00420000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704019000071002001300261#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#11#7#text#45#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>MSc, Techonologist; Dermatolo
gist, Laboratory of Clinical Research in Infectious Dermatology (IPEC/FIOCRUZ)  
  ^cY#v15n2a18.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704012600071002001300197#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#12#8#text#45#<br> <sup>II</sup>Post-D
octorate; Researcher, Laboratory of Clinical Research in Infectious Dermatology 
(IPEC/FIOCRUZ)    ^cY#v15n2a18.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704012800071002001300199#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#13#9#text#45#<br> <sup>III</sup>PhD; 
Researcher, Laboratory of Clinical Research in Infectious Dermatology (IPEC/FIOC
RUZ)</font></p>     ^cY#v15n2a18.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704011800072002001300190#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#14#10#text#45#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a></fon
t></p>     ^cY#v15n2a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#15#11#text#45#<p>&nbsp;</p>     ^cY#v
15n2a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#16#12#text#45#<p>&nbsp;</p>     ^cY#v
15n2a18.htm##
02375000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704214400072002001302216#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#17#13#text#45#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Sporotrichosis is a subacute or chronic 
disease that affects animals and humans caused by the dimorphic fungus <i>Sporot
hrix schenkii.</i><sup>1</sup> An epidemic of sporotrichosis has been noticed in
 the city of Rio de Janeiro from 1998 onwards and having the cat as the main lin
k in the epidemiological chain.<sup>2</sup> We have missed a large proportion of
 these patients and adjuvant cryosurgery with liquid nitrogen<sup>3,4</sup> has 
been performed in patients that persisted with one or two active lesions whereas
 the other healed after 2-3 months of treatment. This study aims at evaluating t
he role of adjuvant treatment in these patients. Methods: 9 patients (7 women/2 
men, mean age 45.8 years-old) with cutaneous-lymphatic and fixed sporotrichosis 
were selected (<a href="#fig1">Figures 1</a> and <a href="#fig2">2</a>). All pat
ients had isolated <i>Sporothrix schenckii</i> in culture (<a href="/img/revista
s/bjid/v15n2/a18fig03.jpg">Figure 3</a>). Results: Patients underwent monthly se
ssions of cryosurgery with liquid nitrogen with two cycles of 15 seconds and hal
o of 5 mm (<a href="#fig4">Figures 4</a> and <a href="/img/revistas/bjid/v15n2/a
18fig05.jpg">5</a>) with an average of 2.2 sessions (range 1-4 sessions). Five p
atients had exclusive use of itraconazole for a mean period of 28.8 weeks (range
 4-56 weeks) and after the introduction of adjuvant therapy were discharged afte
r a mean period of 12 weeks (range 4-36 weeks). The patient who made use of pota
ssium iodide was discharged after two adjuvant therapy sessions, totaling 12 wee
ks of treatment. The three patients who used itraconazole and terbinafine, itrac
onazole used primarily by an average of 21.2 weeks and due to lack of response i
nitiated terbinafine, which when combined with adjuvant therapy were discharged 
after a mean period of 16 weeks (range 4-28 weeks). In conclusion, cryosurgery w
ith liquid nitrogen<sup>4</sup> used in patients with slower response to systemi
c antifungal agents in a few sessions reduces treatment time and thus reducing c
ost and side effects.</font></p>     ^cY#v15n2a18.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#18#14#text#45#<p><a name="fig1"></a><
/p>     ^cY#v15n2a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#19#15#text#45#<p>&nbsp;</p>     ^cY#v
15n2a18.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008000072002001300152#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#20#16#text#45#<p align="center"><img 
src="/img/revistas/bjid/v15n2/a18fig01.jpg"></p>     ^cY#v15n2a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#21#17#text#45#<p>&nbsp;</p>     ^cY#v
15n2a18.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#22#18#text#45#<p><a name="fig2"></a><
/p>     ^cY#v15n2a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#23#19#text#45#<p>&nbsp;</p>     ^cY#v
15n2a18.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008000072002001300152#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#24#20#text#45#<p align="center"><img 
src="/img/revistas/bjid/v15n2/a18fig02.jpg"></p>     ^cY#v15n2a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#25#21#text#45#<p>&nbsp;</p>     ^cY#v
15n2a18.htm##
00266000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003500072002001300107#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#26#22#text#45#<p><a name="fig4"></a><
/p>     ^cY#v15n2a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#27#23#text#45#<p>&nbsp;</p>     ^cY#v
15n2a18.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008000072002001300152#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#28#24#text#45#<p align="center"><img 
src="/img/revistas/bjid/v15n2/a18fig04.jpg"></p>     ^cY#v15n2a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#29#25#text#45#<p>&nbsp;</p>     ^cY#v
15n2a18.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#30#26#text#45#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p>     
^cY#v15n2a18.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704031200074002001300386#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#31#27#text#45#1#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">1. de Lima Barros MB, de O
liveira Schubach A, Galhardo MC <i>et al</i>. Sporotrichosis with widespread cut
aneous lesions: report of 24 cases related to transmission by domestic cats in R
io de Janeiro, Brazil. Int J Dermatol 2003; 42:677-681.    ^cY#v15n2a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#32#28#text#45#</font></p>     ^cY#v15
n2a18.htm##
00507000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704026200074002001300336#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#33#29#text#45#2#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Barros MB, Schubach A d
e O, do Valle AC <i>et al</i>. Cat-transmitted sporotrichosis epidemic in Rio de
 Janeiro, Brazil: description of a series of cases. Clin Infect Dis. 2004; 38:52
9-35.    ^cY#v15n2a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#34#30#text#45#</font></p>     ^cY#v15
n2a18.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704023400074002001300308#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#35#31#text#45#3#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Moraes AM, Velho PENFV,
 Magalh&atilde;es RF. Criocirurgia com nitrog&ecirc;nio l&iacute;quido e as derm
atoses infecciosas. An Bras Dermatol. 2008; 83(4):285-98.    ^cY#v15n2a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#36#32#text#45#</font></p>     ^cY#v15
n2a18.htm##
00448000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704020300074002001300277#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#37#33#text#45#4#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Bargman H. Successful t
reatment of cutaneous sporotrichosis with liquid nitrogen: report of three cases
. Mycoses; 1995; 38:285-7.    ^cY#v15n2a18.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#38#34#text#45#</font></p>     ^cY#v15
n2a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#39#35#text#45#<p>&nbsp;</p>     ^cY#v
15n2a18.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#40#36#text#45#<p>&nbsp;</p>     ^cY#v
15n2a18.htm##
00420000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704018900072002001300261#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#41#37#text#45#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img src
="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:</b>  
  ^cY#v15n2a18.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003400072002001300106#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#42#38#text#45#<br> Cassio Porto Ferre
ira    ^cY#v15n2a18.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004000072002001300112#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#43#39#text#45#<br> Av. Brasil 4365, M
anguinhos    ^cY#v15n2a18.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004500072002001300117#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#44#40#text#45#<br> Rio de Janeiro, Br
azil 21040-900    ^cY#v15n2a18.htm##
00293000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704006200072002001300134#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#45#41#text#45#<br> Fax: 00.55-21-2209
-4110 Phone: 00.55-21-3865-8102    ^cY#v15n2a18.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010500072002001300177#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#46#42#text#45#<br> <a href="mailto:dr
cassioferreira@yahoo.com.br">drcassioferreira@yahoo.com.br</a></font></p>     ^c
Y#v15n2a18.htm##
00325000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009400072002001300166#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#47#43#text#45#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Submitted on: 9/29/2010    ^cY#v15n2a18.
htm##
00268000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003700072002001300109#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#48#44#text#45#<br>   Approved on: 10/
5/2010    ^cY#v15n2a18.htm##
00293000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704006200072002001300134#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a18.htm#S#p#49#45#text#45#<br>   We declare no co
nflict of interest.</font></p>     ^cY#v15n2a18.htm##
00681000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100025000720100030000970100
01900127810000600146012014000152030001500292065000900307064000500316031000300321
014000800324865000900332002001300341035001000354801001500364#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a18.htm#S#c#50#1#text#4#1#^rND^sde Lima Barros^nMB#^r
ND^sde Oliveira Schubach^nA#^rND^sGalhardo^nMC#et al#Sporotrichosis with widespr
ead cutaneous lesions: report of 24 cases related to transmission by domestic ca
ts in Rio de Janeiro, Brazil^len#Int J Dermatol#20030000#2003#42#677-681#2011040
0#v15n2a18.htm#0011-9059#Int J Dermatol##
00631000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100017000720100023000890100
01900112810000600131012010400137030001600241065000900257064000500266031000300271
014000700274865000900281002001300290035001000303801001600313#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a18.htm#S#c#51#2#text#4#2#^rND^sBarros^nMB#^rND^sSchu
bach^nA de O#^rND^sdo Valle^nAC#et al#Cat-transmitted sporotrichosis epidemic in
 Rio de Janeiro, Brazil: description of a series of cases^len#Clin Infect Dis#20
040000#2004#38#529-35#20110400#v15n2a18.htm#1058-4838#Clin Infect Dis##
00590000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100017000720100019000890100
02000108012006800128030001700196065000900213064000500222031000300227032000200230
014000700232865000900239002001300248035001000261801001700271#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a18.htm#S#c#52#3#text#4#3#^rND^sMoraes^nAM#^rND^sVelh
o^nPENFV#^rND^sMagalhães^nRF#Criocirurgia com nitrogênio líquido e as dermatoses
 infecciosas^lpt#An Bras Dermatol#20080000#2008#83#4#285-98#20110400#v15n2a18.ht
m#0365-0596#An Bras Dermatol##
00523000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100017000720120097000890300
00800186065000900194064000500203031000300208014000600211865000900217002001300226
035001000239801000800249#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a18.htm#S
#c#53#4#text#4#4#^rND^sBargman^nH#Successful treatment of cutaneous sporotrichos
is with liquid nitrogen: report of three cases^len#Mycoses#19950000#1995#38#285-
7#20110400#v15n2a18.htm#0933-7407#MYCOSES##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a19.htm#S#o#1#1#text#1#20
110406#124852#v15n2a19.htm#51##
00781000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030001800106
03100030012403200020012706500090012901400110013803500100014912300020015901200970
0161010002200258010003000280070005200310117000600362072000200368002001300370#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a19.htm#S#h#2#1#text#1#oa#en#br1.1#1#
4.0#ILUS#19#BJID050#nd#Braz J Infect Dis#15#2#20110400#^f184^l185#1413-8670#1#Ch
anging trends of dengue disease: a brief report from a tertiary care hospital in
 New Delhi^len#^rND^nMonika^sMatlani#^rND^1A01^nAnita^sChakravarti#Maulana Azad 
Medical College^iA01^cNew Delhi^pIndia#other#6#v15n2a19.htm##
00795000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030001800106
03100030012403200020012706500090012901400110013803500100014912300020015901201110
0161010002200272010003000294070005200324117000600376072000200382002001300384#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a19.htm#S#f#3#1#text#1#oa#en#br1.1#1#
4.0#ILUS#19#BJID050#nd#Braz J Infect Dis#15#2#20110400#^f184^l185#1413-8670#1#<b
>Changing trends of dengue disease</b>: <b>a brief report from a tertiary care h
ospital in New Delhi</b>^len#^rND^nMonika^sMatlani#^rND^1A01^nAnita^sChakravarti
#Maulana Azad Medical College^iA01^cNew Delhi^pIndia#other#6#v15n2a19.htm##
00917000000000421000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101038000500105121000300110049000800113158000300121
03000210012403100030014503200020014806500090015001400110015903500100017012300020
01800120097001820100022002790100030003010700054003311170006003850720002003910020
01300393008008900406#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a19.htm#S#l#4
#1#text#1#^mMar./Apr.^a2011#oa#en#br1.1#1#4.0#ilus#19#BJID050#nd#Braz. j. infect
. dis#15#2#20110400#^f184^l185#1413-8670#1#Changing trends of dengue disease: a 
brief report from a tertiary care hospital in New Delhi^len#^rND^nMonika^sMatlan
i#^rND^1A01^nAnita^sChakravarti#^iA01^1Maulana Azad Medical College^cNew Delhi^p
India#other#6#v15n2a19.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_
arttext&pid=S1413-86702011000200019##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704012400070002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#5#1#text#41#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>LETTER TO THE EDITOR</b><
/font></p>     ^cY#v15n2a19.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#6#2#text#41#<p>&nbsp;</p>     ^cY#v15
n2a19.htm##
00429000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704020000070002001300270#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#7#3#text#41#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Changing trends of de
ngue disease: a brief report from a tertiary care hospital in New Delhi</b></fon
t></p>     ^cY#v15n2a19.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#8#4#text#41#<p>&nbsp;</p>     ^cY#v15
n2a19.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#9#5#text#41#<p>&nbsp;</p>     ^cY#v15
n2a19.htm##
00378000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704014800071002001300219#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#10#6#text#41#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Monika Matlani<sup>I</sup>; Anita Chak
ravarti<sup>II</sup></b></font></p>     ^cY#v15n2a19.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704010200071002001300173#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#11#7#text#41#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>MD, Senior Resident    ^cY#v1
5n2a19.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704012000071002001300191#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#12#8#text#41#<br> <sup>II</sup>MD, Di
rector Professor Microbiology, Maulana Azad Medical College New Delhi, India</fo
nt></p>     ^cY#v15n2a19.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011800071002001300189#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#13#9#text#41#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a></font
></p>     ^cY#v15n2a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#14#10#text#41#<p>&nbsp;</p>     ^cY#v
15n2a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#15#11#text#41#<p>&nbsp;</p>     ^cY#v
15n2a19.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008300072002001300155#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#16#12#text#41#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Dear Editor,    ^cY#v15n2a19.htm##
01010000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704077900072002001300851#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#17#13#text#41#<br> this is in respons
e to the paper "Correlation of disease spectrum among four Dengue serotypes: a f
ive-year hospital based study from India", published by Dr Rajni Kumaria in the 
Journal (vol.14, no. 2).<sup>1</sup> This study was conducted in the virology la
boratory of Maulana Azad Medical College, New Delhi, from January 2002 to Novemb
er 2006 as a part of a project funded by the Indian Council of Medical Research 
(ICMR). The findings obtained from the same laboratory for the subsequent three 
years (2007 -2009) were relatively different from the earlier published one<sup>
1</sup> and are being reported here. We wish to highlight the changing trends in
 the presentation of dengue from the same Dengue Serosurveillance Laboratory dur
ing this period.</font></p>     ^cY#v15n2a19.htm##
01029000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704079800072002001300870#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#18#14#text#41#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">In contrast to 2002-2006 findings where 
Den-2 was the commonest serotype reported, ongoing study observed Den-1 to be th
e most prevalent serotype during 2007-2009. Den-1 was isolated in 50% of RT-PCR 
positive cases (20/40), whereas Den-2, Den-3 and Den-4 were identified in 22.5 %
( 9/40), 15 % (6/40) and 12.5% (5/40) of cases respectively, indicating the repl
acement of earlier circulating Den-2 and Den- 3 by Den-1. Maximum number of Den-
1 cases were isolated in the year 2008 (findings published earlier).<sup>2</sup>
 These findings provide an insight to the changing trend of dengue serotypes ind
icating that all four serotypes are continuously co-circulating, which makes thi
s region prone to epidemic spreads.</font></p>     ^cY#v15n2a19.htm##
01664000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704143300072002001301505#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#19#15#text#41#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Although the abovementioned study<sup>1<
/sup> and few other studies<sup>3</sup> have reported Den-1 to be associated wit
h a milder form of disease, our study demonstrates a rise in number of Den-1 aff
ected severe cases during 2007-2009. Sixty percent of the Den-1 affected cases p
resented with severe DHF. Moreover incidence of arthralgia and myalgia was also 
observed in significantly higher number of Den-1 cases. This increase in DHF cas
es due to Den-1 could have been due to heterologous infection leading to ADE (an
tibody-dependant enhancement) resulting in sss imbalance of the levels of cytoki
nes, or due to some unknown genetic changes in the circulating strain which coul
d have led to increased virulence of the particular strain. Various studies have
 been done to establish correlation between causative serotype and disease outco
me. Some of them have proposed that Den-2 and Den-3 may cause more severe diseas
e,<sup>4,5</sup> however, we observed that even Den-1 can present with severe fo
rm of disease. Few other researchers have also suggested that the DEN-1 strains 
were more pathogenic among children having primary infections.<sup>6</sup> Our f
indings illustrate that each serotype has unique characteristics and can present
 with severe manifestations, in a particular population depending upon its inter
action with the host response.</font></p>     ^cY#v15n2a19.htm##
00687000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704045600072002001300528#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#20#16#text#41#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">For establishing conclusive relationship
 between the serotypes and disease manifestations studies are further ongoing in
 our set up for identifying various virus and host factors responsible for sever
ity of dengue disease. Such studies would help to predict future outbreaks, deve
loping interventions to control dengue outbreaks, and developing an effective de
ngue vaccine.</font></p>     ^cY#v15n2a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#21#17#text#41#<p>&nbsp;</p>     ^cY#v
15n2a19.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#22#18#text#41#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p>     
^cY#v15n2a19.htm##
00474000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704022900074002001300303#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#23#19#text#41#1#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Kumaria R. Correlation 
of disease spectrum among four Dengue serotypes: a five years hospital based stu
dy from India Braz J Infect Dis 2010; 14(2):141-146.    ^cY#v15n2a19.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#24#20#text#41#</font></p>     ^cY#v15
n2a19.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704022200074002001300296#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#25#21#text#41#2#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Chakravarti A, Kumar A,
 Matlani M. Displacement of dengue virus type 3 and type 2 by dengue virus type 
1 in Delhi during 2008. IJMM 2010; 28(4):412.    ^cY#v15n2a19.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#26#22#text#41#</font></p>     ^cY#v15
n2a19.htm##
00468000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704022300074002001300297#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#27#23#text#41#3#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Corwin AL, Larasati RP,
 Bangs MJ <i>et al</i>. Epidemic dengue transmission in southern Sumatra, Indone
sia. Trans R Soc Trop Med Hyg 2001; 95:257-65.    ^cY#v15n2a19.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#28#24#text#41#</font></p>     ^cY#v15
n2a19.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704028800074002001300362#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#29#25#text#41#4#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Endy TP, Nisalak A, Chu
nsuttiwat S <i>et al.</i> Spatial and temporal circulation of dengue virus serot
ypes: a prospective study of primary school children in Kamphaeng Phet, Thailand
. Am J Epidemiol 2002; 56:52-9.    ^cY#v15n2a19.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#30#26#text#41#</font></p>     ^cY#v15
n2a19.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704022200074002001300296#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#31#27#text#41#5#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Kalayanarooj S, Nimmann
itya S. Clinical and laboratory presentations of dengue patients with different 
serotypes. WHODengue Bulletin. 2000; 24:53-9.    ^cY#v15n2a19.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#32#28#text#41#</font></p>     ^cY#v15
n2a19.htm##
00500000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704025500074002001300329#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#33#29#text#41#6#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Nisalak A, Endy TP, Nim
manniya S <i>et al</i>. Serotype-specific dengue virus circulation and dengue di
sease in Bangkok, Thailand from 1973-1979. Am J Trop Med Hyg 2003; 68:191-202.  
  ^cY#v15n2a19.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#34#30#text#41#</font></p>     ^cY#v15
n2a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#35#31#text#41#<p>&nbsp;</p>     ^cY#v
15n2a19.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#36#32#text#41#<p>&nbsp;</p>     ^cY#v
15n2a19.htm##
00420000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704018900072002001300261#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#37#33#text#41#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img src
="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:</b>  
  ^cY#v15n2a19.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003400072002001300106#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#38#34#text#41#<br> Dr. Anita Chakrava
rti    ^cY#v15n2a19.htm##
00304000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007300072002001300145#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#39#35#text#41#<br> Director Professor
 Microbiology Maulana Azad Medical College    ^cY#v15n2a19.htm##
00260000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002900072002001300101#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#40#36#text#41#<br> New Delhi, India  
  ^cY#v15n2a19.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010100072002001300173#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#41#37#text#41#<br> <a href="mailto:an
ita.chakravarti@yahoo.com">anita.chakravarti@yahoo.com</a></font></p>     ^cY#v1
5n2a19.htm##
00326000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009500072002001300167#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#42#38#text#41#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Submitted on: 11/10/2010    ^cY#v15n2a19
.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003800072002001300110#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#43#39#text#41#<br>   Approved on: 11/
13/2010    ^cY#v15n2a19.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704008200072002001300154#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#44#40#text#41#<br>   Financial Suppor
t: Department of Science and Technology , New Delhi    ^cY#v15n2a19.htm##
00293000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704006200072002001300134#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a19.htm#S#p#45#41#text#41#<br>   We declare no co
nflict of interest.</font></p>     ^cY#v15n2a19.htm##
00534000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100017000720120110000890300
01800199710000200217065000900219064000500228031000300233032000200236014000800238
865000900246002001300255#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a19.htm#S
#c#46#1#text#6#1#^rND^sKumaria^nR#Correlation of disease spectrum among four Den
gue serotypes: a five years hospital based study from India^len#Braz J Infect Di
s#2#20100000#2010#14#2#141-146#20110400#v15n2a19.htm##
00562000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100021000720100015000930100
01700108012009500125030000500220710000200225065000900227064000500236031000300241
032000200244020000400246865000900250002001300259#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a19.htm#S#c#47#2#text#6#2#^rND^sChakravarti^nA#^rND^sKumar^nA#^rN
D^sMatlani^nM#Displacement of dengue virus type 3 and type 2 by dengue virus typ
e 1 in Delhi during 2008^len#IJMM#2#20100000#2010#28#4#412#20110400#v15n2a19.htm
##
00602000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100017000720100019000890100
01600108810000600124012006400130030002500194065000900219064000500228031000300233
014000700236865000900243002001300252035001000265801002500275#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a19.htm#S#c#48#3#text#6#3#^rND^sCorwin^nAL#^rND^sLara
sati^nRP#^rND^sBangs^nMJ#et al#Epidemic dengue transmission in southern Sumatra,
 Indonesia^len#Trans R Soc Trop Med Hyg#20010000#2001#95#257-65#20110400#v15n2a1
9.htm#0035-9203#Trans R Soc Trop Med Hyg##
00657000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100015000720100017000870100
02200104810000600126012013900132030001500271065000900286064000500295031000300300
014000500303865000900308002001300317035001000330801001500340#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a19.htm#S#c#49#4#text#6#4#^rND^sEndy^nTP#^rND^sNisala
k^nA#^rND^sChunsuttiwat^nS#et al#Spatial and temporal circulation of dengue viru
s serotypes: a prospective study of primary school children in Kamphaeng Phet, T
hailand^len#Am J Epidemiol#20020000#2002#56#52-9#20110400#v15n2a19.htm#0002-9262
#Am J Epidemiol##
00532000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100022000720100021000940120
08600115030001900201710000200220065000900222064000500231031000300236014000500239
865000900244002001300253#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a19.htm#S
#c#50#5#text#6#5#^rND^sKalayanarooj^nS#^rND^sNimmannitya^nS#Clinical and laborat
ory presentations of dengue patients with different serotypes^len#WHODengue Bull
etin#2#20000000#2000#24#53-9#20110400#v15n2a19.htm##
00627000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100017000720100015000890100
02000104810000600124012010200130030001800232065000900250064000500259031000300264
014000800267865000900275002001300284035001000297801001800307#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a19.htm#S#c#51#6#text#6#6#^rND^sNisalak^nA#^rND^sEndy
^nTP#^rND^sNimmanniya^nS#et al#Serotype-specific dengue virus circulation and de
ngue disease in Bangkok, Thailand from 1973-1979^len#Am J Trop Med Hyg#20030000#
2003#68#191-202#20110400#v15n2a19.htm#0002-9637#Am J Trop Med Hyg##
00273000000000169000450000400060000070200490000670500020005570600020005770000020
00597010002000617090005000637080002000680910009000700920007000790020014000867030
00300100#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a20.html#S#o#1#1#text#1#2
0110406#124854#v15n2a20.html#60##
01269000000000457000450000400060000070200490000670500020005570600020005770000020
00597010002000617090005000637080002000680710003000700400003000730010006000760420
00200082120000400084038000500088038000400093121000300097049000800100158000300108
03000180011103100030012903200020013206500090013401400110014303500100015412300020
01640120152001660100026003180100032003440100029003760100029004050700107004340700
11800541070013000659117000600789072000200795002001400797#v15n2#V:\SciELO\serial\
bjid\v15n2\markup\v15n2a20.html#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ILUS#TAB#20#BJI
D050#nd#Braz J Infect Dis#15#2#20110400#^f186^l187#1413-8670#1#Chronic pelvic pa
in due to Mycobacterium parascrofulaceum in an Iranian patient: first report of 
isolation and molecular characterization from Asia^len#^rND^1A01^nHasan^sShojaei
#^rND^1A02^nAbdolrazagh^sHashemi#^rND^1A03^nParvin^sHeidarieh#^rND^1A02^nAbass^s
Daei-Naser#Isfahan University of Medical Sciences^iA01^1School of Medicine^2Depa
rtment of Microbiology^cIsfahan^pIran#Isfahan University of Medical Sciences^iA0
2^1Infectious Diseases and Tropical Medicine Research Center^cIsfahan^pIran#Tehr
an University of Medical Sciences^iA03^1School of Public Health^2Department of P
athobiology^3Microbiology Group^cTehran^pIran#other#5#v15n2a20.html##
01290000000000457000450000400060000070200490000670500020005570600020005770000020
00597010002000617090005000637080002000680710003000700400003000730010006000760420
00200082120000400084038000500088038000400093121000300097049000800100158000300108
03000180011103100030012903200020013206500090013401400110014303500100015412300020
01640120173001660100026003390100032003650100029003970100029004260700107004550700
11800562070013000680117000600810072000200816002001400818#v15n2#V:\SciELO\serial\
bjid\v15n2\markup\v15n2a20.html#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ILUS#TAB#20#BJI
D050#nd#Braz J Infect Dis#15#2#20110400#^f186^l187#1413-8670#1#<b>Chronic pelvic
 pain due to <i>Mycobacterium parascrofulaceum</i> in an Iranian patient</b>: <b
>first report of isolation and molecular characterization from Asia</b>^len#^rND
^1A01^nHasan^sShojaei#^rND^1A02^nAbdolrazagh^sHashemi#^rND^1A03^nParvin^sHeidari
eh#^rND^1A02^nAbass^sDaei-Naser#Isfahan University of Medical Sciences^iA01^1Sch
ool of Medicine^2Department of Microbiology^cIsfahan^pIran#Isfahan University of
 Medical Sciences^iA02^1Infectious Diseases and Tropical Medicine Research Cente
r^cIsfahan^pIran#Tehran University of Medical Sciences^iA03^1School of Public He
alth^2Department of Pathobiology^3Microbiology Group^cTehran^pIran#other#5#v15n2
a20.html##
01409000000000481000450000400060000070200490000670500020005570600020005770000020
00597010002000617090005000637080002000680640018000700710003000880400003000910010
00600094042000200100120000400102038000500106038000400111121000300115049000800118
15800030012603000210012903100030015003200020015306500090015501400110016403500100
01751230002001850120152001870100026003390100032003650100029003970100029004260700
10900455070012000564070013200684117000600816072000200822002001400824008008900838
#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a20.html#S#l#4#1#text#1#^mMar./Ap
r.^a2011#oa#en#br1.1#1#4.0#ilus#tab#20#BJID050#nd#Braz. j. infect. dis#15#2#2011
0400#^f186^l187#1413-8670#1#Chronic pelvic pain due to Mycobacterium parascroful
aceum in an Iranian patient: first report of isolation and molecular characteriz
ation from Asia^len#^rND^1A01^nHasan^sShojaei#^rND^1A02^nAbdolrazagh^sHashemi#^r
ND^1A03^nParvin^sHeidarieh#^rND^1A02^nAbass^sDaei-Naser#^iA01^1Isfahan Universit
y of Medical Sciences^2School of Medicine^3Department of Microbiology^cIsfahan^p
Iran#^iA02^1Isfahan University of Medical Sciences^2Infectious Diseases and Trop
ical Medicine Research Center^cIsfahan^pIran#^iA03^1Tehran University of Medical
 Sciences^2School of Public Health^3Department of Pathobiology. Microbiology Gro
up^cTehran^pIran#other#5#v15n2a20.html#Internet^ihttp://www.scielo.br/scielo.php
?script=sci_arttext&pid=S1413-86702011000200020##
00355000000000145000450000400060000070200490000670500020005570600020005770000020
0059701000200061709000500063708000300068704012400071002001400195#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#5#1#text#51#<p align="right"><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>LETTER TO THE EDITOR</b>
</font></p>     ^cY#v15n2a20.html##
00253000000000145000450000400060000070200490000670500020005570600020005770000020
0059701000200061709000500063708000300068704002200071002001400093#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#6#2#text#51#<p>&nbsp;</p>     ^cY#v1
5n2a20.html##
00493000000000145000450000400060000070200490000670500020005570600020005770000020
0059701000200061709000500063708000300068704026200071002001400333#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#7#3#text#51#<p><font size="4" face="
Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Chronic pelvic pain 
due to <i>Mycobacterium parascrofulaceum</i> in an Iranian patient: first report
 of isolation and molecular characterization from Asia</b></font></p>     ^cY#v1
5n2a20.html##
00253000000000145000450000400060000070200490000670500020005570600020005770000020
0059701000200061709000500063708000300068704002200071002001400093#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#8#4#text#51#<p>&nbsp;</p>     ^cY#v1
5n2a20.html##
00253000000000145000450000400060000070200490000670500020005570600020005770000020
0059701000200061709000500063708000300068704002200071002001400093#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#9#5#text#51#<p>&nbsp;</p>     ^cY#v1
5n2a20.html##
00444000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000200062709000500064708000300069704021200072002001400284#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#10#6#text#51#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><b>Hasan Shojaei<sup>I</sup>; Abdolrazag
h Hashemi<sup>II</sup>; Parvin Heidarieh<sup>III</sup>; Abass Daei-Naser<sup>IV<
/sup></b></font></p>     ^cY#v15n2a20.html##
00472000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000200062709000500064708000300069704024000072002001400312#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#11#7#text#51#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Dr, Associate Professor; PhD
 in Molecular Microbiology, Department of Microbiology, School of Medicine, Isfa
han University of Medical Sciences, Isfahan, Iran    ^cY#v15n2a20.html##
00395000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000200062709000500064708000300069704016300072002001400235#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#12#8#text#51#<br> <sup>II</sup>Dr., 
Research Associate, Infectious Diseases and Tropical Medicine Research Center, I
sfahan University of Medical Sciences, Isfahan, Iran    ^cY#v15n2a20.html##
00409000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000200062709000500064708000300069704017700072002001400249#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#13#9#text#51#<br>   <sup>III</sup>Dr
, Research Associate, Microbiology Group, Department of Pathobiology, School of 
Public Health, Tehran University of Medical Sciences, Tehran, Iran    ^cY#v15n2a
20.html##
00405000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704017200073002001400245#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#14#10#text#51#<br>   <sup>IV</sup>Re
search Assistant; Infectious Diseases and Tropical Medicine Research Center, Isf
ahan University of Medical Sciences, Isfahan, Iran</font></p>     ^cY#v15n2a20.h
tml##
00351000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704011800073002001400191#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#15#11#text#51#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a></fo
nt></p>     ^cY#v15n2a20.html##
00255000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704002200073002001400095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#16#12#text#51#<p>&nbsp;</p>     ^cY#
v15n2a20.html##
00255000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704002200073002001400095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#17#13#text#51#<p>&nbsp;</p>     ^cY#
v15n2a20.html##
00481000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704024800073002001400321#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#18#14#text#51#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Herein we report a case of chronic pelv
ic pain (CPP) caused by a rare, recently characterized species, <i>M. parascrofu
laceum</i>, from an Iranian middle aged woman.</font></p>     ^cY#v15n2a20.html#
#
00255000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704002200073002001400095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#19#15#text#51#<p>&nbsp;</p>     ^cY#
v15n2a20.html##
00341000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704010800073002001400181#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#20#16#text#51#<p><font size="3" face
="Verdana, Arial, Helvetica, sans-serif"><i><b>CASE REPORT</b></i></font></p>   
  ^cY#v15n2a20.html##
01037000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704080400073002001400877#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#21#17#text#51#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">A 38 year old woman was admitted to the
 hospital because of CPP for over three months. There was no apparent evidence o
f immunodeficiency or HIV infection. In the initial evaluation the urine culture
 for bacteria was sterile. She was empirically started on antibiotic treatment f
or the presumed chlamydial or mycoplasmal infection but no improvement was obser
ved. The patient returned to the hospital due to increasing lower abdominal pain
. Examination of vaginal discharge confirmed the presence of acid-fast bacilli. 
The etiologic agent was assumed to be <i>M. tuberculosis</i> and the patient was
 put on antituberculosis therapy. Two months thereafter due to an aggregated con
dition the patient underwent hysterectomy.</font></p>     ^cY#v15n2a20.html##
00706000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704047300073002001400546#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#22#18#text#51#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Strain M79 was isolated from the remove
d uterus and confirmed by a combination of conventional and molecular tests incl
uding the sequence analyses of 16S rDNA, <i>hsp65, rpoB</i>, and ITS.<sup>1-3</s
up> The GenBank accession numbers of the isolate determined in this work are as 
follow: GU121551, HM229794, HM229795 and HM229796 for the 16S rDNA, ITS, <i>hsp6
5, rpoB</i> genes respectively.</font></p>     ^cY#v15n2a20.html##
00716000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704048300073002001400556#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#23#19#text#51#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Conventional microbiological analysis o
f the isolate revealed a slowly growing yellow pigmented scotochromogenic mycoba
cterial species. It was positive for catalase and urease tests and negative for 
tellurite, nitrate, tween hydrolysis, niacin, arylsulfatase and iron uptake test
s. It was susceptible to amikacin, clarithromycin, rifampicin, doxycycline, sulf
amethoxazole, streptomycin, and imipenem.</font></p>     ^cY#v15n2a20.html##
00859000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704062600073002001400699#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#24#20#text#51#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">The almost complete 16S rDNA gene seque
nce (1,426 bp) of the isolate showed a 99.58% similarity with <i>M. parascrofula
ceum</i>. The signature nucleotide sequences of the isolate showed only a base p
air difference at position 250 compared to that of <i>M. parascrofulaceum</i> ty
pe strain (<a href="/img/revistas/bjid/v15n2/a20tab01.jpg">Table 1</a>). The ITS
, <i>hsp65</i> and <i>rpoB</i> gene sequences of the isolate showed 98.71%, 99.3
9% and 100% similarities with those of the reference strain of <i>M. parascroful
aceum</i>, respectively.</font></p>     ^cY#v15n2a20.html##
00586000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704035300073002001400426#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#25#21#text#51#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">In 2004, Turenne <i>et al.</i> introduc
ed <i>M. parascrofulaceum</i> as a distinct species.<sup>3</sup> Later the organ
ism was isolated from a few clinical samples.<sup>4</sup> However, to the best o
f our knowledge, there have been no reports from the rest of the world.</font></
p>     ^cY#v15n2a20.html##
01107000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704087400073002001400947#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#26#22#text#51#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Genitourinary infection (GUI) due to no
n-tuberculous mycobacteria (NTM) is very rare and infrequently reported.<sup>5</
sup> In the Iranian case herein reported <i>M. parascrofulaceum</i> was isolated
 from a female patient with no apparent immunodeficiency, although she was ill-f
amed in her community for being a woman with high-risk sexual behavior. Given th
at most NTM strains are resistant to traditional antituberculous agents, it is i
mportant to correctly differentiate genitourinary infections caused by NTM from 
genitourinary TB.<sup>5</sup> The clinical management of CPP of this Iranian pat
ient was almost ineffective due misdiagnosis of the causative agent during the i
nitial stages of her infection. This was why the practicing physician eventually
 resorted to surgical operation.</font></p>     ^cY#v15n2a20.html##
00450000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704021700073002001400290#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#27#23#text#51#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">In conclusion, unless the causative org
anism is correctly identified noninvasive treatment of such complex cases is unl
ikely to occur.</font></p>     ^cY#v15n2a20.html##
00255000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704002200073002001400095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#28#24#text#51#<p>&nbsp;</p>     ^cY#
v15n2a20.html##
00347000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704011400073002001400187#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#29#25#text#51#<p><font size="3" face
="Verdana, Arial, Helvetica, sans-serif"><i><b>ACKNOWLEDGMENTS 	</b></i></font><
/p>     ^cY#v15n2a20.html##
00472000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704023900073002001400312#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#30#26#text#51#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">The authors are grateful to the Office 
of Vice-chancellor for Research of Isfahan University of Medical Sciences for fi
nancial support of the current study.</font></p>     ^cY#v15n2a20.html##
00255000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704002200073002001400095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#31#27#text#51#<p>&nbsp;</p>     ^cY#
v15n2a20.html##
00340000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704010700073002001400180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#32#28#text#51#<p><font size="3" face
="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p>    
 ^cY#v15n2a20.html##
00527000000000157000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070888000200073704028000075002001400355#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a20.html#S#p#33#29#text#51#1#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Shojaei H, Magee JG, F
reeman R <i>et al</i>. Mycobacterium elephantis sp. nov., a rapidly growing non-
chromogenic Mycobacterium isolated from an elephant. Int J Syst Evol Microbiol. 
2000; 50 Pt 5:1817-1820.    ^cY#v15n2a20.html##
00253000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704002000073002001400093#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#34#30#text#51#</font></p>     ^cY#v1
5n2a20.html##
00491000000000157000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070888000200073704024400075002001400319#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a20.html#S#p#35#31#text#51#2#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Adekambi T, Colson P, 
Drancourt M. <i>rpoB</i>-based identification of nonpigmented and late-pigmentin
g rapidly growing mycobacteria. J Clin Microbiol 2003; 41:5699-5708.    ^cY#v15n
2a20.html##
00253000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704002000073002001400093#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#36#32#text#51#</font></p>     ^cY#v1
5n2a20.html##
00542000000000157000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070888000200073704029500075002001400370#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a20.html#S#p#37#33#text#51#3#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Turenne CY, Cook VJ, B
urdz TV <i>et al</i>. Mycobacterium parascrofulaceum sp. nov., novel slowly grow
ing, scotochromogenic clinical isolates related to Mycobacterium simiae. Int J S
yst Evol Microbiol. 2004; 54:1543-1551.    ^cY#v15n2a20.html##
00253000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704002000073002001400093#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#38#34#text#51#</font></p>     ^cY#v1
5n2a20.html##
00482000000000157000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070888000200073704023500075002001400310#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a20.html#S#p#39#35#text#51#4#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Tortoli E, Chianura L,
 Fabbro L <i>et al</i>. Infections due to the newly described species Mycobacter
ium parascrofulaceum. J Clin Microbiol. 2005; 43:4286-4287.    ^cY#v15n2a20.html
##
00253000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704002000073002001400093#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#40#36#text#51#</font></p>     ^cY#v1
5n2a20.html##
00529000000000157000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070888000200073704028200075002001400357#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a20.html#S#p#41#37#text#51#5#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Huang CT, Chen CY, Che
n HY <i>et al</i>. Genitourinary infections caused by nontuberculous mycobacteri
a at a university hospital in Taiwan, 1996-2008. Clin Microbiol Infect. 2010;10.
1111/j.1469-0691. 03180.x.    ^cY#v15n2a20.html##
00253000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704002000073002001400093#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#42#38#text#51#</font></p>     ^cY#v1
5n2a20.html##
00255000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704002200073002001400095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#43#39#text#51#<p>&nbsp;</p>     ^cY#
v15n2a20.html##
00255000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704002200073002001400095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#44#40#text#51#<p>&nbsp;</p>     ^cY#
v15n2a20.html##
00422000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704018900073002001400262#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#45#41#text#51#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img sr
c="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:</b> 
   ^cY#v15n2a20.html##
00259000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704002600073002001400099#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#46#42#text#51#<br> Hasan Shojaei    
^cY#v15n2a20.html##
00332000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704009900073002001400172#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#47#43#text#51#<br> Department of Mic
robiology, School of Medicine, Isfahan University of Medical Sciences    ^cY#v15
n2a20.html##
00263000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704003000073002001400103#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#48#44#text#51#<br> Hezarjarib street
    ^cY#v15n2a20.html##
00259000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704002600073002001400099#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#49#45#text#51#<br> Isfahan, Iran    
^cY#v15n2a20.html##
00289000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704005600073002001400129#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#50#46#text#51#<br> Phone: +98-311-79
22409 Fax: +98-311-6688597    ^cY#v15n2a20.html##
00320000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704008700073002001400160#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#51#47#text#51#<br> <a href="mailto:h
asanshojaei@msn.com">hasanshojaei@msn.com</a></font></p>     ^cY#v15n2a20.html##
00328000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704009500073002001400168#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#52#48#text#51#<p><font size="2" face
="Verdana, Arial, Helvetica, sans-serif">Submitted on: 11/23/2010    ^cY#v15n2a2
0.html##
00271000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704003800073002001400111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#53#49#text#51#<br>   Approved on: 12
/28/2010    ^cY#v15n2a20.html##
00399000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704016600073002001400239#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#54#50#text#51#<br>   Financial Suppo
rt: The current study was financially supported by the Office of Vice-chancellor
 for Research of Isfahan University of Medical Sciences.    ^cY#v15n2a20.html##
00295000000000145000450000400060000070200490000670500020005570600020005770000030
0059701000300062709000500065708000300070704006200073002001400135#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a20.html#S#p#55#51#text#51#<br>   We declare no c
onflict of interest.</font></p>     ^cY#v15n2a20.html##
00624000000000301000450000400060000070200490000670500020005570600020005770000030
00597010002000627090005000647080002000691180002000710100017000730100016000900100
01700106810000600123012011300129030002600242710000200268065000900270064000500279
031000300284061000200287014001000289865000900299002001400308#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a20.html#S#c#56#1#text#5#1#^rND^sShojaei^nH#^rND^sMag
ee^nJG#^rND^sFreeman^nR#et al#Mycobacterium elephantis sp. nov., a rapidly growi
ng non-chromogenic Mycobacterium isolated from an elephant^len#Int J Syst Evol M
icrobiol#2#20000000#2000#50#5#1817-1820#20110400#v15n2a20.html##
00605000000000289000450000400060000070200490000670500020005570600020005770000030
00597010002000627090005000647080002000691180002000710100018000730100016000910100
01900107012009500126030001700221065000900238064000500247031000300252014001000255
865000900265002001400274035001000288801001700298#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a20.html#S#c#57#2#text#5#2#^rND^sAdekambi^nT#^rND^sColson^nP#^rND
^sDrancourt^nM#rpoB-based identification of nonpigmented and late-pigmenting rap
idly growing mycobacteria^len#J Clin Microbiol#20030000#2003#41#5699-5708#201104
00#v15n2a20.html#0095-1137#J Clin Microbiol##
00630000000000289000450000400060000070200490000670500020005570600020005770000030
00597010002000627090005000647080002000691180002000710100018000730100015000910100
01600106810000600122012013400128030002600262710000200288065000900290064000500299
031000300304014001000307865000900317002001400326#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a20.html#S#c#58#3#text#5#3#^rND^sTurenne^nCY#^rND^sCook^nVJ#^rND^
sBurdz^nTV#et al#Mycobacterium parascrofulaceum sp. nov., novel slowly growing, 
scotochromogenic clinical isolates related to Mycobacterium simiae^len#Int J Sys
t Evol Microbiol#2#20040000#2004#54#1543-1551#20110400#v15n2a20.html##
00607000000000301000450000400060000070200490000670500020005570600020005770000030
00597010002000627090005000647080002000691180002000710100017000730100018000900100
01600108810000600124012008100130030001700211065000900228064000500237031000300242
014001000245865000900255002001400264035001000278801001700288#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a20.html#S#c#59#4#text#5#4#^rND^sTortoli^nE#^rND^sChi
anura^nL#^rND^sFabbro^nL#et al#Infections due to the newly described species Myc
obacterium parascrofulaceum^len#J Clin Microbiol#20050000#2005#43#4286-4287#2011
0400#v15n2a20.html#0095-1137#J Clin Microbiol##
00606000000000277000450000400060000070200490000670500020005570600020005770000030
00597010002000627090005000647080002000691180002000710100016000730100015000890100
01500104810000600119012011300125030002200238710000200260065000900262064000500271
237002900276865000900305002001400314#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a20.html#S#c#60#5#text#5#5#^rND^sHuang^nCT#^rND^sChen^nCY#^rND^sChen^nHY#et a
l#Genitourinary infections caused by nontuberculous mycobacteria at a university
 hospital in Taiwan, 1996-2008^len#Clin Microbiol Infect#2#20100000#2010#10.1111
/j.1469-0691. 03180.x#20110400#v15n2a20.html##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a21.htm#S#o#1#1#text#1#20
110406#124856#v15n2a21.htm#38##
00681000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030001800106
03100030012403200020012706500090012901400110013803500100014912300020015901200660
0161010002100227010002600248117000600274072000200280002001300282#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#h#2#1#text#1#oa#en#br1.1#1#4.0#ILUS#21#
BJID050#nd#Braz J Infect Dis#15#2#20110400#^f188^l188#1413-8670#1#Primary care p
hysicians and infectious diseases' notification^len#^rND^nPredrag^sDuric#^rND^nS
vetlana^sIli&#263;#other#4#v15n2a21.htm##
00688000000000385000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000800095158000300103030001800106
03100030012403200020012706500090012901400110013803500100014912300020015901200730
0161010002100234010002600255117000600281072000200287002001300289#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#f#3#1#text#1#oa#en#br1.1#1#4.0#ILUS#21#
BJID050#nd#Braz J Infect Dis#15#2#20110400#^f188^l188#1413-8670#1#<b>Primary car
e physicians and infectious diseases' notification</b>^len#^rND^nPredrag^sDuric#
^rND^nSvetlana^sIli&#263;#other#4#v15n2a21.htm##
00815000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101038000500105121000300110049000800113158000300121
03000210012403100030014503200020014806500090015001400110015903500100017012300020
01800120066001820100021002480100026002691170006002950720002003010020013003030080
08900316#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a21.htm#S#l#4#1#text#1#^m
Mar./Apr.^a2011#oa#en#br1.1#1#4.0#ilus#21#BJID050#nd#Braz. j. infect. dis#15#2#2
0110400#^f188^l188#1413-8670#1#Primary care physicians and infectious diseases' 
notification^len#^rND^nPredrag^sDuric#^rND^nSvetlana^sIli&#263;#other#4#v15n2a21
.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-8670
2011000200021##
00353000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704012400070002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#5#1#text#30#<p align="right"><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>LETTER TO THE EDITOR</b><
/font></p>     ^cY#v15n2a21.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#6#2#text#30#<p>&nbsp;</p>     ^cY#v15
n2a21.htm##
00398000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704016900070002001300239#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#7#3#text#30#<p><font size="4" face="V
erdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Primary care physicia
ns and infectious diseases' notification</b></font></p>     ^cY#v15n2a21.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#8#4#text#30#<p>&nbsp;</p>     ^cY#v15
n2a21.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#9#5#text#30#<p>&nbsp;</p>     ^cY#v15
n2a21.htm##
00378000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704014800071002001300219#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#10#6#text#30#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><b>Predrag Duric<sup>I</sup>; Svetlana Il
i&#263;<sup>II</sup></b></font></p>     ^cY#v15n2a21.htm##
00390000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704016000071002001300231#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#11#7#text#30#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Assistant Professor, MD, MSc,
 PhD, - Chief of HIV, hepatitis, SPI and TB Unit    ^cY#v15n2a21.htm##
00369000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704013900071002001300210#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#12#8#text#30#<br> <sup>II</sup>MD, Ch
ief of Unit for Infectious disease surveillance, intestinal, vector borne diseas
es and zoonosis</font></p>     ^cY#v15n2a21.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704011800071002001300189#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#13#9#text#30#<p><font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a></font
></p>     ^cY#v15n2a21.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#14#10#text#30#<p>&nbsp;</p>     ^cY#v
15n2a21.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#15#11#text#30#<p>&nbsp;</p>     ^cY#v
15n2a21.htm##
02683000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704245200072002001302524#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#16#12#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Systematic reporting of infectious disea
ses by health workers and laboratories provides basic data needed for evaluating
 public health conditions.<sup>1</sup> Primary care physicians (n = 277) involve
d in routine infectious disease reporting were involved in this study aiming to 
determine their attitudes towards infectious disease reporting and to measure th
eir medical knowledge, which is important for infectious disease notification. M
ost of the incorrect answers towards knowledge on diagnoses registered in Autono
mous Province of Vojvodina in the previous year were related to tetanus (61.0% i
ncorrect answers - examinees thought the disease was not notified in the previou
s year at all); psittacosis (59.2%); Q fever (56.1%); hemorrhagic fever with ren
al syndrome (54.1%); brucellosis (44.0%); and leptospirosis (38.4%). All of thes
e diseases are zoonosis and all of them require hospitalization and can be fatal
. Lyme's disease is widespread in AP Vojvodina. Yet, 14.4% of physicians were no
t aware of the prevalence of Lyme's disease. With regards to unregistered infect
ious diseases in the AP Vojvodina in the previous year (and in many cases, even 
decades back), the most incorrect answers were related to measles (41.5%) and pe
rtussis (19.1%). There was a single case of measles reported in the AP Vojvodina
 since 2000 with the exception of the measles outbreak in 2007 (22 cases). Cases
 of pertussis are diagnosed very rarely and not every year. On the other hand, i
t must be mentioned that more than 8% of physicians thought that diphtheria was 
still present in Vojvodina (it was eliminated in 1976), and about 5% of physicia
ns thought human rabies was still present in Vojvodina (was eliminated in 1964).
The worst results for familiarity with diseases that require mandatory reporting
 were obtained for congenital rubella syndrome (40.1% of incorrect answers), fol
lowed by streptococcal pneumonia, diseases caused by <i>H. influenzae</i>, lambl
iasis, and abdominal typhus. Closer collaboration and improved communication bet
ween public health officials and primary health physicians, and the appointment 
of personnel dedicated to the notification and reporting of infectious diseases 
in addition to improved training of primary care physicians could advance infect
ious disease reporting and thus increase infectious disease surveillance.<sup>2,
3,4</sup></font></p>     ^cY#v15n2a21.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#17#13#text#30#<p>&nbsp;</p>     ^cY#v
15n2a21.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010700072002001300179#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#18#14#text#30#<p><font size="3" face=
"Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p>     
^cY#v15n2a21.htm##
00582000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704033700074002001300411#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#19#15#text#30#1#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">1. World Health Organizati
on Regional Office for Europe. Technical cooperation. 2003 &#91;cited 2003 Dec 3
0&#93;. Available at: <a href="http://www.who.dk/surveillance/cooperation/200405
28_1" target="_blank">http://www.who.dk/surveillance/cooperation/20040528_1</a>.
    ^cY#v15n2a21.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#20#16#text#30#</font></p>     ^cY#v15
n2a21.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704024100074002001300315#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#21#17#text#30#2#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Keller M, Biench M, Tol
entino H <i>et al</i>. Use of unstructured event-based reports for global infect
ions disease surveillance. Emerg Infect Dis. 2009; 15(5):689-95.    ^cY#v15n2a21
.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#22#18#text#30#</font></p>     ^cY#v15
n2a21.htm##
00541000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704031000072002001300382#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#23#19#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">3. Prato B, Napoli C, Barbuti G, Germina
rio C, Lopalco PL. General practitioners and mandatory surveillance of communica
ble diseases: a descriptive study in Puglia (South Italy) &#91;in Italian&#93;. 
Ann Ig. 2004; 16(3):449-55.</font></p>     ^cY#v15n2a21.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704026300074002001300337#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#24#20#text#30#4#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Seneviratne SL, Gunatil
ake SB, de Silva HJ. Reporting notifiable diseases: methods for improvement, att
itudes and community outcome. Trans R Soc Trop Med Hyg. 1997r; 91(2):135-7</font
></p>     ^cY#v15n2a21.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#25#21#text#30#<p>&nbsp;</p>     ^cY#v
15n2a21.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#26#22#text#30#<p>&nbsp;</p>     ^cY#v
15n2a21.htm##
00420000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704018900072002001300261#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#27#23#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img src
="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:</b>  
  ^cY#v15n2a21.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002600072002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#28#24#text#30#<br> Predrag Duric    ^
cY#v15n2a21.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#29#25#text#30#<br> Futoska 121    ^cY
#v15n2a21.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004700072002001300119#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#30#26#text#30#<br> 21000 Novi Sad AP 
Vojvodina Serbia    ^cY#v15n2a21.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007900072002001300151#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#31#27#text#30#<br> <a href="mailto:du
ricp@gmail.com">duricp@gmail.com</a></font></p>     ^cY#v15n2a21.htm##
00326000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009500072002001300167#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#32#28#text#30#<p><font size="2" face=
"Verdana, Arial, Helvetica, sans-serif">Submitted on: 12/16/2010    ^cY#v15n2a21
.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003800072002001300110#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#33#29#text#30#<br>   Approved on: 12/
16/2010    ^cY#v15n2a21.htm##
00293000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704006200072002001300134#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a21.htm#S#p#34#30#text#30#<br>   We declare no co
nflict of interest.</font></p>     ^cY#v15n2a21.htm##
00505000000000241000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700170054000720180026001260650
00900152064000500161110000900166109001200175037005400187865000900241002001300250
#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a21.htm#S#c#35#1#text#4#1#World H
ealth Organization^dRegional Office for Europe#Technical cooperation^len#2003000
0#2003#20031230#2003 Dec 30#http://www.who.dk/surveillance/cooperation/20040528_
1#20110400#v15n2a21.htm##
00622000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100016000720100016000880100
01900104810000600123012008700129030001700216065000900233064000500242031000300247
032000200250014000700252865000900259002001300268035001000281801001700291#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a21.htm#S#c#36#2#text#4#2#^rND^sKeller^nM
#^rND^sBiench^nM#^rND^sTolentino^nH#et al#Use of unstructured event-based report
s for global infections disease surveillance^len#Emerg Infect Dis#20090000#2009#
15#5#689-95#20110400#v15n2a21.htm#1080-6040#Emerg Infect Dis##
00696000000000325000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100015000720100016000870100
01700103010002000120010001800140012014000158030000700298065000900305064000500314
03100030031903200020032201400070032486500090033100200130034003500100035380100070
0363#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a21.htm#S#c#37#3#text#4#3#^rN
D^sPrato^nB#^rND^sNapoli^nC#^rND^sBarbuti^nG#^rND^sGerminario^nC#^rND^sLopalco^n
PL#General practitioners and mandatory surveillance of communicable diseases: a 
descriptive study in Puglia (South Italy) [in Italian&#093^len#Ann Ig#20040000#2
004#16#3#449-55#20110400#v15n2a21.htm#1120-9135#Ann Ig##
00635000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100022000720100021000940100
01900115012009200134030002500226065000900251064000500260031000300265032000200268
014000600270865000900276002001300285035001000298801002500308#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a21.htm#S#c#38#4#text#4#4#^rND^sSeneviratne^nSL#^rND^
sGunatilake^nSB#^rND^sde Silva^nHJ#Reporting notifiable diseases: methods for im
provement, attitudes and community outcome^len#Trans R Soc Trop Med Hyg#19970000
#1997#91#2#135-7#20110400#v15n2a21.htm#0035-9203#Trans R Soc Trop Med Hyg##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#o#1#1#article#1
#20110406#125353#v15n2a10.htm#140##
02652000000000553000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400110014503500100015601200740
01660100028002400100041002680100033003090700081003420700084004230831422005070850
00801929085002301937085002501960085001601985085001702001085001802018117000602036
072000302042112000902045111001102054114000902065113001102074002001302085#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#h#2#1#article#1#oa#en#br1.1#1#4
.0#ILUS#TAB#10#BJID160#nd#Braz J Infect Dis#15#2#20110400#^f151^l155#1413-8670#D
yslipidemia in AIDS patients on highly active antiretroviral therapy^len#^rND^1A
01^nMax Weyler^sNery#^rND^1A02^nCelina Maria Turchi^sMartelli#^rND^1A02^nMarília
 Dalva^sTurchi#Pontifícia Universidade Católica de Goiás^iA01^1Departamento de M
edicina^pBrazil#Universidade Federal de Goiás^iA02^1Instituto de Patologia Tropi
cal e Saúde Pública#^len^aHighly active antiretroviral therapy (HAART) reduces A
IDS-related morbidity and mortality, however it has been associated with metabol
ic abnormalities. This study estimated the prevalence of lipid abnormalities and
 related factors among patients on HAART. A cross-sectional study was conducted 
on adult patients, in central Brazil. Patients were interviewed, and blood obtai
ned for lipids measurement. Dyslipidemia was defined as total cholesterol (TC) &
gt; 240 mg/dL, low-density lipoprotein (LDL) &gt; 160 mg/dL, triglycerides (TG) 
&gt; 200 and/or high-density lipoprotein (HDL) < 40 mg/dL. Multiple logistic reg
ression analyses were performed (SPSS 13.0). One hundred and thirteen patients w
ere recruited. Mean age was 39.3 years; 68.1% were males; 50.4% were on nucleosi
de reverse transcriptase inhibitors (NRTI) in combination with non-nucleoside re
verse transcriptase inhibitors (NNRTI), while 42.5% were on NRTI in combination 
with protease inhibitors (PIs). The prevalence of dyslipidemia was 66.7%. Low HD
L was the most frequent abnormality (53.5%), followed by high TG (36.1%). Patien
ts on a PI regimen had a 5.2-fold higher risk (95% CI: 1.8-14.8) of dyslipidemia
, even after adjusting for sex, age, and duration of HIV infection/AIDS. The stu
dy discloses a high prevalence rate of dyslipidemia and points out a need for in
tervention programs to reduce future cardiovascular events in patients, on HAART
.#^dnd^i1#^tm^len^kprevalence^i1#^tm^len^kdyslipidemia^i1#^tm^len^kHIV^i1#^tm^le
n^kAIDS^i1#^tm^len^kHAART^i1#other#20#20100305#03/05/2010#20101030#10/30/2010#v1
5n2a10.htm##
02676000000000553000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400110014503500100015601200810
01660100028002470100041002750100033003160700081003490700084004300831439005140850
00801953085002301961085002501984085001602009085001702025085001802042117000602060
072000302066112000902069111001102078114000902089113001102098002001302109#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#f#3#1#article#1#oa#en#br1.1#1#4
.0#ILUS#TAB#10#BJID160#nd#Braz J Infect Dis#15#2#20110400#^f151^l155#1413-8670#<
b>Dyslipidemia in AIDS patients on highly active antiretroviral therapy</b>^len#
^rND^1A01^nMax Weyler^sNery#^rND^1A02^nCelina Maria Turchi^sMartelli#^rND^1A02^n
Marília Dalva^sTurchi#Pontifícia Universidade Católica de Goiás^iA01^1Departamen
to de Medicina^pBrazil#Universidade Federal de Goiás^iA02^1Instituto de Patologi
a Tropical e Saúde Pública#^len^aHighly active antiretroviral therapy (HAART) re
duces AIDS-related morbidity and mortality, however it has been associated with 
metabolic abnormalities. This study estimated the prevalence of lipid abnormalit
ies and related factors among patients on HAART. A cross-sectional study was con
ducted on adult patients, in central Brazil. Patients were interviewed, and bloo
d obtained for lipids measurement. Dyslipidemia was defined as total cholesterol
 (TC) <u>&gt;</u> 240 mg/dL, low-density lipoprotein (LDL) <u>&gt;</u> 160 mg/dL
, triglycerides (TG) &gt; 200 and/or high-density lipoprotein (HDL) &lt; 40 mg/d
L. Multiple logistic regression analyses were performed (SPSS 13.0). One hundred
 and thirteen patients were recruited. Mean age was 39.3 years; 68.1% were males
; 50.4% were on nucleoside reverse transcriptase inhibitors (NRTI) in combinatio
n with non-nucleoside reverse transcriptase inhibitors (NNRTI), while 42.5% were
 on NRTI in combination with protease inhibitors (PIs). The prevalence of dyslip
idemia was 66.7%. Low HDL was the most frequent abnormality (53.5%), followed by
 high TG (36.1%). Patients on a PI regimen had a 5.2-fold higher risk (95% CI: 1
.8-14.8) of dyslipidemia, even after adjusting for sex, age, and duration of HIV
 infection/AIDS. The study discloses a high prevalence rate of dyslipidemia and 
points out a need for intervention programs to reduce future cardiovascular even
ts in patients, on HAART.#^dnd^i1#^tm^len^kprevalence^i1#^tm^len^kdyslipidemia^i
1#^tm^len^kHIV^i1#^tm^len^kAIDS^i1#^tm^len^kHAART^i1#other#20#20100305#03/05/201
0#20101030#10/30/2010#v15n2a10.htm##
02839000000000577000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000210013103100030015203200020015506500090015701400110016603500100
01770120074001870100028002610100041002890100033003300700083003630700086004460831
47100532085000802003085002302011085002502034085001602059085001702075085001802092
11700060211007200030211611200090211911100110212811400090213911300110214800200130
2159008008902172#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#l#4#1#a
rticle#1#^mMar./Apr.^a2011#oa#en#br1.1#1#4.0#ilus#tab#10#BJID160#nd#Braz. j. inf
ect. dis#15#2#20110400#^f151^l155#1413-8670#Dyslipidemia in AIDS patients on hig
hly active antiretroviral therapy^len#^rND^1A01^nMax Weyler^sNery#^rND^1A02^nCel
ina Maria Turchi^sMartelli#^rND^1A02^nMarília Dalva^sTurchi#^iA01^1Pontifícia Un
iversidade Católica de Goiás^2Departamento de Medicina^pBrazil#^iA02^1Universida
de Federal de Goiás^2Instituto de Patologia Tropical e Saúde Pública#^len^aHighl
y active antiretroviral therapy (HAART) reduces AIDS-related morbidity and morta
lity, however it has been associated with metabolic abnormalities. This study es
timated the prevalence of lipid abnormalities and related factors among patients
 on HAART. A cross-sectional study was conducted on adult patients, in central B
razil. Patients were interviewed, and blood obtained for lipids measurement. Dys
lipidemia was defined as total cholesterol (TC) &gt; 240 mg/dL, low-density lipo
protein (LDL) &gt; 160 mg/dL, triglycerides (TG) &gt; 200 and/or high-density li
poprotein (HDL) < 40 mg/dL. Multiple logistic regression analyses were performed
 (SPSS 13.0). One hundred and thirteen patients were recruited. Mean age was 39.
3 years; 68.1 percent were males; 50.4 percent were on nucleoside reverse transc
riptase inhibitors (NRTI) in combination with non-nucleoside reverse transcripta
se inhibitors (NNRTI), while 42.5 percent were on NRTI in combination with prote
ase inhibitors (PIs). The prevalence of dyslipidemia was 66.7 percent. Low HDL w
as the most frequent abnormality (53.5 percent), followed by high TG (36.1 perce
nt). Patients on a PI regimen had a 5.2-fold higher risk (95 percent CI: 1.8-14.
8) of dyslipidemia, even after adjusting for sex, age, and duration of HIV infec
tion/AIDS. The study discloses a high prevalence rate of dyslipidemia and points
 out a need for intervention programs to reduce future cardiovascular events in 
patients, on HAART.#^dnd^i1#^tm^len^kprevalence^i1#^tm^len^kdyslipidemia^i1#^tm^
len^kHIV^i1#^tm^len^kAIDS^i1#^tm^len^kHAART^i1#other#20#20100305#03/05/2010#2010
1030#10/30/2010#v15n2a10.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sc
i_arttext&pid=S1413-86702011000200010##
00356000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012300074002001300197#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#5#1#article#116#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>BRIEF COMMUNICATION</
b></font></p>     ^cY#v15n2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#6#2#article#116#<p>&nbsp;</p>     ^cY
#v15n2a10.htm##
00410000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704017700074002001300251#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#7#3#article#116#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Dyslipidemia in A
IDS patients on highly active antiretroviral therapy</b></font></p>     ^cY#v15n
2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#8#4#article#116#<p>&nbsp;</p>     ^cY
#v15n2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#9#5#article#116#<p>&nbsp;</p>     ^cY
#v15n2a10.htm##
00436000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704020200075002001300277#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#10#6#article#116#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Max Weyler Nery<sup>I</sup>; Celin
a Maria Turchi Martelli<sup>II</sup>; Mar&iacute;lia Dalva Turchi<sup>II</sup></
b></font></p>     ^cY#v15n2a10.htm##
00424000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704019000075002001300265#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#11#7#article#116#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>MD, MSc; Departamento de 
Medicina da Pontif&iacute;cia Universidade Cat&oacute;lica de Goi&aacute;s, Braz
il    ^cY#v15n2a10.htm##
00390000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015600075002001300231#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#12#8#article#116#<br> <sup>II</sup>MD
, PhD; Instituto de Patologia Tropical e Sa&uacute;de P&uacute;blica da Universi
dade Federal de Goi&aacute;s, Brazil</font></p>     ^cY#v15n2a10.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011800075002001300193#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#13#9#article#116#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a></
font></p>     ^cY#v15n2a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#14#10#article#116#<p>&nbsp;</p>     ^
cY#v15n2a10.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#15#11#article#116#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v15n2a10.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#16#12#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
15n2a10.htm##
01750000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704151500076002001301591#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#17#13#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Highly active antiretroviral therapy
 (HAART) reduces AIDS-related morbidity and mortality, however it has been assoc
iated with metabolic abnormalities. This study estimated the prevalence of lipid
 abnormalities and related factors among patients on HAART. A cross-sectional st
udy was conducted on adult patients, in central Brazil. Patients were interviewe
d, and blood obtained for lipids measurement. Dyslipidemia was defined as total 
cholesterol (TC) <u>&gt;</u> 240 mg/dL, low-density lipoprotein (LDL) <u>&gt;</u
> 160 mg/dL, triglycerides (TG) &gt; 200 and/or high-density lipoprotein (HDL) &
lt; 40 mg/dL. Multiple logistic regression analyses were performed (SPSS 13.0). 
One hundred and thirteen patients were recruited. Mean age was 39.3 years; 68.1%
 were males; 50.4% were on nucleoside reverse transcriptase inhibitors (NRTI) in
 combination with non-nucleoside reverse transcriptase inhibitors (NNRTI), while
 42.5% were on NRTI in combination with protease inhibitors (PIs). The prevalenc
e of dyslipidemia was 66.7%. Low HDL was the most frequent abnormality (53.5%), 
followed by high TG (36.1%). Patients on a PI regimen had a 5.2-fold higher risk
 (95% CI: 1.8-14.8) of dyslipidemia, even after adjusting for sex, age, and dura
tion of HIV infection/AIDS. The study discloses a high prevalence rate of dyslip
idemia and points out a need for intervention programs to reduce future cardiova
scular events in patients, on HAART.</font></p>     ^cY#v15n2a10.htm##
00400000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016500076002001300241#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#18#14#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> prevalence; dyslipi
demia; HIV; AIDS; HAART.</font></p> <hr size="1" noshade>     ^cY#v15n2a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#19#15#article#116#<p>&nbsp;</p>     ^
cY#v15n2a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#20#16#article#116#<p>&nbsp;</p>     ^
cY#v15n2a10.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#21#17#article#116#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>INTRODUCTION</b></i></font></p
>     ^cY#v15n2a10.htm##
00554000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031900076002001300395#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#22#18#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Highly active antiretroviral therapy
 (HAART)   reduces the clinical manifestations of HIV infection,   delaying the 
onset of AIDS and substantially   improving the prognosis and quality of life of
 HIV-infected individuals.<sup>1,2</sup></font></p>     ^cY#v15n2a10.htm##
00908000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067300076002001300749#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#23#19#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Since HAART was first introduced, th
e   trend towards a reduced morbidity and mortality   of HIV/AIDS patients has b
een accompanied   by the emergence of side effects and toxicities in   various o
rgans.<sup>3</sup> Metabolic abnormalities such   as dyslipidemias, insulin resi
stance, hyperglycemia   and changes in body fat distribution or   lipodystrophy 
syndrome are classic examples of   this situation.<sup>4</sup> Side effects redu
ces adherence to   treatment, and long term exposure to dyslipidemias   in this 
population may increase the risk of cardiovascular diseases.<sup>5-7</sup></font
></p>     ^cY#v15n2a10.htm##
00798000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056300076002001300639#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#24#20#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Antiretroviral drugs have been widel
y available   in Brazil, since 1996 and approximately   170,000 patients had acc
ess to HAART universally   distributed, by the Brazilian National   Health Syste
m (SUS).<sup>8</sup> Analyses of the impact of   HAART in Brazil have shown a pa
ttern similar   to that described in developed countries, i.e. a   significant r
eduction in opportunistic diseases   with a consequent reduction in AIDS-related
 hospitalizations and mortality.<sup>9</sup></font></p>     ^cY#v15n2a10.htm##
00875000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064000076002001300716#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#25#21#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Dyslipidemias are estimated to be fr
equent   events in patients using HAART; nevertheless,   up to the present time,
 few studies have investigated   the prevalence of these abnormalities   in Braz
il.<sup>10-12</sup> The present study aimed to estimate   the prevalence of dysl
ipidemias in HIVinfected   patients on antiretroviral therapy, in   the central 
part of Brazil, and to evaluate factors   associated with these abnormalities. T
hese   data may help to predict the impact of longterm   antiretroviral therapy 
on cardiovascular diseases in this group.</font></p>     ^cY#v15n2a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#26#22#article#116#<p>&nbsp;</p>     ^
cY#v15n2a10.htm##
00345000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011000076002001300186#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#27#23#article#116#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>MATERIAL AND METHODS</b></font></
p>     ^cY#v15n2a10.htm##
00656000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042100076002001300497#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#28#24#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">HIV-infected patients over 19 years 
of age, who   had been in use of antiretroviral therapy for at   least 30 days, 
were eligible to participate in this study. All of them were registered in the m
ain referral center for HIV/AIDS patients, Hospital for Tropical Diseases Dr. An
uar Auad (HDT/AA), in the city of Goi&acirc;nia, Goi&aacute;s.</font></p>     ^c
Y#v15n2a10.htm##
00602000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036700076002001300443#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#29#25#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">This is a prevalence study with conv
enience sampling. Sample size was calculated to detect prevalences of dyslipidem
ia <u>&gt;</u> 40% in patients on antiretroviral therapy with 10% precision, res
ulting in a required sample of 93 patients. Cases were identified between 2005 a
nd 2006.</font></p>     ^cY#v15n2a10.htm##
00710000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047500076002001300551#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#30#26#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The protocol was approved by the Int
ernal Review Board of the <i>Universidade Federal de Goi&aacute;s</i>. After obt
aining informed consent, patients were interviewed, their medical and laboratory
 records abstracted, and blood obtained for laboratory testing. Patients with a 
history of opportunistic disease diagnosed less than two months prior to the int
erview were excluded from the study.</font></p>     ^cY#v15n2a10.htm##
00936000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070100076002001300777#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#31#27#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A structured interview was administe
red to all participants by the principal investigator to collect social, demogra
phic and clinical data. Patient's clinical charts were also used as data sources
 from which information on duration of antiretroviral therapy, T-CD4+ lymphocyte
 count, HIV-1 viral load and previous lipid evaluations was obtained. For the pu
rposes of analyses, viral load measurement was dichotomized into detectable or u
ndetectable, and T-CD4+ lymphocyte count was classified as &gt; 350 or <u>&lt;</
u> 350 cells/mL. When more than one laboratory evaluation was available, the mos
t recent one was used.</font></p>     ^cY#v15n2a10.htm##
01250000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704101500076002001301091#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#32#28#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Following the interview, the patient
s were referred for blood lipid evaluation, performed after an overnight fasting
 period. Lipid profile was obtained in individuals who were metabolically stable
<sup>13</sup> by measuring total cholesterol (TC), high-density lipoprotein chol
esterol (HDL-C) and triglycerides (TG) using an automated enzymatic method. Low-
density lipoprotein cholesterol (LDL-C) was calculated using Friedwald's formula
 in individuals with triglycerides <u>&lt;</u> 400 mg/dL. Blood lipids were clas
sified as categorical variables and the following situations were defined as dys
lipidemia: TC <u>&gt;</u> 240 mg/dL, LDL-C <u>&gt;</u> 160 mg/dl, TG &gt; 200 mg
/dL and/or HDL-C &lt; 40 mg/dL.<sup>13</sup> To assess cardiovascular risk, Cast
elli's Index I was calculated using the ratio: TC/HDL-C; a Castelli Index I &gt;
 5.1 for men and &gt; 4.4 for women were considered indicative of an elevated ri
sk.<sup>14</sup></font></p>     ^cY#v15n2a10.htm##
00929000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069400076002001300770#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#33#29#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Descriptive and exploratory statisti
cal methods were used: measurements of central tendency and dispersion for conti
nuous variables, frequency distributions with their respective confidence interv
als for categorical variables. Chi-square test or Fisher's exact test were used 
to evaluate differences in frequency distribution. Student's t-test was employed
 to evaluate differences between two means, and the Kruskal-Wallis non-parametri
c test to evaluate differences in duration of antiretroviral therapy. Prevalence
 rates of dyslipidemia were calculated with their respective 95% confidence inte
rvals (95% CI).</font></p>     ^cY#v15n2a10.htm##
01122000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704088700076002001300963#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#34#30#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A case-control analysis was carried 
out to evaluate the association between dyslipidemia and exposure variables. Pat
ients with dyslipidemia were considered "cases" and patients who did not have th
is condition were considered "controls". Odds ratios (OR) and their respective 9
5% confidence intervals (95% CI) were calculated. Multiple logistic regression m
odels were applied with simultaneous adjustment for sex, age and length of time 
since HIV/diagnosis. Interaction between exposure variables were also tested to 
build-up the final logistic model. The correlation between the time on protease 
inhibitors and serum HDL levels was evaluated. A p-value of less than 0.05 was c
onsidered significant. Statistical analyses were performed using Statistical Pac
kage for Social Science software (version 13.0).</font></p>     ^cY#v15n2a10.htm
##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#35#31#article#116#<p>&nbsp;</p>     ^
cY#v15n2a10.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#36#32#article#116#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>RESULTS</b></i></font></p>    
 ^cY#v15n2a10.htm##
00778000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054300076002001300619#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#37#33#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">One hundred and thirteen HIV-infecte
d patients on antiretroviral therapy were enrolled. The mean age of participants
 was 39.3 ± 10.4 years, ranging from 20 to 64 years; 68.1% were males; 52.2% had
 less than 9 years of schooling; and approximately half of them reported very lo
w monthly income (<u>&lt;</u> one minimum wage). T-CD4+ lymphocyte count &gt; 35
0 cells/mL was found in 42.4% of patients, whereas viral load was undetectable i
n 51.9% of participants.</font></p>     ^cY#v15n2a10.htm##
01029000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079400076002001300870#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#38#34#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The most frequently prescribed antir
etroviral regimen consisted of the combination of two nucleoside reverse transcr
iptase inhibitors (NRTI) with non-nucleoside reverse transcriptase inhibitors (N
NRTI), used by 50.4% of the sample, followed by the combination of two NRTI with
 protease inhibitors (PI), used by 42.5% of study participants. Use of three dis
tinct classes of antiretroviral drugs (NRTI, NNRTI and PI) was recorded for 4.4%
 of patients. The majority of patients (64.6%) were on three drugs; 25.7% on fou
r drugs and 8.0% on five or more drugs. The most commonly prescribed drugs were 
lamivudine (92.9%), zidovudine (66.4%), and efavirenz (49.6%). Fifty-five patien
ts (48.7%) were on at least one PI.</font></p>     ^cY#v15n2a10.htm##
00477000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024200076002001300318#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#39#35#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Boosted ritonavir was used with othe
r PI, in 37 patients. The most common combination was ritonavir with atazanavir,
 reported by 26 out of 37 patients (62.2%).</font></p>     ^cY#v15n2a10.htm##
00760000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052500076002001300601#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#40#36#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Change in body fat distribution, aft
er initiating antiretroviral therapy, was perceived by 39.8% of patients, with a
bdominal fat accumulation being the most frequently mentioned (91.1%). Less than
 half the patients (45.1%) reported having previous lipid assessment, and 47.0% 
of these patients reported increased cholesterol and/or triglyceride levels. Amo
ng those who reported abnormal blood lipid levels, 20.8% were on lipid-lowering 
drugs.</font></p>     ^cY#v15n2a10.htm##
00566000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033100076002001300407#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#41#37#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Out of 113 patients interviewed, 97 
had were on antiretroviral therapy for at least 30 days and were evaluated with 
respect to their lipid profile. Length of time on PI was significantly shorter t
han the time on either NRTI or NNRTI (p &lt; 0.043).</font></p>     ^cY#v15n2a10
.htm##
00703000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046800076002001300544#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#42#38#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#tab1">Table 1</a> shows th
e results of the Castelli Index I according to sex and the lipid profile of 97 p
atients evaluated in accordance with the Brazilian Cardiology Society (SBC) clas
sification. Among men 36.9% had a Castelli Index I &gt; 5.1, whereas 40% of the 
women had a Castelli Index I &gt; 4.4, indicating a higher risk of cardiovascula
r disease in this population.</font></p>     ^cY#v15n2a10.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#43#39#article#116#<p><a name="tab1"><
/a></p>     ^cY#v15n2a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#44#40#article#116#<p>&nbsp;</p>     ^
cY#v15n2a10.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#45#41#article#116#<p align="center"><
img src="/img/revistas/bjid/v15n2/a10tab01.jpg"></p>     ^cY#v15n2a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#46#42#article#116#<p>&nbsp;</p>     ^
cY#v15n2a10.htm##
00767000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053200076002001300608#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#47#43#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The majority of patients (66.7%) had
 at least one   laboratory abnormality compatible with a diagnosis of   dyslipid
emia. The most frequent abnormality was low   HDL-C, levels below 40 mg/dL being
 found in 53.7%   of participants. Additionally, 36.1% of the participants   had
 triglyceride levels &gt; 200 mg/dL. HDL-C &lt; 40 mg/dL   and triglycerides &gt
; 200 mg/dL was the most common mixed dyslipidemia, being diagnosed in 27.4% of 
participants.</font></p>     ^cY#v15n2a10.htm##
00510000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027500076002001300351#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#48#44#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Age, duration of HIV/AIDS, sex, vira
l load measurement   and immunological status evaluated by T-CD4+ cell were   no
t significantly different between dyslipidemic and nondyslipidemic patients.</fo
nt></p>     ^cY#v15n2a10.htm##
00808000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057300076002001300649#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#49#45#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In univariate analysis patients on P
I had 3.4-fold greater risk (95% CI: 1.4-8.4) of dyslipidemia compared to patien
ts on regimens that did not include this class of drugs. On the other hand, pati
ents on NNRTI-containing regimens had lower risk of dyslipidemia (OR = 0.3; 95% 
CI: 0.1-0.6). Nevertheless, a significant interaction (p &lt; 0.003) was found b
etween these exposure variables (being on a PI-containing regimen or on an NNRTI
-containing regimen) and the presence of dyslipidemia.</font></p>     ^cY#v15n2a
10.htm##
00714000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047900076002001300555#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#50#46#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">PI were independently associated wit
h dyslipidemia even after simultaneous adjustment for potential confounding fact
ors such as sex, age and duration of HIV infection (OR<sub>adjusted</sub> = 5.2;
 95% CI: 1.8-14.8) as shown in <a href="/img/revistas/bjid/v15n2/a10tab02.jpg">T
able 2</a>. There was no correlation between duration of PI use (in months) and 
serum HDL-C level (r = - 0.2; p = 0.12).</font></p>     ^cY#v15n2a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#51#47#article#116#<p>&nbsp;</p>     ^
cY#v15n2a10.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#52#48#article#116#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>DISCUSSION</b></i></font></p> 
    ^cY#v15n2a10.htm##
00819000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058400076002001300660#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#53#49#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The present study discloses a high p
revalence of dyslipidemia   in patients on antiretroviral therapy in a large cit
y in   central Brazil. These findings suggest a potential risk for the   develop
ment of cardiovascular diseases in a significant proportion   of HIV/AIDS patien
ts in coming years. Therefore,   the benefits obtained with the use of HAART ove
r the past   years may be reduced if measures to minimize the negative   impact 
of cardiovascular disease in this population are not implemented.</font></p>    
 ^cY#v15n2a10.htm##
00500000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026500076002001300341#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#54#50#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The majority of HIV-infected patient
s on HAART, in our setting, were found to have abnormal lipid profile with poten
tial risk for cardiovascular disease in a near future.<sup>7</sup></font></p>   
  ^cY#v15n2a10.htm##
00621000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038600076002001300462#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#55#51#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Patients using lipid-lowering therap
y were not excluded from the present analysis, and, unexpectedly, all of them ha
d some lipid abnormality compatible with the diagnosis of dyslipidemia, suggesti
ng the need for better clinical control, in accordance with the recommendations 
guidelines.<sup>13,15</sup></font></p>     ^cY#v15n2a10.htm##
01217000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704098200076002001301058#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#56#52#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">There are wide variations in the pre
valence rate of dyslipidemia among HIV-infected patients on antiretroviral thera
py. Comparison of results from different prevalence studies should be made with 
caution, taking into consideration differences in methodology, populations studi
ed, antiretroviral regimens used by the patients, and the cut-off points establi
shed to define lipid abnormalities. For the purpose of clinical management, the 
current trend is to attempt to lower blood lipid levels; hence, the cut-off poin
t for the definition of lipid abnormalities is lower.<sup>13</sup> However, in t
he present study, it was decided to apply more conservative criteria with higher
 cut-off limits to define dyslipidemia, thereby guaranteeing greater specificity
 of results. The percentage of lipid abnormalities encountered in this study wou
ld have been even higher if lower cut-off points had been used.</font></p>     ^
cY#v15n2a10.htm##
00894000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065900076002001300735#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#57#53#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In our sample, low HDL was the most 
frequent abnormality (53.7% of patients had levels &lt; 40 mg/dL), followed by e
levated triglyceride levels (36.1% of patients had levels &gt; 200 mg/dL). Appro
ximately 40% of patients had an elevated Castelli Index I, indicating an increas
ed risk for atherosclerotic cardiovascular disease in this population. This inde
x is considered a simple approach for lipid risk assessment, the high total chol
esterol is a marker for atherogenic lipoproteins and low HDL cholesterol correla
tes with risk factors of metabolic syndrome.<sup>14,16</sup></font></p>     ^cY#
v15n2a10.htm##
00895000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066000076002001300736#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#58#54#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Few studies on the prevalence of dys
lipidemia carried out in Brazil have been published.<sup>10-12</sup> In the nort
heast region, a cross-sectional study<sup>12</sup> conducted among a sample of 3
72 patients with and without antiretroviral therapy found high TC, low HDL and h
igh TG levels in 20.1%, 57.1% and 26.5% of subjects, respectively. A study condu
cted in the southeast<sup>11</sup> involving 238 patients, predominantly using P
I, found low HDL in 65% of participants and hypertriglyceridemia in 46% of them,
 using different cut-off points from those used in our study.</font></p>     ^cY
#v15n2a10.htm##
01285000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704105000076002001301126#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#59#55#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Different antiretroviral drugs may b
e associated with abnormalities in lipid profile. Various studies have shown an 
association between the use of PI and dyslipidemia.<sup>5,7,12</sup> The prevale
nce and degree of lipid abnormalities, however, vary between the different drugs
, within a single class and possibly with duration of treatment.<sup>17</sup> Th
e present study was not designed to evaluate differences between drugs within th
e same class. The use of PI was associated with the presence of dyslipidemia eve
n after simultaneous adjustment for possible confounding factors such as sex, ag
e and time since diagnosis of HIV/AIDS. The duration of PI use was not included 
in the logistic regression model. Nevertheless, there was no evidence of any cor
relation between duration of PI use and serum HDL-C levels (p = 0.12). Contrary 
to our findings, another study conducted in Brazil<sup>11</sup> reported a corre
lation between duration of PI use and HDL-C levels.</font></p>     ^cY#v15n2a10.
htm##
00849000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061400076002001300690#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#60#56#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The association between NNRTI use an
d dyslipidemias is controversial. A growing number of reports suggest that use o
f this class of drugs may lead to an increase in lipids.<sup>17,18</sup> In agre
ement with our results, another study conducted in London<sup>19</sup> found no 
increase in total cholesterol or in triglycerides in patients on NNRTI. Other in
vestigators have reported an increase in HDL-C in patients on this class of drug
s, which may have a protective effect against the development of coronary diseas
e.<sup>20</sup></font></p>     ^cY#v15n2a10.htm##
00864000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062900076002001300705#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#61#57#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">One of the limitations of the presen
t study is not having included the cumulative history of the prior use of antire
trovirals. It is possible that patients on PI, mainly those on ritonavir-boosted
 regimens, may have had the disease for a longer time and may have been exposed 
to various drugs previously, which may have interfered in their current lipid pr
ofile. To minimize this effect, an estimation of the time of HIV infection/AIDS 
was included in the logistic regression model as surrogate marker for the time o
f use of antiretroviral drugs.</font></p>     ^cY#v15n2a10.htm##
00681000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044600076002001300522#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#62#58#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Some other methodological issues wit
h respect to the site at which cases were recruited and the sampling process sho
uld also be mentioned. Patients registered at the principal referral service for
 HIV/AIDS in the state of Goi&aacute;s were recruited to this study. This referr
al center is responsible for the notification of almost all cases of AIDS in the
 state.</font></p>     ^cY#v15n2a10.htm##
00607000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037200076002001300448#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#63#59#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Despite 48.1% of these patients had 
a detectable viral load we cannot conclude that they were inappropriately treate
d. Viral load assessment is used to monitor therapy and around half these patien
ts underwent a change in their antiretroviral regimen following evaluation of pl
asma viremia.</font></p>     ^cY#v15n2a10.htm##
00820000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058500076002001300661#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#64#60#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Assuming that the sample of patients
 studied is representative, our results indicate a high prevalence of dyslipidem
ia and risk for the development of cardiovascular disease in a significant propo
rtion of patients with HIV/AIDS in the years to come in central part of Brazil. 
Furthermore, as most of patients unaware of their lipid abnormalities, the findi
ngs of this study underscore the need to adopt strategies to routinely evaluate 
and modify the risk of cardiovascular diseases in this population.</font></p>   
  ^cY#v15n2a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#65#61#article#116#<p>&nbsp;</p>     ^
cY#v15n2a10.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011300076002001300189#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#66#62#article#116#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>ACKNOWLEDGEMENTS</b></i></font
></p>     ^cY#v15n2a10.htm##
00465000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023000076002001300306#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#67#63#article#116#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The authors are grateful to the dire
ctors of the Hospital for Tropical Diseases Dr. Anuar Auad (HDT/AA) of Goi&aacut
e;s State Department of Health.</font></p>     ^cY#v15n2a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#68#64#article#116#<p>&nbsp;</p>     ^
cY#v15n2a10.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#69#65#article#116#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p> 
    ^cY#v15n2a10.htm##
00558000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030900078002001300387#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#70#66#article#116#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Palella FJ, Jr., De
laney KM, Moorman AC <i>et al</i>. Declining morbidity and mortality among patie
nts with advanced human immunodeficiency virus infection. HIV Outpatient Study I
nvestigators. N Engl J Med. 1998 Mar 26; 338(13):853-60.    ^cY#v15n2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#71#67#article#116#</font></p>     ^cY
#v15n2a10.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026600078002001300344#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#72#68#article#116#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Enanoria WT, Ng C, 
Saha SR, Colford Jr JM. Treatment outcomes after highly active antiretroviral th
erapy: a meta-analysis of randomised controlled trials. Lancet Infect Dis. 2004;
 4(7):414-25.    ^cY#v15n2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#73#69#article#116#</font></p>     ^cY
#v15n2a10.htm##
00417000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704016800078002001300246#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#74#70#article#116#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Carr A, Cooper DA. 
Adverse effects of antiretroviral therapy. Lancet. 2000; 356(9239):1423-30.    ^
cY#v15n2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#75#71#article#116#</font></p>     ^cY
#v15n2a10.htm##
00512000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026300078002001300341#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#76#72#article#116#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Wohl DA, McComsey G
, Tebas P <i>et al</i>. Current concepts in the diagnosis and management of meta
bolic complications of HIV infection and its therapy. Clin Infect Dis. 2006; 43(
5):645-53.    ^cY#v15n2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#77#73#article#116#</font></p>     ^cY
#v15n2a10.htm##
00563000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031400078002001300392#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#78#74#article#116#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Rhew DC, Bernal M, 
Aguilar D, Iloeje U, Goetz MB. Association between protease inhibitor use and in
creased cardiovascular risk in patients infected with human immunodeficiency vir
us: a systematic review. Clin Infect Dis. 2003; 37(7):959-72.    ^cY#v15n2a10.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#79#75#article#116#</font></p>     ^cY
#v15n2a10.htm##
00546000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029700078002001300375#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#80#76#article#116#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Saves M, Chene G, D
ucimetiere P <i>et al</i>. Risk factors for coronary heart disease in patients t
reated for human immunodeficiency virus infection compared with the general popu
lation. Clin Infect Dis., 2003; 37(2):292-8.    ^cY#v15n2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#81#77#article#116#</font></p>     ^cY
#v15n2a10.htm##
00476000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022700078002001300305#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#82#78#article#116#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Friis-Moller N, Rei
ss P, Sabin CA <i>et al</i>. Class of antiretroviral drugs and the risk of myoca
rdial infarction. N Engl J Med. 2007; 356(17):1723-35.    ^cY#v15n2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#83#79#article#116#</font></p>     ^cY
#v15n2a10.htm##
00480000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023100078002001300309#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#84#80#article#116#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Grangeiro A Teixeir
a L, Bastos FI, Teixeira P. Sustainability of Brazilian policy for access to ant
iretroviral drugs. Rev Saude Publica. 2006; 40 Suppl:60-9.    ^cY#v15n2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#85#81#article#116#</font></p>     ^cY
#v15n2a10.htm##
00489000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024000078002001300318#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#86#82#article#116#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Dourado I, Veras MA
, Barreira D, de Brito AM. AIDS epidemic trends after the introduction of antire
troviral therapy in Brazil. Rev Saude Publica. 2006; 40 Suppl:9-17.    ^cY#v15n2
a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#87#83#article#116#</font></p>     ^cY
#v15n2a10.htm##
00536000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028600079002001300365#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#88#84#article#116#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Caramelli B, de B
ernoche CY, Sartori AM <i>et al</i>. Hyperlipidemia related to the use of HIV-pr
otease inhibitors: natural history and results of treatment with fenofibrate. Br
az J Infect Dis. 2001; 5(6):332-8.    ^cY#v15n2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#89#85#article#116#</font></p>     ^cY
#v15n2a10.htm##
00529000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027900079002001300358#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#90#86#article#116#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Albuquerque EM, d
e Faria EC, Oliveira HC, Magro DO, Castilho LN. High frequency of Fredricksons p
henotypes IV and IIb in Brazilians infected by human immunodeficiency virus. BMC
 Infect Dis. 2005; 5(1):47.    ^cY#v15n2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#91#87#article#116#</font></p>     ^cY
#v15n2a10.htm##
00571000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704032100079002001300400#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#92#88#article#116#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. de Araujo PS, de 
Alencar Ximenes RA, Lopes CF, Duarte JY, da Silva MM, Carneiro EM. Antiretrovira
l treatment for HIV infection/AIDS and the risk of developing hyperglycemia and 
hyperlipidemia. Rev Inst Med Trop S&atilde;o Paulo. 2007; 49(2):73-8.    ^cY#v15
n2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#93#89#article#116#</font></p>     ^cY
#v15n2a10.htm##
00527000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027700079002001300356#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#94#90#article#116#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. SBC. III Brazilia
n Guidelines on Dyslipidemias and Guideline of Atherosclerosis Prevention from A
therosclerosis Department of Sociedade Brasileira de Cardiologia. Arq Bras Cardi
ol. 2001;77 Suppl 3:1-48.    ^cY#v15n2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#95#91#article#116#</font></p>     ^cY
#v15n2a10.htm##
00466000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704021600079002001300295#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#96#92#article#116#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Castelli WP, Abbo
tt RD, McNamara PM. Summary estimates of cholesterol used to predict coronary he
art disease. Circulation. 1983; 67(4):730-4.    ^cY#v15n2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#97#93#article#116#</font></p>     ^cY
#v15n2a10.htm##
00686000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704043600079002001300515#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#98#94#article#116#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Dube MP, Stein JH
, Aberg JA <i>et al</i>. Guidelines for the evaluation and management of dyslipi
demia in human immunodeficiency virus (HIV)-infected adults receiving antiretrov
iral therapy: recommendations of the HIV Medical Association of the Infectious D
isease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect 
Dis. 2003; 37(5):613-27.    ^cY#v15n2a10.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#99#95#article#116#</font></p>     ^cY
#v15n2a10.htm##
00500000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704024900080002001300329#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#100#96#article#116#16#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Wilson PW, D'Ago
stino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary 
heart disease using risk factor categories. Circulation. 1998; 97(18):1837-47.  
  ^cY#v15n2a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#101#97#article#116#</font></p>     ^c
Y#v15n2a10.htm##
00569000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704031800080002001300398#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#102#98#article#116#17#<p>
<font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Fontas E, van Le
th F, Sabin CA <i>et al</i>. Lipid profiles in HIV-infected patients receiving c
ombination antiretroviral therapy: are different antiretroviral drugs associated
 with different lipid profiles? J Infect Dis. 2004; 189(6):1056-74.    ^cY#v15n2
a10.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#103#99#article#116#</font></p>     ^c
Y#v15n2a10.htm##
00522000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027000081002001300351#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#104#100#article#116#18#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Friis-Moller N,
 Weber R, Reiss P <i>et al</i>. Cardiovascular disease risk factors in HIV patie
nt - association with antiretroviral therapy. Results from the DAD study. Aids. 
2003; 17(8):1179-93.    ^cY#v15n2a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#105#101#article#116#</font></p>     ^
cY#v15n2a10.htm##
00599000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034700081002001300428#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#106#102#article#116#19#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Matthews GV, Mo
yle GJ, Mandalia S, Bower M, Nelson M, Gazzard BG. Absence of association betwee
n individual thymidine analogues or nonnucleoside analogues and lipid abnormalit
ies in HIV-1-infected persons on initial therapy. J Acquir Immune Defic Syndr. 2
000; 24(4):310-5.    ^cY#v15n2a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#107#103#article#116#</font></p>     ^
cY#v15n2a10.htm##
00525000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027300081002001300354#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#108#104#article#116#20#<p
><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. van der Valk M,
 Kastelein JJ, Murphy RL <i>et al</i>. Nevirapinecontaining antiretroviral thera
py in HIV-1 infected patients results in an anti-atherogenic lipid profile. Aids
. 2001; 15(18):2407-14.    ^cY#v15n2a10.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#109#105#article#116#</font></p>     ^
cY#v15n2a10.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#110#106#article#116#<p>&nbsp;</p>    
 ^cY#v15n2a10.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#111#107#article#116#<p>&nbsp;</p>    
 ^cY#v15n2a10.htm##
00426000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018900078002001300267#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#112#108#article#116#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><i
mg src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:
</b>    ^cY#v15n2a10.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011900078002001300197#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#113#109#article#116#<br> Max Weyler N
ery Departamento de Medicina da Pontif&iacute;cia Universidade Cat&oacute;lica d
e Goi&aacute;s    ^cY#v15n2a10.htm##
00324000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008700078002001300165#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#114#110#article#116#<br> Av. Universi
t&aacute;ria, 1440, Setor Universit&aacute;rio, &Aacute;rea IV    ^cY#v15n2a10.h
tm##
00301000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006400078002001300142#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#115#111#article#116#<br> CEP: 74.605-
010 Goi&acirc;nia, Goi&aacute;s, Brasil    ^cY#v15n2a10.htm##
00302000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006500078002001300143#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#116#112#article#116#<br> Phone: (62) 
3250 4000, 3250 4014 Fax: (62) 3250 4024    ^cY#v15n2a10.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008500078002001300163#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#117#113#article#116#<br> <a href="mai
lto:maxwnery@uol.com.br">maxwnery@uol.com.br</a></font></p>     ^cY#v15n2a10.htm
##
00332000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009500078002001300173#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#118#114#article#116#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted on: 03/05/2010    ^cY#v1
5n2a10.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#119#115#article#116#<br>   Approved o
n: 10/30/2010    ^cY#v15n2a10.htm##
00299000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006200078002001300140#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a10.htm#S#p#120#116#article#116#<br>   We declare
 no conflict of interest.</font></p>     ^cY#v15n2a10.htm##
00690000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100022000770100018000990100
01800117810000600135012014200141030001300283065000900296064001200305031000400317
032000300321014000700324865000900331002001300340035001000353801001300363#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#c#121#1#article#20#1#^rND^sPale
lla^nFJ, Jr#^rND^sDelaney^nKM#^rND^sMoorman^nAC#et al#Declining morbidity and mo
rtality among patients with advanced human immunodeficiency virus infection: HIV
 Outpatient Study Investigators^len#N Engl J Med#19980326#1998 Mar 26#338#13#853
-60#20110400#v15n2a10.htm#0028-4793#N Engl J Med##
00628000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100012000960100
01500108010002100123012011500144030001800259710000200277065000900279064000500288
031000200293032000200295014000700297865000900304002001300313#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a10.htm#S#c#122#2#article#20#2#^rND^sEnanoria^nWT#^rN
D^sNg^nC#^rND^sSaha^nSR#^rND^sColford^nJr JM#Treatment outcomes after highly act
ive antiretroviral therapy: a meta-analysis of randomised controlled trials^len#
Lancet Infect Dis#2#20040000#2004#4#7#414-25#20110400#v15n2a10.htm##
00521000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100017000910120
04600108030000700154065000900161064000500170031000400175032000500179014000800184
865000900192002001300201035001000214801000700224#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a10.htm#S#c#123#3#article#20#3#^rND^sCarr^nA#^rND^sCooper^nDA#Adv
erse effects of antiretroviral therapy^len#Lancet#20000000#2000#356#9239#1423-30
#20110400#v15n2a10.htm#0099-5355#Lancet##
00648000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100018000920100
01500110810000600125012011300131030001600244065000900260064000500269031000300274
032000200277014000700279865000900286002001300295035001000308801001600318#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#c#124#4#article#20#4#^rND^sWohl
^nDA#^rND^sMcComsey^nG#^rND^sTebas^nP#et al#Current concepts in the diagnosis an
d management of metabolic complications of HIV infection and its therapy^len#Cli
n Infect Dis#20060000#2006#43#5#645-53#20110400#v15n2a10.htm#1058-4838#Clin Infe
ct Dis##
00730000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100016000920100
01700108010001600125010001600141012015700157030001600314065000900330064000500339
03100030034403200020034701400070034986500090035600200130036503500100037880100160
0388#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#c#125#5#article#20#
5#^rND^sRhew^nDC#^rND^sBernal^nM#^rND^sAguilar^nD#^rND^sIloeje^nU#^rND^sGoetz^nM
B#Association between protease inhibitor use and increased cardiovascular risk i
n patients infected with human immunodeficiency virus: a systematic review^len#C
lin Infect Dis#20030000#2003#37#7#959-72#20110400#v15n2a10.htm#1058-4838#Clin In
fect Dis##
00681000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100015000920100
02100107810000600128012014400134030001600278065000900294064000500303031000300308
032000200311014000600313865000900319002001300328035001000341801001600351#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#c#126#6#article#20#6#^rND^sSave
s^nM#^rND^sChene^nG#^rND^sDucimetiere^nP#et al#Risk factors for coronary heart d
isease in patients treated for human immunodeficiency virus infection compared w
ith the general population^len#Clin Infect Dis#20030000#2003#37#2#292-8#20110400
#v15n2a10.htm#1058-4838#Clin Infect Dis##
00609000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100022000770100015000990100
01600114810000600130012007200136030001300208065000900221064000500230031000400235
032000300239014000800242865000900250002001300259035001000272801001300282#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#c#127#7#article#20#7#^rND^sFrii
s-Moller^nN#^rND^sReiss^nP#^rND^sSabin^nCA#et al#Class of antiretroviral drugs a
nd the risk of myocardial infarction^len#N Engl J Med#20070000#2007#356#17#1723-
35#20110400#v15n2a10.htm#0028-4793#N Engl J Med##
00635000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100018000960100
01700114010001800131012007400149030001800223065000900241064000500250031000300255
032000800258014000500266865000900271002001300280035001000293801001800303#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#c#128#8#article#20#8#^rND^sGran
geiro^nA#^rND^sTeixeira^nL#^rND^sBastos^nFI#^rND^sTeixeira^nP#Sustainability of 
Brazilian policy for access to antiretroviral drugs^len#Rev Saude Publica#200600
00#2006#40#^sSuppl#60-9#20110400#v15n2a10.htm#0034-8910#Rev Saude Publica##
00643000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
01800110010001900128012008400147030001800231065000900249064000500258031000300263
032000800266014000500274865000900279002001300288035001000301801001800311#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#c#129#9#article#20#9#^rND^sDour
ado^nI#^rND^sVeras^nMA#^rND^sBarreira^nD#^rND^sde Brito^nAM#AIDS epidemic trends
 after the introduction of antiretroviral therapy in Brazil^len#Rev Saude Public
a#20060000#2006#40#^sSuppl#9-17#20110400#v15n2a10.htm#0034-8910#Rev Saude Public
a##
00636000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100022000980100
01800120810000600138012012400144030001800268710000200286065000900288064000500297
031000200302032000200304014000600306865000900312002001300321#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a10.htm#S#c#130#10#article#20#10#^rND^sCaramelli^nB#^
rND^sde Bernoche^nCY#^rND^sSartori^nAM#et al#Hyperlipidemia related to the use o
f HIV-protease inhibitors: natural history and results of treatment with fenofib
rate^len#Braz J Infect Dis#2#20010000#2001#5#6#332-8#20110400#v15n2a10.htm##
00660000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100019001010100
01900120010001600139010001900155012011200174030001500286710000200301065000900303
064000500312031000200317032000200319020000300321865000900324002001300333#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#c#131#11#article#20#11#^rND^sAl
buquerque^nEM#^rND^sde Faria^nEC#^rND^sOliveira^nHC#^rND^sMagro^nDO#^rND^sCastil
ho^nLN#High frequency of Fredricksons phenotypes IV and IIb in Brazilians infect
ed by human immunodeficiency virus^len#BMC Infect Dis#2#20050000#2005#5#1#47#201
10400#v15n2a10.htm##
00761000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100029000990100
01600128010001700144010001900161010001900180012011200199030002800311065000900339
06400050034803100030035303200020035601400050035886500090036300200130037203500100
0385801002800395#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#c#132#1
2#article#20#12#^rND^sde Araujo^nPS#^rND^sde Alencar Ximenes^nRA#^rND^sLopes^nCF
#^rND^sDuarte^nJY#^rND^sda Silva^nMM#^rND^sCarneiro^nEM#Antiretroviral treatment
 for HIV infection/AIDS and the risk of developing hyperglycemia and hyperlipide
mia^len#Rev Inst Med Trop São Paulo#20070000#2007#49#2#73-8#20110400#v15n2a10.ht
m#0036-4665#Rev Inst Med Trop São Paulo##
00614000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760110004000790120161000830300
01700244065000900261064000500270031000300275032000400278014000500282865000900287
002001300296035001000309801001700319#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a10.htm#S#c#133#13#article#20#13#SBC#III Brazilian Guidelines on Dyslipidemia
s and Guideline of Atherosclerosis Prevention from Atherosclerosis Department of
 Sociedade Brasileira de Cardiologia^len#Arq Bras Cardiol#20010000#2001#77#^s3#1
-48#20110400#v15n2a10.htm#0066-782X#Arq Bras Cardiol##
00593000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01900115012007600134030001200210065000900222064000500231031000300236032000200239
014000600241865000900247002001300256035001000269801001200279#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a10.htm#S#c#134#14#article#20#14#^rND^sCastelli^nWP#^
rND^sAbbott^nRD#^rND^sMcNamara^nPM#Summary estimates of cholesterol used to pred
ict coronary heart disease^len#Circulation#19830000#1983#67#4#730-4#20110400#v15
n2a10.htm#0009-7322#Circulation##
00822000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01600110810000600126012028600132030001600418065000900434064000500443031000300448
032000200451014000700453865000900460002001300469035001000482801001600492#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#c#135#15#article#20#15#^rND^sDu
be^nMP#^rND^sStein^nJH#^rND^sAberg^nJA#et al#Guidelines for the evaluation and m
anagement of dyslipidemia in human immunodeficiency virus (HIV)-infected adults 
receiving antiretroviral therapy: recommendations of the HIV Medical Association
 of the Infectious Disease Society of America and the Adult AIDS Clinical Trials
 Group^len#Clin Infect Dis#20030000#2003#37#5#613-27#20110400#v15n2a10.htm#1058-
4838#Clin Infect Dis##
00680000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100021000960100
01400117010001900131010002100150010001700171012007000188030001200258065000900270
06400050027903100030028403200030028701400080029086500090029800200130030703500100
0320801001200330#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#c#136#1
6#article#20#16#^rND^sWilson^nPW#^rND^sD'Agostino^nRB#^rND^sLevy^nD#^rND^sBelang
er^nAM#^rND^sSilbershatz^nH#^rND^sKannel^nWB#Prediction of coronary heart diseas
e using risk factor categories^len#Circulation#19980000#1998#97#18#1837-47#20110
400#v15n2a10.htm#0009-7322#Circulation##
00702000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01600113810000600129012016700135030001300302065000900315064000500324031000400329
032000200333014000800335865000900343002001300352035001000365801001300375#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#c#137#17#article#20#17#^rND^sFo
ntas^nE#^rND^svan Leth^nF#^rND^sSabin^nCA#et al#Lipid profiles in HIV-infected p
atients receiving combination antiretroviral therapy: are different antiretrovir
al drugs associated with different lipid profiles?^len#J Infect Dis#20040000#200
4#189#6#1056-74#20110400#v15n2a10.htm#0022-1899#J Infect Dis##
00645000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100015001010100
01500116810000600131012012500137030000500262065000900267064000500276031000300281
032000200284014000800286865000900294002001300303035001000316801000500326#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#c#138#18#article#20#18#^rND^sFr
iis-Moller^nN#^rND^sWeber^nR#^rND^sReiss^nP#et al#Cardiovascular disease risk fa
ctors in HIV patient - association with antiretroviral therapy: Results from the
 DAD study^len#Aids#20030000#2003#17#8#1179-93#20110400#v15n2a10.htm#0269-9370#A
IDS##
00794000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01800114010001500132010001600147010001800163012016200181030002800343065000900371
06400050038003100030038503200020038801400060039086500090039600200130040503500100
0418801002800428#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#c#139#1
9#article#20#19#^rND^sMatthews^nGV#^rND^sMoyle^nGJ#^rND^sMandalia^nS#^rND^sBower
^nM#^rND^sNelson^nM#^rND^sGazzard^nBG#Absence of association between individual 
thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-
infected persons on initial therapy^len#J Acquir Immune Defic Syndr#20000000#200
0#24#4#310-5#20110400#v15n2a10.htm#0894-9255#J Acquir Immune Defic Syndr##
00648000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100020001010100
01700121810000600138012012000144030000500264065000900269064000500278031000300283
032000300286014000800289865000900297002001300306035001000319801000500329#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a10.htm#S#c#140#20#article#20#20#^rND^sva
n der Valk^nM#^rND^sKastelein^nJJ#^rND^sMurphy^nRL#et al#Nevirapinecontaining an
tiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic l
ipid profile^len#Aids#20010000#2001#15#18#2407-14#20110400#v15n2a10.htm#0269-937
0#AIDS##
00274000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00300101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#o#1#1#article#1
#20110406#125356#v15n2a11.htm#93##
03087000000000685000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400110014503500100015601201650
01660100049003310100034003800100032004140100037004460100037004830100030005200700
04100550070007900591070010600670070010600776070012000882083116301002085000802165
08500160217308500360218908500310222508500210225608500170227708500170229411700060
23110720003023171120009023201110011023291140009023401130011023490580009023600580
00502369058000702374058000702381002001302388#v15n2#V:\SciELO\serial\bjid\v15n2\m
arkup\v15n2a11.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#11#BJID160#nd#Br
az J Infect Dis#15#2#20110400#^f156^l158#1413-8670#IL-6 and IL-8 in cerebrospina
l fluid from patients with aseptic meningitis and bacterial meningitis: their po
tential role as a marker for differential diagnosis^len#^rND^1A01 A02^nVitor Lae
rte Laerte^sPinto Junior#^rND^1A03^nMaria Cristina^sRebelo#^rND^1A04^nRachel Nov
aes^sGomes#^rND^1A04^nEdson Fernandes de^sAssis#^rND^1A04^nHugo C^sCastro-Faria-
Neto#^rND^1A05^nMarcio Neves^sBóia#Oswaldo Cruz Foundation^iA01^sDF^pBrazil#Cath
olic University of Brasília^iA02^1School of Medicine^cBrasília^sDF^pBrazil#São S
ebastião Infectious Diseases Institute^iA03^1Meningitis Reference Laboratory^cRi
o de Janeiro^pBrazil#Oswaldo Cruz Foundation^iA04^1Oswaldo Cruz Institute^2Imuno
farmacology Laboratory^cRio de Janeiro^pBrazil#Oswaldo Cruz Foundation^iA05^1Osw
aldo Cruz Institute^2Tropical Medicine Post-graduation Program^cRio de Janeiro^p
Brazil#^len^aCytokines are molecules that act as mediators of immune response; c
erebral spinal fluid (CSF) IL-6 is found in all meningeal inflammatory diseases,
 but IL-8 is associated with acute bacterial meningitis (ABM). A case control st
udy was done to ascertain the discriminatory power of these cytokines in differe
ntiating ABM from aseptic meningitis (AM); IL-6 and IL-8 CSF concentrations were
 tested through ELISA in samples collected from patients who underwent investiga
tion for meningitis. Sixty patients, 18 with AM, nine with bacteriologic confirm
ed ABM and 33 controls, assisted in 2005 (MA and controls) and 2007 (ABM) were i
ncluded. Differently from controls, IL-6 concentrations were increased both in M
A and ABM patients (p < 0.05). CSF IL-8 levels were higher in ABM than in AM and
 controls (p < 0.05). Discriminatory power in ABM as assessed by the area under 
receiver operator (ROC) curve was 0.951 for IL-8, using a cut-off of 1.685 ng/dL
 (100% of sensitivity and 94% of specificity). The CSF concentration of both IL-
6 and IL-8 are increased in the presence of meningeal inflammation, IL-8 could b
e an important tool to differentiate ABM from AM.#^dnd^i1#^tm^len^kCSF^i1#^tm^le
n^kinflammation meningitis^i1#^tm^len^kaseptic meningitis^i1#^tm^len^kbacteria^i
1#^tm^len^kIL-6^i1#^tm^len^kIL-8^i1#other#10#20100525#05/25/2010#20101113#11/13/
2010#PAPES IV#CNPq#FAPERJ#PRONEX#v15n2a11.htm##
03107000000000685000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400110014503500100015601201790
01660100049003450100034003940100032004280100037004600100037004970100030005340700
04100564070007900605070010600684070010600790070012000896083116901016085000802185
08500160219308500360220908500310224508500210227608500170229708500170231411700060
23310720003023371120009023401110011023491140009023601130011023690580009023800580
00502389058000702394058000702401002001302408#v15n2#V:\SciELO\serial\bjid\v15n2\m
arkup\v15n2a11.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#11#BJID160#nd#Br
az J Infect Dis#15#2#20110400#^f156^l158#1413-8670#<b>IL-6 and IL-8 in cerebrosp
inal fluid from patients with aseptic meningitis and bacterial meningitis</b>: <
b>their potential role as a marker for differential diagnosis</b>^len#^rND^1A01 
A02^nVitor Laerte Laerte^sPinto Junior#^rND^1A03^nMaria Cristina^sRebelo#^rND^1A
04^nRachel Novaes^sGomes#^rND^1A04^nEdson Fernandes de^sAssis#^rND^1A04^nHugo C^
sCastro-Faria-Neto#^rND^1A05^nMarcio Neves^sBóia#Oswaldo Cruz Foundation^iA01^sD
F^pBrazil#Catholic University of Brasília^iA02^1School of Medicine^cBrasília^sDF
^pBrazil#São Sebastião Infectious Diseases Institute^iA03^1Meningitis Reference 
Laboratory^cRio de Janeiro^pBrazil#Oswaldo Cruz Foundation^iA04^1Oswaldo Cruz In
stitute^2Imunofarmacology Laboratory^cRio de Janeiro^pBrazil#Oswaldo Cruz Founda
tion^iA05^1Oswaldo Cruz Institute^2Tropical Medicine Post-graduation Program^cRi
o de Janeiro^pBrazil#^len^aCytokines are molecules that act as mediators of immu
ne response; cerebral spinal fluid (CSF) IL-6 is found in all meningeal inflamma
tory diseases, but IL-8 is associated with acute bacterial meningitis (ABM). A c
ase control study was done to ascertain the discriminatory power of these cytoki
nes in differentiating ABM from aseptic meningitis (AM); IL-6 and IL-8 CSF conce
ntrations were tested through ELISA in samples collected from patients who under
went investigation for meningitis. Sixty patients, 18 with AM, nine with bacteri
ologic confirmed ABM and 33 controls, assisted in 2005 (MA and controls) and 200
7 (ABM) were included. Differently from controls, IL-6 concentrations were incre
ased both in MA and ABM patients (p &lt; 0.05). CSF IL-8 levels were higher in A
BM than in AM and controls (p &lt; 0.05). Discriminatory power in ABM as assesse
d by the area under receiver operator (ROC) curve was 0.951 for IL-8, using a cu
t-off of 1.685 ng/dL (100% of sensitivity and 94% of specificity). The CSF conce
ntration of both IL-6 and IL-8 are increased in the presence of meningeal inflam
mation, IL-8 could be an important tool to differentiate ABM from AM.#^dnd^i1#^t
m^len^kCSF^i1#^tm^len^kinflammation meningitis^i1#^tm^len^kaseptic meningitis^i1
#^tm^len^kbacteria^i1#^tm^len^kIL-6^i1#^tm^len^kIL-8^i1#other#10#20100525#05/25/
2010#20101113#11/13/2010#PAPES IV#CNPq#FAPERJ#PRONEX#v15n2a11.htm##
03245000000000709000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000210013103100030015203200020015506500090015701400110016603500100
01770120165001870100049003520100034004010100032004350100037004670100037005040100
03000541070004300571070008100614070010800695070010800803070012200911083117701033
08500080221008500160221808500360223408500310227008500210230108500170232208500170
23391170006023560720003023621120009023651110011023741140009023851130011023940580
00902405058000502414058000702419058000702426002001302433008008902446#v15n2#V:\Sc
iELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#l#4#1#article#1#^mMar./Apr.^a2011#o
a#en#br1.1#1#4.0#ilus#tab#11#BJID160#nd#Braz. j. infect. dis#15#2#20110400#^f156
^l158#1413-8670#IL-6 and IL-8 in cerebrospinal fluid from patients with aseptic 
meningitis and bacterial meningitis: their potential role as a marker for differ
ential diagnosis^len#^rND^1A01 A02^nVitor Laerte Laerte^sPinto Junior#^rND^1A03^
nMaria Cristina^sRebelo#^rND^1A04^nRachel Novaes^sGomes#^rND^1A04^nEdson Fernand
es de^sAssis#^rND^1A04^nHugo C^sCastro-Faria-Neto#^rND^1A05^nMarcio Neves^sBóia#
^iA01^1Oswaldo Cruz Foundation^sDF^pBrazil#^iA02^1Catholic University of Brasíli
a^2School of Medicine^cBrasília^sDF^pBrazil#^iA03^1São Sebastião Infectious Dise
ases Institute^2Meningitis Reference Laboratory^cRio de Janeiro^pBrazil#^iA04^1O
swaldo Cruz Foundation^2Oswaldo Cruz Institute^3Imunofarmacology Laboratory^cRio
 de Janeiro^pBrazil#^iA05^1Oswaldo Cruz Foundation^2Oswaldo Cruz Institute^3Trop
ical Medicine Post-graduation Program^cRio de Janeiro^pBrazil#^len^aCytokines ar
e molecules that act as mediators of immune response; cerebral spinal fluid (CSF
) IL-6 is found in all meningeal inflammatory diseases, but IL-8 is associated w
ith acute bacterial meningitis (ABM). A case control study was done to ascertain
 the discriminatory power of these cytokines in differentiating ABM from aseptic
 meningitis (AM); IL-6 and IL-8 CSF concentrations were tested through ELISA in 
samples collected from patients who underwent investigation for meningitis. Sixt
y patients, 18 with AM, nine with bacteriologic confirmed ABM and 33 controls, a
ssisted in 2005 (MA and controls) and 2007 (ABM) were included. Differently from
 controls, IL-6 concentrations were increased both in MA and ABM patients (p < 0
.05). CSF IL-8 levels were higher in ABM than in AM and controls (p < 0.05). Dis
criminatory power in ABM as assessed by the area under receiver operator (ROC) c
urve was 0.951 for IL-8, using a cut-off of 1.685 ng/dL (100 percent of sensitiv
ity and 94 percent of specificity). The CSF concentration of both IL-6 and IL-8 
are increased in the presence of meningeal inflammation, IL-8 could be an import
ant tool to differentiate ABM from AM.#^dnd^i1#^tm^len^kCSF^i1#^tm^len^kinflamma
tion meningitis^i1#^tm^len^kaseptic meningitis^i1#^tm^len^kbacteria^i1#^tm^len^k
IL-6^i1#^tm^len^kIL-8^i1#other#10#20100525#05/25/2010#20101113#11/13/2010#PAPES 
IV#CNPq#FAPERJ#PRONEX#v15n2a11.htm#Internet^ihttp://www.scielo.br/scielo.php?scr
ipt=sci_arttext&pid=S1413-86702011000200011##
00355000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704012300073002001300196#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#5#1#article#79#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>BRIEF COMMUNICATION</b
></font></p>     ^cY#v15n2a11.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#6#2#article#79#<p>&nbsp;</p>     ^cY#
v15n2a11.htm##
00500000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704026800073002001300341#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#7#3#article#79#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>IL-6 and IL-8 in c
erebrospinal fluid from patients with aseptic meningitis and bacterial meningiti
s: their potential role as a marker for differential diagnosis</b></font></p>   
  ^cY#v15n2a11.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#8#4#article#79#<p>&nbsp;</p>     ^cY#
v15n2a11.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#9#5#article#79#<p>&nbsp;</p>     ^cY#
v15n2a11.htm##
00557000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704032400074002001300398#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#10#6#article#79#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Vitor Laerte Laerte Pinto Junior<su
p>I</sup>; Maria Cristina Rebelo<sup>II</sup>; Rachel Novaes Gomes<sup>III</sup>
; Edson Fernandes de Assis<sup>III</sup>; Hugo C Castro-Faria-Neto<sup>III</sup>
; Marcio Neves B&oacute;ia<sup>IV</sup></b></font></p>     ^cY#v15n2a11.htm##
00465000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704023200074002001300306#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#11#7#article#79#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>MD, PhD, Oswaldo Cruz Foun
dation, Bras&iacute;lia, DF, Brazil School of Medicine, Catholic University of B
ras&iacute;lia, Bras&iacute;lia, DF, Brazil    ^cY#v15n2a11.htm##
00373000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704014000074002001300214#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#12#8#article#79#<br> <sup>II</sup>Men
ingitis Reference Laboratory, S&atilde;o Sebasti&atilde;o Infectious Diseases In
stitute, Rio de Janeiro, Brazil    ^cY#v15n2a11.htm##
00372000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704013900074002001300213#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#13#9#article#79#<br>   <sup>III</sup>
MSc, PhD, Imunofarmacology Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foun
dation, Rio de Janeiro, Brazil    ^cY#v15n2a11.htm##
00396000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704016200075002001300237#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#14#10#article#79#<br>   <sup>IV</sup>
MD, PhD Tropical Medicine Post-graduation Program, Oswaldo Cruz Institute, Oswal
do Cruz Foundation, Rio de Janeiro, Brazil</font></p>     ^cY#v15n2a11.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011800075002001300193#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#15#11#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a></
font></p>     ^cY#v15n2a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#16#12#article#79#<p>&nbsp;</p>     ^c
Y#v15n2a11.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004400075002001300119#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#17#13#article#79#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v15n2a11.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009800075002001300173#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#18#14#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v1
5n2a11.htm##
01479000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704124500075002001301320#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#19#15#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Cytokines are molecules that act as m
ediators of immune response; cerebral spinal fluid (CSF) IL-6 is found in all me
ningeal inflammatory diseases, but IL-8 is associated with acute bacterial menin
gitis (ABM). A case control study was done to ascertain the discriminatory power
 of these cytokines in differentiating ABM from aseptic meningitis (AM); IL-6 an
d IL-8 CSF concentrations were tested through ELISA in samples collected from pa
tients who underwent investigation for meningitis. Sixty patients, 18 with AM, n
ine with bacteriologic confirmed ABM and 33 controls, assisted in 2005 (MA and c
ontrols) and 2007 (ABM) were included. Differently from controls, IL-6 concentra
tions were increased both in MA and ABM patients (p &lt; 0.05). CSF IL-8 levels 
were higher in ABM than in AM and controls (p &lt; 0.05). Discriminatory power i
n ABM as assessed by the area under receiver operator (ROC) curve was 0.951 for 
IL-8, using a cut-off of 1.685 ng/dL (100% of sensitivity and 94% of specificity
). The CSF concentration of both IL-6 and IL-8 are increased in the presence of 
meningeal inflammation, IL-8 could be an important tool to differentiate ABM fro
m AM.</font></p>     ^cY#v15n2a11.htm##
00427000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704019300075002001300268#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#20#16#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> CSF; inflammation me
ningitis; aseptic meningitis; bacteria; IL-6; IL-8.</font></p> <hr size="1" nosh
ade>     ^cY#v15n2a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#21#17#article#79#<p>&nbsp;</p>     ^c
Y#v15n2a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#22#18#article#79#<p>&nbsp;</p>     ^c
Y#v15n2a11.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011000075002001300185#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#23#19#article#79#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>INTRODUCTION </b></i></font></p
>     ^cY#v15n2a11.htm##
00755000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704052100075002001300596#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#24#20#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Cytokines are molecules involved in t
he modulation   of immune and inflammatory processes.   Interleukin-6 (IL-6) is 
a cytokine of both innate   and adaptive immunity and exerts diverse   actions. 
The main cellular action of IL-6 is to   stimulate the growth of B lymphocytes w
hich   have differentiated into antibody producing   cells. Interleukin-8 (IL-8)
 acts as chemoattractant for neutrophils to the site of inflammation.<sup>1</sup
></font></p>     ^cY#v15n2a11.htm##
00859000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704062500075002001300700#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#25#21#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Elevated CSF cytokine levels are undi
sputed   markers of meningeal inflammation,<sup>2</sup> but a   specific profile
 of cytokine concentration for   differential diagnostic purposes is not yet ava
ilable.   CSF levels of IL-6 are indiscriminately elevated   in all kinds of men
ingitis,<sup>3</sup> and do not   contribute to this purpose. Some studies that 
  measured CSF IL-8 concentrations found high   levels of this chemokine associa
ted mainly   with bacterial meningitis, but its role in aseptic meningitis remai
ns elusive.<sup>4,5</sup></font></p>     ^cY#v15n2a11.htm##
00953000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704071900075002001300794#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#26#22#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Differentiation between aseptic menin
gitis   and acute bacterial meningitis (ABM) in some   instances can be puzzling
. The search for clinical   markers and laboratory tests to help in this   task 
is crucial in order to optimize the treatment   of these conditions. A suitable 
diagnostic   tool has been pursued for many years, but until   now little has be
en added to clinical practice.<sup>6-8</sup>   The importance of an early differ
entiation   between these two conditions resides in the   choice of the proper t
reatment regimen and in   the need for inpatient care, especially in ABM, which 
has a poor prognosis if left untreated.</font></p>     ^cY#v15n2a11.htm##
00594000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704036000075002001300435#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#27#23#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The aim of our study was to measure C
SF   IL-6 and IL-8 in patients with aseptic meningitis,   bacterial meningitis a
nd normal controls in   order to investigate these cytokines as potential   tool
s in the differential diagnosis of bacterial meningitis from aseptic meningitis.
</font></p>     ^cY#v15n2a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#28#24#article#79#<p>&nbsp;</p>     ^c
Y#v15n2a11.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011000075002001300185#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#29#25#article#79#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>PATIENTS AND METHODS</b></font></p
>     ^cY#v15n2a11.htm##
01229000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704099500075002001301070#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#30#26#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">We performed a case-control study wit
h CSF   samples from patients assisted in <i>Instituto Estadual   de Infectologi
a</i> S&atilde;o Sebasti&atilde;o (IEISS),   the referral center for infectious 
diseases in   Rio de Janeiro State. AM and control samples   were collected duri
ng the year of 2005,   whereas ABM CSF samples were collected in 2007. Sixty pat
ients were selected, 18 had aseptic meningitis, nine had confirmed laboratorial 
diagnosis of meningitis caused by <i>Neisseria meningitidis</i>, and 33 had no m
eningitis (controls). The diagnostic criteria for aseptic meningitis were CSF to
tal leukocyte count above five cells, negative bacteriological tests and a clini
cal condition compatible with meningitis. Patients with bacterial meningitis wer
e selected on the grounds of a positive CSF culture or a reactive latex for <i>N
. meningitidis</i>. Controls were included if the CSF analyses were normal.</fon
t></p>     ^cY#v15n2a11.htm##
00518000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704028400075002001300359#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#31#27#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">This study was designed according to 
Brazilian laws for research involving human beings and was approved by the Ethic
al Committee of Evandro Chagas Clinical Research Institute, FIOCRUZ, Rio de Jane
iro.</font></p>     ^cY#v15n2a11.htm##
00732000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704049800075002001300573#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#32#28#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">CSF samples were selected by simple r
andom sampling from patients undergoing evaluation for meningitis. No patient wa
s submitted to lumbar puncture only for the purpose of collecting samples for th
e study. The CSF was analyzed for cellular content, protein and glucose levels a
nd bacteriological tests using laboratory routine methods. CSF was stored at -20
ºC and centrifuged for cytokine concentration measurement.</font></p>     ^cY#v1
5n2a11.htm##
00614000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704038000075002001300455#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#33#29#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">We performed IL-6 and IL-8 measuremen
ts from CSF samples by ELISA using specific monoclonal antibodies (Duo set kit -
 R&amp;D systems) according to the manufacturer's instructions. The results were
 analyzed by Soft Max Pro software based on the concentrations of the standard c
urves of each assay.</font></p>     ^cY#v15n2a11.htm##
00876000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704064200075002001300717#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#34#30#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Statistical analyses were performed u
sing SPSS for Windows 13.0 (SPSS Inc., Chicago, IL, USA). Measurements of centra
l tendency and dispersion for continuous variables (median, standard deviation a
nd range) were used and comparisons between them were tested using Mann-Whitney 
U-test. Receiver operating characteristic curve (ROC) was computed, and the area
 under the ROC curve (AUROC) was used to evaluate the ability of IL-8 to discrim
inate bacterial meningitis from aseptic meningitis. The optimum cut-off was defi
ned as the value that maximized the AUROC.</font></p>     ^cY#v15n2a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#35#31#article#79#<p>&nbsp;</p>     ^c
Y#v15n2a11.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010400075002001300179#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#36#32#article#79#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>RESULTS</b></i></font></p>     
^cY#v15n2a11.htm##
00688000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704045400075002001300529#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#37#33#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">We analyzed 60 CSF samples; the demog
raphical characteristics, the results for routine CSF analysis and IL-6/IL-8 ass
ay results are shown in <a href="/img/revistas/bjid/v15n2/a11tab01.jpg">Table 1<
/a>. The groups had no statistically significant difference in demographic aspec
ts (p &gt; 0.05), but they were different regarding CSF inflammatory parameters 
(p &lt; 0.05).</font></p>     ^cY#v15n2a11.htm##
00823000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704058900075002001300664#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#38#34#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">IL-6 concentrations were very similar
 between aseptic meningitis and bacterial meningitis cases, with no significant 
difference (p &gt; 0.05). Conversely, CSF IL-8 concentrations were higher in the
 bacterial meningitis group with a significant difference when compared to the a
septic meningitis group (p &lt; 0.05). Both IL-6 and IL-8 concentrations in meni
ngitis cases (aseptic and bacterial) were markedly different from the concentrat
ions found in the CSF of patients in the control group (p &lt; 0.05).</font></p>
     ^cY#v15n2a11.htm##
00776000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704054200075002001300617#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#39#35#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">We calculated the area under the ROC 
curve to analyze the power of IL-8 to discriminate bacterial meningitis from ase
ptic meningitis. IL-8 appeared as an excellent marker for differentiating ABM fr
om AM (AUROC = 0.95, 95% CI = 0.855 to 1.046; p &lt; 0.05) when the cut-off leve
l of 1.685 ng/dL was used. At this cut-off, IL-8 had 100% sensitivity and 94% sp
ecificity. AUROC for others CSF inflammatory parameters are summarized in <a hre
f="#tab2">Table 2</a>.</font></p>     ^cY#v15n2a11.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003500075002001300110#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#40#36#article#79#<p><a name="tab2"></
a></p>     ^cY#v15n2a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#41#37#article#79#<p>&nbsp;</p>     ^c
Y#v15n2a11.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704008000075002001300155#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#42#38#article#79#<p align="center"><i
mg src="/img/revistas/bjid/v15n2/a11tab02.jpg"></p>     ^cY#v15n2a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#43#39#article#79#<p>&nbsp;</p>     ^c
Y#v15n2a11.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010700075002001300182#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#44#40#article#79#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>DISCUSSION</b></i></font></p>  
   ^cY#v15n2a11.htm##
00710000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704047600075002001300551#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#45#41#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">In our study, we found that IL-6 and 
IL-8 are important inflammatory mediators in all cases with meningitis. CSF conc
entrations of these molecules in meningitis cases were significantly different w
hen compared to the control group. Analyzing these mediators individually we fou
nd that CSF IL-8 concentration in ABM at the moment of diagnosis was markedly hi
gher than in AM group (p &lt; 0.05).</font></p>     ^cY#v15n2a11.htm##
00608000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704037400075002001300449#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#46#42#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">As a retrospective study performed in
 a referral center, selection bias is a possible methodological problem, but the
 different groups were comparable. Another possible limitation was the lack of e
tiological diagnosis of AM cases, even without laboratorial evidence of bacteria
l involvement.</font></p>     ^cY#v15n2a11.htm##
01740000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704150600075002001301581#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#47#43#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">IL-6 concentrations were higher in bo
th AM and ABM groups demonstrating that this molecule acts as mediator in mening
eal inflammation, serving as a non-specific inflammatory marker.<sup>9</sup> Thi
s is in agreement with other studies which also compared the levels of IL-6 in c
ases of bacterial and aseptic meningitis and did not find significant difference
s.<sup>3,10</sup> CSF IL-8 measurement in these two types of meningitis were per
formed in a study conducted by Lopez-Cortez <i>et al.</i> in 1995.<sup>4</sup> P
atients with bacterial meningitis had higher concentrations of this chemokine in
 CSF compared to AM cases. The authors suggested a cut-off of 2.5 ng/dL for CSF 
IL-8 concentration using only the dispersion graph for this concentration. Osteg
aard <i>et al.</i> in 1996 conducted a study in which CSF IL-8 concentrations we
re also compared between these two groups of patients and controls concluding th
at IL-8 concentrations were higher in the ABM group. In our study we determined 
the value of 1.685 ng/dL as the best cut-off, performing a ROC curve, which is d
esigned for this purpose. The accuracy of this cut-off was also excellent. It is
 important to note that cut-off values for IL-8 may vary depending on variations
 of the methodology or reagents used, and before standardized tests are availabl
e one must determine the specific cut-off value under the conditions employed to
 ensure the best accuracy.</font></p>     ^cY#v15n2a11.htm##
00782000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704054800075002001300623#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#48#44#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">In order to confirm whether the measu
rement of CSF IL-8 had the power to discriminate bacterial meningitis from asept
ic meningitis, we have performed the AUROC for CSF protein level and total leuko
cyte count which are of indisputable importance in the differential diagnosis of
 acute meningitis. The AUROC evidenced that IL-8 had the same power of CSF prote
in, leukocyte count and glucose level. CSF IL-6 concentration showed little util
ity in this differentiation.</font></p>     ^cY#v15n2a11.htm##
00849000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704061500075002001300690#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#49#45#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The cost for cytokines determination 
in biological samples has decreased significantly over the past decade as availa
bility has increased. In fact, it will probably decrease even further if measure
ments of cytokines become standard clinical analysis in the hospital setting. Im
portantly, IL-8 measurements is not a substitute for CSF protein, glucose or leu
kocyte determinations, but rather an additional and useful input information tha
t may help diagnosis in cases where a clear diagnosis cannot be reached by stand
ard techniques.</font></p>     ^cY#v15n2a11.htm##
00896000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704066200075002001300737#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#50#46#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Differential diagnosis between asepti
c and bacterial meningitis in some instances can be difficult. A trustworthy lab
oratory marker would facilitate the clinical decision of interrupting antimicrob
ial therapy and avoiding unnecessary hospitalization. CSF IL-8 concentrations ab
ove 1.685 ng/dL would indicate bacterial meningitis confirming other clinical an
d laboratory findings. More studies performed in suitable models of meningitis a
re needed in order to establish the routine use of inflammatory markers in the d
iagnosis of infectious diseases of the central nervous system.</font></p>     ^c
Y#v15n2a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#51#47#article#79#<p>&nbsp;</p>     ^c
Y#v15n2a11.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010700075002001300182#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#52#48#article#79#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p>  
   ^cY#v15n2a11.htm##
00434000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704018600077002001300263#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#53#49#article#79#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Abbas AK, Lichtman A
H, Pillai S. Cellular and molecular immunology. 6 ed. Philadelphia: Saunders Els
evier; 2007.    ^cY#v15n2a11.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#54#50#article#79#</font></p>     ^cY#
v15n2a11.htm##
00499000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704025100077002001300328#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#55#51#article#79#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Nagafuchi M, Nagafuc
hi Y, Sato R <i>et al.</i> Adult meningism and viral meningitis, 1997-2004: clin
ical data and cerebrospinal fluid cytokines. Intern Med 2006; 45(21):1209-12.   
 ^cY#v15n2a11.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#56#52#article#79#</font></p>     ^cY#
v15n2a11.htm##
00564000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704031600077002001300393#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#57#53#article#79#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Lopez-Cortes LF, Cru
z-Ruiz M, Gomez-Mateos J <i>et al</i>. Interleukin 6 in cerebrospinal fluid of p
atients with meningitis is not a useful diagnostic marker in the differential di
agnosis of meningitis. Ann Clin Biochem 1997; 34 (Pt 2):165-9.    ^cY#v15n2a11.h
tm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#58#54#article#79#</font></p>     ^cY#
v15n2a11.htm##
00594000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704034600077002001300423#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#59#55#article#79#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Lopez-Cortes LF, Cru
z-Ruiz M, Gomez-Mateos J, Viciana-Fernandez P, Martinez-Marcos FJ, Pachon J. Int
erleukin-8 in cerebrospinal fluid from patients with meningitis of different eti
ologies: its possible role as neutrophil chemotactic factor. J Infect Dis 1995;1
72(2):581-4.    ^cY#v15n2a11.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#60#56#article#79#</font></p>     ^cY#
v15n2a11.htm##
00463000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704021500077002001300292#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#61#57#article#79#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Seki T, Joh K, Oh-is
hi T. Augmented production of interleukin-8 in cerebrospinal fluid in bacterial 
meningitis. Immunology 1993; 80(2):333-5.    ^cY#v15n2a11.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#62#58#article#79#</font></p>     ^cY#
v15n2a11.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704027800077002001300355#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#63#59#article#79#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Nigrovic LE, Kupperm
ann N, Macias CG <i>et al.</i> Clinical prediction rule for identifying children
 with cerebrospinal fluid pleocytosis at very low risk of bacterial meningitis. 
Jama 2007; 297(1):52-60.    ^cY#v15n2a11.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#64#60#article#79#</font></p>     ^cY#
v15n2a11.htm##
00534000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704028600077002001300363#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#65#61#article#79#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Ostergaard C, Benfie
ld TL, Sellebjerg F, Kronborg G, Lohse N, Lundgren JD. Interleukin-8 in cerebros
pinal fluid from patients with septic and aseptic meningitis. Eur J Clin Microbi
ol Infect Dis 1996; 15(2):166-9.    ^cY#v15n2a11.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#66#62#article#79#</font></p>     ^cY#
v15n2a11.htm##
00491000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704024300077002001300320#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#67#63#article#79#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Spanos A, Harrell FE
, Jr., Durack DT. Differential diagnosis of acute meningitis. An analysis of the
 predictive value of initial observations. Jama 1989; 262(19):2700-7.    ^cY#v15
n2a11.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#68#64#article#79#</font></p>     ^cY#
v15n2a11.htm##
00500000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704025200077002001300329#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#69#65#article#79#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Chavanet P, Bonnotte
 B, Guiguet M <i>et al.</i> High concentrations of intrathecal interleukin-6 in 
human bacterial and nonbacterial meningitis. J Infect Dis 1992; 166(2):428-31.  
  ^cY#v15n2a11.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#70#66#article#79#</font></p>     ^cY#
v15n2a11.htm##
00482000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704023300078002001300311#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#71#67#article#79#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Mukai AO, Krebs VL
, Bertoli CJ, Okay TS. TNF-alpha and IL-6 in the diagnosis of bacterial and asep
tic meningitis in children. Pediatr Neurol 2006; 34(1):25-9.    ^cY#v15n2a11.htm
##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#72#68#article#79#</font></p>     ^cY#
v15n2a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#73#69#article#79#<p>&nbsp;</p>     ^c
Y#v15n2a11.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#74#70#article#79#<p>&nbsp;</p>     ^c
Y#v15n2a11.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704018900075002001300264#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#75#71#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img 
src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:</b
>    ^cY#v15n2a11.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003800075002001300113#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#76#72#article#79#<br> Vitor Laerte Pi
nto Junior    ^cY#v15n2a11.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704012200075002001300197#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#77#73#article#79#<br> Oswaldo Cruz Fo
undation - Bras&iacute;lia University Campus Darcy Ribeiro, UnB Postal Box 04311
 ZIP 70904-970    ^cY#v15n2a11.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003800075002001300113#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#78#74#article#79#<br> Phone/fax: 55 6
1 33294600    ^cY#v15n2a11.htm##
00325000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009100075002001300166#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#79#75#article#79#<br> <a href="mailto
:vitorlaerte@fiocruz.br">vitorlaerte@fiocruz.br</a></font></p>     ^cY#v15n2a11.
htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009500075002001300170#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#80#76#article#79#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Submitted on: 05/25/2010    ^cY#v15n2
a11.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003800075002001300113#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#81#77#article#79#<br>   Approved on: 
11/13/2010    ^cY#v15n2a11.htm##
00298000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006400075002001300139#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#82#78#article#79#<br>   Financial Sup
port: PAPES IV; CNPq, FAPERJ, PRONEX    ^cY#v15n2a11.htm##
00296000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006200075002001300137#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a11.htm#S#p#83#79#article#79#<br>   We declare no
 conflict of interest.</font></p>     ^cY#v15n2a11.htm##
00500000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740160016000760160019000920160
01600111018003800127063000200165066001300167062001800180065000900198064000500207
865000900212002001300221#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S
#c#84#1#article#10#1#^rND^sAbbas^nAK#^rND^sLichtman^nAH#^rND^sPillai^nS#Cellular
 and molecular immunology^len#6#Philadelphia#Saunders Elsevier#20070000#2007#201
10400#v15n2a11.htm##
00631000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100019000760100019000950100
01400114810000600128012010100134030001100235065000900246064000500255031000300260
032000300263014000800266865000900274002001300283035001000296801001100306#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#c#85#2#article#10#2#^rND^sNagaf
uchi^nM#^rND^sNagafuchi^nY#^rND^sSato^nR#et al#Adult meningism and viral meningi
tis, 1997-2004: clinical data and cerebrospinal fluid cytokines^len#Intern Med#2
0060000#2006#45#21#1209-12#20110400#v15n2a11.htm#0918-2918#Intern Med##
00698000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100023000760100019000990100
02200118810000600140012014700146030001700293065000900310064000500319031000300324
061000200327014000600329865000900335002001300344035001000357801001700367#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#c#86#3#article#10#3#^rND^sLopez
-Cortes^nLF#^rND^sCruz-Ruiz^nM#^rND^sGomez-Mateos^nJ#et al#Interleukin 6 in cere
brospinal fluid of patients with meningitis is not a useful diagnostic marker in
 the differential diagnosis of meningitis^len#Ann Clin Biochem#19970000#1997#34#
2#165-9#20110400#v15n2a11.htm#0004-5632#Ann Clin Biochem##
00778000000000337000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100023000760100019000990100
02200118010002700140010002600167010001600193012014700209030001300356065000900369
06400050037803100040038303200020038701400060038986500090039500200130040403500100
0417801001300427#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#c#87#4#
article#10#4#^rND^sLopez-Cortes^nLF#^rND^sCruz-Ruiz^nM#^rND^sGomez-Mateos^nJ#^rN
D^sViciana-Fernandez^nP#^rND^sMartinez-Marcos^nFJ#^rND^sPachon^nJ#Interleukin-8 
in cerebrospinal fluid from patients with meningitis of different etiologies: it
s possible role as neutrophil chemotactic factor^len#J Infect Dis#19950000#1995#
172#2#581-4#20110400#v15n2a11.htm#0022-1899#J Infect Dis##
00590000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100014000760100013000900100
01700103012008900120030001100209065000900220064000500229031000300234032000200237
014000600239865000900245002001300254035001000267801001100277#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a11.htm#S#c#88#5#article#10#5#^rND^sSeki^nT#^rND^sJoh
^nK#^rND^sOh-ishi^nT#Augmented production of interleukin-8 in cerebrospinal flui
d in bacterial meningitis^len#Immunology#19930000#1993#80#2#333-5#20110400#v15n2
a11.htm#0019-2805#Immunology##
00652000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100019000760100020000950100
01700115810000600132012013200138030000500270065000900275064000500284031000400289
032000200293014000600295865000900301002001300310035001000323801000500333#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#c#89#6#article#10#6#^rND^sNigro
vic^nLE#^rND^sKuppermann^nN#^rND^sMacias^nCG#et al#Clinical prediction rule for 
identifying children with cerebrospinal fluid pleocytosis at very low risk of ba
cterial meningitis^len#Jama#20070000#2007#297#1#52-60#20110400#v15n2a11.htm#0098
-7484#JAMA##
00736000000000337000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100020000760100019000960100
02000115010001800135010001500153010001900168012009000187030003200277065000900309
06400050031803100030032303200020032601400060032886500090033400200130034303500100
0356801003200366#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#c#90#7#
article#10#7#^rND^sOstergaard^nC#^rND^sBenfield^nTL#^rND^sSellebjerg^nF#^rND^sKr
onborg^nG#^rND^sLohse^nN#^rND^sLundgren^nJD#Interleukin-8 in cerebrospinal fluid
 from patients with septic and aseptic meningitis^len#Eur J Clin Microbiol Infec
t Dis#19960000#1996#15#2#166-9#20110400#v15n2a11.htm#0722-2211#Eur J Clin Microb
iol Infect Dis##
00611000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100016000760100022000920100
01700114012010800131030000500239065000900244064000500253031000400258032000300262
014000700265865000900272002001300281035001000294801000500304#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a11.htm#S#c#91#8#article#10#8#^rND^sSpanos^nA#^rND^sH
arrell^nFE, Jr#^rND^sDurack^nDT#Differential diagnosis of acute meningitis: An a
nalysis of the predictive value of initial observations^len#Jama#19890000#1989#2
62#19#2700-7#20110400#v15n2a11.htm#0098-7484#JAMA##
00634000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100018000760100018000940100
01700112810000600129012010000135030001300235065000900248064000500257031000400262
032000200266014000700268865000900275002001300284035001000297801001300307#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#c#92#9#article#10#9#^rND^sChava
net^nP#^rND^sBonnotte^nB#^rND^sGuiguet^nM#et al#High concentrations of intrathec
al interleukin-6 in human bacterial and nonbacterial meningitis^len#J Infect Dis
#19920000#1992#166#2#428-31#20110400#v15n2a11.htm#0022-1899#J Infect Dis##
00631000000000313000450000400060000070200480000670500020005470600020005670000030
00587010003000617090008000647080003000721180003000750100016000780100016000940100
01800110010001500128012008800143030001500231065000900246064000500255031000300260
032000200263014000500265865000900270002001300279035001000292801001500302#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a11.htm#S#c#93#10#article#10#10#^rND^sMuk
ai^nAO#^rND^sKrebs^nVL#^rND^sBertoli^nCJ#^rND^sOkay^nTS#TNF-alpha and IL-6 in th
e diagnosis of bacterial and aseptic meningitis in children^len#Pediatr Neurol#2
0060000#2006#34#1#25-9#20110400#v15n2a11.htm#0887-8994#Pediatr Neurol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#o#1#1#article#1
#20110406#125359#v15n2a12.htm#135##
03247000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030001800109
03100030012703200020013006500090013201400110014103500100015201200720016201000360
02340100035002700100038003050700091003430700119004340700066005530700065006190700
08400684070007300768083149600841085000802337085002402345085003002369085002502399
08500380242411700060246207200030246811200090247111100110248011400090249111300110
2500058006002511058006102571002001302632#v15n2#V:\SciELO\serial\bjid\v15n2\marku
p\v15n2a12.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#12#BJID160#nd#Braz J Inf
ect Dis#15#2#20110400#^f159^l162#1413-8670#Absence of occult hepatitis B among b
lood donors in southern Brazil^len#^rND^1A01 A02^nFernando Herz^sWolff#^rND^1A03
 A04^nSandra Costa^sFuchs#^rND^1A04 A05 A06^nAjacio BM^sBrandão#National Institu
te of Science and Technology for Health Technology Assessment^iA01^pBrazil#Unive
rsidade Federal do Rio Grande do Sul^iA02^1Faculdade de Medicina^2Post-graduatio
n Program in Epidemiology^pBrazil#UFRGS^iA03^1Faculdade de Medicina^2Departament
 of Social Medicine#Instituto de Avaliação de Tecnologias em Saúde^iA04^1UFRGS^2
HCPA#Universidade Federal de Ciências da Saúde de Porto Alegre^iA05^1Faculty of 
Medicine#UFCSPA^iA06^1Faculdade de Medicina^2Internal Medicine Department^pBrazi
l#^len^aBACKGROUND: Occult hepatitis B virus (HBV) infection is characterized by
 the detection of HBV DNA in serum and/or in liver in the absence of detectable 
hepatitis B surface antigen (HBsAg). The reported prevalence of occult hepatitis
 B varies markedly among populations and according to the sensitivity of the HBV
 DNA assay. The aim of the present study was to describe the prevalence of occul
t hepatitis B among HCV-infected and non-infected blood donors in Porto Alegre, 
Southern Brazil, using a highly sensitive real time polymerase chain reaction (P
CR) method. METHODOLOGY: Between 1995 and 1997 a sample of 178 blood donors with
 two positive anti-HCV ELISA tests were consecutively selected as cases, and 356
 anti-HCV negative donors were selected as controls. Blood donors were randomly 
selected from eight blood centers in Porto Alegre, Southern Brazil, representati
ve of the whole blood donor population. Blood samples were kept at 70ºC and defr
osted for the first time for the analysis of this report. Tests previously perfo
rmed in the laboratory using the same real time PCR for HBV DNA had sensitivity 
for detecting as low as 9 copies/mL. Among 158 blood samples from HBsAg-negative
 blood donors, five were anti-HBc positive, 53 tested positive for anti-HCV and 
105 had anti-HCV negative. The samples analysis was performed in duplicate and a
ll blood samples tested negative for HBV DNA. CONCLUSION: The result reflects a 
very low prevalence of occult hepatitis B in our setting.#^dnd^i1#^tm^len^khepat
itis B^i1#^tm^len^khepatitis B virus^i1#^tm^len^kblood donors^i1#^tm^len^kseroep
idemiologic studies^i1#other#23#20100621#06/21/2010#20100712#07/12/2010#Coordena
ção de Aperfeiçoamento de Pessoal de Nível Superior#National Counsel of Technolo
gical and Scientific Development#v15n2a12.htm##
03275000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090121000300095049000800098158000300106030001800109
03100030012703200020013006500090013201400110014103500100015201200790016201000360
02410100035002770100038003120700091003500700119004410700066005600700065006260700
08400691070007300775083151700848085000802365085002402373085003002397085002502427
08500380245211700060249007200030249611200090249911100110250811400090251911300110
2528058006002539058006102599002001302660#v15n2#V:\SciELO\serial\bjid\v15n2\marku
p\v15n2a12.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#12#BJID160#nd#Braz J Inf
ect Dis#15#2#20110400#^f159^l162#1413-8670#<b>Absence of occult hepatitis B amon
g blood donors in southern Brazil</b>^len#^rND^1A01 A02^nFernando Herz^sWolff#^r
ND^1A03 A04^nSandra Costa^sFuchs#^rND^1A04 A05 A06^nAjacio BM^sBrandão#National 
Institute of Science and Technology for Health Technology Assessment^iA01^pBrazi
l#Universidade Federal do Rio Grande do Sul^iA02^1Faculdade de Medicina^2Post-gr
aduation Program in Epidemiology^pBrazil#UFRGS^iA03^1Faculdade de Medicina^2Depa
rtament of Social Medicine#Instituto de Avaliação de Tecnologias em Saúde^iA04^1
UFRGS^2HCPA#Universidade Federal de Ciências da Saúde de Porto Alegre^iA05^1Facu
lty of Medicine#UFCSPA^iA06^1Faculdade de Medicina^2Internal Medicine Department
^pBrazil#^len^a<b>BACKGROUND:</b> Occult hepatitis B virus (HBV) infection is ch
aracterized by the detection of HBV DNA in serum and/or in liver in the absence 
of detectable hepatitis B surface antigen (HBsAg). The reported prevalence of oc
cult hepatitis B varies markedly among populations and according to the sensitiv
ity of the HBV DNA assay. The aim of the present study was to describe the preva
lence of occult hepatitis B among HCV-infected and non-infected blood donors in 
Porto Alegre, Southern Brazil, using a highly sensitive real time polymerase cha
in reaction (PCR) method. <b>METHODOLOGY:</b> Between 1995 and 1997 a sample of 
178 blood donors with two positive anti-HCV ELISA tests were consecutively selec
ted as cases, and 356 anti-HCV negative donors were selected as controls. Blood 
donors were randomly selected from eight blood centers in Porto Alegre, Southern
 Brazil, representative of the whole blood donor population. Blood samples were 
kept at 70ºC and defrosted for the first time for the analysis of this report. T
ests previously performed in the laboratory using the same real time PCR for HBV
 DNA had sensitivity for detecting as low as 9 copies/mL. Among 158 blood sample
s from HBsAg-negative blood donors, five were anti-HBc positive, 53 tested posit
ive for anti-HCV and 105 had anti-HCV negative. The samples analysis was perform
ed in duplicate and all blood samples tested negative for HBV DNA. <b>CONCLUSION
:</b> The result reflects a very low prevalence of occult hepatitis B in our set
ting.#^dnd^i1#^tm^len^khepatitis B^i1#^tm^len^khepatitis B virus^i1#^tm^len^kblo
od donors^i1#^tm^len^kseroepidemiologic studies^i1#other#23#20100621#06/21/2010#
20100712#07/12/2010#Coordenação de Aperfeiçoamento de Pessoal de Nível Superior#
National Counsel of Technological and Scientific Development#v15n2a12.htm##
03393000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108121000300113049000800116158000300124
03000210012703100030014803200020015106500090015301400110016203500100017301200720
01830100036002550100035002910100038003260700093003640700121004570700068005780700
06700646070008600713070007500799083149600874085000802370085002402378085003002402
08500250243208500380245711700060249507200030250111200090250411100110251311400090
2524113001102533058006002544058006102604002001302665008008902678#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#l#4#1#article#1#^mMar./Apr.^a2011#oa#en
#br1.1#1#4.0#ilus#12#BJID160#nd#Braz. j. infect. dis#15#2#20110400#^f159^l162#14
13-8670#Absence of occult hepatitis B among blood donors in southern Brazil^len#
^rND^1A01 A02^nFernando Herz^sWolff#^rND^1A03 A04^nSandra Costa^sFuchs#^rND^1A04
 A05 A06^nAjacio BM^sBrandão#^iA01^1National Institute of Science and Technology
 for Health Technology Assessment^pBrazil#^iA02^1Universidade Federal do Rio Gra
nde do Sul^2Faculdade de Medicina^3Post-graduation Program in Epidemiology^pBraz
il#^iA03^1UFRGS^2Faculdade de Medicina^3Departament of Social Medicine#^iA04^1In
stituto de Avaliação de Tecnologias em Saúde^2UFRGS^3HCPA#^iA05^1Universidade Fe
deral de Ciências da Saúde de Porto Alegre^2Faculty of Medicine#^iA06^1UFCSPA^2F
aculdade de Medicina^3Internal Medicine Department^pBrazil#^len^aBACKGROUND: Occ
ult hepatitis B virus (HBV) infection is characterized by the detection of HBV D
NA in serum and/or in liver in the absence of detectable hepatitis B surface ant
igen (HBsAg). The reported prevalence of occult hepatitis B varies markedly amon
g populations and according to the sensitivity of the HBV DNA assay. The aim of 
the present study was to describe the prevalence of occult hepatitis B among HCV
-infected and non-infected blood donors in Porto Alegre, Southern Brazil, using 
a highly sensitive real time polymerase chain reaction (PCR) method. METHODOLOGY
: Between 1995 and 1997 a sample of 178 blood donors with two positive anti-HCV 
ELISA tests were consecutively selected as cases, and 356 anti-HCV negative dono
rs were selected as controls. Blood donors were randomly selected from eight blo
od centers in Porto Alegre, Southern Brazil, representative of the whole blood d
onor population. Blood samples were kept at 70ºC and defrosted for the first tim
e for the analysis of this report. Tests previously performed in the laboratory 
using the same real time PCR for HBV DNA had sensitivity for detecting as low as
 9 copies/mL. Among 158 blood samples from HBsAg-negative blood donors, five wer
e anti-HBc positive, 53 tested positive for anti-HCV and 105 had anti-HCV negati
ve. The samples analysis was performed in duplicate and all blood samples tested
 negative for HBV DNA. CONCLUSION: The result reflects a very low prevalence of 
occult hepatitis B in our setting.#^dnd^i1#^tm^len^khepatitis B^i1#^tm^len^khepa
titis B virus^i1#^tm^len^kblood donors^i1#^tm^len^kseroepidemiologic studies^i1#
other#23#20100621#06/21/2010#20100712#07/12/2010#Coordenação de Aperfeiçoamento 
de Pessoal de Nível Superior#National Counsel of Technological and Scientific De
velopment#v15n2a12.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_artt
ext&pid=S1413-86702011000200012##
00356000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012300074002001300197#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#5#1#article#108#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>BRIEF COMMUNICATION</
b></font></p>     ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#6#2#article#108#<p>&nbsp;</p>     ^cY
#v15n2a12.htm##
00408000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704017500074002001300249#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#7#3#article#108#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Absence of occult
 hepatitis B among blood donors in southern Brazil</b></font></p>     ^cY#v15n2a
12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#8#4#article#108#<p>&nbsp;</p>     ^cY
#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#9#5#article#108#<p>&nbsp;</p>     ^cY
#v15n2a12.htm##
00428000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704019400075002001300269#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#10#6#article#108#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Fernando Herz Wolff<sup>I</sup>; S
andra Costa Fuchs<sup>II</sup>; Ajacio BM Brand&atilde;o<sup>III</sup></b></font
></p>     ^cY#v15n2a12.htm##
00565000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704033100075002001300406#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#11#7#article#108#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>MD, PhD. Researcher of th
e National Institute of Science and Technology for Health Technology Assessment 
(IATS) - CNPq/Brazil; Post-graduation Program in Epidemiology, Faculdade de Medi
cina, Universidade Federal do Rio Grande do Sul - UFRGS, Brazil    ^cY#v15n2a12.
htm##
00554000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704032000075002001300395#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#12#8#article#108#<br> <sup>II</sup>As
sociate Professor, Departament of Social Medicine, Faculdade de Medicina,UFRGS; 
Researcher, Instituto de Avalia&ccedil;&atilde;o de Tecnologias em Sa&uacute;de 
- HCPA/UFRGS/CNPQ; National Institute for Science and Technology for Health Tech
nology Assessment (IATS/ CNPq), Porto Alegre, Brazil    ^cY#v15n2a12.htm##
00573000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704033900075002001300414#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#13#9#article#108#<br> <sup>III</sup>D
irector, Faculty of Medicine and Associate Professor, Universidade Federal de Ci
&ecirc;ncias da Sa&uacute;de de Porto Alegre UFCSPA; Researcher, Instituto de Av
alia&ccedil;&atilde;o de Tecnologias em Sa&uacute;de - HCPA/UFRGS/CNPQ; Internal
 Medicine Department, Faculdade de Medicina, UFCSPA, Brazil</font></p>     ^cY#v
15n2a12.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#14#10#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a><
/font></p>     ^cY#v15n2a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#15#11#article#108#<p>&nbsp;</p>     ^
cY#v15n2a12.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#16#12#article#108#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v15n2a12.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#17#13#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
15n2a12.htm##
00876000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064100076002001300717#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#18#14#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>BACKGROUND:</b> Occult hepatitis 
B virus (HBV) infection is characterized by the detection of HBV DNA in serum an
d/or in liver in the absence of detectable hepatitis B surface antigen (HBsAg). 
The reported prevalence of occult hepatitis B varies markedly among populations 
and according to the sensitivity of the HBV DNA assay. The aim of the present st
udy was to describe the prevalence of occult hepatitis B among HCV-infected and 
non-infected blood donors in Porto Alegre, Southern Brazil, using a highly sensi
tive real time polymerase chain reaction (PCR) method.    ^cY#v15n2a12.htm##
01090000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085500076002001300931#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#19#15#article#108#<br>   <b>METHODOLO
GY:</b> Between 1995 and 1997 a sample of 178 blood donors with two positive ant
i-HCV ELISA tests were consecutively selected as cases, and 356 anti-HCV negativ
e donors were selected as controls. Blood donors were randomly selected from eig
ht blood centers in Porto Alegre, Southern Brazil, representative of the whole b
lood donor population. Blood samples were kept at 70ºC and defrosted for the fir
st time for the analysis of this report. Tests previously performed in the labor
atory using the same real time PCR for HBV DNA had sensitivity for detecting as 
low as 9 copies/mL. Among 158 blood samples from HBsAg-negative blood donors, fi
ve were anti-HBc positive, 53 tested positive for anti-HCV and 105 had anti-HCV 
negative. The samples analysis was performed in duplicate and all blood samples 
tested negative for HBV DNA.    ^cY#v15n2a12.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012300076002001300199#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#20#16#article#108#<br> <b>CONCLUSION:
</b> The result reflects a very low prevalence of occult hepatitis B in our sett
ing.</font></p>     ^cY#v15n2a12.htm##
00429000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019400076002001300270#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#21#17#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> hepatitis B; hepati
tis B virus; blood donors; seroepidemiologic studies.</font></p> <hr size="1" no
shade>     ^cY#v15n2a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#22#18#article#108#<p>&nbsp;</p>     ^
cY#v15n2a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#23#19#article#108#<p>&nbsp;</p>     ^
cY#v15n2a12.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#24#20#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>INTRODUCTION</b></i></font></p
>     ^cY#v15n2a12.htm##
01005000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077000076002001300846#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#25#21#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Occult hepatitis B virus (HBV) infec
tion is a well-recognized clinical entity characterized by the detection of HBV-
deoxyribonucleic acid (DNA) in serum and/or in liver in the absence of detectabl
e hepatitis B surface antigen (HBsAg). Occult HBV infection has been described n
ot only in patients who have resolved an acute or chronic HBV infection, but als
o in patients without any serological markers of past HBV infection. <sup>1</sup
> The prevalence of occult hepatitis B found in 15 different studies ranged from
 1 to 95%,<sup>1</sup> which might be accounted to differences between endemic a
nd not endemic areas, presence of risk factors and to the sensitivity of the HBV
-DNA assay.</font></p>     ^cY#v15n2a12.htm##
00848000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061300076002001300689#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#26#22#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Hepatitis B and C coinfection is com
monly reported all over the world and high coinfection rates are attributed to t
he viruses sharing the same modes of transmission and being endemic in some regi
ons.<sup>2</sup> Since this coinfection is highly prevalent, occult hepatitis B 
has been extensively investigated in hepatitis C virus (HCV) infected patients. 
It has been estimated a rate of 20-30% of occult hepatitis B in international st
udies,<sup>3</sup> but in some areas occult HBV infection has not been detected.
<sup>4,5</sup></font></p>     ^cY#v15n2a12.htm##
00676000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044100076002001300517#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#27#23#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In the report by Shetty <i>et al</i>
, the authors described 28% prevalence of occult hepatitis B based on serum samp
les, and 50% on liver specimens of a liver transplant population. <sup>6</sup> A
ssociation between hepatocellular carcinoma and high prevalence of occult hepati
tis B raises concerns regarding the detection of the occult hepatitis B infectio
n.</font></p>     ^cY#v15n2a12.htm##
00562000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032700076002001300403#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#28#24#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The aim of the present report was to
 describe the prevalence of occult hepatitis B among HCV-infected blood donors (
cases) and non-infected controls, in Southern Brazil, using a highly sensitive r
eal-time polymerase chain reaction (PCR) method.</font></p>     ^cY#v15n2a12.htm
##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#29#25#article#108#<p>&nbsp;</p>     ^
cY#v15n2a12.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#30#26#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>METHODS</b></i></font></p>    
 ^cY#v15n2a12.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#31#27#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Ethics statement</b></font></p>  
   ^cY#v15n2a12.htm##
00852000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061700076002001300693#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#32#28#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The study was approved by the Ethics
 Committees of the following institutions invited to participate in the study: <
i>Hospital de Cl&iacute;nicas de Porto Alegre, Santa Casa de Miseric&oacute;rdia
 de Porto Alegre, Hospital Moinhos de Vento, Hospital Ernesto Dorneles, Laborat&
oacute;rio Marques-Pereira, Hospital Nossa Senhora da Concei&ccedil;&atilde;o, H
ospital S&atilde;o Lucas, Hemocentro do Rio Grande do Sul.</i> All participants 
signed a consent form in accordance to the ethical guidelines of the 1975 Declar
ation of Helsinki.</font></p>     ^cY#v15n2a12.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#33#29#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Participants</b></font></p>     ^
cY#v15n2a12.htm##
00808000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057300076002001300649#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#34#30#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A random sample of blood donors was 
selected from eight blood centers in Porto Alegre, Southern Brazil, between 1995
 and 1997, in order to represent the blood donor population. Blood samples were 
taken from all participants for the pre-donation testing and a 2 mL sub-sample w
as kept apart for further analysis. From the initial sample, 178 blood donors wi
th two positive anti-HCV ELISA tests were consecutively selected as cases, and 3
56 anti-HCV negative donors were selected as controls.</font></p>     ^cY#v15n2a
12.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#35#31#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Description of procedures</b></fo
nt></p>     ^cY#v15n2a12.htm##
00691000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045600076002001300532#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#36#32#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The samples were centrifuged less th
an 4 hours after the collection and frozen at -70ºC. The samples were defrosted 
at a single time for the analysis of this study. All tests were carried out at S
imbios Biotechnology in Brazil, a reference laboratory for molecular biology in 
our region. Sampling details and other results of the study were described elsew
here.<sup>7</sup></font></p>     ^cY#v15n2a12.htm##
00387000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015200076002001300228#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#37#33#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>DNA extraction method and real
-time PCR detection assay</b></i></font></p>     ^cY#v15n2a12.htm##
01580000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704134500076002001301421#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#38#34#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The DNA extraction was made as descr
ibed by Kramvis <i>et al</i>.<sup>8</sup> For phenol-chloroform DNA extraction, 
a 200 &#181;L aliquot of serum was incubated at 70ºC for 2 hours in the presence
 of 400 mg of proteinase K, 1% sodium dodecyl sulfate, and 2.5 mM disodium EDTA.
 The suspension was sequentially extracted with phenol and then chloroform. DNA 
was precipitated with 0.3 M sodium acetate and then with absolute ethanol, washe
d with 70% ethanol, vacuum dried, and then dissolved in 50 &#181;L of best-quali
ty water (BQW). The material was than exposed to GeneReleaser, which is a propri
etary reagent that can release DNA from serum. Lysis is accomplished directly in
 the amplification tube in a thermocycler. A 20 &#181;L volume of GeneReleaser w
as added to 5 &#181;L of serum, and the extraction was performed in a programmab
le thermal cycler according to the manufacturer's directions as follows: 65ºC he
ld for 30 seconds, 8ºC held for 30 seconds, 65ºC held for 90 seconds, 97ºC held 
for 180 seconds, 8ºC held for 60 seconds, 65ºC held for 180 seconds, 97ºC held f
or 60 seconds, 65ºC held for 60 seconds, and 80ºC held until the PCR mixture was
 added. The end product (25 &#181;L) was used as the template for the 100 &#181;
L first-round PCR mixture.</font></p>     ^cY#v15n2a12.htm##
02087000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704185200076002001301928#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#39#35#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Real-time PCR detection assay was ma
de as described by Pas <i>et al</i>.<sup>9</sup> PCR primers and probe were desi
gned using Primer Express software (PE Biosystems, Nieuwerkerk a/d IJssel, The N
etherlands). Amplification was performed in a 50 &#181;L reaction mixture contai
ning 2x TaqMan Universal MasterMix (PE Biosystems), 45 pmol of forward primer (5
9-GGA.CCC.CTG.CTC.GTG. TTA. CA-39, nucleotides 184 to 203), 45 pmol of reverse p
rimer (59-GAG.AGA.AGT. CCA.CCM.CGA.GTC.TAG.A-39, nucleotides 273 to 249), 15 pmo
l of TaqMan probe (59-FAM-TGT.TGA.CAA.RAA. TCC.TCA.CCA.TAC.CRC. AGA-TAMRA-39, nu
cleotides 218 to 247), and 10 &#181;L of isolated DNA. Primers and probe were se
lected in the pre-S gene of the HBV genome and generated a product of 89 bp. All
 isolations and amplification reactions were performed in duplicate. After prepa
ration of the reaction mixtures in 96-well plates, the plates were centrifuged a
t 1,200 rpm for 1 min in a Rotina 48R swing rotor to remove small air bubbles in
 the vessels. Amplification and detection were performed with an ABI Prism 7700 
Sequence Detection System (PE Biosystems). After incubation for 2 min at 50ºC, w
hich enables uracil N9-glycosylase (present in the 23 Universal MasterMix) to in
activate possible contaminating amplicons, incubation for 10 min at 95ºC allowed
 AmpliTaq Gold polymerase to activate and inactivate the uracil N9-glycosylase. 
The PCR cycling program consisted of 45 two-step cycles of 15 seconds at 95ºC an
d 60 seconds at 60ºC. For standardization of the real-time PCR detection assay, 
a standard curve of the plasmid ranging from 10 million to 670 copies/mL and a r
un control of 30,000 copies/mL (CLB) were included in each run. Validation of th
e plasmid controls was done with the VQC panel (CLB).</font></p>     ^cY#v15n2a1
2.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012300076002001300199#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#40#36#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Diagnostic properties of the test
</b></font></p>     ^cY#v15n2a12.htm##
00626000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039100076002001300467#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#41#37#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">For clinical purposes, this techniqu
e is able to detect 200 viral copies/mL and it has high reproducibility. For res
earch purposes, we considered any viral load detected as a positive PCR. Previou
s testing performed by Simbios laboratory, using the same technique, detected vi
ral loads as low as 9 copies/mL.</font></p>     ^cY#v15n2a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#42#38#article#108#<p>&nbsp;</p>     ^
cY#v15n2a12.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#43#39#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>RESULTS</b></i></font></p>    
 ^cY#v15n2a12.htm##
00818000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058300076002001300659#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#44#40#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In this analysis, 158 samples of blo
od donors from one of the main blood centers were tested. All samples were from 
HBsAg negative participants and five blood donors tested positive for hepatitis 
B core antibodies (anti-HBc). Fifty three individuals tested positive for anti-H
CV and 105 were anti-HCV negative. The analysis of samples was performed in dupl
icate and all samples tested negative for HBV-DNA. Since all 158 samples tested 
were negative, we decided to stop testing the remaining samples.</font></p>     
^cY#v15n2a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#45#41#article#108#<p>&nbsp;</p>     ^
cY#v15n2a12.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#46#42#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>DISCUSSION</b></i></font></p> 
    ^cY#v15n2a12.htm##
00968000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073300076002001300809#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#47#43#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The zero prevalence of occult hepati
tis B among blood donors, detected in our study, is far from the 28% serum HBV D
NA prevalence among the liver transplant population reported by Shetty <i>et al<
/i>.<sup>6</sup> Our result is in accordance with other studies carried out in B
razil to detect HBV in serum among hepatocellular carcinoma patients<sup>5</sup>
 and among liver transplant patients.<sup>10</sup> Even considering that occult 
HBV might be more prevalent in end-stage liver disease population, such as that 
studied by Shetty <i>et al</i>.,<sup>6</sup> than in healthy blood donors, it wa
s anticipated at least a few occult hepatitis B cases.</font></p>     ^cY#v15n2a
12.htm##
00873000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063800076002001300714#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#48#44#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The screening procedures in the bloo
d centers included an interview of candidates to donate, precluding from donatio
n the unhealthy or high risk individuals. This screening might have lowered the 
occult hepatitis B prevalence in the sample in comparison to the real prevalence
 in the general population. However, HBV and HCV share routes of transmission an
d risk factors, and blood donor candidates were detected as HCV cases. Even so, 
53 HCV cases and 105 anti-HCV negative controls might have not enough statistica
l power to detect a case of occult HBV.</font></p>     ^cY#v15n2a12.htm##
01286000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704105100076002001301127#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#49#45#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">False-negative results obtained from
 HBV-DNA detection could be another reason for not finding a single positive cas
e. In our study, the lacking of occult hepatitis B cases might not be attributed
 to false-negative tests. The DNA extraction method and the real-time PCR techni
que, used for HBV-DNA detection, is the one currently adopted in referent labora
tories and very low viral loads have been detected in Simbios laboratory on anot
her ongoing study. However, there are theoretical problems related to the storag
e of the samples. Our samples had been maintained frozen and stored at -70ºC on 
average for seven years. There were no voluntary or involuntary thaws in the per
iod, what gives our sample an additional guaranty of quality. Because HBV is a D
NA virus, the possibility that the freezing time could have spoiled the samples 
is remote. Studies that had used samples with multiple freezing and thawing cycl
es have not had their results affected.<sup>11</sup></font></p>     ^cY#v15n2a12
.htm##
01107000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087200076002001300948#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#50#46#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Whether individuals with occult HBV 
infection are at risk for unfavorable endpoints still is an unresolved issue. Co
nsiderable data suggest that occult infection may contribute to chronic liver da
mage,<sup>12-14</sup> the development of hepatocellular carcinoma,<sup>15-18</su
p> transmission<sup>19,20</sup> and reactivation of chronic hepatitis B.<sup>21-
23</sup> Therefore, despite some controversy concerning its clinical significanc
e, improving the knowledge on different aspects of occult HBV infection is a mat
ter of concern worldwide, as we can see by the high number of new published pape
rs on this topic. Our paper helps researchers and clinicians to better understan
d how relevant (or not) is occult hepatitis B in our setting, and, probably in o
ther low-prevalence HBV settings.</font></p>     ^cY#v15n2a12.htm##
00951000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071600076002001300792#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#51#47#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The main reasons for the differences
 in occult hepatitis B rates among studies seem to be the genuine variability on
 the hepatitis B prevalence - either occult or not - in several regions of the w
orld, in regions of the same country, and according to characteristics of the st
udied population. Therefore, we believe that the result of our study reflects a 
true negative result in a sample with extremely low prevalence of occult hepatit
is B. As our sample size (158 individuals) is only able to detect prevalence rat
es over 0.6%, we may estimate from 0 to 0.6% the prevalence of occult hepatitis 
B in blood donors in southern Brazil.</font></p>     ^cY#v15n2a12.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#52#48#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Limitations</b></font></p>     ^c
Y#v15n2a12.htm##
00699000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046400076002001300540#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#53#49#article#108#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The results refer to blood samples c
ollected 12 to 14 years ago, an issue that may rise concerns about how updated a
re the information we present. Considering that the prevalence of hepatitis B an
d C and their risk factors have not changed much in this period, we have no reas
on to believe the prevalence of occult hepatitis B would be different if more re
cent samples were tested.</font></p>     ^cY#v15n2a12.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#54#50#article#108#<p>&nbsp;</p>     ^
cY#v15n2a12.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#55#51#article#108#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p> 
    ^cY#v15n2a12.htm##
00400000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015100078002001300229#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#56#52#article#108#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Torbenson M, Thomas
 DL. Occult hepatitis B. Lancet Infect Dis 2002; 2:479-86.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#57#53#article#108#</font></p>     ^cY
#v15n2a12.htm##
00453000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020400078002001300282#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#58#54#article#108#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Bowden S, Bartholom
eusz A, Locarnini S. Lamivudine resistant occult HBV: implications for public he
alth? J Hepatol 2003; 38:526-8.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#59#55#article#108#</font></p>     ^cY
#v15n2a12.htm##
00536000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028700078002001300365#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#60#56#article#108#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Br&eacute;chot C, T
hiers V, Kremsdorf D <i>et al</i>. Persistent Hepatitis B Virus Infection in Sub
jects Without Hepatitis B Surface Antigen: Clinically Significant or Purely "Occ
ult"? Hepatology 2001; 34:194-203.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#61#57#article#108#</font></p>     ^cY
#v15n2a12.htm##
00531000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028200078002001300360#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#62#58#article#108#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Souza LO, Pinho JR,
 Carrilho FJ, da Silva LC. Absence of hepatitis B virus DNA in patients with hep
atitis C and non-A-E hepatitis in the State of S&atilde;o Paulo, Brazil. Braz J 
Med Biol Res 2004; 37:1665-8.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#63#59#article#108#</font></p>     ^cY
#v15n2a12.htm##
00547000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029800078002001300376#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#64#60#article#108#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Alencar RS, Gomes M
M, Sitnik R <i>et al</i>. Low occurrence of occult hepatitis B virus infection a
nd high frequency of hepatitis C virus genotype 3 in hepatocellular carcinoma in
 Brazil. Braz J Med Biol Res 2008; 41:235-40.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#65#61#article#108#</font></p>     ^cY
#v15n2a12.htm##
00519000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027000078002001300348#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#66#62#article#108#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Shetty K, Hussain M
, Nei L, Reddy KR, Lok AS. Prevalence and significance of occult hepatitis B in 
a liver transplant population with chronic hepatitis C. Liver Transpl 2008; 14:5
34-40</font></p>     ^cY#v15n2a12.htm##
00481000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023200078002001300310#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#67#63#article#108#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Brand&atilde;o ABM,
 Fuchs SC. Risk Factors for hepatitis C infecton among blood donors in southern 
Brazil: a case-control study. BMC Gastroenterol 2002; 2:18.    ^cY#v15n2a12.htm#
#
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#68#64#article#108#</font></p>     ^cY
#v15n2a12.htm##
00520000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027100078002001300349#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#69#65#article#108#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Kramvis A, Bukofzer
 S, Kew MC. Comparison of Hepatitis B Virus DNA Extractions from Serum by the QI
Aamp Blood Kit, GeneReleaser, and the Phenol-Chloroform Method J. Clin. Microbio
l 1996; 34:2731-3.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#70#66#article#108#</font></p>     ^cY
#v15n2a12.htm##
00542000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029300078002001300371#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#71#67#article#108#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Pas SD, Fries E, de
 Man RA, Osterhaus ADME, Niester HGM. Development of a Quantitative Real-Time De
tection Assay for Hepatitis B Virus DNA and Comparison with Two Commercial Assay
s. J. Clin. Microbiol 2000; 38:2897-901.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#72#68#article#108#</font></p>     ^cY
#v15n2a12.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029100079002001300370#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#73#69#article#108#10#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Branco F, Mattos 
AA, Coral GP <i>et al</i>. Occult hepatitis B virus infection in patients with c
hronic liver disease due to hepatitis C virus and hepatocellular carcinoma in Br
azil. Arq Gastroenterol 2007; 44:58-63.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#74#70#article#108#</font></p>     ^cY
#v15n2a12.htm##
00546000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029600079002001300375#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#75#71#article#108#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Krajden M, Minor 
JM, Rifkin O, Comanor L. Effect of Multiple Freeze-Thaw Cycles on Hepatitis B Vi
rus DNA and Hepatitis C Virus RNA Quantification as Measured with Branched-DNA T
echnology. J Clin Microbiol 1999; 37:1683-6.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#76#72#article#108#</font></p>     ^cY
#v15n2a12.htm##
00491000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024100079002001300320#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#77#73#article#108#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Cacciola I, Polli
cino T, Squadrito G <i>et al</i>. Occult hepatitis B virus infection in patients
 with chronic hepatitis C liver disease. N Engl J Med 1999; 341:22-6;    ^cY#v15
n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#78#74#article#108#</font></p>     ^cY
#v15n2a12.htm##
00558000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704030800079002001300387#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#79#75#article#108#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Fukuda R, Ishimur
a N, Niigaki M <i>et al</i>. Serologically silent hepatitis B virus co-infection
 in patients with hepatitis C virus-associated chronic liver disease: clinical a
nd virological significance. J Med Virol 1999; 58:201-7.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#80#76#article#108#</font></p>     ^cY
#v15n2a12.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026300079002001300342#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#81#77#article#108#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Mrani S, Chemin I
, Menouar K <i>et al</i>. Occult HBV infection may represent a major risk factor
 of nonresponse to antiviral therapy of chronic hepatitis C. J Med Virol 2007; 7
9: 1075-81.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#82#78#article#108#</font></p>     ^cY
#v15n2a12.htm##
00538000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028800079002001300367#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#83#79#article#108#15#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Paterlini P, Dris
s F, Nalpas B <i>et al</i>. Persistence of hepatitis B and hepatitis C viral gen
omes in primary liver cancers from HBsAg-negative patients: a study of a low-end
emic area. Hepatology 1993; 17:20-9.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#84#80#article#108#</font></p>     ^cY
#v15n2a12.htm##
00566000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704031600079002001300395#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#85#81#article#108#16#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Takeuchi M, Fujim
oto J, Niwamoto H, Yamamoto Y, Okamoto E. Frequent detection of hepatitis B viru
s X-gene DNA in hepatocellular carcinoma and adjacent liver tissue in hepatitis 
B surface antigennegative patients. Dig Dig Sci 1997; 42:2264-9.    ^cY#v15n2a12
.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#86#82#article#108#</font></p>     ^cY
#v15n2a12.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704030700079002001300386#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#87#83#article#108#17#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Lee DS, Huh K, Le
e EH <i>et al</i>. HCV and HBV coexist in HBsAg-negative patients with HCV virae
mia: possibility of coinfection in these patients must be considered in HBV-high
 endemic area. J Gastroenterol Hepatol 1997; 12:855-61.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#88#84#article#108#</font></p>     ^cY
#v15n2a12.htm##
00456000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020600079002001300285#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#89#85#article#108#18#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Koike K, Tsutsumi
 T, Fujie H, Shintani Y, Kyoji M. Molecular mechanism of viral hepatocarcinogene
sis. Oncology 2002; 62 (S1):29-37.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#90#86#article#108#</font></p>     ^cY
#v15n2a12.htm##
00499000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024900079002001300328#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#91#87#article#108#19#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Satake M, Taira R
, Yugi H <i>et al</i>. Infectivity of blood components with low hepatitis B viru
s DNA levels identified in a lookback program. Transfusion 2007; 47:1197-205.   
 ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#92#88#article#108#</font></p>     ^cY
#v15n2a12.htm##
00428000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704017800079002001300257#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#93#89#article#108#20#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Candotti D, Allai
n JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol 2009; 51:79
8-809.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#94#90#article#108#</font></p>     ^cY
#v15n2a12.htm##
00519000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026900079002001300348#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#95#91#article#108#21#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Lok ASF, Liang RH
S, Chiu EKW <i>et al</i>. Reactivation of hepatitis B virus replication in patie
nts receiving cytotoxic therapy. Report of a prospective study. Gastroenterology
 1999; 100:182-8.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#96#92#article#108#</font></p>     ^cY
#v15n2a12.htm##
00588000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704033800079002001300417#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#97#93#article#108#22#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Wu JM, Huang YH, 
Lee PC, Lin HC, Lee SD. Fatal reactivation of hepatitis B virus in a patient who
 was hepatitis B surface antigen negative and core antibody body positive before
 receiving chemotherapy for non-Hodgkin lymphoma. J Clin Gastroenterol 2009; 43:
496-8.    ^cY#v15n2a12.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#98#94#article#108#</font></p>     ^cY
#v15n2a12.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029100079002001300370#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#99#95#article#108#23#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Bloquel B, Jeulin
 H, Burty C <i>et al</i>. Occult hepatitis B infection in patients infected with
 HIV: report of two cases of hepatitis B reactivation and prevalence in a hospit
al cohort. J Med Virol 2010; 82:206-12.    ^cY#v15n2a12.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#100#96#article#108#</font></p>     ^c
Y#v15n2a12.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002200077002001300099#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#101#97#article#108#<p>&nbsp;</p>     
^cY#v15n2a12.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002200077002001300099#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#102#98#article#108#<p>&nbsp;</p>     
^cY#v15n2a12.htm##
00425000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704018900077002001300266#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#103#99#article#108#<p><font size="2" 
face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><im
g src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:<
/b>    ^cY#v15n2a12.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003200078002001300110#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#104#100#article#108#<br> Fernando Her
z Wolff    ^cY#v15n2a12.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005000078002001300128#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#105#101#article#108#<br> Rua Dr. Frei
re Alem&atilde;o 351 /703    ^cY#v15n2a12.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004600078002001300124#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#106#102#article#108#<br> 90450060 Por
to Alegre, RS, Brazil    ^cY#v15n2a12.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005000078002001300128#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#107#103#article#108#<br> Phone: 55 51
 30296136, 55 51 92490979    ^cY#v15n2a12.htm##
00382000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704014500078002001300223#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#108#104#article#108#<br> <a href="mai
lto:fhwolff@gmail.com">fhwolff@gmail.com</a>, <a href="mailto:fhwolff@terra.com.
br">fhwolff@terra.com.br</a></font></p>     ^cY#v15n2a12.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009500078002001300173#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#109#105#article#108#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted on: 06/21/2010    ^cY#v1
5n2a12.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#110#106#article#108#<br>   Approved o
n: 07/12/2010    ^cY#v15n2a12.htm##
00604000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704036700078002001300445#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#111#107#article#108#<br>   Financial 
Support: This study was funded by a grant from Coordena&ccedil;&atilde;o de Aper
fei&ccedil;oamento de Pessoal de N&iacute;vel Superior (CAPES), and National Cou
nsel of Technological and Scientific Development (CNPq). The funders had no role
 in study design, data collection and analysis, decision to publish, or preparat
ion of the manuscript.    ^cY#v15n2a12.htm##
00299000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006200078002001300140#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a12.htm#S#p#112#108#article#108#<br>   We declare
 no conflict of interest.</font></p>     ^cY#v15n2a12.htm##
00467000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100017000960120
02300113030001800136710000200154065000900156064000500165031000200170014000700172
865000900179002001300188#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S
#c#113#1#article#23#1#^rND^sTorbenson^nM#^rND^sThomas^nDL#Occult hepatitis B^len
#Lancet Infect Dis#2#20020000#2002#2#479-86#20110400#v15n2a12.htm##
00569000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100023000930100
01900116012006900135030001000204065000900214064000500223031000300228014000600231
865000900237002001300246035001000259801001000269#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a12.htm#S#c#114#2#article#23#2#^rND^sBowden^nS#^rND^sBartholomeus
z^nA#^rND^sLocarnini^nS#Lamivudine resistant occult HBV: implications for public
 health?^len#J Hepatol#20030000#2003#38#526-8#20110400#v15n2a12.htm#0168-8278#J 
Hepatol##
00651000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
01900110810000600129012013500135030001100270065000900281064000500290031000300295
014000800298865000900306002001300315035001000328801001100338#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a12.htm#S#c#115#3#article#23#3#^rND^sBréchot^nC#^rND^
sThiers^nV#^rND^sKremsdorf^nD#et al#Persistent Hepatitis B Virus Infection in Su
bjects Without Hepatitis B Surface Antigen: Clinically Significant or Purely "Oc
cult"?^len#Hepatology#20010000#2001#34#194-203#20110400#v15n2a12.htm#0161-0538#H
EPATOLOGY##
00667000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01900109010001900128012012200147030002000269065000900289064000500298031000300303
014000700306865000900313002001300322035001000335801002000345#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a12.htm#S#c#116#4#article#23#4#^rND^sSouza^nLO#^rND^s
Pinho^nJR#^rND^sCarrilho^nFJ#^rND^sda Silva^nLC#Absence of hepatitis B virus DNA
 in patients with hepatitis C and non-A-E hepatitis in the State of São Paulo, B
razil^len#Braz J Med Biol Res#20040000#2004#37#1665-8#20110400#v15n2a12.htm#0100
-879X#Braz J Med Biol Res##
00677000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950100
01600111810000600127012014600133030002000279065000900299064000500308031000300313
014000700316865000900323002001300332035001000345801002000355#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a12.htm#S#c#117#5#article#23#5#^rND^sAlencar^nRS#^rND
^sGomes^nMM#^rND^sSitnik^nR#et al#Low occurrence of occult hepatitis B virus inf
ection and high frequency of hepatitis C virus genotype 3 in hepatocellular carc
inoma in Brazil^len#Braz J Med Biol Res#20080000#2008#41#235-40#20110400#v15n2a1
2.htm#0100-879X#Braz J Med Biol Res##
00629000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930100
01300110010001600123010001400139012011200153030001400265710000200279065000900281
064000500290031000300295014000700298865000900305002001300314#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a12.htm#S#c#118#6#article#23#6#^rND^sShetty^nK#^rND^s
Hussain^nM#^rND^sNei^nL#^rND^sReddy^nKR#^rND^sLok^nAS#Prevalence and significanc
e of occult hepatitis B in a liver transplant population with chronic hepatitis 
C^len#Liver Transpl#2#20080000#2008#14#534-40#20110400#v15n2a12.htm##
00541000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100016000960120
10200112030001800214710000200232065000900234064000500243031000200248020000300250
865000900253002001300262#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S
#c#119#7#article#23#7#^rND^sBrandão^nABM#^rND^sFuchs^nSC#Risk Factors for hepati
tis C infecton among blood donors in southern Brazil: a case-control study^len#B
MC Gastroenterol#2#20020000#2002#2#18#20110400#v15n2a12.htm##
00645000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
01400112012013500126030001900261065000900280064000500289031000300294014000700297
865000900304002001300313035001000326801001900336#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a12.htm#S#c#120#8#article#23#8#^rND^sKramvis^nA#^rND^sBukofzer^nS
#^rND^sKew^nMC#Comparison of Hepatitis B Virus DNA Extractions from Serum by the
 QIAamp Blood Kit, GeneReleaser, and the Phenol-Chloroform Method^len#J. Clin. M
icrobiol#19960000#1996#34#2731-3#20110400#v15n2a12.htm#0095-1137#J. clin. Microb
iol##
00702000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100015000910100
01700106010002200123010001900145012012800164030001900292065000900311064000500320
031000300325014000900328865000900337002001300346035001000359801001900369#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#c#121#9#article#23#9#^rND^sPas^
nSD#^rND^sFries^nE#^rND^sde Man^nRA#^rND^sOsterhaus^nADME#^rND^sNiester^nHGM#Dev
elopment of a Quantitative Real-Time Detection Assay for Hepatitis B Virus DNA a
nd Comparison with Two Commercial Assays^len#J. Clin. Microbiol#20000000#2000#38
#2897-901#20110400#v15n2a12.htm#0095-1137#J. clin. Microbiol##
00669000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01600112810000600128012014200134030001800276065000900294064000500303031000300308
014000600311865000900317002001300326035001000339801001800349#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a12.htm#S#c#122#10#article#23#10#^rND^sBranco^nF#^rND
^sMattos^nAA#^rND^sCoral^nGP#et al#Occult hepatitis B virus infection in patient
s with chronic liver disease due to hepatitis C virus and hepatocellular carcino
ma in Brazil^len#Arq Gastroenterol#20070000#2007#44#58-63#20110400#v15n2a12.htm#
0004-2803#Arq Gastroenterol##
00686000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01600112010001700128012014900145030001700294065000900311064000500320031000300325
014000700328865000900335002001300344035001000357801001700367#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a12.htm#S#c#123#11#article#23#11#^rND^sKrajden^nM#^rN
D^sMinor^nJM#^rND^sRifkin^nO#^rND^sComanor^nL#Effect of Multiple Freeze-Thaw Cyc
les on Hepatitis B Virus DNA and Hepatitis C Virus RNA Quantification as Measure
d with Branched-DNA Technology^len#J Clin Microbiol#19990000#1999#37#1683-6#2011
0400#v15n2a12.htm#0095-1137#J Clin Microbiol##
00614000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01900116810000600135012009000141030001300231065000900244064000500253031000400258
014000500262865000900267002001300276035001000289801001300299#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a12.htm#S#c#124#12#article#23#12#^rND^sCacciola^nI#^r
ND^sPollicino^nT#^rND^sSquadrito^nG#et al#Occult hepatitis B virus infection in 
patients with chronic hepatitis C liver disease^len#N Engl J Med#19990000#1999#3
41#22-6#20110400#v15n2a12.htm#0028-4793#N Engl J Med##
00680000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01700113810000600130012016300136030001200299065000900311064000500320031000300325
014000600328865000900334002001300343035001000356801001200366#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a12.htm#S#c#125#13#article#23#13#^rND^sFukuda^nR#^rND
^sIshimura^nN#^rND^sNiigaki^nM#et al#Serologically silent hepatitis B virus co-i
nfection in patients with hepatitis C virus-associated chronic liver disease: cl
inical and virological significance^len#J Med Virol#19990000#1999#58#201-7#20110
400#v15n2a12.htm#0146-6615#J Med Virol##
00634000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01700110810000600127012011800133030001200251065000900263064000500272031000300277
014000800280865000900288002001300297035001000310801001200320#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a12.htm#S#c#126#14#article#23#14#^rND^sMrani^nS#^rND^
sChemin^nI#^rND^sMenouar^nK#et al#Occult HBV infection may represent a major ris
k factor of nonresponse to antiviral therapy of chronic hepatitis C^len#J Med Vi
rol#20070000#2007#79#1075-81#20110400#v15n2a12.htm#0146-6615#J Med Virol##
00659000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100015000980100
01600113810000600129012014600135030001100281065000900292064000500301031000300306
014000500309865000900314002001300323035001000336801001100346#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a12.htm#S#c#127#15#article#23#15#^rND^sPaterlini^nP#^
rND^sDriss^nF#^rND^sNalpas^nB#et al#Persistence of hepatitis B and hepatitis C v
iral genomes in primary liver cancers from HBsAg-negative patients: a study of a
 low-endemic area^len#Hepatology#19930000#1993#17#20-9#20110400#v15n2a12.htm#016
1-0538#HEPATOLOGY##
00687000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01800115010001800133010001700151012015700168030001200325710000200337065000900339
064000500348031000300353014000700356865000900363002001300372#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a12.htm#S#c#128#16#article#23#16#^rND^sTakeuchi^nM#^r
ND^sFujimoto^nJ#^rND^sNiwamoto^nH#^rND^sYamamoto^nY#^rND^sOkamoto^nE#Frequent de
tection of hepatitis B virus X-gene DNA in hepatocellular carcinoma and adjacent
 liver tissue in hepatitis B surface antigennegative patients^len#Dig Dig Sci#2#
19970000#1997#42#2264-9#20110400#v15n2a12.htm##
00691000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100013000930100
01400106810000600120012015900126030002400285065000900309064000500318031000300323
014000700326865000900333002001300342035001000355801002400365#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a12.htm#S#c#129#17#article#23#17#^rND^sLee^nDS#^rND^s
Huh^nK#^rND^sLee^nEH#et al#HCV and HBV coexist in HBsAg-negative patients with H
CV viraemia: possibility of coinfection in these patients must be considered in 
HBV-high endemic area^len#J Gastroenterol Hepatol#19970000#1997#12#855-61#201104
00#v15n2a12.htm#0815-9319#J Gastroenterol Hepatol##
00617000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940100
01500112010001800127010001500145012005400160030000900214065000900223064000500232
03100030023703200040024001400060024486500090025000200130025903500100027280100090
0282#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#c#130#18#article#23
#18#^rND^sKoike^nK#^rND^sTsutsumi^nT#^rND^sFujie^nH#^rND^sShintani^nY#^rND^sKyoj
i^nM#Molecular mechanism of viral hepatocarcinogenesis^len#Oncology#20020000#200
2#62#^s1#29-37#20110400#v15n2a12.htm#0030-2414#Oncology##
00621000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01400110810000600124012010700130030001200237065000900249064000500258031000300263
014000900266865000900275002001300284035001000297801001200307#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a12.htm#S#c#131#19#article#23#19#^rND^sSatake^nM#^rND
^sTaira^nR#^rND^sYugi^nH#et al#Infectivity of blood components with low hepatiti
s B virus DNA levels identified in a lookback program^len#Transfusion#20070000#2
007#47#1197-205#20110400#v15n2a12.htm#0041-1132#Transfusion##
00525000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970120
05600114030001000170065000900180064000500189031000300194014000800197865000900205
002001300214035001000227801001000237#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a12.htm#S#c#132#20#article#23#20#^rND^sCandotti^nD#^rND^sAllain^nJP#Transfusi
on-transmitted hepatitis B virus infection^len#J Hepatol#20090000#2009#51#798-80
9#20110400#v15n2a12.htm#0168-8278#J Hepatol##
00646000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01600111810000600127012012100133030001700254065000900271064000500280031000400285
014000600289865000900295002001300304035001000317801001700327#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a12.htm#S#c#133#21#article#23#21#^rND^sLok^nASF#^rND^
sLiang^nRHS#^rND^sChiu^nEKW#et al#Reactivation of hepatitis B virus replication 
in patients receiving cytotoxic therapy: Report of a prospective study^len#Gastr
oenterology#19990000#1999#100#182-8#20110400#v15n2a12.htm#0016-5085#Gastroentero
logy##
00750000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100016000920100
01400108010001400122010001400136012018900150030002100339065000900360064000500369
031000300374014000600377865000900383002001300392035001000405801002100415#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a12.htm#S#c#134#22#article#23#22#^rND^sWu
^nJM#^rND^sHuang^nYH#^rND^sLee^nPC#^rND^sLin^nHC#^rND^sLee^nSD#Fatal reactivatio
n of hepatitis B virus in a patient who was hepatitis B surface antigen negative
 and core antibody body positive before receiving chemotherapy for non-Hodgkin l
ymphoma^len#J Clin Gastroenterol#20090000#2009#43#496-8#20110400#v15n2a12.htm#01
92-0790#J Clin Gastroenterol##
00663000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01500112810000600127012014800133030001200281065000900293064000500302031000300307
014000700310865000900317002001300326035001000339801001200349#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a12.htm#S#c#135#23#article#23#23#^rND^sBloquel^nB#^rN
D^sJeulin^nH#^rND^sBurty^nC#et al#Occult hepatitis B infection in patients infec
ted with HIV: report of two cases of hepatitis B reactivation and prevalence in 
a hospital cohort^len#J Med Virol#20100000#2010#82#206-12#20110400#v15n2a12.htm#
0146-6615#J Med Virol##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#o#1#1#article#1
#20110406#125402#v15n2a13.htm#120##
02784000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400110014503500100015601200760
01660100025002420100028002670100023002950100028003180700092003460700065004380700
08000503070003300583083135700616085000801973085002301981085002402004085004002028
11700060206807200030207411200090207711100110208611400090209711300110210605800270
2117058000902144060001602153002001302169#v15n2#V:\SciELO\serial\bjid\v15n2\marku
p\v15n2a13.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#13#BJID160#nd#Braz J
 Infect Dis#15#2#20110400#^f163^l166#1413-8670#Difficulties with interferon trea
tment in former intravenous drug users^len#^rND^1A01^nGábor^sGazdag#^rND^1A02^nG
ergely^sHorváth#^rND^1A03^nOlga^sSzabó#^rND^1A04^nGabor S^sUngvari#Szent István 
Szent László Hospitals^iA01^1Consultation-Liaison Psychiatric Service^pHungary#N
ational Center for Epidemiology^iA02^1Drug Focal Point^pHungary#Szent István Sze
nt László Hospitals^iA03^1Hepatology Outpatient Clinic^pHungary#Graylands Hospit
al^iA04^pHungary#^len^aOBJECTIVES: Intravenous drug use accounts for most of the
 new hepatitis C infections worldwide. Although there is an urgent need for anti
viral treatment of infected intravenous drug users (IDUs), several factors compr
omise their treatment including lack of treatment adherence and high dropout rat
e. The aim of this study was to compare antiviral treatment-related problems amo
ng former IDUs to HCV-infected patients without a history of IDU. METHODS: This 
was a retrospective chart review of HCV-infected IDUs who received combined anti
viral therapy at the Hepatology Outpatient Clinic of Szent László Hospital betwe
en 1 January 2006 and 31 December 2008. A control group of interferon treated pa
tients with no history of IDU matched for age and sex was selected. RESULTS: Dro
pout rate was significantly higher in the IDU group (p = 0.016). Treatment respo
nse at the 12th week of treatment was significantly better in the IDU group (p =
 0.004). Significantly more IDUs underwent antiviral treatment while in prison (
p = 0.008). CONCLUSIONS: In this study higher dropout rate was found among IDUs.
 IDUs had a better response rate to antiviral therapy compared to controls. More
 attention should be paid to factors that worsen treatment adherence of IDUs - p
articularly lack of abstinence - in order to increase the effectiveness of antiv
iral therapy.#^dnd^i1#^tm^len^kpsychiatry^i1#^tm^len^khepatitis C^i1#^tm^len^ksu
bstance-related disorders^i1#other#20#20100715#07/15/2010#20101014#10/14/2010#Mi
nistry of Social Affairs#ESZA Kht#KABKT-M-08-0003#v15n2a13.htm##
02888000000000601000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400110014503500100015601200830
01660100025002490100028002740100023003020100028003250700092003530700065004450700
08000510070003300590083138500623085000802008085002302016085002402039085004002063
11700060210307200030210911200090211211100110212111400090213211300110214105800270
2152058000902179060008502188002001302273#v15n2#V:\SciELO\serial\bjid\v15n2\marku
p\v15n2a13.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#13#BJID160#nd#Braz J
 Infect Dis#15#2#20110400#^f163^l166#1413-8670#<b>Difficulties with interferon t
reatment in former intravenous drug users</b>^len#^rND^1A01^nGábor^sGazdag#^rND^
1A02^nGergely^sHorváth#^rND^1A03^nOlga^sSzabó#^rND^1A04^nGabor S^sUngvari#Szent 
István Szent László Hospitals^iA01^1Consultation-Liaison Psychiatric Service^pHu
ngary#National Center for Epidemiology^iA02^1Drug Focal Point^pHungary#Szent Ist
ván Szent László Hospitals^iA03^1Hepatology Outpatient Clinic^pHungary#Graylands
 Hospital^iA04^pHungary#^len^a<b>OBJECTIVES:</b> Intravenous drug use accounts f
or most of the new hepatitis C infections worldwide. Although there is an urgent
 need for antiviral treatment of infected intravenous drug users (IDUs), several
 factors compromise their treatment including lack of treatment adherence and hi
gh dropout rate. The aim of this study was to compare antiviral treatment-relate
d problems among former IDUs to HCV-infected patients without a history of IDU. 
<b>METHODS:</b> This was a retrospective chart review of HCV-infected IDUs who r
eceived combined antiviral therapy at the Hepatology Outpatient Clinic of Szent 
László Hospital between 1 January 2006 and 31 December 2008. A control group of 
interferon treated patients with no history of IDU matched for age and sex was s
elected. <b>RESULTS:</b> Dropout rate was significantly higher in the IDU group 
(p = 0.016). Treatment response at the 12th week of treatment was significantly 
better in the IDU group (p = 0.004). Significantly more IDUs underwent antiviral
 treatment while in prison (p = 0.008). <b>CONCLUSIONS:</b> In this study higher
 dropout rate was found among IDUs. IDUs had a better response rate to antiviral
 therapy compared to controls. More attention should be paid to factors that wor
sen treatment adherence of IDUs - particularly lack of abstinence - in order to 
increase the effectiveness of antiviral therapy.#^dnd^i1#^tm^len^kpsychiatry^i1#
^tm^len^khepatitis C^i1#^tm^len^ksubstance-related disorders^i1#other#20#2010071
5#07/15/2010#20101014#10/14/2010#Ministry of Social Affairs#ESZA Kht#<span lang=
EN-US style='font-size:10.0pt;font-family:Verdana'>KABKT-M-08-0003</span>#v15n2a
13.htm##
02926000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000210013103100030015203200020015506500090015701400110016603500100
01770120076001870100025002630100028002880100023003160100028003390700094003670700
06700461070008200528070003500610083135700645085000802002085002302010085002402033
08500400205711700060209707200030210311200090210611100110211511400090212611300110
2135058002702146058000902173060001602182002001302198008008902211#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#l#4#1#article#1#^mMar./Apr.^a2011#oa#en
#br1.1#1#4.0#ilus#tab#13#BJID160#nd#Braz. j. infect. dis#15#2#20110400#^f163^l16
6#1413-8670#Difficulties with interferon treatment in former intravenous drug us
ers^len#^rND^1A01^nGábor^sGazdag#^rND^1A02^nGergely^sHorváth#^rND^1A03^nOlga^sSz
abó#^rND^1A04^nGabor S^sUngvari#^iA01^1Szent István Szent László Hospitals^2Cons
ultation-Liaison Psychiatric Service^pHungary#^iA02^1National Center for Epidemi
ology^2Drug Focal Point^pHungary#^iA03^1Szent István Szent László Hospitals^2Hep
atology Outpatient Clinic^pHungary#^iA04^1Graylands Hospital^pHungary#^len^aOBJE
CTIVES: Intravenous drug use accounts for most of the new hepatitis C infections
 worldwide. Although there is an urgent need for antiviral treatment of infected
 intravenous drug users (IDUs), several factors compromise their treatment inclu
ding lack of treatment adherence and high dropout rate. The aim of this study wa
s to compare antiviral treatment-related problems among former IDUs to HCV-infec
ted patients without a history of IDU. METHODS: This was a retrospective chart r
eview of HCV-infected IDUs who received combined antiviral therapy at the Hepato
logy Outpatient Clinic of Szent László Hospital between 1 January 2006 and 31 De
cember 2008. A control group of interferon treated patients with no history of I
DU matched for age and sex was selected. RESULTS: Dropout rate was significantly
 higher in the IDU group (p = 0.016). Treatment response at the 12th week of tre
atment was significantly better in the IDU group (p = 0.004). Significantly more
 IDUs underwent antiviral treatment while in prison (p = 0.008). CONCLUSIONS: In
 this study higher dropout rate was found among IDUs. IDUs had a better response
 rate to antiviral therapy compared to controls. More attention should be paid t
o factors that worsen treatment adherence of IDUs - particularly lack of abstine
nce - in order to increase the effectiveness of antiviral therapy.#^dnd^i1#^tm^l
en^kpsychiatry^i1#^tm^len^khepatitis C^i1#^tm^len^ksubstance-related disorders^i
1#other#20#20100715#07/15/2010#20101014#10/14/2010#Ministry of Social Affairs#ES
ZA Kht#KABKT-M-08-0003#v15n2a13.htm#Internet^ihttp://www.scielo.br/scielo.php?sc
ript=sci_arttext&pid=S1413-86702011000200013##
00355000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704012300073002001300196#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#5#1#article#96#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>BRIEF COMMUNICATION</b
></font></p>     ^cY#v15n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#6#2#article#96#<p>&nbsp;</p>     ^cY#
v15n2a13.htm##
00411000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704017900073002001300252#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#7#3#article#96#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Difficulties with 
interferon treatment in former intravenous drug users</b></font></p>     ^cY#v15
n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#8#4#article#96#<p>&nbsp;</p>     ^cY#
v15n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#9#5#article#96#<p>&nbsp;</p>     ^cY#
v15n2a13.htm##
00454000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704022100074002001300295#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#10#6#article#96#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>G&aacute;bor Gazdag<sup>I</sup>; Ge
rgely Horv&aacute;th<sup>II</sup>; Olga Szab&oacute;<sup>III</sup>; Gabor S Ungv
ari<sup>IV</sup></b></font></p>     ^cY#v15n2a13.htm##
00436000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704020300074002001300277#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#11#7#article#96#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>MD, PhD, Consultation-Liai
son Psychiatric Service, Szent Istv&aacute;n and Szent L&aacute;szl&oacute; Hosp
itals, Hungary    ^cY#v15n2a13.htm##
00323000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704009000074002001300164#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#12#8#article#96#<br> <sup>II</sup>MSc
, Drug Focal Point, National Center for Epidemiology, Hungary    ^cY#v15n2a13.ht
m##
00365000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704013200074002001300206#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#13#9#article#96#<br>   <sup>III</sup>
MD, Hepatology Outpatient Clinic, Szent Istv&aacute;n and Szent L&aacute;szl&oac
ute; Hospitals, Hungary    ^cY#v15n2a13.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007600075002001300151#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#14#10#article#96#<br>   <sup>IV</sup>
MD, PhD, Graylands Hospital, Hungary</font></p>     ^cY#v15n2a13.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011800075002001300193#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#15#11#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a></
font></p>     ^cY#v15n2a13.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#16#12#article#96#<p>&nbsp;</p>     ^c
Y#v15n2a13.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004400075002001300119#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#17#13#article#96#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v15n2a13.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009800075002001300173#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#18#14#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v1
5n2a13.htm##
00754000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704052000075002001300595#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#19#15#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>OBJECTIVES:</b> Intravenous drug u
se accounts for most of the new hepatitis C infections worldwide. Although there
 is an urgent need for antiviral treatment of infected intravenous drug users (I
DUs), several factors compromise their treatment including lack of treatment adh
erence and high dropout rate. The aim of this study was to compare antiviral tre
atment-related problems among former IDUs to HCV-infected patients without a his
tory of IDU.    ^cY#v15n2a13.htm##
00589000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704035500075002001300430#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#20#16#article#96#<br> <b>METHODS:</b>
 This was a retrospective chart review of HCV-infected IDUs who received combine
d antiviral therapy at the Hepatology Outpatient Clinic of Szent L&aacute;szl&oa
cute; Hospital between 1 January 2006 and 31 December 2008. A control group of i
nterferon treated patients with no history of IDU matched for age and sex was se
lected.    ^cY#v15n2a13.htm##
00519000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704028500075002001300360#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#21#17#article#96#<br>   <b>RESULTS:</
b> Dropout rate was significantly higher in the IDU group (p = 0.016). Treatment
 response at the 12th week of treatment was significantly better in the IDU grou
p (p = 0.004). Significantly more IDUs underwent antiviral treatment while in pr
ison (p = 0.008).    ^cY#v15n2a13.htm##
00589000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704035500075002001300430#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#22#18#article#96#<br>   <b>CONCLUSION
S:</b> In this study higher dropout rate was found among IDUs. IDUs had a better
 response rate to antiviral therapy compared to controls. More attention should 
be paid to factors that worsen treatment adherence of IDUs - particularly lack o
f abstinence - in order to increase the effectiveness of antiviral therapy.</fon
t></p>     ^cY#v15n2a13.htm##
00409000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704017500075002001300250#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#23#19#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> psychiatry; hepatiti
s C; substance-related disorders.</font></p> <hr size="1" noshade>     ^cY#v15n2
a13.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#24#20#article#96#<p>&nbsp;</p>     ^c
Y#v15n2a13.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#25#21#article#96#<p>&nbsp;</p>     ^c
Y#v15n2a13.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010900075002001300184#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#26#22#article#96#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>INTRODUCTION</b></i></font></p>
     ^cY#v15n2a13.htm##
00936000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704070200075002001300777#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#27#23#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">In several European countries the pre
valence of hepatitis C virus (HCV) infection in intravenous drug users (IDUs) is
 above 70%.<sup>1-3</sup> In Hungary until 2006 only limited data from health se
rvice providers were available.<sup>4-6</sup> Hungarian surveys reported 10- 30%
 HCV prevalence rates in IDUs. Starting in 2006, the annual screening of IDUs co
vering specialized outpatient clinics and needle/syringe programs (NSP) using 'd
ried blood spot' techniques yielded a national prevalence of about 25%, though i
n Budapest the prevalence was considerably higher, 36% and in one NSP it even re
ached 70%.<sup>7</sup></font></p>     ^cY#v15n2a13.htm##
01386000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704115200075002001301227#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#28#24#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The most effective current therapy of
 HCV infection is pegylated interferon and ribavirin combination that could achi
eve sustained treatment response in 50-60% of the cases.<sup>8,9</sup> There is 
no generally accepted recommendation concerning the antiviral treatment of activ
e IDUs. Some authors argue that active IDU is a contraindication for combination
 therapy, partly due to their poor treatment adherence and partly to the increas
ed likelihood of re-infection.<sup>10</sup> Others regard treatment necessary fo
r harm-reduction and preventing further spreading of infection.<sup>11</sup> The
re is growing evidence that even in active IDUs the benefit of antiviral treatme
nt exceeds the risks of side effects and re-infection.<sup>12</sup> Both active 
and former IDUs have a significantly higher dropout rate compared to HCV-infecte
d patients without a history of illicit drug use.<sup>13,14</sup> In Budapest, t
he Hepatology Outpatient Clinic of Szent L&aacute;szl&oacute; Hospital plays a k
ey role in the examination and antiviral treatment of HCV positive IDUs.</font><
/p>     ^cY#v15n2a13.htm##
00502000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704026800075002001300343#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#29#25#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The aim of this study was to compare 
antiviral treatment-related problems among HCV-infected patients with and withou
t a history of illicit drug use in the period between 2006 and 2008.</font></p> 
    ^cY#v15n2a13.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#30#26#article#96#<p>&nbsp;</p>     ^c
Y#v15n2a13.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010400075002001300179#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#31#27#article#96#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>METHODS</b></i></font></p>     
^cY#v15n2a13.htm##
00870000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704063600075002001300711#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#32#28#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">This was a retrospective chart review
 of HCV-infected IDUs who received combined antiviral therapy at the Hepatology 
Outpatient Clinic of Szent L&aacute;szl&oacute; Hospital between 1 January 2006 
and 31 December 2008. A control group of interferon-treated patients without a h
istory of drug use matched for age and sex was selected. The following treatment
 outcomes were analyzed: HCV-PCR results, dropout rate, treatment response, and 
psychiatric complications. The percentage of patients receiving antiviral therap
y while in prison was also recorded.</font></p>     ^cY#v15n2a13.htm##
00675000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704044100075002001300516#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#33#29#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">For statistical analysis the SPSS 10.
0 package (Statistical Package for Social Sciences, Chicago, IL, USA) was used. 
Descriptive data were presented with means and standard deviations. Binomial dat
a were compared with the chi-square test; if the value in a cell was less than f
ive, the Fisher exact test was applied. Statistical significance was set at 0.05
.</font></p>     ^cY#v15n2a13.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#34#30#article#96#<p>&nbsp;</p>     ^c
Y#v15n2a13.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010400075002001300179#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#35#31#article#96#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>RESULTS</b></i></font></p>     
^cY#v15n2a13.htm##
01309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704107500075002001301150#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#36#32#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Of the 6,759 patients who attended th
e Hepatology Outpatient Clinic between 1 January 2006 and 31 December 2008, 123 
had a history of IDU and 36 of them (28%; 29 men and 7 women) received antiviral
 treatment for chronic hepatitis C. The mean ages of the sample and the control 
group were 34.44 ± 8.85 and 34.56 ± 8.85, respectively. Ten of the 36 IDUs dropp
ed out during treatment (<a href="/img/revistas/bjid/v15n2/a13tab01.jpg">Table 1
</a>). <a href="/img/revistas/bjid/v15n2/a13tab02.jpg">Table 2</a> shows the com
parison between IDUs and controls with respect to treatment. Two IDU patients we
re on methadone maintenance, another two on buprenorphin+naloxon maintenance whi
le undergoing antiviral treatment; none of these four IDUs dropped out. Abstinen
ce was ascertained in 7 of the 36 IDU subjects by psychiatric evaluation. Anothe
r five cases were assessed by a psychiatrist (GG) to monitor their ongoing psych
iatric treatment or to treat the side effects due to the antiviral therapy.</fon
t></p>     ^cY#v15n2a13.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#37#33#article#96#<p>&nbsp;</p>     ^c
Y#v15n2a13.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010700075002001300182#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#38#34#article#96#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>DISCUSSION</b></i></font></p>  
   ^cY#v15n2a13.htm##
00729000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704049500075002001300570#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#39#35#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">It is estimated that there are at lea
st 2000 IDUs in Budapest,<sup>15</sup> and at least 700 of them could be infecte
d with HCV. Yet, only 123 (18%) sought treatment in these three years at the Hep
atology Outpatient Clinic of Szent L&aacute;szl&oacute; Hospital. This low propo
rtion clearly indicates the need for increasing the efforts to better identify H
CV-infected IDUs, a rather difficult task.<sup>16</sup></font></p>     ^cY#v15n2
a13.htm##
01376000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704114200075002001301217#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#40#36#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">In this study, IDU patients premature
ly terminated treatment more frequently (p = 0.016) than the control group; in t
hree cases due to somatic and in one due to psychiatric complications (<a href="
/img/revistas/bjid/v15n2/a13tab01.jpg">Table 1</a>). Five patients dropped out f
or unknown reasons; four received antiviral combination therapy while in prison,
 while the fifth patient reported itching and loss of appetite. Similar dropout 
rate (31%) was found by Seal <i>et al.</i>,<sup>17</sup> and the corresponding f
igure was even higher (43%) in a German report<sup>13</sup> than the 28% seen in
 this study. A possible explanation for the lower dropout rate could be that in 
our hepatology center only 28% of the HCV-infected IDU patients received antivir
al treatment, as opposed to 89% in Schaefer <i>et al</i>'s study which included 
non-IDU patients as well. All four patients in substitution therapy adhered to t
reatment and three became HCV-PCR negative by week 12. By the end of the study p
eriod, however, only one completed the treatment successfully.</font></p>     ^c
Y#v15n2a13.htm##
00919000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704068500075002001300760#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#41#37#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">In the group of IDUs, 50% and 63% bec
ame HCV-PCR negative by the 12<sup>th</sup> and 24<sup>th</sup> week, respective
ly. At the 12th week the IDU group showed significantly better response to treat
ment than the control group (p = 0.004) indicating a more rapid treatment respon
se by IDUs; however, this difference disappeared by the 24<sup>th</sup> week. ID
Us' better antiviral treatment response is also supported by the finding that fe
wer cases of IDUs needed prolonged (up to 18 months) treatment and rapid respons
e was more frequent, though these differences did not reach statistical signific
ance.</font></p>     ^cY#v15n2a13.htm##
00692000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704045800075002001300533#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#42#38#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The response rate of IDUs at week 24 
in this study was rather high (63% were HCV-PCR negative) in comparison to other
 studies.<sup>13,18</sup> This could be explained by the possibility of having m
ore frequent genotypes 2 and 3 in the sample of IDUs,<sup>19</sup> as patients w
ith these two genotypes respond better to antiviral treatment than genotypes 1 a
nd 4.<sup>20</sup></font></p>     ^cY#v15n2a13.htm##
01210000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704097600075002001301051#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#43#39#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The need for psychiatric evaluation w
ere significantly more often<sup>13</sup> in the group of IDUs, although the eva
luation mainly aimed at confirming abstinence. Serious psychiatric problems resu
lting in termination of treatment were restricted to the IDU group. In one case,
 tetrahydrocannabinol (THC) abuse during antiviral therapy led to psychosis; ano
ther patient who had been on psychiatric treatment discontinued antiviral therap
y after one month. Schaefer <i>et al</i>.<sup>13</sup> found similar reasons for
 treatment termination among IDUs. Though psychiatric complications were observe
d slightly more frequently in the control group compared to IDUs (8 vs. 5), psyc
hiatric evaluation was requested for only one case and no patient dropped out fr
om interferon therapy because of psychiatric reasons. In four cases the treating
 physicians recommended short-term anxiolytic treatment.</font></p>     ^cY#v15n
2a13.htm##
00479000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704024500075002001300320#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#44#40#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The results of this study should be i
nterpreted with caution due to the relatively small sample size and the inaccura
cies inherent to retrospective chart reviews.</font></p>     ^cY#v15n2a13.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#45#41#article#96#<p>&nbsp;</p>     ^c
Y#v15n2a13.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010700075002001300182#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#46#42#article#96#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>CONCLUSION</b></i></font></p>  
   ^cY#v15n2a13.htm##
00629000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704039500075002001300470#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#47#43#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">In this study, higher dropout rate wa
s found among IDUs who otherwise had a better response to antiviral therapy comp
ared to controls. More attention should be paid to factors that worsen treatment
 adherence of IDUs - particularly lack of abstinence - in order to increase the 
effectiveness of antiviral therapy.</font></p>     ^cY#v15n2a13.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#48#44#article#96#<p>&nbsp;</p>     ^c
Y#v15n2a13.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010700075002001300182#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#49#45#article#96#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p>  
   ^cY#v15n2a13.htm##
00518000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704027000077002001300347#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#50#46#article#96#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Quaglio GL, Lugoboni
 F, Pajusco B <i>et al</i>. Hepatitis C virus infection: prevalence, predictor v
ariables and prevention opportunities among drug users in Italy. J Viral Hepat 2
003; 10:394-400.    ^cY#v15n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#51#47#article#96#</font></p>     ^cY#
v15n2a13.htm##
00568000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704032000077002001300397#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#52#48#article#96#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Gerlich M, Gschwend 
P, Uchtenhagen A, Kr&auml;mer A, Rehm J. Prevalence of hepatitis and HIV infecti
ons and vaccination rates in patients entering the heroin-assisted treatment in 
Switzerland between 1994 and 2002. Eur J Epidemiol 2006; 21:545-9.    ^cY#v15n2a
13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#53#49#article#96#</font></p>     ^cY#
v15n2a13.htm##
00528000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704028000077002001300357#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#54#50#article#96#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Lidman C, Norden L, 
Kabera M <i>et al</i>. Hepatitis C infection among injection drug users in Stock
holm Sweden: Prevalence and gender. Scand J Infect Dis Jun 2009; 11:1-6. (Epub a
head of print)</font></p>     ^cY#v15n2a13.htm##
00581000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704033300077002001300410#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#55#51#article#96#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Gerevich J. A drogfo
gyaszt&oacute;k ambul&aacute;ns kezel&eacute;s&eacute;nek szempontjai. (Issues i
n the outpatient treatment of drug addict patients.) In: Addikci&oacute;k (Addic
tions), Eds: N&eacute;meth A., Gerevich J. Budapest, Medicina, 2000, pp. 52-72. 
   ^cY#v15n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#56#52#article#96#</font></p>     ^cY#
v15n2a13.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704023800077002001300315#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#57#53#article#96#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Osztrogon&aacute;cz 
H, Gerevich J, Horv&aacute;th G, Tolvaj G, D&aacute;vid K. Prevalence of chronic
 viral hepatitis in drug abusers. Orv Hetil 2000; 141(14):715-8.    ^cY#v15n2a13
.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#58#54#article#96#</font></p>     ^cY#
v15n2a13.htm##
00782000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704053400077002001300611#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#59#55#article#96#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Csoh&aacute;n &Aacut
e;, Csorba J, Keller &Eacute;, Zacher G. A drogfogyaszt&aacute;s eg&eacute;szs&e
acute;g&uuml;gyi vonatkoz&aacute;sai &eacute;s k&ouml;vetkezm&eacute;nyei. (Heal
th aspects and consequences of drug abuse.) In: Jelent&eacute;s a magyarorsz&aac
ute;gi k&aacute;b&iacute;t&oacute;szerhelyzetr&#337;l (Report about the Hungaria
n drug situation.) Eds.: Ny&iacute;r&aacute;dy A., Felvinczi K., Budapest, ICSSZ
EM Professional series, 2004, pp. 81-89.    ^cY#v15n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#60#56#article#96#</font></p>     ^cY#
v15n2a13.htm##
00688000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704044000077002001300517#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#61#57#article#96#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Tak&aacute;cs IG. HI
V- &eacute;s hepatitiszprevalenci&aacute;k alakul&aacute;sa az intrav&eacute;n&a
acute;s haszn&aacute;l&oacute;k k&ouml;z&ouml;tt. (Tendencies of HIV and hepatit
is prevalence in intravenous drug users.) In Drogpolitika sz&aacute;mokban. (Dru
g policy in numbers.) Eds.: Felvinczy K, Ny&iacute;r&aacute;dy A. Budapest, LHar
mattan, 2009, pp. 265-268.    ^cY#v15n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#62#58#article#96#</font></p>     ^cY#
v15n2a13.htm##
00571000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704032300077002001300400#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#63#59#article#96#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Reichard O, Norkgran
s G, Fryd&eacute;n A, Braconier JH, S&ouml;nnerborg A, Weiland O. Comparison of 
3 quantitative HCV RNA assays-accuracy of baseline viral load to predict treatme
nt outcome in chronic hepatitis C. Scand J Infect Dis 1998; 30:441-6.    ^cY#v15
n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#64#60#article#96#</font></p>     ^cY#
v15n2a13.htm##
00647000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704039900077002001300476#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#65#61#article#96#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Poynard T, Marcellin
 P, Lee SS <i>et al</i>. Randomised trial of interferon alpha2b plus ribavirin f
or 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks 
for treatment of chronic infection with hepatitis C virus. International Hepatit
is Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-32.    ^cY#v15n2a1
3.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#66#62#article#96#</font></p>     ^cY#
v15n2a13.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704021100078002001300289#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#67#63#article#96#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Jowett SL, Agarwal
 K, Smith BC <i>et al</i>. Managing chronic hepatitis C acquired through intrave
nous drug use. Q J Med 2001; 94:153-8.    ^cY#v15n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#68#64#article#96#</font></p>     ^cY#
v15n2a13.htm##
00518000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704026900078002001300347#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#69#65#article#96#11#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Serfaty MA, Lawrin
e A, Smith B <i>et al</i>.: Risk factors and medical follow up of drug users tes
ted for hepatitis C - can the risk of transmission be reduced? Drug Alcohol Rev 
1997; 16:339-47.    ^cY#v15n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#70#66#article#96#</font></p>     ^cY#
v15n2a13.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704022200078002001300300#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#71#67#article#96#12#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Hellard M, Sacks-D
avis R, Gold J. Hepatitis C treatment for injecting drug users: a review of the 
available evidence. Clin Inf Dis 2009; 49:561-73.    ^cY#v15n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#72#68#article#96#</font></p>     ^cY#
v15n2a13.htm##
00529000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704028000078002001300358#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#73#69#article#96#13#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Schaefer M, Schmid
t F, Folwaczny C <i>et al</i>. Adherence and mental side effects during hepatiti
s C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hep
atology 2003; 37(2):443-51.    ^cY#v15n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#74#70#article#96#</font></p>     ^cY#
v15n2a13.htm##
00505000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704025600078002001300334#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#75#71#article#96#14#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Cournot M, Glibert
 A, Castel F <i>et al</i>. Management of hepatitis C in active drug users: exper
ience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004; 28:533
-9.    ^cY#v15n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#76#72#article#96#</font></p>     ^cY#
v15n2a13.htm##
00622000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704037300078002001300451#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#77#73#article#96#15#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Nemzeti Drog F&oac
ute;kuszpont: 2009-es &eacute;ves jelent&eacute;s a magyarorsz&aacute;gi k&aacut
e;b&iacute;t&oacute;szer helyzetr&#337;l az EMCDDA sz&aacute;m&aacute;ra. 6.2 fe
jezet. (Hungarian Drug Focal Point: 2009 report on the drug use in Hungary for E
MCDDA. Chapter 6.2) NFP, Budapest, 2009.    ^cY#v15n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#78#74#article#96#</font></p>     ^cY#
v15n2a13.htm##
00504000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704025500078002001300333#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#79#75#article#96#16#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Shad J, Person J, 
Brann O <i>et al</i>. How often are referred chronic hepatitis C patients candid
ates for antiviral therapy (Abstract). Hepatology 2000; 32(Suppl):283A</font></p
>     ^cY#v15n2a13.htm##
00558000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704030900078002001300387#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#80#76#article#96#17#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Seal KH, Currie SL
, Shen H <i>et al</i>. Hepatitis C treatment candidacy and outcomes among 4318 U
S veterans with chronic hepatitis C virus infection: does a history of injection
 drog use matter? J Clin Gastroenterol 2007; 41:199-205.    ^cY#v15n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#81#77#article#96#</font></p>     ^cY#
v15n2a13.htm##
00566000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704031700078002001300395#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#82#78#article#96#18#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Robaeys G, Van Vli
erberghe H, Mathei C <i>et al</i>. Similar compliance and effect of treatment in
 chronic hepatitis C resulting from intravenous drug use in comparison with othe
r infection causes. Eur J Gastroenterol Hepatol 2006; 18:159-66.    ^cY#v15n2a13
.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#83#79#article#96#</font></p>     ^cY#
v15n2a13.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704024900078002001300327#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#84#80#article#96#19#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Galeazzi B, Tufano
 A, Barbierato E, Bortolotti F. Hepatitis C virus infection in Italian intraveno
us drug users: epidemiological and clinical aspects. Liver 1995; 15:209-212.    
^cY#v15n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#85#81#article#96#</font></p>     ^cY#
v15n2a13.htm##
00553000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704030400078002001300382#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#86#82#article#96#20#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">20. McHutchinson JG, G
ordon SC, Schiff ER <i>et al</i>. Interferon alfa-2b alone or in combination wit
h Ribavirin as initial treatment for chronic hepatitis C. Hepatitis Intervention
al Therapy Group. N Engl J Med 1998; 339:1485-1492.    ^cY#v15n2a13.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#87#83#article#96#</font></p>     ^cY#
v15n2a13.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#88#84#article#96#<p>&nbsp;</p>     ^c
Y#v15n2a13.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#89#85#article#96#<p>&nbsp;</p>     ^c
Y#v15n2a13.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704018900075002001300264#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#90#86#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img 
src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:</b
>    ^cY#v15n2a13.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002500075002001300100#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#91#87#article#96#<br> Gabor Gazdag   
 ^cY#v15n2a13.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011500075002001300190#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#92#88#article#96#<br> Consultation-Li
aison Psychiatric Service, Szent Istv&aacute;n and Szent L&aacute;szl&oacute; Ho
spitals    ^cY#v15n2a13.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004500075002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#93#89#article#96#<br> Gy&aacute;li &u
acute;t 5-7. 1097    ^cY#v15n2a13.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003100075002001300106#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#94#90#article#96#<br> Budapest,  Hung
ary    ^cY#v15n2a13.htm##
00274000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004000075002001300115#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#95#91#article#96#<br> Phone/fax: 00-3
6-1-455-8125    ^cY#v15n2a13.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007500075002001300150#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#96#92#article#96#<br> <a href="mailto
:gazdag@lamb.hu">gazdag@lamb.hu</a></font></p>     ^cY#v15n2a13.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009500075002001300170#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#97#93#article#96#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Submitted on: 07/15/2010    ^cY#v15n2
a13.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003800075002001300113#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#98#94#article#96#<br>   Approved on: 
10/14/2010    ^cY#v15n2a13.htm##
00376000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704014200075002001300217#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#99#95#article#96#<br>   Financial Sup
port: The study was funded by a grant from the Ministry of Social Affairs throug
h ESZA Kht. (No: KABKT-M-08-0003).    ^cY#v15n2a13.htm##
00297000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000300073704006200076002001300138#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a13.htm#S#p#100#96#article#96#<br>   We declare n
o conflict of interest.</font></p>     ^cY#v15n2a13.htm##
00643000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100018000950100
01700113810000600130012012000136030001400256065000900270064000500279031000300284
014000800287865000900295002001300304035001000317801001400327#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a13.htm#S#c#101#1#article#20#1#^rND^sQuaglio^nGL#^rND
^sLugoboni^nF#^rND^sPajusco^nB#et al#Hepatitis C virus infection: prevalence, pr
edictor variables and prevention opportunities among drug users in Italy^len#J V
iral Hepat#20030000#2003#10#394-400#20110400#v15n2a13.htm#1352-0504#J Viral Hepa
t##
00721000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
02100112010001600133010001400149012015700163030001600320065000900336064000500345
031000300350014000600353865000900359002001300368035001000381801001600391#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#c#102#2#article#20#2#^rND^sGerl
ich^nM#^rND^sGschwend^nP#^rND^sUchtenhagen^nA#^rND^sKrämer^nA#^rND^sRehm^nJ#Prev
alence of hepatitis and HIV infections and vaccination rates in patients enterin
g the heroin-assisted treatment in Switzerland between 1994 and 2002^len#Eur J E
pidemiol#20060000#2006#21#545-9#20110400#v15n2a13.htm#0392-2990#Eur J Epidemiol#
#
00656000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01600109810000600125012009600131030001900227065000900246064000900255031000300264
014000400267061002000271865000900291002001300300035001000313801001900323#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#c#103#3#article#20#3#^rND^sLidm
an^nC#^rND^sNorden^nL#^rND^sKabera^nM#et al#Hepatitis C infection among injectio
n drug users in Stockholm Sweden: Prevalence and gender^len#Scand J Infect Dis#2
0090600#Jun 2009#11#1-6#Epub ahead of print#20110400#v15n2a13.htm#0036-5548#Scan
d J Infect Dis##
00535000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120054000950180
01400149016001600163016001800179066000900197062000900206065000900215064000500224
014000600229865000900235002001300244#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a13.htm#S#c#104#4#article#20#4#^rND^sGerevich^nJ#A drogfogyasztók ambuláns ke
zelésének szempontjai^lhu#Addikciók^lhu#^rED^sNémeth^nA#^rED^sGerevich^nJ#Budape
st#Medicina#20000000#2000#52-72#20110400#v15n2a13.htm##
00628000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100022000770100018000990100
01700117010001600134010001500150012005800165030001000223065000900233064000500242
03100040024703200030025101400060025486500090026000200130026903500100028280100100
0292#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#c#105#5#article#20#
5#^rND^sOsztrogonácz^nH#^rND^sGerevich^nJ#^rND^sHorváth^nG#^rND^sTolvaj^nG#^rND^
sDávid^nK#Prevalence of chronic viral hepatitis in drug abusers^len#Orv Hetil#20
000000#2000#141#14#715-8#20110400#v15n2a13.htm#0030-6002#Orv Hetil##
00690000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01600109010001600125012006500141018005500206016001700261016001900278066000900297
062002800306065000900334064000500343014000600348865000900354002001300363#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#c#106#6#article#20#6#^rND^sCsoh
án^nÁ#^rND^sCsorba^nJ#^rND^sKeller^nÉ#^rND^sZacher^nG#A drogfogyasztás egészségü
gyi vonatkozásai és következményei^lhu#Jelentés a magyarországi kábítószerhelyze
tr&#337;l^lhu#^rED^sNyírády^nA#^rED^sFelvinczi^nK#Budapest#ICSSZEM Professional 
series#20040000#2004#81-89#20110400#v15n2a13.htm##
00575000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770120076000940180
02700170016001900197016001700216066000900233062001100242065000900253064000500262
014000800267865000900275002001300284#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a13.htm#S#c#107#7#article#20#7#^rND^sTakács^nIG#HIV- és hepatitiszprevalenciá
k alakulása az intravénás használók között^lhu#Drogpolitika számokban^lhu#^rED^s
Felvinczy^nK#^rED^sNyírády^nA#Budapest#LHarmattan#20090000#2009#265-268#20110400
#v15n2a13.htm##
00738000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100019000950100
01600114010002000130010002000150010001700170012013200187030001900319065000900338
06400050034703100030035201400060035586500090036100200130037003500100038380100190
0393#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#c#108#8#article#20#
8#^rND^sReichard^nO#^rND^sNorkgrans^nG#^rND^sFrydén^nA#^rND^sBraconier^nJH#^rND^
sSönnerborg^nA#^rND^sWeiland^nO#Comparison of 3 quantitative HCV RNA assays-accu
racy of baseline viral load to predict treatment outcome in chronic hepatitis C^
len#Scand J Infect Dis#19980000#1998#30#441-6#20110400#v15n2a13.htm#0036-5548#Sc
and J Infect Dis##
00765000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100019000940100
01400113810000600127012025800133030000700391065000900398064000500407031000400412
014000800416865000900424002001300433035001000446801000700456#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a13.htm#S#c#109#9#article#20#9#^rND^sPoynard^nT#^rND^
sMarcellin^nP#^rND^sLee^nSS#et al#Randomised trial of interferon alpha2b plus ri
bavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 
48 weeks for treatment of chronic infection with hepatitis C virus: Internationa
l Hepatitis Interventional Therapy Group (IHIT)^len#Lancet#19980000#1998#352#142
6-32#20110400#v15n2a13.htm#0099-5355#Lancet##
00579000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01600113810000600129012007100135030000800206065000900214064000500223031000300228
014000600231865000900237002001300246035001000259801000800269#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a13.htm#S#c#110#10#article#20#10#^rND^sJowett^nSL#^rN
D^sAgarwal^nK#^rND^sSmith^nBC#et al#Managing chronic hepatitis C acquired throug
h intravenous drug use^len#Q J Med#20010000#2001#94#153-8#20110400#v15n2a13.htm#
0033-5622#Q J Med##
00609000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01500114810000600129012011900135030001700254710000200271065000900273064000500282
031000300287014000700290865000900297002001300306#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a13.htm#S#c#111#11#article#20#11#^rND^sSerfaty^nMA#^rND^sLawrine^
nA#^rND^sSmith^nB#et al#Risk factors and medical follow up of drug users tested 
for hepatitis C - can the risk of transmission be reduced?^len#Drug Alcohol Rev#
2#19970000#1997#16#339-47#20110400#v15n2a13.htm##
00557000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100021000960100
01400117012008700131030001300218710000200231065000900233064000500242031000300247
014000700250865000900257002001300266#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a13.htm#S#c#112#12#article#20#12#^rND^sHellard^nM#^rND^sSacks-Davis^nR#^rND^s
Gold^nJ#Hepatitis C treatment for injecting drug users: a review of the availabl
e evidence^len#Clin Inf Dis#2#20090000#2009#49#561-73#20110400#v15n2a13.htm##
00662000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01900114810000600133012012900139030001100268065000900279064000500288031000300293
032000200296014000700298865000900305002001300314035001000327801001100337#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#c#113#13#article#20#13#^rND^sSc
haefer^nM#^rND^sSchmidt^nF#^rND^sFolwaczny^nC#et al#Adherence and mental side ef
fects during hepatitis C treatment with interferon alfa and ribavirin in psychia
tric risk groups^len#Hepatology#20030000#2003#37#2#443-51#20110400#v15n2a13.htm#
0161-0538#HEPATOLOGY##
00640000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01600113810000600129012010000135030002400235065000900259064000500268031000300273
014000600276865000900282002001300291035001000304801002400314#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a13.htm#S#c#114#14#article#20#14#^rND^sCournot^nM#^rN
D^sGlibert^nA#^rND^sCastel^nF#et al#Management of hepatitis C in active drug use
rs: experience of an addiction care hepatology unit^len#Gastroenterol Clin Biol#
20040000#2004#28#533-9#20110400#v15n2a13.htm#0399-8320#Gastroenterol Clin Biol##
00471000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760180125000790620004002040660
00900208065000900217064000500226865000900231002001300240#v15n2#V:\SciELO\serial\
bjid\v15n2\markup\v15n2a13.htm#S#c#115#15#article#20#15#Nemzeti Drog Fókuszpont:
 2009-es éves jelentés a magyarországi kábítószer helyzetr&#337;l az EMCDDA szám
ára. 6.2 fejezet^lhu#NFP#Budapest#20090000#2009#20110400#v15n2a13.htm##
00627000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100016000930100
01500109810000600124012010000130030001100230065000900241064000500250031000300255
032000800258020000400266865000900270002001300279035001000292801001100302#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a13.htm#S#c#116#16#article#20#16#^rND^sSh
ad^nJ#^rND^sPerson^nJ#^rND^sBrann^nO#et al#How often are referred chronic hepati
tis C patients candidates for antiviral therapy (Abstract)^len#Hepatology#200000
00#2000#32#^sSuppl#283#20110400#v15n2a13.htm#0161-0538#HEPATOLOGY##
00691000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01400111810000600125012015900131030002100290065000900311064000500320031000300325
014000800328865000900336002001300345035001000358801002100368#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a13.htm#S#c#117#17#article#20#17#^rND^sSeal^nKH#^rND^
sCurrie^nSL#^rND^sShen^nH#et al#Hepatitis C treatment candidacy and outcomes amo
ng 4318 US veterans with chronic hepatitis C virus infection: does a history of 
injection drog use matter?^len#J Clin Gastroenterol#20070000#2007#41#199-205#201
10400#v15n2a13.htm#0192-0790#J Clin Gastroenterol##
00705000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100025000960100
01600121810000600137012014800143030002800291065000900319064000500328031000300333
014000700336865000900343002001300352035001000365801002800375#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a13.htm#S#c#118#18#article#20#18#^rND^sRobaeys^nG#^rN
D^sVan Vlierberghe^nH#^rND^sMathei^nC#et al#Similar compliance and effect of tre
atment in chronic hepatitis C resulting from intravenous drug use in comparison 
with other infection causes^len#Eur J Gastroenterol Hepatol#20060000#2006#18#159
-66#20110400#v15n2a13.htm#0954-691X#Eur J Gastroenterol Hepatol##
00628000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
02000113010002000133012010400153030000600257065000900263064000500272031000300277
014000800280865000900288002001300297035001000310801000600320#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a13.htm#S#c#119#19#article#20#19#^rND^sGaleazzi^nB#^r
ND^sTufano^nA#^rND^sBarbierato^nE#^rND^sBortolotti^nF#Hepatitis C virus infectio
n in Italian intravenous drug users: epidemiological and clinical aspects^len#Li
ver#19950000#1995#15#209-212#20110400#v15n2a13.htm#0106-9543#Liver##
00677000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100017001020100
01700119810000600136012014700142030001300289065000900302064000500311031000400316
014001000320865000900330002001300339035001000352801001300362#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a13.htm#S#c#120#20#article#20#20#^rND^sMcHutchinson^n
JG#^rND^sGordon^nSC#^rND^sSchiff^nER#et al#Interferon alfa-2b alone or in combin
ation with Ribavirin as initial treatment for chronic hepatitis C: Hepatitis Int
erventional Therapy Group^len#N Engl J Med#19980000#1998#339#1485-1492#20110400#
v15n2a13.htm#0028-4793#N Engl J Med##
00274000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00300101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#o#1#1#article#1
#20110406#125405#v15n2a14.htm#81##
02523000000000565000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400110014503500100015601200840
01660100036002500100033002860100043003190100031003620100037003930700076004300700
07800506083115800584085000801742085003101750085002801781085003701809117000601846
07200030185211200090185511100110186411400090187511300110188405800490189500200130
1944#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#h#2#1#article#1#oa#
en#br1.1#1#4.0#ILUS#TAB#14#BJID160#nd#Braz J Infect Dis#15#2#20110400#^f167^l169
#1413-8670#Cefepime versus extended spectrum &#946;-lactamase-producing Enteroba
cteriaceae^len#^rND^1A01^nKeite da Silva^sNogueira#^rND^1A01^nAlessandra Vale^sD
aur#^rND^1A01^nIara Taborda de Messias^sReason#^rND^1A02^nAna Cristina^sGales#^r
ND^1A01^nLibera Maria Dalla^sCosta#Universidade Federal do Paraná^iA01^1Hospital
 de Clínicas^cCuritiba^pBrazil#Universidade Federal de São Paulo^iA02^1Laboratór
io Alerta^cSão Paulo^pBrazil#^len^aThe objective of this study was to evaluate t
he susceptibility to cefepime of a large group of ESBL- producing enterobacteria
 recently isolated in a Brazilian teaching hospital . The study included 280 str
ains of ESBL-producing enterobacteria, isolated between 2005 and 2008. The prese
nce of the genes blaCTX-M, blaTEM and blaSHV was determined by PCR and confirmed
 by nucleotide sequencing. Susceptibility testing for cefepime was performed by 
disc-diffusion, agar dilution method and E-test®. Among the isolates, 34 (12.1%)
 presented a cefepime inhibition zone &gt; 21 and MIC < 8 mg/L by agar dilution 
and E-strip methods. The use of cefepime for the treatment of infections caused 
by ESBL-producing bacteria has been controversial. Some studies of PD/PK show th
e probability of achieving the required PD parameters for cefepime, when the MIC
s were < 8 mg/L, whereas others have reported therapeutic failure with the same 
MIC. Additional data is essential to come to terms about the report and treatmen
t with cefepime in ESBL-producing organisms especially when these microorganisms
 are isolated from sterile sites and from critically ill patients.#^dnd^i1#^tm^l
en^kenterobacteriaceae^i1#^tm^len^kbeta-lactamases^i1#^tm^len^kcephalosporin res
istance^i1#other#11#20100721#07/21/2010#20100816#08/16/2010#Fundação da Universi
dade Federal do Paraná^dUFPR#v15n2a14.htm##
02636000000000565000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400110014503500100015601201120
01660100036002780100033003140100043003470100031003900100037004210700076004580700
07800534083124300612085000801855085003101863085002801894085003701922117000601959
07200030196511200090196811100110197711400090198811300110199705800490200800200130
2057#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#f#3#1#article#1#oa#
en#br1.1#1#4.0#ILUS#TAB#14#BJID160#nd#Braz J Infect Dis#15#2#20110400#^f167^l169
#1413-8670#<b>Cefepime versus extended spectrum</b> <b>&#946;</b><b>-lactamase-p
roducing <i>Enterobacteriaceae</i></b>^len#^rND^1A01^nKeite da Silva^sNogueira#^
rND^1A01^nAlessandra Vale^sDaur#^rND^1A01^nIara Taborda de Messias^sReason#^rND^
1A02^nAna Cristina^sGales#^rND^1A01^nLibera Maria Dalla^sCosta#Universidade Fede
ral do Paraná^iA01^1Hospital de Clínicas^cCuritiba^pBrazil#Universidade Federal 
de São Paulo^iA02^1Laboratório Alerta^cSão Paulo^pBrazil#^len^aThe objective of 
this study was to evaluate the susceptibility to cefepime of a large group of ES
BL- producing enterobacteria recently isolated in a Brazilian teaching hospital 
. The study included 280 strains of ESBL-producing enterobacteria, isolated betw
een 2005 and 2008. The presence of the genes <i>bla</i><sub>CTX-M</sub><i>, bla<
/i><sub>TEM</sub> and <i>bla</i><sub>SHV</sub> was determined by PCR and confirm
ed by nucleotide sequencing. Susceptibility testing for cefepime was performed b
y disc-diffusion, agar dilution method and E-test<sup>®</sup>. Among the isolate
s, 34 (12.1%) presented a cefepime inhibition zone <u>&gt;</u> 21 and MIC <u>&lt
;</u> 8 mg/L by agar dilution and E-strip methods. The use of cefepime for the t
reatment of infections caused by ESBL-producing bacteria has been controversial.
 Some studies of PD/PK show the probability of achieving the required PD paramet
ers for cefepime, when the MICs were &lt; 8 mg/L, whereas others have reported t
herapeutic failure with the same MIC. Additional data is essential to come to te
rms about the report and treatment with cefepime in ESBL-producing organisms esp
ecially when these microorganisms are isolated from sterile sites and from criti
cally ill patients.#^dnd^i1#^tm^len^kenterobacteriaceae^i1#^tm^len^kbeta-lactama
ses^i1#^tm^len^kcephalosporin resistance^i1#other#11#20100721#07/21/2010#2010081
6#08/16/2010#Fundação da Universidade Federal do Paraná^dUFPR#v15n2a14.htm##
02668000000000589000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000210013103100030015203200020015506500090015701400110016603500100
01770120084001870100036002710100033003070100043003400100031003830100037004140700
07800451070008000529083116500609085000801774085003101782085002801813085003701841
11700060187807200030188411200090188711100110189611400090190711300110191605800490
1927002001301976008008901989#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a14.h
tm#S#l#4#1#article#1#^mMar./Apr.^a2011#oa#en#br1.1#1#4.0#ilus#tab#14#BJID160#nd#
Braz. j. infect. dis#15#2#20110400#^f167^l169#1413-8670#Cefepime versus extended
 spectrum &#946;-lactamase-producing Enterobacteriaceae^len#^rND^1A01^nKeite da 
Silva^sNogueira#^rND^1A01^nAlessandra Vale^sDaur#^rND^1A01^nIara Taborda de Mess
ias^sReason#^rND^1A02^nAna Cristina^sGales#^rND^1A01^nLibera Maria Dalla^sCosta#
^iA01^1Universidade Federal do Paraná^2Hospital de Clínicas^cCuritiba^pBrazil#^i
A02^1Universidade Federal de São Paulo^2Laboratório Alerta^cSão Paulo^pBrazil#^l
en^aThe objective of this study was to evaluate the susceptibility to cefepime o
f a large group of ESBL- producing enterobacteria recently isolated in a Brazili
an teaching hospital . The study included 280 strains of ESBL-producing enteroba
cteria, isolated between 2005 and 2008. The presence of the genes blaCTX-M, blaT
EM and blaSHV was determined by PCR and confirmed by nucleotide sequencing. Susc
eptibility testing for cefepime was performed by disc-diffusion, agar dilution m
ethod and E-test®. Among the isolates, 34 (12.1 percent) presented a cefepime in
hibition zone &gt; 21 and MIC < 8 mg/L by agar dilution and E-strip methods. The
 use of cefepime for the treatment of infections caused by ESBL-producing bacter
ia has been controversial. Some studies of PD/PK show the probability of achievi
ng the required PD parameters for cefepime, when the MICs were < 8 mg/L, whereas
 others have reported therapeutic failure with the same MIC. Additional data is 
essential to come to terms about the report and treatment with cefepime in ESBL-
producing organisms especially when these microorganisms are isolated from steri
le sites and from critically ill patients.#^dnd^i1#^tm^len^kenterobacteriaceae^i
1#^tm^len^kbeta-lactamases^i1#^tm^len^kcephalosporin resistance^i1#other#11#2010
0721#07/21/2010#20100816#08/16/2010#Fundação da Universidade Federal do Paraná^d
UFPR#v15n2a14.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&p
id=S1413-86702011000200014##
00355000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704012300073002001300196#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#5#1#article#66#<p align="right"><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>BRIEF COMMUNICATION</b
></font></p>     ^cY#v15n2a14.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#6#2#article#66#<p>&nbsp;</p>     ^cY#
v15n2a14.htm##
00529000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704029700073002001300370#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#7#3#article#66#<p><font size="4" face
="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Cefepime versus ex
tended spectrum</b> </font><b><font size="4">&#946;</font></b><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>-lactamase-producing <i>Enterobacte
riaceae</i></b></font></p>     ^cY#v15n2a14.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#8#4#article#66#<p>&nbsp;</p>     ^cY#
v15n2a14.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#9#5#article#66#<p>&nbsp;</p>     ^cY#
v15n2a14.htm##
00510000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704027700074002001300351#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#10#6#article#66#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Keite da Silva Nogueira<sup>I</sup>
; Alessandra Vale Daur<sup>I</sup>; Iara Taborda de Messias Reason<sup>II</sup>;
 Ana Cristina Gales<sup>III</sup>; Libera Maria Dalla Costa<sup>II</sup></b></fo
nt></p>     ^cY#v15n2a14.htm##
00424000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704019100074002001300265#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#11#7#article#66#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>MSc, Pharmacist, Hospital 
de Cl&iacute;nicas, Universidade Federal do Paran&aacute; - UFPR, Curitiba, Braz
il    ^cY#v15n2a14.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704009600074002001300170#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#12#8#article#66#<br>   <sup>II</sup>P
hD, Researcher, Hospital de Cl&iacute;nicas, UFPR, Curitiba, Brazil    ^cY#v15n2
a14.htm##
00372000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704013900074002001300213#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#13#9#article#66#<br>   <sup>III</sup>
PhD, Laborat&oacute;rio Alerta, Universidade Federal de S&atilde;o Paulo, S&atil
de;o Paulo, Brazil</font></p>     ^cY#v15n2a14.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704011800075002001300193#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#14#10#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a></
font></p>     ^cY#v15n2a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#15#11#article#66#<p>&nbsp;</p>     ^c
Y#v15n2a14.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004400075002001300119#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#16#12#article#66#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#v15n2a14.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009800075002001300173#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#17#13#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v1
5n2a14.htm##
01557000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704132300075002001301398#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#18#14#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The objective of this study was to ev
aluate the susceptibility to cefepime of a large group of ESBL- producing entero
bacteria recently isolated in a Brazilian teaching hospital . The study included
 280 strains of ESBL-producing enterobacteria, isolated between 2005 and 2008. T
he presence of the genes <i>bla</i><sub>CTX-M</sub><i>, bla</i><sub>TEM</sub> an
d <i>bla</i><sub>SHV</sub> was determined by PCR and confirmed by nucleotide seq
uencing. Susceptibility testing for cefepime was performed by disc-diffusion, ag
ar dilution method and E-test<sup>&reg;</sup>. Among the isolates, 34 (12.1%) pr
esented a cefepime inhibition zone <u>&gt;</u> 21 and MIC <u>&lt;</u> 8 mg/L by 
agar dilution and E-strip methods. The use of cefepime for the treatment of infe
ctions caused by ESBL-producing bacteria has been controversial. Some studies of
 PD/PK show the probability of achieving the required PD parameters for cefepime
, when the MICs were &lt; 8 mg/L, whereas others have reported therapeutic failu
re with the same MIC. Additional data is essential to come to terms about the re
port and treatment with cefepime in ESBL-producing organisms especially when the
se microorganisms are isolated from sterile sites and from critically ill patien
ts.</font></p>     ^cY#v15n2a14.htm##
00418000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704018400075002001300259#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#19#15#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> enterobacteriaceae; 
beta-lactamases; cephalosporin resistance.</font></p> <hr size="1" noshade>     
^cY#v15n2a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#20#16#article#66#<p>&nbsp;</p>     ^c
Y#v15n2a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#21#17#article#66#<p>&nbsp;</p>     ^c
Y#v15n2a14.htm##
01838000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704160400075002001301679#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#22#18#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The Clinical Laboratory Standards Ins
titute (CLSI) has recommended, in the period of 2005 to 2009, to perform additio
nal tests for the detection of extended-spectrum beta-lactamases (ESBL) producti
on among <i>Escherichia coli, Klebsiella</i> spp. and <i>Proteus mirabilis</i> i
solates. Strains screened as ESBL-producers were reported as resistant to all pe
nicillins, cephalosporins, and monobactams, regardless of the susceptibility tes
t results. The extra step required to perform these tests and the increasing pre
valence of ESBL among other <i>Enterobacteriaceae</i> have lead specialists to f
ind an alternative to prevent misuse of cephalosporins. Moreover, clinical studi
es have demonstrated that the success of cephalosporin therapy is more related t
o the minimum inhibitory concentration (MIC) than to the presence of mechanisms 
of resistance such as the ESBL production. Based on this knowledge the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI recommendati
ons have been changed.<sup>1,2</sup> In the CLSI guideline M100-S20 (2010), new 
susceptibility breakpoints were proposed for ceftriaxone (<u>&lt;</u> 1 &#181;g/
mL), cefotaxime (<u>&lt;</u> 1 &#181;g/mL), ceftazidime (<u>&lt;</u> 4 &#181; g/
mL) and aztreonam (<u>&lt;</u> 4 mg/L), but not for cefepime (<u>&lt;</u> 8 &#18
1;g/mL).<sup>1</sup> According to this document, the performance of additional t
ests for ESBL detection would be no longer necessary except for epidemiological 
or infection control purposes.<sup>1,2</sup></font></p>     ^cY#v15n2a14.htm##
01401000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704116700075002001301242#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#23#19#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Cefepime, a fourth-generation cephalo
sporin, has been introduced into clinical practice in the mid 1990's.<sup>3</sup
> It has been recommended for treatment of <i>Enterobacteriaceae</i> infections 
as it has rapid penetration through the outer cell membrane and is stable agains
t AmpC enzymes. Cefepime also demonstrates "<i>in vitro</i>" activity against ES
BL-producing <i>Enterobacteriaceae</i>. In addition, the inoculum effect has not
 been correlated to cefepime MICs in animal models of ESBL infections.<sup>4</su
p> Studies in animal models suggest that the cephalosporin pharmacokinetic and p
harmacodynamic (pK/pD) target is similar for the treatment of ESBL- or non- ESBL
-producing pathogens (50% T &gt; MIC). Other parameters such as AUC/MIC &gt; 1,6
54 and C<sub>min</sub>/MIC &gt; 7.6 also indicated good correlation with clinica
l cure and bacteriological eradication. According to these studies, cefepime cur
rent therapeutic dosages would be sufficient to reach the PK/PD target. In this 
manner, it was not necessary to reduce cefepime susceptibility breakpoints.<sup>
5</sup></font></p>     ^cY#v15n2a14.htm##
01002000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704076800075002001300843#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#24#20#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The prescription of cefepime for the 
treatment of ESBL infections imposes a serious clinical dilemma. On one hand, cl
inical use of cefepime probably would reduce carbapenem consumption. However, tr
eatment failure with cefepime has been reported, especially, in nosocomial pneum
onia due to ESBL-producing <i>Enterobacteriaceae</i> even in those with MICs <u>
&lt;</u> 8 mg/L.<sup>3</sup> In addition, some pK/pD studies show that the proba
bility of achieving the pK/pD target with cefepime is lower when the pathogen MI
Cs varied from 1 to 8 mg/L. In these cases, to achieve the desired pK/pD target,
 cefepime should be prescribed in prolonged or continuous infusion regimens.<sup
>5</sup></font></p>     ^cY#v15n2a14.htm##
00501000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704026700075002001300342#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#25#21#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The main objective of our study was t
o evaluate cefepime susceptibility in a large group of ESBL-producing <i>Enterob
acteriaceae</i> recently isolated at a Brazilian teaching hospital.</font></p>  
   ^cY#v15n2a14.htm##
01171000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704093700075002001301012#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#26#22#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Clinical isolates of ESBL-producing <
i>Enterobacteriaceae</i> (n = 280) collected from distinct body sites of patient
s at the   Hospital of the <i>Universidade Federal do Paran&aacute;</i> (HC/UFPR
,   Curitiba, Southern Brazil) were studied. Only a single representative   of a
 pulsed field gel electrophoresis (PFGE) pattern   was included. Species identif
ication was carried out using   the VITEK system (bioM&eacute;rieux, Hazelwood, 
MO). Susceptibility   to cefepime was determined by disc-diffusion, agar   dilut
ion method and E-test<sup>&reg;</sup> according to CLSI guidelines<sup>6</sup> a
nd manufacturer's instructions (BioMerieux, Hazelwood,   MO), respectively. ESBL
 encoded genes, <i>bla</i><sub>CTX-M</sub>, <i>bla</i><sub>TEM</sub> or <i>bla</
i><sub>SHV</sub> were analysed by polymerase chain reaction (PCR) and DNA sequen
cing.<sup>7</sup></font></p>     ^cY#v15n2a14.htm##
01274000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704104000075002001301115#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#27#23#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">The cumulative frequency distribution
 of cefepime is   shown in <a href="/img/revistas/bjid/v15n2/a14tab01.jpg">Table
 1</a>. Among 280 strains of <i>Enterobacteriaceae</i>,   34 (12.1%) isolates sh
owed cefepime inhibition zones <u>&gt;</u> 21 mm or MICs <u>&lt;</u> 8 &#181;g/m
L by disc-diffusion and agar   dilution/E-test methods, respectively, and would 
be classified as susceptible to cefepime. They were isolated from blood (8), cer
ebrospinal fluid (2), peritoneal fluids (3) and   urine (21) of patients hospita
lized at intensive care units   (12), surgical wards (9) and other clinics (13).
 <i>K. pneumoniae</i> (64.7%) and E. cloacae (20.6%) were the most frequent   sp
ecies susceptible to cefepime. Regarding the ESBL genes   encoded by the Enterob
acteriaceae isolates, <i>bla</i><sub>CTX-M-2</sub> and <i>bla</i><sub>SHV-12</su
b> were the most frequently detected among isolates susceptible to cefepime as d
epicted in <a href="#fig1">Figure 1</a>.</font></p>     ^cY#v15n2a14.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003500075002001300110#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#28#24#article#66#<p><a name="fig1"></
a></p>     ^cY#v15n2a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#29#25#article#66#<p>&nbsp;</p>     ^c
Y#v15n2a14.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704008000075002001300155#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#30#26#article#66#<p align="center"><i
mg src="/img/revistas/bjid/v15n2/a14fig01.jpg"></p>     ^cY#v15n2a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#31#27#article#66#<p>&nbsp;</p>     ^c
Y#v15n2a14.htm##
01468000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704123400075002001301309#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#32#28#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Some studies have previously shown th
at extended-spectrum beta-lactamases are prevalent in many countries around the 
world, chiefly in South America. Using previous CLSI guidelines, all those isola
tes would have been considered cefepime-resistant. This recommendation leads to 
increased use of carbapenems and limited the use of cefepime in ESBL infections.
 Our study shows that 12.1% of the ESBL-producing <i>Enterobacteriaceae</i> test
ed were susceptible to cefepime. This phenotype was found most frequently in SHV
-12-producing <i>K. pneumoniae</i>; however, a significant number of CTX-M-produ
cing isolates, which are the most prevalent in South America, was also susceptib
le to cefepime. In other geographic regions, where group TEM or SHV is prevalent
, the cefepime susceptibility among ESBL-producing isolates might be even higher
. In North America, 93.8% and 92.0% of the ESBL-producing <i>E. coli</i> and -<i
>K. pneumoniae</i>, respectively, were susceptible to cefepime.<sup>8</sup> In T
aiwan, Liao <i>et al</i>. reported that 77% and 73.4% of the ESBL-producing <i>E
. coli</i> and <i>K. pneumoniae</i> were cefepime susceptible.<sup>9</sup></font
></p>     ^cY#v15n2a14.htm##
01242000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704100800075002001301083#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#33#29#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">In this study, 4.8% of ESBL-producing
 enterobacteria isolates have shown MIC <u>&lt;</u> 1 mg/L. PK/PD studies sugges
t that successful outcome using conventional regimens of cefepime (50% T &gt; MI
C) could be achieved for treatment of infections caused by such isolates, regard
less ESBL production.<sup>5</sup> Most authors would consider acceptable the cli
nical use of cefepime in these conditions. However, clinical outcomes are contra
dictory for infections caused by isolates, in which MICs varied from 1 to 8 mg/L
. For infections caused by such isolates, pK/pD studies have demonstrated that t
he pharmacodynamic target could be achieved only if the infusion time or dosage 
were modified.<sup>4</sup> In this manner, EUCAST recommends that only isolates 
exhibiting MICs for cephalosporins, including cefepime, <u>&lt;</u> 1 mg/L must 
be reported as susceptible to cephalosporins, regardless of ESBL production.<sup
>2</sup></font></p>     ^cY#v15n2a14.htm##
01333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704109900075002001301174#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#34#30#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Several reports have shown therapeuti
c failure when the patient had received cefepime for treatment of non-urinary in
fections caused by ESBL-producing organisms. These data indicate that the body s
ite of infection might affect cefepime effectiveness.<sup>11</sup> In our study,
 although most of the ESBL-producing isolates susceptible to cefepime were from 
urinary tract infections, 38.2% of these isolates were originated from sterile b
ody sites of infection and 35% were from critically ill patients, increasing the
 chance of a possible therapeutic failure. In addition, the safety of using cefe
pime has been questioned. A metanalysis study associated the use of cefepime wit
h increase in the mortality rates.<sup>12</sup> Although this finding has been q
uestioned by some authors, other studies have reported many untoward effects of 
this drug.<sup>3</sup> Therefore, the prescription of modified cefepime regimens
 especially those using higher doses need more extensive evaluation before their
 use is encouraged.</font></p>     ^cY#v15n2a14.htm##
00863000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704062900075002001300704#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#35#31#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">At this moment, it would be difficult
 to consider cefepime a safe option for treating ESBL infections, particularly t
hose caused by isolates with MICs between 1 and 8 mg/L or cultured from sterile 
sites and/or from critically ill patients. Moreover, the discordance between CLS
I and EUCAST guidelines may cause confusion among microbiologists and infectious
 diseases specialists. While the role of cefepime in the treatment of ESBL infec
tions is not established by clinical studies, compliance with the European guide
lines seems more appropriate.</font></p>     ^cY#v15n2a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#36#32#article#66#<p>&nbsp;</p>     ^c
Y#v15n2a14.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010700075002001300182#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#37#33#article#66#<p><font size="3" fa
ce="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p>  
   ^cY#v15n2a14.htm##
00499000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704025100077002001300328#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#38#34#article#66#1#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Clinical Laboratory 
and Standard Institute. Performance Standards for Antimicrobial Susceptibility T
esting;Twentieth Informational Supplement M100-S20. Pennsylvania: CLSI; 2010.   
 ^cY#v15n2a14.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#39#35#article#66#</font></p>     ^cY#
v15n2a14.htm##
00569000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704032100077002001300398#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#40#36#article#66#2#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">2. European Committee o
n Antimicrobial Susceptibility Testing. Breakpoints and expert rules for 3<sup>r
d</sup> and 4<sup>th</sup> generation cephalosporins and <i>Enterobacteriaceae</
i> with and without beta-lactam resistance organisms. EUCAST. 2009.    ^cY#v15n2
a14.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#41#37#article#66#</font></p>     ^cY#
v15n2a14.htm##
00472000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704022400077002001300301#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#42#38#article#66#3#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Endimiani A, Perez F
, Bonomo RA. Cefepime: a reappraisal in an era of increasing antimicrobial resis
tance. Expert Rev Anti Infect Ther 2008; 6:805-24.    ^cY#v15n2a14.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#43#39#article#66#</font></p>     ^cY#
v15n2a14.htm##
00571000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704032300077002001300400#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#44#40#article#66#4#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Maglio D, Ong C, Ban
evicius MA <i>et al</i>. Determination of the in vivo pharmacodynamic profile of
 cefepime against extended-spectrum-beta-lactamase-producing <i>Escherichia coli
</i> at various inocula. Antimicrob Agents Chemother 2004; 48:1941-7.    ^cY#v15
n2a14.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#45#41#article#66#</font></p>     ^cY#
v15n2a14.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704023700077002001300314#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#46#42#article#66#5#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Lee, S Y, Kuti JL, N
icolau DP. Cefepime pharmacodynamics in patients with extended spectrum beta-lac
tamase (ESBL) and non-ESBL infections. J Infect 2007; 54:463-8.    ^cY#v15n2a14.
htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#47#43#article#66#</font></p>     ^cY#
v15n2a14.htm##
00509000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704026100077002001300338#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#48#44#article#66#6#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Clinical Laboratory 
and Standard Institute. Performance Standards for Antimicrobial Disk Susceptibil
ity Tests; approved Standard - Tenth Edition document M02-A10. Pennsylvania CLSI
; 2009.    ^cY#v15n2a14.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#49#45#article#66#</font></p>     ^cY#
v15n2a14.htm##
00542000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704029400077002001300371#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#50#46#article#66#7#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Payne DJ, Thomsom CJ
. Molecular approaches for the detection and Identification of beta-lactamases. 
In: Woodford N, Johnson AP eds. Molecular Bacteriology: Protocols and Clinical A
pplications. Totowa: Humana Press. 1998.    ^cY#v15n2a14.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#51#47#article#66#</font></p>     ^cY#
v15n2a14.htm##
00607000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704035900077002001300436#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#52#48#article#66#8#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Sader, H S, Fritsche
 TR, Jones RN. Potency and spectrum trends for cefepime tested against 65746 cli
nical bacterial isolates collected in North American medical centers: results fr
om the SENTRY Antimicrobial Surveillance Program (1998-2003). Diagn Microbiol In
fect Dis 2005; 52:265-73.    ^cY#v15n2a14.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#53#49#article#66#</font></p>     ^cY#
v15n2a14.htm##
00618000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704037000077002001300447#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#54#50#article#66#9#<p><fo
nt size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Liao CH, Sheng WH, W
ang JT <i>et al</i>. In vitro activities of 16 antimicrobial agents against clin
ical isolates of extended-spectrum beta-lactamase-producing <i>Escherichia coli<
/i> and <i>Klebsiella</i> pneumoniae in two regional hospitals in Taiwan. J Micr
obiol Immunol Infect 2006; 39:59-66.    ^cY#v15n2a14.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#55#51#article#66#</font></p>     ^cY#
v15n2a14.htm##
00553000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704030400078002001300382#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#56#52#article#66#10#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Kotapati S, Kuti J
L, Nightingale CH, Nicolau DP. Clinical implications of extended spectrum beta-l
actamase (ESBL) producing <i>Klebsiella</i> species and <i>Escherichia coli</i> 
on cefepime effectiveness. J Infect 2005; 51:211-7.    ^cY#v15n2a14.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#57#53#article#66#</font></p>     ^cY#
v15n2a14.htm##
00478000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704022900078002001300307#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#58#54#article#66#11#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Yahav D, Paul M, F
raser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic rev
iew and meta-analysis. Lancet Infect Dis 2007; 7:338-48.    ^cY#v15n2a14.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#59#55#article#66#</font></p>     ^cY#
v15n2a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#60#56#article#66#<p>&nbsp;</p>     ^c
Y#v15n2a14.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#61#57#article#66#<p>&nbsp;</p>     ^c
Y#v15n2a14.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704018900075002001300264#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#62#58#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img 
src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:</b
>    ^cY#v15n2a14.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003800075002001300113#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#63#59#article#66#<br>   Keite da Silv
a Nogueira    ^cY#v15n2a14.htm##
00294000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006000075002001300135#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#64#60#article#66#<br>   Rua Comendado
r Macedo, 275. Ap.63. , Curitiba    ^cY#v15n2a14.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704005400075002001300129#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#65#61#article#66#<br>   80060-030 Cen
tro, Paran&aacute;, Brazil    ^cY#v15n2a14.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009900075002001300174#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#66#62#article#66#<br>   <a href="mail
to:keitenogueira@hotmail.com">keitenogueira@hotmail.com</a></font></p>     ^cY#v
15n2a14.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009500075002001300170#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#67#63#article#66#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif">Submitted on: 07/21/2010    ^cY#v15n2
a14.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003800075002001300113#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#68#64#article#66#<br>   Approved on: 
08/16/2010    ^cY#v15n2a14.htm##
00382000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704014800075002001300223#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#69#65#article#66#<br>   Financial Sup
port: This work was supported by FUNPAR - Funda&ccedil;&atilde;o da Universidade
 Federal do Paran&aacute; (FUNPAR/UFPR).    ^cY#v15n2a14.htm##
00297000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006300075002001300138#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a14.htm#S#p#70#66#article#66#<br>   We declare no
 conflicts of interest.</font></p>     ^cY#v15n2a14.htm##
00517000000000229000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740170043000760180112001190660
01500231062000500246065000900251064000500260865000900265002001300274#v15n2#V:\Sc
iELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#c#71#1#article#11#1#Clinical Labora
tory and Standard Institute#Performance Standards for Antimicrobial Susceptibili
ty Testing: Twentieth Informational Supplement M100-S20^len#^ePennsylvania#CLSI#
20100000#2010#20110400#v15n2a14.htm##
00544000000000217000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740170059000760180148001350620
00700283065000900290064000500299865000900304002001300313#v15n2#V:\SciELO\serial\
bjid\v15n2\markup\v15n2a14.htm#S#c#72#2#article#11#2#European Committee on Antim
icrobial Susceptibility Testing#Breakpoints and expert rules for 3rd and 4th gen
eration cephalosporins and Enterobacteriaceae with and without beta-lactam resis
tance organisms^len#EUCAST#20090000#2009#20110400#v15n2a14.htm##
00557000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100019000760100015000950100
01700110012007700127030002800204710000200232065000900234064000500243031000200248
014000700250865000900257002001300266#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a14.htm#S#c#73#3#article#11#3#^rND^sEndimiani^nA#^rND^sPerez^nF#^rND^sBonomo^
nRA#Cefepime: a reappraisal in an era of increasing antimicrobial resistance^len
#Expert Rev Anti Infect Ther#2#20080000#2008#6#805-24#20110400#v15n2a14.htm##
00702000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100016000760100013000920100
02100105810000600126012015600132030002800288065000900316064000500325031000300330
014000700333865000900340002001300349035001000362801002800372#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a14.htm#S#c#74#4#article#11#4#^rND^sMaglio^nD#^rND^sO
ng^nC#^rND^sBanevicius^nMA#et al#Determination of the in vivo pharmacodynamic pr
ofile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia
 coli at various inocula^len#Antimicrob Agents Chemother#20040000#2004#48#1941-7
#20110400#v15n2a14.htm#0066-4804#Antimicrob Agents Chemother##
00598000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100015000760100015000910100
01800106012011100124030000900235065000900244064000500253031000300258014000600261
865000900267002001300276035001000289801000900299#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a14.htm#S#c#75#5#article#11#5#^rND^sLee^nS Y#^rND^sKuti^nJL#^rND^
sNicolau^nDP#Cefepime pharmacodynamics in patients with extended spectrum beta-l
actamase (ESBL) and non-ESBL infections^len#J Infect#20070000#2007#54#463-8#2011
0400#v15n2a14.htm#0163-4453#J Infect##
00524000000000229000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740170043000760180121001190660
01300240062000500253065000900258064000500267865000900272002001300281#v15n2#V:\Sc
iELO\serial\bjid\v15n2\markup\v15n2a14.htm#S#c#76#6#article#11#6#Clinical Labora
tory and Standard Institute#Performance Standards for Antimicrobial Disk Suscept
ibility Tests; approved Standard: Tenth Edition document M02-A10^len#Pennsylvani
a#CLSI#20090000#2009#20110400#v15n2a14.htm##
00625000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100016000760100018000920120
08100110016001800191016001800209018006400227066000700291062001300298065000900311
064000500320865000900325002001300334#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a14.htm#S#c#77#7#article#11#7#^rND^sPayne^nDJ#^rND^sThomsom^nCJ#Molecular app
roaches for the detection and Identification of beta-lactamases^len#^rED^sWoodfo
rd^nN#^rED^sJohnson^nAP#Molecular Bacteriology: Protocols and Clinical Applicati
ons^len#Totowa#Humana Press#19980000#1998#20110400#v15n2a14.htm##
00738000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100017000760100019000930100
01600112012021000128030002700338065000900365064000500374031000300379014000700382
865000900389002001300398035001000411801002700421#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a14.htm#S#c#78#8#article#11#8#^rND^sSader^nH S#^rND^sFritsche^nTR
#^rND^sJones^nRN#Potency and spectrum trends for cefepime tested against 65746 c
linical bacterial isolates collected in North American medical centers: results 
from the SENTRY Antimicrobial Surveillance Program (1998-2003)^len#Diagn Microbi
ol Infect Dis#20050000#2005#52#265-73#20110400#v15n2a14.htm#0732-8893#Diagn Micr
obiol Infect Dis##
00694000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740100015000760100016000910100
01500107810000600122012020200128030002700330710000200357065000900359064000500368
031000300373014000600376865000900382002001300391#v15n2#V:\SciELO\serial\bjid\v15
n2\markup\v15n2a14.htm#S#c#79#9#article#11#9#^rND^sLiao^nCH#^rND^sSheng^nWH#^rND
^sWang^nJT#et al#In vitro activities of 16 antimicrobial agents against clinical
 isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Kle
bsiella pneumoniae in two regional hospitals in Taiwan^len#J Microbiol Immunol I
nfect#2#20060000#2006#39#59-66#20110400#v15n2a14.htm##
00671000000000301000450000400060000070200480000670500020005470600020005670000030
00587010003000617090008000647080003000721180003000750100018000780100015000960100
02200111010001800133012014500151030000900296065000900305064000500314031000300319
014000600322865000900328002001300337035001000350801000900360#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a14.htm#S#c#80#10#article#11#10#^rND^sKotapati^nS#^rN
D^sKuti^nJL#^rND^sNightingale^nCH#^rND^sNicolau^nDP#Clinical implications of ext
ended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichi
a coli on cefepime effectiveness^len#J Infect#20050000#2005#51#211-7#20110400#v1
5n2a14.htm#0163-4453#J Infect##
00599000000000301000450000400060000070200480000670500020005470600020005670000030
00587010003000617090008000647080003000721180003000750100015000780100014000930100
01600107010001500123010001900138012007500157030001800232710000200250065000900252
064000500261031000200266014000700268865000900275002001300284#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a14.htm#S#c#81#11#article#11#11#^rND^sYahav^nD#^rND^s
Paul^nM#^rND^sFraser^nA#^rND^sSarid^nN#^rND^sLeibovici^nL#Efficacy and safety of
 cefepime: a systematic review and meta-analysis^len#Lancet Infect Dis#2#2007000
0#2007#7#338-48#20110400#v15n2a14.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#o#1#1#article#1
#20110406#125407#v15n2a15.htm#122##
02528000000000565000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400110014503500100015601201120
01660100030002780100041003080100046003490100038003950100031004330700045004640700
02600509070004600535083120400581085000801785085004401793085001601837085004701853
11700060190007200030190611200090190911100110191811400090192911300110193800200130
1949#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#h#2#1#article#1#oa#
en#br1.1#1#4.0#ILUS#TAB#15#BJID160#nd#Braz J Infect Dis#15#2#20110400#^f170^l173
#1413-8670#Clinical aspects of influenza A (H1N1) in HIV-infected individuals in
 São Paulo during the pandemic of 2009^len#^rND^1A01^nRosana Del^sBianco#^rND^1A
01^nMaria Silvia Biagioni^sSantos#^rND^1A02^nMaria Clara Gianna Garcia^sRibeiro#
^rND^1A03^nAna Teresa Rodriguez^sViso#^rND^1A01^nValquíria^sCarvalho#SES SP^iA01
^1CRT DST AIDS^2Inpatient Service#SES SP^iA02^1CRT DST AIDS#SES SP^iA03^1CRT DST
 AIDS^2Ambulatory Service#^len^aOBJECTIVE: To describe the clinical aspects of H
1N1 among HIV coinfected patients seen at a reference center for AIDS treatment 
in São Paulo, Brazil. Design: Observational and prospective cohort study. METHOD
S: Descriptive study of clinical and laboratory investigation of HIV-infected pa
tients with confirmed diagnosis of influenza A (H1N1) in 2009. We analyzed patie
nts monitored in CRT/DST/AIDS, a specialized service for people living with HIV,
 located in São Paulo, Brazil. RESULTS: 108 individuals presented with symptoms 
of H1N1 infection at the CRT DST/AIDS in 2009. Eighteen patients (16.7%) had con
firmation of the diagnosis of influenza A. Among the confirmed cases, ten (55.6%
) were hospitalized and eight (44.4%) were outpatients. Dyspnea was present in n
ine patients (50%), hemoptysis in three (16%). Six patients (60%) required thera
py with supplemental oxygen. All patients had good clinical outcomes and none di
ed. CONCLUSIONS: In our hospital, the symptoms that led patients to seek medical
 care were similar to the common flu. Hospital admission and the early introduct
ion of antibiotics associated with oseltamivir may have been the cause of the fa
vorable outcome of our cases.#^dnd^i1#^tm^len^kinfluenza A virus, H1N1 subtype^i
1#^tm^len^kHIV^i1#^tm^len^kacquired immunodeficiency syndrome^i1#other#14#201008
10#08/10/2010#20100927#09/27/2010#v15n2a15.htm##
02563000000000565000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000180011303100030013103200020013406500090013601400110014503500100015601201190
01660100030002850100041003150100046003560100038004020100031004400700045004710700
02600516070004600542083123200588085000801820085004401828085001601872085004701888
11700060193507200030194111200090194411100110195311400090196411300110197300200130
1984#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#f#3#1#article#1#oa#
en#br1.1#1#4.0#ILUS#TAB#15#BJID160#nd#Braz J Infect Dis#15#2#20110400#^f170^l173
#1413-8670#<b>Clinical aspects of influenza A (H1N1) in HIV-infected individuals
 in São Paulo during the pandemic of 2009</b>^len#^rND^1A01^nRosana Del^sBianco#
^rND^1A01^nMaria Silvia Biagioni^sSantos#^rND^1A02^nMaria Clara Gianna Garcia^sR
ibeiro#^rND^1A03^nAna Teresa Rodriguez^sViso#^rND^1A01^nValquíria^sCarvalho#SES 
SP^iA01^1CRT DST AIDS^2Inpatient Service#SES SP^iA02^1CRT DST AIDS#SES SP^iA03^1
CRT DST AIDS^2Ambulatory Service#^len^a<b>OBJECTIVE:</b> To describe the clinica
l aspects of H1N1 among HIV coinfected patients seen at a reference center for A
IDS treatment in São Paulo, Brazil. Design: Observational and prospective cohort
 study. <b>METHODS:</b> Descriptive study of clinical and laboratory investigati
on of HIV-infected patients with confirmed diagnosis of influenza A (H1N1) in 20
09. We analyzed patients monitored in CRT/DST/AIDS, a specialized service for pe
ople living with HIV, located in São Paulo, Brazil. <b>RESULTS:</b> 108 individu
als presented with symptoms of H1N1 infection at the CRT DST/AIDS in 2009. Eight
een patients (16.7%) had confirmation of the diagnosis of influenza A. Among the
 confirmed cases, ten (55.6%) were hospitalized and eight (44.4%) were outpatien
ts. Dyspnea was present in nine patients (50%), hemoptysis in three (16%). Six p
atients (60%) required therapy with supplemental oxygen. All patients had good c
linical outcomes and none died. <b>CONCLUSIONS:</b> In our hospital, the symptom
s that led patients to seek medical care were similar to the common flu. Hospita
l admission and the early introduction of antibiotics associated with oseltamivi
r may have been the cause of the favorable outcome of our cases.#^dnd^i1#^tm^len
^kinfluenza A virus, H1N1 subtype^i1#^tm^len^kHIV^i1#^tm^len^kacquired immunodef
iciency syndrome^i1#other#14#20100810#08/10/2010#20100927#09/27/2010#v15n2a15.ht
m##
02710000000000589000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000210013103100030015203200020015506500090015701400110016603500100
01770120112001870100030002990100041003290100046003700100038004160100031004540700
04700485070002800532070004800560083124600608085000801854085004401862085001601906
08500470192211700060196907200030197511200090197811100110198711400090199811300110
2007002001302018008008902031#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.h
tm#S#l#4#1#article#1#^mMar./Apr.^a2011#oa#en#br1.1#1#4.0#ilus#tab#15#BJID160#nd#
Braz. j. infect. dis#15#2#20110400#^f170^l173#1413-8670#Clinical aspects of infl
uenza A (H1N1) in HIV-infected individuals in São Paulo during the pandemic of 2
009^len#^rND^1A01^nRosana Del^sBianco#^rND^1A01^nMaria Silvia Biagioni^sSantos#^
rND^1A02^nMaria Clara Gianna Garcia^sRibeiro#^rND^1A03^nAna Teresa Rodriguez^sVi
so#^rND^1A01^nValquíria^sCarvalho#^iA01^1SES SP^2CRT DST AIDS^3Inpatient Service
#^iA02^1SES SP^2CRT DST AIDS#^iA03^1SES SP^2CRT DST AIDS^3Ambulatory Service#^le
n^aOBJECTIVE: To describe the clinical aspects of H1N1 among HIV coinfected pati
ents seen at a reference center for AIDS treatment in São Paulo, Brazil. Design:
 Observational and prospective cohort study. METHODS: Descriptive study of clini
cal and laboratory investigation of HIV-infected patients with confirmed diagnos
is of influenza A (H1N1) in 2009. We analyzed patients monitored in CRT/DST/AIDS
, a specialized service for people living with HIV, located in São Paulo, Brazil
. RESULTS: 108 individuals presented with symptoms of H1N1 infection at the CRT 
DST/AIDS in 2009. Eighteen patients (16.7 percent) had confirmation of the diagn
osis of influenza A. Among the confirmed cases, ten (55.6 percent) were hospital
ized and eight (44.4 percent) were outpatients. Dyspnea was present in nine pati
ents (50 percent), hemoptysis in three (16 percent). Six patients (60 percent) r
equired therapy with supplemental oxygen. All patients had good clinical outcome
s and none died. CONCLUSIONS: In our hospital, the symptoms that led patients to
 seek medical care were similar to the common flu. Hospital admission and the ea
rly introduction of antibiotics associated with oseltamivir may have been the ca
use of the favorable outcome of our cases.#^dnd^i1#^tm^len^kinfluenza A virus, H
1N1 subtype^i1#^tm^len^kHIV^i1#^tm^len^kacquired immunodeficiency syndrome^i1#ot
her#14#20100810#08/10/2010#20100927#09/27/2010#v15n2a15.htm#Internet^ihttp://www
.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000200015##
00356000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012300074002001300197#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#5#1#article#104#<p align="right"><fon
t size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>BRIEF COMMUNICATION</
b></font></p>     ^cY#v15n2a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#6#2#article#104#<p>&nbsp;</p>     ^cY
#v15n2a15.htm##
00455000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704022200074002001300296#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#7#3#article#104#<p><font size="4" fac
e="Verdana, Arial, Helvetica, sans-serif"><a name="add"></a><b>Clinical aspects 
of influenza A (H1N1) in HIV-infected individuals in S&atilde;o Paulo during the
 pandemic of 2009</b></font></p>     ^cY#v15n2a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#8#4#article#104#<p>&nbsp;</p>     ^cY
#v15n2a15.htm##
00523000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704029000074002001300364#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#9#5#article#104#<p><font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif"><b>Rosana Del Bianco<sup>I</sup>; Mari
a Silvia Biagioni Santos<sup>II</sup>; Maria Clara Gianna Garcia Ribeiro<sup>III
</sup>; Ana Teresa Rodriguez Viso<sup>IV</sup>; Valqu&iacute;ria Carvalho<sup>V<
/sup></b></font></p>     ^cY#v15n2a15.htm##
00399000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704016500075002001300240#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#10#6#article#104#<p><font size="2" fa
ce="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Master's Degree in Infect
ology; Director of Inpatient Service, CRT DST AIDS-SES SP    ^cY#v15n2a15.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704009600075002001300171#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#11#7#article#104#<br> <sup>II</sup>MD
, Infectologist; Physician of Inpatient Service, CRT DST AIDS-SES SP    ^cY#v15n
2a15.htm##
00318000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704008400075002001300159#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#12#8#article#104#<br>   <sup>III</sup
>MD, Sanitarist; Technical Director, CRT DST AIDS-SES SP    ^cY#v15n2a15.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704010100075002001300176#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#13#9#article#104#<br>   <sup>IV</sup>
MD; PhD, Infectology; Director of Ambulatory Service, CRT DST AIDS-SES SP    ^cY
#v15n2a15.htm##
00357000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012200076002001300198#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#14#10#article#104#<br>   <sup>V</sup>
Master's Degree in Infectology; Physician of Inpatient Service, CRT DST AIDS-SES
 SP</font></p>     ^cY#v15n2a15.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#15#11#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence to</a><
/font></p>     ^cY#v15n2a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#16#12#article#104#<p>&nbsp;</p>     ^
cY#v15n2a15.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#17#13#article#104#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#v15n2a15.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#18#14#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>     ^cY#v
15n2a15.htm##
00521000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028600076002001300362#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#19#15#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>OBJECTIVE:</b> To describe the cl
inical aspects of H1N1 among HIV coinfected patients seen at a reference center 
for AIDS treatment in S&atilde;o Paulo, Brazil. Design: Observational and prospe
ctive cohort study.    ^cY#v15n2a15.htm##
00538000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030300076002001300379#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#20#16#article#104#<br> <b>METHODS:</b
> Descriptive study of clinical and laboratory investigation of HIV-infected pat
ients with confirmed diagnosis of influenza A (H1N1) in 2009. We analyzed patien
ts monitored in CRT/DST/AIDS, a specialized service for people living with HIV, 
located in S&atilde;o Paulo, Brazil.    ^cY#v15n2a15.htm##
00709000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047400076002001300550#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#21#17#article#104#<br>   <b>RESULTS:<
/b> 108 individuals presented with symptoms of H1N1 infection at the CRT DST/AID
S in 2009. Eighteen patients (16.7%) had confirmation of the diagnosis of influe
nza A. Among the confirmed cases, ten (55.6%) were hospitalized and eight (44.4%
) were outpatients. Dyspnea was present in nine patients (50%), hemoptysis in th
ree (16%). Six patients (60%) required therapy with supplemental oxygen. All pat
ients had good clinical outcomes and none died.    ^cY#v15n2a15.htm##
00534000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029900076002001300375#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#22#18#article#104#<br>   <b>CONCLUSIO
NS:</b> In our hospital, the symptoms that led patients to seek medical care wer
e similar to the common flu. Hospital admission and the early introduction of an
tibiotics associated with oseltamivir may have been the cause of the favorable o
utcome of our cases.</font></p>     ^cY#v15n2a15.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019500076002001300271#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#23#19#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><b>Keywords:</b> influenza A virus, 
H1N1 subtype; HIV; acquired immunodeficiency syndrome.</font></p> <hr size="1" n
oshade>     ^cY#v15n2a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#24#20#article#104#<p>&nbsp;</p>     ^
cY#v15n2a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#25#21#article#104#<p>&nbsp;</p>     ^
cY#v15n2a15.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010900076002001300185#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#26#22#article#104#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>INTRODUCTION</b></i></font></p
>     ^cY#v15n2a15.htm##
00891000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065600076002001300732#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#27#23#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In April 2009, a new viral subtype o
f influenza virus was identified in Mexico, United States and Canada.<sup>1,2</s
up> In July 2009 the first cases of sustained transmission of influenza A (H1N1)
 were confirmed in Brazil.<sup>1,3</sup> Cases of severe acute respiratory syndr
ome associated with influenza A started to be described in all regions of Brazil
. Many patients presented pulmonary complications, especially children, pregnant
 women, obese and people with comorbidities, such as diabetes, hypertension, car
diovascular disease, immunodeficiencies and malignancies.</font></p>     ^cY#v15
n2a15.htm##
00665000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043000076002001300506#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#28#24#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Sustained transmission of H1N1 virus
 in Brazil had already been declared.<sup>1,3</sup> In this new epidemic scenari
o, the Health Ministry in Brazil started to give priority to the investigation a
nd treatment of patients with severe acute respiratory syndrome (SARS) and those
 who were at risk for complications, as patients with chronic diseases.</font></
p>     ^cY#v15n2a15.htm##
00583000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034800076002001300424#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#29#25#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Initially, even patients with mild s
ymptoms were hospitalized, considering the possibility of an evolution with grea
ter severity in this group of patients. Later, with more data on H1N1 and on dis
ease outcome, only cases with more severe symptoms were hospitalized.</font></p>
     ^cY#v15n2a15.htm##
00461000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022600076002001300302#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#30#26#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Until July 29, 2009, among 543 confi
rmed cases of SARS in Brazil, 56 patients died, which corresponds to a lethality
 rate of 10.3%.<sup>3</sup></font></p>     ^cY#v15n2a15.htm##
00516000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028100076002001300357#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#31#27#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In S&atilde;o Paulo, by the end of J
uly, there were 2,078 suspected cases reported, 894 confirmed cases and 27 death
s, representing 48.2% of total deaths due to H1N1 infection in Brazil.<sup>2</su
p></font></p>     ^cY#v15n2a15.htm##
00813000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057800076002001300654#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#32#28#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">It is known that the H1N1 infection 
in HIV patients is potentially more serious,<sup>5,6</sup> but despite the incre
asingly emerging information about the pathogenesis and clinical course of the i
nfection caused by H1N1, there are still little data available on the course of 
infection in HIV patients. Considering the scarcity of data in the literature on
 H1N1 infection in HIV patients, we decided to conduct an analysis of patients w
ith confirmed influenza A who received care in our service.</font></p>     ^cY#v
15n2a15.htm##
00693000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045800076002001300534#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#33#29#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Our study aimed to describe the main
 clinical, laboratory and radiological findings in HIV-infected patients with co
nfirmed influenza A (H1N1) infection at the Center for Reference and Training in
 STD / AIDS of Health Secretariat of S&atilde;o Paulo (CRT DST/AIDS), a highly s
pecialized health care center for people living with HIV, located in S&atilde;o 
Paulo city, Brazil.</font></p>     ^cY#v15n2a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#34#30#article#104#<p>&nbsp;</p>     ^
cY#v15n2a15.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#35#31#article#104#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>METHODOLOGY</b></i></font></p>
     ^cY#v15n2a15.htm##
00662000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042700076002001300503#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#36#32#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">A descriptive clinical and laborator
ial study was conducted with all cases with confirmed diagnosis of influenza A (
H1N1) among HIV-infected individuals attended at CRT/STD/AIDS. Confirmed cases o
f influenza A were defined as patients with a positive PCR (real-time reverse tr
anscriptase polymerase chain reaction assay) for influenza A (H1N1).</font></p> 
    ^cY#v15n2a15.htm##
01457000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704122200076002001301298#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#37#33#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The PCR test at nasopharyngeal secre
tions was collected at admission to the service among those with symptoms sugges
tive of influenza, such as high fever, cough, myalgia, sore throat and respirato
ry distress. The samples were sent to Adolfo Lutz Institute (ALI), the reference
 laboratory for diagnosis of influenza A (H1N1) in S&atilde;o Paulo, for analysi
s. Data was prospectively collected. A protocol with patient information as iden
tification, epidemiological history of exposure to H1N1, data related to the HIV
 infection (including use of antiretroviral and adherence to them, history of im
munization against seasonal influenza in the past year, tobacco use, comorbiditi
es, signs of influenza and related symptoms) were collected. Results of radiolog
ical and laboratory tests of each patient were also included. These questionnair
es were completed by infectious disease specialists who were providing care to p
atients. We used the same instrument for inpatients and outpatients evaluation. 
The questionnaires were reviewed by the principal investigator and when importan
t data were missing, it was retrieved from the medical records.</font></p>     ^
cY#v15n2a15.htm##
00506000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027100076002001300347#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#38#34#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Body mass index (BMI) of all patient
s were calculated to determine if there was obesity or not. In this study, any p
atient with a BMI greater than 30 kg/m<sup>2</sup> was considered obese.</font><
/p>     ^cY#v15n2a15.htm##
00526000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029100076002001300367#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#39#35#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The case definition of pneumonia was
 the presence of acute pulmonary infiltrate associated with the presence of one 
or more of the following signs or symptoms: dyspnea, fever, hypoxemia, cough and
 chest pain.</font></p>     ^cY#v15n2a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#40#36#article#104#<p>&nbsp;</p>     ^
cY#v15n2a15.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#41#37#article#104#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>RESULTS</b></i></font></p>    
 ^cY#v15n2a15.htm##
00652000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041700076002001300493#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#42#38#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Our study was conducted from July 22
 to October 30, 2009. During this period 108 samples of nasopharyngeal swabs wer
e tested for H1N1 infection in HIV-infected individuals. Eighteen HIV-infected t
ested positive for H1N1 (first positive test result at 22<sup>nd</sup> July 2009
. Last positive result at 23<sup>rd</sup> September 2009).</font></p>     ^cY#v1
5n2a15.htm##
00453000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021800076002001300294#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#43#39#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The obtained convenience sample of e
ighteen patients with positive PCR were followed-up. No pregnant patient was inc
luded in our study.</font></p>     ^cY#v15n2a15.htm##
00708000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047300076002001300549#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#44#40#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Among the eighteen confirmed patient
s with H1N1 infection, ten (55.6%) were hospitalized and eight (44.4%) were trea
ted as outpatients. Thirteen (73%) were male and five female (27%). The mean age
 was 41.3 years (ranging from 12 to 59 years) and body mass index (BMI) ranged f
rom 16.7 to 31.5 (mean 24). Seventeen patients (94%) were on antiretroviral ther
apy (<a href="#tab1">Table 1</a>).</font></p>     ^cY#v15n2a15.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003500076002001300111#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#45#41#article#104#<p><a name="tab1"><
/a></p>     ^cY#v15n2a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#46#42#article#104#<p>&nbsp;</p>     ^
cY#v15n2a15.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008000076002001300156#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#47#43#article#104#<p align="center"><
img src="/img/revistas/bjid/v15n2/a15tab01.jpg"></p>     ^cY#v15n2a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#48#44#article#104#<p>&nbsp;</p>     ^
cY#v15n2a15.htm##
00687000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045200076002001300528#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#49#45#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">CD4 count ranged from 271,149 cells/
mm<sup>3</sup>, with an average of 600 cells/mm<sup>3</sup>. Only three patients
 (16%) had CD4 counts below 200 cells/mm<sup>3</sup>. HIV viral load was undetec
table in fourteen patients (77%). The mean length of HIV infection was thirteen 
years. Only nine patients (50%) had received seasonal influenza vaccine in the p
revious year.</font></p>     ^cY#v15n2a15.htm##
00548000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031300076002001300389#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#50#46#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">For other comorbidities, five (27%) 
had hypertension, two (11%) had diabetes, three (16%) had depression and two (11
%) had a history of pulmonary tuberculosis. One case (5%) had been diagnosed of 
asthma and two (11%) were smokers.</font></p>     ^cY#v15n2a15.htm##
00721000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048600076002001300562#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#51#47#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Regarding symptoms, sixteen patients
 (88%) had fever over 38ºC that lasted up to twelve days when they were diagnose
d with influenza A. Myalgia was present in nine patients (50%), arthralgia in on
ly one case (5%). Cough was reported by all patients (100%). Dyspnea was present
 in nine patients (50%), hemoptysis in three cases (16%). Chest x-rays were avai
lable for sixteen patients. Four patients (25%)</font></p>     ^cY#v15n2a15.htm#
#
00935000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070000076002001300776#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#52#48#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">had diffuse interstitial infiltrates
, one case (6%) showed bilateral alveolar infiltrate, one showed an opacity in t
he right base, and ten of sixteen (62.5%) patients had normal chest radiology. H
ypoxemia (pO<sub>2</sub> &lt; 70 mmHg), and pneumonia were detected in six patie
nts. Six patients (33%) required therapy with supplemental oxygen through a Vent
uri mask and one also needed CPAP. There was no need for mechanical ventilation 
in any patient. In the group of ten inpatients, increased LDH was found in three
 patients (30%). Only one patient had thrombocytopenia (10%). Three patients had
 increased CPK (30%).</font></p>     ^cY#v15n2a15.htm##
00564000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032900076002001300405#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#53#49#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The average hospital stay was 5.3 da
ys. Sixteen patients (88%) received treatment with oseltamivir for five days and
 in twelve cases (66%) it was necessary to combine treatment with antibiotics. N
o patient received treatment with corticosteroids.</font></p>     ^cY#v15n2a15.h
tm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#54#50#article#104#<p>&nbsp;</p>     ^
cY#v15n2a15.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#55#51#article#104#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>DISCUSSION</b></i></font></p> 
    ^cY#v15n2a15.htm##
00715000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048000076002001300556#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#56#52#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Considering the scarcity of data in 
the literature on H1N1 infection in HIV patients, we decided to perform an analy
sis of patients with confirmed influenza A in our service. A total of 108 sample
s of nasopharyngeal swabs were tested for H1N1 infection, but only eighteen turn
ed out positive. In consequence, the number of patients evaluated was small, and
 this limitation should be borne in mind.</font></p>     ^cY#v15n2a15.htm##
01138000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704090300076002001300979#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#57#53#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Another study of hospitalized HIV-in
fected patients with H1N1 in the United States showed that most of them with imm
unosuppression and preexisting conditions, had developed more severe H1N1 infect
ion.<sup>4,6</sup> However, in our service, all confirmed cases of influenza A h
ad satisfactory outcomes. The vast majority of patients had high CD4 (above 500 
cells/mm<sup>3</sup> ) and undetectable HIV RNA quantitative, which may have con
tributed to this favorable development. However, it is noteworthy that even thos
e who had low CD4 progressed well. Antiviral therapy (Oseltamivir 150 mg/day) wa
s initiated early on and the majority of patients presented with normal chest x-
ray, in contrast with other studies that observed greater pulmonary involvement.
<sup>8</sup> Only one patient in our study was considered obese.</font></p>     
^cY#v15n2a15.htm##
00659000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042400076002001300500#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#58#54#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Associated bacterial infections were
 common in our study, especially pneumonia, otitis and sinusitis with negative b
lood cultures. Many patients had to receive both antibiotics and Oseltamivir. Co
mplications observed were: pneumonia (six patients, 33%), sinusitis (one patient
, 5%), pancreatitis (one case, 5%) and otitis (two patients 11%).</font></p>    
 ^cY#v15n2a15.htm##
00514000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027900076002001300355#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#59#55#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In an autopsy study performed in 77 
patients with death attributed to H1N1 infection, 22 had histopathological and i
mmunohistochemical evidence of concomitant bacterial lung infection.<sup>9</sup>
</font></p>     ^cY#v15n2a15.htm##
00587000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035200076002001300428#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#60#56#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The association between bacterial pn
eumonia and influenza has been well documented through experience gained in othe
r influenza epidemics.<sup>10</sup> These data point to the fact that concomitan
t bacterial infections may contribute to mortality in patients with H1N1.</font>
</p>     ^cY#v15n2a15.htm##
00772000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053700076002001300613#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#61#57#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Many of our inpatients were treated 
with antibiotics early on. Two patients who did not receive antibiotics returned
 later with important bacterial complications. One had severe pneumonia within t
hirty days of treatment with Oseltamivir, requiring hospitalization, intravenous
 antibiotic therapy and use of supplemental oxygen. Another patient presented wi
th otitis media with suppuration few days after initiation of treatment for H1N1
 with Oseltamivir.</font></p>     ^cY#v15n2a15.htm##
00531000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029600076002001300372#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#62#58#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">In addition to pneumonia and otitis,
 sinusitis was also found. We believe that in HIV-infected patients, antibiotics
 should be strongly considered because of the possibility of unfavorable outcome
s in these cases.</font></p>     ^cY#v15n2a15.htm##
00684000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044900076002001300525#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#63#59#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">One patient tested positive for H1N1
 twelve days after onset of symptoms. This patient presented with more severe sy
mptoms. This finding is consistent with the data shown by a study conducted in M
exico that evaluated HIV-infected patients with H1N1.This study showed that dura
tion of disease was higher in HIV-infected compared to HIV-negative patients.<su
p>10</sup></font></p>     ^cY#v15n2a15.htm##
00681000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044600076002001300522#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#64#60#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Finally, some patients in our study 
persisted with positive H1N1 (RT-PCR) samples even after full treatment with Ose
ltamivir (five days). This should be valued, since persistence of viral replicat
ion after treatment with antiviral drugs may be related to the emergence of resi
stant strains. The same finding was described in the aforementioned study.<sup>1
0</sup></font></p>     ^cY#v15n2a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#65#61#article#104#<p>&nbsp;</p>     ^
cY#v15n2a15.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#66#62#article#104#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>CONCLUSION</b></i></font></p> 
    ^cY#v15n2a15.htm##
00558000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032300076002001300399#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#67#63#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">The presence of OIs or bacterial inf
ection suggests a more complicated course of the disease and may mask the influe
nza symptoms and signs, resulting in delayed treatment with a consequent increas
ed risk for a more severe disease and death.</font></p>     ^cY#v15n2a15.htm##
00518000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028300076002001300359#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#68#64#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">HIV-infected patients should be rout
inely screened for influenza in the context of an outbreak and OIs, and should h
ave early antiviral treatment and early indication of flu vaccine.<sup>7,11-13</
sup></font></p>     ^cY#v15n2a15.htm##
00458000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022300076002001300299#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#69#65#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">Admission to the hospital and early 
introduction of antibiotics associated with Oseltamivir may explain the favorabl
e outcomes of our cases.</font></p>     ^cY#v15n2a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#70#66#article#104#<p>&nbsp;</p>     ^
cY#v15n2a15.htm##
00347000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011200076002001300188#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#71#67#article#104#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>ACKNOWLEDGMENTS</b></i></font>
</p>     ^cY#v15n2a15.htm##
00579000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034400076002001300420#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#72#68#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif">We are very thankful to Dr. Naila Ja
nilde Seabra Santos, Dr. Marco Victoria of WHO and everybody who was involved in
 this project, specially the team of nurses and physicians who provided assistan
ce to the patients and helped us to reach this favorable outcome.</font></p>    
 ^cY#v15n2a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#73#69#article#104#<p>&nbsp;</p>     ^
cY#v15n2a15.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010700076002001300183#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#74#70#article#104#<p><font size="3" f
ace="Verdana, Arial, Helvetica, sans-serif"><i><b>REFERENCES</b></i></font></p> 
    ^cY#v15n2a15.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028400078002001300362#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#75#71#article#104#1#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Writing Committee o
f the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Cl
inical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med
 2010; 362:17081719</font></p>     ^cY#v15n2a15.htm##
00626000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704037700078002001300455#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#76#72#article#104#2#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Centro de Vigil&aci
rc;ncia Epidemiol&oacute;gica "Prof. Alexandre Vranjac". Coordenadoria de Contro
le de Doen&ccedil;as. Secretaria de Estado da Sa&uacute;de. S&atilde;o Paulo, SP
, Brasil Informe epidemiol&oacute;gico influenza pand&ecirc;mica H1N1 2009 - Abr
il, 2010. Bepa Abril 2010; 7(76)</font></p>     ^cY#v15n2a15.htm##
00506000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025700078002001300335#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#77#73#article#104#3#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Freitas GD, Carvalh
anas TRMP, Liphaus BL <i>et al</i>. Influenza A/H1N1: cen&aacute;rio atual e nov
os desafios. BEPA, Bol. epidemiol. paul. (Online) &#91;online&#93;. 2009; 6(67)2
430.    ^cY#v15n2a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#78#74#article#104#</font></p>     ^cY
#v15n2a15.htm##
00484000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023500078002001300313#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#79#75#article#104#4#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Jain S, Kamimoto L,
 Bramley AM <i>et al</i>. Hospitalized Patients with 2009 H1N1 Influenza in the 
United States, April June 2009. N Engl J Med 2009; 361:193544.    ^cY#v15n2a15.h
tm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#80#76#article#104#</font></p>     ^cY
#v15n2a15.htm##
00456000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020700078002001300285#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#81#77#article#104#5#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Clinical management
 of human infection with pandemic (H1N1) 2009: revised guidance. Geneva: World H
ealth Organization, November 2009.    ^cY#v15n2a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#82#78#article#104#</font></p>     ^cY
#v15n2a15.htm##
00638000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704038900078002001300467#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#83#79#article#104#6#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Updated Interim Rec
ommendations - HIV Infected Adults and Adolescents: Considerations for Clinician
s Regarding 2009 H1N1 Influenza. Atlanta: Centers for Disease Control and Preven
tion, October, 21, 2009. <a href="http://www.cdc.gov/h1n1flu/guidance_hiv.htm" t
arget="_blank">www.cdc.gov/h1n1flu/guidance_hiv.htm</a>.    ^cY#v15n2a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#84#80#article#104#</font></p>     ^cY
#v15n2a15.htm##
00442000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019300078002001300271#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#85#81#article#104#7#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Del Rio C. New CDC 
Interim Guidance on HIV and H1N1. Journal Watch HIV/AIDS Clinical Care. November
 2, 2009</font></p>     ^cY#v15n2a15.htm##
00484000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023500078002001300313#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#86#82#article#104#8#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Aviram G, Bar-Shai 
A, Sosna J <i>et al.</i> H1N1 influenza: initial chest radiographic findings in 
helping predict patient outcome. Radiology. 2010; 255(1):2529.    ^cY#v15n2a15.h
tm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#87#83#article#104#</font></p>     ^cY
#v15n2a15.htm##
00432000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704018300078002001300261#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#88#84#article#104#9#<p><f
ont size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Morbidity and Morta
lity Weekly Report <a href="http://www.cdc.gov/mmwr" target="_blank">www.cdc.gov
/mmwr</a>.    ^cY#v15n2a15.htm##
00436000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704018600079002001300265#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#89#85#article#104#10# Bac
terial Coinfections in Lung Tissue Specimens from Fatal Cases of 2009. Pandemic 
Influenza A (H1N1) - United States, May - August 2009. 2009; 58 (Early Release):
14</font></p>     ^cY#v15n2a15.htm##
00677000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704042700079002001300506#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#90#86#article#104#11#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Teran GR, de la R
osa Zamboni D, V&aacute;zquez P&eacute;rez Y <i>et al.</i> Clinical Features of 
Subjects Infected with HIV and H1N1 Influenza V&iacute;rus. Inst Natl de Enferme
dades Respiratorias, Mexico City, Mexico. In: Program and abstracts: 17a Confere
nces on Retroviruses and Opportunistic Infections, CROI, S&atilde;o Francisco, 2
010</font></p>     ^cY#v15n2a15.htm##
00597000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704034700079002001300426#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#91#87#article#104#12#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Zarychanski R, St
uart TL, Kumar A <i>et al.</i> Correlates of severe disease in patients with 200
9 pandemic influenza (H1N1) virus infection. Early release, published at <a href
="http://www.cmaj.ca" target="_blank">www.cmaj.ca</a> on January 21, 2010. Subje
ct to revision.    ^cY#v15n2a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#92#88#article#104#</font></p>     ^cY
#v15n2a15.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024300079002001300322#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#93#89#article#104#13#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. McGeer A, Green K
A, Plevneshi A <i>et al</i>. Antiviral therapy and outcomes of influenza requiri
ng hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:156875.    ^cY#v
15n2a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#94#90#article#104#</font></p>     ^cY
#v15n2a15.htm##
00505000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704025500079002001300334#v15
n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#95#91#article#104#14#<p><
font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Lee N, Cockram CS
, Chan PK <i>et al.</i> Antiviral treatment for patients hospitalized with sever
e influenza infection may affect clinical outcomes. Clin Infect Dis 2008; 46:132
34.    ^cY#v15n2a15.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#96#92#article#104#</font></p>     ^cY
#v15n2a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#97#93#article#104#<p>&nbsp;</p>     ^
cY#v15n2a15.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#98#94#article#104#<p>&nbsp;</p>     ^
cY#v15n2a15.htm##
00424000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018900076002001300265#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#99#95#article#104#<p><font size="2" f
ace="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="#add"><img
 src="/img/revistas/bjid/v15n2/seta.jpg" border="0"></a> <b>Correspondence to:</
b>    ^cY#v15n2a15.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704004300077002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#100#96#article#104#<br>   Maria Silvi
a Biagioni Santos    ^cY#v15n2a15.htm##
00263000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002700077002001300104#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#101#97#article#104#<br>   CRT DST AID
S    ^cY#v15n2a15.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704004600077002001300123#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#102#98#article#104#<br>   Rua Santa C
ruz 81, Vila Mariana    ^cY#v15n2a15.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704004300077002001300120#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#103#99#article#104#<br>   S&atilde;o 
Paulo, SP, Brazil    ^cY#v15n2a15.htm##
00295000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005800078002001300136#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#104#100#article#104#<br>   Phone: +55
-11-50879887 Fax: +55-11-50879886    ^cY#v15n2a15.htm##
00326000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008900078002001300167#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#105#101#article#104#<br>   <a href="m
ailto:msbiagioni@gmail.com">msbiagioni@gmail.com</a></font></p>     ^cY#v15n2a15
.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009500078002001300173#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#106#102#article#104#<p><font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">Submitted on: 08/10/2010    ^cY#v1
5n2a15.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#107#103#article#104#<br>   Approved o
n: 09/27/2010    ^cY#v15n2a15.htm##
00299000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006200078002001300140#v15n2#V:\SciELO
\serial\bjid\v15n2\markup\v15n2a15.htm#S#p#108#104#article#104#<br>   We declare
 no conflict of interest.</font></p>     ^cY#v15n2a15.htm##
00597000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750110096000770120073001730300
01300246065000900259064000500268031000400273061000900277865000900286002001300295
035001000308801001300318#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S
#c#109#1#article#14#1#Writing Committee of the WHO Consultation on Clinical Aspe
cts of Pandemic (H1N1) 2009 Influenza#Clinical aspects of pandemic 2009 influenz
a A (H1N1) virus infection^len#N Engl J Med#20100000#2010#362#17081719#20110400#
v15n2a15.htm#0028-4793#N Engl J Med##
00621000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750110062000770110091001390120
07100230030000500301710000200306065000900308064001100317031000200328032000300330
865000900333002001300342#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S
#c#110#2#article#14#2#Centro de Vigilância Epidemiológica "Prof. Alexandre Vranj
ac"#Secretaria de Estado da Saúde. São Paulo, SP, Brasil^dCoordenadoria de Contr
ole de Doenças#Informe epidemiológico influenza pandêmica H1N1 2009 - Abril, 201
0^lpt#Bepa#2#20100400#Abril 2010#7#76#20110400#v15n2a15.htm##
00592000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100024000950100
01800119810000600137012005300143030002700196710000200223061000700225065000900232
064000500241031000200246032000300248020000500251865000900256002001300265#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#c#111#3#article#14#3#^rND^sFrei
tas^nGD#^rND^sCarvalhanas^nTRMP#^rND^sLiphaus^nBL#et al#Influenza A/H1N1: cenári
o atual e novos desafios^lpt#BEPA, Bol. epidemiol. paul#2#Online#20090000#2009#6
#67#2430#20110400#v15n2a15.htm##
00607000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100018000910100
01800109810000600127012008900133030001300222065000900235064000500244031000400249
061000700253865000900260002001300269035001000282801001300292#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a15.htm#S#c#112#4#article#14#4#^rND^sJain^nS#^rND^sKa
mimoto^nL#^rND^sBramley^nAM#et al#Hospitalized Patients with 2009 H1N1 Influenza
 in the United States, April June 2009^len#N Engl J Med#20090000#2009#361#193544
#20110400#v15n2a15.htm#0028-4793#N Engl J Med##
00460000000000217000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750180087000770660007001640620
02600171065000900197064001400206865000900220002001300229#v15n2#V:\SciELO\serial\
bjid\v15n2\markup\v15n2a15.htm#S#c#113#5#article#14#5#Clinical management of hum
an infection with pandemic (H1N1) 2009: revised guidance^len#Geneva#World Health
 Organization#20091100#November 2009#20110400#v15n2a15.htm##
00578000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750180134000770660008002110620
04300219065000900262064001800271037003700289865000900326002001300335#v15n2#V:\Sc
iELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#c#114#6#article#14#6#Updated Interi
m Recommendations: HIV Infected Adults and Adolescents: Considerations for Clini
cians Regarding 2009 H1N1 Influenza^len#Atlanta#Centers for Disease Control and 
Prevention#20091021#October, 21, 2009#www.cdc.gov/h1n1flu/guidance_hiv.htm#20110
400#v15n2a15.htm##
00456000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770120045000940300
03700139710000200176065000900178064001700187865000900204002001300213#v15n2#V:\Sc
iELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#c#115#7#article#14#7#^rND^sDel Rio^
nC#New CDC Interim Guidance on HIV and H1N1^len#Journal Watch HIV/AIDS Clinical 
Care#2#20091102#November 2, 2009#20110400#v15n2a15.htm##
00614000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100018000930100
01500111810000600126012009100132030001000223065000900233064000500242031000400247
032000200251020000500253865000900258002001300267035001000280801001000290#v15n2#V
:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S#c#116#8#article#14#8#^rND^sAvir
am^nG#^rND^sBar-Shai^nA#^rND^sSosna^nJ#et al#H1N1 influenza: initial chest radio
graphic findings in helping predict patient outcome^len#Radiology#20100000#2010#
255#1#2529#20110400#v15n2a15.htm#0033-8419#Radiology##
00408000000000205000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750300038000770370017001158650
00900132002001300141035001000154801003800164#v15n2#V:\SciELO\serial\bjid\v15n2\m
arkup\v15n2a15.htm#S#c#117#9#article#14#9#Morbidity and Mortality Weekly Report#
www.cdc.gov/mmwr#20110400#v15n2a15.htm#0091-0031#MORBIDITY AND MORTALITY WEEKLY 
REPORT##
00491000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000730180141000760650009002170640005002260310
00300231061001400234020000300248865000900251002001300260#v15n2#V:\SciELO\serial\
bjid\v15n2\markup\v15n2a15.htm#S#c#118#10#article#14#Bacterial Coinfections in L
ung Tissue Specimens from Fatal Cases of 2009: Pandemic Influenza A (H1N1) - Uni
ted States, May - August 2009^len#20090000#2009#58#Early Release#14#20110400#v15
n2a15.htm##
00721000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100028000950100
02300123810000600146012013900152018002600291053006700317056001700384055001200401
054000800413865000900421002001300430#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v1
5n2a15.htm#S#c#119#11#article#14#10#^rND^sTeran^nGR#^rND^sde la Rosa Zamboni^nD#
^rND^sVázquez Pérez^nY#et al#Clinical Features of Subjects Infected with HIV and
 H1N1 Influenza Vírus: Inst Natl de Enfermedades Respiratorias, Mexico City, Mex
ico^len#Program and abstracts^len#Conferences on Retroviruses and Opportunistic 
Infections^n17^i1^i1#São Francisco^i1#20100000^i1#2010^i1#20110400#v15n2a15.htm#
#
00581000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160021000790160017001000160
01500117810000600132018009700138037001200235065000900247064001700256061002000273
865000900293002001300302#v15n2#V:\SciELO\serial\bjid\v15n2\markup\v15n2a15.htm#S
#c#120#12#article#14#11#^rND^sZarychanski^nR#^rND^sStuart^nTL#^rND^sKumar^nA#et 
al#Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) 
virus infection^len#www.cmaj.ca#20100121#January 21, 2010#Subject to revision#20
110400#v15n2a15.htm##
00619000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01900111810000600130012009300136030001600229065000900245064000500254031000300259
061000700262865000900269002001300278035001000291801001600301#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a15.htm#S#c#121#13#article#14#12#^rND^sMcGeer^nA#^rND
^sGreen^nKA#^rND^sPlevneshi^nA#et al#Antiviral therapy and outcomes of influenza
 requiring hospitalization in Ontario, Canada^len#Clin Infect Dis#20070000#2007#
45#156875#20110400#v15n2a15.htm#1058-4838#Clin Infect Dis##
00631000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100018000920100
01500110810000600125012011100131030001600242065000900258064000500267031000300272
061000600275865000900281002001300290035001000303801001600313#v15n2#V:\SciELO\ser
ial\bjid\v15n2\markup\v15n2a15.htm#S#c#122#14#article#14#13#^rND^sLee^nN#^rND^sC
ockram^nCS#^rND^sChan^nPK#et al#Antiviral treatment for patients hospitalized wi
th severe influenza infection may affect clinical outcomes^len#Clin Infect Dis#2
0080000#2008#46#13234#20110400#v15n2a15.htm#1058-4838#Clin Infect Dis##
